<?xml version="1.0" encoding="UTF-8"?>
<document id="60796" schemaversion="0.12" type="main" date="2018-06-16T13:34:41+10:00" version="current" level="processed"><documentinfo><uri id="60796" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/book-main.psml" decodedpath="/ps/test/local3/books/book-main.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" created="2018-06-15T10:34:32+10:00" modified="2018-06-16T13:34:41+10:00" title="Main Book"><displaytitle>Main Book</displaytitle></uri></documentinfo><fragmentinfo><locator id="44749" fragment="60796-toc" editid="108242" modified="2018-06-16T13:34:41+10:00"></locator></fragmentinfo><metadata></metadata><section id="60796-metadata" edit="false"><properties-fragment id="60796-metadata"><property name="creator" value="Department of Health"></property><property name="title" value="Main Book"></property><property name="effectivemonth" value="May 2018"></property></properties-fragment></section><section id="60796-xrefs"><xref-fragment id="60796-toc">
<blockxref id="107697" title="therapeuticindex-PL.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="60476" href="dynamic/PL/therapeuticindex-PL.psml" urititle="Therapeutic Index - Palliative Care - PL" mediatype="application/vnd.pageseeder.psml+xml"><document id="60476" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="60476" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/therapeuticindex-PL.psml" decodedpath="/ps/test/local3/books/dynamic/PL/therapeuticindex-PL.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:32+10:00" title="Therapeutic Index - Palliative Care - PL"><displaytitle>Therapeutic Index - Palliative Care - PL</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107697" title="" type="none" forwardtype="embed" forwardtitle="therapeuticindex-PL.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="43867" fragment="60476-2" editid="106803" modified="2018-06-15T10:34:28+10:00"></locator></fragmentinfo><metadata></metadata><section id="60476-1"><fragment id="60476-1"><block label="mps3indexsectionbreak">PL</block><block label="schedule-heading">Palliative Care</block></fragment><fragment id="60476-2"><block label="index"><para>ALIMENTARY TRACT AND METABOLISM<inline label="indexpageref"><xref id="106783" title="ALIMENTARY TRACT AND METABOLISM" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59571" href="#59571" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index2"><para indent="1">STOMATOLOGICAL PREPARATIONS<inline label="indexpageref"><xref id="106784" title="STOMATOLOGICAL PREPARATIONS" frag="A01" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59571" href="#59571-A01" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index3"><para indent="2">STOMATOLOGICAL PREPARATIONS<inline label="indexpageref"><xref id="106785" title="STOMATOLOGICAL PREPARATIONS" frag="A01A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59571" href="#59571-A01A" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index2"><para indent="1">DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS<inline label="indexpageref"><xref id="106786" title="DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS" frag="A03" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59571" href="#59571-A03" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index3"><para indent="2">BELLADONNA AND DERIVATIVES, PLAIN<inline label="indexpageref"><xref id="106787" title="BELLADONNA AND DERIVATIVES, PLAIN" frag="A03B" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59571" href="#59571-A03B" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index3"><para indent="2">PROPULSIVES<inline label="indexpageref"><xref id="106788" title="PROPULSIVES" frag="A03F" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59571" href="#59571-A03F" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index2"><para indent="1">DRUGS FOR CONSTIPATION<inline label="indexpageref"><xref id="106789" title="DRUGS FOR CONSTIPATION" frag="A06" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59571" href="#59571-A06" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index3"><para indent="2">DRUGS FOR CONSTIPATION<inline label="indexpageref"><xref id="106790" title="DRUGS FOR CONSTIPATION" frag="A06A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59571" href="#59571-A06A" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index"><para>MUSCULO-SKELETAL SYSTEM<inline label="indexpageref"><xref id="106791" title="MUSCULO-SKELETAL SYSTEM" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60534" href="#60534" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">MUSCULO-SKELETAL SYSTEM</xref></inline></para></block><block label="index2"><para indent="1">ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS<inline label="indexpageref"><xref id="106792" title="ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS" frag="M01" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60534" href="#60534-M01" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">MUSCULO-SKELETAL SYSTEM</xref></inline></para></block><block label="index3"><para indent="2">ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS<inline label="indexpageref"><xref id="106793" title="ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS" frag="M01A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60534" href="#60534-M01A" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">MUSCULO-SKELETAL SYSTEM</xref></inline></para></block><block label="index"><para>NERVOUS SYSTEM<inline label="indexpageref"><xref id="106794" title="NERVOUS SYSTEM" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60709" href="#60709" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block><block label="index2"><para indent="1">ANALGESICS<inline label="indexpageref"><xref id="106795" title="ANALGESICS" frag="N02" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60709" href="#60709-N02" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block><block label="index3"><para indent="2">OPIOIDS<inline label="indexpageref"><xref id="106796" title="OPIOIDS" frag="N02A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60709" href="#60709-N02A" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block><block label="index3"><para indent="2">OTHER ANALGESICS AND ANTIPYRETICS<inline label="indexpageref"><xref id="106797" title="OTHER ANALGESICS AND ANTIPYRETICS" frag="N02B" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60709" href="#60709-N02B" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block><block label="index2"><para indent="1">ANTIEPILEPTICS<inline label="indexpageref"><xref id="106798" title="ANTIEPILEPTICS" frag="N03" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60709" href="#60709-N03" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block><block label="index3"><para indent="2">ANTIEPILEPTICS<inline label="indexpageref"><xref id="106799" title="ANTIEPILEPTICS" frag="N03A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60709" href="#60709-N03A" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block><block label="index2"><para indent="1">PSYCHOLEPTICS<inline label="indexpageref"><xref id="106800" title="PSYCHOLEPTICS" frag="N05" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60709" href="#60709-N05" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block><block label="index3"><para indent="2">ANXIOLYTICS<inline label="indexpageref"><xref id="106801" title="ANXIOLYTICS" frag="N05B" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60709" href="#60709-N05B" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block><block label="index3"><para indent="2">HYPNOTICS AND SEDATIVES<inline label="indexpageref"><xref id="106802" title="HYPNOTICS AND SEDATIVES" frag="N05C" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60709" href="#60709-N05C" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block></fragment></section></document></blockxref>
<blockxref id="107698" title="PL.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="60920" href="dynamic/PL.psml" urititle="Palliative Care" mediatype="application/vnd.pageseeder.psml+xml"><document id="60920" schemaversion="0.12" date="2018-06-15T10:35:17+10:00" version="current" level="processed"><documentinfo><uri id="60920" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL.psml" decodedpath="/ps/test/local3/books/dynamic/PL.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:33+10:00" modified="2018-06-15T10:35:17+10:00" title="Palliative Care"><displaytitle>Palliative Care</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107698" title="" type="none" forwardtype="embed" forwardtitle="PL.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="44914" fragment="60920-d114e887392" editid="107867" modified="2018-06-15T10:34:33+10:00"></locator></fragmentinfo><metadata></metadata><section id="60920-1"><fragment id="60920-1"><block label="mps3sectionbreak">PL</block></fragment></section><section id="60920-d114e887392"><xref-fragment id="60920-d114e887392"><blockxref id="107864" title="ALIMENTARY TRACT AND METABOLISM" frag="default" reversefrag="d114e887392" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="59571" href="dynamic/PL/atc/A.psml" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml"><document id="59571" schemaversion="0.12" date="2018-06-15T10:34:33+10:00" version="current" level="processed"><documentinfo><uri id="59571" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/atc/A.psml" decodedpath="/ps/test/local3/books/dynamic/PL/atc/A.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:18+10:00" modified="2018-06-15T10:34:33+10:00" title="ALIMENTARY TRACT AND METABOLISM"><displaytitle>ALIMENTARY TRACT AND METABOLISM</displaytitle></uri><reversexrefs><reversexref uriid="60476" href="dynamic/PL/therapeuticindex-PL.psml" frag="2" urititle="Therapeutic Index - Palliative Care - PL" mediatype="application/vnd.pageseeder.psml+xml" id="106783" title="Untitled" type="none" forwardtype="none" forwardtitle="ALIMENTARY TRACT AND METABOLISM" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60920" href="dynamic/PL.psml" frag="d114e887392" urititle="Palliative Care" mediatype="application/vnd.pageseeder.psml+xml" id="107864" title="PL" type="none" forwardtype="embed" forwardtitle="ALIMENTARY TRACT AND METABOLISM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="41995" fragment="59571-A06AG21264011000036101" editid="104910" modified="2018-06-15T10:34:18+10:00"></locator><locator id="43868" fragment="59571-A01"><reversexrefs><reversexref uriid="60476" href="dynamic/PL/therapeuticindex-PL.psml" frag="2" urititle="Therapeutic Index - Palliative Care - PL" mediatype="application/vnd.pageseeder.psml+xml" id="106784" title="Untitled" type="none" forwardtype="none" forwardtitle="STOMATOLOGICAL PREPARATIONS" forwarddisplay="document" forwardfrag="A01"></reversexref></reversexrefs></locator><locator id="43871" fragment="59571-A03B"><reversexrefs><reversexref uriid="60476" href="dynamic/PL/therapeuticindex-PL.psml" frag="2" urititle="Therapeutic Index - Palliative Care - PL" mediatype="application/vnd.pageseeder.psml+xml" id="106787" title="Untitled" type="none" forwardtype="none" forwardtitle="BELLADONNA AND DERIVATIVES, PLAIN" forwarddisplay="document" forwardfrag="A03B"></reversexref></reversexrefs></locator><locator id="43869" fragment="59571-A01A"><reversexrefs><reversexref uriid="60476" href="dynamic/PL/therapeuticindex-PL.psml" frag="2" urititle="Therapeutic Index - Palliative Care - PL" mediatype="application/vnd.pageseeder.psml+xml" id="106785" title="Untitled" type="none" forwardtype="none" forwardtitle="STOMATOLOGICAL PREPARATIONS" forwarddisplay="document" forwardfrag="A01A"></reversexref></reversexrefs></locator><locator id="42001" fragment="59571-A06AC21778011000036106" editid="104913" modified="2018-06-15T10:34:18+10:00"></locator><locator id="41989" fragment="59571-A01AD21819011000036105" editid="104907" modified="2018-06-15T10:34:18+10:00"></locator><locator id="41993" fragment="59571-A06AB21264011000036101" editid="104909" modified="2018-06-15T10:34:18+10:00"></locator><locator id="43873" fragment="59571-A06"><reversexrefs><reversexref uriid="60476" href="dynamic/PL/therapeuticindex-PL.psml" frag="2" urititle="Therapeutic Index - Palliative Care - PL" mediatype="application/vnd.pageseeder.psml+xml" id="106789" title="Untitled" type="none" forwardtype="none" forwardtitle="DRUGS FOR CONSTIPATION" forwarddisplay="document" forwardfrag="A06"></reversexref></reversexrefs></locator><locator id="42003" fragment="59571-A06AD87750011000036101" editid="104914" modified="2018-06-15T10:34:18+10:00"></locator><locator id="43874" fragment="59571-A06A"><reversexrefs><reversexref uriid="60476" href="dynamic/PL/therapeuticindex-PL.psml" frag="2" urititle="Therapeutic Index - Palliative Care - PL" mediatype="application/vnd.pageseeder.psml+xml" id="106790" title="Untitled" type="none" forwardtype="none" forwardtitle="DRUGS FOR CONSTIPATION" forwarddisplay="document" forwardfrag="A06A"></reversexref></reversexrefs></locator><locator id="41987" fragment="59571-A06AG21630011000036102" editid="104906" modified="2018-06-15T10:34:18+10:00"></locator><locator id="43872" fragment="59571-A03F"><reversexrefs><reversexref uriid="60476" href="dynamic/PL/therapeuticindex-PL.psml" frag="2" urititle="Therapeutic Index - Palliative Care - PL" mediatype="application/vnd.pageseeder.psml+xml" id="106788" title="Untitled" type="none" forwardtype="none" forwardtitle="PROPULSIVES" forwarddisplay="document" forwardfrag="A03F"></reversexref></reversexrefs></locator><locator id="41985" fragment="59571-A06AD32631011000036109" editid="104905" modified="2018-06-15T10:34:18+10:00"></locator><locator id="41997" fragment="59571-A06AH79730011000036107" editid="104911" modified="2018-06-15T10:34:18+10:00"></locator><locator id="41991" fragment="59571-A03BB21580011000036102" editid="104908" modified="2018-06-15T10:34:18+10:00"></locator><locator id="41999" fragment="59571-A03FA21569011000036105" editid="104912" modified="2018-06-15T10:34:18+10:00"></locator><locator id="43870" fragment="59571-A03"><reversexrefs><reversexref uriid="60476" href="dynamic/PL/therapeuticindex-PL.psml" frag="2" urititle="Therapeutic Index - Palliative Care - PL" mediatype="application/vnd.pageseeder.psml+xml" id="106786" title="Untitled" type="none" forwardtype="none" forwardtitle="DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS" forwarddisplay="document" forwardfrag="A03"></reversexref></reversexrefs></locator></fragmentinfo><metadata></metadata><section id="59571-A"><fragment id="59571-A"><block label="ATCLevel1"><para>ALIMENTARY TRACT AND METABOLISM</para></block></fragment></section><section id="59571-A01"><fragment id="59571-A01"><block label="ATCLevel2"><para>STOMATOLOGICAL PREPARATIONS</para></block></fragment></section><section id="59571-A01A"><fragment id="59571-A01A"><block label="ATCLevel3"><para>STOMATOLOGICAL PREPARATIONS</para></block></fragment></section><section id="59571-A01AD"><fragment id="59571-A01AD"><block label="ATCLevel4"><para>Other agents for local oral treatment</para></block></fragment></section><section id="59571-A01AD21819011000036105"><xref-fragment id="59571-A01AD21819011000036105"><blockxref id="104897" title="BENZYDAMINE" frag="default" reversefrag="A01AD21819011000036105" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="59772" href="dynamic/PL/drug/21819011000036105-A01AD.psml" urititle="BENZYDAMINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59772" schemaversion="0.12" date="2018-06-15T10:34:18+10:00" version="current" level="processed"><documentinfo><uri id="59772" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/21819011000036105-A01AD.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/21819011000036105-A01AD.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:18+10:00" title="BENZYDAMINE"><displaytitle>BENZYDAMINE</displaytitle></uri><reversexrefs><reversexref uriid="59571" href="dynamic/PL/atc/A.psml" frag="A01AD21819011000036105" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="104897" title="PL" type="none" forwardtype="embed" forwardtitle="BENZYDAMINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59772-21819011000036105-1"><fragment id="59772-21819011000036105-1"><block label="DrugName">BENZYDAMINE<inline label="genericindexfield">XE "BENZYDAMINE"</inline></block></fragment></section><section id="59772-d5459e16"><fragment id="59772-d5459e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">6197</block><block label="RestrictionText"><para>Painful mouth</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care.</para></item></list></block></fragment></section><section id="59772-5385K"><fragment id="59772-5385K"><block label="FormAndStrength">benzydamine hydrochloride 0.15% mouthwash, 500 mL</block><table role="PL"><row><cell><block label="DrugItemCode">5385K<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">24.18</block></cell><cell><block label="MRVSN">25.39</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Difflam [IL]<inline label="genericindexfieldbrand"><italic>XE "Difflam(IL)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59571-A03"><fragment id="59571-A03"><block label="ATCLevel2"><para>DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS</para></block></fragment></section><section id="59571-A03B"><fragment id="59571-A03B"><block label="ATCLevel3"><para>BELLADONNA AND DERIVATIVES, PLAIN</para></block></fragment></section><section id="59571-A03BB"><fragment id="59571-A03BB"><block label="ATCLevel4"><para>Belladonna alkaloids, semisynthetic, quaternary ammonium compounds</para></block></fragment></section><section id="59571-A03BB21580011000036102"><xref-fragment id="59571-A03BB21580011000036102"><blockxref id="104898" title="HYOSCINE BUTYLBROMIDE" frag="default" reversefrag="A03BB21580011000036102" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="60254" href="dynamic/PL/drug/21580011000036102-A03BB.psml" urititle="HYOSCINE BUTYLBROMIDE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60254" schemaversion="0.12" date="2018-06-15T10:34:18+10:00" version="current" level="processed"><documentinfo><uri id="60254" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/21580011000036102-A03BB.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/21580011000036102-A03BB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:26+10:00" modified="2018-06-15T10:34:18+10:00" title="HYOSCINE BUTYLBROMIDE"><displaytitle>HYOSCINE BUTYLBROMIDE</displaytitle></uri><reversexrefs><reversexref uriid="59571" href="dynamic/PL/atc/A.psml" frag="A03BB21580011000036102" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="104898" title="PL" type="none" forwardtype="embed" forwardtitle="HYOSCINE BUTYLBROMIDE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60254-21580011000036102-1"><fragment id="60254-21580011000036102-1"><block label="DrugName">HYOSCINE BUTYLBROMIDE<inline label="genericindexfield">XE "HYOSCINE BUTYLBROMIDE"</inline></block></fragment></section><section id="60254-d5461e16"><fragment id="60254-d5461e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">6207</block><block label="RestrictionText"><para>For use in patients receiving palliative care</para></block></fragment></section><section id="60254-5317W"><fragment id="60254-5317W"><block label="FormAndStrength">hyoscine butylbromide 20 mg/mL injection, 5 x 1 mL ampoules</block><table role="PL"><row><cell><block label="DrugItemCode">5317W<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">6</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>85.15</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Buscopan [VZ]<inline label="genericindexfieldbrand"><italic>XE "Buscopan(VZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">HYOSCINE BUTYLBROMIDE SXP [XC]<inline label="genericindexfieldbrand"><italic>XE "HYOSCINE BUTYLBROMIDE SXP (XC)" \i </italic></inline></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59571-A03F"><fragment id="59571-A03F"><block label="ATCLevel3"><para>PROPULSIVES</para></block></fragment></section><section id="59571-A03FA"><fragment id="59571-A03FA"><block label="ATCLevel4"><para>Propulsives</para></block></fragment></section><section id="59571-A03FA21569011000036105"><xref-fragment id="59571-A03FA21569011000036105"><blockxref id="104902" title="METOCLOPRAMIDE" frag="default" reversefrag="A03FA21569011000036105" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="60478" href="dynamic/PL/drug/21569011000036105-A03FA.psml" urititle="METOCLOPRAMIDE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60478" schemaversion="0.12" date="2018-06-15T10:34:18+10:00" version="current" level="processed"><documentinfo><uri id="60478" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/21569011000036105-A03FA.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/21569011000036105-A03FA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:18+10:00" title="METOCLOPRAMIDE"><displaytitle>METOCLOPRAMIDE</displaytitle></uri><reversexrefs><reversexref uriid="59571" href="dynamic/PL/atc/A.psml" frag="A03FA21569011000036105" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="104902" title="PL" type="none" forwardtype="embed" forwardtitle="METOCLOPRAMIDE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60478-21569011000036105-1"><fragment id="60478-21569011000036105-1"><block label="DrugName">METOCLOPRAMIDE<inline label="genericindexfield">XE "METOCLOPRAMIDE"</inline></block></fragment></section><section id="60478-d5463e16"><fragment id="60478-d5463e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">6084</block><block label="RestrictionText"><para>Nausea or gastric stasis</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care.</para></item></list></block></fragment></section><section id="60478-10762K"><fragment id="60478-10762K"><block label="FormAndStrength">metoclopramide hydrochloride 10 mg/2 mL injection, 10 x 2 mL ampoules</block><table role="PL"><row><cell><block label="DrugItemCode">10762K<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>33.95</block></cell><cell><block label="MRVSN">35.16</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Maxolon [IL]<inline label="genericindexfieldbrand"><italic>XE "Maxolon(IL)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59571-A06"><fragment id="59571-A06"><block label="ATCLevel2"><para>DRUGS FOR CONSTIPATION</para></block></fragment></section><section id="59571-A06A"><fragment id="59571-A06A"><block label="ATCLevel3"><para>DRUGS FOR CONSTIPATION</para></block></fragment></section><section id="59571-A06AB"><fragment id="59571-A06AB"><block label="ATCLevel4"><para>Contact laxatives</para></block></fragment></section><section id="59571-A06AB21264011000036101"><xref-fragment id="59571-A06AB21264011000036101"><blockxref id="104899" title="BISACODYL" frag="default" reversefrag="A06AB21264011000036101" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="60817" href="dynamic/PL/drug/21264011000036101-A06AB.psml" urititle="BISACODYL" mediatype="application/vnd.pageseeder.psml+xml"><document id="60817" schemaversion="0.12" date="2018-06-15T10:34:18+10:00" version="current" level="processed"><documentinfo><uri id="60817" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/21264011000036101-A06AB.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/21264011000036101-A06AB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:18+10:00" title="BISACODYL"><displaytitle>BISACODYL</displaytitle></uri><reversexrefs><reversexref uriid="59571" href="dynamic/PL/atc/A.psml" frag="A06AB21264011000036101" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="104899" title="PL" type="none" forwardtype="embed" forwardtitle="BISACODYL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60817-21264011000036101-1"><fragment id="60817-21264011000036101-1"><block label="DrugName">BISACODYL<inline label="genericindexfield">XE "BISACODYL:.Palliative Care"</inline></block></fragment></section><section id="60817-d5465e16"><fragment id="60817-d5465e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Constipation</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care.</para></item></list></block></fragment></section><section id="60817-5303D"><fragment id="60817-5303D"><block label="FormAndStrength">bisacodyl 10 mg suppository, 10</block><table role="PL"><row><cell><block label="DrugItemCode">5303D<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>23.71</block></cell><cell><block label="MRVSN">24.92</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Petrus Bisacodyl Suppositories [PP]<inline label="genericindexfieldbrand"><italic>XE "Petrus Bisacodyl Suppositories(PP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium"><inline label="BrandPricePremium"><sup>B</sup>1.29
</inline></block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>25.00</block></cell><cell><block label="MRVSN">24.92</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Dulcolax [VZ]<inline label="genericindexfieldbrand"><italic>XE "Dulcolax(VZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60817-5301B"><fragment id="60817-5301B"><block label="FormAndStrength">bisacodyl 5 mg enteric tablet, 200</block><table role="PL"><row><cell><block label="DrugItemCode">5301B<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.08</block></cell><cell><block label="MRVSN">18.29</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Lax-Tab [AE]<inline label="genericindexfieldbrand"><italic>XE "Lax-Tab(AE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60817-5304E"><fragment id="60817-5304E"><block label="FormAndStrength">bisacodyl 10 mg suppository, 12</block><table role="PL"><row><cell><block label="DrugItemCode">5304E<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>21.43</block></cell><cell><block label="MRVSN">22.64</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Petrus Bisacodyl Suppositories [PP]<inline label="genericindexfieldbrand"><italic>XE "Petrus Bisacodyl Suppositories(PP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59571-A06AC"><fragment id="59571-A06AC"><block label="ATCLevel4"><para>Bulk-forming laxatives</para></block></fragment></section><section id="59571-A06AC21778011000036106"><xref-fragment id="59571-A06AC21778011000036106"><blockxref id="104903" title="RHAMNUS FRANGULA + STERCULIA" frag="default" reversefrag="A06AC21778011000036106" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="59654" href="dynamic/PL/drug/21778011000036106-A06AC.psml" urititle="RHAMNUS FRANGULA + STERCULIA" mediatype="application/vnd.pageseeder.psml+xml"><document id="59654" schemaversion="0.12" date="2018-06-15T10:34:18+10:00" version="current" level="processed"><documentinfo><uri id="59654" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/21778011000036106-A06AC.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/21778011000036106-A06AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:19+10:00" modified="2018-06-15T10:34:18+10:00" title="RHAMNUS FRANGULA + STERCULIA"><displaytitle>RHAMNUS FRANGULA + STERCULIA</displaytitle></uri><reversexrefs><reversexref uriid="59571" href="dynamic/PL/atc/A.psml" frag="A06AC21778011000036106" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="104903" title="PL" type="none" forwardtype="embed" forwardtitle="RHAMNUS FRANGULA + STERCULIA" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59654-21778011000036106-1"><fragment id="59654-21778011000036106-1"><block label="DrugName">RHAMNUS FRANGULA + STERCULIA<inline label="genericindexfield">XE "RHAMNUS FRANGULA + STERCULIA"</inline></block></fragment></section><section id="59654-d5467e16"><fragment id="59654-d5467e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Constipation</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care.</para></item></list></block></fragment></section><section id="59654-5322D"><fragment id="59654-5322D"><block label="FormAndStrength">rhamnus frangula 80 mg/g + sterculia 620 mg/g granules, 500 g</block><table role="PL"><row><cell><block label="DrugItemCode">5322D<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">27.57</block></cell><cell><block label="MRVSN">28.78</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Normacol Plus [NE]<inline label="genericindexfieldbrand"><italic>XE "Normacol Plus(NE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59571-A06AD"><fragment id="59571-A06AD"><block label="ATCLevel4"><para>Osmotically acting laxatives</para></block></fragment></section><section id="59571-A06AD87750011000036101"><xref-fragment id="59571-A06AD87750011000036101"><blockxref id="104904" title="MACROGOL-3350" frag="default" reversefrag="A06AD87750011000036101" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="60628" href="dynamic/PL/drug/87750011000036101-A06AD.psml" urititle="MACROGOL-3350" mediatype="application/vnd.pageseeder.psml+xml"><document id="60628" schemaversion="0.12" date="2018-06-15T10:34:18+10:00" version="current" level="processed"><documentinfo><uri id="60628" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/87750011000036101-A06AD.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/87750011000036101-A06AD.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:30+10:00" modified="2018-06-15T10:34:18+10:00" title="MACROGOL-3350"><displaytitle>MACROGOL-3350</displaytitle></uri><reversexrefs><reversexref uriid="59571" href="dynamic/PL/atc/A.psml" frag="A06AD87750011000036101" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="104904" title="PL" type="none" forwardtype="embed" forwardtitle="MACROGOL-3350" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60628-87750011000036101-1"><fragment id="60628-87750011000036101-1"><block label="DrugName">MACROGOL-3350<inline label="genericindexfield">XE "MACROGOL-3350"</inline></block></fragment></section><section id="60628-d5469e26"><fragment id="60628-d5469e26"><block label="NoteText"><para>Pharmaceutical benefits that have the form macrogol-3350 1 g/g oral liquid: powder for, 510 g and pharmaceutical benefits that have the form macrogol-3350 1 g/g oral liquid: powder for, 30 x 17 g sachets are equivalent for the purposes of substitution.</para></block></fragment></section><section id="60628-d5469e16"><fragment id="60628-d5469e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">6170</block><block label="RestrictionText"><para>Constipation</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care.</para></item></list></block></fragment></section><section id="60628-2351R"><fragment id="60628-2351R"><block label="FormAndStrength">macrogol-3350 1 g/g oral liquid: powder for, 30 x 17 g sachets</block><table role="PL"><row><cell><block label="DrugItemCode">2351R<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>26.23</block></cell><cell><block label="MRVSN">27.44</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Herron ClearLax [ON]<inline label="genericindexfieldbrand"><italic>XE "Herron ClearLax(ON)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60628-5426N"><fragment id="60628-5426N"><block label="FormAndStrength">macrogol-3350 1 g/g powder for oral liquid, 510 g</block><table role="PL"><row><cell><block label="DrugItemCode">5426N<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>26.23</block></cell><cell><block label="MRVSN">27.44</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">OsmoLax [KY]<inline label="genericindexfieldbrand"><italic>XE "OsmoLax(KY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59571-A06AD32631011000036109"><xref-fragment id="59571-A06AD32631011000036109"><blockxref id="104895" title="MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE" frag="default" reversefrag="A06AD32631011000036109" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="60590" href="dynamic/PL/drug/32631011000036109-A06AD.psml" urititle="MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60590" schemaversion="0.12" date="2018-06-15T10:34:18+10:00" version="current" level="processed"><documentinfo><uri id="60590" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/32631011000036109-A06AD.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/32631011000036109-A06AD.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:29+10:00" modified="2018-06-15T10:34:18+10:00" title="MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE"><displaytitle>MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE</displaytitle></uri><reversexrefs><reversexref uriid="59571" href="dynamic/PL/atc/A.psml" frag="A06AD32631011000036109" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="104895" title="PL" type="none" forwardtype="embed" forwardtitle="MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60590-32631011000036109-1"><fragment id="60590-32631011000036109-1"><block label="DrugName">MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE<inline label="genericindexfield">XE "MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE"</inline></block></fragment></section><section id="60590-d5471e16"><fragment id="60590-d5471e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">6171</block><block label="RestrictionText"><para>Constipation</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care.</para></item></list></block></fragment></section><section id="60590-10127B"><fragment id="60590-10127B"><block label="FormAndStrength">macrogol-3350 13.12 g/25 mL + sodium chloride 350.7 mg/25 mL + potassium chloride 46.6 mg/25 mL (0.63 mmol/25 mL potassium) + sodium bicarbonate 178.5 mg/25 mL oral liquid, 500 mL</block><table role="PL"><row><cell><block label="DrugItemCode">10127B<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>21.17</block></cell><cell><block label="MRVSN">22.38</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Movicol Liquid [NE]<inline label="genericindexfieldbrand"><italic>XE "Movicol Liquid(NE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60590-5389P"><fragment id="60590-5389P"><block label="FormAndStrength">macrogol-3350 13.12 g + sodium chloride 350.7 mg + potassium chloride 46.6 mg (0.63 mmol potassium) + sodium bicarbonate 178.5 mg solution, 30 sachets</block><table role="PL"><row><cell><block label="DrugItemCode">5389P<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>26.23</block></cell><cell><block label="MRVSN">27.44</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-MACROGOL plus ELECTROLYTES [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-MACROGOL plus ELECTROLYTES(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Chemists' Own Macrogol with Electrolytes [RW]<inline label="genericindexfieldbrand"><italic>XE "Chemists' Own Macrogol with Electrolytes (RW)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">LaxaCon [EA]<inline label="genericindexfieldbrand"><italic>XE "LaxaCon(EA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">lax-sachets [AE]<inline label="genericindexfieldbrand"><italic>XE "lax-sachets (AE)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Macrovic [RF]<inline label="genericindexfieldbrand"><italic>XE "Macrovic(RF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Molaxole [GO]<inline label="genericindexfieldbrand"><italic>XE "Molaxole (GO)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Movicol [NE]<inline label="genericindexfieldbrand"><italic>XE "Movicol(NE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59571-A06AG"><fragment id="59571-A06AG"><block label="ATCLevel4"><para>Enemas</para></block></fragment></section><section id="59571-A06AG21264011000036101"><xref-fragment id="59571-A06AG21264011000036101"><blockxref id="104900" title="BISACODYL" frag="default" reversefrag="A06AG21264011000036101" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="60495" href="dynamic/PL/drug/21264011000036101-A06AG.psml" urititle="BISACODYL" mediatype="application/vnd.pageseeder.psml+xml"><document id="60495" schemaversion="0.12" date="2018-06-15T10:34:18+10:00" version="current" level="processed"><documentinfo><uri id="60495" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/21264011000036101-A06AG.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/21264011000036101-A06AG.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:18+10:00" title="BISACODYL"><displaytitle>BISACODYL</displaytitle></uri><reversexrefs><reversexref uriid="59571" href="dynamic/PL/atc/A.psml" frag="A06AG21264011000036101" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="104900" title="PL" type="none" forwardtype="embed" forwardtitle="BISACODYL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60495-21264011000036101-1"><fragment id="60495-21264011000036101-1"><block label="DrugName">BISACODYL<inline label="genericindexfield">XE "BISACODYL:.Palliative Care"</inline></block></fragment></section><section id="60495-d5473e16"><fragment id="60495-d5473e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Constipation</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care.</para></item></list></block></fragment></section><section id="60495-5302C"><fragment id="60495-5302C"><block label="FormAndStrength">bisacodyl 10 mg/5 mL enema, 25 x 5 mL</block><table role="PL"><row><cell><block label="DrugItemCode">5302C<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">38.50</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Bisalax [AS]<inline label="genericindexfieldbrand"><italic>XE "Bisalax(AS)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59571-A06AG21630011000036102"><xref-fragment id="59571-A06AG21630011000036102"><blockxref id="104896" title="CITRIC ACID + LAURYL SULFOACETATE SODIUM + SORBITOL" frag="default" reversefrag="A06AG21630011000036102" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="60140" href="dynamic/PL/drug/21630011000036102-A06AG.psml" urititle="CITRIC ACID + LAURYL SULFOACETATE SODIUM + SORBITOL" mediatype="application/vnd.pageseeder.psml+xml"><document id="60140" schemaversion="0.12" date="2018-06-15T10:34:18+10:00" version="current" level="processed"><documentinfo><uri id="60140" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/21630011000036102-A06AG.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/21630011000036102-A06AG.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:25+10:00" modified="2018-06-15T10:34:18+10:00" title="CITRIC ACID + LAURYL SULFOACETATE SODIUM + SORBITOL"><displaytitle>CITRIC ACID + LAURYL SULFOACETATE SODIUM + SORBITOL</displaytitle></uri><reversexrefs><reversexref uriid="59571" href="dynamic/PL/atc/A.psml" frag="A06AG21630011000036102" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="104896" title="PL" type="none" forwardtype="embed" forwardtitle="CITRIC ACID + LAURYL SULFOACETATE SODIUM + SORBITOL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60140-21630011000036102-1"><fragment id="60140-21630011000036102-1"><block label="DrugName">CITRIC ACID + LAURYL SULFOACETATE SODIUM + SORBITOL<inline label="genericindexfield">XE "CITRIC ACID + LAURYL SULFOACETATE SODIUM + SORBITOL"</inline></block></fragment></section><section id="60140-d5475e16"><fragment id="60140-d5475e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Constipation</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care.</para></item></list></block></fragment></section><section id="60140-5331N"><fragment id="60140-5331N"><block label="FormAndStrength">sodium citrate dihydrate 450 mg/5 mL + lauryl sulfoacetate sodium 45 mg/5 mL + sorbitol 3.125 g/5 mL enema, 12 x 5 mL</block><table role="PL"><row><cell><block label="DrugItemCode">5331N<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>29.35</block></cell><cell><block label="MRVSN">30.56</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Micolette [AE]<inline label="genericindexfieldbrand"><italic>XE "Micolette(AE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59571-A06AH"><fragment id="59571-A06AH"><block label="ATCLevel4"><para>Peripheral opioid receptor antagonists</para></block></fragment></section><section id="59571-A06AH79730011000036107"><xref-fragment id="59571-A06AH79730011000036107"><blockxref id="104901" title="METHYLNALTREXONE" frag="default" reversefrag="A06AH79730011000036107" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="60893" href="dynamic/PL/drug/79730011000036107-A06AH.psml" urititle="METHYLNALTREXONE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60893" schemaversion="0.12" date="2018-06-15T10:34:18+10:00" version="current" level="processed"><documentinfo><uri id="60893" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/79730011000036107-A06AH.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/79730011000036107-A06AH.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:33+10:00" modified="2018-06-15T10:34:18+10:00" title="METHYLNALTREXONE"><displaytitle>METHYLNALTREXONE</displaytitle></uri><reversexrefs><reversexref uriid="59571" href="dynamic/PL/atc/A.psml" frag="A06AH79730011000036107" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="104901" title="PL" type="none" forwardtype="embed" forwardtitle="METHYLNALTREXONE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60893-79730011000036107-1"><fragment id="60893-79730011000036107-1"><block label="DrugName">METHYLNALTREXONE<inline label="genericindexfield">XE "METHYLNALTREXONE"</inline></block></fragment></section><section id="60893-d5477e16"><fragment id="60893-d5477e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">6180</block><block label="RestrictionText"><para>Opioid-induced constipation</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be in combination with oral laxatives,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be receiving palliative care,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have failed to respond to laxatives.</para></item></list></block></fragment></section><section id="60893-5424L"><fragment id="60893-5424L"><block label="FormAndStrength">METHYLNALTREXONE Solution for injection containing methylnaltrexone bromide 12 mg in 0.6 mL, 7</block><table role="PL"><row><cell><block label="DrugItemCode">5424L<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">263.80</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Relistor [LM]<inline label="genericindexfieldbrand"><italic>XE "Relistor(LM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60893-5423K"><fragment id="60893-5423K"><block label="FormAndStrength">methylnaltrexone bromide 12 mg/0.6 mL injection, 0.6 mL vial</block><table role="PL"><row><cell><block label="DrugItemCode">5423K<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">7</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>263.77</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Relistor [LM]<inline label="genericindexfieldbrand"><italic>XE "Relistor(LM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref><blockxref id="107865" title="MUSCULO-SKELETAL SYSTEM" frag="default" reversefrag="d114e887392" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="60534" href="dynamic/PL/atc/M.psml" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml"><document id="60534" schemaversion="0.12" date="2018-06-15T10:34:33+10:00" version="current" level="processed"><documentinfo><uri id="60534" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/atc/M.psml" decodedpath="/ps/test/local3/books/dynamic/PL/atc/M.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:29+10:00" modified="2018-06-15T10:34:33+10:00" title="MUSCULO-SKELETAL SYSTEM"><displaytitle>MUSCULO-SKELETAL SYSTEM</displaytitle></uri><reversexrefs><reversexref uriid="60476" href="dynamic/PL/therapeuticindex-PL.psml" frag="2" urititle="Therapeutic Index - Palliative Care - PL" mediatype="application/vnd.pageseeder.psml+xml" id="106791" title="Untitled" type="none" forwardtype="none" forwardtitle="MUSCULO-SKELETAL SYSTEM" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60920" href="dynamic/PL.psml" frag="d114e887392" urititle="Palliative Care" mediatype="application/vnd.pageseeder.psml+xml" id="107865" title="PL" type="none" forwardtype="embed" forwardtitle="MUSCULO-SKELETAL SYSTEM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="43877" fragment="60534-M01A"><reversexrefs><reversexref uriid="60476" href="dynamic/PL/therapeuticindex-PL.psml" frag="2" urititle="Therapeutic Index - Palliative Care - PL" mediatype="application/vnd.pageseeder.psml+xml" id="106793" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS" forwarddisplay="document" forwardfrag="M01A"></reversexref></reversexrefs></locator><locator id="44176" fragment="60534-M01AE21304011000036105" editid="107101" modified="2018-06-15T10:34:29+10:00"></locator><locator id="43876" fragment="60534-M01"><reversexrefs><reversexref uriid="60476" href="dynamic/PL/therapeuticindex-PL.psml" frag="2" urititle="Therapeutic Index - Palliative Care - PL" mediatype="application/vnd.pageseeder.psml+xml" id="106792" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS" forwarddisplay="document" forwardfrag="M01"></reversexref></reversexrefs></locator><locator id="44174" fragment="60534-M01AB21288011000036105" editid="107100" modified="2018-06-15T10:34:29+10:00"></locator><locator id="44178" fragment="60534-M01AB21301011000036107" editid="107102" modified="2018-06-15T10:34:29+10:00"></locator><locator id="44172" fragment="60534-M01AE21885011000036105" editid="107099" modified="2018-06-15T10:34:29+10:00"></locator></fragmentinfo><metadata></metadata><section id="60534-M"><fragment id="60534-M"><block label="ATCLevel1"><para>MUSCULO-SKELETAL SYSTEM</para></block></fragment></section><section id="60534-M01"><fragment id="60534-M01"><block label="ATCLevel2"><para>ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS</para></block></fragment></section><section id="60534-M01A"><fragment id="60534-M01A"><block label="ATCLevel3"><para>ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS</para></block></fragment></section><section id="60534-M01AB"><fragment id="60534-M01AB"><block label="ATCLevel4"><para>Acetic acid derivatives and related substances</para></block></fragment></section><section id="60534-M01AB21288011000036105"><xref-fragment id="60534-M01AB21288011000036105"><blockxref id="107096" title="DICLOFENAC" frag="default" reversefrag="M01AB21288011000036105" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="60059" href="dynamic/PL/drug/21288011000036105-M01AB.psml" urititle="DICLOFENAC" mediatype="application/vnd.pageseeder.psml+xml"><document id="60059" schemaversion="0.12" date="2018-06-15T10:34:29+10:00" version="current" level="processed"><documentinfo><uri id="60059" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/21288011000036105-M01AB.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/21288011000036105-M01AB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:24+10:00" modified="2018-06-15T10:34:29+10:00" title="DICLOFENAC"><displaytitle>DICLOFENAC</displaytitle></uri><reversexrefs><reversexref uriid="60534" href="dynamic/PL/atc/M.psml" frag="M01AB21288011000036105" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107096" title="PL" type="none" forwardtype="embed" forwardtitle="DICLOFENAC" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60059-21288011000036105-1"><fragment id="60059-21288011000036105-1"><block label="DrugName">DICLOFENAC<inline label="genericindexfield">XE "DICLOFENAC:.Palliative Care"</inline></block></fragment></section><section id="60059-d5479e16"><fragment id="60059-d5479e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Severe pain</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care.</para></item></list></block></fragment></section><section id="60059-5362F"><fragment id="60059-5362F"><block label="FormAndStrength">diclofenac sodium 50 mg enteric tablet, 50</block><table role="PL"><row><cell><block label="DrugItemCode">5362F<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">13.14</block></cell><cell><block label="MRVSN">14.35</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Diclofenac [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Diclofenac(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Clonac 50 [RW]<inline label="genericindexfieldbrand"><italic>XE "Clonac 50 (RW)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Diclofenac Amneal [ED]<inline label="genericindexfieldbrand"><italic>XE "Diclofenac Amneal(ED)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Diclofenac AN [EA]<inline label="genericindexfieldbrand"><italic>XE "Diclofenac AN (EA)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Diclofenac Sandoz [SZ]<inline label="genericindexfieldbrand"><italic>XE "Diclofenac Sandoz(SZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Fenac [AF]<inline label="genericindexfieldbrand"><italic>XE "Fenac (AF)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Pharmacor Diclofenac 50 [CR]<inline label="genericindexfieldbrand"><italic>XE "Pharmacor Diclofenac 50(CR)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium"><inline label="BrandPricePremium"><sup>B</sup>3.46
</inline></block></cell><cell><block label="DPMQ">16.60</block></cell><cell><block label="MRVSN">14.35</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Voltaren 50 [NV]<inline label="genericindexfieldbrand"><italic>XE "Voltaren 50(NV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60059-5361E"><fragment id="60059-5361E"><block label="FormAndStrength">diclofenac sodium 25 mg enteric tablet, 50</block><table role="PL"><row><cell><block label="DrugItemCode">5361E<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>14.03</block></cell><cell><block label="MRVSN">15.24</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Diclofenac [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Diclofenac(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Clonac 25 [RW]<inline label="genericindexfieldbrand"><italic>XE "Clonac 25 (RW)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Diclofenac Amneal [ED]<inline label="genericindexfieldbrand"><italic>XE "Diclofenac Amneal(ED)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Diclofenac AN [EA]<inline label="genericindexfieldbrand"><italic>XE "Diclofenac AN (EA)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Diclofenac Sandoz [SZ]<inline label="genericindexfieldbrand"><italic>XE "Diclofenac Sandoz(SZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Fenac 25 [AF]<inline label="genericindexfieldbrand"><italic>XE "Fenac 25 (AF)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium"><inline label="BrandPricePremium"><sup>B</sup>3.44
</inline></block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>17.47</block></cell><cell><block label="MRVSN">15.24</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Voltaren 25 [NV]<inline label="genericindexfieldbrand"><italic>XE "Voltaren 25(NV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60059-5363G"><fragment id="60059-5363G"><block label="FormAndStrength">diclofenac sodium 100 mg suppository, 20</block><table role="PL"><row><cell><block label="DrugItemCode">5363G<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>27.51</block></cell><cell><block label="MRVSN">28.72</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Voltaren 100 [NV]<inline label="genericindexfieldbrand"><italic>XE "Voltaren 100(NV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60534-M01AB21301011000036107"><xref-fragment id="60534-M01AB21301011000036107"><blockxref id="107098" title="INDOMETACIN" frag="default" reversefrag="M01AB21301011000036107" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="60243" href="dynamic/PL/drug/21301011000036107-M01AB.psml" urititle="INDOMETACIN" mediatype="application/vnd.pageseeder.psml+xml"><document id="60243" schemaversion="0.12" date="2018-06-15T10:34:29+10:00" version="current" level="processed"><documentinfo><uri id="60243" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/21301011000036107-M01AB.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/21301011000036107-M01AB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:26+10:00" modified="2018-06-15T10:34:29+10:00" title="INDOMETACIN"><displaytitle>INDOMETACIN</displaytitle></uri><reversexrefs><reversexref uriid="60534" href="dynamic/PL/atc/M.psml" frag="M01AB21301011000036107" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107098" title="PL" type="none" forwardtype="embed" forwardtitle="INDOMETACIN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60243-21301011000036107-1"><fragment id="60243-21301011000036107-1"><block label="DrugName">INDOMETACIN<inline label="genericindexfield">XE "INDOMETACIN"</inline></block></fragment></section><section id="60243-d5481e16"><fragment id="60243-d5481e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Severe pain</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care.</para></item></list></block></fragment></section><section id="60243-5378C"><fragment id="60243-5378C"><block label="FormAndStrength">indometacin 100 mg suppository, 20</block><table role="PL"><row><cell><block label="DrugItemCode">5378C<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>25.07</block></cell><cell><block label="MRVSN">26.28</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Indocid [AS]<inline label="genericindexfieldbrand"><italic>XE "Indocid(AS)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60243-5377B"><fragment id="60243-5377B"><block label="FormAndStrength">indometacin 25 mg capsule, 50</block><table role="PL"><row><cell><block label="DrugItemCode">5377B<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>16.69</block></cell><cell><block label="MRVSN">17.90</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Arthrexin [AF]<inline label="genericindexfieldbrand"><italic>XE "Arthrexin(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium"><inline label="BrandPricePremium"><sup>B</sup>4.04
</inline></block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>20.73</block></cell><cell><block label="MRVSN">17.90</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Indocid [AS]<inline label="genericindexfieldbrand"><italic>XE "Indocid(AS)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60534-M01AE"><fragment id="60534-M01AE"><block label="ATCLevel4"><para>Propionic acid derivatives</para></block></fragment></section><section id="60534-M01AE21885011000036105"><xref-fragment id="60534-M01AE21885011000036105"><blockxref id="107095" title="IBUPROFEN" frag="default" reversefrag="M01AE21885011000036105" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="60720" href="dynamic/PL/drug/21885011000036105-M01AE.psml" urititle="IBUPROFEN" mediatype="application/vnd.pageseeder.psml+xml"><document id="60720" schemaversion="0.12" date="2018-06-15T10:34:29+10:00" version="current" level="processed"><documentinfo><uri id="60720" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/21885011000036105-M01AE.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/21885011000036105-M01AE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:31+10:00" modified="2018-06-15T10:34:29+10:00" title="IBUPROFEN"><displaytitle>IBUPROFEN</displaytitle></uri><reversexrefs><reversexref uriid="60534" href="dynamic/PL/atc/M.psml" frag="M01AE21885011000036105" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107095" title="PL" type="none" forwardtype="embed" forwardtitle="IBUPROFEN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60720-21885011000036105-1"><fragment id="60720-21885011000036105-1"><block label="DrugName">IBUPROFEN<inline label="genericindexfield">XE "IBUPROFEN"</inline></block></fragment></section><section id="60720-d5483e16"><fragment id="60720-d5483e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Severe pain</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care.</para></item></list></block></fragment></section><section id="60720-5368M"><fragment id="60720-5368M"><block label="FormAndStrength">ibuprofen 400 mg tablet, 30</block><table role="PL"><row><cell><block label="DrugItemCode">5368M<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>16.84</block></cell><cell><block label="MRVSN">18.05</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Ibuprofen 400 [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Ibuprofen 400(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Brufen [GO]<inline label="genericindexfieldbrand"><italic>XE "Brufen (GO)" \i </italic></inline></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60534-M01AE21304011000036105"><xref-fragment id="60534-M01AE21304011000036105"><blockxref id="107097" title="NAPROXEN" frag="default" reversefrag="M01AE21304011000036105" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="60777" href="dynamic/PL/drug/21304011000036105-M01AE.psml" urititle="NAPROXEN" mediatype="application/vnd.pageseeder.psml+xml"><document id="60777" schemaversion="0.12" date="2018-06-15T10:34:29+10:00" version="current" level="processed"><documentinfo><uri id="60777" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/21304011000036105-M01AE.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/21304011000036105-M01AE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:31+10:00" modified="2018-06-15T10:34:29+10:00" title="NAPROXEN"><displaytitle>NAPROXEN</displaytitle></uri><reversexrefs><reversexref uriid="60534" href="dynamic/PL/atc/M.psml" frag="M01AE21304011000036105" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107097" title="PL" type="none" forwardtype="embed" forwardtitle="NAPROXEN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60777-21304011000036105-1"><fragment id="60777-21304011000036105-1"><block label="DrugName">NAPROXEN<inline label="genericindexfield">XE "NAPROXEN"</inline></block></fragment></section><section id="60777-d5485e16"><fragment id="60777-d5485e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Severe pain</para><para><bold>Treatment criteria:</bold></para><list><item><para>Patient must be undergoing palliative care.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be unable to take a solid dose form of a non-steroidal anti-inflammatory agent.</para></item></list></block></fragment></section><section id="60777-5397C"><fragment id="60777-5397C"><block label="FormAndStrength">naproxen 125 mg/5 mL oral liquid, 474 mL</block><table role="PL"><row><cell><block label="DrugItemCode">5397C<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">121.27</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Phebra Naproxen Suspension [PL]<inline label="genericindexfieldbrand"><italic>XE "Phebra Naproxen Suspension(PL)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60777-21304011000036105-2"><fragment id="60777-21304011000036105-2"><block label="DrugName">NAPROXEN<inline label="genericindexfield">XE "NAPROXEN"</inline></block></fragment></section><section id="60777-d5487e16"><fragment id="60777-d5487e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Severe pain</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care.</para></item></list></block></fragment></section><section id="60777-5346J"><fragment id="60777-5346J"><block label="FormAndStrength">naproxen 500 mg tablet, 50</block><table role="PL"><row><cell><block label="DrugItemCode">5346J<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">16.46</block></cell><cell><block label="MRVSN">17.67</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Inza 500 [AF]<inline label="genericindexfieldbrand"><italic>XE "Inza 500(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium"><inline label="BrandPricePremium"><sup>B</sup>1.12
</inline></block></cell><cell><block label="DPMQ">17.58</block></cell><cell><block label="MRVSN">17.67</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Naprosyn [IX]<inline label="genericindexfieldbrand"><italic>XE "Naprosyn(IX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60777-5347K"><fragment id="60777-5347K"><block label="FormAndStrength">naproxen 750 mg modified release tablet, 28</block><table role="PL"><row><cell><block label="DrugItemCode">5347K<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">16.01</block></cell><cell><block label="MRVSN">17.22</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Proxen SR 750 [IY]<inline label="genericindexfieldbrand"><italic>XE "Proxen SR 750(IY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium"><inline label="BrandPricePremium"><sup>B</sup>1.06
</inline></block></cell><cell><block label="DPMQ">17.07</block></cell><cell><block label="MRVSN">17.22</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Naprosyn SR750 [IX]<inline label="genericindexfieldbrand"><italic>XE "Naprosyn SR750(IX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60777-5345H"><fragment id="60777-5345H"><block label="FormAndStrength">naproxen 250 mg tablet, 50</block><table role="PL"><row><cell><block label="DrugItemCode">5345H<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>18.35</block></cell><cell><block label="MRVSN">19.56</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Inza 250 [AF]<inline label="genericindexfieldbrand"><italic>XE "Inza 250(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium"><inline label="BrandPricePremium"><sup>B</sup>2.24
</inline></block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>20.59</block></cell><cell><block label="MRVSN">19.56</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Naprosyn [IX]<inline label="genericindexfieldbrand"><italic>XE "Naprosyn(IX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60777-5348L"><fragment id="60777-5348L"><block label="FormAndStrength">naproxen 1 g modified release tablet, 28</block><table role="PL"><row><cell><block label="DrugItemCode">5348L<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.65</block></cell><cell><block label="MRVSN">18.86</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Proxen SR 1000 [IY]<inline label="genericindexfieldbrand"><italic>XE "Proxen SR 1000(IY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium"><inline label="BrandPricePremium"><sup>B</sup>1.12
</inline></block></cell><cell><block label="DPMQ">18.77</block></cell><cell><block label="MRVSN">18.86</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Naprosyn SR1000 [IX]<inline label="genericindexfieldbrand"><italic>XE "Naprosyn SR1000(IX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60777-21304011000036105-3"><fragment id="60777-21304011000036105-3"><block label="DrugName">NAPROXEN<inline label="genericindexfield">XE "NAPROXEN"</inline></block></fragment></section><section id="60777-d5489e26"><fragment id="60777-d5489e26"><block label="NoteText"><para>Naproxen sodium 550 mg is approximately equivalent to 500 mg of naproxen acid.</para></block></fragment></section><section id="60777-d5489e16"><fragment id="60777-d5489e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Severe pain</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care.</para></item></list></block></fragment></section><section id="60777-5353R"><fragment id="60777-5353R"><block label="FormAndStrength">naproxen sodium 550 mg tablet, 50</block><table role="PL"><row><cell><block label="DrugItemCode">5353R<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">16.61</block></cell><cell><block label="MRVSN">17.82</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Crysanal [IY]<inline label="genericindexfieldbrand"><italic>XE "Crysanal(IY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium"><inline label="BrandPricePremium"><sup>B</sup>1.89
</inline></block></cell><cell><block label="DPMQ">18.50</block></cell><cell><block label="MRVSN">17.82</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Anaprox 550 [IX]<inline label="genericindexfieldbrand"><italic>XE "Anaprox 550(IX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref><blockxref id="107866" title="NERVOUS SYSTEM" frag="default" reversefrag="d114e887392" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="60709" href="dynamic/PL/atc/N.psml" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml"><document id="60709" schemaversion="0.12" date="2018-06-15T10:34:33+10:00" version="current" level="processed"><documentinfo><uri id="60709" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/atc/N.psml" decodedpath="/ps/test/local3/books/dynamic/PL/atc/N.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:31+10:00" modified="2018-06-15T10:34:33+10:00" title="NERVOUS SYSTEM"><displaytitle>NERVOUS SYSTEM</displaytitle></uri><reversexrefs><reversexref uriid="60476" href="dynamic/PL/therapeuticindex-PL.psml" frag="2" urititle="Therapeutic Index - Palliative Care - PL" mediatype="application/vnd.pageseeder.psml+xml" id="106794" title="Untitled" type="none" forwardtype="none" forwardtitle="NERVOUS SYSTEM" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60920" href="dynamic/PL.psml" frag="d114e887392" urititle="Palliative Care" mediatype="application/vnd.pageseeder.psml+xml" id="107866" title="PL" type="none" forwardtype="embed" forwardtitle="NERVOUS SYSTEM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="43882" fragment="60709-N03"><reversexrefs><reversexref uriid="60476" href="dynamic/PL/therapeuticindex-PL.psml" frag="2" urititle="Therapeutic Index - Palliative Care - PL" mediatype="application/vnd.pageseeder.psml+xml" id="106798" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIEPILEPTICS" forwarddisplay="document" forwardfrag="N03"></reversexref></reversexrefs></locator><locator id="44302" fragment="60709-N02AA21252011000036100" editid="107231" modified="2018-06-15T10:34:31+10:00"></locator><locator id="44294" fragment="60709-N02BE21433011000036107" editid="107227" modified="2018-06-15T10:34:31+10:00"></locator><locator id="44290" fragment="60709-N05CD21647011000036102" editid="107225" modified="2018-06-15T10:34:31+10:00"></locator><locator id="44304" fragment="60709-N02AC21357011000036109" editid="107232" modified="2018-06-15T10:34:31+10:00"></locator><locator id="43879" fragment="60709-N02"><reversexrefs><reversexref uriid="60476" href="dynamic/PL/therapeuticindex-PL.psml" frag="2" urititle="Therapeutic Index - Palliative Care - PL" mediatype="application/vnd.pageseeder.psml+xml" id="106795" title="Untitled" type="none" forwardtype="none" forwardtitle="ANALGESICS" forwarddisplay="document" forwardfrag="N02"></reversexref></reversexrefs></locator><locator id="43886" fragment="60709-N05C"><reversexrefs><reversexref uriid="60476" href="dynamic/PL/therapeuticindex-PL.psml" frag="2" urititle="Therapeutic Index - Palliative Care - PL" mediatype="application/vnd.pageseeder.psml+xml" id="106802" title="Untitled" type="none" forwardtype="none" forwardtitle="HYPNOTICS AND SEDATIVES" forwarddisplay="document" forwardfrag="N05C"></reversexref></reversexrefs></locator><locator id="43884" fragment="60709-N05"><reversexrefs><reversexref uriid="60476" href="dynamic/PL/therapeuticindex-PL.psml" frag="2" urititle="Therapeutic Index - Palliative Care - PL" mediatype="application/vnd.pageseeder.psml+xml" id="106800" title="Untitled" type="none" forwardtype="none" forwardtitle="PSYCHOLEPTICS" forwarddisplay="document" forwardfrag="N05"></reversexref></reversexrefs></locator><locator id="44308" fragment="60709-N05CD21825011000036102" editid="107234" modified="2018-06-15T10:34:31+10:00"></locator><locator id="44296" fragment="60709-N05BA21541011000036102" editid="107228" modified="2018-06-15T10:34:31+10:00"></locator><locator id="44292" fragment="60709-N05BA21688011000036107" editid="107226" modified="2018-06-15T10:34:31+10:00"></locator><locator id="43885" fragment="60709-N05B"><reversexrefs><reversexref uriid="60476" href="dynamic/PL/therapeuticindex-PL.psml" frag="2" urititle="Therapeutic Index - Palliative Care - PL" mediatype="application/vnd.pageseeder.psml+xml" id="106801" title="Untitled" type="none" forwardtype="none" forwardtitle="ANXIOLYTICS" forwarddisplay="document" forwardfrag="N05B"></reversexref></reversexrefs></locator><locator id="43883" fragment="60709-N03A"><reversexrefs><reversexref uriid="60476" href="dynamic/PL/therapeuticindex-PL.psml" frag="2" urititle="Therapeutic Index - Palliative Care - PL" mediatype="application/vnd.pageseeder.psml+xml" id="106799" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIEPILEPTICS" forwarddisplay="document" forwardfrag="N03A"></reversexref></reversexrefs></locator><locator id="44306" fragment="60709-N03AE21226011000036100" editid="107233" modified="2018-06-15T10:34:31+10:00"></locator><locator id="43880" fragment="60709-N02A"><reversexrefs><reversexref uriid="60476" href="dynamic/PL/therapeuticindex-PL.psml" frag="2" urititle="Therapeutic Index - Palliative Care - PL" mediatype="application/vnd.pageseeder.psml+xml" id="106796" title="Untitled" type="none" forwardtype="none" forwardtitle="OPIOIDS" forwarddisplay="document" forwardfrag="N02A"></reversexref></reversexrefs></locator><locator id="43881" fragment="60709-N02B"><reversexrefs><reversexref uriid="60476" href="dynamic/PL/therapeuticindex-PL.psml" frag="2" urititle="Therapeutic Index - Palliative Care - PL" mediatype="application/vnd.pageseeder.psml+xml" id="106797" title="Untitled" type="none" forwardtype="none" forwardtitle="OTHER ANALGESICS AND ANTIPYRETICS" forwarddisplay="document" forwardfrag="N02B"></reversexref></reversexrefs></locator><locator id="44300" fragment="60709-N02AB21258011000036102" editid="107230" modified="2018-06-15T10:34:31+10:00"></locator><locator id="44298" fragment="60709-N02AE21232011000036101" editid="107229" modified="2018-06-15T10:34:31+10:00"></locator></fragmentinfo><metadata></metadata><section id="60709-N"><fragment id="60709-N"><block label="ATCLevel1"><para>NERVOUS SYSTEM</para></block></fragment></section><section id="60709-N02"><fragment id="60709-N02"><block label="ATCLevel2"><para>ANALGESICS</para></block></fragment></section><section id="60709-N02A"><fragment id="60709-N02A"><block label="ATCLevel3"><para>OPIOIDS</para></block></fragment></section><section id="60709-N02AA"><fragment id="60709-N02AA"><block label="ATCLevel4"><para>Natural opium alkaloids</para></block></fragment></section><section id="60709-N02AA21252011000036100"><xref-fragment id="60709-N02AA21252011000036100"><blockxref id="107221" title="MORPHINE" frag="default" reversefrag="N02AA21252011000036100" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="60186" href="dynamic/PL/drug/21252011000036100-N02AA.psml" urititle="MORPHINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60186" schemaversion="0.12" date="2018-06-15T10:34:31+10:00" version="current" level="processed"><documentinfo><uri id="60186" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/21252011000036100-N02AA.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/21252011000036100-N02AA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:25+10:00" modified="2018-06-15T10:34:31+10:00" title="MORPHINE"><displaytitle>MORPHINE</displaytitle></uri><reversexrefs><reversexref uriid="60709" href="dynamic/PL/atc/N.psml" frag="N02AA21252011000036100" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107221" title="PL" type="none" forwardtype="embed" forwardtitle="MORPHINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60186-21252011000036100-1"><fragment id="60186-21252011000036100-1"><block label="DrugName">MORPHINE<inline label="genericindexfield">XE "MORPHINE"</inline></block></fragment></section><section id="60186-d5491e15"><fragment id="60186-d5491e15"><block label="CautionText"><para>The risk of drug dependence is high.</para></block></fragment></section><section id="60186-d5491e36"><fragment id="60186-d5491e36"><block label="NoteText"><para>Telephone approvals are limited to 1 month's therapy.</para></block></fragment></section><section id="60186-d5491e19"><fragment id="60186-d5491e19"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Chronic severe disabling pain</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care,</para></item></list><para><bold>AND</bold></para><list><item><para>The condition must be unresponsive to non-opioid analgesics.</para></item></list></block></fragment></section><section id="60186-5391R"><fragment id="60186-5391R"><block label="FormAndStrength">morphine sulfate pentahydrate 200 mg modified release tablet, 28</block><table role="PL"><row><cell><block label="DrugItemCode">5391R<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">116.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">MS Contin [MF]<inline label="genericindexfieldbrand"><italic>XE "MS Contin(MF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60186-21252011000036100-2"><fragment id="60186-21252011000036100-2"><block label="DrugName">MORPHINE<inline label="genericindexfield">XE "MORPHINE"</inline></block></fragment></section><section id="60186-d5493e15"><fragment id="60186-d5493e15"><block label="CautionText"><para>The risk of drug dependence is high.</para></block></fragment></section><section id="60186-d5493e36"><fragment id="60186-d5493e36"><block label="NoteText"><para>Telephone approvals are limited to 1 month's therapy.</para></block></fragment></section><section id="60186-d5493e19"><fragment id="60186-d5493e19"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Severe disabling pain</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care,</para></item></list><para><bold>AND</bold></para><list><item><para>The condition must be unresponsive to non-opioid analgesics.</para></item></list></block></fragment></section><section id="60186-5393W"><fragment id="60186-5393W"><block label="FormAndStrength">morphine sulfate pentahydrate 10 mg tablet, 20</block><table role="PL"><row><cell><block label="DrugItemCode">5393W<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.61</block></cell><cell><block label="MRVSN">19.82</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Sevredol [MF]<inline label="genericindexfieldbrand"><italic>XE "Sevredol(MF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60186-5394X"><fragment id="60186-5394X"><block label="FormAndStrength">morphine sulfate pentahydrate 20 mg tablet, 20</block><table role="PL"><row><cell><block label="DrugItemCode">5394X<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">19.43</block></cell><cell><block label="MRVSN">20.64</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Sevredol [MF]<inline label="genericindexfieldbrand"><italic>XE "Sevredol(MF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60709-N02AB"><fragment id="60709-N02AB"><block label="ATCLevel4"><para>Phenylpiperidine derivatives</para></block></fragment></section><section id="60709-N02AB21258011000036102"><xref-fragment id="60709-N02AB21258011000036102"><blockxref id="107220" title="FENTANYL" frag="default" reversefrag="N02AB21258011000036102" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="60643" href="dynamic/PL/drug/21258011000036102-N02AB.psml" urititle="FENTANYL" mediatype="application/vnd.pageseeder.psml+xml"><document id="60643" schemaversion="0.12" date="2018-06-15T10:34:31+10:00" version="current" level="processed"><documentinfo><uri id="60643" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/21258011000036102-N02AB.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/21258011000036102-N02AB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:30+10:00" modified="2018-06-15T10:34:31+10:00" title="FENTANYL"><displaytitle>FENTANYL</displaytitle></uri><reversexrefs><reversexref uriid="60709" href="dynamic/PL/atc/N.psml" frag="N02AB21258011000036102" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107220" title="PL" type="none" forwardtype="embed" forwardtitle="FENTANYL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60643-21258011000036102-1"><fragment id="60643-21258011000036102-1"><block label="DrugName">FENTANYL<inline label="genericindexfield">XE "FENTANYL"</inline></block></fragment></section><section id="60643-d5495e15"><fragment id="60643-d5495e15"><block label="CautionText"><para>The risk of drug dependence is high.</para></block></fragment></section><section id="60643-d5495e66"><fragment id="60643-d5495e66"><block label="NoteText"><para><bold>Shared Care Model</bold>:</para><para>For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.</para></block></fragment></section><section id="60643-d5495e73"><fragment id="60643-d5495e73"><block label="NoteText"><para>No increase in the maximum number of repeats may be authorised.</para></block></fragment></section><section id="60643-d5495e19"><fragment id="60643-d5495e19"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Breakthrough pain</para><para>Treatment Phase: Initial treatment for dose titration</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have cancer,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have pain directly attributable to cancer,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be assessed as receiving adequate management of their persistent pain with opioids,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously experienced inadequate pain relief following adequate doses of short acting opioids for the treatment of breakthrough pain; OR</para></item><item><para>The treatment must be used as short acting opioids are considered clinically inappropriate; OR</para></item><item><para>Patient must have previously experienced adverse effects following the use of short acting opioids for breakthrough pain.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Patient must be undergoing palliative care.</para></item></list></block></fragment></section><section id="60643-10604D"><fragment id="60643-10604D"><block label="FormAndStrength">fentanyl 600 microgram sublingual tablet, 10</block><table role="PL"><row><cell><block label="DrugItemCode">10604D<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">87.21</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Abstral [FK]<inline label="genericindexfieldbrand"><italic>XE "Abstral(FK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-5406M"><fragment id="60643-5406M"><block label="FormAndStrength">FENTANYL Lozenge 1600 micrograms (as citrate), 9</block><table role="PL"><row><cell><block label="DrugItemCode">5406M<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">96.35</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Actiq [TB]<inline label="genericindexfieldbrand"><italic>XE "Actiq(TB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-10603C"><fragment id="60643-10603C"><block label="FormAndStrength">fentanyl 400 microgram sublingual tablet, 10</block><table role="PL"><row><cell><block label="DrugItemCode">10603C<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">87.21</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Abstral [FK]<inline label="genericindexfieldbrand"><italic>XE "Abstral(FK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-10606F"><fragment id="60643-10606F"><block label="FormAndStrength">fentanyl 300 microgram sublingual tablet, 10</block><table role="PL"><row><cell><block label="DrugItemCode">10606F<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">87.21</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Abstral [FK]<inline label="genericindexfieldbrand"><italic>XE "Abstral(FK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-10612M"><fragment id="60643-10612M"><block label="FormAndStrength">fentanyl 800 microgram sublingual tablet, 10</block><table role="PL"><row><cell><block label="DrugItemCode">10612M<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">87.21</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Abstral [FK]<inline label="genericindexfieldbrand"><italic>XE "Abstral(FK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-10601Y"><fragment id="60643-10601Y"><block label="FormAndStrength">fentanyl 100 microgram sublingual tablet, 10</block><table role="PL"><row><cell><block label="DrugItemCode">10601Y<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>160.32</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Abstral [FK]<inline label="genericindexfieldbrand"><italic>XE "Abstral(FK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-5405L"><fragment id="60643-5405L"><block label="FormAndStrength">FENTANYL Lozenge 1200 micrograms (as citrate), 9</block><table role="PL"><row><cell><block label="DrugItemCode">5405L<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">96.35</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Actiq [TB]<inline label="genericindexfieldbrand"><italic>XE "Actiq(TB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-5402H"><fragment id="60643-5402H"><block label="FormAndStrength">FENTANYL Lozenge 400 micrograms (as citrate), 9</block><table role="PL"><row><cell><block label="DrugItemCode">5402H<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">96.35</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Actiq [TB]<inline label="genericindexfieldbrand"><italic>XE "Actiq(TB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-10600X"><fragment id="60643-10600X"><block label="FormAndStrength">fentanyl 200 microgram sublingual tablet, 10</block><table role="PL"><row><cell><block label="DrugItemCode">10600X<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>160.32</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Abstral [FK]<inline label="genericindexfieldbrand"><italic>XE "Abstral(FK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-5403J"><fragment id="60643-5403J"><block label="FormAndStrength">FENTANYL Lozenge 600 micrograms (as citrate), 9</block><table role="PL"><row><cell><block label="DrugItemCode">5403J<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">96.35</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Actiq [TB]<inline label="genericindexfieldbrand"><italic>XE "Actiq(TB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-5401G"><fragment id="60643-5401G"><block label="FormAndStrength">FENTANYL Lozenge 200 micrograms (as citrate), 9</block><table role="PL"><row><cell><block label="DrugItemCode">5401G<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">96.35</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Actiq [TB]<inline label="genericindexfieldbrand"><italic>XE "Actiq(TB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-5404K"><fragment id="60643-5404K"><block label="FormAndStrength">FENTANYL Lozenge 800 micrograms (as citrate), 9</block><table role="PL"><row><cell><block label="DrugItemCode">5404K<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">96.35</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Actiq [TB]<inline label="genericindexfieldbrand"><italic>XE "Actiq(TB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-21258011000036102-2"><fragment id="60643-21258011000036102-2"><block label="DrugName">FENTANYL<inline label="genericindexfield">XE "FENTANYL"</inline></block></fragment></section><section id="60643-d5497e15"><fragment id="60643-d5497e15"><block label="CautionText"><para>The risk of drug dependence is high.</para></block></fragment></section><section id="60643-d5497e66"><fragment id="60643-d5497e66"><block label="NoteText"><para><bold>Shared Care Model</bold>:</para><para>For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.</para></block></fragment></section><section id="60643-d5497e73"><fragment id="60643-d5497e73"><block label="NoteText"><para>No increase in the maximum number of repeats may be authorised.</para></block></fragment></section><section id="60643-d5497e19"><fragment id="60643-d5497e19"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Breakthrough pain</para><para>Treatment Phase: Initial treatment for dose titration</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have cancer,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have pain directly attributable to cancer,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be assessed as receiving adequate management of their persistent pain with opioids,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously experienced inadequate pain relief following adequate doses of short acting opioids for the treatment of breakthrough pain; OR</para></item><item><para>The treatment must be used as short acting opioids are considered clinically inappropriate; OR</para></item><item><para>Patient must have previously experienced adverse effects following the use of short acting opioids for breakthrough pain.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Patient must be undergoing palliative care.</para></item></list></block></fragment></section><section id="60643-10722H"><fragment id="60643-10722H"><block label="FormAndStrength">fentanyl 600 microgram orally disintegrating tablet, 4</block><table role="PL"><row><cell><block label="DrugItemCode">10722H<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>72.60</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Fentora [TB]<inline label="genericindexfieldbrand"><italic>XE "Fentora(TB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-10739F"><fragment id="60643-10739F"><block label="FormAndStrength">fentanyl 400 microgram orally disintegrating tablet, 4</block><table role="PL"><row><cell><block label="DrugItemCode">10739F<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>72.60</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Fentora [TB]<inline label="genericindexfieldbrand"><italic>XE "Fentora(TB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-10729Q"><fragment id="60643-10729Q"><block label="FormAndStrength">fentanyl 100 microgram orally disintegrating tablet, 4</block><table role="PL"><row><cell><block label="DrugItemCode">10729Q<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>72.60</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Fentora [TB]<inline label="genericindexfieldbrand"><italic>XE "Fentora(TB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-10697B"><fragment id="60643-10697B"><block label="FormAndStrength">fentanyl 200 microgram orally disintegrating tablet, 4</block><table role="PL"><row><cell><block label="DrugItemCode">10697B<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>72.60</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Fentora [TB]<inline label="genericindexfieldbrand"><italic>XE "Fentora(TB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-10723J"><fragment id="60643-10723J"><block label="FormAndStrength">fentanyl 800 microgram orally disintegrating tablet, 4</block><table role="PL"><row><cell><block label="DrugItemCode">10723J<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>72.60</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Fentora [TB]<inline label="genericindexfieldbrand"><italic>XE "Fentora(TB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-21258011000036102-3"><fragment id="60643-21258011000036102-3"><block label="DrugName">FENTANYL<inline label="genericindexfield">XE "FENTANYL"</inline></block></fragment></section><section id="60643-d5499e15"><fragment id="60643-d5499e15"><block label="CautionText"><para>The risk of drug dependence is high.</para></block></fragment></section><section id="60643-d5499e66"><fragment id="60643-d5499e66"><block label="NoteText"><para><bold>Shared Care Model</bold>:</para><para>For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.</para></block></fragment></section><section id="60643-d5499e73"><fragment id="60643-d5499e73"><block label="NoteText"><para>For first continuing supply, applications for increased repeats for up to 3 months' supply may be authorised.</para></block></fragment></section><section id="60643-d5499e76"><fragment id="60643-d5499e76"><block label="NoteText"><para>Where consultation with a palliative care specialist or service has occurred, applications for increased repeats for up to 3 months' supply may be authorised.</para></block></fragment></section><section id="60643-d5499e79"><fragment id="60643-d5499e79"><block label="NoteText"><para>Telephone approvals are limited to 1 months' therapy.</para></block></fragment></section><section id="60643-d5499e19"><fragment id="60643-d5499e19"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Breakthrough pain</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have cancer,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have pain directly attributable to cancer,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be assessed as receiving adequate management of their persistent pain with opioids,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously experienced inadequate pain relief following adequate doses of short acting opioids for the treatment of breakthrough pain; OR</para></item><item><para>The treatment must be used as short acting opioids are considered clinically inappropriate; OR</para></item><item><para>Patient must have previously experienced adverse effects following the use of short acting opioids for breakthrough pain.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Patient must be undergoing palliative care.</para></item></list></block></fragment></section><section id="60643-10613N"><fragment id="60643-10613N"><block label="FormAndStrength">fentanyl 600 microgram sublingual tablet, 30</block><table role="PL"><row><cell><block label="DrugItemCode">10613N<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>461.84</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Abstral [FK]<inline label="genericindexfieldbrand"><italic>XE "Abstral(FK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-5410R"><fragment id="60643-5410R"><block label="FormAndStrength">FENTANYL Lozenge 800 micrograms (as citrate), 30</block><table role="PL"><row><cell><block label="DrugItemCode">5410R<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>575.36</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Actiq [TB]<inline label="genericindexfieldbrand"><italic>XE "Actiq(TB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-5412W"><fragment id="60643-5412W"><block label="FormAndStrength">FENTANYL Lozenge 1600 micrograms (as citrate), 30</block><table role="PL"><row><cell><block label="DrugItemCode">5412W<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>575.36</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Actiq [TB]<inline label="genericindexfieldbrand"><italic>XE "Actiq(TB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-5408P"><fragment id="60643-5408P"><block label="FormAndStrength">FENTANYL Lozenge 400 micrograms (as citrate), 30</block><table role="PL"><row><cell><block label="DrugItemCode">5408P<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>575.36</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Actiq [TB]<inline label="genericindexfieldbrand"><italic>XE "Actiq(TB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-10607G"><fragment id="60643-10607G"><block label="FormAndStrength">fentanyl 200 microgram sublingual tablet, 30</block><table role="PL"><row><cell><block label="DrugItemCode">10607G<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>461.84</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Abstral [FK]<inline label="genericindexfieldbrand"><italic>XE "Abstral(FK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-10602B"><fragment id="60643-10602B"><block label="FormAndStrength">fentanyl 100 microgram sublingual tablet, 30</block><table role="PL"><row><cell><block label="DrugItemCode">10602B<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>461.84</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Abstral [FK]<inline label="genericindexfieldbrand"><italic>XE "Abstral(FK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-10608H"><fragment id="60643-10608H"><block label="FormAndStrength">fentanyl 400 microgram sublingual tablet, 30</block><table role="PL"><row><cell><block label="DrugItemCode">10608H<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>461.84</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Abstral [FK]<inline label="genericindexfieldbrand"><italic>XE "Abstral(FK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-5409Q"><fragment id="60643-5409Q"><block label="FormAndStrength">FENTANYL Lozenge 600 micrograms (as citrate), 30</block><table role="PL"><row><cell><block label="DrugItemCode">5409Q<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>575.36</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Actiq [TB]<inline label="genericindexfieldbrand"><italic>XE "Actiq(TB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-5411T"><fragment id="60643-5411T"><block label="FormAndStrength">FENTANYL Lozenge 1200 micrograms (as citrate), 30</block><table role="PL"><row><cell><block label="DrugItemCode">5411T<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>575.36</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Actiq [TB]<inline label="genericindexfieldbrand"><italic>XE "Actiq(TB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-10610K"><fragment id="60643-10610K"><block label="FormAndStrength">fentanyl 300 microgram sublingual tablet, 30</block><table role="PL"><row><cell><block label="DrugItemCode">10610K<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>461.84</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Abstral [FK]<inline label="genericindexfieldbrand"><italic>XE "Abstral(FK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-10611L"><fragment id="60643-10611L"><block label="FormAndStrength">fentanyl 800 microgram sublingual tablet, 30</block><table role="PL"><row><cell><block label="DrugItemCode">10611L<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>461.84</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Abstral [FK]<inline label="genericindexfieldbrand"><italic>XE "Abstral(FK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-5407N"><fragment id="60643-5407N"><block label="FormAndStrength">FENTANYL Lozenge 200 micrograms (as citrate), 30</block><table role="PL"><row><cell><block label="DrugItemCode">5407N<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>575.36</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Actiq [TB]<inline label="genericindexfieldbrand"><italic>XE "Actiq(TB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-21258011000036102-4"><fragment id="60643-21258011000036102-4"><block label="DrugName">FENTANYL<inline label="genericindexfield">XE "FENTANYL"</inline></block></fragment></section><section id="60643-d5501e15"><fragment id="60643-d5501e15"><block label="CautionText"><para>The risk of drug dependence is high.</para></block></fragment></section><section id="60643-d5501e66"><fragment id="60643-d5501e66"><block label="NoteText"><para><bold>Shared Care Model</bold>:</para><para>For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.</para></block></fragment></section><section id="60643-d5501e73"><fragment id="60643-d5501e73"><block label="NoteText"><para>For first continuing supply, applications for increased repeats for up to 3 months' supply may be authorised.</para></block></fragment></section><section id="60643-d5501e76"><fragment id="60643-d5501e76"><block label="NoteText"><para>Where consultation with a palliative care specialist or service has occurred, applications for increased repeats for up to 3 months' supply may be authorised.</para></block></fragment></section><section id="60643-d5501e79"><fragment id="60643-d5501e79"><block label="NoteText"><para>Telephone approvals are limited to 1 months' therapy.</para></block></fragment></section><section id="60643-d5501e19"><fragment id="60643-d5501e19"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Breakthrough pain</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have cancer,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have pain directly attributable to cancer,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be assessed as receiving adequate management of their persistent pain with opioids,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously experienced inadequate pain relief following adequate doses of short acting opioids for the treatment of breakthrough pain; OR</para></item><item><para>The treatment must be used as short acting opioids are considered clinically inappropriate; OR</para></item><item><para>Patient must have previously experienced adverse effects following the use of short acting opioids for breakthrough pain.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Patient must be undergoing palliative care.</para></item></list></block></fragment></section><section id="60643-10698C"><fragment id="60643-10698C"><block label="FormAndStrength">fentanyl 200 microgram orally disintegrating tablet, 28</block><table role="PL"><row><cell><block label="DrugItemCode">10698C<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>431.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Fentora [TB]<inline label="genericindexfieldbrand"><italic>XE "Fentora(TB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-10684H"><fragment id="60643-10684H"><block label="FormAndStrength">fentanyl 100 microgram orally disintegrating tablet, 28</block><table role="PL"><row><cell><block label="DrugItemCode">10684H<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>431.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Fentora [TB]<inline label="genericindexfieldbrand"><italic>XE "Fentora(TB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-10738E"><fragment id="60643-10738E"><block label="FormAndStrength">fentanyl 800 microgram orally disintegrating tablet, 28</block><table role="PL"><row><cell><block label="DrugItemCode">10738E<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>431.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Fentora [TB]<inline label="genericindexfieldbrand"><italic>XE "Fentora(TB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-10737D"><fragment id="60643-10737D"><block label="FormAndStrength">fentanyl 400 microgram orally disintegrating tablet, 28</block><table role="PL"><row><cell><block label="DrugItemCode">10737D<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>431.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Fentora [TB]<inline label="genericindexfieldbrand"><italic>XE "Fentora(TB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60643-10713W"><fragment id="60643-10713W"><block label="FormAndStrength">fentanyl 600 microgram orally disintegrating tablet, 28</block><table role="PL"><row><cell><block label="DrugItemCode">10713W<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>431.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Fentora [TB]<inline label="genericindexfieldbrand"><italic>XE "Fentora(TB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60709-N02AC"><fragment id="60709-N02AC"><block label="ATCLevel4"><para>Diphenylpropylamine derivatives</para></block></fragment></section><section id="60709-N02AC21357011000036109"><xref-fragment id="60709-N02AC21357011000036109"><blockxref id="107222" title="METHADONE" frag="default" reversefrag="N02AC21357011000036109" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="59909" href="dynamic/PL/drug/21357011000036109-N02AC.psml" urititle="METHADONE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59909" schemaversion="0.12" date="2018-06-15T10:34:31+10:00" version="current" level="processed"><documentinfo><uri id="59909" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/21357011000036109-N02AC.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/21357011000036109-N02AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:31+10:00" title="METHADONE"><displaytitle>METHADONE</displaytitle></uri><reversexrefs><reversexref uriid="60709" href="dynamic/PL/atc/N.psml" frag="N02AC21357011000036109" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107222" title="PL" type="none" forwardtype="embed" forwardtitle="METHADONE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59909-21357011000036109-1"><fragment id="59909-21357011000036109-1"><block label="DrugName">METHADONE<inline label="genericindexfield">XE "METHADONE:.Palliative Care"</inline></block></fragment></section><section id="59909-d5503e15"><fragment id="59909-d5503e15"><block label="CautionText"><para>The risk of drug dependence is high.</para></block></fragment></section><section id="59909-d5503e38"><fragment id="59909-d5503e38"><block label="NoteText"><para>Where consultation with a palliative care specialist or service has occurred, applications for increased repeats for up to 3 months' supply may be authorised.</para></block></fragment></section><section id="59909-d5503e41"><fragment id="59909-d5503e41"><block label="NoteText"><para>Telephone approvals are limited to 1 month's therapy.</para></block></fragment></section><section id="59909-d5503e44"><fragment id="59909-d5503e44"><block label="NoteText"><para><bold>Shared Care Model</bold>:</para><para>For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.</para></block></fragment></section><section id="59909-d5503e19"><fragment id="59909-d5503e19"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Chronic severe disabling pain</para><para>Treatment Phase: Initial treatment, for up to 3 months</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care,</para></item></list><para><bold>AND</bold></para><list><item><para>The condition must be unresponsive to non-opioid analgesics.</para></item></list></block></fragment></section><section id="59909-5399E"><fragment id="59909-5399E"><block label="FormAndStrength">methadone hydrochloride 5 mg/mL oral liquid, 200 mL</block><table role="PL"><row><cell><block label="DrugItemCode">5399E<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">22.60</block></cell><cell><block label="MRVSN">23.81</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Aspen Methadone Syrup [QA]<inline label="genericindexfieldbrand"><italic>XE "Aspen Methadone Syrup(QA):.Palliative Care" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59909-21357011000036109-2"><fragment id="59909-21357011000036109-2"><block label="DrugName">METHADONE<inline label="genericindexfield">XE "METHADONE:.Palliative Care"</inline></block></fragment></section><section id="59909-d5505e15"><fragment id="59909-d5505e15"><block label="CautionText"><para>The risk of drug dependence is high.</para></block></fragment></section><section id="59909-d5505e38"><fragment id="59909-d5505e38"><block label="NoteText"><para>Where consultation with a palliative care specialist or service has occurred, applications for increased repeats for up to 3 months' supply may be authorised.</para></block></fragment></section><section id="59909-d5505e41"><fragment id="59909-d5505e41"><block label="NoteText"><para>Telephone approvals are limited to 1 month's therapy.</para></block></fragment></section><section id="59909-d5505e44"><fragment id="59909-d5505e44"><block label="NoteText"><para><bold>Shared Care Model</bold>:</para><para>For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.</para></block></fragment></section><section id="59909-d5505e19"><fragment id="59909-d5505e19"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Chronic severe disabling pain</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care,</para></item></list><para><bold>AND</bold></para><list><item><para>The condition must be unresponsive to non-opioid analgesics.</para></item></list></block></fragment></section><section id="59909-5400F"><fragment id="59909-5400F"><block label="FormAndStrength">methadone hydrochloride 5 mg/mL oral liquid, 200 mL</block><table role="PL"><row><cell><block label="DrugItemCode">5400F<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">22.60</block></cell><cell><block label="MRVSN">23.81</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Aspen Methadone Syrup [QA]<inline label="genericindexfieldbrand"><italic>XE "Aspen Methadone Syrup(QA):.Palliative Care" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60709-N02AE"><fragment id="60709-N02AE"><block label="ATCLevel4"><para>Oripavine derivatives</para></block></fragment></section><section id="60709-N02AE21232011000036101"><xref-fragment id="60709-N02AE21232011000036101"><blockxref id="107219" title="BUPRENORPHINE" frag="default" reversefrag="N02AE21232011000036101" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="60899" href="dynamic/PL/drug/21232011000036101-N02AE.psml" urititle="BUPRENORPHINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60899" schemaversion="0.12" date="2018-06-15T10:34:31+10:00" version="current" level="processed"><documentinfo><uri id="60899" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/21232011000036101-N02AE.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/21232011000036101-N02AE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:33+10:00" modified="2018-06-15T10:34:31+10:00" title="BUPRENORPHINE"><displaytitle>BUPRENORPHINE</displaytitle></uri><reversexrefs><reversexref uriid="60709" href="dynamic/PL/atc/N.psml" frag="N02AE21232011000036101" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107219" title="PL" type="none" forwardtype="embed" forwardtitle="BUPRENORPHINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60899-21232011000036101-1"><fragment id="60899-21232011000036101-1"><block label="DrugName">BUPRENORPHINE<inline label="genericindexfield">XE "BUPRENORPHINE:.Palliative Care"</inline></block></fragment></section><section id="60899-d5507e15"><fragment id="60899-d5507e15"><block label="CautionText"><para>The risk of drug dependence is high.</para></block></fragment></section><section id="60899-d5507e36"><fragment id="60899-d5507e36"><block label="NoteText"><para>Telephone approvals are limited to 1 month's therapy.</para></block></fragment></section><section id="60899-d5507e19"><fragment id="60899-d5507e19"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Chronic severe disabling pain</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care,</para></item></list><para><bold>AND</bold></para><list><item><para>The condition must be unresponsive to non-opioid analgesics.</para></item></list></block></fragment></section><section id="60899-10959T"><fragment id="60899-10959T"><block label="FormAndStrength">buprenorphine 40 microgram/hour patch, 2</block><table role="PL"><row><cell><block label="DrugItemCode">10959T<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>148.52</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norspan [MF]<inline label="genericindexfieldbrand"><italic>XE "Norspan(MF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60899-10970J"><fragment id="60899-10970J"><block label="FormAndStrength">buprenorphine 20 microgram/hour patch, 2</block><table role="PL"><row><cell><block label="DrugItemCode">10970J<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>94.76</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norspan [MF]<inline label="genericindexfieldbrand"><italic>XE "Norspan(MF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60899-10948F"><fragment id="60899-10948F"><block label="FormAndStrength">buprenorphine 10 microgram/hour patch, 2</block><table role="PL"><row><cell><block label="DrugItemCode">10948F<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>66.38</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norspan [MF]<inline label="genericindexfieldbrand"><italic>XE "Norspan(MF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60899-10964C"><fragment id="60899-10964C"><block label="FormAndStrength">buprenorphine 25 microgram/hour patch, 2</block><table role="PL"><row><cell><block label="DrugItemCode">10964C<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>108.20</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norspan [MF]<inline label="genericindexfieldbrand"><italic>XE "Norspan(MF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60899-10953L"><fragment id="60899-10953L"><block label="FormAndStrength">buprenorphine 15 microgram/hour patch, 2</block><table role="PL"><row><cell><block label="DrugItemCode">10953L<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>80.56</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norspan [MF]<inline label="genericindexfieldbrand"><italic>XE "Norspan(MF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60899-10957Q"><fragment id="60899-10957Q"><block label="FormAndStrength">buprenorphine 5 microgram/hour patch, 2</block><table role="PL"><row><cell><block label="DrugItemCode">10957Q<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>43.14</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norspan [MF]<inline label="genericindexfieldbrand"><italic>XE "Norspan(MF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60899-10949G"><fragment id="60899-10949G"><block label="FormAndStrength">buprenorphine 30 microgram/hour patch, 2</block><table role="PL"><row><cell><block label="DrugItemCode">10949G<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>121.64</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norspan [MF]<inline label="genericindexfieldbrand"><italic>XE "Norspan(MF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60709-N02B"><fragment id="60709-N02B"><block label="ATCLevel3"><para>OTHER ANALGESICS AND ANTIPYRETICS</para></block></fragment></section><section id="60709-N02BE"><fragment id="60709-N02BE"><block label="ATCLevel4"><para>Anilides</para></block></fragment></section><section id="60709-N02BE21433011000036107"><xref-fragment id="60709-N02BE21433011000036107"><blockxref id="107217" title="PARACETAMOL" frag="default" reversefrag="N02BE21433011000036107" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="60201" href="dynamic/PL/drug/21433011000036107-N02BE.psml" urititle="PARACETAMOL" mediatype="application/vnd.pageseeder.psml+xml"><document id="60201" schemaversion="0.12" date="2018-06-15T10:34:31+10:00" version="current" level="processed"><documentinfo><uri id="60201" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/21433011000036107-N02BE.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/21433011000036107-N02BE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:25+10:00" modified="2018-06-15T10:34:31+10:00" title="PARACETAMOL"><displaytitle>PARACETAMOL</displaytitle></uri><reversexrefs><reversexref uriid="60709" href="dynamic/PL/atc/N.psml" frag="N02BE21433011000036107" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107217" title="PL" type="none" forwardtype="embed" forwardtitle="PARACETAMOL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60201-21433011000036107-1"><fragment id="60201-21433011000036107-1"><block label="DrugName">PARACETAMOL<inline label="genericindexfield">XE "PARACETAMOL"</inline></block></fragment></section><section id="60201-d5509e16"><fragment id="60201-d5509e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Analgesia or fever</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be intolerant to alternative therapy.</para></item></list></block></fragment></section><section id="60201-5319Y"><fragment id="60201-5319Y"><block label="FormAndStrength">paracetamol 500 mg suppository, 24</block><table role="PL"><row><cell><block label="DrugItemCode">5319Y<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>82.07</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Panadol [GC]<inline label="genericindexfieldbrand"><italic>XE "Panadol(GC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60201-21433011000036107-2"><fragment id="60201-21433011000036107-2"><block label="DrugName">PARACETAMOL<inline label="genericindexfield">XE "PARACETAMOL"</inline></block></fragment></section><section id="60201-d5511e33"><fragment id="60201-d5511e33"><block label="NoteText"><para>Pharmaceutical benefits that have the form paracetamol 665 mg tablet: modified release, 96 and pharmaceutical benefits that have the form paracetamol 665 mg tablet: modified release, 192 are equivalent for the purposes of substitution.</para></block></fragment></section><section id="60201-d5511e16"><fragment id="60201-d5511e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Analgesia or fever</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be intolerant to alternative therapy.</para></item></list></block></fragment></section><section id="60201-10796F"><fragment id="60201-10796F"><block label="FormAndStrength">paracetamol 665 mg tablet: modified release, 192</block><table role="PL"><row><cell><block label="DrugItemCode">10796F<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.55</block></cell><cell><block label="MRVSN">19.76</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Osteomol 665 Paracetamol [CR]<inline label="genericindexfieldbrand"><italic>XE "Osteomol 665 Paracetamol(CR)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60201-5343F"><fragment id="60201-5343F"><block label="FormAndStrength">paracetamol 665 mg modified release tablet, 96</block><table role="PL"><row><cell><block label="DrugItemCode">5343F<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>18.55</block></cell><cell><block label="MRVSN">19.76</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APOHEALTH Osteo Relief Paracetamol 665 mg [TX]<inline label="genericindexfieldbrand"><italic>XE "APOHEALTH Osteo Relief Paracetamol 665 mg(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Osteomol 665 Paracetamol [CR]<inline label="genericindexfieldbrand"><italic>XE "Osteomol 665 Paracetamol (CR)" \i </italic></inline></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60709-N03"><fragment id="60709-N03"><block label="ATCLevel2"><para>ANTIEPILEPTICS</para></block></fragment></section><section id="60709-N03A"><fragment id="60709-N03A"><block label="ATCLevel3"><para>ANTIEPILEPTICS</para></block></fragment></section><section id="60709-N03AE"><fragment id="60709-N03AE"><block label="ATCLevel4"><para>Benzodiazepine derivatives</para></block></fragment></section><section id="60709-N03AE21226011000036100"><xref-fragment id="60709-N03AE21226011000036100"><blockxref id="107223" title="CLONAZEPAM" frag="default" reversefrag="N03AE21226011000036100" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="60560" href="dynamic/PL/drug/21226011000036100-N03AE.psml" urititle="CLONAZEPAM" mediatype="application/vnd.pageseeder.psml+xml"><document id="60560" schemaversion="0.12" date="2018-06-15T10:34:31+10:00" version="current" level="processed"><documentinfo><uri id="60560" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/21226011000036100-N03AE.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/21226011000036100-N03AE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:29+10:00" modified="2018-06-15T10:34:31+10:00" title="CLONAZEPAM"><displaytitle>CLONAZEPAM</displaytitle></uri><reversexrefs><reversexref uriid="60709" href="dynamic/PL/atc/N.psml" frag="N03AE21226011000036100" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107223" title="PL" type="none" forwardtype="embed" forwardtitle="CLONAZEPAM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60560-21226011000036100-1"><fragment id="60560-21226011000036100-1"><block label="DrugName">CLONAZEPAM<inline label="genericindexfield">XE "CLONAZEPAM"</inline></block></fragment></section><section id="60560-d5513e33"><fragment id="60560-d5513e33"><block label="NoteText"><para>No increase in the maximum number of repeats may be authorised.</para></block></fragment></section><section id="60560-d5513e16"><fragment id="60560-d5513e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Myoclonus</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be for prophylaxis or prevention of the indication,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be receiving palliative care.</para></item></list></block></fragment></section><section id="60560-5338Y"><fragment id="60560-5338Y"><block label="FormAndStrength">clonazepam 2 mg tablet, 100</block><table role="PL"><row><cell><block label="DrugItemCode">5338Y<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">21.80</block></cell><cell><block label="MRVSN">23.01</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Paxam 2 [AF]<inline label="genericindexfieldbrand"><italic>XE "Paxam 2(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium"><inline label="BrandPricePremium"><sup>B</sup>2.30
</inline></block></cell><cell><block label="DPMQ">24.10</block></cell><cell><block label="MRVSN">23.01</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Rivotril [RO]<inline label="genericindexfieldbrand"><italic>XE "Rivotril(RO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60560-5339B"><fragment id="60560-5339B"><block label="FormAndStrength">clonazepam 2.5 mg/mL (0.1 mg/drop) oral liquid, 10 mL</block><table role="PL"><row><cell><block label="DrugItemCode">5339B<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>18.59</block></cell><cell><block label="MRVSN">19.80</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Rivotril [RO]<inline label="genericindexfieldbrand"><italic>XE "Rivotril(RO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60560-5337X"><fragment id="60560-5337X"><block label="FormAndStrength">clonazepam 500 microgram tablet, 100</block><table role="PL"><row><cell><block label="DrugItemCode">5337X<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">16.78</block></cell><cell><block label="MRVSN">17.99</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Paxam 0.5 [AF]<inline label="genericindexfieldbrand"><italic>XE "Paxam 0.5(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium"><inline label="BrandPricePremium"><sup>B</sup>1.84
</inline></block></cell><cell><block label="DPMQ">18.62</block></cell><cell><block label="MRVSN">17.99</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Rivotril [RO]<inline label="genericindexfieldbrand"><italic>XE "Rivotril(RO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60709-N05"><fragment id="60709-N05"><block label="ATCLevel2"><para>PSYCHOLEPTICS</para></block></fragment></section><section id="60709-N05B"><fragment id="60709-N05B"><block label="ATCLevel3"><para>ANXIOLYTICS</para></block></fragment></section><section id="60709-N05BA"><fragment id="60709-N05BA"><block label="ATCLevel4"><para>Benzodiazepine derivatives</para></block></fragment></section><section id="60709-N05BA21688011000036107"><xref-fragment id="60709-N05BA21688011000036107"><blockxref id="107216" title="DIAZEPAM" frag="default" reversefrag="N05BA21688011000036107" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="59745" href="dynamic/PL/drug/21688011000036107-N05BA.psml" urititle="DIAZEPAM" mediatype="application/vnd.pageseeder.psml+xml"><document id="59745" schemaversion="0.12" date="2018-06-15T10:34:31+10:00" version="current" level="processed"><documentinfo><uri id="59745" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/21688011000036107-N05BA.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/21688011000036107-N05BA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:20+10:00" modified="2018-06-15T10:34:31+10:00" title="DIAZEPAM"><displaytitle>DIAZEPAM</displaytitle></uri><reversexrefs><reversexref uriid="60709" href="dynamic/PL/atc/N.psml" frag="N05BA21688011000036107" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107216" title="PL" type="none" forwardtype="embed" forwardtitle="DIAZEPAM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59745-21688011000036107-1"><fragment id="59745-21688011000036107-1"><block label="DrugName">DIAZEPAM<inline label="genericindexfield">XE "DIAZEPAM"</inline></block></fragment></section><section id="59745-d5515e26"><fragment id="59745-d5515e26"><block label="NoteText"><para>No increase in the maximum number of repeats may be authorised.</para></block></fragment></section><section id="59745-d5515e16"><fragment id="59745-d5515e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Anxiety</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care.</para></item></list></block></fragment></section><section id="59745-5355W"><fragment id="59745-5355W"><block label="FormAndStrength">diazepam 2 mg tablet, 50</block><table role="PL"><row><cell><block label="DrugItemCode">5355W<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">12.41</block></cell><cell><block label="MRVSN">13.62</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Diazepam [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Diazepam(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Valpam 2 [RW]<inline label="genericindexfieldbrand"><italic>XE "Valpam 2 (RW)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium"><inline label="BrandPricePremium"><sup>B</sup>2.99
</inline></block></cell><cell><block label="DPMQ">15.40</block></cell><cell><block label="MRVSN">13.62</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Antenex 2 [AF]<inline label="genericindexfieldbrand"><italic>XE "Antenex 2(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59745-5356X"><fragment id="59745-5356X"><block label="FormAndStrength">diazepam 5 mg tablet, 50</block><table role="PL"><row><cell><block label="DrugItemCode">5356X<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">12.48</block></cell><cell><block label="MRVSN">13.69</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Antenex 5 [AF]<inline label="genericindexfieldbrand"><italic>XE "Antenex 5(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Diazepam [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Diazepam (TX)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Ranzepam [RA]<inline label="genericindexfieldbrand"><italic>XE "Ranzepam(RA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Valpam 5 [RW]<inline label="genericindexfieldbrand"><italic>XE "Valpam 5 (RW)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium"><inline label="BrandPricePremium"><sup>B</sup>2.19
</inline></block></cell><cell><block label="DPMQ">14.67</block></cell><cell><block label="MRVSN">13.69</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Valium [RO]<inline label="genericindexfieldbrand"><italic>XE "Valium(RO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60709-N05BA21541011000036102"><xref-fragment id="60709-N05BA21541011000036102"><blockxref id="107218" title="OXAZEPAM" frag="default" reversefrag="N05BA21541011000036102" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="60718" href="dynamic/PL/drug/21541011000036102-N05BA.psml" urititle="OXAZEPAM" mediatype="application/vnd.pageseeder.psml+xml"><document id="60718" schemaversion="0.12" date="2018-06-15T10:34:31+10:00" version="current" level="processed"><documentinfo><uri id="60718" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/21541011000036102-N05BA.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/21541011000036102-N05BA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:31+10:00" modified="2018-06-15T10:34:31+10:00" title="OXAZEPAM"><displaytitle>OXAZEPAM</displaytitle></uri><reversexrefs><reversexref uriid="60709" href="dynamic/PL/atc/N.psml" frag="N05BA21541011000036102" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107218" title="PL" type="none" forwardtype="embed" forwardtitle="OXAZEPAM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60718-21541011000036102-1"><fragment id="60718-21541011000036102-1"><block label="DrugName">OXAZEPAM<inline label="genericindexfield">XE "OXAZEPAM"</inline></block></fragment></section><section id="60718-d5517e26"><fragment id="60718-d5517e26"><block label="NoteText"><para>No increase in the maximum number of repeats may be authorised.</para></block></fragment></section><section id="60718-d5517e16"><fragment id="60718-d5517e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Anxiety</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care.</para></item></list></block></fragment></section><section id="60718-5371Q"><fragment id="60718-5371Q"><block label="FormAndStrength">oxazepam 15 mg tablet, 25</block><table role="PL"><row><cell><block label="DrugItemCode">5371Q<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>13.93</block></cell><cell><block label="MRVSN">15.14</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Alepam 15 [AF]<inline label="genericindexfieldbrand"><italic>XE "Alepam 15(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium"><inline label="BrandPricePremium"><sup>B</sup>5.32
</inline></block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>19.25</block></cell><cell><block label="MRVSN">15.14</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Serepax [QA]<inline label="genericindexfieldbrand"><italic>XE "Serepax(QA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60718-5372R"><fragment id="60718-5372R"><block label="FormAndStrength">oxazepam 30 mg tablet, 25</block><table role="PL"><row><cell><block label="DrugItemCode">5372R<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>13.25</block></cell><cell><block label="MRVSN">14.46</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Alepam 30 [AF]<inline label="genericindexfieldbrand"><italic>XE "Alepam 30(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Oxazepam [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Oxazepam (TX)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Murelax [RW]<inline label="genericindexfieldbrand"><italic>XE "Murelax(RW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium"><inline label="BrandPricePremium"><sup>B</sup>4.66
</inline></block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>17.91</block></cell><cell><block label="MRVSN">14.46</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Serepax [QA]<inline label="genericindexfieldbrand"><italic>XE "Serepax(QA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60709-N05C"><fragment id="60709-N05C"><block label="ATCLevel3"><para>HYPNOTICS AND SEDATIVES</para></block></fragment></section><section id="60709-N05CD"><fragment id="60709-N05CD"><block label="ATCLevel4"><para>Benzodiazepine derivatives</para></block></fragment></section><section id="60709-N05CD21647011000036102"><xref-fragment id="60709-N05CD21647011000036102"><blockxref id="107215" title="NITRAZEPAM" frag="default" reversefrag="N05CD21647011000036102" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="59715" href="dynamic/PL/drug/21647011000036102-N05CD.psml" urititle="NITRAZEPAM" mediatype="application/vnd.pageseeder.psml+xml"><document id="59715" schemaversion="0.12" date="2018-06-15T10:34:31+10:00" version="current" level="processed"><documentinfo><uri id="59715" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/21647011000036102-N05CD.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/21647011000036102-N05CD.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:20+10:00" modified="2018-06-15T10:34:31+10:00" title="NITRAZEPAM"><displaytitle>NITRAZEPAM</displaytitle></uri><reversexrefs><reversexref uriid="60709" href="dynamic/PL/atc/N.psml" frag="N05CD21647011000036102" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107215" title="PL" type="none" forwardtype="embed" forwardtitle="NITRAZEPAM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59715-21647011000036102-1"><fragment id="59715-21647011000036102-1"><block label="DrugName">NITRAZEPAM<inline label="genericindexfield">XE "NITRAZEPAM:.Palliative Care"</inline></block></fragment></section><section id="59715-d5519e26"><fragment id="59715-d5519e26"><block label="NoteText"><para>No increase in the maximum number of repeats may be authorised.</para></block></fragment></section><section id="59715-d5519e16"><fragment id="59715-d5519e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Insomnia</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care.</para></item></list></block></fragment></section><section id="59715-5359C"><fragment id="59715-5359C"><block label="FormAndStrength">nitrazepam 5 mg tablet, 25</block><table role="PL"><row><cell><block label="DrugItemCode">5359C<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>14.31</block></cell><cell><block label="MRVSN">15.52</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Alodorm [AF]<inline label="genericindexfieldbrand"><italic>XE "Alodorm(AF):.Palliative Care" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium"><inline label="BrandPricePremium"><sup>B</sup>2.48
</inline></block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>16.79</block></cell><cell><block label="MRVSN">15.52</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Mogadon [IL]<inline label="genericindexfieldbrand"><italic>XE "Mogadon(IL):.Palliative Care" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60709-N05CD21825011000036102"><xref-fragment id="60709-N05CD21825011000036102"><blockxref id="107224" title="TEMAZEPAM" frag="default" reversefrag="N05CD21825011000036102" reversetitle="PL" reverselink="true" reversetype="none" display="document" type="embed" uriid="60873" href="dynamic/PL/drug/21825011000036102-N05CD.psml" urititle="TEMAZEPAM" mediatype="application/vnd.pageseeder.psml+xml"><document id="60873" schemaversion="0.12" date="2018-06-15T10:34:31+10:00" version="current" level="processed"><documentinfo><uri id="60873" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/PL/drug/21825011000036102-N05CD.psml" decodedpath="/ps/test/local3/books/dynamic/PL/drug/21825011000036102-N05CD.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:31+10:00" title="TEMAZEPAM"><displaytitle>TEMAZEPAM</displaytitle></uri><reversexrefs><reversexref uriid="60709" href="dynamic/PL/atc/N.psml" frag="N05CD21825011000036102" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107224" title="PL" type="none" forwardtype="embed" forwardtitle="TEMAZEPAM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60873-21825011000036102-1"><fragment id="60873-21825011000036102-1"><block label="DrugName">TEMAZEPAM<inline label="genericindexfield">XE "TEMAZEPAM"</inline></block></fragment></section><section id="60873-d5521e26"><fragment id="60873-d5521e26"><block label="NoteText"><para>No increase in the maximum number of repeats may be authorised.</para></block></fragment></section><section id="60873-d5521e16"><fragment id="60873-d5521e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Insomnia</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving palliative care.</para></item></list></block></fragment></section><section id="60873-5375X"><fragment id="60873-5375X"><block label="FormAndStrength">temazepam 10 mg tablet, 25</block><table role="PL"><row><cell><block label="DrugItemCode">5375X<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>13.25</block></cell><cell><block label="MRVSN">14.46</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Temazepam [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Temazepam(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Temaze [AF]<inline label="genericindexfieldbrand"><italic>XE "Temaze (AF)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Temtabs [FM]<inline label="genericindexfieldbrand"><italic>XE "Temtabs(FM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium"><inline label="BrandPricePremium"><sup>B</sup>6.96
</inline></block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>20.21</block></cell><cell><block label="MRVSN">14.46</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Normison [QA]<inline label="genericindexfieldbrand"><italic>XE "Normison(QA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref></xref-fragment></section></document></blockxref>
<blockxref id="107703" title="therapeuticindex-CA.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="59844" href="dynamic/CA/therapeuticindex-CA.psml" urititle="Therapeutic Index - Highly Specialised Drugs Program (Community Access) - CA" mediatype="application/vnd.pageseeder.psml+xml"><document id="59844" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="59844" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/therapeuticindex-CA.psml" decodedpath="/ps/test/local3/books/dynamic/CA/therapeuticindex-CA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:32+10:00" title="Therapeutic Index - Highly Specialised Drugs Program (Community Access) - CA"><displaytitle>Therapeutic Index - Highly Specialised Drugs Program (Community Access) - CA</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107703" title="" type="none" forwardtype="embed" forwardtitle="therapeuticindex-CA.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="42603" fragment="59844-2" editid="105525" modified="2018-06-15T10:34:21+10:00"></locator></fragmentinfo><metadata></metadata><section id="59844-1"><fragment id="59844-1"><block label="mps3indexsectionbreak">CA</block><block label="schedule-heading">Highly Specialised Drugs Program (Community Access)</block></fragment><fragment id="59844-2"><block label="index"><para>SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS<inline label="indexpageref"><xref id="105513" title="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60686" href="#60686" urititle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" mediatype="application/vnd.pageseeder.psml+xml">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</xref></inline></para></block><block label="index2"><para indent="1">PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES<inline label="indexpageref"><xref id="105514" title="PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES" frag="H01" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60686" href="#60686-H01" urititle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" mediatype="application/vnd.pageseeder.psml+xml">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</xref></inline></para></block><block label="index3"><para indent="2">HYPOTHALAMIC HORMONES<inline label="indexpageref"><xref id="105515" title="HYPOTHALAMIC HORMONES" frag="H01C" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60686" href="#60686-H01C" urititle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" mediatype="application/vnd.pageseeder.psml+xml">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</xref></inline></para></block><block label="index"><para>ANTIINFECTIVES FOR SYSTEMIC USE<inline label="indexpageref"><xref id="105516" title="ANTIINFECTIVES FOR SYSTEMIC USE" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59926" href="#59926" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml">ANTIINFECTIVES FOR SYSTEMIC USE</xref></inline></para></block><block label="index2"><para indent="1">ANTIVIRALS FOR SYSTEMIC USE<inline label="indexpageref"><xref id="105517" title="ANTIVIRALS FOR SYSTEMIC USE" frag="J05" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59926" href="#59926-J05" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml">ANTIINFECTIVES FOR SYSTEMIC USE</xref></inline></para></block><block label="index3"><para indent="2">DIRECT ACTING ANTIVIRALS<inline label="indexpageref"><xref id="105518" title="DIRECT ACTING ANTIVIRALS" frag="J05A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59926" href="#59926-J05A" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml">ANTIINFECTIVES FOR SYSTEMIC USE</xref></inline></para></block><block label="index"><para>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS<inline label="indexpageref"><xref id="105519" title="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60002" href="#60002" urititle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" mediatype="application/vnd.pageseeder.psml+xml">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</xref></inline></para></block><block label="index2"><para indent="1">IMMUNOSTIMULANTS<inline label="indexpageref"><xref id="105520" title="IMMUNOSTIMULANTS" frag="L03" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60002" href="#60002-L03" urititle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" mediatype="application/vnd.pageseeder.psml+xml">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</xref></inline></para></block><block label="index3"><para indent="2">IMMUNOSTIMULANTS<inline label="indexpageref"><xref id="105521" title="IMMUNOSTIMULANTS" frag="L03A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60002" href="#60002-L03A" urititle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" mediatype="application/vnd.pageseeder.psml+xml">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</xref></inline></para></block><block label="index"><para>NERVOUS SYSTEM<inline label="indexpageref"><xref id="105522" title="NERVOUS SYSTEM" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60468" href="#60468" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block><block label="index2"><para indent="1">PSYCHOLEPTICS<inline label="indexpageref"><xref id="105523" title="PSYCHOLEPTICS" frag="N05" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60468" href="#60468-N05" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block><block label="index3"><para indent="2">ANTIPSYCHOTICS<inline label="indexpageref"><xref id="105524" title="ANTIPSYCHOTICS" frag="N05A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60468" href="#60468-N05A" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block></fragment></section></document></blockxref>
<blockxref id="107704" title="CA.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="60519" href="dynamic/CA.psml" urititle="Highly Specialised Drugs Program (Community Access)" mediatype="application/vnd.pageseeder.psml+xml"><document id="60519" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="60519" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA.psml" decodedpath="/ps/test/local3/books/dynamic/CA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:29+10:00" modified="2018-06-15T10:34:32+10:00" title="Highly Specialised Drugs Program (Community Access)"><displaytitle>Highly Specialised Drugs Program (Community Access)</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107704" title="" type="none" forwardtype="embed" forwardtitle="CA.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="44155" fragment="60519-d114e746881" editid="107076" modified="2018-06-15T10:34:29+10:00"></locator></fragmentinfo><metadata></metadata><section id="60519-1"><fragment id="60519-1"><block label="mps3sectionbreak">CA</block></fragment></section><section id="60519-d114e746881"><xref-fragment id="60519-d114e746881"><blockxref id="107072" title="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" frag="default" reversefrag="d114e746881" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60686" href="dynamic/CA/atc/H.psml" urititle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" mediatype="application/vnd.pageseeder.psml+xml"><document id="60686" schemaversion="0.12" date="2018-06-15T10:35:08+10:00" version="current" level="processed"><documentinfo><uri id="60686" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/atc/H.psml" decodedpath="/ps/test/local3/books/dynamic/CA/atc/H.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:30+10:00" modified="2018-06-15T10:35:08+10:00" title="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS"><displaytitle>SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</displaytitle></uri><reversexrefs><reversexref uriid="59844" href="dynamic/CA/therapeuticindex-CA.psml" frag="2" urititle="Therapeutic Index - Highly Specialised Drugs Program (Community Access) - CA" mediatype="application/vnd.pageseeder.psml+xml" id="105513" title="Untitled" type="none" forwardtype="none" forwardtitle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60519" href="dynamic/CA.psml" frag="d114e746881" urititle="Highly Specialised Drugs Program (Community Access)" mediatype="application/vnd.pageseeder.psml+xml" id="107072" title="CA" type="none" forwardtype="embed" forwardtitle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="42604" fragment="60686-H01"><reversexrefs><reversexref uriid="59844" href="dynamic/CA/therapeuticindex-CA.psml" frag="2" urititle="Therapeutic Index - Highly Specialised Drugs Program (Community Access) - CA" mediatype="application/vnd.pageseeder.psml+xml" id="105514" title="Untitled" type="none" forwardtype="none" forwardtitle="PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES" forwarddisplay="document" forwardfrag="H01"></reversexref></reversexrefs></locator><locator id="44287" fragment="60686-H01CB21278011000036100" editid="107212" modified="2018-06-15T10:34:30+10:00"></locator><locator id="42605" fragment="60686-H01C"><reversexrefs><reversexref uriid="59844" href="dynamic/CA/therapeuticindex-CA.psml" frag="2" urititle="Therapeutic Index - Highly Specialised Drugs Program (Community Access) - CA" mediatype="application/vnd.pageseeder.psml+xml" id="105515" title="Untitled" type="none" forwardtype="none" forwardtitle="HYPOTHALAMIC HORMONES" forwarddisplay="document" forwardfrag="H01C"></reversexref></reversexrefs></locator></fragmentinfo><metadata></metadata><section id="60686-H"><fragment id="60686-H"><block label="ATCLevel1"><para>SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</para></block></fragment></section><section id="60686-H01"><fragment id="60686-H01"><block label="ATCLevel2"><para>PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES</para></block></fragment></section><section id="60686-H01C"><fragment id="60686-H01C"><block label="ATCLevel3"><para>HYPOTHALAMIC HORMONES</para></block></fragment></section><section id="60686-H01CB"><fragment id="60686-H01CB"><block label="ATCLevel4"><para>Somatostatin and analogues</para></block></fragment></section><section id="60686-H01CB21278011000036100"><xref-fragment id="60686-H01CB21278011000036100"><blockxref id="107211" title="LANREOTIDE" frag="default" reversefrag="H01CB21278011000036100" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60728" href="dynamic/CA/drug/21278011000036100-H01CB.psml" urititle="LANREOTIDE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60728" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60728" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21278011000036100-H01CB.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21278011000036100-H01CB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:31+10:00" modified="2018-06-15T10:34:30+10:00" title="LANREOTIDE"><displaytitle>LANREOTIDE</displaytitle></uri><reversexrefs><reversexref uriid="60686" href="dynamic/CA/atc/H.psml" frag="H01CB21278011000036100" urititle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" mediatype="application/vnd.pageseeder.psml+xml" id="107211" title="CA" type="none" forwardtype="embed" forwardtitle="LANREOTIDE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60728-21278011000036100-1"><fragment id="60728-21278011000036100-1"><block label="DrugName">LANREOTIDE<inline label="genericindexfield">XE "LANREOTIDE"</inline></block></fragment></section><section id="60728-d4432e16"><fragment id="60728-d4432e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">7532</block><block label="RestrictionText"><para>Acromegaly</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised treatment with this drug for this condition,</para></item></list><para><bold>AND</bold></para><list><item><para>The condition must be active,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be after failure of other therapy including dopamine agonists; OR</para></item><item><para>The treatment must be as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; OR</para></item><item><para>The treatment must be in a patient who is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must cease in a patient treated with radiotherapy if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose),</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must cease if IGF1 is not lower after 3 months of treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not be given concomitantly with PBS-subsidised pegvisomant.</para></item></list> <para>In a patient treated with radiotherapy, lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission. </para></block></fragment></section><section id="60728-d4432e117"><fragment id="60728-d4432e117"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">7509</block><block label="RestrictionText"><para>Functional carcinoid tumour</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised treatment with this drug for this condition,</para></item></list><para><bold>AND</bold></para><list><item><para>The condition must be causing intractable symptoms,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be one in whom surgery or antineoplastic therapy has failed or is inappropriate,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 120 mg every 28 days.</para></item></list> <para>Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose.</para></block></fragment></section><section id="60728-11315M"><fragment id="60728-11315M"><block label="FormAndStrength">lanreotide 60 mg/0.5 mL injection, 0.5 mL syringe</block><table role="CA"><row><cell><block label="DrugItemCode">11315M<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>2602.65</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Somatuline Autogel [IS]<inline label="genericindexfieldbrand"><italic>XE "Somatuline Autogel(IS)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60728-11316N"><fragment id="60728-11316N"><block label="FormAndStrength">lanreotide 90 mg/0.5 mL injection, 0.5 mL syringe</block><table role="CA"><row><cell><block label="DrugItemCode">11316N<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>3448.15</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Somatuline Autogel [IS]<inline label="genericindexfieldbrand"><italic>XE "Somatuline Autogel(IS)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60728-11289E"><fragment id="60728-11289E"><block label="FormAndStrength">lanreotide 120 mg/0.5 mL injection, 0.5 mL syringe</block><table role="CA"><row><cell><block label="DrugItemCode">11289E<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>4303.15</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Somatuline Autogel [IS]<inline label="genericindexfieldbrand"><italic>XE "Somatuline Autogel(IS)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref><blockxref id="107073" title="ANTIINFECTIVES FOR SYSTEMIC USE" frag="default" reversefrag="d114e746881" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="59926" href="dynamic/CA/atc/J.psml" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59926" schemaversion="0.12" date="2018-06-15T10:34:29+10:00" version="current" level="processed"><documentinfo><uri id="59926" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/atc/J.psml" decodedpath="/ps/test/local3/books/dynamic/CA/atc/J.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:29+10:00" title="ANTIINFECTIVES FOR SYSTEMIC USE"><displaytitle>ANTIINFECTIVES FOR SYSTEMIC USE</displaytitle></uri><reversexrefs><reversexref uriid="59844" href="dynamic/CA/therapeuticindex-CA.psml" frag="2" urititle="Therapeutic Index - Highly Specialised Drugs Program (Community Access) - CA" mediatype="application/vnd.pageseeder.psml+xml" id="105516" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIINFECTIVES FOR SYSTEMIC USE" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60519" href="dynamic/CA.psml" frag="d114e746881" urititle="Highly Specialised Drugs Program (Community Access)" mediatype="application/vnd.pageseeder.psml+xml" id="107073" title="CA" type="none" forwardtype="embed" forwardtitle="ANTIINFECTIVES FOR SYSTEMIC USE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="42992" fragment="59926-J05AR13531000144105" editid="105920" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42974" fragment="59926-J05AB21698011000036108" editid="105911" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42982" fragment="59926-J05AF21467011000036106" editid="105915" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42607" fragment="59926-J05"><reversexrefs><reversexref uriid="59844" href="dynamic/CA/therapeuticindex-CA.psml" frag="2" urititle="Therapeutic Index - Highly Specialised Drugs Program (Community Access) - CA" mediatype="application/vnd.pageseeder.psml+xml" id="105517" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIVIRALS FOR SYSTEMIC USE" forwarddisplay="document" forwardfrag="J05"></reversexref></reversexrefs></locator><locator id="42998" fragment="59926-J05AF11541000144100" editid="105923" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42964" fragment="59926-J05AF21490011000036108" editid="105906" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42976" fragment="59926-J05AX171081000036101" editid="105912" modified="2018-06-15T10:34:22+10:00"></locator><locator id="43018" fragment="59926-J05AF21664011000036103" editid="105933" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42968" fragment="59926-J05AF21873011000036104" editid="105908" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42958" fragment="59926-J05AR21556011000036109" editid="105903" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42978" fragment="59926-J05AG21616011000036105" editid="105913" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42990" fragment="59926-J05AR14111000144105" editid="105919" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42956" fragment="59926-J05AR21345011000036102" editid="105902" modified="2018-06-15T10:34:22+10:00"></locator><locator id="43016" fragment="59926-J05AE21324011000036104" editid="105932" modified="2018-06-15T10:34:22+10:00"></locator><locator id="43020" fragment="59926-J05AE21820011000036106" editid="105934" modified="2018-06-15T10:34:22+10:00"></locator><locator id="43012" fragment="59926-J05AF21665011000036104" editid="105930" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42952" fragment="59926-J05AR424901000144108" editid="105900" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42994" fragment="59926-J05AR420271000144104" editid="105921" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42970" fragment="59926-J05AR691321000168103" editid="105909" modified="2018-06-15T10:34:22+10:00"></locator><locator id="43010" fragment="59926-J05AF11951000144109" editid="105929" modified="2018-06-15T10:34:22+10:00"></locator><locator id="43026" fragment="59926-J05AG21551011000036104" editid="105937" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42608" fragment="59926-J05A"><reversexrefs><reversexref uriid="59844" href="dynamic/CA/therapeuticindex-CA.psml" frag="2" urititle="Therapeutic Index - Highly Specialised Drugs Program (Community Access) - CA" mediatype="application/vnd.pageseeder.psml+xml" id="105518" title="Untitled" type="none" forwardtype="none" forwardtitle="DIRECT ACTING ANTIVIRALS" forwarddisplay="document" forwardfrag="J05A"></reversexref></reversexrefs></locator><locator id="43024" fragment="59926-J05AB21859011000036104" editid="105936" modified="2018-06-15T10:34:22+10:00"></locator><locator id="43006" fragment="59926-J05AX50741011000036103" editid="105927" modified="2018-06-15T10:34:22+10:00"></locator><locator id="43002" fragment="59926-J05AE32622011000036101" editid="105925" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42954" fragment="59926-J05AE21626011000036102" editid="105901" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42986" fragment="59926-J05AG77467011000036101" editid="105917" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42948" fragment="59926-J05AX37767011000036101" editid="105898" modified="2018-06-15T10:34:22+10:00"></locator><locator id="43014" fragment="59926-J05AE21811011000036106" editid="105931" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42972" fragment="59926-J05AF21314011000036107" editid="105910" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42984" fragment="59926-J05AR320321000144100" editid="105916" modified="2018-06-15T10:34:22+10:00"></locator><locator id="43022" fragment="59926-J05AG14661000036100" editid="105935" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42996" fragment="59926-J05AR21904011000036103" editid="105922" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42962" fragment="59926-J05AE736661000168106" editid="105905" modified="2018-06-15T10:34:22+10:00"></locator><locator id="43004" fragment="59926-J05AF21429011000036108" editid="105926" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42960" fragment="59926-J05AR379171000144108" editid="105904" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42950" fragment="59926-J05AR420411000144108" editid="105899" modified="2018-06-15T10:34:22+10:00"></locator><locator id="43008" fragment="59926-J05AX21744011000036100" editid="105928" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42966" fragment="59926-J05AE21438011000036102" editid="105907" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42988" fragment="59926-J05AR21390011000036103" editid="105918" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42980" fragment="59926-J05AR12261000144105" editid="105914" modified="2018-06-15T10:34:22+10:00"></locator><locator id="43000" fragment="59926-J05AE21424011000036107" editid="105924" modified="2018-06-15T10:34:22+10:00"></locator></fragmentinfo><metadata></metadata><section id="59926-J"><fragment id="59926-J"><block label="ATCLevel1"><para>ANTIINFECTIVES FOR SYSTEMIC USE</para></block></fragment></section><section id="59926-J05"><fragment id="59926-J05"><block label="ATCLevel2"><para>ANTIVIRALS FOR SYSTEMIC USE</para></block></fragment></section><section id="59926-J05A"><fragment id="59926-J05A"><block label="ATCLevel3"><para>DIRECT ACTING ANTIVIRALS</para></block></fragment></section><section id="59926-J05AB"><fragment id="59926-J05AB"><block label="ATCLevel4"><para>Nucleosides and nucleotides excl. reverse transcriptase inhibitors</para></block></fragment></section><section id="59926-J05AB21698011000036108"><xref-fragment id="59926-J05AB21698011000036108"><blockxref id="105871" title="GANCICLOVIR" frag="default" reversefrag="J05AB21698011000036108" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60508" href="dynamic/CA/drug/21698011000036108-J05AB.psml" urititle="GANCICLOVIR" mediatype="application/vnd.pageseeder.psml+xml"><document id="60508" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60508" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21698011000036108-J05AB.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21698011000036108-J05AB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:22+10:00" title="GANCICLOVIR"><displaytitle>GANCICLOVIR</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AB21698011000036108" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105871" title="CA" type="none" forwardtype="embed" forwardtitle="GANCICLOVIR" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60508-21698011000036108-1"><fragment id="60508-21698011000036108-1"><block label="DrugName">GANCICLOVIR<inline label="genericindexfield">XE "GANCICLOVIR"</inline></block></fragment></section><section id="60508-d4435e16"><fragment id="60508-d4435e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5000</block><block label="RestrictionText"><para>Cytomegalovirus retinitis</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be severely immunocompromised, inculding due to HIV infection.</para></item></list></block></fragment></section><section id="60508-10328N"><fragment id="60508-10328N"><block label="FormAndStrength">ganciclovir 500 mg injection, 5 vials</block><table role="CA"><row><cell><block label="DrugItemCode">10328N<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>471.91</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Cymevene [RO]<inline label="genericindexfieldbrand"><italic>XE "Cymevene(RO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AB21859011000036104"><xref-fragment id="59926-J05AB21859011000036104"><blockxref id="105896" title="VALGANCICLOVIR" frag="default" reversefrag="J05AB21859011000036104" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60829" href="dynamic/CA/drug/21859011000036104-J05AB.psml" urititle="VALGANCICLOVIR" mediatype="application/vnd.pageseeder.psml+xml"><document id="60829" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60829" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21859011000036104-J05AB.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21859011000036104-J05AB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:22+10:00" title="VALGANCICLOVIR"><displaytitle>VALGANCICLOVIR</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AB21859011000036104" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105896" title="CA" type="none" forwardtype="embed" forwardtitle="VALGANCICLOVIR" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60829-21859011000036104-1"><fragment id="60829-21859011000036104-1"><block label="DrugName">VALGANCICLOVIR<inline label="genericindexfield">XE "VALGANCICLOVIR"</inline></block></fragment></section><section id="60829-d4437e16"><fragment id="60829-d4437e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4980</block><block label="RestrictionText"><para>Cytomegalovirus retinitis</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have HIV infection.</para></item></list></block></fragment></section><section id="60829-10306K"><fragment id="60829-10306K"><block label="FormAndStrength">valganciclovir 450 mg tablet, 60</block><table role="CA"><row><cell><block label="DrugItemCode">10306K<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>3631.45</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Valcyte [RO]<inline label="genericindexfieldbrand"><italic>XE "Valcyte(RO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Valganciclovir AN [JO]<inline label="genericindexfieldbrand"><italic>XE "Valganciclovir AN (JO)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Valganciclovir Juno [JU]<inline label="genericindexfieldbrand"><italic>XE "Valganciclovir Juno(JU)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Valganciclovir Mylan [AF]<inline label="genericindexfieldbrand"><italic>XE "Valganciclovir Mylan (AF)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Valganciclovir Sandoz [SZ]<inline label="genericindexfieldbrand"><italic>XE "Valganciclovir Sandoz(SZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60829-10277X"><fragment id="60829-10277X"><block label="FormAndStrength">valganciclovir 50 mg/mL powder for oral liquid, 100 mL</block><table role="CA"><row><cell><block label="DrugItemCode">10277X<br></br></block></cell><cell><block label="MaxQuantity">11</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline><inline label="ExtemporaneouslyPrepared">#</inline>4396.02</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Valcyte [RO]<inline label="genericindexfieldbrand"><italic>XE "Valcyte(RO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AE"><fragment id="59926-J05AE"><block label="ATCLevel4"><para>Protease inhibitors</para></block></fragment></section><section id="59926-J05AE21324011000036104"><xref-fragment id="59926-J05AE21324011000036104"><blockxref id="105892" title="ATAZANAVIR" frag="default" reversefrag="J05AE21324011000036104" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60518" href="dynamic/CA/drug/21324011000036104-J05AE.psml" urititle="ATAZANAVIR" mediatype="application/vnd.pageseeder.psml+xml"><document id="60518" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60518" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21324011000036104-J05AE.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21324011000036104-J05AE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:29+10:00" modified="2018-06-15T10:34:22+10:00" title="ATAZANAVIR"><displaytitle>ATAZANAVIR</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AE21324011000036104" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105892" title="CA" type="none" forwardtype="embed" forwardtitle="ATAZANAVIR" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60518-21324011000036104-1"><fragment id="60518-21324011000036104-1"><block label="DrugName">ATAZANAVIR<inline label="genericindexfield">XE "ATAZANAVIR"</inline></block></fragment></section><section id="60518-d4439e16"><fragment id="60518-d4439e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4512</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60518-d4439e60"><fragment id="60518-d4439e60"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4454</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60518-10321F"><fragment id="60518-10321F"><block label="FormAndStrength">atazanavir 300 mg capsule, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10321F<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1038.43</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Reyataz [BQ]<inline label="genericindexfieldbrand"><italic>XE "Reyataz(BQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60518-10349Q"><fragment id="60518-10349Q"><block label="FormAndStrength">atazanavir 200 mg capsule, 60</block><table role="CA"><row><cell><block label="DrugItemCode">10349Q<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1369.33</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Reyataz [BQ]<inline label="genericindexfieldbrand"><italic>XE "Reyataz(BQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60518-10276W"><fragment id="60518-10276W"><block label="FormAndStrength">atazanavir 150 mg capsule, 60</block><table role="CA"><row><cell><block label="DrugItemCode">10276W<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1038.43</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Reyataz [BQ]<inline label="genericindexfieldbrand"><italic>XE "Reyataz(BQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AE736661000168106"><xref-fragment id="59926-J05AE736661000168106"><blockxref id="105865" title="ATAZANAVIR + COBICISTAT" frag="default" reversefrag="J05AE736661000168106" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60431" href="dynamic/CA/drug/736661000168106-J05AE.psml" urititle="ATAZANAVIR + COBICISTAT" mediatype="application/vnd.pageseeder.psml+xml"><document id="60431" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60431" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/736661000168106-J05AE.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/736661000168106-J05AE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:22+10:00" title="ATAZANAVIR + COBICISTAT"><displaytitle>ATAZANAVIR + COBICISTAT</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AE736661000168106" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105865" title="CA" type="none" forwardtype="embed" forwardtitle="ATAZANAVIR + COBICISTAT" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60431-736661000168106-1"><fragment id="60431-736661000168106-1"><block label="DrugName">ATAZANAVIR + COBICISTAT<inline label="genericindexfield">XE "ATAZANAVIR + COBICISTAT"</inline></block></fragment></section><section id="60431-d4442e16"><fragment id="60431-d4442e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4512</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60431-d4442e60"><fragment id="60431-d4442e60"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4454</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60431-10692R"><fragment id="60431-10692R"><block label="FormAndStrength">atazanavir 300 mg + cobicistat 150 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10692R<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1116.57</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Evotaz [BQ]<inline label="genericindexfieldbrand"><italic>XE "Evotaz(BQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AE32622011000036101"><xref-fragment id="59926-J05AE32622011000036101"><blockxref id="105885" title="DARUNAVIR" frag="default" reversefrag="J05AE32622011000036101" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="59683" href="dynamic/CA/drug/32622011000036101-J05AE.psml" urititle="DARUNAVIR" mediatype="application/vnd.pageseeder.psml+xml"><document id="59683" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="59683" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/32622011000036101-J05AE.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/32622011000036101-J05AE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:20+10:00" modified="2018-06-15T10:34:22+10:00" title="DARUNAVIR"><displaytitle>DARUNAVIR</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AE32622011000036101" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105885" title="CA" type="none" forwardtype="embed" forwardtitle="DARUNAVIR" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59683-32622011000036101-1"><fragment id="59683-32622011000036101-1"><block label="DrugName">DARUNAVIR<inline label="genericindexfield">XE "DARUNAVIR"</inline></block></fragment></section><section id="59683-d4445e16"><fragment id="59683-d4445e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5094</block><block label="RestrictionText"><para>Human immunodeficiency virus (HIV) infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be in addition to optimised background therapy,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be co-administered with 100 mg ritonavir twice daily,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have experienced virological failure or clinical failure or genotypic resistance after at least one antiretroviral regimen.</para></item></list> <para>Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity.</para></block></fragment></section><section id="59683-10287K"><fragment id="59683-10287K"><block label="FormAndStrength">darunavir 150 mg tablet, 240</block><table role="CA"><row><cell><block label="DrugItemCode">10287K<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">1043.27</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Prezista [JC]<inline label="genericindexfieldbrand"><italic>XE "Prezista(JC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59683-10329P"><fragment id="59683-10329P"><block label="FormAndStrength">darunavir 600 mg tablet, 60</block><table role="CA"><row><cell><block label="DrugItemCode">10329P<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>2039.69</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Prezista [JC]<inline label="genericindexfieldbrand"><italic>XE "Prezista(JC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59683-32622011000036101-2"><fragment id="59683-32622011000036101-2"><block label="DrugName">DARUNAVIR<inline label="genericindexfield">XE "DARUNAVIR"</inline></block></fragment></section><section id="59683-d4447e16"><fragment id="59683-d4447e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4313</block><block label="RestrictionText"><para>Human immunodeficiency virus (HIV) infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be in addition to optimised background therapy,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be co-administered with 100 mg ritonavir,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have experienced virological failure or clinical failure or genotypic resistance after at least one antiretroviral regimen,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have demonstrated darunavir resistance associated mutations detected on resistance testing.</para></item></list> <para>Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity.</para></block></fragment></section><section id="59683-10367P"><fragment id="59683-10367P"><block label="FormAndStrength">darunavir 800 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10367P<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1375.51</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Prezista [JC]<inline label="genericindexfieldbrand"><italic>XE "Prezista(JC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AE21811011000036106"><xref-fragment id="59926-J05AE21811011000036106"><blockxref id="105891" title="FOSAMPRENAVIR" frag="default" reversefrag="J05AE21811011000036106" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60618" href="dynamic/CA/drug/21811011000036106-J05AE.psml" urititle="FOSAMPRENAVIR" mediatype="application/vnd.pageseeder.psml+xml"><document id="60618" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60618" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21811011000036106-J05AE.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21811011000036106-J05AE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:30+10:00" modified="2018-06-15T10:34:22+10:00" title="FOSAMPRENAVIR"><displaytitle>FOSAMPRENAVIR</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AE21811011000036106" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105891" title="CA" type="none" forwardtype="embed" forwardtitle="FOSAMPRENAVIR" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60618-21811011000036106-1"><fragment id="60618-21811011000036106-1"><block label="DrugName">FOSAMPRENAVIR<inline label="genericindexfield">XE "FOSAMPRENAVIR"</inline></block></fragment></section><section id="60618-d4449e16"><fragment id="60618-d4449e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4512</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60618-d4449e60"><fragment id="60618-d4449e60"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4454</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60618-10337C"><fragment id="60618-10337C"><block label="FormAndStrength">fosamprenavir 700 mg tablet, 60</block><table role="CA"><row><cell><block label="DrugItemCode">10337C<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>756.37</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Telzir [VI]<inline label="genericindexfieldbrand"><italic>XE "Telzir(VI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AE21424011000036107"><xref-fragment id="59926-J05AE21424011000036107"><blockxref id="105884" title="INDINAVIR" frag="default" reversefrag="J05AE21424011000036107" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60812" href="dynamic/CA/drug/21424011000036107-J05AE.psml" urititle="INDINAVIR" mediatype="application/vnd.pageseeder.psml+xml"><document id="60812" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60812" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21424011000036107-J05AE.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21424011000036107-J05AE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:22+10:00" title="INDINAVIR"><displaytitle>INDINAVIR</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AE21424011000036107" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105884" title="CA" type="none" forwardtype="embed" forwardtitle="INDINAVIR" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60812-21424011000036107-1"><fragment id="60812-21424011000036107-1"><block label="DrugName">INDINAVIR<inline label="genericindexfield">XE "INDINAVIR"</inline></block></fragment></section><section id="60812-d4452e16"><fragment id="60812-d4452e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4512</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60812-d4452e60"><fragment id="60812-d4452e60"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4454</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60812-10363K"><fragment id="60812-10363K"><block label="FormAndStrength">indinavir 400 mg capsule, 180</block><table role="CA"><row><cell><block label="DrugItemCode">10363K<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>906.23</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Crixivan 400 mg [MK]<inline label="genericindexfieldbrand"><italic>XE "Crixivan 400 mg(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AE21438011000036102"><xref-fragment id="59926-J05AE21438011000036102"><blockxref id="105867" title="RITONAVIR" frag="default" reversefrag="J05AE21438011000036102" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60026" href="dynamic/CA/drug/21438011000036102-J05AE.psml" urititle="RITONAVIR" mediatype="application/vnd.pageseeder.psml+xml"><document id="60026" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60026" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21438011000036102-J05AE.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21438011000036102-J05AE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:24+10:00" modified="2018-06-15T10:34:22+10:00" title="RITONAVIR"><displaytitle>RITONAVIR</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AE21438011000036102" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105867" title="CA" type="none" forwardtype="embed" forwardtitle="RITONAVIR" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60026-21438011000036102-1"><fragment id="60026-21438011000036102-1"><block label="DrugName">RITONAVIR<inline label="genericindexfield">XE "RITONAVIR"</inline></block></fragment></section><section id="60026-d4455e16"><fragment id="60026-d4455e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4512</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60026-d4455e60"><fragment id="60026-d4455e60"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4454</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60026-10300D"><fragment id="60026-10300D"><block label="FormAndStrength">ritonavir 600 mg/7.5 mL oral liquid, 90 mL</block><table role="CA"><row><cell><block label="DrugItemCode">10300D<br></br></block></cell><cell><block label="MaxQuantity">10</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>906.25</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norvir [VE]<inline label="genericindexfieldbrand"><italic>XE "Norvir(VE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60026-10273Q"><fragment id="60026-10273Q"><block label="FormAndStrength">ritonavir 100 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10273Q<br></br></block></cell><cell><block label="MaxQuantity">24</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>978.19</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norvir [VE]<inline label="genericindexfieldbrand"><italic>XE "Norvir(VE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AE21626011000036102"><xref-fragment id="59926-J05AE21626011000036102"><blockxref id="105861" title="SAQUINAVIR" frag="default" reversefrag="J05AE21626011000036102" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60782" href="dynamic/CA/drug/21626011000036102-J05AE.psml" urititle="SAQUINAVIR" mediatype="application/vnd.pageseeder.psml+xml"><document id="60782" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60782" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21626011000036102-J05AE.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21626011000036102-J05AE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:22+10:00" title="SAQUINAVIR"><displaytitle>SAQUINAVIR</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AE21626011000036102" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105861" title="CA" type="none" forwardtype="embed" forwardtitle="SAQUINAVIR" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60782-21626011000036102-1"><fragment id="60782-21626011000036102-1"><block label="DrugName">SAQUINAVIR<inline label="genericindexfield">XE "SAQUINAVIR"</inline></block></fragment></section><section id="60782-d4458e16"><fragment id="60782-d4458e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4512</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60782-d4458e60"><fragment id="60782-d4458e60"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4454</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60782-10335Y"><fragment id="60782-10335Y"><block label="FormAndStrength">saquinavir 500 mg tablet, 120</block><table role="CA"><row><cell><block label="DrugItemCode">10335Y<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1006.13</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Invirase [RO]<inline label="genericindexfieldbrand"><italic>XE "Invirase(RO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AE21820011000036106"><xref-fragment id="59926-J05AE21820011000036106"><blockxref id="105894" title="TIPRANAVIR" frag="default" reversefrag="J05AE21820011000036106" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60237" href="dynamic/CA/drug/21820011000036106-J05AE.psml" urititle="TIPRANAVIR" mediatype="application/vnd.pageseeder.psml+xml"><document id="60237" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60237" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21820011000036106-J05AE.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21820011000036106-J05AE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:26+10:00" modified="2018-06-15T10:34:22+10:00" title="TIPRANAVIR"><displaytitle>TIPRANAVIR</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AE21820011000036106" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105894" title="CA" type="none" forwardtype="embed" forwardtitle="TIPRANAVIR" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60237-21820011000036106-1"><fragment id="60237-21820011000036106-1"><block label="DrugName">TIPRANAVIR<inline label="genericindexfield">XE "TIPRANAVIR"</inline></block></fragment></section><section id="60237-d4461e16"><fragment id="60237-d4461e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5764</block><block label="RestrictionText"><para>HIV infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be in addition to optimised background therapy,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be antiretroviral experienced,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be co-administered with 200 mg ritonavir twice daily,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have experienced virological failure or clinical failure or genotypic resistance after each of at least 3 different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes.</para></item></list> <para>Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity.</para></block></fragment></section><section id="60237-10344K"><fragment id="60237-10344K"><block label="FormAndStrength">tipranavir 250 mg capsule, 120</block><table role="CA"><row><cell><block label="DrugItemCode">10344K<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1675.07</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Aptivus [BY]<inline label="genericindexfieldbrand"><italic>XE "Aptivus(BY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AF"><fragment id="59926-J05AF"><block label="ATCLevel4"><para>Nucleoside and nucleotide reverse transcriptase inhibitors</para></block></fragment></section><section id="59926-J05AF21664011000036103"><xref-fragment id="59926-J05AF21664011000036103"><blockxref id="105893" title="ABACAVIR" frag="default" reversefrag="J05AF21664011000036103" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60671" href="dynamic/CA/drug/21664011000036103-J05AF.psml" urititle="ABACAVIR" mediatype="application/vnd.pageseeder.psml+xml"><document id="60671" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60671" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21664011000036103-J05AF.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21664011000036103-J05AF.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:30+10:00" modified="2018-06-15T10:34:22+10:00" title="ABACAVIR"><displaytitle>ABACAVIR</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AF21664011000036103" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105893" title="CA" type="none" forwardtype="embed" forwardtitle="ABACAVIR" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60671-21664011000036103-1"><fragment id="60671-21664011000036103-1"><block label="DrugName">ABACAVIR<inline label="genericindexfield">XE "ABACAVIR"</inline></block></fragment></section><section id="60671-d4463e16"><fragment id="60671-d4463e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4512</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60671-d4463e60"><fragment id="60671-d4463e60"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4454</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60671-10294T"><fragment id="60671-10294T"><block label="FormAndStrength">abacavir 300 mg tablet, 60</block><table role="CA"><row><cell><block label="DrugItemCode">10294T<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>564.39</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Ziagen [VI]<inline label="genericindexfieldbrand"><italic>XE "Ziagen(VI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60671-10356C"><fragment id="60671-10356C"><block label="FormAndStrength">abacavir 20 mg/mL oral liquid, 240 mL</block><table role="CA"><row><cell><block label="DrugItemCode">10356C<br></br></block></cell><cell><block label="MaxQuantity">8</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>656.35</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Ziagen [VI]<inline label="genericindexfieldbrand"><italic>XE "Ziagen(VI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AF11951000144109"><xref-fragment id="59926-J05AF11951000144109"><blockxref id="105889" title="ADEFOVIR DIPIVOXIL" frag="default" reversefrag="J05AF11951000144109" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60483" href="dynamic/CA/drug/11951000144109-J05AF.psml" urititle="ADEFOVIR DIPIVOXIL" mediatype="application/vnd.pageseeder.psml+xml"><document id="60483" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60483" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/11951000144109-J05AF.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/11951000144109-J05AF.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:22+10:00" title="ADEFOVIR DIPIVOXIL"><displaytitle>ADEFOVIR DIPIVOXIL</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AF11951000144109" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105889" title="CA" type="none" forwardtype="embed" forwardtitle="ADEFOVIR DIPIVOXIL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60483-11951000144109-1"><fragment id="60483-11951000144109-1"><block label="DrugName">ADEFOVIR DIPIVOXIL<inline label="genericindexfield">XE "ADEFOVIR DIPIVOXIL"</inline></block></fragment></section><section id="60483-d4466e43"><fragment id="60483-d4466e43"><block label="NoteText"><para>Patients may receive treatment in combination with lamivudine but not with other PBS-subsidised antihepadnaviral therapy.</para></block></fragment></section><section id="60483-d4466e16"><fragment id="60483-d4466e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4490</block><block label="RestrictionText"><para>Chronic hepatitis B infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must not have cirrhosis,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have failed antihepadnaviral therapy,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration, in conjunction with documented chronic hepatitis B infection; OR</para></item><item><para>Patient must have repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months whilst on previous antihepadnaviral therapy, except in patients with evidence of poor compliance.</para></item></list></block></fragment></section><section id="60483-d4466e73"><fragment id="60483-d4466e73"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4510</block><block label="RestrictionText"><para>Chronic hepatitis B infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have cirrhosis,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have failed antihepadnaviral therapy,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have detectable HBV DNA.</para></item></list> <para>Patients with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.</para></block></fragment></section><section id="60483-10290N"><fragment id="60483-10290N"><block label="FormAndStrength">adefovir dipivoxil 10 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10290N<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1097.15</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Adefovir [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Adefovir(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Hepsera [GI]<inline label="genericindexfieldbrand"><italic>XE "Hepsera (GI)" \i </italic></inline></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AF21467011000036106"><xref-fragment id="59926-J05AF21467011000036106"><blockxref id="105875" title="DIDANOSINE" frag="default" reversefrag="J05AF21467011000036106" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60271" href="dynamic/CA/drug/21467011000036106-J05AF.psml" urititle="DIDANOSINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60271" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60271" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21467011000036106-J05AF.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21467011000036106-J05AF.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:26+10:00" modified="2018-06-15T10:34:22+10:00" title="DIDANOSINE"><displaytitle>DIDANOSINE</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AF21467011000036106" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105875" title="CA" type="none" forwardtype="embed" forwardtitle="DIDANOSINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60271-21467011000036106-1"><fragment id="60271-21467011000036106-1"><block label="DrugName">DIDANOSINE<inline label="genericindexfield">XE "DIDANOSINE"</inline></block></fragment></section><section id="60271-d4469e16"><fragment id="60271-d4469e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4512</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60271-d4469e60"><fragment id="60271-d4469e60"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4454</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60271-10313T"><fragment id="60271-10313T"><block label="FormAndStrength">didanosine 400 mg enteric capsule, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10313T<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>652.89</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Videx EC [BQ]<inline label="genericindexfieldbrand"><italic>XE "Videx EC(BQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60271-10364L"><fragment id="60271-10364L"><block label="FormAndStrength">didanosine 250 mg enteric capsule, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10364L<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>410.73</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Videx EC [BQ]<inline label="genericindexfieldbrand"><italic>XE "Videx EC(BQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AF21873011000036104"><xref-fragment id="59926-J05AF21873011000036104"><blockxref id="105868" title="EMTRICITABINE" frag="default" reversefrag="J05AF21873011000036104" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60182" href="dynamic/CA/drug/21873011000036104-J05AF.psml" urititle="EMTRICITABINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60182" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60182" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21873011000036104-J05AF.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21873011000036104-J05AF.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:25+10:00" modified="2018-06-15T10:34:22+10:00" title="EMTRICITABINE"><displaytitle>EMTRICITABINE</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AF21873011000036104" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105868" title="CA" type="none" forwardtype="embed" forwardtitle="EMTRICITABINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60182-21873011000036104-1"><fragment id="60182-21873011000036104-1"><block label="DrugName">EMTRICITABINE<inline label="genericindexfield">XE "EMTRICITABINE"</inline></block></fragment></section><section id="60182-d4472e16"><fragment id="60182-d4472e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4512</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60182-d4472e60"><fragment id="60182-d4472e60"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4454</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60182-10274R"><fragment id="60182-10274R"><block label="FormAndStrength">emtricitabine 200 mg capsule, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10274R<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>564.39</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Emtriva [GI]<inline label="genericindexfieldbrand"><italic>XE "Emtriva(GI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AF21490011000036108"><xref-fragment id="59926-J05AF21490011000036108"><blockxref id="105866" title="ENTECAVIR" frag="default" reversefrag="J05AF21490011000036108" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60584" href="dynamic/CA/drug/21490011000036108-J05AF.psml" urititle="ENTECAVIR" mediatype="application/vnd.pageseeder.psml+xml"><document id="60584" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60584" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21490011000036108-J05AF.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21490011000036108-J05AF.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:29+10:00" modified="2018-06-15T10:34:22+10:00" title="ENTECAVIR"><displaytitle>ENTECAVIR</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AF21490011000036108" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105866" title="CA" type="none" forwardtype="embed" forwardtitle="ENTECAVIR" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60584-21490011000036108-1"><fragment id="60584-21490011000036108-1"><block label="DrugName">ENTECAVIR<inline label="genericindexfield">XE "ENTECAVIR"</inline></block></fragment></section><section id="60584-d4475e16"><fragment id="60584-d4475e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4993</block><block label="RestrictionText"><para>Chronic hepatitis B infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must not have cirrhosis,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have elevated HBV DNA levels greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, in conjunction with documented hepatitis B infection; OR</para></item><item><para>Patient must have elevated HBV DNA levels greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative, in conjunction with documented hepatitis B infection,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of chronic liver injury determined by confirmed elevated serum ALT or liver biopsy.</para></item></list></block></fragment></section><section id="60584-d4475e70"><fragment id="60584-d4475e70"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5036</block><block label="RestrictionText"><para>Chronic hepatitis B infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have cirrhosis,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have detectable HBV DNA.</para></item></list> <para>Patients with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.</para></block></fragment></section><section id="60584-10279B"><fragment id="60584-10279B"><block label="FormAndStrength">entecavir monohydrate 500 microgram tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10279B<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>495.21</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Baraclude [BQ]<inline label="genericindexfieldbrand"><italic>XE "Baraclude(BQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">ENTAC [LR]<inline label="genericindexfieldbrand"><italic>XE "ENTAC (LR)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Entecavir Amneal [EA]<inline label="genericindexfieldbrand"><italic>XE "Entecavir Amneal(EA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Entecavir APOTEX [TX]<inline label="genericindexfieldbrand"><italic>XE "Entecavir APOTEX (TX)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Entecavir GH [GQ]<inline label="genericindexfieldbrand"><italic>XE "Entecavir GH(GQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Entecavir Mylan [AF]<inline label="genericindexfieldbrand"><italic>XE "Entecavir Mylan (AF)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">ENTECAVIR RBX [RA]<inline label="genericindexfieldbrand"><italic>XE "ENTECAVIR RBX(RA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Entecavir Sandoz [SZ]<inline label="genericindexfieldbrand"><italic>XE "Entecavir Sandoz (SZ)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">ENTECLUDE [RW]<inline label="genericindexfieldbrand"><italic>XE "ENTECLUDE(RW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60584-21490011000036108-2"><fragment id="60584-21490011000036108-2"><block label="DrugName">ENTECAVIR<inline label="genericindexfield">XE "ENTECAVIR"</inline></block></fragment></section><section id="60584-d4478e43"><fragment id="60584-d4478e43"><block label="NoteText"><para>PBS-subsidised entecavir monohydrate must be used as monotherapy.</para></block></fragment></section><section id="60584-d4478e16"><fragment id="60584-d4478e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5044</block><block label="RestrictionText"><para>Chronic hepatitis B infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must not have cirrhosis,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have failed lamivudine,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration, in conjunction with documented chronic hepatitis B infection; OR</para></item><item><para>Patient must have repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months whilst on previous antihepadnaviral therapy, except in patients with evidence of poor compliance.</para></item></list></block></fragment></section><section id="60584-d4478e73"><fragment id="60584-d4478e73"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5037</block><block label="RestrictionText"><para>Chronic hepatitis B infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have cirrhosis,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have failed lamivudine,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have detectable HBV DNA.</para></item></list> <para>Patients with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.</para></block></fragment></section><section id="60584-10353X"><fragment id="60584-10353X"><block label="FormAndStrength">entecavir monohydrate 1 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10353X<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>800.85</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Baraclude [BQ]<inline label="genericindexfieldbrand"><italic>XE "Baraclude(BQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">ENTAC [LR]<inline label="genericindexfieldbrand"><italic>XE "ENTAC (LR)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Entecavir Amneal [EA]<inline label="genericindexfieldbrand"><italic>XE "Entecavir Amneal(EA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Entecavir APOTEX [TX]<inline label="genericindexfieldbrand"><italic>XE "Entecavir APOTEX (TX)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Entecavir GH [GQ]<inline label="genericindexfieldbrand"><italic>XE "Entecavir GH(GQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Entecavir Mylan [AF]<inline label="genericindexfieldbrand"><italic>XE "Entecavir Mylan (AF)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">ENTECAVIR RBX [RA]<inline label="genericindexfieldbrand"><italic>XE "ENTECAVIR RBX(RA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Entecavir Sandoz [SZ]<inline label="genericindexfieldbrand"><italic>XE "Entecavir Sandoz (SZ)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">ENTECLUDE [RW]<inline label="genericindexfieldbrand"><italic>XE "ENTECLUDE(RW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AF21665011000036104"><xref-fragment id="59926-J05AF21665011000036104"><blockxref id="105890" title="LAMIVUDINE" frag="default" reversefrag="J05AF21665011000036104" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60539" href="dynamic/CA/drug/21665011000036104-J05AF.psml" urititle="LAMIVUDINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60539" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60539" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21665011000036104-J05AF.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21665011000036104-J05AF.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:29+10:00" modified="2018-06-15T10:34:22+10:00" title="LAMIVUDINE"><displaytitle>LAMIVUDINE</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AF21665011000036104" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105890" title="CA" type="none" forwardtype="embed" forwardtitle="LAMIVUDINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60539-21665011000036104-1"><fragment id="60539-21665011000036104-1"><block label="DrugName">LAMIVUDINE<inline label="genericindexfield">XE "LAMIVUDINE"</inline></block></fragment></section><section id="60539-d4481e16"><fragment id="60539-d4481e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4512</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60539-d4481e60"><fragment id="60539-d4481e60"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4454</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60539-10311Q"><fragment id="60539-10311Q"><block label="FormAndStrength">lamivudine 300 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10311Q<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>143.41</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">3TC [VI]<inline label="genericindexfieldbrand"><italic>XE "3TC(VI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Lamivudine Alphapharm [AF]<inline label="genericindexfieldbrand"><italic>XE "Lamivudine Alphapharm (AF)" \i </italic></inline></block></cell></row></table></fragment></section><section id="60539-10320E"><fragment id="60539-10320E"><block label="FormAndStrength">lamivudine 10 mg/mL oral liquid, 240 mL</block><table role="CA"><row><cell><block label="DrugItemCode">10320E<br></br></block></cell><cell><block label="MaxQuantity">8</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>472.91</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">3TC [VI]<inline label="genericindexfieldbrand"><italic>XE "3TC(VI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60539-10348P"><fragment id="60539-10348P"><block label="FormAndStrength">lamivudine 150 mg tablet, 60</block><table role="CA"><row><cell><block label="DrugItemCode">10348P<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>143.41</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">3TC [VI]<inline label="genericindexfieldbrand"><italic>XE "3TC(VI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Lamivudine Alphapharm [AF]<inline label="genericindexfieldbrand"><italic>XE "Lamivudine Alphapharm (AF)" \i </italic></inline></block></cell></row></table></fragment></section><section id="60539-21665011000036104-2"><fragment id="60539-21665011000036104-2"><block label="DrugName">LAMIVUDINE<inline label="genericindexfield">XE "LAMIVUDINE"</inline></block></fragment></section><section id="60539-d4484e16"><fragment id="60539-d4484e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4993</block><block label="RestrictionText"><para>Chronic hepatitis B infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must not have cirrhosis,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have elevated HBV DNA levels greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, in conjunction with documented hepatitis B infection; OR</para></item><item><para>Patient must have elevated HBV DNA levels greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative, in conjunction with documented hepatitis B infection,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of chronic liver injury determined by confirmed elevated serum ALT or liver biopsy.</para></item></list></block></fragment></section><section id="60539-d4484e70"><fragment id="60539-d4484e70"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5036</block><block label="RestrictionText"><para>Chronic hepatitis B infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have cirrhosis,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have detectable HBV DNA.</para></item></list> <para>Patients with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.</para></block></fragment></section><section id="60539-10338D"><fragment id="60539-10338D"><block label="FormAndStrength">lamivudine 5 mg/mL oral liquid, 240 mL</block><table role="CA"><row><cell><block label="DrugItemCode">10338D<br></br></block></cell><cell><block label="MaxQuantity">5</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>138.40</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Zeffix [RW]<inline label="genericindexfieldbrand"><italic>XE "Zeffix(RW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60539-10315X"><fragment id="60539-10315X"><block label="FormAndStrength">lamivudine 100 mg tablet, 28</block><table role="CA"><row><cell><block label="DrugItemCode">10315X<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>80.55</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Zetlam [AF]<inline label="genericindexfieldbrand"><italic>XE "Zetlam(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium"><inline label="BrandPricePremium"><sup>B</sup>1.20
</inline></block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>81.75</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Zeffix [RW]<inline label="genericindexfieldbrand"><italic>XE "Zeffix(RW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AF21314011000036107"><xref-fragment id="59926-J05AF21314011000036107"><blockxref id="105870" title="STAVUDINE" frag="default" reversefrag="J05AF21314011000036107" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60443" href="dynamic/CA/drug/21314011000036107-J05AF.psml" urititle="STAVUDINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60443" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60443" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21314011000036107-J05AF.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21314011000036107-J05AF.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:22+10:00" title="STAVUDINE"><displaytitle>STAVUDINE</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AF21314011000036107" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105870" title="CA" type="none" forwardtype="embed" forwardtitle="STAVUDINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60443-21314011000036107-1"><fragment id="60443-21314011000036107-1"><block label="DrugName">STAVUDINE<inline label="genericindexfield">XE "STAVUDINE"</inline></block></fragment></section><section id="60443-d4487e16"><fragment id="60443-d4487e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4512</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60443-d4487e60"><fragment id="60443-d4487e60"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4454</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60443-10271N"><fragment id="60443-10271N"><block label="FormAndStrength">stavudine 30 mg capsule, 60</block><table role="CA"><row><cell><block label="DrugItemCode">10271N<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>666.51</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Zerit [BQ]<inline label="genericindexfieldbrand"><italic>XE "Zerit(BQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60443-10312R"><fragment id="60443-10312R"><block label="FormAndStrength">stavudine 40 mg capsule, 60</block><table role="CA"><row><cell><block label="DrugItemCode">10312R<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>886.29</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Zerit [BQ]<inline label="genericindexfieldbrand"><italic>XE "Zerit(BQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AF11541000144100"><xref-fragment id="59926-J05AF11541000144100"><blockxref id="105883" title="TENOFOVIR" frag="default" reversefrag="J05AF11541000144100" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="61009" href="dynamic/CA/drug/11541000144100-J05AF.psml" urititle="TENOFOVIR" mediatype="application/vnd.pageseeder.psml+xml"><document id="61009" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="61009" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/11541000144100-J05AF.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/11541000144100-J05AF.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:34+10:00" modified="2018-06-15T10:34:22+10:00" title="TENOFOVIR"><displaytitle>TENOFOVIR</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AF11541000144100" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105883" title="CA" type="none" forwardtype="embed" forwardtitle="TENOFOVIR" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="61009-11541000144100-1"><fragment id="61009-11541000144100-1"><block label="DrugName">TENOFOVIR<inline label="genericindexfield">XE "TENOFOVIR"</inline></block></fragment></section><section id="61009-d4490e35"><fragment id="61009-d4490e35"><block label="NoteText"><para>Pharmaceutical benefits that have the forms tenofovir disoproxil phosphate 291 mg tablet, tenofovir disoproxil maleate 300 mg tablet, and tenofovir disoproxil fumarate 300 mg tablet are equivalent for the purposes of substitution.</para></block></fragment></section><section id="61009-d4490e16"><fragment id="61009-d4490e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">6998</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="61009-d4490e63"><fragment id="61009-d4490e63"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">6982</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="61009-d4490e110"><fragment id="61009-d4490e110"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">6980</block><block label="RestrictionText"><para>Chronic hepatitis B infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have cirrhosis,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be nucleoside analogue naive,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have detectable HBV DNA,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be the sole PBS-subsidised therapy for this condition.</para></item></list> <para>Patients with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.</para></block></fragment></section><section id="61009-d4490e144"><fragment id="61009-d4490e144"><block label="NoteText"><para>Patients may receive treatment in combination with lamivudine but not with other PBS-subsidised antihepadnaviral therapy.</para></block></fragment></section><section id="61009-d4490e179"><fragment id="61009-d4490e179"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">6992</block><block label="RestrictionText"><para>Chronic hepatitis B infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must not have cirrhosis,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be nucleoside analogue naive,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have elevated HBV DNA levels greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, in conjunction with documented hepatitis B infection; OR</para></item><item><para>Patient must have elevated HBV DNA levels greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative, in conjunction with documented hepatitis B infection,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of chronic liver injury determined by: (i) confirmed elevated serum ALT; or (ii) liver biopsy,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be the sole PBS-subsidised therapy for this condition.</para></item></list></block></fragment></section><section id="61009-d4490e220"><fragment id="61009-d4490e220"><block label="NoteText"><para>Patients may receive treatment in combination with lamivudine but not with other PBS-subsidised antihepadnaviral therapy.</para></block></fragment></section><section id="61009-d4490e257"><fragment id="61009-d4490e257"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">6983</block><block label="RestrictionText"><para>Chronic hepatitis B infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have cirrhosis,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have failed antihepadnaviral therapy,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have detectable HBV DNA.</para></item></list> <para>Patients with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.</para></block></fragment></section><section id="61009-d4490e284"><fragment id="61009-d4490e284"><block label="NoteText"><para>Patients may receive treatment in combination with lamivudine but not with other PBS-subsidised antihepadnaviral therapy.</para></block></fragment></section><section id="61009-d4490e317"><fragment id="61009-d4490e317"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">6984</block><block label="RestrictionText"><para>Chronic hepatitis B infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must not have cirrhosis,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have failed antihepadnaviral therapy,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration, in conjunction with documented chronic hepatitis B infection; OR</para></item><item><para>Patient must have repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months whilst on previous antihepadnaviral therapy, except in patients with evidence of poor compliance.</para></item></list></block></fragment></section><section id="61009-d4490e344"><fragment id="61009-d4490e344"><block label="NoteText"><para>Patients may receive treatment in combination with lamivudine but not with other PBS-subsidised antihepadnaviral therapy.</para></block></fragment></section><section id="61009-10310P"><fragment id="61009-10310P"><block label="FormAndStrength">tenofovir disoproxil fumarate 300 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10310P<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>809.03</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Viread [GI]<inline label="genericindexfieldbrand"><italic>XE "Viread(GI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="61009-11142K"><fragment id="61009-11142K"><block label="FormAndStrength">tenofovir disoproxil phosphate 291 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">11142K<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>809.03</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Tenofovir GH [GQ]<inline label="genericindexfieldbrand"><italic>XE "Tenofovir GH(GQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="61009-11155D"><fragment id="61009-11155D"><block label="FormAndStrength">tenofovir disoproxil maleate 300 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">11155D<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>809.03</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Tenofovir Disoproxil Mylan [AF]<inline label="genericindexfieldbrand"><italic>XE "Tenofovir Disoproxil Mylan(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AF21429011000036108"><xref-fragment id="59926-J05AF21429011000036108"><blockxref id="105886" title="ZIDOVUDINE" frag="default" reversefrag="J05AF21429011000036108" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60804" href="dynamic/CA/drug/21429011000036108-J05AF.psml" urititle="ZIDOVUDINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60804" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60804" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21429011000036108-J05AF.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21429011000036108-J05AF.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:22+10:00" title="ZIDOVUDINE"><displaytitle>ZIDOVUDINE</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AF21429011000036108" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105886" title="CA" type="none" forwardtype="embed" forwardtitle="ZIDOVUDINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60804-21429011000036108-1"><fragment id="60804-21429011000036108-1"><block label="DrugName">ZIDOVUDINE<inline label="genericindexfield">XE "ZIDOVUDINE"</inline></block></fragment></section><section id="60804-d4497e16"><fragment id="60804-d4497e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4512</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60804-d4497e60"><fragment id="60804-d4497e60"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4454</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60804-10266H"><fragment id="60804-10266H"><block label="FormAndStrength">zidovudine 100 mg capsule, 100</block><table role="CA"><row><cell><block label="DrugItemCode">10266H<br></br></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>819.15</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Retrovir [VI]<inline label="genericindexfieldbrand"><italic>XE "Retrovir(VI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60804-10361H"><fragment id="60804-10361H"><block label="FormAndStrength">zidovudine 50 mg/5 mL oral liquid, 200 mL</block><table role="CA"><row><cell><block label="DrugItemCode">10361H<br></br></block></cell><cell><block label="MaxQuantity">15</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>672.40</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Retrovir [VI]<inline label="genericindexfieldbrand"><italic>XE "Retrovir(VI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60804-10360G"><fragment id="60804-10360G"><block label="FormAndStrength">zidovudine 250 mg capsule, 40</block><table role="CA"><row><cell><block label="DrugItemCode">10360G<br></br></block></cell><cell><block label="MaxQuantity">6</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1218.31</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Retrovir [VI]<inline label="genericindexfieldbrand"><italic>XE "Retrovir(VI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AG"><fragment id="59926-J05AG"><block label="ATCLevel4"><para>Non-nucleoside reverse transcriptase inhibitors</para></block></fragment></section><section id="59926-J05AG21616011000036105"><xref-fragment id="59926-J05AG21616011000036105"><blockxref id="105873" title="EFAVIRENZ" frag="default" reversefrag="J05AG21616011000036105" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="59841" href="dynamic/CA/drug/21616011000036105-J05AG.psml" urititle="EFAVIRENZ" mediatype="application/vnd.pageseeder.psml+xml"><document id="59841" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="59841" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21616011000036105-J05AG.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21616011000036105-J05AG.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:22+10:00" title="EFAVIRENZ"><displaytitle>EFAVIRENZ</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AG21616011000036105" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105873" title="CA" type="none" forwardtype="embed" forwardtitle="EFAVIRENZ" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59841-21616011000036105-1"><fragment id="59841-21616011000036105-1"><block label="DrugName">EFAVIRENZ<inline label="genericindexfield">XE "EFAVIRENZ"</inline></block></fragment></section><section id="59841-d4500e16"><fragment id="59841-d4500e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4512</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="59841-d4500e60"><fragment id="59841-d4500e60"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4454</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="59841-10336B"><fragment id="59841-10336B"><block label="FormAndStrength">efavirenz 200 mg tablet, 90</block><table role="CA"><row><cell><block label="DrugItemCode">10336B<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>543.79</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Stocrin [MK]<inline label="genericindexfieldbrand"><italic>XE "Stocrin(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59841-10366N"><fragment id="59841-10366N"><block label="FormAndStrength">efavirenz 600 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10366N<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>543.79</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Stocrin [MK]<inline label="genericindexfieldbrand"><italic>XE "Stocrin(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59841-10275T"><fragment id="59841-10275T"><block label="FormAndStrength">efavirenz 30 mg/mL oral liquid, 180 mL</block><table role="CA"><row><cell><block label="DrugItemCode">10275T<br></br></block></cell><cell><block label="MaxQuantity">7</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>570.65</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Stocrin [MK]<inline label="genericindexfieldbrand"><italic>XE "Stocrin(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AG77467011000036101"><xref-fragment id="59926-J05AG77467011000036101"><blockxref id="105877" title="ETRAVIRINE" frag="default" reversefrag="J05AG77467011000036101" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60630" href="dynamic/CA/drug/77467011000036101-J05AG.psml" urititle="ETRAVIRINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60630" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60630" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/77467011000036101-J05AG.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/77467011000036101-J05AG.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:30+10:00" modified="2018-06-15T10:34:22+10:00" title="ETRAVIRINE"><displaytitle>ETRAVIRINE</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AG77467011000036101" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105877" title="CA" type="none" forwardtype="embed" forwardtitle="ETRAVIRINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60630-77467011000036101-1"><fragment id="60630-77467011000036101-1"><block label="DrugName">ETRAVIRINE<inline label="genericindexfield">XE "ETRAVIRINE"</inline></block></fragment></section><section id="60630-d4503e16"><fragment id="60630-d4503e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5014</block><block label="RestrictionText"><para>HIV infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be in addition to optimised background therapy,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be antiretroviral experienced,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have experienced virological failure or clinical failure or genotypic resistance after each of at least 3 different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes.</para></item></list> <para>Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity.</para></block></fragment></section><section id="60630-10301E"><fragment id="60630-10301E"><block label="FormAndStrength">etravirine 200 mg tablet, 60</block><table role="CA"><row><cell><block label="DrugItemCode">10301E<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1218.51</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Intelence [JC]<inline label="genericindexfieldbrand"><italic>XE "Intelence(JC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AG21551011000036104"><xref-fragment id="59926-J05AG21551011000036104"><blockxref id="105897" title="NEVIRAPINE" frag="default" reversefrag="J05AG21551011000036104" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60805" href="dynamic/CA/drug/21551011000036104-J05AG.psml" urititle="NEVIRAPINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60805" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60805" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21551011000036104-J05AG.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21551011000036104-J05AG.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:22+10:00" title="NEVIRAPINE"><displaytitle>NEVIRAPINE</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AG21551011000036104" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105897" title="CA" type="none" forwardtype="embed" forwardtitle="NEVIRAPINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60805-21551011000036104-1"><fragment id="60805-21551011000036104-1"><block label="DrugName">NEVIRAPINE<inline label="genericindexfield">XE "NEVIRAPINE"</inline></block></fragment></section><section id="60805-d4505e16"><fragment id="60805-d4505e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4526</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have been stabilised on nevirapine immediate release,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60805-d4505e60"><fragment id="60805-d4505e60"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4454</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60805-10303G"><fragment id="60805-10303G"><block label="FormAndStrength">nevirapine 400 mg modified release tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10303G<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>334.01</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Nevirapine XR APOTEX [TX]<inline label="genericindexfieldbrand"><italic>XE "Nevirapine XR APOTEX(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Viramune XR [BY]<inline label="genericindexfieldbrand"><italic>XE "Viramune XR (BY)" \i </italic></inline></block></cell></row></table></fragment></section><section id="60805-21551011000036104-2"><fragment id="60805-21551011000036104-2"><block label="DrugName">NEVIRAPINE<inline label="genericindexfield">XE "NEVIRAPINE"</inline></block></fragment></section><section id="60805-d4508e16"><fragment id="60805-d4508e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4512</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60805-d4508e60"><fragment id="60805-d4508e60"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4454</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60805-10319D"><fragment id="60805-10319D"><block label="FormAndStrength">nevirapine 10 mg/mL oral liquid, 240 mL</block><table role="CA"><row><cell><block label="DrugItemCode">10319D<br></br></block></cell><cell><block label="MaxQuantity">10</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1397.15</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Viramune [BY]<inline label="genericindexfieldbrand"><italic>XE "Viramune(BY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60805-10304H"><fragment id="60805-10304H"><block label="FormAndStrength">nevirapine 200 mg tablet, 60</block><table role="CA"><row><cell><block label="DrugItemCode">10304H<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>334.01</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Nevirapine Alphapharm [AF]<inline label="genericindexfieldbrand"><italic>XE "Nevirapine Alphapharm(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Viramune [BY]<inline label="genericindexfieldbrand"><italic>XE "Viramune (BY)" \i </italic></inline></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AG14661000036100"><xref-fragment id="59926-J05AG14661000036100"><blockxref id="105895" title="RILPIVIRINE" frag="default" reversefrag="J05AG14661000036100" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="59708" href="dynamic/CA/drug/14661000036100-J05AG.psml" urititle="RILPIVIRINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59708" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="59708" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/14661000036100-J05AG.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/14661000036100-J05AG.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:20+10:00" modified="2018-06-15T10:34:22+10:00" title="RILPIVIRINE"><displaytitle>RILPIVIRINE</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AG14661000036100" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105895" title="CA" type="none" forwardtype="embed" forwardtitle="RILPIVIRINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59708-14661000036100-1"><fragment id="59708-14661000036100-1"><block label="DrugName">RILPIVIRINE<inline label="genericindexfield">XE "RILPIVIRINE"</inline></block></fragment></section><section id="59708-d4511e16"><fragment id="59708-d4511e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4512</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="59708-d4511e60"><fragment id="59708-d4511e60"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4454</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="59708-10298B"><fragment id="59708-10298B"><block label="FormAndStrength">rilpivirine 25 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10298B<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>543.79</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Edurant [JC]<inline label="genericindexfieldbrand"><italic>XE "Edurant(JC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AR"><fragment id="59926-J05AR"><block label="ATCLevel4"><para>Antivirals for treatment of HIV infections, combinations</para></block></fragment></section><section id="59926-J05AR21390011000036103"><xref-fragment id="59926-J05AR21390011000036103"><blockxref id="105878" title="ABACAVIR + LAMIVUDINE" frag="default" reversefrag="J05AR21390011000036103" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60131" href="dynamic/CA/drug/21390011000036103-J05AR.psml" urititle="ABACAVIR + LAMIVUDINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60131" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60131" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21390011000036103-J05AR.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21390011000036103-J05AR.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:25+10:00" modified="2018-06-15T10:34:22+10:00" title="ABACAVIR + LAMIVUDINE"><displaytitle>ABACAVIR + LAMIVUDINE</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AR21390011000036103" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105878" title="CA" type="none" forwardtype="embed" forwardtitle="ABACAVIR + LAMIVUDINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60131-21390011000036103-1"><fragment id="60131-21390011000036103-1"><block label="DrugName">ABACAVIR + LAMIVUDINE<inline label="genericindexfield">XE "ABACAVIR + LAMIVUDINE"</inline></block></fragment></section><section id="60131-d4514e49"><fragment id="60131-d4514e49"><block label="NoteText"><para>Pharmaceutical benefits that have the form tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg and pharmaceutical benefits that have the form tablet containing abacavir 600 mg (as hydrochloride) with lamivudine 300 mg are equivalent for the purposes of substitution.</para></block></fragment></section><section id="60131-d4514e16"><fragment id="60131-d4514e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4527</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 12 years or older,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must weigh 40 kg or more.</para></item></list></block></fragment></section><section id="60131-d4514e81"><fragment id="60131-d4514e81"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4528</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 12 years or older,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must weigh 40 kg or more.</para></item></list></block></fragment></section><section id="60131-10357D"><fragment id="60131-10357D"><block label="FormAndStrength">abacavir 600 mg + lamivudine 300 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10357D<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>611.49</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Abacavir/Lamivudine 600/300 APOTEX [TX]<inline label="genericindexfieldbrand"><italic>XE "Abacavir/Lamivudine 600/300 APOTEX(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Abacavir/Lamivudine Mylan [AF]<inline label="genericindexfieldbrand"><italic>XE "Abacavir/Lamivudine Mylan (AF)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Kivexa [VI]<inline label="genericindexfieldbrand"><italic>XE "Kivexa(VI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60131-11246X"><fragment id="60131-11246X"><block label="FormAndStrength">abacavir 600 mg + lamivudine 300 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">11246X<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>611.49</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Abacavir/Lamivudine GH 600/300 [GQ]<inline label="genericindexfieldbrand"><italic>XE "Abacavir/Lamivudine GH 600/300(GQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AR21556011000036109"><xref-fragment id="59926-J05AR21556011000036109"><blockxref id="105863" title="ABACAVIR + LAMIVUDINE + ZIDOVUDINE" frag="default" reversefrag="J05AR21556011000036109" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="61034" href="dynamic/CA/drug/21556011000036109-J05AR.psml" urititle="ABACAVIR + LAMIVUDINE + ZIDOVUDINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="61034" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="61034" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21556011000036109-J05AR.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21556011000036109-J05AR.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:34+10:00" modified="2018-06-15T10:34:22+10:00" title="ABACAVIR + LAMIVUDINE + ZIDOVUDINE"><displaytitle>ABACAVIR + LAMIVUDINE + ZIDOVUDINE</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AR21556011000036109" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105863" title="CA" type="none" forwardtype="embed" forwardtitle="ABACAVIR + LAMIVUDINE + ZIDOVUDINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="61034-21556011000036109-1"><fragment id="61034-21556011000036109-1"><block label="DrugName">ABACAVIR + LAMIVUDINE + ZIDOVUDINE<inline label="genericindexfield">XE "ABACAVIR + LAMIVUDINE + ZIDOVUDINE"</inline></block></fragment></section><section id="61034-d4517e16"><fragment id="61034-d4517e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4495</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 12 years or older,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must weigh 40 kg or more.</para></item></list></block></fragment></section><section id="61034-d4517e69"><fragment id="61034-d4517e69"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4480</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 12 years or older,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must weigh 40 kg or more.</para></item></list></block></fragment></section><section id="61034-10305J"><fragment id="61034-10305J"><block label="FormAndStrength">abacavir 300 mg + lamivudine 150 mg + zidovudine 300 mg tablet, 60</block><table role="CA"><row><cell><block label="DrugItemCode">10305J<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>829.79</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Trizivir [VI]<inline label="genericindexfieldbrand"><italic>XE "Trizivir(VI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AR379171000144108"><xref-fragment id="59926-J05AR379171000144108"><blockxref id="105864" title="DARUNAVIR + COBICISTAT" frag="default" reversefrag="J05AR379171000144108" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60751" href="dynamic/CA/drug/379171000144108-J05AR.psml" urititle="DARUNAVIR + COBICISTAT" mediatype="application/vnd.pageseeder.psml+xml"><document id="60751" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60751" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/379171000144108-J05AR.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/379171000144108-J05AR.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:31+10:00" modified="2018-06-15T10:34:22+10:00" title="DARUNAVIR + COBICISTAT"><displaytitle>DARUNAVIR + COBICISTAT</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AR379171000144108" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105864" title="CA" type="none" forwardtype="embed" forwardtitle="DARUNAVIR + COBICISTAT" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60751-379171000144108-1"><fragment id="60751-379171000144108-1"><block label="DrugName">DARUNAVIR + COBICISTAT<inline label="genericindexfield">XE "DARUNAVIR + COBICISTAT"</inline></block></fragment></section><section id="60751-d4520e16"><fragment id="60751-d4520e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">6413</block><block label="RestrictionText"><para>Human immunodeficiency virus (HIV) infection</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not be in combination with ritonavir.</para></item></list></block></fragment></section><section id="60751-d4520e42"><fragment id="60751-d4520e42"><block label="NoteText"><para>The cobicistat component of the darunavir + cobicistat combination product provides the necessary pharmacokinetic enhancement of darunavir to achieve therapeutic levels of darunavir.</para></block></fragment></section><section id="60751-d4520e72"><fragment id="60751-d4520e72"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">6428</block><block label="RestrictionText"><para>Human immunodeficiency virus (HIV) infection</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not be in combination with ritonavir.</para></item></list></block></fragment></section><section id="60751-d4520e98"><fragment id="60751-d4520e98"><block label="NoteText"><para>The cobicistat component of the darunavir + cobicistat combination product provides the necessary pharmacokinetic enhancement of darunavir to achieve therapeutic levels of darunavir.</para></block></fragment></section><section id="60751-d4520e128"><fragment id="60751-d4520e128"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">6377</block><block label="RestrictionText"><para>Human immunodeficiency virus (HIV) infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be in addition to optimised background therapy,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not be in combination with ritonavir,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have experienced virological failure or clinical failure or genotypic resistance after at least one antiretroviral regimen.</para></item></list> <para>Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity.</para></block></fragment></section><section id="60751-d4520e162"><fragment id="60751-d4520e162"><block label="NoteText"><para>The cobicistat component of the darunavir + cobicistat combination product provides the necessary pharmacokinetic enhancement of darunavir to achieve therapeutic levels of darunavir.</para></block></fragment></section><section id="60751-10903W"><fragment id="60751-10903W"><block label="FormAndStrength">darunavir 800 mg + cobicistat 150 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10903W<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1341.39</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Prezcobix [JC]<inline label="genericindexfieldbrand"><italic>XE "Prezcobix(JC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AR691321000168103"><xref-fragment id="59926-J05AR691321000168103"><blockxref id="105869" title="DOLUTEGRAVIR + ABACAVIR + LAMIVUDINE" frag="default" reversefrag="J05AR691321000168103" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60492" href="dynamic/CA/drug/691321000168103-J05AR.psml" urititle="DOLUTEGRAVIR + ABACAVIR + LAMIVUDINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60492" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60492" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/691321000168103-J05AR.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/691321000168103-J05AR.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:22+10:00" title="DOLUTEGRAVIR + ABACAVIR + LAMIVUDINE"><displaytitle>DOLUTEGRAVIR + ABACAVIR + LAMIVUDINE</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AR691321000168103" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105869" title="CA" type="none" forwardtype="embed" forwardtitle="DOLUTEGRAVIR + ABACAVIR + LAMIVUDINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60492-691321000168103-1"><fragment id="60492-691321000168103-1"><block label="DrugName">DOLUTEGRAVIR + ABACAVIR + LAMIVUDINE<inline label="genericindexfield">XE "DOLUTEGRAVIR + ABACAVIR + LAMIVUDINE"</inline></block></fragment></section><section id="60492-d4524e16"><fragment id="60492-d4524e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4495</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 12 years or older,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must weigh 40 kg or more.</para></item></list></block></fragment></section><section id="60492-d4524e69"><fragment id="60492-d4524e69"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4480</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 12 years or older,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must weigh 40 kg or more.</para></item></list></block></fragment></section><section id="60492-10345L"><fragment id="60492-10345L"><block label="FormAndStrength">dolutegravir 50 mg + abacavir 600 mg + lamivudine 300 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10345L<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1847.83</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Triumeq [VI]<inline label="genericindexfieldbrand"><italic>XE "Triumeq(VI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AR424901000144108"><xref-fragment id="59926-J05AR424901000144108"><blockxref id="105860" title="EMTRICITABINE + RILPIVIRINE + TENOFOVIR ALAFENAMIDE" frag="default" reversefrag="J05AR424901000144108" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="59901" href="dynamic/CA/drug/424901000144108-J05AR.psml" urititle="EMTRICITABINE + RILPIVIRINE + TENOFOVIR ALAFENAMIDE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59901" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="59901" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/424901000144108-J05AR.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/424901000144108-J05AR.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:22+10:00" title="EMTRICITABINE + RILPIVIRINE + TENOFOVIR ALAFENAMIDE"><displaytitle>EMTRICITABINE + RILPIVIRINE + TENOFOVIR ALAFENAMIDE</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AR424901000144108" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105860" title="CA" type="none" forwardtype="embed" forwardtitle="EMTRICITABINE + RILPIVIRINE + TENOFOVIR ALAFENAMIDE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59901-424901000144108-1"><fragment id="59901-424901000144108-1"><block label="DrugName">EMTRICITABINE + RILPIVIRINE + TENOFOVIR ALAFENAMIDE<inline label="genericindexfield">XE "EMTRICITABINE + RILPIVIRINE + TENOFOVIR ALAFENAMIDE"</inline></block></fragment></section><section id="59901-d4527e16"><fragment id="59901-d4527e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4522</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive.</para></item></list></block></fragment></section><section id="59901-d4527e51"><fragment id="59901-d4527e51"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4470</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection.</para></item></list></block></fragment></section><section id="59901-11104K"><fragment id="59901-11104K"><block label="FormAndStrength">emtricitabine 200 mg + rilpivirine 25 mg + tenofovir alafenamide 25 mg tablet, 30 tablets</block><table role="CA"><row><cell><block label="DrugItemCode">11104K<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>2016.85</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Odefsey [GI]<inline label="genericindexfieldbrand"><italic>XE "Odefsey(GI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AR420271000144104"><xref-fragment id="59926-J05AR420271000144104"><blockxref id="105881" title="EMTRICITABINE + TENOFOVIR ALAFENAMIDE" frag="default" reversefrag="J05AR420271000144104" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="59931" href="dynamic/CA/drug/420271000144104-J05AR.psml" urititle="EMTRICITABINE + TENOFOVIR ALAFENAMIDE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59931" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="59931" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/420271000144104-J05AR.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/420271000144104-J05AR.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:22+10:00" title="EMTRICITABINE + TENOFOVIR ALAFENAMIDE"><displaytitle>EMTRICITABINE + TENOFOVIR ALAFENAMIDE</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AR420271000144104" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105881" title="CA" type="none" forwardtype="embed" forwardtitle="EMTRICITABINE + TENOFOVIR ALAFENAMIDE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59931-420271000144104-1"><fragment id="59931-420271000144104-1"><block label="DrugName">EMTRICITABINE + TENOFOVIR ALAFENAMIDE<inline label="genericindexfield">XE "EMTRICITABINE + TENOFOVIR ALAFENAMIDE"</inline></block></fragment></section><section id="59931-d4530e16"><fragment id="59931-d4530e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4512</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="59931-d4530e60"><fragment id="59931-d4530e60"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4454</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="59931-11113X"><fragment id="59931-11113X"><block label="FormAndStrength">emtricitabine 200 mg + tenofovir alafenamide 25 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">11113X<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1500.85</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Descovy [GI]<inline label="genericindexfieldbrand"><italic>XE "Descovy(GI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59931-11099E"><fragment id="59931-11099E"><block label="FormAndStrength">emtricitabine 200 mg + tenofovir alafenamide 10 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">11099E<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1500.85</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Descovy [GI]<inline label="genericindexfieldbrand"><italic>XE "Descovy(GI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AR21904011000036103"><xref-fragment id="59926-J05AR21904011000036103"><blockxref id="105882" title="LAMIVUDINE + ZIDOVUDINE" frag="default" reversefrag="J05AR21904011000036103" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="59852" href="dynamic/CA/drug/21904011000036103-J05AR.psml" urititle="LAMIVUDINE + ZIDOVUDINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59852" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="59852" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21904011000036103-J05AR.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21904011000036103-J05AR.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:22+10:00" title="LAMIVUDINE + ZIDOVUDINE"><displaytitle>LAMIVUDINE + ZIDOVUDINE</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AR21904011000036103" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105882" title="CA" type="none" forwardtype="embed" forwardtitle="LAMIVUDINE + ZIDOVUDINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59852-21904011000036103-1"><fragment id="59852-21904011000036103-1"><block label="DrugName">LAMIVUDINE + ZIDOVUDINE<inline label="genericindexfield">XE "LAMIVUDINE + ZIDOVUDINE"</inline></block></fragment></section><section id="59852-d4533e16"><fragment id="59852-d4533e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4512</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="59852-d4533e60"><fragment id="59852-d4533e60"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4454</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="59852-10284G"><fragment id="59852-10284G"><block label="FormAndStrength">lamivudine 150 mg + zidovudine 300 mg tablet, 60</block><table role="CA"><row><cell><block label="DrugItemCode">10284G<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>370.01</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Combivir [VI]<inline label="genericindexfieldbrand"><italic>XE "Combivir(VI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Lamivudine 150 mg + Zidovudine 300 mg Alphapharm [AF]<inline label="genericindexfieldbrand"><italic>XE "Lamivudine 150 mg + Zidovudine 300 mg Alphapharm (AF)" \i </italic></inline></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AR21345011000036102"><xref-fragment id="59926-J05AR21345011000036102"><blockxref id="105862" title="LOPINAVIR + RITONAVIR" frag="default" reversefrag="J05AR21345011000036102" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="59800" href="dynamic/CA/drug/21345011000036102-J05AR.psml" urititle="LOPINAVIR + RITONAVIR" mediatype="application/vnd.pageseeder.psml+xml"><document id="59800" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="59800" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21345011000036102-J05AR.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21345011000036102-J05AR.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:22+10:00" title="LOPINAVIR + RITONAVIR"><displaytitle>LOPINAVIR + RITONAVIR</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AR21345011000036102" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105862" title="CA" type="none" forwardtype="embed" forwardtitle="LOPINAVIR + RITONAVIR" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59800-21345011000036102-1"><fragment id="59800-21345011000036102-1"><block label="DrugName">LOPINAVIR + RITONAVIR<inline label="genericindexfield">XE "LOPINAVIR + RITONAVIR"</inline></block></fragment></section><section id="59800-d4536e16"><fragment id="59800-d4536e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4512</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="59800-d4536e60"><fragment id="59800-d4536e60"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4454</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="59800-10272P"><fragment id="59800-10272P"><block label="FormAndStrength">lopinavir 200 mg + ritonavir 50 mg tablet, 120</block><table role="CA"><row><cell><block label="DrugItemCode">10272P<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1408.93</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Kaletra [VE]<inline label="genericindexfieldbrand"><italic>XE "Kaletra(VE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59800-10285H"><fragment id="59800-10285H"><block label="FormAndStrength">lopinavir 100 mg + ritonavir 25 mg tablet, 60</block><table role="CA"><row><cell><block label="DrugItemCode">10285H<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>361.21</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Kaletra [VE]<inline label="genericindexfieldbrand"><italic>XE "Kaletra(VE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59800-10327M"><fragment id="59800-10327M"><block label="FormAndStrength">lopinavir 400 mg/5 mL + ritonavir 100 mg/5 mL oral liquid, 60 mL</block><table role="CA"><row><cell><block label="DrugItemCode">10327M<br></br></block></cell><cell><block label="MaxQuantity">10</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1329.55</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Kaletra [VE]<inline label="genericindexfieldbrand"><italic>XE "Kaletra(VE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AR12261000144105"><xref-fragment id="59926-J05AR12261000144105"><blockxref id="105874" title="TENOFOVIR + EMTRICITABINE" frag="default" reversefrag="J05AR12261000144105" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60973" href="dynamic/CA/drug/12261000144105-J05AR.psml" urititle="TENOFOVIR + EMTRICITABINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60973" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60973" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/12261000144105-J05AR.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/12261000144105-J05AR.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:33+10:00" modified="2018-06-15T10:34:22+10:00" title="TENOFOVIR + EMTRICITABINE"><displaytitle>TENOFOVIR + EMTRICITABINE</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AR12261000144105" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105874" title="CA" type="none" forwardtype="embed" forwardtitle="TENOFOVIR + EMTRICITABINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60973-12261000144105-1"><fragment id="60973-12261000144105-1"><block label="DrugName">TENOFOVIR + EMTRICITABINE<inline label="genericindexfield">XE "TENOFOVIR + EMTRICITABINE"</inline></block></fragment></section><section id="60973-d4539e35"><fragment id="60973-d4539e35"><block label="NoteText"><para>Pharmaceutical benefits that have the forms tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg tablet, tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg tablet, and tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg tablet are equivalent for the purposes of substitution.</para></block></fragment></section><section id="60973-d4539e16"><fragment id="60973-d4539e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">6985</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60973-d4539e63"><fragment id="60973-d4539e63"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">6986</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60973-10347N"><fragment id="60973-10347N"><block label="FormAndStrength">tenofovir disoproxil fumarate 300 mg + emtricitabine 200 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10347N<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>465.45</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Truvada [GI]<inline label="genericindexfieldbrand"><italic>XE "Truvada(GI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60973-11146P"><fragment id="60973-11146P"><block label="FormAndStrength">tenofovir disoproxil phosphate 291 mg + emtricitabine 200 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">11146P<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>465.45</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Tenofovir EMT GH [GQ]<inline label="genericindexfieldbrand"><italic>XE "Tenofovir EMT GH(GQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60973-11149T"><fragment id="60973-11149T"><block label="FormAndStrength">tenofovir disoproxil maleate 300 mg + emtricitabine 200 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">11149T<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>465.45</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Tenofovir Disoproxil Emtricitabine Mylan 300/200 [AF]<inline label="genericindexfieldbrand"><italic>XE "Tenofovir Disoproxil Emtricitabine Mylan 300/200(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AR13531000144105"><xref-fragment id="59926-J05AR13531000144105"><blockxref id="105880" title="TENOFOVIR + EMTRICITABINE + EFAVIRENZ" frag="default" reversefrag="J05AR13531000144105" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60633" href="dynamic/CA/drug/13531000144105-J05AR.psml" urititle="TENOFOVIR + EMTRICITABINE + EFAVIRENZ" mediatype="application/vnd.pageseeder.psml+xml"><document id="60633" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60633" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/13531000144105-J05AR.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/13531000144105-J05AR.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:30+10:00" modified="2018-06-15T10:34:22+10:00" title="TENOFOVIR + EMTRICITABINE + EFAVIRENZ"><displaytitle>TENOFOVIR + EMTRICITABINE + EFAVIRENZ</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AR13531000144105" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105880" title="CA" type="none" forwardtype="embed" forwardtitle="TENOFOVIR + EMTRICITABINE + EFAVIRENZ" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60633-13531000144105-1"><fragment id="60633-13531000144105-1"><block label="DrugName">TENOFOVIR + EMTRICITABINE + EFAVIRENZ<inline label="genericindexfield">XE "TENOFOVIR + EMTRICITABINE + EFAVIRENZ"</inline></block></fragment></section><section id="60633-d4542e16"><fragment id="60633-d4542e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4522</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive.</para></item></list></block></fragment></section><section id="60633-d4542e51"><fragment id="60633-d4542e51"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4470</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection.</para></item></list></block></fragment></section><section id="60633-10297Y"><fragment id="60633-10297Y"><block label="FormAndStrength">tenofovir disoproxil fumarate 300 mg + emtricitabine 200 mg + efavirenz 600 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10297Y<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1784.25</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Atripla [GI]<inline label="genericindexfieldbrand"><italic>XE "Atripla(GI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AR320321000144100"><xref-fragment id="59926-J05AR320321000144100"><blockxref id="105876" title="TENOFOVIR + EMTRICITABINE + ELVITEGRAVIR + COBICISTAT" frag="default" reversefrag="J05AR320321000144100" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60605" href="dynamic/CA/drug/320321000144100-J05AR.psml" urititle="TENOFOVIR + EMTRICITABINE + ELVITEGRAVIR + COBICISTAT" mediatype="application/vnd.pageseeder.psml+xml"><document id="60605" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60605" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/320321000144100-J05AR.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/320321000144100-J05AR.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:30+10:00" modified="2018-06-15T10:34:22+10:00" title="TENOFOVIR + EMTRICITABINE + ELVITEGRAVIR + COBICISTAT"><displaytitle>TENOFOVIR + EMTRICITABINE + ELVITEGRAVIR + COBICISTAT</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AR320321000144100" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105876" title="CA" type="none" forwardtype="embed" forwardtitle="TENOFOVIR + EMTRICITABINE + ELVITEGRAVIR + COBICISTAT" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60605-320321000144100-1"><fragment id="60605-320321000144100-1"><block label="DrugName">TENOFOVIR + EMTRICITABINE + ELVITEGRAVIR + COBICISTAT<inline label="genericindexfield">XE "TENOFOVIR + EMTRICITABINE + ELVITEGRAVIR + COBICISTAT"</inline></block></fragment></section><section id="60605-d4545e16"><fragment id="60605-d4545e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4522</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive.</para></item></list></block></fragment></section><section id="60605-d4545e51"><fragment id="60605-d4545e51"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4470</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection.</para></item></list></block></fragment></section><section id="60605-10307L"><fragment id="60605-10307L"><block label="FormAndStrength">tenofovir disoproxil fumarate 300 mg + emtricitabine 200 mg + elvitegravir 150 mg + cobicistat 150 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10307L<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1784.25</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Stribild [GI]<inline label="genericindexfieldbrand"><italic>XE "Stribild(GI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AR14111000144105"><xref-fragment id="59926-J05AR14111000144105"><blockxref id="105879" title="TENOFOVIR + EMTRICITABINE + RILPIVIRINE" frag="default" reversefrag="J05AR14111000144105" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="59722" href="dynamic/CA/drug/14111000144105-J05AR.psml" urititle="TENOFOVIR + EMTRICITABINE + RILPIVIRINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59722" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="59722" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/14111000144105-J05AR.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/14111000144105-J05AR.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:20+10:00" modified="2018-06-15T10:34:22+10:00" title="TENOFOVIR + EMTRICITABINE + RILPIVIRINE"><displaytitle>TENOFOVIR + EMTRICITABINE + RILPIVIRINE</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AR14111000144105" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105879" title="CA" type="none" forwardtype="embed" forwardtitle="TENOFOVIR + EMTRICITABINE + RILPIVIRINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59722-14111000144105-1"><fragment id="59722-14111000144105-1"><block label="DrugName">TENOFOVIR + EMTRICITABINE + RILPIVIRINE<inline label="genericindexfield">XE "TENOFOVIR + EMTRICITABINE + RILPIVIRINE"</inline></block></fragment></section><section id="59722-d4548e16"><fragment id="59722-d4548e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4522</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive.</para></item></list></block></fragment></section><section id="59722-d4548e51"><fragment id="59722-d4548e51"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4470</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection.</para></item></list></block></fragment></section><section id="59722-10314W"><fragment id="59722-10314W"><block label="FormAndStrength">tenofovir disoproxil fumarate 300 mg + emtricitabine 200 mg + rilpivirine 25 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10314W<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1784.25</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Eviplera [GI]<inline label="genericindexfieldbrand"><italic>XE "Eviplera(GI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AR420411000144108"><xref-fragment id="59926-J05AR420411000144108"><blockxref id="105859" title="TENOFOVIR ALAFENAMIDE + EMTRICITABINE + ELVITEGRAVIR + COBICISTAT" frag="default" reversefrag="J05AR420411000144108" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="59981" href="dynamic/CA/drug/420411000144108-J05AR.psml" urititle="TENOFOVIR ALAFENAMIDE + EMTRICITABINE + ELVITEGRAVIR + COBICISTAT" mediatype="application/vnd.pageseeder.psml+xml"><document id="59981" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="59981" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/420411000144108-J05AR.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/420411000144108-J05AR.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:23+10:00" modified="2018-06-15T10:34:22+10:00" title="TENOFOVIR ALAFENAMIDE + EMTRICITABINE + ELVITEGRAVIR + COBICISTAT"><displaytitle>TENOFOVIR ALAFENAMIDE + EMTRICITABINE + ELVITEGRAVIR + COBICISTAT</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AR420411000144108" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105859" title="CA" type="none" forwardtype="embed" forwardtitle="TENOFOVIR ALAFENAMIDE + EMTRICITABINE + ELVITEGRAVIR + COBICISTAT" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59981-420411000144108-1"><fragment id="59981-420411000144108-1"><block label="DrugName">TENOFOVIR ALAFENAMIDE + EMTRICITABINE + ELVITEGRAVIR + COBICISTAT<inline label="genericindexfield">XE "TENOFOVIR ALAFENAMIDE + EMTRICITABINE + ELVITEGRAVIR + COBICISTAT"</inline></block></fragment></section><section id="59981-d4551e16"><fragment id="59981-d4551e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4522</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive.</para></item></list></block></fragment></section><section id="59981-d4551e51"><fragment id="59981-d4551e51"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4470</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection.</para></item></list></block></fragment></section><section id="59981-11114Y"><fragment id="59981-11114Y"><block label="FormAndStrength">tenofovir alafenamide 10 mg + emtricitabine 200 mg + elvitegravir 150 mg + cobicistat 150 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">11114Y<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>2016.85</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genvoya [GI]<inline label="genericindexfieldbrand"><italic>XE "Genvoya(GI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AX"><fragment id="59926-J05AX"><block label="ATCLevel4"><para>Other antivirals</para></block></fragment></section><section id="59926-J05AX171081000036101"><xref-fragment id="59926-J05AX171081000036101"><blockxref id="105872" title="DOLUTEGRAVIR" frag="default" reversefrag="J05AX171081000036101" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60117" href="dynamic/CA/drug/171081000036101-J05AX.psml" urititle="DOLUTEGRAVIR" mediatype="application/vnd.pageseeder.psml+xml"><document id="60117" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60117" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/171081000036101-J05AX.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/171081000036101-J05AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:25+10:00" modified="2018-06-15T10:34:22+10:00" title="DOLUTEGRAVIR"><displaytitle>DOLUTEGRAVIR</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AX171081000036101" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105872" title="CA" type="none" forwardtype="embed" forwardtitle="DOLUTEGRAVIR" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60117-171081000036101-1"><fragment id="60117-171081000036101-1"><block label="DrugName">DOLUTEGRAVIR<inline label="genericindexfield">XE "DOLUTEGRAVIR"</inline></block></fragment></section><section id="60117-d4554e16"><fragment id="60117-d4554e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4512</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60117-d4554e60"><fragment id="60117-d4554e60"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4454</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="60117-10283F"><fragment id="60117-10283F"><block label="FormAndStrength">dolutegravir 50 mg tablet, 30</block><table role="CA"><row><cell><block label="DrugItemCode">10283F<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1378.25</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tivicay [VI]<inline label="genericindexfieldbrand"><italic>XE "Tivicay(VI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AX21744011000036100"><xref-fragment id="59926-J05AX21744011000036100"><blockxref id="105888" title="ENFUVIRTIDE" frag="default" reversefrag="J05AX21744011000036100" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="59670" href="dynamic/CA/drug/21744011000036100-J05AX.psml" urititle="ENFUVIRTIDE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59670" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="59670" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21744011000036100-J05AX.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21744011000036100-J05AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:19+10:00" modified="2018-06-15T10:34:22+10:00" title="ENFUVIRTIDE"><displaytitle>ENFUVIRTIDE</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AX21744011000036100" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105888" title="CA" type="none" forwardtype="embed" forwardtitle="ENFUVIRTIDE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59670-21744011000036100-1"><fragment id="59670-21744011000036100-1"><block label="DrugName">ENFUVIRTIDE<inline label="genericindexfield">XE "ENFUVIRTIDE"</inline></block></fragment></section><section id="59670-d4557e16"><fragment id="59670-d4557e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5014</block><block label="RestrictionText"><para>HIV infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be in addition to optimised background therapy,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be antiretroviral experienced,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have experienced virological failure or clinical failure or genotypic resistance after each of at least 3 different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes.</para></item></list> <para>Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity.</para></block></fragment></section><section id="59670-10365M"><fragment id="59670-10365M"><block label="FormAndStrength">enfuvirtide 90 mg injection [60 vials] (&amp;) inert substance diluent [60 x 1.1 mL vials], 1 pack</block><table role="CA"><row><cell><block label="DrugItemCode">10365M<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>4251.85</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Fuzeon [RO]<inline label="genericindexfieldbrand"><italic>XE "Fuzeon(RO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AX50741011000036103"><xref-fragment id="59926-J05AX50741011000036103"><blockxref id="105887" title="MARAVIROC" frag="default" reversefrag="J05AX50741011000036103" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="61022" href="dynamic/CA/drug/50741011000036103-J05AX.psml" urititle="MARAVIROC" mediatype="application/vnd.pageseeder.psml+xml"><document id="61022" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="61022" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/50741011000036103-J05AX.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/50741011000036103-J05AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:34+10:00" modified="2018-06-15T10:34:22+10:00" title="MARAVIROC"><displaytitle>MARAVIROC</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AX50741011000036103" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105887" title="CA" type="none" forwardtype="embed" forwardtitle="MARAVIROC" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="61022-50741011000036103-1"><fragment id="61022-50741011000036103-1"><block label="DrugName">MARAVIROC<inline label="genericindexfield">XE "MARAVIROC"</inline></block></fragment></section><section id="61022-d4559e16"><fragment id="61022-d4559e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5008</block><block label="RestrictionText"><para>HIV infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be infected with CCR5-tropic HIV-1,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in addition to optimised background therapy,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have experienced virological failure or clinical failure or genotypic resistance after each of at least 3 different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes.</para></item></list> <para>Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity.</para> <para>A tropism assay to determine CCR5 only strain status must be performed prior to initiation. Individuals with CXCR4 tropism demonstrated at any time point are not eligible.</para></block></fragment></section><section id="61022-10355B"><fragment id="61022-10355B"><block label="FormAndStrength">maraviroc 300 mg tablet, 60</block><table role="CA"><row><cell><block label="DrugItemCode">10355B<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1790.79</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Celsentri [VI]<inline label="genericindexfieldbrand"><italic>XE "Celsentri(VI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="61022-10318C"><fragment id="61022-10318C"><block label="FormAndStrength">maraviroc 150 mg tablet, 60</block><table role="CA"><row><cell><block label="DrugItemCode">10318C<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1790.79</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Celsentri [VI]<inline label="genericindexfieldbrand"><italic>XE "Celsentri(VI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59926-J05AX37767011000036101"><xref-fragment id="59926-J05AX37767011000036101"><blockxref id="105858" title="RALTEGRAVIR" frag="default" reversefrag="J05AX37767011000036101" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="61042" href="dynamic/CA/drug/37767011000036101-J05AX.psml" urititle="RALTEGRAVIR" mediatype="application/vnd.pageseeder.psml+xml"><document id="61042" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="61042" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/37767011000036101-J05AX.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/37767011000036101-J05AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:34+10:00" modified="2018-06-15T10:34:22+10:00" title="RALTEGRAVIR"><displaytitle>RALTEGRAVIR</displaytitle></uri><reversexrefs><reversexref uriid="59926" href="dynamic/CA/atc/J.psml" frag="J05AX37767011000036101" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="105858" title="CA" type="none" forwardtype="embed" forwardtitle="RALTEGRAVIR" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="61042-37767011000036101-1"><fragment id="61042-37767011000036101-1"><block label="DrugName">RALTEGRAVIR<inline label="genericindexfield">XE "RALTEGRAVIR"</inline></block></fragment></section><section id="61042-d4561e16"><fragment id="61042-d4561e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4512</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be antiretroviral treatment naive,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="61042-d4561e60"><fragment id="61042-d4561e60"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4454</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents.</para></item></list></block></fragment></section><section id="61042-10286J"><fragment id="61042-10286J"><block label="FormAndStrength">raltegravir 400 mg tablet, 60</block><table role="CA"><row><cell><block label="DrugItemCode">10286J<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1311.69</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Isentress [MK]<inline label="genericindexfieldbrand"><italic>XE "Isentress(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="61042-11248B"><fragment id="61042-11248B"><block label="FormAndStrength">raltegravir 600 mg tablet, 60</block><table role="CA"><row><cell><block label="DrugItemCode">11248B<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1311.69</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Isentress HD [MK]<inline label="genericindexfieldbrand"><italic>XE "Isentress HD(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="61042-37767011000036101-2"><fragment id="61042-37767011000036101-2"><block label="DrugName">RALTEGRAVIR<inline label="genericindexfield">XE "RALTEGRAVIR"</inline></block></fragment></section><section id="61042-d4564e16"><fragment id="61042-d4564e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4275</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Initial</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be antiretroviral experienced with at least 6 months therapy with 2 alternate classes of anti-retroviral therapy,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a CD4 count of less than 500 per cubic millimetre; OR</para></item><item><para>Patient must have symptomatic HIV disease.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 2 years or older.</para></item></list></block></fragment></section><section id="61042-d4564e83"><fragment id="61042-d4564e83"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4274</block><block label="RestrictionText"><para>HIV infection</para><para>Treatment Phase: Continuing</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be in combination with other antiretroviral agents,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be antiretroviral experienced with at least 6 months therapy with 2 alternate classes of anti-retroviral therapy,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy for HIV infection.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 2 years or older.</para></item></list></block></fragment></section><section id="61042-10326L"><fragment id="61042-10326L"><block label="FormAndStrength">raltegravir 100 mg chewable tablet, 60</block><table role="CA"><row><cell><block label="DrugItemCode">10326L<br></br></block></cell><cell><block label="MaxQuantity">6</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1970.95</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Isentress [MK]<inline label="genericindexfieldbrand"><italic>XE "Isentress(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="61042-10299C"><fragment id="61042-10299C"><block label="FormAndStrength">raltegravir 25 mg chewable tablet, 60</block><table role="CA"><row><cell><block label="DrugItemCode">10299C<br></br></block></cell><cell><block label="MaxQuantity">6</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>507.37</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Isentress [MK]<inline label="genericindexfieldbrand"><italic>XE "Isentress(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref><blockxref id="107074" title="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" frag="default" reversefrag="d114e746881" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60002" href="dynamic/CA/atc/L.psml" urititle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" mediatype="application/vnd.pageseeder.psml+xml"><document id="60002" schemaversion="0.12" date="2018-06-15T10:34:29+10:00" version="current" level="processed"><documentinfo><uri id="60002" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/atc/L.psml" decodedpath="/ps/test/local3/books/dynamic/CA/atc/L.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:23+10:00" modified="2018-06-15T10:34:29+10:00" title="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"><displaytitle>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</displaytitle></uri><reversexrefs><reversexref uriid="59844" href="dynamic/CA/therapeuticindex-CA.psml" frag="2" urititle="Therapeutic Index - Highly Specialised Drugs Program (Community Access) - CA" mediatype="application/vnd.pageseeder.psml+xml" id="105519" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60519" href="dynamic/CA.psml" frag="d114e746881" urititle="Highly Specialised Drugs Program (Community Access)" mediatype="application/vnd.pageseeder.psml+xml" id="107074" title="CA" type="none" forwardtype="embed" forwardtitle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="42610" fragment="60002-L03"><reversexrefs><reversexref uriid="59844" href="dynamic/CA/therapeuticindex-CA.psml" frag="2" urititle="Therapeutic Index - Highly Specialised Drugs Program (Community Access) - CA" mediatype="application/vnd.pageseeder.psml+xml" id="105520" title="Untitled" type="none" forwardtype="none" forwardtitle="IMMUNOSTIMULANTS" forwarddisplay="document" forwardfrag="L03"></reversexref></reversexrefs></locator><locator id="42611" fragment="60002-L03A"><reversexrefs><reversexref uriid="59844" href="dynamic/CA/therapeuticindex-CA.psml" frag="2" urititle="Therapeutic Index - Highly Specialised Drugs Program (Community Access) - CA" mediatype="application/vnd.pageseeder.psml+xml" id="105521" title="Untitled" type="none" forwardtype="none" forwardtitle="IMMUNOSTIMULANTS" forwarddisplay="document" forwardfrag="L03A"></reversexref></reversexrefs></locator><locator id="43080" fragment="60002-L03AB21788011000036101" editid="105998" modified="2018-06-15T10:34:23+10:00"></locator><locator id="43084" fragment="60002-L03AB21525011000036103" editid="106000" modified="2018-06-15T10:34:23+10:00"></locator><locator id="43082" fragment="60002-L03AB21592011000036102" editid="105999" modified="2018-06-15T10:34:23+10:00"></locator></fragmentinfo><metadata></metadata><section id="60002-L"><fragment id="60002-L"><block label="ATCLevel1"><para>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</para></block></fragment></section><section id="60002-L03"><fragment id="60002-L03"><block label="ATCLevel2"><para>IMMUNOSTIMULANTS</para></block></fragment></section><section id="60002-L03A"><fragment id="60002-L03A"><block label="ATCLevel3"><para>IMMUNOSTIMULANTS</para></block></fragment></section><section id="60002-L03AB"><fragment id="60002-L03AB"><block label="ATCLevel4"><para>Interferons</para></block></fragment></section><section id="60002-L03AB21592011000036102"><xref-fragment id="60002-L03AB21592011000036102"><blockxref id="105996" title="INTERFERON ALFA-2A" frag="default" reversefrag="L03AB21592011000036102" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="59883" href="dynamic/CA/drug/21592011000036102-L03AB.psml" urititle="INTERFERON ALFA-2A" mediatype="application/vnd.pageseeder.psml+xml"><document id="59883" schemaversion="0.12" date="2018-06-15T10:34:23+10:00" version="current" level="processed"><documentinfo><uri id="59883" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21592011000036102-L03AB.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21592011000036102-L03AB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:23+10:00" title="INTERFERON ALFA-2A"><displaytitle>INTERFERON ALFA-2A</displaytitle></uri><reversexrefs><reversexref uriid="60002" href="dynamic/CA/atc/L.psml" frag="L03AB21592011000036102" urititle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" mediatype="application/vnd.pageseeder.psml+xml" id="105996" title="CA" type="none" forwardtype="embed" forwardtitle="INTERFERON ALFA-2A" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59883-21592011000036102-1"><fragment id="59883-21592011000036102-1"><block label="DrugName">INTERFERON ALFA-2A<inline label="genericindexfield">XE "INTERFERON ALFA-2A"</inline></block></fragment></section><section id="59883-d4567e16"><fragment id="59883-d4567e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4993</block><block label="RestrictionText"><para>Chronic hepatitis B infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must not have cirrhosis,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have elevated HBV DNA levels greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, in conjunction with documented hepatitis B infection; OR</para></item><item><para>Patient must have elevated HBV DNA levels greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative, in conjunction with documented hepatitis B infection,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of chronic liver injury determined by confirmed elevated serum ALT or liver biopsy.</para></item></list></block></fragment></section><section id="59883-d4567e70"><fragment id="59883-d4567e70"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5036</block><block label="RestrictionText"><para>Chronic hepatitis B infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have cirrhosis,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have detectable HBV DNA.</para></item></list> <para>Patients with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.</para></block></fragment></section><section id="59883-10369R"><fragment id="59883-10369R"><block label="FormAndStrength">interferon alfa-2a 9 million units/0.5 mL injection, 0.5 mL syringe</block><table role="CA"><row><cell><block label="DrugItemCode">10369R<br></br></block></cell><cell><block label="MaxQuantity">30</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>2594.35</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Roferon-A [RO]<inline label="genericindexfieldbrand"><italic>XE "Roferon-A(RO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59883-10317B"><fragment id="59883-10317B"><block label="FormAndStrength">interferon alfa-2a 3 million units/0.5 mL injection, 0.5 mL syringe</block><table role="CA"><row><cell><block label="DrugItemCode">10317B<br></br></block></cell><cell><block label="MaxQuantity">30</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>890.35</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Roferon-A [RO]<inline label="genericindexfieldbrand"><italic>XE "Roferon-A(RO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60002-L03AB21525011000036103"><xref-fragment id="60002-L03AB21525011000036103"><blockxref id="105997" title="INTERFERON ALFA-2B" frag="default" reversefrag="L03AB21525011000036103" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60915" href="dynamic/CA/drug/21525011000036103-L03AB.psml" urititle="INTERFERON ALFA-2B" mediatype="application/vnd.pageseeder.psml+xml"><document id="60915" schemaversion="0.12" date="2018-06-15T10:34:23+10:00" version="current" level="processed"><documentinfo><uri id="60915" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21525011000036103-L03AB.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21525011000036103-L03AB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:33+10:00" modified="2018-06-15T10:34:23+10:00" title="INTERFERON ALFA-2B"><displaytitle>INTERFERON ALFA-2B</displaytitle></uri><reversexrefs><reversexref uriid="60002" href="dynamic/CA/atc/L.psml" frag="L03AB21525011000036103" urititle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" mediatype="application/vnd.pageseeder.psml+xml" id="105997" title="CA" type="none" forwardtype="embed" forwardtitle="INTERFERON ALFA-2B" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60915-21525011000036103-1"><fragment id="60915-21525011000036103-1"><block label="DrugName">INTERFERON ALFA-2B<inline label="genericindexfield">XE "INTERFERON ALFA-2B"</inline></block></fragment></section><section id="60915-d4570e16"><fragment id="60915-d4570e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4993</block><block label="RestrictionText"><para>Chronic hepatitis B infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must not have cirrhosis,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have elevated HBV DNA levels greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, in conjunction with documented hepatitis B infection; OR</para></item><item><para>Patient must have elevated HBV DNA levels greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative, in conjunction with documented hepatitis B infection,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of chronic liver injury determined by confirmed elevated serum ALT or liver biopsy.</para></item></list></block></fragment></section><section id="60915-d4570e70"><fragment id="60915-d4570e70"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5036</block><block label="RestrictionText"><para>Chronic hepatitis B infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have cirrhosis,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have detectable HBV DNA.</para></item></list> <para>Patients with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.</para></block></fragment></section><section id="60915-10339E"><fragment id="60915-10339E"><block label="FormAndStrength">interferon alfa-2b 25 million units/2.5 mL injection, 2.5 mL vial</block><table role="CA"><row><cell><block label="DrugItemCode">10339E<br></br></block></cell><cell><block label="MaxQuantity">15</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>3584.80</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Intron A [MK]<inline label="genericindexfieldbrand"><italic>XE "Intron A(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60915-10316Y"><fragment id="60915-10316Y"><block label="FormAndStrength">interferon alfa-2b 30 million units/1.2 mL injection, 1.2 mL</block><table role="CA"><row><cell><block label="DrugItemCode">10316Y<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>595.81</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Intron A Redipen [MK]<inline label="genericindexfieldbrand"><italic>XE "Intron A Redipen(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60915-10291P"><fragment id="60915-10291P"><block label="FormAndStrength">interferon alfa-2b 18 million units/1.2 mL injection, 1.2 mL</block><table role="CA"><row><cell><block label="DrugItemCode">10291P<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>360.33</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Intron A Redipen [MK]<inline label="genericindexfieldbrand"><italic>XE "Intron A Redipen(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60915-10370T"><fragment id="60915-10370T"><block label="FormAndStrength">interferon alfa-2b 10 million units/mL injection, 5 x 1 mL vials</block><table role="CA"><row><cell><block label="DrugItemCode">10370T<br></br></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1462.18</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Intron A [MK]<inline label="genericindexfieldbrand"><italic>XE "Intron A(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60915-10292Q"><fragment id="60915-10292Q"><block label="FormAndStrength">interferon alfa-2b 60 million units/1.2 mL injection, 1.2 mL</block><table role="CA"><row><cell><block label="DrugItemCode">10292Q<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1179.17</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Intron A Redipen [MK]<inline label="genericindexfieldbrand"><italic>XE "Intron A Redipen(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60915-10340F"><fragment id="60915-10340F"><block label="FormAndStrength">interferon alfa-2b 18 million units/3 mL injection, 3 mL vial</block><table role="CA"><row><cell><block label="DrugItemCode">10340F<br></br></block></cell><cell><block label="MaxQuantity">15</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>2594.20</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Intron A [MK]<inline label="genericindexfieldbrand"><italic>XE "Intron A(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60002-L03AB21788011000036101"><xref-fragment id="60002-L03AB21788011000036101"><blockxref id="105995" title="PEGINTERFERON ALFA-2A" frag="default" reversefrag="L03AB21788011000036101" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60453" href="dynamic/CA/drug/21788011000036101-L03AB.psml" urititle="PEGINTERFERON ALFA-2A" mediatype="application/vnd.pageseeder.psml+xml"><document id="60453" schemaversion="0.12" date="2018-06-15T10:34:23+10:00" version="current" level="processed"><documentinfo><uri id="60453" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21788011000036101-L03AB.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21788011000036101-L03AB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:23+10:00" title="PEGINTERFERON ALFA-2A"><displaytitle>PEGINTERFERON ALFA-2A</displaytitle></uri><reversexrefs><reversexref uriid="60002" href="dynamic/CA/atc/L.psml" frag="L03AB21788011000036101" urititle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" mediatype="application/vnd.pageseeder.psml+xml" id="105995" title="CA" type="none" forwardtype="embed" forwardtitle="PEGINTERFERON ALFA-2A" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60453-21788011000036101-1"><fragment id="60453-21788011000036101-1"><block label="DrugName">PEGINTERFERON ALFA-2A<inline label="genericindexfield">XE "PEGINTERFERON ALFA-2A"</inline></block></fragment></section><section id="60453-d4573e15"><fragment id="60453-d4573e15"><block label="CautionText"><para>Treatment with peginterferon alfa has been associated with depression and suicide in some patients. Patients with a history of suicidal ideation or depressive illness should be warned of the risks. Psychiatric status during therapy should be monitored.</para></block></fragment></section><section id="60453-d4573e19"><fragment id="60453-d4573e19"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5010</block><block label="RestrictionText"><para>Chronic hepatitis B infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must not have cirrhosis,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received peginterferon alfa therapy for the treatment of hepatitis B,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have elevated HBV DNA levels greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, in conjunction with documented hepatitis B infection; OR</para></item><item><para>Patient must have elevated HBV DNA levels greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative, in conjunction with documented hepatitis B infection,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of chronic liver injury determined by confirmed elevated serum ALT or liver biopsy,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be the sole PBS-subsidised therapy for this condition.</para></item></list></block></fragment></section><section id="60453-d4573e94"><fragment id="60453-d4573e94"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5067</block><block label="RestrictionText"><para>Chronic hepatitis B infection</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have cirrhosis,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have detectable HBV DNA,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be the sole PBS-subsidised therapy for this condition,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be limited to 1 course of treatment for a maximum duration of 48 weeks.</para></item></list> <para>Patients with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.</para></block></fragment></section><section id="60453-10278Y"><fragment id="60453-10278Y"><block label="FormAndStrength">peginterferon alfa-2a 180 microgram/0.5 mL injection, 4 x 0.5 mL syringes</block><table role="CA"><row><cell><block label="DrugItemCode">10278Y<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>2612.59</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Pegasys [RO]<inline label="genericindexfieldbrand"><italic>XE "Pegasys(RO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60453-10280C"><fragment id="60453-10280C"><block label="FormAndStrength">peginterferon alfa-2a 135 microgram/0.5 mL injection, 4 x 0.5 mL syringes</block><table role="CA"><row><cell><block label="DrugItemCode">10280C<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>2262.37</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Pegasys [RO]<inline label="genericindexfieldbrand"><italic>XE "Pegasys(RO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref><blockxref id="107075" title="NERVOUS SYSTEM" frag="default" reversefrag="d114e746881" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60468" href="dynamic/CA/atc/N.psml" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml"><document id="60468" schemaversion="0.12" date="2018-06-15T10:34:29+10:00" version="current" level="processed"><documentinfo><uri id="60468" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/atc/N.psml" decodedpath="/ps/test/local3/books/dynamic/CA/atc/N.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:29+10:00" title="NERVOUS SYSTEM"><displaytitle>NERVOUS SYSTEM</displaytitle></uri><reversexrefs><reversexref uriid="59844" href="dynamic/CA/therapeuticindex-CA.psml" frag="2" urititle="Therapeutic Index - Highly Specialised Drugs Program (Community Access) - CA" mediatype="application/vnd.pageseeder.psml+xml" id="105522" title="Untitled" type="none" forwardtype="none" forwardtitle="NERVOUS SYSTEM" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60519" href="dynamic/CA.psml" frag="d114e746881" urititle="Highly Specialised Drugs Program (Community Access)" mediatype="application/vnd.pageseeder.psml+xml" id="107075" title="CA" type="none" forwardtype="embed" forwardtitle="NERVOUS SYSTEM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="42614" fragment="60468-N05A"><reversexrefs><reversexref uriid="59844" href="dynamic/CA/therapeuticindex-CA.psml" frag="2" urititle="Therapeutic Index - Highly Specialised Drugs Program (Community Access) - CA" mediatype="application/vnd.pageseeder.psml+xml" id="105524" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIPSYCHOTICS" forwarddisplay="document" forwardfrag="N05A"></reversexref></reversexrefs></locator><locator id="42613" fragment="60468-N05"><reversexrefs><reversexref uriid="59844" href="dynamic/CA/therapeuticindex-CA.psml" frag="2" urititle="Therapeutic Index - Highly Specialised Drugs Program (Community Access) - CA" mediatype="application/vnd.pageseeder.psml+xml" id="105523" title="Untitled" type="none" forwardtype="none" forwardtitle="PSYCHOLEPTICS" forwarddisplay="document" forwardfrag="N05"></reversexref></reversexrefs></locator><locator id="43759" fragment="60468-N05AH21222011000036104" editid="106676" modified="2018-06-15T10:34:28+10:00"></locator></fragmentinfo><metadata></metadata><section id="60468-N"><fragment id="60468-N"><block label="ATCLevel1"><para>NERVOUS SYSTEM</para></block></fragment></section><section id="60468-N05"><fragment id="60468-N05"><block label="ATCLevel2"><para>PSYCHOLEPTICS</para></block></fragment></section><section id="60468-N05A"><fragment id="60468-N05A"><block label="ATCLevel3"><para>ANTIPSYCHOTICS</para></block></fragment></section><section id="60468-N05AH"><fragment id="60468-N05AH"><block label="ATCLevel4"><para>Diazepines, oxazepines, thiazepines and oxepines</para></block></fragment></section><section id="60468-N05AH21222011000036104"><xref-fragment id="60468-N05AH21222011000036104"><blockxref id="106675" title="CLOZAPINE" frag="default" reversefrag="N05AH21222011000036104" reversetitle="CA" reverselink="true" reversetype="none" display="document" type="embed" uriid="60875" href="dynamic/CA/drug/21222011000036104-N05AH.psml" urititle="CLOZAPINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60875" schemaversion="0.12" date="2018-06-15T10:34:28+10:00" version="current" level="processed"><documentinfo><uri id="60875" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/CA/drug/21222011000036104-N05AH.psml" decodedpath="/ps/test/local3/books/dynamic/CA/drug/21222011000036104-N05AH.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:28+10:00" title="CLOZAPINE"><displaytitle>CLOZAPINE</displaytitle></uri><reversexrefs><reversexref uriid="60468" href="dynamic/CA/atc/N.psml" frag="N05AH21222011000036104" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="106675" title="CA" type="none" forwardtype="embed" forwardtitle="CLOZAPINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60875-21222011000036104-1"><fragment id="60875-21222011000036104-1"><block label="DrugName">CLOZAPINE<inline label="genericindexfield">XE "CLOZAPINE"</inline></block></fragment></section><section id="60875-d4576e63"><fragment id="60875-d4576e63"><block label="NoteText"><para>Patients receiving clozapine under the PBS listing must be registered in the clozapine patient monitoring program relevant for the brand of clozapine being prescribed and dispensed: Novartis Clozaril Patient Monitoring System (eCPMS) or Hospira Clopineconnect.</para></block></fragment></section><section id="60875-d4576e16"><fragment id="60875-d4576e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4998</block><block label="RestrictionText"><para>Schizophrenia</para><para>Treatment Phase: Continuing treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a psychiatrist; OR</para></item><item><para>Must be treated by an authorised medical practitioner, with the agreement of the treating psychiatrist.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received PBS-subsidised therapy with this drug for this condition,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have completed at least 18 weeks therapy,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be on a clozapine dosage considered stable by a treating psychiatrist,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be under the supervision and direction of a psychiatrist reviewing the patient at regular intervals.</para></item></list> <para>A medical practitioner should request a quantity sufficient for up to one month's supply. Up to 5 repeats will be authorised. </para></block></fragment></section><section id="60875-10288L"><fragment id="60875-10288L"><block label="FormAndStrength">clozapine 200 mg tablet, 100</block><table role="CA"><row><cell><block label="DrugItemCode">10288L<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>511.31</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Clopine 200 [PF]<inline label="genericindexfieldbrand"><italic>XE "Clopine 200(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60875-10302F"><fragment id="60875-10302F"><block label="FormAndStrength">clozapine 50 mg tablet, 100</block><table role="CA"><row><cell><block label="DrugItemCode">10302F<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>141.61</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Clopine 50 [PF]<inline label="genericindexfieldbrand"><italic>XE "Clopine 50(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60875-10341G"><fragment id="60875-10341G"><block label="FormAndStrength">clozapine 50 mg/mL oral liquid, 100 mL</block><table role="CA"><row><cell><block label="DrugItemCode">10341G<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">147.55</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Clopine Suspension [PF]<inline label="genericindexfieldbrand"><italic>XE "Clopine Suspension(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60875-10289M"><fragment id="60875-10289M"><block label="FormAndStrength">clozapine 25 mg tablet, 100</block><table role="CA"><row><cell><block label="DrugItemCode">10289M<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>75.79</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Clopine 25 [PF]<inline label="genericindexfieldbrand"><italic>XE "Clopine 25(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Clozaril 25 [GO]<inline label="genericindexfieldbrand"><italic>XE "Clozaril 25 (GO)" \i </italic></inline></block></cell></row></table></fragment></section><section id="60875-10358E"><fragment id="60875-10358E"><block label="FormAndStrength">clozapine 100 mg tablet, 100</block><table role="CA"><row><cell><block label="DrugItemCode">10358E<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>259.23</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Clopine 100 [PF]<inline label="genericindexfieldbrand"><italic>XE "Clopine 100(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Clozaril 100 [GO]<inline label="genericindexfieldbrand"><italic>XE "Clozaril 100 (GO)" \i </italic></inline></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref></xref-fragment></section></document></blockxref>
<blockxref id="107705" title="therapeuticindex-MF.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="60211" href="dynamic/MF/therapeuticindex-MF.psml" urititle="Therapeutic Index - Botulinum Toxin Program - MF" mediatype="application/vnd.pageseeder.psml+xml"><document id="60211" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="60211" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/MF/therapeuticindex-MF.psml" decodedpath="/ps/test/local3/books/dynamic/MF/therapeuticindex-MF.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:26+10:00" modified="2018-06-15T10:34:32+10:00" title="Therapeutic Index - Botulinum Toxin Program - MF"><displaytitle>Therapeutic Index - Botulinum Toxin Program - MF</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107705" title="" type="none" forwardtype="embed" forwardtitle="therapeuticindex-MF.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="43382" fragment="60211-2" editid="106301" modified="2018-06-15T10:34:26+10:00"></locator></fragmentinfo><metadata></metadata><section id="60211-1"><fragment id="60211-1"><block label="mps3indexsectionbreak">MF</block><block label="schedule-heading">Botulinum Toxin Program</block></fragment><fragment id="60211-2"><block label="index"><para>MUSCULO-SKELETAL SYSTEM<inline label="indexpageref"><xref id="106298" title="MUSCULO-SKELETAL SYSTEM" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60918" href="#60918" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">MUSCULO-SKELETAL SYSTEM</xref></inline></para></block><block label="index2"><para indent="1">MUSCLE RELAXANTS<inline label="indexpageref"><xref id="106299" title="MUSCLE RELAXANTS" frag="M03" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60918" href="#60918-M03" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">MUSCULO-SKELETAL SYSTEM</xref></inline></para></block><block label="index3"><para indent="2">MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS<inline label="indexpageref"><xref id="106300" title="MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS" frag="M03A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60918" href="#60918-M03A" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">MUSCULO-SKELETAL SYSTEM</xref></inline></para></block></fragment></section></document></blockxref>
<blockxref id="107706" title="MF.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="59861" href="dynamic/MF.psml" urititle="Botulinum Toxin Program" mediatype="application/vnd.pageseeder.psml+xml"><document id="59861" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="59861" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/MF.psml" decodedpath="/ps/test/local3/books/dynamic/MF.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:32+10:00" title="Botulinum Toxin Program"><displaytitle>Botulinum Toxin Program</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107706" title="" type="none" forwardtype="embed" forwardtitle="MF.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="42634" fragment="59861-d114e902788" editid="105545" modified="2018-06-15T10:34:22+10:00"></locator></fragmentinfo><metadata></metadata><section id="59861-1"><fragment id="59861-1"><block label="mps3sectionbreak">MF</block></fragment></section><section id="59861-d114e902788"><xref-fragment id="59861-d114e902788"><blockxref id="105544" title="MUSCULO-SKELETAL SYSTEM" frag="default" reversefrag="d114e902788" reversetitle="MF" reverselink="true" reversetype="none" display="document" type="embed" uriid="60918" href="dynamic/MF/atc/M.psml" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml"><document id="60918" schemaversion="0.12" date="2018-06-15T10:35:17+10:00" version="current" level="processed"><documentinfo><uri id="60918" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/MF/atc/M.psml" decodedpath="/ps/test/local3/books/dynamic/MF/atc/M.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:33+10:00" modified="2018-06-15T10:35:17+10:00" title="MUSCULO-SKELETAL SYSTEM"><displaytitle>MUSCULO-SKELETAL SYSTEM</displaytitle></uri><reversexrefs><reversexref uriid="59861" href="dynamic/MF.psml" frag="d114e902788" urititle="Botulinum Toxin Program" mediatype="application/vnd.pageseeder.psml+xml" id="105544" title="MF" type="none" forwardtype="embed" forwardtitle="MUSCULO-SKELETAL SYSTEM" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60211" href="dynamic/MF/therapeuticindex-MF.psml" frag="2" urititle="Therapeutic Index - Botulinum Toxin Program - MF" mediatype="application/vnd.pageseeder.psml+xml" id="106298" title="Untitled" type="none" forwardtype="none" forwardtitle="MUSCULO-SKELETAL SYSTEM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="44910" fragment="60918-M03AX177251000036108" editid="107852" modified="2018-06-15T10:34:33+10:00"></locator><locator id="43384" fragment="60918-M03A"><reversexrefs><reversexref uriid="60211" href="dynamic/MF/therapeuticindex-MF.psml" frag="2" urititle="Therapeutic Index - Botulinum Toxin Program - MF" mediatype="application/vnd.pageseeder.psml+xml" id="106300" title="Untitled" type="none" forwardtype="none" forwardtitle="MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS" forwarddisplay="document" forwardfrag="M03A"></reversexref></reversexrefs></locator><locator id="44908" fragment="60918-M03AX32611011000036100" editid="107851" modified="2018-06-15T10:34:33+10:00"></locator><locator id="43383" fragment="60918-M03"><reversexrefs><reversexref uriid="60211" href="dynamic/MF/therapeuticindex-MF.psml" frag="2" urititle="Therapeutic Index - Botulinum Toxin Program - MF" mediatype="application/vnd.pageseeder.psml+xml" id="106299" title="Untitled" type="none" forwardtype="none" forwardtitle="MUSCLE RELAXANTS" forwarddisplay="document" forwardfrag="M03"></reversexref></reversexrefs></locator><locator id="44912" fragment="60918-M03AX21857011000036106" editid="107853" modified="2018-06-15T10:34:33+10:00"></locator></fragmentinfo><metadata></metadata><section id="60918-M"><fragment id="60918-M"><block label="ATCLevel1"><para>MUSCULO-SKELETAL SYSTEM</para></block></fragment></section><section id="60918-M03"><fragment id="60918-M03"><block label="ATCLevel2"><para>MUSCLE RELAXANTS</para></block></fragment></section><section id="60918-M03A"><fragment id="60918-M03A"><block label="ATCLevel3"><para>MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS</para></block></fragment></section><section id="60918-M03AX"><fragment id="60918-M03AX"><block label="ATCLevel4"><para>Other muscle relaxants, peripherally acting agents</para></block></fragment></section><section id="60918-M03AX21857011000036106"><xref-fragment id="60918-M03AX21857011000036106"><blockxref id="107850" title="BOTULINUM TOXIN TYPE A" frag="default" reversefrag="M03AX21857011000036106" reversetitle="MF" reverselink="true" reversetype="none" display="document" type="embed" uriid="59789" href="dynamic/MF/drug/21857011000036106-M03AX.psml" urititle="BOTULINUM TOXIN TYPE A" mediatype="application/vnd.pageseeder.psml+xml"><document id="59789" schemaversion="0.12" date="2018-06-15T10:34:33+10:00" version="current" level="processed"><documentinfo><uri id="59789" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/MF/drug/21857011000036106-M03AX.psml" decodedpath="/ps/test/local3/books/dynamic/MF/drug/21857011000036106-M03AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:33+10:00" title="BOTULINUM TOXIN TYPE A"><displaytitle>BOTULINUM TOXIN TYPE A</displaytitle></uri><reversexrefs><reversexref uriid="60918" href="dynamic/MF/atc/M.psml" frag="M03AX21857011000036106" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107850" title="MF" type="none" forwardtype="embed" forwardtitle="BOTULINUM TOXIN TYPE A" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59789-21857011000036106-1"><fragment id="59789-21857011000036106-1"><block label="DrugName">BOTULINUM TOXIN TYPE A<inline label="genericindexfield">XE "BOTULINUM TOXIN TYPE A"</inline></block></fragment></section><section id="59789-d5523e15"><fragment id="59789-d5523e15"><block label="CautionText"><para>Contraindications to treatment include known sensitivity to botulinum toxin.</para></block></fragment></section><section id="59789-d5523e55"><fragment id="59789-d5523e55"><block label="NoteText"><para>The units used to express the potency of botulinum toxin preparations currently available for PBS subsidy are not equivalent.</para></block></fragment></section><section id="59789-d5523e19"><fragment id="59789-d5523e19"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5221</block><block label="RestrictionText"><para>Blepharospasm or hemifacial spasm</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have blepharospasm; OR</para></item><item><para>Patient must have hemifacial spasm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a neurologist; OR</para></item><item><para>Must be treated by an ophthalmologist; OR</para></item><item><para>Must be treated by an otolaryngology head and neck surgeon; OR</para></item><item><para>Must be treated by a plastic surgeon.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 12 years or older.</para></item></list></block></fragment></section><section id="59789-10997T"><fragment id="59789-10997T"><block label="FormAndStrength">botulinum toxin type A 100 units injection, 1 vial</block><table role="MF"><row><cell><block label="DrugItemCode">10997T<br></br></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1626.07</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Botox [AG]<inline label="genericindexfieldbrand"><italic>XE "Botox(AG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59789-21857011000036106-2"><fragment id="59789-21857011000036106-2"><block label="DrugName">BOTULINUM TOXIN TYPE A<inline label="genericindexfield">XE "BOTULINUM TOXIN TYPE A"</inline></block></fragment></section><section id="59789-d5525e15"><fragment id="59789-d5525e15"><block label="CautionText"><para>Contraindications to treatment include known sensitivity to botulinum toxin.</para></block></fragment></section><section id="59789-d5525e52"><fragment id="59789-d5525e52"><block label="NoteText"><para>The units used to express the potency of botulinum toxin preparations currently available for PBS subsidy are not equivalent.</para></block></fragment></section><section id="59789-d5525e19"><fragment id="59789-d5525e19"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5406</block><block label="RestrictionText"><para>Spasmodic torticollis</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have spasmodic torticollis,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be as monotherapy; OR</para></item><item><para>The treatment must be as adjunctive therapy to current standard care.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a neurologist; OR</para></item><item><para>Must be treated by a plastic surgeon; OR</para></item><item><para>Must be treated by a rehabilitation specialist.</para></item></list></block></fragment></section><section id="59789-11023E"><fragment id="59789-11023E"><block label="FormAndStrength">botulinum toxin type A 100 units injection, 1 vial</block><table role="MF"><row><cell><block label="DrugItemCode">11023E<br></br></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1626.07</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Botox [AG]<inline label="genericindexfieldbrand"><italic>XE "Botox(AG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59789-21857011000036106-3"><fragment id="59789-21857011000036106-3"><block label="DrugName">BOTULINUM TOXIN TYPE A<inline label="genericindexfield">XE "BOTULINUM TOXIN TYPE A"</inline></block></fragment></section><section id="59789-d5527e15"><fragment id="59789-d5527e15"><block label="CautionText"><para>Contraindications to treatment include known sensitivity to botulinum toxin.</para></block></fragment></section><section id="59789-d5527e81"><fragment id="59789-d5527e81"><block label="NoteText"><para>The units used to express the potency of botulinum toxin preparations currently available for PBS subsidy are not equivalent.</para></block></fragment></section><section id="59789-d5527e84"><fragment id="59789-d5527e84"><block label="NoteText"><para>Special Pricing Arrangements apply.</para></block></fragment></section><section id="59789-d5527e19"><fragment id="59789-d5527e19"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5409</block><block label="RestrictionText"><para>Urinary incontinence</para><para><bold>Clinical criteria:</bold></para><list><item><para>The condition must be due to neurogenic detrusor overactivity, as demonstrated by urodynamic study,</para></item></list><para><bold>AND</bold></para><list><item><para>The condition must be inadequately controlled by anti-cholinergic therapy,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must experience at least 14 episodes of urinary incontinence per week prior to commencement of treatment with Botulinum Toxin Type A Neurotoxin Complex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be willing and able to self-catheterise,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not continue if the patient does not achieve a 50% or greater reduction from baseline in urinary incontinence episodes 6-12 weeks after the first treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have multiple sclerosis; OR</para></item><item><para>Patient must have a spinal cord injury; OR</para></item><item><para>Patient must be aged 18 years or older and have spina bifida.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a urologist; OR</para></item><item><para>Must be treated by a urogynaecologist.</para></item></list></block></fragment></section><section id="59789-10993N"><fragment id="59789-10993N"><block label="FormAndStrength">botulinum toxin type A 100 units injection, 1 vial</block><table role="MF"><row><cell><block label="DrugItemCode">10993N<br></br></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1626.07</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Botox [AG]<inline label="genericindexfieldbrand"><italic>XE "Botox(AG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59789-21857011000036106-4"><fragment id="59789-21857011000036106-4"><block label="DrugName">BOTULINUM TOXIN TYPE A<inline label="genericindexfield">XE "BOTULINUM TOXIN TYPE A"</inline></block></fragment></section><section id="59789-d5529e15"><fragment id="59789-d5529e15"><block label="CautionText"><para>Contraindications to treatment include known sensitivity to botulinum toxin.</para></block></fragment></section><section id="59789-d5529e66"><fragment id="59789-d5529e66"><block label="NoteText"><para>The units used to express the potency of botulinum toxin preparations currently available for PBS subsidy are not equivalent.</para></block></fragment></section><section id="59789-d5529e19"><fragment id="59789-d5529e19"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5359</block><block label="RestrictionText"><para>Dynamic equinus foot deformity</para><para><bold>Clinical criteria:</bold></para><list><item><para>The condition must be due to spasticity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have cerebral palsy,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be ambulant.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged from 2 to 17 years inclusive.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a neurologist; OR</para></item><item><para>Must be treated by an orthopaedic surgeon; OR</para></item><item><para>Must be treated by a paediatrician; OR</para></item><item><para>Must be treated by a rehabilitation specialist.</para></item></list></block></fragment></section><section id="59789-d5529e107"><fragment id="59789-d5529e107"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5407</block><block label="RestrictionText"><para>Dynamic equinus foot deformity</para><para><bold>Clinical criteria:</bold></para><list><item><para>The condition must be due to spasticity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have cerebral palsy,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be ambulant,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have commenced PBS-subsidised treatment with Botulinum Toxin Type A Purified Neurotoxin Complex as a paediatric patient.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 18 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a neurologist; OR</para></item><item><para>Must be treated by an orthopaedic surgeon; OR</para></item><item><para>Must be treated by a paediatrician; OR</para></item><item><para>Must be treated by a rehabilitation specialist.</para></item></list></block></fragment></section><section id="59789-10998W"><fragment id="59789-10998W"><block label="FormAndStrength">botulinum toxin type A 100 units injection, 1 vial</block><table role="MF"><row><cell><block label="DrugItemCode">10998W<br></br></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1626.07</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Botox [AG]<inline label="genericindexfieldbrand"><italic>XE "Botox(AG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59789-21857011000036106-5"><fragment id="59789-21857011000036106-5"><block label="DrugName">BOTULINUM TOXIN TYPE A<inline label="genericindexfield">XE "BOTULINUM TOXIN TYPE A"</inline></block></fragment></section><section id="59789-d5532e15"><fragment id="59789-d5532e15"><block label="CautionText"><para>Contraindications to treatment include known sensitivity to botulinum toxin.</para></block></fragment></section><section id="59789-d5532e68"><fragment id="59789-d5532e68"><block label="NoteText"><para>The units used to express the potency of botulinum toxin preparations currently available for PBS subsidy are not equivalent.</para></block></fragment></section><section id="59789-d5532e71"><fragment id="59789-d5532e71"><block label="NoteText"><para>Special Pricing Arrangements apply.</para></block></fragment></section><section id="59789-d5532e19"><fragment id="59789-d5532e19"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5262</block><block label="RestrictionText"><para>Chronic migraine</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a neurologist.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have experienced an average of 15 or more headache days per month, with at least 8 days of migraine, over a period of at least 6 months, prior to commencement of treatment with botulinum toxin type A neurotoxin,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have experienced an inadequate response, intolerance or a contraindication to at least three prophylactic migraine medications prior to commencement of treatment with botulinum toxin type A neurotoxin,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have achieved and maintained a 50% or greater reduction from baseline in the number of headache days per month after two treatment cycles (each of 12 weeks duration) in order to be eligible for continuing PBS-subsidised treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be appropriately managed by his or her practitioner for medication overuse headache, prior to initiation of treatment with botulinum toxin.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 18 years or older.</para></item></list> <para>Prophylactic migraine medications are propanolol, amitriptylin, methsergide, pizotifen, cyproheptadine or topiramate.</para></block></fragment></section><section id="59789-11000Y"><fragment id="59789-11000Y"><block label="FormAndStrength">botulinum toxin type A 100 units injection, 1 vial</block><table role="MF"><row><cell><block label="DrugItemCode">11000Y<br></br></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1626.07</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Botox [AG]<inline label="genericindexfieldbrand"><italic>XE "Botox(AG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59789-21857011000036106-6"><fragment id="59789-21857011000036106-6"><block label="DrugName">BOTULINUM TOXIN TYPE A<inline label="genericindexfield">XE "BOTULINUM TOXIN TYPE A"</inline></block></fragment></section><section id="59789-d5534e15"><fragment id="59789-d5534e15"><block label="CautionText"><para>Contraindications to treatment include known sensitivity to botulinum toxin.</para></block></fragment></section><section id="59789-d5534e75"><fragment id="59789-d5534e75"><block label="NoteText"><para>The units used to express the potency of botulinum toxin preparations currently available for PBS subsidy are not equivalent.</para></block></fragment></section><section id="59789-d5534e78"><fragment id="59789-d5534e78"><block label="NoteText"><para>Special Pricing Arrangements apply.</para></block></fragment></section><section id="59789-d5534e19"><fragment id="59789-d5534e19"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">6953</block><block label="RestrictionText"><para>Urinary incontinence</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a urologist; OR</para></item><item><para>Must be treated by a gynaecologist.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>The condition must be due to idiopathic overactive bladder,</para></item></list><para><bold>AND</bold></para><list><item><para>The condition must have been inadequately controlled by therapy involving at least two alternative anti-cholinergic agents,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must experience at least 14 episodes of urinary incontinence per week prior to commencement of treatment with botulinum toxin type A neurotoxin complex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be willing and able to self-catheterise,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not continue if the patient does not achieve a 50% or greater reduction from baseline in urinary incontinence episodes 6-12 weeks after the first treatment.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 18 years or older.</para></item></list></block></fragment></section><section id="59789-11004E"><fragment id="59789-11004E"><block label="FormAndStrength">botulinum toxin type A 100 units injection, 1 vial</block><table role="MF"><row><cell><block label="DrugItemCode">11004E<br></br></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1626.07</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Botox [AG]<inline label="genericindexfieldbrand"><italic>XE "Botox(AG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59789-21857011000036106-7"><fragment id="59789-21857011000036106-7"><block label="DrugName">BOTULINUM TOXIN TYPE A<inline label="genericindexfield">XE "BOTULINUM TOXIN TYPE A"</inline></block></fragment></section><section id="59789-d5536e15"><fragment id="59789-d5536e15"><block label="CautionText"><para>Contraindications to treatment include known sensitivity to botulinum toxin.</para></block></fragment></section><section id="59789-d5536e55"><fragment id="59789-d5536e55"><block label="NoteText"><para>The units used to express the potency of botulinum toxin preparations currently available for PBS subsidy are not equivalent.</para></block></fragment></section><section id="59789-d5536e58"><fragment id="59789-d5536e58"><block label="NoteText"><para>Special Pricing Arrangements apply.</para></block></fragment></section><section id="59789-d5536e19"><fragment id="59789-d5536e19"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5408</block><block label="RestrictionText"><para>Severe primary axillary hyperhidrosis</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously failed topical aluminium chloride hexahydrate after one to two months of treatment; OR</para></item><item><para>Patient must be intolerant to topical aluminium chloride hexahydrate treatment.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 12 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a dermatologist; OR</para></item><item><para>Must be treated by a neurologist; OR</para></item><item><para>Must be treated by a paediatrician.</para></item></list> <para>Maximum number of treatments per year is 3, with no less than 4 months to elapse between treatments.</para></block></fragment></section><section id="59789-11016T"><fragment id="59789-11016T"><block label="FormAndStrength">botulinum toxin type A 100 units injection, 1 vial</block><table role="MF"><row><cell><block label="DrugItemCode">11016T<br></br></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1626.07</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Botox [AG]<inline label="genericindexfieldbrand"><italic>XE "Botox(AG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59789-21857011000036106-8"><fragment id="59789-21857011000036106-8"><block label="DrugName">BOTULINUM TOXIN TYPE A<inline label="genericindexfield">XE "BOTULINUM TOXIN TYPE A"</inline></block></fragment></section><section id="59789-d5538e15"><fragment id="59789-d5538e15"><block label="CautionText"><para>Contraindications to treatment include known sensitivity to botulinum toxin.</para></block></fragment></section><section id="59789-d5538e55"><fragment id="59789-d5538e55"><block label="NoteText"><para>The units used to express the potency of botulinum toxin preparations currently available for PBS subsidy are not equivalent.</para></block></fragment></section><section id="59789-d5538e19"><fragment id="59789-d5538e19"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5178</block><block label="RestrictionText"><para>Moderate to severe spasticity of the upper limb</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have cerebral palsy.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged from 2 to 17 years inclusive.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a neurologist; OR</para></item><item><para>Must be treated by an orthopaedic surgeon; OR</para></item><item><para>Must be treated by a paediatrician; OR</para></item><item><para>Must be treated by a rehabilitation specialist; OR</para></item><item><para>Must be treated by a plastic surgeon.</para></item></list></block></fragment></section><section id="59789-d5538e94"><fragment id="59789-d5538e94"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5261</block><block label="RestrictionText"><para>Moderate to severe spasticity of the upper limb</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have cerebral palsy,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have commenced PBS-subsidised treatment with Botulinum Type A Neurotoxin Complex as a paediatric patient.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 18 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a neurologist; OR</para></item><item><para>Must be treated by an orthopaedic surgeon; OR</para></item><item><para>Must be treated by a paediatrician; OR</para></item><item><para>Must be treated by a rehabilitation specialist; OR</para></item><item><para>Must be treated by a plastic surgeon.</para></item></list></block></fragment></section><section id="59789-d5538e137"><fragment id="59789-d5538e137"><block label="NoteText"><para>Contact the Department of Human Services before commencing PBS-subsidised treatment in cerebral palsy patients who have been treated for moderate to severe spasticity of the upper limb with non-PBS-subsidised botulinum toxin prior to the age of 18.</para></block></fragment></section><section id="59789-d5538e181"><fragment id="59789-d5538e181"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5220</block><block label="RestrictionText"><para>Moderate to severe spasticity of the upper limb following a stroke</para><para><bold>Clinical criteria:</bold></para><list><item><para>The condition must be moderate to severe spasticity of the upper limb/s following stroke, defined as a Modified Ashworth Scale rating of 3 or more,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not be initiated until three months post-stroke,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must only be used as second line therapy when standard management has failed; OR</para></item><item><para>The treatment must only be used as an adjunct to physical therapy,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not continue if the patient does not respond (defined as not having had a decrease in spasticity rating greater than 1, using the Modified Ashworth Scale, in at least one joint) after two treatment periods (total Botox, Dysport, and Xeomin),</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not exceed 4 treatment periods (total Botox, Dysport, and Xeomin) per upper limb per lifetime,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have established severe contracture in the limb to be treated.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 18 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a neurologist; OR</para></item><item><para>Must be treated by an orthopaedic surgeon; OR</para></item><item><para>Must be treated by a rehabilitation specialist; OR</para></item><item><para>Must be treated by a plastic surgeon; OR</para></item><item><para>Must be treated by a geriatrician.</para></item></list> <para>The date of the stroke must be documented in the patient's medical records when treatment is initiated.</para> <para>Standard management includes physiotherapy and/or oral spasticity agents.</para></block></fragment></section><section id="59789-10999X"><fragment id="59789-10999X"><block label="FormAndStrength">botulinum toxin type A 100 units injection, 1 vial</block><table role="MF"><row><cell><block label="DrugItemCode">10999X<br></br></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1626.07</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Botox [AG]<inline label="genericindexfieldbrand"><italic>XE "Botox(AG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60918-M03AX32611011000036100"><xref-fragment id="60918-M03AX32611011000036100"><blockxref id="107848" title="CLOSTRIDIUM BOTULINUM TYPE A TOXIN-HAEMAGGLUTININ COMPLEX" frag="default" reversefrag="M03AX32611011000036100" reversetitle="MF" reverselink="true" reversetype="none" display="document" type="embed" uriid="60626" href="dynamic/MF/drug/32611011000036100-M03AX.psml" urititle="CLOSTRIDIUM BOTULINUM TYPE A TOXIN-HAEMAGGLUTININ COMPLEX" mediatype="application/vnd.pageseeder.psml+xml"><document id="60626" schemaversion="0.12" date="2018-06-15T10:34:33+10:00" version="current" level="processed"><documentinfo><uri id="60626" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/MF/drug/32611011000036100-M03AX.psml" decodedpath="/ps/test/local3/books/dynamic/MF/drug/32611011000036100-M03AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:30+10:00" modified="2018-06-15T10:34:33+10:00" title="CLOSTRIDIUM BOTULINUM TYPE A TOXIN-HAEMAGGLUTININ COMPLEX"><displaytitle>CLOSTRIDIUM BOTULINUM TYPE A TOXIN-HAEMAGGLUTININ COMPLEX</displaytitle></uri><reversexrefs><reversexref uriid="60918" href="dynamic/MF/atc/M.psml" frag="M03AX32611011000036100" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107848" title="MF" type="none" forwardtype="embed" forwardtitle="CLOSTRIDIUM BOTULINUM TYPE A TOXIN-HAEMAGGLUTININ COMPLEX" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60626-32611011000036100-1"><fragment id="60626-32611011000036100-1"><block label="DrugName">CLOSTRIDIUM BOTULINUM TYPE A TOXIN-HAEMAGGLUTININ COMPLEX<inline label="genericindexfield">XE "CLOSTRIDIUM BOTULINUM TYPE A TOXIN-HAEMAGGLUTININ COMPLEX"</inline></block></fragment></section><section id="60626-d5542e15"><fragment id="60626-d5542e15"><block label="CautionText"><para>Contraindications to treatment include known sensitivity to botulinum toxin.</para></block></fragment></section><section id="60626-d5542e100"><fragment id="60626-d5542e100"><block label="NoteText"><para>The units used to express the potency of botulinum toxin preparations currently available for PBS subsidy are not equivalent.</para></block></fragment></section><section id="60626-d5542e19"><fragment id="60626-d5542e19"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5220</block><block label="RestrictionText"><para>Moderate to severe spasticity of the upper limb following a stroke</para><para><bold>Clinical criteria:</bold></para><list><item><para>The condition must be moderate to severe spasticity of the upper limb/s following stroke, defined as a Modified Ashworth Scale rating of 3 or more,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not be initiated until three months post-stroke,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must only be used as second line therapy when standard management has failed; OR</para></item><item><para>The treatment must only be used as an adjunct to physical therapy,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not continue if the patient does not respond (defined as not having had a decrease in spasticity rating greater than 1, using the Modified Ashworth Scale, in at least one joint) after two treatment periods (total Botox, Dysport, and Xeomin),</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not exceed 4 treatment periods (total Botox, Dysport, and Xeomin) per upper limb per lifetime,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have established severe contracture in the limb to be treated.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 18 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a neurologist; OR</para></item><item><para>Must be treated by an orthopaedic surgeon; OR</para></item><item><para>Must be treated by a rehabilitation specialist; OR</para></item><item><para>Must be treated by a plastic surgeon; OR</para></item><item><para>Must be treated by a geriatrician.</para></item></list> <para>The date of the stroke must be documented in the patient's medical records when treatment is initiated.</para> <para>Standard management includes physiotherapy and/or oral spasticity agents.</para></block></fragment></section><section id="60626-10988H"><fragment id="60626-10988H"><block label="FormAndStrength">clostridium botulinum type A toxin-haemagglutinin complex 500 units injection, 1 vial</block><table role="MF"><row><cell><block label="DrugItemCode">10988H<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1272.29</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Dysport [IS]<inline label="genericindexfieldbrand"><italic>XE "Dysport(IS)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60626-10982B"><fragment id="60626-10982B"><block label="FormAndStrength">clostridium botulinum type A toxin-haemagglutinin complex 300 units injection, 1 vial</block><table role="MF"><row><cell><block label="DrugItemCode">10982B<br></br></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1420.91</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Dysport [IS]<inline label="genericindexfieldbrand"><italic>XE "Dysport(IS)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60626-32611011000036100-2"><fragment id="60626-32611011000036100-2"><block label="DrugName">CLOSTRIDIUM BOTULINUM TYPE A TOXIN-HAEMAGGLUTININ COMPLEX<inline label="genericindexfield">XE "CLOSTRIDIUM BOTULINUM TYPE A TOXIN-HAEMAGGLUTININ COMPLEX"</inline></block></fragment></section><section id="60626-d5544e15"><fragment id="60626-d5544e15"><block label="CautionText"><para>Contraindications to treatment include known sensitivity to botulinum toxin.</para></block></fragment></section><section id="60626-d5544e55"><fragment id="60626-d5544e55"><block label="NoteText"><para>The units used to express the potency of botulinum toxin preparations currently available for PBS subsidy are not equivalent.</para></block></fragment></section><section id="60626-d5544e19"><fragment id="60626-d5544e19"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5405</block><block label="RestrictionText"><para>Blepharospasm or hemifacial spasm</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have blepharospasm; OR</para></item><item><para>Patient must have hemifacial spasm.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 18 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a neurologist; OR</para></item><item><para>Must be treated by an ophthalmologist; OR</para></item><item><para>Must be treated by an otolaryngology head and neck surgeon; OR</para></item><item><para>Must be treated by a plastic surgeon.</para></item></list></block></fragment></section><section id="60626-11022D"><fragment id="60626-11022D"><block label="FormAndStrength">clostridium botulinum type A toxin-haemagglutinin complex 500 units injection, 1 vial</block><table role="MF"><row><cell><block label="DrugItemCode">11022D<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1272.29</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Dysport [IS]<inline label="genericindexfieldbrand"><italic>XE "Dysport(IS)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60626-10987G"><fragment id="60626-10987G"><block label="FormAndStrength">clostridium botulinum type A toxin-haemagglutinin complex 300 units injection, 1 vial</block><table role="MF"><row><cell><block label="DrugItemCode">10987G<br></br></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1420.91</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Dysport [IS]<inline label="genericindexfieldbrand"><italic>XE "Dysport(IS)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60626-32611011000036100-3"><fragment id="60626-32611011000036100-3"><block label="DrugName">CLOSTRIDIUM BOTULINUM TYPE A TOXIN-HAEMAGGLUTININ COMPLEX<inline label="genericindexfield">XE "CLOSTRIDIUM BOTULINUM TYPE A TOXIN-HAEMAGGLUTININ COMPLEX"</inline></block></fragment></section><section id="60626-d5546e15"><fragment id="60626-d5546e15"><block label="CautionText"><para>Contraindications to treatment include known sensitivity to botulinum toxin.</para></block></fragment></section><section id="60626-d5546e52"><fragment id="60626-d5546e52"><block label="NoteText"><para>The units used to express the potency of botulinum toxin preparations currently available for PBS subsidy are not equivalent.</para></block></fragment></section><section id="60626-d5546e19"><fragment id="60626-d5546e19"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5406</block><block label="RestrictionText"><para>Spasmodic torticollis</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have spasmodic torticollis,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be as monotherapy; OR</para></item><item><para>The treatment must be as adjunctive therapy to current standard care.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a neurologist; OR</para></item><item><para>Must be treated by a plastic surgeon; OR</para></item><item><para>Must be treated by a rehabilitation specialist.</para></item></list></block></fragment></section><section id="60626-11015R"><fragment id="60626-11015R"><block label="FormAndStrength">clostridium botulinum type A toxin-haemagglutinin complex 500 units injection, 1 vial</block><table role="MF"><row><cell><block label="DrugItemCode">11015R<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1272.29</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Dysport [IS]<inline label="genericindexfieldbrand"><italic>XE "Dysport(IS)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60626-11007H"><fragment id="60626-11007H"><block label="FormAndStrength">clostridium botulinum type A toxin-haemagglutinin complex 300 units injection, 1 vial</block><table role="MF"><row><cell><block label="DrugItemCode">11007H<br></br></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1420.91</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Dysport [IS]<inline label="genericindexfieldbrand"><italic>XE "Dysport(IS)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60626-32611011000036100-4"><fragment id="60626-32611011000036100-4"><block label="DrugName">CLOSTRIDIUM BOTULINUM TYPE A TOXIN-HAEMAGGLUTININ COMPLEX<inline label="genericindexfield">XE "CLOSTRIDIUM BOTULINUM TYPE A TOXIN-HAEMAGGLUTININ COMPLEX"</inline></block></fragment></section><section id="60626-d5548e15"><fragment id="60626-d5548e15"><block label="CautionText"><para>Contraindications to treatment include known sensitivity to botulinum toxin.</para></block></fragment></section><section id="60626-d5548e66"><fragment id="60626-d5548e66"><block label="NoteText"><para>The units used to express the potency of botulinum toxin preparations currently available for PBS subsidy are not equivalent.</para></block></fragment></section><section id="60626-d5548e19"><fragment id="60626-d5548e19"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5359</block><block label="RestrictionText"><para>Dynamic equinus foot deformity</para><para><bold>Clinical criteria:</bold></para><list><item><para>The condition must be due to spasticity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have cerebral palsy,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be ambulant.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged from 2 to 17 years inclusive.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a neurologist; OR</para></item><item><para>Must be treated by an orthopaedic surgeon; OR</para></item><item><para>Must be treated by a paediatrician; OR</para></item><item><para>Must be treated by a rehabilitation specialist.</para></item></list></block></fragment></section><section id="60626-d5548e107"><fragment id="60626-d5548e107"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5332</block><block label="RestrictionText"><para>Dynamic equinus foot deformity</para><para><bold>Clinical criteria:</bold></para><list><item><para>The condition must be due to spasticity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be an ambulant cerebral palsy patient,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have commenced on PBS-subsidised treatment with clostridium botulinum type A toxin-haemagglutinin complex as a paediatric patient.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 18 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a neurologist; OR</para></item><item><para>Must be treated by an orthopaedic surgeon; OR</para></item><item><para>Must be treated by a paediatrician; OR</para></item><item><para>Must be treated by a rehabilitation specialist.</para></item></list></block></fragment></section><section id="60626-11006G"><fragment id="60626-11006G"><block label="FormAndStrength">clostridium botulinum type A toxin-haemagglutinin complex 500 units injection, 1 vial</block><table role="MF"><row><cell><block label="DrugItemCode">11006G<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1272.29</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Dysport [IS]<inline label="genericindexfieldbrand"><italic>XE "Dysport(IS)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60626-10981Y"><fragment id="60626-10981Y"><block label="FormAndStrength">clostridium botulinum type A toxin-haemagglutinin complex 300 units injection, 1 vial</block><table role="MF"><row><cell><block label="DrugItemCode">10981Y<br></br></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1420.91</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Dysport [IS]<inline label="genericindexfieldbrand"><italic>XE "Dysport(IS)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60918-M03AX177251000036108"><xref-fragment id="60918-M03AX177251000036108"><blockxref id="107849" title="INCOBOTULINUMTOXINA" frag="default" reversefrag="M03AX177251000036108" reversetitle="MF" reverselink="true" reversetype="none" display="document" type="embed" uriid="60957" href="dynamic/MF/drug/177251000036108-M03AX.psml" urititle="INCOBOTULINUMTOXINA" mediatype="application/vnd.pageseeder.psml+xml"><document id="60957" schemaversion="0.12" date="2018-06-15T10:34:33+10:00" version="current" level="processed"><documentinfo><uri id="60957" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/MF/drug/177251000036108-M03AX.psml" decodedpath="/ps/test/local3/books/dynamic/MF/drug/177251000036108-M03AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:33+10:00" modified="2018-06-15T10:34:33+10:00" title="INCOBOTULINUMTOXINA"><displaytitle>INCOBOTULINUMTOXINA</displaytitle></uri><reversexrefs><reversexref uriid="60918" href="dynamic/MF/atc/M.psml" frag="M03AX177251000036108" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107849" title="MF" type="none" forwardtype="embed" forwardtitle="INCOBOTULINUMTOXINA" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60957-177251000036108-1"><fragment id="60957-177251000036108-1"><block label="DrugName">INCOBOTULINUMTOXINA<inline label="genericindexfield">XE "INCOBOTULINUMTOXINA"</inline></block></fragment></section><section id="60957-d5551e15"><fragment id="60957-d5551e15"><block label="CautionText"><para>Contraindications to treatment include known sensitivity to botulinum toxin.</para></block></fragment></section><section id="60957-d5551e100"><fragment id="60957-d5551e100"><block label="NoteText"><para>The units used to express the potency of botulinum toxin preparations currently available for PBS subsidy are not equivalent.</para></block></fragment></section><section id="60957-d5551e19"><fragment id="60957-d5551e19"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5220</block><block label="RestrictionText"><para>Moderate to severe spasticity of the upper limb following a stroke</para><para><bold>Clinical criteria:</bold></para><list><item><para>The condition must be moderate to severe spasticity of the upper limb/s following stroke, defined as a Modified Ashworth Scale rating of 3 or more,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not be initiated until three months post-stroke,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must only be used as second line therapy when standard management has failed; OR</para></item><item><para>The treatment must only be used as an adjunct to physical therapy,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not continue if the patient does not respond (defined as not having had a decrease in spasticity rating greater than 1, using the Modified Ashworth Scale, in at least one joint) after two treatment periods (total Botox, Dysport, and Xeomin),</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not exceed 4 treatment periods (total Botox, Dysport, and Xeomin) per upper limb per lifetime,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have established severe contracture in the limb to be treated.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 18 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a neurologist; OR</para></item><item><para>Must be treated by an orthopaedic surgeon; OR</para></item><item><para>Must be treated by a rehabilitation specialist; OR</para></item><item><para>Must be treated by a plastic surgeon; OR</para></item><item><para>Must be treated by a geriatrician.</para></item></list> <para>The date of the stroke must be documented in the patient's medical records when treatment is initiated.</para> <para>Standard management includes physiotherapy and/or oral spasticity agents.</para></block></fragment></section><section id="60957-10983C"><fragment id="60957-10983C"><block label="FormAndStrength">incobotulinumtoxinA 100 mouse LD50  units injection, 1 x 100 mouse LD50 units vial</block><table role="MF"><row><cell><block label="DrugItemCode">10983C<br></br></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1547.15</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Xeomin [EZ]<inline label="genericindexfieldbrand"><italic>XE "Xeomin(EZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60957-177251000036108-2"><fragment id="60957-177251000036108-2"><block label="DrugName">INCOBOTULINUMTOXINA<inline label="genericindexfield">XE "INCOBOTULINUMTOXINA"</inline></block></fragment></section><section id="60957-d5553e15"><fragment id="60957-d5553e15"><block label="CautionText"><para>Contraindications to treatment include known sensitivity to botulinum toxin.</para></block></fragment></section><section id="60957-d5553e52"><fragment id="60957-d5553e52"><block label="NoteText"><para>The units used to express the potency of botulinum toxin preparations currently available for PBS subsidy are not equivalent.</para></block></fragment></section><section id="60957-d5553e19"><fragment id="60957-d5553e19"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5360</block><block label="RestrictionText"><para>Blepharospasm</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have blepharospasm.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 18 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a neurologist; OR</para></item><item><para>Must be treated by an ophthalmologist; OR</para></item><item><para>Must be treated by an otolaryngology head and neck surgeon; OR</para></item><item><para>Must be treated by a plastic surgeon.</para></item></list></block></fragment></section><section id="60957-10994P"><fragment id="60957-10994P"><block label="FormAndStrength">incobotulinumtoxinA 100 mouse LD50  units injection, 1 x 100 mouse LD50 units vial</block><table role="MF"><row><cell><block label="DrugItemCode">10994P<br></br></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1547.15</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Xeomin [EZ]<inline label="genericindexfieldbrand"><italic>XE "Xeomin(EZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60957-177251000036108-3"><fragment id="60957-177251000036108-3"><block label="DrugName">INCOBOTULINUMTOXINA<inline label="genericindexfield">XE "INCOBOTULINUMTOXINA"</inline></block></fragment></section><section id="60957-d5555e15"><fragment id="60957-d5555e15"><block label="CautionText"><para>Contraindications to treatment include known sensitivity to botulinum toxin.</para></block></fragment></section><section id="60957-d5555e59"><fragment id="60957-d5555e59"><block label="NoteText"><para>The units used to express the potency of botulinum toxin preparations currently available for PBS subsidy are not equivalent.</para></block></fragment></section><section id="60957-d5555e19"><fragment id="60957-d5555e19"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5222</block><block label="RestrictionText"><para>Spasmodic torticollis</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have spasmodic torticollis,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be as monotherapy; OR</para></item><item><para>The treatment must be as adjunctive therapy to current standard care.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a neurologist; OR</para></item><item><para>Must be treated by a plastic surgeon; OR</para></item><item><para>Must be treated by a rehabilitation specialist.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 18 years or older.</para></item></list></block></fragment></section><section id="60957-11005F"><fragment id="60957-11005F"><block label="FormAndStrength">incobotulinumtoxinA 100 mouse LD50  units injection, 1 x 100 mouse LD50 units vial</block><table role="MF"><row><cell><block label="DrugItemCode">11005F<br></br></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1547.15</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Xeomin [EZ]<inline label="genericindexfieldbrand"><italic>XE "Xeomin(EZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref></xref-fragment></section></document></blockxref>
<blockxref id="107707" title="therapeuticindex-GH.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="59740" href="dynamic/GH/therapeuticindex-GH.psml" urititle="Therapeutic Index - Growth Hormone Program - GH" mediatype="application/vnd.pageseeder.psml+xml"><document id="59740" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="59740" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/GH/therapeuticindex-GH.psml" decodedpath="/ps/test/local3/books/dynamic/GH/therapeuticindex-GH.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:20+10:00" modified="2018-06-15T10:34:32+10:00" title="Therapeutic Index - Growth Hormone Program - GH"><displaytitle>Therapeutic Index - Growth Hormone Program - GH</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107707" title="" type="none" forwardtype="embed" forwardtitle="therapeuticindex-GH.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="42259" fragment="59740-2" editid="105172" modified="2018-06-15T10:34:20+10:00"></locator></fragmentinfo><metadata></metadata><section id="59740-1"><fragment id="59740-1"><block label="mps3indexsectionbreak">GH</block><block label="schedule-heading">Growth Hormone Program</block></fragment><fragment id="59740-2"><block label="index"><para>SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS<inline label="indexpageref"><xref id="105169" title="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60855" href="#60855" urititle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" mediatype="application/vnd.pageseeder.psml+xml">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</xref></inline></para></block><block label="index2"><para indent="1">PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES<inline label="indexpageref"><xref id="105170" title="PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES" frag="H01" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60855" href="#60855-H01" urititle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" mediatype="application/vnd.pageseeder.psml+xml">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</xref></inline></para></block><block label="index3"><para indent="2">ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES<inline label="indexpageref"><xref id="105171" title="ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES" frag="H01A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60855" href="#60855-H01A" urititle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" mediatype="application/vnd.pageseeder.psml+xml">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</xref></inline></para></block></fragment></section></document></blockxref>
<blockxref id="107708" title="GH.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="59956" href="dynamic/GH.psml" urititle="Growth Hormone Program" mediatype="application/vnd.pageseeder.psml+xml"><document id="59956" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="59956" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/GH.psml" decodedpath="/ps/test/local3/books/dynamic/GH.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:23+10:00" modified="2018-06-15T10:34:32+10:00" title="Growth Hormone Program"><displaytitle>Growth Hormone Program</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107708" title="" type="none" forwardtype="embed" forwardtitle="GH.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="43067" fragment="59956-d114e912236" editid="105983" modified="2018-06-15T10:34:23+10:00"></locator></fragmentinfo><metadata></metadata><section id="59956-1"><fragment id="59956-1"><block label="mps3sectionbreak">GH</block></fragment></section><section id="59956-d114e912236"><xref-fragment id="59956-d114e912236"><blockxref id="105982" title="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" frag="default" reversefrag="d114e912236" reversetitle="GH" reverselink="true" reversetype="none" display="document" type="embed" uriid="60855" href="dynamic/GH/atc/H.psml" urititle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" mediatype="application/vnd.pageseeder.psml+xml"><document id="60855" schemaversion="0.12" date="2018-06-15T10:35:15+10:00" version="current" level="processed"><documentinfo><uri id="60855" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/GH/atc/H.psml" decodedpath="/ps/test/local3/books/dynamic/GH/atc/H.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:35:15+10:00" title="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS"><displaytitle>SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</displaytitle></uri><reversexrefs><reversexref uriid="59740" href="dynamic/GH/therapeuticindex-GH.psml" frag="2" urititle="Therapeutic Index - Growth Hormone Program - GH" mediatype="application/vnd.pageseeder.psml+xml" id="105169" title="Untitled" type="none" forwardtype="none" forwardtitle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="59956" href="dynamic/GH.psml" frag="d114e912236" urititle="Growth Hormone Program" mediatype="application/vnd.pageseeder.psml+xml" id="105982" title="GH" type="none" forwardtype="embed" forwardtitle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="42261" fragment="60855-H01A"><reversexrefs><reversexref uriid="59740" href="dynamic/GH/therapeuticindex-GH.psml" frag="2" urititle="Therapeutic Index - Growth Hormone Program - GH" mediatype="application/vnd.pageseeder.psml+xml" id="105171" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES" forwarddisplay="document" forwardfrag="H01A"></reversexref></reversexrefs></locator><locator id="42260" fragment="60855-H01"><reversexrefs><reversexref uriid="59740" href="dynamic/GH/therapeuticindex-GH.psml" frag="2" urititle="Therapeutic Index - Growth Hormone Program - GH" mediatype="application/vnd.pageseeder.psml+xml" id="105170" title="Untitled" type="none" forwardtype="none" forwardtitle="PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES" forwarddisplay="document" forwardfrag="H01"></reversexref></reversexrefs></locator><locator id="44807" fragment="60855-H01AC21295011000036100" editid="107748" modified="2018-06-15T10:34:32+10:00"></locator></fragmentinfo><metadata></metadata><section id="60855-H"><fragment id="60855-H"><block label="ATCLevel1"><para>SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</para></block></fragment></section><section id="60855-H01"><fragment id="60855-H01"><block label="ATCLevel2"><para>PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES</para></block></fragment></section><section id="60855-H01A"><fragment id="60855-H01A"><block label="ATCLevel3"><para>ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES</para></block></fragment></section><section id="60855-H01AC"><fragment id="60855-H01AC"><block label="ATCLevel4"><para>Somatropin and somatropin agonists</para></block></fragment></section><section id="60855-H01AC21295011000036100"><xref-fragment id="60855-H01AC21295011000036100"><blockxref id="107747" title="SOMATROPIN" frag="default" reversefrag="H01AC21295011000036100" reversetitle="GH" reverselink="true" reversetype="none" display="document" type="embed" uriid="59697" href="dynamic/GH/drug/21295011000036100-H01AC.psml" urititle="SOMATROPIN" mediatype="application/vnd.pageseeder.psml+xml"><document id="59697" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="59697" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/GH/drug/21295011000036100-H01AC.psml" decodedpath="/ps/test/local3/books/dynamic/GH/drug/21295011000036100-H01AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:20+10:00" modified="2018-06-15T10:34:32+10:00" title="SOMATROPIN"><displaytitle>SOMATROPIN</displaytitle></uri><reversexrefs><reversexref uriid="60855" href="dynamic/GH/atc/H.psml" frag="H01AC21295011000036100" urititle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" mediatype="application/vnd.pageseeder.psml+xml" id="107747" title="GH" type="none" forwardtype="embed" forwardtitle="SOMATROPIN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59697-21295011000036100-1"><fragment id="59697-21295011000036100-1"><block label="DrugName">SOMATROPIN<inline label="genericindexfield">XE "SOMATROPIN"</inline></block></fragment></section><section id="59697-d5596e160"><fragment id="59697-d5596e160"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5596e16"><fragment id="59697-d5596e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height below the 1st percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have maturational or constitutional delay in combination with an estimated mature height equal to or above 160.1 cm; OR</para></item><item><para>Patient must be female and must not have maturational or constitutional delay in combination with an estimated mature height equal to or above 148.0 cm.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation of the patient's maturational or constitutional delay status; AND</para><para>6. If the patient has maturational or constitutional delay, confirmation that the patient has an estimated mature height below the 1st adult height percentile; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5596e260"><fragment id="59697-d5596e260"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height below the 1st percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Biochemical growth hormone deficiency should not be secondary to an intracranial lesion or cranial irradiation for applications under this category.</para></block></fragment></section><section id="59697-d5596e503"><fragment id="59697-d5596e503"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have had an intracranial lesion and have undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para></item><item><para>Patient must have had an intracranial lesion, have received medical advice that it is unsafe to treat the intracranial lesion, and have undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para></item><item><para>Patient must have received cranial irradiation without having had an intracranial lesion, and have undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. (a) Confirmation that the patient has had an intracranial lesion and has undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para><para>(b) Confirmation that the patient has had an intracranial lesion, has received medical advice that it is unsafe to treat the intracranial lesion, and has undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para><para>(c) Confirmation that the patient has received cranial irradiation without having had an intracranial lesion, and has undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5596e763"><fragment id="59697-d5596e763"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be male and have commenced puberty (demonstrated by Tanner stage 2 genital or pubic hair development or testicular volumes greater than or equal to 4 mL) before the chronological age of 9 years; OR</para></item><item><para>Patient must be female and have commenced puberty (demonstrated by Tanner stage 2 breast or pubic hair development) before the chronological age of 8 years; OR</para></item><item><para>Patient must be female and menarche occurred before the chronological age of 10 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. Confirmation that the patient has precocious puberty; AND</para><para>7. Confirmation that the patient is undergoing Gonadotropin Releasing Hormone agonist therapy, for pubertal suppression; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5596e993"><fragment id="59697-d5596e993"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a structural lesion that is not neoplastic; OR</para></item><item><para>Patient must have had a structural lesion that was neoplastic and have undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para></item><item><para>Patient must have a structural lesion that is neoplastic, have received medical advice that it is unsafe to treat the structural lesion, and have undergone a 12 month period of observation since initial diagnosis of the structural lesion,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have other hypothalamic/pituitary hormone deficits (includes ACTH, TSH, GnRH and/or vasopressin/ADH deficiencies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have hypothalamic obesity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity above the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of greater than 8 cm per year,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. (a) Confirmation that the patient has a structural lesion that is not neoplastic; OR</para><para>(b) Confirmation that the patient had a structural lesion that was neoplastic and has undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para><para>(c) Confirmation that the patient has a structural lesion that is neoplastic, has received medical advice that it is unsafe to treat the structural lesion, and has undergone a 12 month period of observation since initial diagnosis of the structural lesion; AND</para><para>7. Confirmation that the patient has other hypothalamic/pituitary hormone deficits; AND</para><para>8. Confirmation that the patient has hypothalamic obesity; AND</para><para>9. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Testing for biochemical growth hormone deficiency must have been performed at a time when all other pituitary hormone deficits were being adequately replaced.</para></block></fragment></section><section id="59697-d5596e1285"><fragment id="59697-d5596e1285"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height at or below the 95<sup>th</sup> percentile for age on the Turner syndrome growth curve for girls,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in all cells (45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in some cells (mosaic 46XX/45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as genetic loss or rearrangement of an X chromosome (such as isochromosome X, ring-chromosome, or partial deletion of an X chromosome), and gender of rearing is female,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation that the patient has diagnostic results consistent with Turner syndrome; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5596e1497"><fragment id="59697-d5596e1497"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height below the 1<sup>st</sup> percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation that the patient has diagnostic results consistent with a short stature homeobox (SHOX) gene disorder; AND</para><para>6. If the patient's condition is secondary to mixed gonadal dysgenesis, confirmation that an appropriate plan of management for the patient's increased risk of gonadoblastoma is in place; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5596e1743"><fragment id="59697-d5596e1743"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height at or below the 25th percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, and not have undergone a renal transplant; OR</para></item><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, have undergone a renal transplant, and have undergone a 12 month period of observation following the transplant,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity equal to or less than the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity equal to or less than the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity equal to or less than the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity equal to or less than the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity equal to or less than the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation that the patient has an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> ; AND</para><para>6. If a renal transplant has taken place, confirmation that the patient has undergone a 12 month period of observation following transplantation; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-10518N"><fragment id="59697-10518N"><block label="FormAndStrength">somatropin 5 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10518N<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">223.37</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Omnitrope Surepal 5 [SZ]<inline label="genericindexfieldbrand"><italic>XE "Omnitrope Surepal 5(SZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10446T"><fragment id="59697-10446T"><block label="FormAndStrength">somatropin 15 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10446T<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">655.80</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Omnitrope Surepal 15 [SZ]<inline label="genericindexfieldbrand"><italic>XE "Omnitrope Surepal 15(SZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10514J"><fragment id="59697-10514J"><block label="FormAndStrength">somatropin 10 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10514J<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">439.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Omnitrope Surepal 10 [SZ]<inline label="genericindexfieldbrand"><italic>XE "Omnitrope Surepal 10(SZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-6311E"><fragment id="59697-6311E"><block label="FormAndStrength">somatropin 10 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">6311E<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">439.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">SciTropin A [SA]<inline label="genericindexfieldbrand"><italic>XE "SciTropin A(SA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-21295011000036100-2"><fragment id="59697-21295011000036100-2"><block label="DrugName">SOMATROPIN<inline label="genericindexfield">XE "SOMATROPIN"</inline></block></fragment></section><section id="59697-d5605e153"><fragment id="59697-d5605e153"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5605e16"><fragment id="59697-d5605e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height below the 1st percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have maturational or constitutional delay in combination with an estimated mature height equal to or above 160.1 cm; OR</para></item><item><para>Patient must be female and must not have maturational or constitutional delay in combination with an estimated mature height equal to or above 148.0 cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation of the patient's maturational or constitutional delay status; AND</para><para>6. If the patient has maturational or constitutional delay, confirmation that the patient has an estimated mature height below the 1st adult height percentile; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5605e251"><fragment id="59697-d5605e251"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height below the 1st percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Biochemical growth hormone deficiency should not be secondary to an intracranial lesion or cranial irradiation for applications under this category.</para></block></fragment></section><section id="59697-d5605e484"><fragment id="59697-d5605e484"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have had an intracranial lesion and have undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para></item><item><para>Patient must have had an intracranial lesion, have received medical advice that it is unsafe to treat the intracranial lesion, and have undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para></item><item><para>Patient must have received cranial irradiation without having had an intracranial lesion, and have undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. (a) Confirmation that the patient has had an intracranial lesion and has undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para><para>(b) Confirmation that the patient has had an intracranial lesion, has received medical advice that it is unsafe to treat the intracranial lesion, and has undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para><para>(c) Confirmation that the patient has received cranial irradiation without having had an intracranial lesion, and has undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5605e735"><fragment id="59697-d5605e735"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a chronological age of less than 2 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a documented clinical risk of hypoglycaemia,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. Confirmation that the patient has a documented clinical risk of hypoglycaemia; AND</para><para>5. Confirmation that the patient has documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5605e898"><fragment id="59697-d5605e898"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be male and have commenced puberty (demonstrated by Tanner stage 2 genital or pubic hair development or testicular volumes greater than or equal to 4 mL) before the chronological age of 9 years; OR</para></item><item><para>Patient must be female and have commenced puberty (demonstrated by Tanner stage 2 breast or pubic hair development) before the chronological age of 8 years; OR</para></item><item><para>Patient must be female and menarche occurred before the chronological age of 10 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. Confirmation that the patient has precocious puberty; AND</para><para>7. Confirmation that the patient is undergoing Gonadotropin Releasing Hormone agonist therapy, for pubertal suppression; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5605e1119"><fragment id="59697-d5605e1119"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a structural lesion that is not neoplastic; OR</para></item><item><para>Patient must have had a structural lesion that was neoplastic and have undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para></item><item><para>Patient must have a structural lesion that is neoplastic, have received medical advice that it is unsafe to treat the structural lesion, and have undergone a 12 month period of observation since initial diagnosis of the structural lesion,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have other hypothalamic/pituitary hormone deficits (includes ACTH, TSH, GnRH and/or vasopressin/ADH deficiencies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have hypothalamic obesity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity above the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of greater than 8 cm per year,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. (a) Confirmation that the patient has a structural lesion that is not neoplastic; OR</para><para>(b) Confirmation that the patient had a structural lesion that was neoplastic and has undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para><para>(c) Confirmation that the patient has a structural lesion that is neoplastic, has received medical advice that it is unsafe to treat the structural lesion, and has undergone a 12 month period of observation since initial diagnosis of the structural lesion; AND</para><para>7. Confirmation that the patient has other hypothalamic/pituitary hormone deficits; AND</para><para>8. Confirmation that the patient has hypothalamic obesity; AND</para><para>9. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Testing for biochemical growth hormone deficiency must have been performed at a time when all other pituitary hormone deficits were being adequately replaced.</para></block></fragment></section><section id="59697-d5605e1401"><fragment id="59697-d5605e1401"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height at or below the 95<sup>th</sup> percentile for age on the Turner syndrome growth curve for girls,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in all cells (45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in some cells (mosaic 46XX/45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as genetic loss or rearrangement of an X chromosome (such as isochromosome X, ring-chromosome, or partial deletion of an X chromosome), and gender of rearing is female,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation that the patient has diagnostic results consistent with Turner syndrome; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5605e1604"><fragment id="59697-d5605e1604"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height below the 1st percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation that the patient has diagnostic results consistent with a short stature homeobox (SHOX) gene disorder; AND</para><para>6. If the patient's condition is secondary to mixed gonadal dysgenesis, confirmation that an appropriate plan of management for the patient's increased risk of gonadoblastoma is in place; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-6266T"><fragment id="59697-6266T"><block label="FormAndStrength">somatropin 4 mg injection [1 vial] (&amp;) inert substance diluent [1 vial], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">6266T<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">180.12</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Zomacton [FP]<inline label="genericindexfieldbrand"><italic>XE "Zomacton(FP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-6310D"><fragment id="59697-6310D"><block label="FormAndStrength">somatropin 10 mg injection [1 vial] (&amp;) inert substance diluent [1 mL syringe], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">6310D<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">439.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Zomacton [FP]<inline label="genericindexfieldbrand"><italic>XE "Zomacton(FP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-21295011000036100-3"><fragment id="59697-21295011000036100-3"><block label="DrugName">SOMATROPIN<inline label="genericindexfield">XE "SOMATROPIN"</inline></block></fragment></section><section id="59697-d5614e153"><fragment id="59697-d5614e153"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5614e16"><fragment id="59697-d5614e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height below the 1st percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have maturational or constitutional delay in combination with an estimated mature height equal to or above 160.1 cm; OR</para></item><item><para>Patient must be female and must not have maturational or constitutional delay in combination with an estimated mature height equal to or above 148.0 cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation of the patient's maturational or constitutional delay status; AND</para><para>6. If the patient has maturational or constitutional delay, confirmation that the patient has an estimated mature height below the 1st adult height percentile; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5614e251"><fragment id="59697-d5614e251"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height below the 1st percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Biochemical growth hormone deficiency should not be secondary to an intracranial lesion or cranial irradiation for applications under this category.</para></block></fragment></section><section id="59697-d5614e484"><fragment id="59697-d5614e484"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have had an intracranial lesion and have undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para></item><item><para>Patient must have had an intracranial lesion, have received medical advice that it is unsafe to treat the intracranial lesion, and have undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para></item><item><para>Patient must have received cranial irradiation without having had an intracranial lesion, and have undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. (a) Confirmation that the patient has had an intracranial lesion and has undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para><para>(b) Confirmation that the patient has had an intracranial lesion, has received medical advice that it is unsafe to treat the intracranial lesion, and has undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para><para>(c) Confirmation that the patient has received cranial irradiation without having had an intracranial lesion, and has undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5614e735"><fragment id="59697-d5614e735"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a chronological age of less than 2 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a documented clinical risk of hypoglycaemia,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. Confirmation that the patient has a documented clinical risk of hypoglycaemia; AND</para><para>5. Confirmation that the patient has documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5614e898"><fragment id="59697-d5614e898"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be male and have commenced puberty (demonstrated by Tanner stage 2 genital or pubic hair development or testicular volumes greater than or equal to 4 mL) before the chronological age of 9 years; OR</para></item><item><para>Patient must be female and have commenced puberty (demonstrated by Tanner stage 2 breast or pubic hair development) before the chronological age of 8 years; OR</para></item><item><para>Patient must be female and menarche occurred before the chronological age of 10 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. Confirmation that the patient has precocious puberty; AND</para><para>7. Confirmation that the patient is undergoing Gonadotropin Releasing Hormone agonist therapy, for pubertal suppression; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5614e1119"><fragment id="59697-d5614e1119"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a structural lesion that is not neoplastic; OR</para></item><item><para>Patient must have had a structural lesion that was neoplastic and have undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para></item><item><para>Patient must have a structural lesion that is neoplastic, have received medical advice that it is unsafe to treat the structural lesion, and have undergone a 12 month period of observation since initial diagnosis of the structural lesion,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have other hypothalamic/pituitary hormone deficits (includes ACTH, TSH, GnRH and/or vasopressin/ADH deficiencies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have hypothalamic obesity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity above the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of greater than 8 cm per year,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. (a) Confirmation that the patient has a structural lesion that is not neoplastic; OR</para><para>(b) Confirmation that the patient had a structural lesion that was neoplastic and has undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para><para>(c) Confirmation that the patient has a structural lesion that is neoplastic, has received medical advice that it is unsafe to treat the structural lesion, and has undergone a 12 month period of observation since initial diagnosis of the structural lesion; AND</para><para>7. Confirmation that the patient has other hypothalamic/pituitary hormone deficits; AND</para><para>8. Confirmation that the patient has hypothalamic obesity; AND</para><para>9. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Testing for biochemical growth hormone deficiency must have been performed at a time when all other pituitary hormone deficits were being adequately replaced.</para></block></fragment></section><section id="59697-d5614e1401"><fragment id="59697-d5614e1401"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height at or below the 95<sup>th</sup> percentile for age on the Turner syndrome growth curve for girls,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in all cells (45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in some cells (mosaic 46XX/45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as genetic loss or rearrangement of an X chromosome (such as isochromosome X, ring-chromosome, or partial deletion of an X chromosome), and gender of rearing is female,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation that the patient has diagnostic results consistent with Turner syndrome; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5614e1604"><fragment id="59697-d5614e1604"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height below the 1st percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation that the patient has diagnostic results consistent with a short stature homeobox (SHOX) gene disorder; AND</para><para>6. If the patient's condition is secondary to mixed gonadal dysgenesis, confirmation that an appropriate plan of management for the patient's increased risk of gonadoblastoma is in place; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5614e1835"><fragment id="59697-d5614e1835"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height at or below the 25th percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, and not have undergone a renal transplant; OR</para></item><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, have undergone a renal transplant, and have undergone a 12 month period of observation following the transplant,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity equal to or less than the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity equal to or less than the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity equal to or less than the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity equal to or less than the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity equal to or less than the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation that the patient has an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> ; AND</para><para>6. If a renal transplant has taken place, confirmation that the patient has undergone a 12 month period of observation following transplantation; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-5822K"><fragment id="59697-5822K"><block label="FormAndStrength">somatropin 6 mg/1.03 mL injection, 1.03 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">5822K<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">266.61</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Saizen [SG]<inline label="genericindexfieldbrand"><italic>XE "Saizen(SG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-5824M"><fragment id="59697-5824M"><block label="FormAndStrength">somatropin 12 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">5824M<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">526.07</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Saizen [SG]<inline label="genericindexfieldbrand"><italic>XE "Saizen(SG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-3388H"><fragment id="59697-3388H"><block label="FormAndStrength">somatropin 20 mg/2.5 mL injection, 2.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">3388H<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">872.01</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Saizen [SG]<inline label="genericindexfieldbrand"><italic>XE "Saizen(SG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-21295011000036100-4"><fragment id="59697-21295011000036100-4"><block label="DrugName">SOMATROPIN<inline label="genericindexfield">XE "SOMATROPIN"</inline></block></fragment></section><section id="59697-d5624e153"><fragment id="59697-d5624e153"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5624e16"><fragment id="59697-d5624e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height below the 1st percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have maturational or constitutional delay in combination with an estimated mature height equal to or above 160.1 cm; OR</para></item><item><para>Patient must be female and must not have maturational or constitutional delay in combination with an estimated mature height equal to or above 148.0 cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation of the patient's maturational or constitutional delay status; AND</para><para>6. If the patient has maturational or constitutional delay, confirmation that the patient has an estimated mature height below the 1st adult height percentile; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5624e251"><fragment id="59697-d5624e251"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height below the 1st percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Biochemical growth hormone deficiency should not be secondary to an intracranial lesion or cranial irradiation for applications under this category.</para></block></fragment></section><section id="59697-d5624e484"><fragment id="59697-d5624e484"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have had an intracranial lesion and have undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para></item><item><para>Patient must have had an intracranial lesion, have received medical advice that it is unsafe to treat the intracranial lesion, and have undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para></item><item><para>Patient must have received cranial irradiation without having had an intracranial lesion, and have undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. (a) Confirmation that the patient has had an intracranial lesion and has undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para><para>(b) Confirmation that the patient has had an intracranial lesion, has received medical advice that it is unsafe to treat the intracranial lesion, and has undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para><para>(c) Confirmation that the patient has received cranial irradiation without having had an intracranial lesion, and has undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5624e735"><fragment id="59697-d5624e735"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a chronological age of less than 2 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a documented clinical risk of hypoglycaemia,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. Confirmation that the patient has a documented clinical risk of hypoglycaemia; AND</para><para>5. Confirmation that the patient has documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5624e898"><fragment id="59697-d5624e898"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be male and have commenced puberty (demonstrated by Tanner stage 2 genital or pubic hair development or testicular volumes greater than or equal to 4 mL) before the chronological age of 9 years; OR</para></item><item><para>Patient must be female and have commenced puberty (demonstrated by Tanner stage 2 breast or pubic hair development) before the chronological age of 8 years; OR</para></item><item><para>Patient must be female and menarche occurred before the chronological age of 10 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. Confirmation that the patient has precocious puberty; AND</para><para>7. Confirmation that the patient is undergoing Gonadotropin Releasing Hormone agonist therapy, for pubertal suppression; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5624e1119"><fragment id="59697-d5624e1119"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a structural lesion that is not neoplastic; OR</para></item><item><para>Patient must have had a structural lesion that was neoplastic and have undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para></item><item><para>Patient must have a structural lesion that is neoplastic, have received medical advice that it is unsafe to treat the structural lesion, and have undergone a 12 month period of observation since initial diagnosis of the structural lesion,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have other hypothalamic/pituitary hormone deficits (includes ACTH, TSH, GnRH and/or vasopressin/ADH deficiencies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have hypothalamic obesity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity above the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of greater than 8 cm per year,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. (a) Confirmation that the patient has a structural lesion that is not neoplastic; OR</para><para>(b) Confirmation that the patient had a structural lesion that was neoplastic and has undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para><para>(c) Confirmation that the patient has a structural lesion that is neoplastic, has received medical advice that it is unsafe to treat the structural lesion, and has undergone a 12 month period of observation since initial diagnosis of the structural lesion; AND</para><para>7. Confirmation that the patient has other hypothalamic/pituitary hormone deficits; AND</para><para>8. Confirmation that the patient has hypothalamic obesity; AND</para><para>9. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Testing for biochemical growth hormone deficiency must have been performed at a time when all other pituitary hormone deficits were being adequately replaced.</para></block></fragment></section><section id="59697-d5624e1401"><fragment id="59697-d5624e1401"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height at or below the 95<sup>th</sup> percentile for age on the Turner syndrome growth curve for girls,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in all cells (45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in some cells (mosaic 46XX/45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as genetic loss or rearrangement of an X chromosome (such as isochromosome X, ring-chromosome, or partial deletion of an X chromosome), and gender of rearing is female,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation that the patient has diagnostic results consistent with Turner syndrome; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5624e1604"><fragment id="59697-d5624e1604"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height below the 1st percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation that the patient has diagnostic results consistent with a short stature homeobox (SHOX) gene disorder; AND</para><para>6. If the patient's condition is secondary to mixed gonadal dysgenesis, confirmation that an appropriate plan of management for the patient's increased risk of gonadoblastoma is in place; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5624e1835"><fragment id="59697-d5624e1835"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height at or below the 25th percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, and not have undergone a renal transplant; OR</para></item><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, have undergone a renal transplant, and have undergone a 12 month period of observation following the transplant,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity equal to or less than the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity equal to or less than the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity equal to or less than the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity equal to or less than the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity equal to or less than the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation that the patient has an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> ; AND</para><para>6. If a renal transplant has taken place, confirmation that the patient has undergone a 12 month period of observation following transplantation; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-9604L"><fragment id="59697-9604L"><block label="FormAndStrength">somatropin 10 mg/2 mL injection, 2 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">9604L<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">439.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">NutropinAq [IS]<inline label="genericindexfieldbrand"><italic>XE "NutropinAq(IS)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-5818F"><fragment id="59697-5818F"><block label="FormAndStrength">somatropin 5 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">5818F<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">223.37</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norditropin FlexPro [NO]<inline label="genericindexfieldbrand"><italic>XE "Norditropin FlexPro(NO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-6295H"><fragment id="59697-6295H"><block label="FormAndStrength">somatropin 5 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">6295H<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">223.37</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norditropin SimpleXx [NO]<inline label="genericindexfieldbrand"><italic>XE "Norditropin SimpleXx(NO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-5820H"><fragment id="59697-5820H"><block label="FormAndStrength">somatropin 15 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">5820H<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">655.80</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norditropin FlexPro [NO]<inline label="genericindexfieldbrand"><italic>XE "Norditropin FlexPro(NO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-6297K"><fragment id="59697-6297K"><block label="FormAndStrength">somatropin 15 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">6297K<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">655.80</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norditropin SimpleXx [NO]<inline label="genericindexfieldbrand"><italic>XE "Norditropin SimpleXx(NO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-5819G"><fragment id="59697-5819G"><block label="FormAndStrength">somatropin 10 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">5819G<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">439.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norditropin FlexPro [NO]<inline label="genericindexfieldbrand"><italic>XE "Norditropin FlexPro(NO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-6296J"><fragment id="59697-6296J"><block label="FormAndStrength">somatropin 10 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">6296J<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">439.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norditropin SimpleXx [NO]<inline label="genericindexfieldbrand"><italic>XE "Norditropin SimpleXx(NO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-21295011000036100-5"><fragment id="59697-21295011000036100-5"><block label="DrugName">SOMATROPIN<inline label="genericindexfield">XE "SOMATROPIN"</inline></block></fragment></section><section id="59697-d5634e153"><fragment id="59697-d5634e153"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5634e16"><fragment id="59697-d5634e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height below the 1st percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have maturational or constitutional delay in combination with an estimated mature height equal to or above 160.1 cm; OR</para></item><item><para>Patient must be female and must not have maturational or constitutional delay in combination with an estimated mature height equal to or above 148.0 cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation of the patient's maturational or constitutional delay status; AND</para><para>6. If the patient has maturational or constitutional delay, confirmation that the patient has an estimated mature height below the 1st adult height percentile; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5634e251"><fragment id="59697-d5634e251"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height below the 1st percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Biochemical growth hormone deficiency should not be secondary to an intracranial lesion or cranial irradiation for applications under this category.</para></block></fragment></section><section id="59697-d5634e484"><fragment id="59697-d5634e484"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have had an intracranial lesion and have undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para></item><item><para>Patient must have had an intracranial lesion, have received medical advice that it is unsafe to treat the intracranial lesion, and have undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para></item><item><para>Patient must have received cranial irradiation without having had an intracranial lesion, and have undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. (a) Confirmation that the patient has had an intracranial lesion and has undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para><para>(b) Confirmation that the patient has had an intracranial lesion, has received medical advice that it is unsafe to treat the intracranial lesion, and has undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para><para>(c) Confirmation that the patient has received cranial irradiation without having had an intracranial lesion, and has undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5634e735"><fragment id="59697-d5634e735"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a chronological age of less than 2 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a documented clinical risk of hypoglycaemia,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. Confirmation that the patient has a documented clinical risk of hypoglycaemia; AND</para><para>5. Confirmation that the patient has documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5634e898"><fragment id="59697-d5634e898"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be male and have commenced puberty (demonstrated by Tanner stage 2 genital or pubic hair development or testicular volumes greater than or equal to 4 mL) before the chronological age of 9 years; OR</para></item><item><para>Patient must be female and have commenced puberty (demonstrated by Tanner stage 2 breast or pubic hair development) before the chronological age of 8 years; OR</para></item><item><para>Patient must be female and menarche occurred before the chronological age of 10 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. Confirmation that the patient has precocious puberty; AND</para><para>7. Confirmation that the patient is undergoing Gonadotropin Releasing Hormone agonist therapy, for pubertal suppression; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5634e1119"><fragment id="59697-d5634e1119"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a structural lesion that is not neoplastic; OR</para></item><item><para>Patient must have had a structural lesion that was neoplastic and have undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para></item><item><para>Patient must have a structural lesion that is neoplastic, have received medical advice that it is unsafe to treat the structural lesion, and have undergone a 12 month period of observation since initial diagnosis of the structural lesion,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have other hypothalamic/pituitary hormone deficits (includes ACTH, TSH, GnRH and/or vasopressin/ADH deficiencies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have hypothalamic obesity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity above the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of greater than 8 cm per year,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. (a) Confirmation that the patient has a structural lesion that is not neoplastic; OR</para><para>(b) Confirmation that the patient had a structural lesion that was neoplastic and has undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para><para>(c) Confirmation that the patient has a structural lesion that is neoplastic, has received medical advice that it is unsafe to treat the structural lesion, and has undergone a 12 month period of observation since initial diagnosis of the structural lesion; AND</para><para>7. Confirmation that the patient has other hypothalamic/pituitary hormone deficits; AND</para><para>8. Confirmation that the patient has hypothalamic obesity; AND</para><para>9. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Testing for biochemical growth hormone deficiency must have been performed at a time when all other pituitary hormone deficits were being adequately replaced.</para></block></fragment></section><section id="59697-d5634e1401"><fragment id="59697-d5634e1401"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height at or below the 95<sup>th</sup> percentile for age on the Turner syndrome growth curve for girls,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in all cells (45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in some cells (mosaic 46XX/45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as genetic loss or rearrangement of an X chromosome (such as isochromosome X, ring-chromosome, or partial deletion of an X chromosome), and gender of rearing is female,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation that the patient has diagnostic results consistent with Turner syndrome; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5634e1604"><fragment id="59697-d5634e1604"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height below the 1st percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation that the patient has diagnostic results consistent with a short stature homeobox (SHOX) gene disorder; AND</para><para>6. If the patient's condition is secondary to mixed gonadal dysgenesis, confirmation that an appropriate plan of management for the patient's increased risk of gonadoblastoma is in place; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5634e1835"><fragment id="59697-d5634e1835"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height at or below the 25th percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, and not have undergone a renal transplant; OR</para></item><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, have undergone a renal transplant, and have undergone a 12 month period of observation following the transplant,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity equal to or less than the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity equal to or less than the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity equal to or less than the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity equal to or less than the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity equal to or less than the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be prepubertal.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation that the patient has an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> ; AND</para><para>6. If a renal transplant has taken place, confirmation that the patient has undergone a 12 month period of observation following transplantation; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-6345Y"><fragment id="59697-6345Y"><block label="FormAndStrength">somatropin 24 mg injection [1 cartridge] (&amp;) inert substance diluent [3.15 mL syringe], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">6345Y<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">1044.99</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Humatrope [LY]<inline label="genericindexfieldbrand"><italic>XE "Humatrope(LY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-6169Q"><fragment id="59697-6169Q"><block label="FormAndStrength">somatropin 6 mg injection [1 cartridge] (&amp;) inert substance diluent [3.15 mL syringe], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">6169Q<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">266.61</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Humatrope [LY]<inline label="genericindexfieldbrand"><italic>XE "Humatrope(LY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-6170R"><fragment id="59697-6170R"><block label="FormAndStrength">somatropin 12 mg injection [1 cartridge] (&amp;) inert substance diluent [3.15 mL syringe], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">6170R<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">526.07</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Humatrope [LY]<inline label="genericindexfieldbrand"><italic>XE "Humatrope(LY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-21295011000036100-6"><fragment id="59697-21295011000036100-6"><block label="DrugName">SOMATROPIN<inline label="genericindexfield">XE "SOMATROPIN"</inline></block></fragment></section><section id="59697-d5644e153"><fragment id="59697-d5644e153"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5644e16"><fragment id="59697-d5644e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height below the 1st percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have maturational or constitutional delay in combination with an estimated mature height equal to or above 160.1 cm; OR</para></item><item><para>Patient must be female and must not have maturational or constitutional delay in combination with an estimated mature height equal to or above 148.0 cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation of the patient's maturational or constitutional delay status; AND</para><para>6. If the patient has maturational or constitutional delay, confirmation that the patient has an estimated mature height below the 1st adult height percentile; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5644e251"><fragment id="59697-d5644e251"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height below the 1st percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Biochemical growth hormone deficiency should not be secondary to an intracranial lesion or cranial irradiation for applications under this category.</para></block></fragment></section><section id="59697-d5644e484"><fragment id="59697-d5644e484"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have had an intracranial lesion and have undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para></item><item><para>Patient must have had an intracranial lesion, have received medical advice that it is unsafe to treat the intracranial lesion, and have undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para></item><item><para>Patient must have received cranial irradiation without having had an intracranial lesion, and have undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. (a) Confirmation that the patient has had an intracranial lesion and has undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para><para>(b) Confirmation that the patient has had an intracranial lesion, has received medical advice that it is unsafe to treat the intracranial lesion, and has undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para><para>(c) Confirmation that the patient has received cranial irradiation without having had an intracranial lesion, and has undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5644e735"><fragment id="59697-d5644e735"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a chronological age of less than 2 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a documented clinical risk of hypoglycaemia,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. Confirmation that the patient has a documented clinical risk of hypoglycaemia; AND</para><para>5. Confirmation that the patient has documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5644e898"><fragment id="59697-d5644e898"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be male and have commenced puberty (demonstrated by Tanner stage 2 genital or pubic hair development or testicular volumes greater than or equal to 4 mL) before the chronological age of 9 years; OR</para></item><item><para>Patient must be female and have commenced puberty (demonstrated by Tanner stage 2 breast or pubic hair development) before the chronological age of 8 years; OR</para></item><item><para>Patient must be female and menarche occurred before the chronological age of 10 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. Confirmation that the patient has precocious puberty; AND</para><para>7. Confirmation that the patient is undergoing Gonadotropin Releasing Hormone agonist therapy, for pubertal suppression; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5644e1119"><fragment id="59697-d5644e1119"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a structural lesion that is not neoplastic; OR</para></item><item><para>Patient must have had a structural lesion that was neoplastic and have undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para></item><item><para>Patient must have a structural lesion that is neoplastic, have received medical advice that it is unsafe to treat the structural lesion, and have undergone a 12 month period of observation since initial diagnosis of the structural lesion,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have other hypothalamic/pituitary hormone deficits (includes ACTH, TSH, GnRH and/or vasopressin/ADH deficiencies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have hypothalamic obesity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity above the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity above the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of greater than 8 cm per year,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. (a) Confirmation that the patient has a structural lesion that is not neoplastic; OR</para><para>(b) Confirmation that the patient had a structural lesion that was neoplastic and has undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para><para>(c) Confirmation that the patient has a structural lesion that is neoplastic, has received medical advice that it is unsafe to treat the structural lesion, and has undergone a 12 month period of observation since initial diagnosis of the structural lesion; AND</para><para>7. Confirmation that the patient has other hypothalamic/pituitary hormone deficits; AND</para><para>8. Confirmation that the patient has hypothalamic obesity; AND</para><para>9. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Testing for biochemical growth hormone deficiency must have been performed at a time when all other pituitary hormone deficits were being adequately replaced.</para></block></fragment></section><section id="59697-d5644e1401"><fragment id="59697-d5644e1401"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height at or below the 95<sup>th</sup> percentile for age on the Turner syndrome growth curve for girls,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in all cells (45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in some cells (mosaic 46XX/45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as genetic loss or rearrangement of an X chromosome (such as isochromosome X, ring-chromosome, or partial deletion of an X chromosome), and gender of rearing is female,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation that the patient has diagnostic results consistent with Turner syndrome; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5644e1604"><fragment id="59697-d5644e1604"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Initial treatment</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height below the 1st percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity below the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity below the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation that the patient has diagnostic results consistent with a short stature homeobox (SHOX) gene disorder; AND</para><para>6. If the patient's condition is secondary to mixed gonadal dysgenesis, confirmation that an appropriate plan of management for the patient's increased risk of gonadoblastoma is in place; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5644e1835"><fragment id="59697-d5644e1835"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a current height at or below the 25th percentile for age and sex,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, and not have undergone a renal transplant; OR</para></item><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, have undergone a renal transplant, and have undergone a 12 month period of observation following the transplant,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, have a chronological age of at least 12 years and a growth velocity equal to or less than the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be male, have a bone age of at least 10 years and a growth velocity equal to or less than the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a chronological age of at least 10 years and a growth velocity equal to or less than the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must be female, have a bone age of at least 8 years and a growth velocity equal to or less than the 25th percentile for bone age and sex measured over a 6 month interval; OR</para></item><item><para>Patient must have a growth velocity equal to or less than the 25th percentile for bone age and sex measured over both 12 and 6 month intervals; OR</para></item><item><para>Patient must have a bone age of 2.5 years or less and an annual growth velocity of 8 cm per year or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. (a) A minimum of 12 months of recent growth data (height and weight) at intervals no greater than six months. The most recent data must not be older than three months; OR</para><para>(b) A minimum of 6 months of recent growth data (height and weight) for older children (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over). The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation that the patient has an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> ; AND</para><para>6. If a renal transplant has taken place, confirmation that the patient has undergone a 12 month period of observation following transplantation; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5644e2084"><fragment id="59697-d5644e2084"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and poor body composition due to Prader-Willi syndrome</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have diagnostic results consistent with Prader-Willi syndrome (the condition must be genetically proven); OR</para></item><item><para>Patient must have a clinical diagnosis of Prader-Willi syndrome, confirmed by a clinical geneticist,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have been evaluated via polysomnography for airway obstruction and apnoea within the last 12 months with no sleep disorders identified; OR</para></item><item><para>Patient must have been evaluated via polysomnography for airway obstruction and apnoea within the last 12 months with sleep disorders identified which are not of sufficient severity to require treatment; OR</para></item><item><para>Patient must have been evaluated via polysomnography for airway obstruction and apnoea within the last 12 months with sleep disorders identified for which the patient is currently receiving ameliorative treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have uncontrolled morbid obesity, defined as a body weight greater than 200% of ideal body weight for height and sex, with ideal body weight derived by calculating the 50th percentile weight for the patient's current height,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have previously received treatment under the PBS S100 Growth Hormone Program,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a chronological age of 18 years or greater.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a specialist or consultant physician in general paediatrics in consultation with a nominated specialist or consultant physician in paediatric endocrinology.</para></item></list> <para>The maximum duration of the initial treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for initial treatment; AND</para><para>3. A minimum of 6 months of recent growth data (height, weight and waist circumference). The most recent data must not be older than three months; AND</para><para>4. The date that skeletal maturity was achieved (if applicable); AND</para><para>5. (a) Confirmation that the patient has diagnostic results consistent with Prader-Willi syndrome; OR</para><para>(b) Confirmation that the patient has a clinical diagnosis of Prader-Willi syndrome, confirmed by a clinical geneticist</para><para>6. Confirmation that the patient has been evaluated via polysomnography for airway obstruction and apnoea within the last 12 months and any sleep disorders identified via polysomnography that required treatment have been addressed; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with 1 repeat allowed)</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-6314H"><fragment id="59697-6314H"><block label="FormAndStrength">somatropin 1 mg injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">6314H<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">309.85</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-9585L"><fragment id="59697-9585L"><block label="FormAndStrength">SOMATROPIN (Recombinant human growth hormone) Powder for injection 5 mg (15 i.u.) with diluent in pre-filled pen (with preservative), 1</block><table role="GH"><row><cell><block label="DrugItemCode">9585L<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">223.37</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin GoQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin GoQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-6319N"><fragment id="59697-6319N"><block label="FormAndStrength">somatropin 2 mg injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">6319N<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">612.55</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-6317L"><fragment id="59697-6317L"><block label="FormAndStrength">somatropin 1.6 mg injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">6317L<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">491.48</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-6315J"><fragment id="59697-6315J"><block label="FormAndStrength">somatropin 1.2 mg injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">6315J<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">370.39</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-9586M"><fragment id="59697-9586M"><block label="FormAndStrength">SOMATROPIN (Recombinant human growth hormone) Powder for injection 12 mg (36 i.u.) with diluent in pre-filled pen (with preservative), 1</block><table role="GH"><row><cell><block label="DrugItemCode">9586M<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">526.07</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin GoQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin GoQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-6313G"><fragment id="59697-6313G"><block label="FormAndStrength">somatropin 800 microgram injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">6313G<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">249.31</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-6316K"><fragment id="59697-6316K"><block label="FormAndStrength">somatropin 1.4 mg injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">6316K<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">430.93</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-9628R"><fragment id="59697-9628R"><block label="FormAndStrength">somatropin 600 microgram injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">9628R<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">188.78</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10902T"><fragment id="59697-10902T"><block label="FormAndStrength">somatropin 400 microgram injection, syringe [7] (&amp;) inert substance diluent, syringe [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10902T<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">128.23</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-6318M"><fragment id="59697-6318M"><block label="FormAndStrength">somatropin 1.8 mg injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">6318M<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">552.02</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-6312F"><fragment id="59697-6312F"><block label="FormAndStrength">somatropin 12 mg injection [1 cartridge] (&amp;) inert substance diluent [1 mL cartridge], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">6312F<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">526.07</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-21295011000036100-7"><fragment id="59697-21295011000036100-7"><block label="DrugName">SOMATROPIN<inline label="genericindexfield">XE "SOMATROPIN"</inline></block></fragment></section><section id="59697-d5655e127"><fragment id="59697-d5655e127"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5655e16"><fragment id="59697-d5655e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature and slow growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5655e222"><fragment id="59697-d5655e222"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with biochemical growth hormone deficiency category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5655e413"><fragment id="59697-d5655e413"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the growth retardation secondary to an intracranial lesion, or cranial irradiation category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5655e604"><fragment id="59697-d5655e604"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a chronological age of 5 years or greater.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>When a patient receiving treatment under the indication risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants reaches or surpasses 5 years of age (chronological), prescribers should seek reclassification to the indication 'short stature due to biochemical growth hormone deficiency'.</para></block></fragment></section><section id="59697-d5655e795"><fragment id="59697-d5655e795"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the biochemical growth hormone deficiency and precocious puberty category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5655e986"><fragment id="59697-d5655e986"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5655e1177"><fragment id="59697-d5655e1177"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with Turner syndrome category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an annualised growth velocity for bone age at or above the mean growth velocity for untreated Turner Syndrome girls (using the Turner Syndrome - Ranke growth velocity chart) while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0 cm.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5655e1372"><fragment id="59697-d5655e1372"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature due to short stature homeobox (SHOX) gene disorders category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5655e1578"><fragment id="59697-d5655e1578"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature and slow growth,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication short stature associated with chronic renal insufficiency, have undergone a renal transplant and a 12 month period of observation following the transplant, and have an estimated glomerular filtration rate of greater than or equal to 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula; OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months;</para><para>OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment; AND</para><para>4. A bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5655e1856"><fragment id="59697-d5655e1856"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and have reached or surpassed 5 years of age (chronological); OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(c) Confirmation that the patient has previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and has reached or surpassed 5 years of age (chronological); AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Biochemical growth hormone deficiency should not be secondary to an intracranial lesion or cranial irradiation for applications under this category.</para></block></fragment></section><section id="59697-d5655e2213"><fragment id="59697-d5655e2213"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than growth retardation secondary to an intracranial lesion, or cranial irradiation,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had an intracranial lesion and have undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para></item><item><para>Patient must have had an intracranial lesion, have received medical advice that it is unsafe to treat the intracranial lesion, and have undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para></item><item><para>Patient must have received cranial irradiation without having had an intracranial lesion, and have undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8cm per year or less in the 12 month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has had an intracranial lesion and has undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para><para>(b) Confirmation that the patient has had an intracranial lesion, has received medical advice that it is unsafe to treat the intracranial lesion, and has undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para><para>(c) Confirmation that the patient has received cranial irradiation without having had an intracranial lesion, and has undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5655e2558"><fragment id="59697-d5655e2558"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a chronological age of less than 2 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a documented clinical risk of hypoglycaemia,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. Confirmation that the patient has a documented clinical risk of hypoglycaemia; AND</para><para>4. Confirmation that the patient has documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5655e2781"><fragment id="59697-d5655e2781"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than biochemical growth hormone deficiency and precocious puberty,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and have commenced puberty (demonstrated by Tanner stage 2 genital or pubic hair development or testicular volumes greater than or equal to 4 mL) before the chronological age of 9 years; OR</para></item><item><para>Patient must be female and have commenced puberty (demonstrated by Tanner stage 2 breast or pubic hair development) before the chronological age of 8 years; OR</para></item><item><para>Patient must be female and menarche occurred before the chronological age of 10 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. Confirmation that the patient has precocious puberty; AND</para><para>4. Confirmation that the patient is undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5655e3058"><fragment id="59697-d5655e3058"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a structural lesion that is not neoplastic; OR</para></item><item><para>Patient must have had a structural lesion that was neoplastic and have undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para></item><item><para>Patient must have a structural lesion that is neoplastic, have received medical advice that it is unsafe to treat the structural lesion, and have undergone a 12 month period of observation since initial diagnosis of the structural lesion,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have other hypothalamic/pituitary hormone deficits (includes ACTH, TSH, GnRH and/or vasopressin/ADH deficiencies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have hypothalamic obesity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity above the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8 cm per year or greater in the twelve month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has a structural lesion that is not neoplastic; OR</para><para>(b) Confirmation that the patient had a structural lesion that was neoplastic and has undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para><para>(c) Confirmation that the patient has a structural lesion that is neoplastic, has received medical advice that it is unsafe to treat the structural lesion, and has undergone a 12 month period of observation since initial diagnosis of the structural lesion; AND</para><para>6. Confirmation that the patient has other hypothalamic/pituitary hormone deficits; AND</para><para>7. Confirmation that the patient has hypothalamic obesity; AND</para><para>8. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>9. A bone age result performed within the last 12 months; AND</para><para>10. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5655e3400"><fragment id="59697-d5655e3400"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with Turner syndrome,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a height at or below the 95th percentile for age on the Turner syndrome growth curve for girls immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in all cells (45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in some cells (mosaic 46XX/45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as genetic loss or rearrangement of an X chromosome (such as isochromosome X, ring-chromosome, or partial deletion of an X chromosome), and gender of rearing is female,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0 cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. A height measurement from immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with Turner syndrome; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5655e3656"><fragment id="59697-d5655e3656"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature due to short stature homeobox (SHOX) gene disorders,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8 cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with a short stature homeobox (SHOX) gene disorder; AND</para><para>5. If the patient's condition is secondary to mixed gonadal dysgenesis, confirmation that an appropriate plan of management for the patient's increased risk of gonadoblastoma is in place; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-10452D"><fragment id="59697-10452D"><block label="FormAndStrength">somatropin 4 mg injection [1 vial] (&amp;) inert substance diluent [1 vial], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10452D<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">180.12</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Zomacton [FP]<inline label="genericindexfieldbrand"><italic>XE "Zomacton(FP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10440L"><fragment id="59697-10440L"><block label="FormAndStrength">somatropin 10 mg injection [1 vial] (&amp;) inert substance diluent [1 mL syringe], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10440L<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">439.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Zomacton [FP]<inline label="genericindexfieldbrand"><italic>XE "Zomacton(FP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-21295011000036100-8"><fragment id="59697-21295011000036100-8"><block label="DrugName">SOMATROPIN<inline label="genericindexfield">XE "SOMATROPIN"</inline></block></fragment></section><section id="59697-d5672e152"><fragment id="59697-d5672e152"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5672e16"><fragment id="59697-d5672e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature and slow growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5672e144"><fragment id="59697-d5672e144"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5672e253"><fragment id="59697-d5672e253"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with biochemical growth hormone deficiency category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5672e371"><fragment id="59697-d5672e371"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5672e476"><fragment id="59697-d5672e476"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the growth retardation secondary to an intracranial lesion, or cranial irradiation category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5672e594"><fragment id="59697-d5672e594"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5672e699"><fragment id="59697-d5672e699"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a chronological age of 5 years or greater.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5672e814"><fragment id="59697-d5672e814"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5672e917"><fragment id="59697-d5672e917"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the biochemical growth hormone deficiency and precocious puberty category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5672e1042"><fragment id="59697-d5672e1042"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5672e1149"><fragment id="59697-d5672e1149"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5672e1267"><fragment id="59697-d5672e1267"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5672e1372"><fragment id="59697-d5672e1372"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with Turner syndrome category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5672e1494"><fragment id="59697-d5672e1494"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5672e1599"><fragment id="59697-d5672e1599"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature due to short stature homeobox (SHOX) gene disorders category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5672e1737"><fragment id="59697-d5672e1737"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5672e1850"><fragment id="59697-d5672e1850"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature and slow growth,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication short stature associated with chronic renal insufficiency, have undergone a renal transplant and a 12 month period of observation following the transplant, and have an estimated glomerular filtration rate of greater than or equal to 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula; OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment; AND</para><para>4. A bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5672e2133"><fragment id="59697-d5672e2133"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and have reached or surpassed 5 years of age (chronological); OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(c) Confirmation that the patient has previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and has reached or surpassed 5 years of age (chronological); AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Biochemical growth hormone deficiency should not be secondary to an intracranial lesion or cranial irradiation for applications under this category.</para></block></fragment></section><section id="59697-d5672e2499"><fragment id="59697-d5672e2499"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than growth retardation secondary to an intracranial lesion, or cranial irradiation,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had an intracranial lesion and have undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para></item><item><para>Patient must have had an intracranial lesion, have received medical advice that it is unsafe to treat the intracranial lesion, and have undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para></item><item><para>Patient must have received cranial irradiation without having had an intracranial lesion, and have undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8cm per year or less in the 12 month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has had an intracranial lesion and has undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para><para>(b) Confirmation that the patient has had an intracranial lesion, has received medical advice that it is unsafe to treat the intracranial lesion, and has undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para><para>(c) Confirmation that the patient has received cranial irradiation without having had an intracranial lesion, and has undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5672e2853"><fragment id="59697-d5672e2853"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a chronological age of less than 2 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a documented clinical risk of hypoglycaemia,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. Confirmation that the patient has a documented clinical risk of hypoglycaemia; AND</para><para>4. Confirmation that the patient has documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5672e3090"><fragment id="59697-d5672e3090"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than biochemical growth hormone deficiency and precocious puberty,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and have commenced puberty (demonstrated by Tanner stage 2 genital or pubic hair development or testicular volumes greater than or equal to 4 mL) before the chronological age of 9 years; OR</para></item><item><para>Patient must be female and have commenced puberty (demonstrated by Tanner stage 2 breast or pubic hair development) before the chronological age of 8 years; OR</para></item><item><para>Patient must be female and menarche occurred before the chronological age of 10 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. Confirmation that the patient has precocious puberty; AND</para><para>4. Confirmation that the patient is undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5672e3376"><fragment id="59697-d5672e3376"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a structural lesion that is not neoplastic; OR</para></item><item><para>Patient must have had a structural lesion that was neoplastic and have undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para></item><item><para>Patient must have a structural lesion that is neoplastic, have received medical advice that it is unsafe to treat the structural lesion, and have undergone a 12 month period of observation since initial diagnosis of the structural lesion,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have other hypothalamic/pituitary hormone deficits (includes ACTH, TSH, GnRH and/or vasopressin/ADH deficiencies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have hypothalamic obesity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity above the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8 cm per year or greater in the twelve month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has a structural lesion that is not neoplastic; OR</para><para>(b) Confirmation that the patient had a structural lesion that was neoplastic and has undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para><para>(c) Confirmation that the patient has a structural lesion that is neoplastic, has received medical advice that it is unsafe to treat the structural lesion, and has undergone a 12 month period of observation since initial diagnosis of the structural lesion; AND</para><para>6. Confirmation that the patient has other hypothalamic/pituitary hormone deficits; AND</para><para>7. Confirmation that the patient has hypothalamic obesity; AND</para><para>8. Recent growth data (height and weight, not older than three months); AND</para><para>9. A bone age result performed within the last 12 months; AND</para><para>10. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5672e3727"><fragment id="59697-d5672e3727"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with Turner syndrome,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a height at or below the 95th percentile for age on the Turner syndrome growth curve for girls immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in all cells (45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in some cells (mosaic 46XX/45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as genetic loss or rearrangement of an X chromosome (such as isochromosome X, ring-chromosome, or partial deletion of an X chromosome), and gender of rearing is female,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. A height measurement from immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with Turner syndrome; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5672e3992"><fragment id="59697-d5672e3992"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature due to short stature homeobox (SHOX) gene disorders,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8 cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with a short stature homeobox (SHOX) gene disorder; AND</para><para>5. If the patient's condition is secondary to mixed gonadal dysgenesis, confirmation that an appropriate plan of management for the patient's increased risk of gonadoblastoma is in place; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-10447W"><fragment id="59697-10447W"><block label="FormAndStrength">somatropin 4 mg injection [1 vial] (&amp;) inert substance diluent [1 vial], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10447W<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">180.12</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Zomacton [FP]<inline label="genericindexfieldbrand"><italic>XE "Zomacton(FP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10455G"><fragment id="59697-10455G"><block label="FormAndStrength">somatropin 10 mg injection [1 vial] (&amp;) inert substance diluent [1 mL syringe], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10455G<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">439.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Zomacton [FP]<inline label="genericindexfieldbrand"><italic>XE "Zomacton(FP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-21295011000036100-9"><fragment id="59697-21295011000036100-9"><block label="DrugName">SOMATROPIN<inline label="genericindexfield">XE "SOMATROPIN"</inline></block></fragment></section><section id="59697-d5689e134"><fragment id="59697-d5689e134"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5689e16"><fragment id="59697-d5689e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature and slow growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5689e231"><fragment id="59697-d5689e231"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with biochemical growth hormone deficiency category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5689e431"><fragment id="59697-d5689e431"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature due to growth retardation secondary to an intracranial lesion, or cranial irradiation category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5689e631"><fragment id="59697-d5689e631"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a chronological age of 5 years or greater.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>When a patient receiving treatment under the indication risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants reaches or surpasses 5 years of age (chronological), prescribers should seek reclassification to the indication 'short stature due to biochemical growth hormone deficiency'.</para></block></fragment></section><section id="59697-d5689e831"><fragment id="59697-d5689e831"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the biochemical growth hormone deficiency and precocious puberty category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5689e1031"><fragment id="59697-d5689e1031"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5689e1231"><fragment id="59697-d5689e1231"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with Turner syndrome category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an annualised growth velocity for bone age at or above the mean growth velocity for untreated Turner Syndrome girls (using the Turner Syndrome - Ranke growth velocity chart) while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0 cm.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5689e1435"><fragment id="59697-d5689e1435"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature due to short stature homeobox (SHOX) gene disorders category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5689e1650"><fragment id="59697-d5689e1650"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with chronic renal insufficiency category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have undergone a renal transplant within the 12 month period immediately prior to the date of application,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an eGFR equal to or greater than 30mL/min/1.73m<sup>2</sup>,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5689e1785"><fragment id="59697-d5689e1785"><block label="NoteText"><para>If a patient receiving treatment under the indication short stature due to chronic renal insufficiency undergoes a renal transplant and 12 months post-transplant has an eGFR of equal to or greater than 30mL/min/1.73m<sup>2</sup> prescribers should seek reclassification to the indication short stature and slow growth.</para></block></fragment></section><section id="59697-d5689e1895"><fragment id="59697-d5689e1895"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature and slow growth,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication short stature associated with chronic renal insufficiency, have undergone a renal transplant and a 12 month period of observation following the transplant, and have an estimated glomerular filtration rate of greater than or equal to 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula; OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months;</para><para>OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment; AND</para><para>4. A bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5689e2182"><fragment id="59697-d5689e2182"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and have reached or surpassed 5 years of age (chronological); OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(c) Confirmation that the patient has previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and has reached or surpassed 5 years of age (chronological); AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Biochemical growth hormone deficiency should not be secondary to an intracranial lesion or cranial irradiation for applications under this category.</para></block></fragment></section><section id="59697-d5689e2549"><fragment id="59697-d5689e2549"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than growth retardation secondary to an intracranial lesion, or cranial irradiation,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had an intracranial lesion and have undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para></item><item><para>Patient must have had an intracranial lesion, have received medical advice that it is unsafe to treat the intracranial lesion, and have undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para></item><item><para>Patient must have received cranial irradiation without having had an intracranial lesion, and have undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8cm per year or less in the 12 month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a paediatric endocrinologist; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with an endocrinologist specialising in paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has had an intracranial lesion and has undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para><para>(b) Confirmation that the patient has had an intracranial lesion, has received medical advice that it is unsafe to treat the intracranial lesion, and has undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para><para>(c) Confirmation that the patient has received cranial irradiation without having had an intracranial lesion, and has undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5689e2902"><fragment id="59697-d5689e2902"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than biochemical growth hormone deficiency and precocious puberty,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and have commenced puberty (demonstrated by Tanner stage 2 genital or pubic hair development or testicular volumes greater than or equal to 4 mL) before the chronological age of 9 years; OR</para></item><item><para>Patient must be female and have commenced puberty (demonstrated by Tanner stage 2 breast or pubic hair development) before the chronological age of 8 years; OR</para></item><item><para>Patient must be female and menarche occurred before the chronological age of 10 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. Confirmation that the patient has precocious puberty; AND</para><para>4. Confirmation that the patient is undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5689e3188"><fragment id="59697-d5689e3188"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a structural lesion that is not neoplastic; OR</para></item><item><para>Patient must have had a structural lesion that was neoplastic and have undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para></item><item><para>Patient must have a structural lesion that is neoplastic, have received medical advice that it is unsafe to treat the structural lesion, and have undergone a 12 month period of observation since initial diagnosis of the structural lesion,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have other hypothalamic/pituitary hormone deficits (includes ACTH, TSH, GnRH and/or vasopressin/ADH deficiencies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have hypothalamic obesity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity above the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8 cm per year or greater in the twelve month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has a structural lesion that is not neoplastic; OR</para><para>(b) Confirmation that the patient had a structural lesion that was neoplastic and has undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para><para>(c) Confirmation that the patient has a structural lesion that is neoplastic, has received medical advice that it is unsafe to treat the structural lesion, and has undergone a 12 month period of observation since initial diagnosis of the structural lesion; AND</para><para>6. Confirmation that the patient has other hypothalamic/pituitary hormone deficits; AND</para><para>7. Confirmation that the patient has hypothalamic obesity; AND</para><para>8. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>9. A bone age result performed within the last 12 months; AND</para><para>10. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5689e3539"><fragment id="59697-d5689e3539"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with Turner syndrome,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a height at or below the 95th percentile for age on the Turner syndrome growth curve for girls immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in all cells (45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in some cells (mosaic 46XX/45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as genetic loss or rearrangement of an X chromosome (such as isochromosome X, ring-chromosome, or partial deletion of an X chromosome), and gender of rearing is female,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0 cm.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. A height measurement from immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with Turner syndrome; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5689e3804"><fragment id="59697-d5689e3804"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature due to short stature homeobox (SHOX) gene disorders,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8 cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with a short stature homeobox (SHOX) gene disorder; AND</para><para>5. If the patient's condition is secondary to mixed gonadal dysgenesis, confirmation that an appropriate plan of management for the patient's increased risk of gonadoblastoma is in place; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5689e4099"><fragment id="59697-d5689e4099"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with chronic renal insufficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, and not have undergone a renal transplant; OR</para></item><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, have undergone a renal transplant, and have undergone a 12 month period of observation following the transplant,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has an estimated glomerular filtration rate less than 30ml/minute/1.73m<sup>2</sup> ; AND</para><para>5. If a renal transplant has taken place, confirmation that the patient has undergone a 12 month period of observation following transplantation; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5689e4310"><fragment id="59697-d5689e4310"><block label="NoteText"><para>If a patient receiving treatment under the indication short stature due to chronic renal insufficiency undergoes a renal transplant and 12 months post-transplant has an eGFR of equal to or greater than 30mL/min/1.73m<sup>2</sup> prescribers should seek reclassification to the indication short stature and slow growth.</para></block></fragment></section><section id="59697-10507B"><fragment id="59697-10507B"><block label="FormAndStrength">somatropin 5 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10507B<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">223.37</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Omnitrope Surepal 5 [SZ]<inline label="genericindexfieldbrand"><italic>XE "Omnitrope Surepal 5(SZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10490D"><fragment id="59697-10490D"><block label="FormAndStrength">somatropin 15 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10490D<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">655.80</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Omnitrope Surepal 15 [SZ]<inline label="genericindexfieldbrand"><italic>XE "Omnitrope Surepal 15(SZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10441M"><fragment id="59697-10441M"><block label="FormAndStrength">somatropin 10 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10441M<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">439.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">SciTropin A [SA]<inline label="genericindexfieldbrand"><italic>XE "SciTropin A(SA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10506Y"><fragment id="59697-10506Y"><block label="FormAndStrength">somatropin 10 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10506Y<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">439.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Omnitrope Surepal 10 [SZ]<inline label="genericindexfieldbrand"><italic>XE "Omnitrope Surepal 10(SZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-21295011000036100-10"><fragment id="59697-21295011000036100-10"><block label="DrugName">SOMATROPIN<inline label="genericindexfield">XE "SOMATROPIN"</inline></block></fragment></section><section id="59697-d5707e127"><fragment id="59697-d5707e127"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5707e16"><fragment id="59697-d5707e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature and slow growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5707e222"><fragment id="59697-d5707e222"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with biochemical growth hormone deficiency category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5707e413"><fragment id="59697-d5707e413"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the growth retardation secondary to an intracranial lesion, or cranial irradiation category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5707e604"><fragment id="59697-d5707e604"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a chronological age of 5 years or greater.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>When a patient receiving treatment under the indication risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants reaches or surpasses 5 years of age (chronological), prescribers should seek reclassification to the indication 'short stature due to biochemical growth hormone deficiency'.</para></block></fragment></section><section id="59697-d5707e795"><fragment id="59697-d5707e795"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the biochemical growth hormone deficiency and precocious puberty category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5707e986"><fragment id="59697-d5707e986"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5707e1177"><fragment id="59697-d5707e1177"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with Turner syndrome category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an annualised growth velocity for bone age at or above the mean growth velocity for untreated Turner Syndrome girls (using the Turner Syndrome - Ranke growth velocity chart) while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0 cm.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5707e1372"><fragment id="59697-d5707e1372"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature due to short stature homeobox (SHOX) gene disorders category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5707e1578"><fragment id="59697-d5707e1578"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with chronic renal insufficiency category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have undergone a renal transplant within the 12 month period immediately prior to the date of application,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an eGFR equal to or greater than 30mL/min/1.73m<sup>2</sup>,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5707e1706"><fragment id="59697-d5707e1706"><block label="NoteText"><para>If a patient receiving treatment under the indication short stature due to chronic renal insufficiency undergoes a renal transplant and 12 months post-transplant has an eGFR of equal to or greater than 30mL/min/1.73m<sup>2</sup> prescribers should seek reclassification to the indication short stature and slow growth.</para></block></fragment></section><section id="59697-d5707e1814"><fragment id="59697-d5707e1814"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature and slow growth,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication short stature associated with chronic renal insufficiency, have undergone a renal transplant and a 12 month period of observation following the transplant, and have an estimated glomerular filtration rate of greater than or equal to 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula; OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months;</para><para>OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment; AND</para><para>4. A bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5707e2092"><fragment id="59697-d5707e2092"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and have reached or surpassed 5 years of age (chronological); OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(c) Confirmation that the patient has previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and has reached or surpassed 5 years of age (chronological); AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Biochemical growth hormone deficiency should not be secondary to an intracranial lesion or cranial irradiation for applications under this category.</para></block></fragment></section><section id="59697-d5707e2450"><fragment id="59697-d5707e2450"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than growth retardation secondary to an intracranial lesion, or cranial irradiation,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had an intracranial lesion and have undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para></item><item><para>Patient must have had an intracranial lesion, have received medical advice that it is unsafe to treat the intracranial lesion, and have undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para></item><item><para>Patient must have received cranial irradiation without having had an intracranial lesion, and have undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8cm per year or less in the 12 month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has had an intracranial lesion and has undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para><para>(b) Confirmation that the patient has had an intracranial lesion, has received medical advice that it is unsafe to treat the intracranial lesion, and has undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para><para>(c) Confirmation that the patient has received cranial irradiation without having had an intracranial lesion, and has undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5707e2794"><fragment id="59697-d5707e2794"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a chronological age of less than 2 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a documented clinical risk of hypoglycaemia,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. Confirmation that the patient has a documented clinical risk of hypoglycaemia; AND</para><para>4. Confirmation that the patient has documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5707e3017"><fragment id="59697-d5707e3017"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than biochemical growth hormone deficiency and precocious puberty,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and have commenced puberty (demonstrated by Tanner stage 2 genital or pubic hair development or testicular volumes greater than or equal to 4 mL) before the chronological age of 9 years; OR</para></item><item><para>Patient must be female and have commenced puberty (demonstrated by Tanner stage 2 breast or pubic hair development) before the chronological age of 8 years; OR</para></item><item><para>Patient must be female and menarche occurred before the chronological age of 10 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. Confirmation that the patient has precocious puberty; AND</para><para>4. Confirmation that the patient is undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5707e3294"><fragment id="59697-d5707e3294"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a structural lesion that is not neoplastic; OR</para></item><item><para>Patient must have had a structural lesion that was neoplastic and have undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para></item><item><para>Patient must have a structural lesion that is neoplastic, have received medical advice that it is unsafe to treat the structural lesion, and have undergone a 12 month period of observation since initial diagnosis of the structural lesion,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have other hypothalamic/pituitary hormone deficits (includes ACTH, TSH, GnRH and/or vasopressin/ADH deficiencies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have hypothalamic obesity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity above the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8 cm per year or greater in the twelve month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has a structural lesion that is not neoplastic; OR</para><para>(b) Confirmation that the patient had a structural lesion that was neoplastic and has undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para><para>(c) Confirmation that the patient has a structural lesion that is neoplastic, has received medical advice that it is unsafe to treat the structural lesion, and has undergone a 12 month period of observation since initial diagnosis of the structural lesion; AND</para><para>6. Confirmation that the patient has other hypothalamic/pituitary hormone deficits; AND</para><para>7. Confirmation that the patient has hypothalamic obesity; AND</para><para>8. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>9. A bone age result performed within the last 12 months; AND</para><para>10. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5707e3636"><fragment id="59697-d5707e3636"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with Turner syndrome,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a height at or below the 95th percentile for age on the Turner syndrome growth curve for girls immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in all cells (45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in some cells (mosaic 46XX/45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as genetic loss or rearrangement of an X chromosome (such as isochromosome X, ring-chromosome, or partial deletion of an X chromosome), and gender of rearing is female,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0 cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. A height measurement from immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with Turner syndrome; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5707e3892"><fragment id="59697-d5707e3892"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature due to short stature homeobox (SHOX) gene disorders,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8 cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with a short stature homeobox (SHOX) gene disorder; AND</para><para>5. If the patient's condition is secondary to mixed gonadal dysgenesis, confirmation that an appropriate plan of management for the patient's increased risk of gonadoblastoma is in place; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5707e4178"><fragment id="59697-d5707e4178"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with chronic renal insufficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, and not have undergone a renal transplant; OR</para></item><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, have undergone a renal transplant, and have undergone a 12 month period of observation following the transplant,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has an estimated glomerular filtration rate less than 30ml/minute/1.73m<sup>2</sup> ; AND</para><para>5. If a renal transplant has taken place, confirmation that the patient has undergone a 12 month period of observation following transplantation; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5707e4382"><fragment id="59697-d5707e4382"><block label="NoteText"><para>If a patient receiving treatment under the indication short stature due to chronic renal insufficiency undergoes a renal transplant and 12 months post-transplant has an eGFR of equal to or greater than 30mL/min/1.73m<sup>2</sup> prescribers should seek reclassification to the indication short stature and slow growth.</para></block></fragment></section><section id="59697-10478L"><fragment id="59697-10478L"><block label="FormAndStrength">somatropin 10 mg/2 mL injection, 2 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10478L<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">439.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">NutropinAq [IS]<inline label="genericindexfieldbrand"><italic>XE "NutropinAq(IS)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10432C"><fragment id="59697-10432C"><block label="FormAndStrength">somatropin 5 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10432C<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">223.37</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norditropin FlexPro [NO]<inline label="genericindexfieldbrand"><italic>XE "Norditropin FlexPro(NO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10469B"><fragment id="59697-10469B"><block label="FormAndStrength">somatropin 5 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10469B<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">223.37</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norditropin SimpleXx [NO]<inline label="genericindexfieldbrand"><italic>XE "Norditropin SimpleXx(NO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10449Y"><fragment id="59697-10449Y"><block label="FormAndStrength">somatropin 15 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10449Y<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">655.80</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norditropin FlexPro [NO]<inline label="genericindexfieldbrand"><italic>XE "Norditropin FlexPro(NO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10468Y"><fragment id="59697-10468Y"><block label="FormAndStrength">somatropin 15 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10468Y<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">655.80</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norditropin SimpleXx [NO]<inline label="genericindexfieldbrand"><italic>XE "Norditropin SimpleXx(NO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10439K"><fragment id="59697-10439K"><block label="FormAndStrength">somatropin 10 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10439K<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">439.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norditropin SimpleXx [NO]<inline label="genericindexfieldbrand"><italic>XE "Norditropin SimpleXx(NO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10451C"><fragment id="59697-10451C"><block label="FormAndStrength">somatropin 10 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10451C<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">439.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norditropin FlexPro [NO]<inline label="genericindexfieldbrand"><italic>XE "Norditropin FlexPro(NO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-21295011000036100-11"><fragment id="59697-21295011000036100-11"><block label="DrugName">SOMATROPIN<inline label="genericindexfield">XE "SOMATROPIN"</inline></block></fragment></section><section id="59697-d5726e127"><fragment id="59697-d5726e127"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5726e16"><fragment id="59697-d5726e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature and slow growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5726e222"><fragment id="59697-d5726e222"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with biochemical growth hormone deficiency category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5726e413"><fragment id="59697-d5726e413"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the growth retardation secondary to an intracranial lesion, or cranial irradiation category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5726e604"><fragment id="59697-d5726e604"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a chronological age of 5 years or greater.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>When a patient receiving treatment under the indication risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants reaches or surpasses 5 years of age (chronological), prescribers should seek reclassification to the indication 'short stature due to biochemical growth hormone deficiency'.</para></block></fragment></section><section id="59697-d5726e795"><fragment id="59697-d5726e795"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the biochemical growth hormone deficiency and precocious puberty category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5726e986"><fragment id="59697-d5726e986"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5726e1177"><fragment id="59697-d5726e1177"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with Turner syndrome category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an annualised growth velocity for bone age at or above the mean growth velocity for untreated Turner Syndrome girls (using the Turner Syndrome - Ranke growth velocity chart) while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0 cm.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5726e1372"><fragment id="59697-d5726e1372"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature due to short stature homeobox (SHOX) gene disorders category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5726e1578"><fragment id="59697-d5726e1578"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature and slow growth,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication short stature associated with chronic renal insufficiency, have undergone a renal transplant and a 12 month period of observation following the transplant, and have an estimated glomerular filtration rate of greater than or equal to 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula; OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months;</para><para>OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment; AND</para><para>4. A bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5726e1856"><fragment id="59697-d5726e1856"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and have reached or surpassed 5 years of age (chronological); OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(c) Confirmation that the patient has previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and has reached or surpassed 5 years of age (chronological); AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Biochemical growth hormone deficiency should not be secondary to an intracranial lesion or cranial irradiation for applications under this category.</para></block></fragment></section><section id="59697-d5726e2213"><fragment id="59697-d5726e2213"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than growth retardation secondary to an intracranial lesion, or cranial irradiation,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had an intracranial lesion and have undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para></item><item><para>Patient must have had an intracranial lesion, have received medical advice that it is unsafe to treat the intracranial lesion, and have undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para></item><item><para>Patient must have received cranial irradiation without having had an intracranial lesion, and have undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8cm per year or less in the 12 month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has had an intracranial lesion and has undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para><para>(b) Confirmation that the patient has had an intracranial lesion, has received medical advice that it is unsafe to treat the intracranial lesion, and has undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para><para>(c) Confirmation that the patient has received cranial irradiation without having had an intracranial lesion, and has undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5726e2558"><fragment id="59697-d5726e2558"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a chronological age of less than 2 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a documented clinical risk of hypoglycaemia,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. Confirmation that the patient has a documented clinical risk of hypoglycaemia; AND</para><para>4. Confirmation that the patient has documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5726e2781"><fragment id="59697-d5726e2781"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than biochemical growth hormone deficiency and precocious puberty,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and have commenced puberty (demonstrated by Tanner stage 2 genital or pubic hair development or testicular volumes greater than or equal to 4 mL) before the chronological age of 9 years; OR</para></item><item><para>Patient must be female and have commenced puberty (demonstrated by Tanner stage 2 breast or pubic hair development) before the chronological age of 8 years; OR</para></item><item><para>Patient must be female and menarche occurred before the chronological age of 10 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. Confirmation that the patient has precocious puberty; AND</para><para>4. Confirmation that the patient is undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5726e3058"><fragment id="59697-d5726e3058"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a structural lesion that is not neoplastic; OR</para></item><item><para>Patient must have had a structural lesion that was neoplastic and have undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para></item><item><para>Patient must have a structural lesion that is neoplastic, have received medical advice that it is unsafe to treat the structural lesion, and have undergone a 12 month period of observation since initial diagnosis of the structural lesion,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have other hypothalamic/pituitary hormone deficits (includes ACTH, TSH, GnRH and/or vasopressin/ADH deficiencies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have hypothalamic obesity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity above the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8 cm per year or greater in the twelve month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has a structural lesion that is not neoplastic; OR</para><para>(b) Confirmation that the patient had a structural lesion that was neoplastic and has undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para><para>(c) Confirmation that the patient has a structural lesion that is neoplastic, has received medical advice that it is unsafe to treat the structural lesion, and has undergone a 12 month period of observation since initial diagnosis of the structural lesion; AND</para><para>6. Confirmation that the patient has other hypothalamic/pituitary hormone deficits; AND</para><para>7. Confirmation that the patient has hypothalamic obesity; AND</para><para>8. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>9. A bone age result performed within the last 12 months; AND</para><para>10. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5726e3400"><fragment id="59697-d5726e3400"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with Turner syndrome,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a height at or below the 95th percentile for age on the Turner syndrome growth curve for girls immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in all cells (45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in some cells (mosaic 46XX/45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as genetic loss or rearrangement of an X chromosome (such as isochromosome X, ring-chromosome, or partial deletion of an X chromosome), and gender of rearing is female,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0 cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. A height measurement from immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with Turner syndrome; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5726e3656"><fragment id="59697-d5726e3656"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature due to short stature homeobox (SHOX) gene disorders,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8 cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with a short stature homeobox (SHOX) gene disorder; AND</para><para>5. If the patient's condition is secondary to mixed gonadal dysgenesis, confirmation that an appropriate plan of management for the patient's increased risk of gonadoblastoma is in place; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5726e3942"><fragment id="59697-d5726e3942"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with chronic renal insufficiency category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have undergone a renal transplant within the 12 month period immediately prior to the date of application,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an eGFR equal to or greater than 30mL/min/1.73m<sup>2</sup>,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5726e4077"><fragment id="59697-d5726e4077"><block label="NoteText"><para>If a patient receiving treatment under the indication short stature due to chronic renal insufficiency undergoes a renal transplant and 12 months post-transplant has an eGFR of equal to or greater than 30mL/min/1.73m<sup>2</sup> prescribers should seek reclassification to the indication short stature and slow growth.</para></block></fragment></section><section id="59697-d5726e4187"><fragment id="59697-d5726e4187"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with chronic renal insufficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, and not have undergone a renal transplant; OR</para></item><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, have undergone a renal transplant, and have undergone a 12 month period of observation following the transplant,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has an estimated glomerular filtration rate less than 30ml/minute/1.73m<sup>2</sup> ; AND</para><para>5. If a renal transplant has taken place, confirmation that the patient has undergone a 12 month period of observation following transplantation; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5726e4398"><fragment id="59697-d5726e4398"><block label="NoteText"><para>If a patient receiving treatment under the indication short stature due to chronic renal insufficiency undergoes a renal transplant and 12 months post-transplant has an eGFR of equal to or greater than 30mL/min/1.73m<sup>2</sup> prescribers should seek reclassification to the indication short stature and slow growth.</para></block></fragment></section><section id="59697-10462P"><fragment id="59697-10462P"><block label="FormAndStrength">somatropin 6 mg/1.03 mL injection, 1.03 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10462P<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">266.61</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Saizen [SG]<inline label="genericindexfieldbrand"><italic>XE "Saizen(SG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10483R"><fragment id="59697-10483R"><block label="FormAndStrength">somatropin 12 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10483R<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">526.07</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Saizen [SG]<inline label="genericindexfieldbrand"><italic>XE "Saizen(SG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10497L"><fragment id="59697-10497L"><block label="FormAndStrength">somatropin 20 mg/2.5 mL injection, 2.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10497L<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">872.01</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Saizen [SG]<inline label="genericindexfieldbrand"><italic>XE "Saizen(SG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-21295011000036100-12"><fragment id="59697-21295011000036100-12"><block label="DrugName">SOMATROPIN<inline label="genericindexfield">XE "SOMATROPIN"</inline></block></fragment></section><section id="59697-d5745e127"><fragment id="59697-d5745e127"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5745e16"><fragment id="59697-d5745e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature and slow growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5745e222"><fragment id="59697-d5745e222"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with biochemical growth hormone deficiency category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5745e413"><fragment id="59697-d5745e413"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the growth retardation secondary to an intracranial lesion, or cranial irradiation category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5745e604"><fragment id="59697-d5745e604"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a chronological age of 5 years or greater.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>When a patient receiving treatment under the indication risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants reaches or surpasses 5 years of age (chronological), prescribers should seek reclassification to the indication 'short stature due to biochemical growth hormone deficiency'.</para></block></fragment></section><section id="59697-d5745e795"><fragment id="59697-d5745e795"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the biochemical growth hormone deficiency and precocious puberty category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5745e986"><fragment id="59697-d5745e986"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5745e1177"><fragment id="59697-d5745e1177"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with Turner syndrome category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an annualised growth velocity for bone age at or above the mean growth velocity for untreated Turner Syndrome girls (using the Turner Syndrome - Ranke growth velocity chart) while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0 cm.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5745e1372"><fragment id="59697-d5745e1372"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature due to short stature homeobox (SHOX) gene disorders category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5745e1578"><fragment id="59697-d5745e1578"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with chronic renal insufficiency category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have undergone a renal transplant within the 12 month period immediately prior to the date of application,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an eGFR equal to or greater than 30mL/min/1.73m<sup>2</sup>,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be prepubertal.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5745e1713"><fragment id="59697-d5745e1713"><block label="NoteText"><para>If a patient receiving treatment under the indication short stature due to chronic renal insufficiency undergoes a renal transplant and 12 months post-transplant has an eGFR of equal to or greater than 30mL/min/1.73m<sup>2</sup> prescribers should seek reclassification to the indication short stature and slow growth.</para></block></fragment></section><section id="59697-d5745e1823"><fragment id="59697-d5745e1823"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature and slow growth,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication short stature associated with chronic renal insufficiency, have undergone a renal transplant and a 12 month period of observation following the transplant, and have an estimated glomerular filtration rate of greater than or equal to 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula; OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months;</para><para>OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment; AND</para><para>4. A bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5745e2101"><fragment id="59697-d5745e2101"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and have reached or surpassed 5 years of age (chronological); OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(c) Confirmation that the patient has previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and has reached or surpassed 5 years of age (chronological); AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Biochemical growth hormone deficiency should not be secondary to an intracranial lesion or cranial irradiation for applications under this category.</para></block></fragment></section><section id="59697-d5745e2459"><fragment id="59697-d5745e2459"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than growth retardation secondary to an intracranial lesion, or cranial irradiation,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had an intracranial lesion and have undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para></item><item><para>Patient must have had an intracranial lesion, have received medical advice that it is unsafe to treat the intracranial lesion, and have undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para></item><item><para>Patient must have received cranial irradiation without having had an intracranial lesion, and have undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8cm per year or less in the 12 month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has had an intracranial lesion and has undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para><para>(b) Confirmation that the patient has had an intracranial lesion, has received medical advice that it is unsafe to treat the intracranial lesion, and has undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para><para>(c) Confirmation that the patient has received cranial irradiation without having had an intracranial lesion, and has undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5745e2803"><fragment id="59697-d5745e2803"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a chronological age of less than 2 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a documented clinical risk of hypoglycaemia,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. Confirmation that the patient has a documented clinical risk of hypoglycaemia; AND</para><para>4. Confirmation that the patient has documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5745e3026"><fragment id="59697-d5745e3026"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than biochemical growth hormone deficiency and precocious puberty,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and have commenced puberty (demonstrated by Tanner stage 2 genital or pubic hair development or testicular volumes greater than or equal to 4 mL) before the chronological age of 9 years; OR</para></item><item><para>Patient must be female and have commenced puberty (demonstrated by Tanner stage 2 breast or pubic hair development) before the chronological age of 8 years; OR</para></item><item><para>Patient must be female and menarche occurred before the chronological age of 10 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. Confirmation that the patient has precocious puberty; AND</para><para>4. Confirmation that the patient is undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5745e3303"><fragment id="59697-d5745e3303"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a structural lesion that is not neoplastic; OR</para></item><item><para>Patient must have had a structural lesion that was neoplastic and have undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para></item><item><para>Patient must have a structural lesion that is neoplastic, have received medical advice that it is unsafe to treat the structural lesion, and have undergone a 12 month period of observation since initial diagnosis of the structural lesion,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have other hypothalamic/pituitary hormone deficits (includes ACTH, TSH, GnRH and/or vasopressin/ADH deficiencies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have hypothalamic obesity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity above the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8 cm per year or greater in the twelve month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has a structural lesion that is not neoplastic; OR</para><para>(b) Confirmation that the patient had a structural lesion that was neoplastic and has undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para><para>(c) Confirmation that the patient has a structural lesion that is neoplastic, has received medical advice that it is unsafe to treat the structural lesion, and has undergone a 12 month period of observation since initial diagnosis of the structural lesion; AND</para><para>6. Confirmation that the patient has other hypothalamic/pituitary hormone deficits; AND</para><para>7. Confirmation that the patient has hypothalamic obesity; AND</para><para>8. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>9. A bone age result performed within the last 12 months; AND</para><para>10. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5745e3645"><fragment id="59697-d5745e3645"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with Turner syndrome,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a height at or below the 95th percentile for age on the Turner syndrome growth curve for girls immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in all cells (45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in some cells (mosaic 46XX/45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as genetic loss or rearrangement of an X chromosome (such as isochromosome X, ring-chromosome, or partial deletion of an X chromosome), and gender of rearing is female,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0 cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. A height measurement from immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with Turner syndrome; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5745e3901"><fragment id="59697-d5745e3901"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature due to short stature homeobox (SHOX) gene disorders,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8 cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with a short stature homeobox (SHOX) gene disorder; AND</para><para>5. If the patient's condition is secondary to mixed gonadal dysgenesis, confirmation that an appropriate plan of management for the patient's increased risk of gonadoblastoma is in place; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5745e4187"><fragment id="59697-d5745e4187"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with chronic renal insufficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, and not have undergone a renal transplant; OR</para></item><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, have undergone a renal transplant, and have undergone a 12 month period of observation following the transplant,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be prepubertal.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has an estimated glomerular filtration rate less than 30ml/minute/1.73m<sup>2</sup> ; AND</para><para>5. If a renal transplant has taken place, confirmation that the patient has undergone a 12 month period of observation following transplantation; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5745e4398"><fragment id="59697-d5745e4398"><block label="NoteText"><para>If a patient receiving treatment under the indication short stature due to chronic renal insufficiency undergoes a renal transplant and 12 months post-transplant has an eGFR of equal to or greater than 30mL/min/1.73m<sup>2</sup> prescribers should seek reclassification to the indication short stature and slow growth.</para></block></fragment></section><section id="59697-10476J"><fragment id="59697-10476J"><block label="FormAndStrength">somatropin 24 mg injection [1 cartridge] (&amp;) inert substance diluent [3.15 mL syringe], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10476J<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">1044.99</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Humatrope [LY]<inline label="genericindexfieldbrand"><italic>XE "Humatrope(LY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10482Q"><fragment id="59697-10482Q"><block label="FormAndStrength">somatropin 6 mg injection [1 cartridge] (&amp;) inert substance diluent [3.15 mL syringe], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10482Q<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">266.61</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Humatrope [LY]<inline label="genericindexfieldbrand"><italic>XE "Humatrope(LY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10487Y"><fragment id="59697-10487Y"><block label="FormAndStrength">somatropin 12 mg injection [1 cartridge] (&amp;) inert substance diluent [3.15 mL syringe], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10487Y<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">526.07</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Humatrope [LY]<inline label="genericindexfieldbrand"><italic>XE "Humatrope(LY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-21295011000036100-13"><fragment id="59697-21295011000036100-13"><block label="DrugName">SOMATROPIN<inline label="genericindexfield">XE "SOMATROPIN"</inline></block></fragment></section><section id="59697-d5764e159"><fragment id="59697-d5764e159"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5764e16"><fragment id="59697-d5764e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature and slow growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5764e151"><fragment id="59697-d5764e151"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5764e262"><fragment id="59697-d5764e262"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with biochemical growth hormone deficiency category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5764e387"><fragment id="59697-d5764e387"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5764e494"><fragment id="59697-d5764e494"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the growth retardation secondary to an intracranial lesion, or cranial irradiation category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5764e619"><fragment id="59697-d5764e619"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5764e726"><fragment id="59697-d5764e726"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a chronological age of 5 years or greater.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5764e848"><fragment id="59697-d5764e848"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5764e953"><fragment id="59697-d5764e953"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the biochemical growth hormone deficiency and precocious puberty category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5764e1085"><fragment id="59697-d5764e1085"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5764e1194"><fragment id="59697-d5764e1194"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5764e1319"><fragment id="59697-d5764e1319"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5764e1426"><fragment id="59697-d5764e1426"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with Turner syndrome category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5764e1555"><fragment id="59697-d5764e1555"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5764e1662"><fragment id="59697-d5764e1662"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature due to short stature homeobox (SHOX) gene disorders category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5764e1808"><fragment id="59697-d5764e1808"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5764e1923"><fragment id="59697-d5764e1923"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with chronic renal insufficiency category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have undergone a renal transplant within the 12 month period immediately prior to the date of application,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an eGFR equal to or greater than 30mL/min/1.73m<sup>2</sup>,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation that the patient has an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> ; AND</para><para>6. If a renal transplant has taken place, confirmation that the patient has undergone a 12 month period of observation following transplantation; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>If a patient receiving treatment under the indication 'short stature associated with chronic renal insufficiency' undergoes a renal transplant and 12 months post-transplant has an eGFR of equal to or greater than 30mL/min/1.73m<sup>2</sup> prescribers should seek reclassification to the indication short stature and slow growth.</para></block></fragment></section><section id="59697-d5764e2089"><fragment id="59697-d5764e2089"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5764e2219"><fragment id="59697-d5764e2219"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature and slow growth,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication short stature associated with chronic renal insufficiency, have undergone a renal transplant and a 12 month period of observation following the transplant, and have an estimated glomerular filtration rate of greater than or equal to 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula; OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment; AND</para><para>4. A bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5764e2511"><fragment id="59697-d5764e2511"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and have reached or surpassed 5 years of age (chronological); OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(c) Confirmation that the patient has previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and has reached or surpassed 5 years of age (chronological); AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Biochemical growth hormone deficiency should not be secondary to an intracranial lesion or cranial irradiation for applications under this category.</para></block></fragment></section><section id="59697-d5764e2887"><fragment id="59697-d5764e2887"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than growth retardation secondary to an intracranial lesion, or cranial irradiation,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had an intracranial lesion and have undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para></item><item><para>Patient must have had an intracranial lesion, have received medical advice that it is unsafe to treat the intracranial lesion, and have undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para></item><item><para>Patient must have received cranial irradiation without having had an intracranial lesion, and have undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8cm per year or less in the 12 month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has had an intracranial lesion and has undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para><para>(b) Confirmation that the patient has had an intracranial lesion, has received medical advice that it is unsafe to treat the intracranial lesion, and has undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para><para>(c) Confirmation that the patient has received cranial irradiation without having had an intracranial lesion, and has undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5764e3250"><fragment id="59697-d5764e3250"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than biochemical growth hormone deficiency and precocious puberty,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and have commenced puberty (demonstrated by Tanner stage 2 genital or pubic hair development or testicular volumes greater than or equal to 4 mL) before the chronological age of 9 years; OR</para></item><item><para>Patient must be female and have commenced puberty (demonstrated by Tanner stage 2 breast or pubic hair development) before the chronological age of 8 years; OR</para></item><item><para>Patient must be female and menarche occurred before the chronological age of 10 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. Confirmation that the patient has precocious puberty; AND</para><para>4. Confirmation that the patient is undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5764e3545"><fragment id="59697-d5764e3545"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a structural lesion that is not neoplastic; OR</para></item><item><para>Patient must have had a structural lesion that was neoplastic and have undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para></item><item><para>Patient must have a structural lesion that is neoplastic, have received medical advice that it is unsafe to treat the structural lesion, and have undergone a 12 month period of observation since initial diagnosis of the structural lesion,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have other hypothalamic/pituitary hormone deficits (includes ACTH, TSH, GnRH and/or vasopressin/ADH deficiencies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have hypothalamic obesity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity above the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8 cm per year or greater in the twelve month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has a structural lesion that is not neoplastic; OR</para><para>(b) Confirmation that the patient had a structural lesion that was neoplastic and has undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para><para>(c) Confirmation that the patient has a structural lesion that is neoplastic, has received medical advice that it is unsafe to treat the structural lesion, and has undergone a 12 month period of observation since initial diagnosis of the structural lesion; AND</para><para>6. Confirmation that the patient has other hypothalamic/pituitary hormone deficits; AND</para><para>7. Confirmation that the patient has hypothalamic obesity; AND</para><para>8. Recent growth data (height and weight, not older than three months); AND</para><para>9. A bone age result performed within the last 12 months; AND</para><para>10. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5764e3905"><fragment id="59697-d5764e3905"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature assciated with Turner syndrome,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a height at or below the 95th percentile for age on the Turner syndrome growth curve for girls immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in all cells (45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in some cells (mosaic 46XX/45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as genetic loss or rearrangement of an X chromosome (such as isochromosome X, ring-chromosome, or partial deletion of an X chromosome), and gender of rearing is female,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. A height measurement from immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with Turner syndrome; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5764e4179"><fragment id="59697-d5764e4179"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature due to short stature homeobox (SHOX) gene disorders,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8 cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with a short stature homeobox (SHOX) gene disorder; AND</para><para>5. If the patient's condition is secondary to mixed gonadal dysgenesis, confirmation that an appropriate plan of management for the patient's increased risk of gonadoblastoma is in place; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5764e4483"><fragment id="59697-d5764e4483"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with chronic renal insufficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, and not have undergone a renal transplant; OR</para></item><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, have undergone a renal transplant, and have undergone a 12 month period of observation following the transplant,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> ; AND</para><para>5. If a renal transplant has taken place, confirmation that the patient has undergone a 12 month period of observation following transplantation; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5764e4701"><fragment id="59697-d5764e4701"><block label="NoteText"><para>If a patient receiving treatment under the indication short stature due to chronic renal insufficiency undergoes a renal transplant and 12 months post-transplant has an eGFR of equal to or greater than 30mL/min/1.73m<sup>2</sup> prescribers should seek reclassification to the indication short stature and slow growth.</para></block></fragment></section><section id="59697-10512G"><fragment id="59697-10512G"><block label="FormAndStrength">somatropin 5 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10512G<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">223.37</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Omnitrope Surepal 5 [SZ]<inline label="genericindexfieldbrand"><italic>XE "Omnitrope Surepal 5(SZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10485W"><fragment id="59697-10485W"><block label="FormAndStrength">somatropin 15 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10485W<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">655.80</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Omnitrope Surepal 15 [SZ]<inline label="genericindexfieldbrand"><italic>XE "Omnitrope Surepal 15(SZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10481P"><fragment id="59697-10481P"><block label="FormAndStrength">somatropin 10 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10481P<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">439.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">SciTropin A [SA]<inline label="genericindexfieldbrand"><italic>XE "SciTropin A(SA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10519P"><fragment id="59697-10519P"><block label="FormAndStrength">somatropin 10 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10519P<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">439.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Omnitrope Surepal 10 [SZ]<inline label="genericindexfieldbrand"><italic>XE "Omnitrope Surepal 10(SZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-21295011000036100-14"><fragment id="59697-21295011000036100-14"><block label="DrugName">SOMATROPIN<inline label="genericindexfield">XE "SOMATROPIN"</inline></block></fragment></section><section id="59697-d5782e152"><fragment id="59697-d5782e152"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5782e16"><fragment id="59697-d5782e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature and slow growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5782e144"><fragment id="59697-d5782e144"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5782e253"><fragment id="59697-d5782e253"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with biochemical growth hormone deficiency category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5782e371"><fragment id="59697-d5782e371"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5782e476"><fragment id="59697-d5782e476"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the growth retardation secondary to an intracranial lesion, or cranial irradiation category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5782e594"><fragment id="59697-d5782e594"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5782e699"><fragment id="59697-d5782e699"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a chronological age of 5 years or greater.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5782e814"><fragment id="59697-d5782e814"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5782e917"><fragment id="59697-d5782e917"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the biochemical growth hormone deficiency and precocious puberty category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5782e1042"><fragment id="59697-d5782e1042"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5782e1149"><fragment id="59697-d5782e1149"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5782e1267"><fragment id="59697-d5782e1267"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5782e1372"><fragment id="59697-d5782e1372"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with Turner syndrome category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5782e1494"><fragment id="59697-d5782e1494"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5782e1599"><fragment id="59697-d5782e1599"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature due to short stature homeobox (SHOX) gene disorders category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5782e1737"><fragment id="59697-d5782e1737"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5782e1850"><fragment id="59697-d5782e1850"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with chronic renal insufficiency category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have undergone a renal transplant within the 12 month period immediately prior to the date of application,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an eGFR equal to or greater than 30mL/min/1.73m<sup>2</sup>,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be prepubertal.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation that the patient has an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> ; AND</para><para>6. If a renal transplant has taken place, confirmation that the patient has undergone a 12 month period of observation following transplantation; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>If a patient receiving treatment under the indication 'short stature associated with chronic renal insufficiency' undergoes a renal transplant and 12 months post-transplant has an eGFR of equal to or greater than 30mL/min/1.73m<sup>2</sup> prescribers should seek reclassification to the indication short stature and slow growth.</para></block></fragment></section><section id="59697-d5782e2016"><fragment id="59697-d5782e2016"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5782e2146"><fragment id="59697-d5782e2146"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature and slow growth,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication short stature associated with chronic renal insufficiency, have undergone a renal transplant and a 12 month period of observation following the transplant, and have an estimated glomerular filtration rate of greater than or equal to 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula; OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment; AND</para><para>4. A bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5782e2429"><fragment id="59697-d5782e2429"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and have reached or surpassed 5 years of age (chronological); OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(c) Confirmation that the patient has previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and has reached or surpassed 5 years of age (chronological); AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Biochemical growth hormone deficiency should not be secondary to an intracranial lesion or cranial irradiation for applications under this category.</para></block></fragment></section><section id="59697-d5782e2796"><fragment id="59697-d5782e2796"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than growth retardation secondary to an intracranial lesion, or cranial irradiation,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had an intracranial lesion and have undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para></item><item><para>Patient must have had an intracranial lesion, have received medical advice that it is unsafe to treat the intracranial lesion, and have undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para></item><item><para>Patient must have received cranial irradiation without having had an intracranial lesion, and have undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8cm per year or less in the 12 month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has had an intracranial lesion and has undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para><para>(b) Confirmation that the patient has had an intracranial lesion, has received medical advice that it is unsafe to treat the intracranial lesion, and has undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para><para>(c) Confirmation that the patient has received cranial irradiation without having had an intracranial lesion, and has undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5782e3149"><fragment id="59697-d5782e3149"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a chronological age of less than 2 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a documented clinical risk of hypoglycaemia,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. Confirmation that the patient has a documented clinical risk of hypoglycaemia; AND</para><para>4. Confirmation that the patient has documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5782e3386"><fragment id="59697-d5782e3386"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than biochemical growth hormone deficiency and precocious puberty,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and have commenced puberty (demonstrated by Tanner stage 2 genital or pubic hair development or testicular volumes greater than or equal to 4 mL) before the chronological age of 9 years; OR</para></item><item><para>Patient must be female and have commenced puberty (demonstrated by Tanner stage 2 breast or pubic hair development) before the chronological age of 8 years; OR</para></item><item><para>Patient must be female and menarche occurred before the chronological age of 10 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. Confirmation that the patient has precocious puberty; AND</para><para>4. Confirmation that the patient is undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5782e3672"><fragment id="59697-d5782e3672"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a structural lesion that is not neoplastic; OR</para></item><item><para>Patient must have had a structural lesion that was neoplastic and have undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para></item><item><para>Patient must have a structural lesion that is neoplastic, have received medical advice that it is unsafe to treat the structural lesion, and have undergone a 12 month period of observation since initial diagnosis of the structural lesion,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have other hypothalamic/pituitary hormone deficits (includes ACTH, TSH, GnRH and/or vasopressin/ADH deficiencies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have hypothalamic obesity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity above the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8 cm per year or greater in the twelve month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has a structural lesion that is not neoplastic; OR</para><para>(b) Confirmation that the patient had a structural lesion that was neoplastic and has undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para><para>(c) Confirmation that the patient has a structural lesion that is neoplastic, has received medical advice that it is unsafe to treat the structural lesion, and has undergone a 12 month period of observation since initial diagnosis of the structural lesion; AND</para><para>6. Confirmation that the patient has other hypothalamic/pituitary hormone deficits; AND</para><para>7. Confirmation that the patient has hypothalamic obesity; AND</para><para>8. Recent growth data (height and weight, not older than three months); AND</para><para>9. A bone age result performed within the last 12 months; AND</para><para>10. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5782e4023"><fragment id="59697-d5782e4023"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with Turner syndrome,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a height at or below the 95th percentile for age on the Turner syndrome growth curve for girls immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in all cells (45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in some cells (mosaic 46XX/45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as genetic loss or rearrangement of an X chromosome (such as isochromosome X, ring-chromosome, or partial deletion of an X chromosome), and gender of rearing is female,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. A height measurement from immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with Turner syndrome; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5782e4288"><fragment id="59697-d5782e4288"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature due to short stature homeobox (SHOX) gene disorders,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8 cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with a short stature homeobox (SHOX) gene disorder; AND</para><para>5. If the patient's condition is secondary to mixed gonadal dysgenesis, confirmation that an appropriate plan of management for the patient's increased risk of gonadoblastoma is in place; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5782e4583"><fragment id="59697-d5782e4583"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with chronic renal insufficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, and not have undergone a renal transplant; OR</para></item><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, have undergone a renal transplant, and have undergone a 12 month period of observation following the transplant,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be prepubertal.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> ; AND</para><para>5. If a renal transplant has taken place, confirmation that the patient has undergone a 12 month period of observation following transplantation; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5782e4801"><fragment id="59697-d5782e4801"><block label="NoteText"><para>If a patient receiving treatment under the indication short stature due to chronic renal insufficiency undergoes a renal transplant and 12 months post-transplant has an eGFR of equal to or greater than 30mL/min/1.73m<sup>2</sup> prescribers should seek reclassification to the indication short stature and slow growth.</para></block></fragment></section><section id="59697-10502R"><fragment id="59697-10502R"><block label="FormAndStrength">somatropin 24 mg injection [1 cartridge] (&amp;) inert substance diluent [3.15 mL syringe], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10502R<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">1044.99</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Humatrope [LY]<inline label="genericindexfieldbrand"><italic>XE "Humatrope(LY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10429X"><fragment id="59697-10429X"><block label="FormAndStrength">somatropin 6 mg injection [1 cartridge] (&amp;) inert substance diluent [3.15 mL syringe], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10429X<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">266.61</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Humatrope [LY]<inline label="genericindexfieldbrand"><italic>XE "Humatrope(LY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10461N"><fragment id="59697-10461N"><block label="FormAndStrength">somatropin 12 mg injection [1 cartridge] (&amp;) inert substance diluent [3.15 mL syringe], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10461N<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">526.07</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Humatrope [LY]<inline label="genericindexfieldbrand"><italic>XE "Humatrope(LY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-21295011000036100-15"><fragment id="59697-21295011000036100-15"><block label="DrugName">SOMATROPIN<inline label="genericindexfield">XE "SOMATROPIN"</inline></block></fragment></section><section id="59697-d5801e152"><fragment id="59697-d5801e152"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5801e16"><fragment id="59697-d5801e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature and slow growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5801e144"><fragment id="59697-d5801e144"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5801e253"><fragment id="59697-d5801e253"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with biochemical growth hormone deficiency category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5801e371"><fragment id="59697-d5801e371"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5801e476"><fragment id="59697-d5801e476"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the growth retardation secondary to an intracranial lesion, or cranial irradiation category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5801e594"><fragment id="59697-d5801e594"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5801e699"><fragment id="59697-d5801e699"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a chronological age of 5 years or greater.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5801e814"><fragment id="59697-d5801e814"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5801e917"><fragment id="59697-d5801e917"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the biochemical growth hormone deficiency and precocious puberty category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5801e1042"><fragment id="59697-d5801e1042"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5801e1149"><fragment id="59697-d5801e1149"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5801e1267"><fragment id="59697-d5801e1267"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5801e1372"><fragment id="59697-d5801e1372"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with Turner syndrome category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5801e1494"><fragment id="59697-d5801e1494"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5801e1599"><fragment id="59697-d5801e1599"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature due to short stature homeobox (SHOX) gene disorders category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5801e1737"><fragment id="59697-d5801e1737"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5801e1850"><fragment id="59697-d5801e1850"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with chronic renal insufficiency category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have undergone a renal transplant within the 12 month period immediately prior to the date of application,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an eGFR equal to or greater than 30mL/min/1.73m<sup>2</sup>,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation that the patient has an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> ; AND</para><para>6. If a renal transplant has taken place, confirmation that the patient has undergone a 12 month period of observation following transplantation; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>If a patient receiving treatment under the indication 'short stature associated with chronic renal insufficiency' undergoes a renal transplant and 12 months post-transplant has an eGFR of equal to or greater than 30mL/min/1.73m<sup>2</sup> prescribers should seek reclassification to the indication short stature and slow growth.</para></block></fragment></section><section id="59697-d5801e2009"><fragment id="59697-d5801e2009"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5801e2137"><fragment id="59697-d5801e2137"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature and slow growth,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication short stature associated with chronic renal insufficiency, have undergone a renal transplant and a 12 month period of observation following the transplant, and have an estimated glomerular filtration rate of greater than or equal to 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula; OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment; AND</para><para>4. A bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5801e2420"><fragment id="59697-d5801e2420"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and have reached or surpassed 5 years of age (chronological); OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(c) Confirmation that the patient has previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and has reached or surpassed 5 years of age (chronological); AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Biochemical growth hormone deficiency should not be secondary to an intracranial lesion or cranial irradiation for applications under this category.</para></block></fragment></section><section id="59697-d5801e2787"><fragment id="59697-d5801e2787"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than growth retardation secondary to an intracranial lesion, or cranial irradiation,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had an intracranial lesion and have undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para></item><item><para>Patient must have had an intracranial lesion, have received medical advice that it is unsafe to treat the intracranial lesion, and have undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para></item><item><para>Patient must have received cranial irradiation without having had an intracranial lesion, and have undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8cm per year or less in the 12 month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has had an intracranial lesion and has undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para><para>(b) Confirmation that the patient has had an intracranial lesion, has received medical advice that it is unsafe to treat the intracranial lesion, and has undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para><para>(c) Confirmation that the patient has received cranial irradiation without having had an intracranial lesion, and has undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5801e3140"><fragment id="59697-d5801e3140"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a chronological age of less than 2 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a documented clinical risk of hypoglycaemia,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. Confirmation that the patient has a documented clinical risk of hypoglycaemia; AND</para><para>4. Confirmation that the patient has documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5801e3377"><fragment id="59697-d5801e3377"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than biochemical growth hormone deficiency and precocious puberty,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and have commenced puberty (demonstrated by Tanner stage 2 genital or pubic hair development or testicular volumes greater than or equal to 4 mL) before the chronological age of 9 years; OR</para></item><item><para>Patient must be female and have commenced puberty (demonstrated by Tanner stage 2 breast or pubic hair development) before the chronological age of 8 years; OR</para></item><item><para>Patient must be female and menarche occurred before the chronological age of 10 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. Confirmation that the patient has precocious puberty; AND</para><para>4. Confirmation that the patient is undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5801e3663"><fragment id="59697-d5801e3663"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a structural lesion that is not neoplastic; OR</para></item><item><para>Patient must have had a structural lesion that was neoplastic and have undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para></item><item><para>Patient must have a structural lesion that is neoplastic, have received medical advice that it is unsafe to treat the structural lesion, and have undergone a 12 month period of observation since initial diagnosis of the structural lesion,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have other hypothalamic/pituitary hormone deficits (includes ACTH, TSH, GnRH and/or vasopressin/ADH deficiencies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have hypothalamic obesity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity above the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8 cm per year or greater in the twelve month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has a structural lesion that is not neoplastic; OR</para><para>(b) Confirmation that the patient had a structural lesion that was neoplastic and has undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para><para>(c) Confirmation that the patient has a structural lesion that is neoplastic, has received medical advice that it is unsafe to treat the structural lesion, and has undergone a 12 month period of observation since initial diagnosis of the structural lesion; AND</para><para>6. Confirmation that the patient has other hypothalamic/pituitary hormone deficits; AND</para><para>7. Confirmation that the patient has hypothalamic obesity; AND</para><para>8. Recent growth data (height and weight, not older than three months); AND</para><para>9. A bone age result performed within the last 12 months; AND</para><para>10. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5801e4014"><fragment id="59697-d5801e4014"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with Turner syndrome,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a height at or below the 95th percentile for age on the Turner syndrome growth curve for girls immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in all cells (45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in some cells (mosaic 46XX/45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as genetic loss or rearrangement of an X chromosome (such as isochromosome X, ring-chromosome, or partial deletion of an X chromosome), and gender of rearing is female,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. A height measurement from immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with Turner syndrome; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5801e4279"><fragment id="59697-d5801e4279"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature due to short stature homeobox (SHOX) gene disorders,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8 cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with a short stature homeobox (SHOX) gene disorder; AND</para><para>5. If the patient's condition is secondary to mixed gonadal dysgenesis, confirmation that an appropriate plan of management for the patient's increased risk of gonadoblastoma is in place; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5801e4574"><fragment id="59697-d5801e4574"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with chronic renal insufficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, and not have undergone a renal transplant; OR</para></item><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, have undergone a renal transplant, and have undergone a 12 month period of observation following the transplant,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> ; AND</para><para>5. If a renal transplant has taken place, confirmation that the patient has undergone a 12 month period of observation following transplantation; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5801e4785"><fragment id="59697-d5801e4785"><block label="NoteText"><para>If a patient receiving treatment under the indication short stature due to chronic renal insufficiency undergoes a renal transplant and 12 months post-transplant has an eGFR of equal to or greater than 30mL/min/1.73m<sup>2</sup> prescribers should seek reclassification to the indication short stature and slow growth.</para></block></fragment></section><section id="59697-10438J"><fragment id="59697-10438J"><block label="FormAndStrength">somatropin 10 mg/2 mL injection, 2 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10438J<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">439.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">NutropinAq [IS]<inline label="genericindexfieldbrand"><italic>XE "NutropinAq(IS)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10437H"><fragment id="59697-10437H"><block label="FormAndStrength">somatropin 5 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10437H<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">223.37</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norditropin SimpleXx [NO]<inline label="genericindexfieldbrand"><italic>XE "Norditropin SimpleXx(NO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10467X"><fragment id="59697-10467X"><block label="FormAndStrength">somatropin 5 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10467X<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">223.37</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norditropin FlexPro [NO]<inline label="genericindexfieldbrand"><italic>XE "Norditropin FlexPro(NO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10470C"><fragment id="59697-10470C"><block label="FormAndStrength">somatropin 15 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10470C<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">655.80</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norditropin SimpleXx [NO]<inline label="genericindexfieldbrand"><italic>XE "Norditropin SimpleXx(NO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10489C"><fragment id="59697-10489C"><block label="FormAndStrength">somatropin 15 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10489C<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">655.80</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norditropin FlexPro [NO]<inline label="genericindexfieldbrand"><italic>XE "Norditropin FlexPro(NO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10448X"><fragment id="59697-10448X"><block label="FormAndStrength">somatropin 10 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10448X<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">439.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norditropin SimpleXx [NO]<inline label="genericindexfieldbrand"><italic>XE "Norditropin SimpleXx(NO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10496K"><fragment id="59697-10496K"><block label="FormAndStrength">somatropin 10 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10496K<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">439.58</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Norditropin FlexPro [NO]<inline label="genericindexfieldbrand"><italic>XE "Norditropin FlexPro(NO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-21295011000036100-16"><fragment id="59697-21295011000036100-16"><block label="DrugName">SOMATROPIN<inline label="genericindexfield">XE "SOMATROPIN"</inline></block></fragment></section><section id="59697-d5820e152"><fragment id="59697-d5820e152"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5820e16"><fragment id="59697-d5820e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature and slow growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5820e144"><fragment id="59697-d5820e144"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5820e253"><fragment id="59697-d5820e253"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with biochemical growth hormone deficiency category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5820e371"><fragment id="59697-d5820e371"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5820e476"><fragment id="59697-d5820e476"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the growth retardation secondary to an intracranial lesion, or cranial irradiation category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5820e594"><fragment id="59697-d5820e594"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5820e699"><fragment id="59697-d5820e699"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a chronological age of 5 years or greater.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5820e814"><fragment id="59697-d5820e814"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5820e917"><fragment id="59697-d5820e917"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the biochemical growth hormone deficiency and precocious puberty category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5820e1042"><fragment id="59697-d5820e1042"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5820e1149"><fragment id="59697-d5820e1149"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5820e1267"><fragment id="59697-d5820e1267"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5820e1372"><fragment id="59697-d5820e1372"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with Turner syndrome category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5820e1494"><fragment id="59697-d5820e1494"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5820e1599"><fragment id="59697-d5820e1599"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature due to short stature homeobox (SHOX) gene disorders category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5820e1737"><fragment id="59697-d5820e1737"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5820e1850"><fragment id="59697-d5820e1850"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature and slow growth,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication short stature associated with chronic renal insufficiency, have undergone a renal transplant and a 12 month period of observation following the transplant, and have an estimated glomerular filtration rate of greater than or equal to 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula; OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment; AND</para><para>4. A bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5820e2133"><fragment id="59697-d5820e2133"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and have reached or surpassed 5 years of age (chronological); OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(c) Confirmation that the patient has previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and has reached or surpassed 5 years of age (chronological); AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Biochemical growth hormone deficiency should not be secondary to an intracranial lesion or cranial irradiation for applications under this category.</para></block></fragment></section><section id="59697-d5820e2499"><fragment id="59697-d5820e2499"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than growth retardation secondary to an intracranial lesion, or cranial irradiation,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had an intracranial lesion and have undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para></item><item><para>Patient must have had an intracranial lesion, have received medical advice that it is unsafe to treat the intracranial lesion, and have undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para></item><item><para>Patient must have received cranial irradiation without having had an intracranial lesion, and have undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8cm per year or less in the 12 month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has had an intracranial lesion and has undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para><para>(b) Confirmation that the patient has had an intracranial lesion, has received medical advice that it is unsafe to treat the intracranial lesion, and has undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para><para>(c) Confirmation that the patient has received cranial irradiation without having had an intracranial lesion, and has undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5820e2853"><fragment id="59697-d5820e2853"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a chronological age of less than 2 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a documented clinical risk of hypoglycaemia,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. Confirmation that the patient has a documented clinical risk of hypoglycaemia; AND</para><para>4. Confirmation that the patient has documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5820e3090"><fragment id="59697-d5820e3090"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than biochemical growth hormone deficiency and precocious puberty,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and have commenced puberty (demonstrated by Tanner stage 2 genital or pubic hair development or testicular volumes greater than or equal to 4 mL) before the chronological age of 9 years; OR</para></item><item><para>Patient must be female and have commenced puberty (demonstrated by Tanner stage 2 breast or pubic hair development) before the chronological age of 8 years; OR</para></item><item><para>Patient must be female and menarche occurred before the chronological age of 10 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. Confirmation that the patient has precocious puberty; AND</para><para>4. Confirmation that the patient is undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5820e3376"><fragment id="59697-d5820e3376"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a structural lesion that is not neoplastic; OR</para></item><item><para>Patient must have had a structural lesion that was neoplastic and have undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para></item><item><para>Patient must have a structural lesion that is neoplastic, have received medical advice that it is unsafe to treat the structural lesion, and have undergone a 12 month period of observation since initial diagnosis of the structural lesion,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have other hypothalamic/pituitary hormone deficits (includes ACTH, TSH, GnRH and/or vasopressin/ADH deficiencies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have hypothalamic obesity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity above the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8 cm per year or greater in the twelve month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has a structural lesion that is not neoplastic; OR</para><para>(b) Confirmation that the patient had a structural lesion that was neoplastic and has undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para><para>(c) Confirmation that the patient has a structural lesion that is neoplastic, has received medical advice that it is unsafe to treat the structural lesion, and has undergone a 12 month period of observation since initial diagnosis of the structural lesion; AND</para><para>6. Confirmation that the patient has other hypothalamic/pituitary hormone deficits; AND</para><para>7. Confirmation that the patient has hypothalamic obesity; AND</para><para>8. Recent growth data (height and weight, not older than three months); AND</para><para>9. A bone age result performed within the last 12 months; AND</para><para>10. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5820e3727"><fragment id="59697-d5820e3727"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with Turner syndrome,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a height at or below the 95th percentile for age on the Turner syndrome growth curve for girls immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in all cells (45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in some cells (mosaic 46XX/45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as genetic loss or rearrangement of an X chromosome (such as isochromosome X, ring-chromosome, or partial deletion of an X chromosome), and gender of rearing is female,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. A height measurement from immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with Turner syndrome; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5820e3992"><fragment id="59697-d5820e3992"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature due to short stature homeobox (SHOX) gene disorders,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8 cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with a short stature homeobox (SHOX) gene disorder; AND</para><para>5. If the patient's condition is secondary to mixed gonadal dysgenesis, confirmation that an appropriate plan of management for the patient's increased risk of gonadoblastoma is in place; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5820e4287"><fragment id="59697-d5820e4287"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with chronic renal insufficiency category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have undergone a renal transplant within the 12 month period immediately prior to the date of application,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an eGFR equal to or greater than 30mL/min/1.73m<sup>2</sup>,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation that the patient has an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> ; AND</para><para>6. If a renal transplant has taken place, confirmation that the patient has undergone a 12 month period of observation following transplantation; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>If a patient receiving treatment under the indication 'short stature associated with chronic renal insufficiency' undergoes a renal transplant and 12 months post-transplant has an eGFR of equal to or greater than 30mL/min/1.73m<sup>2</sup> prescribers should seek reclassification to the indication short stature and slow growth.</para></block></fragment></section><section id="59697-d5820e4453"><fragment id="59697-d5820e4453"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5820e4583"><fragment id="59697-d5820e4583"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with chronic renal insufficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, and not have undergone a renal transplant; OR</para></item><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, have undergone a renal transplant, and have undergone a 12 month period of observation following the transplant,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be aged 3 years or older.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> ; AND</para><para>5. If a renal transplant has taken place, confirmation that the patient has undergone a 12 month period of observation following transplantation; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5820e4801"><fragment id="59697-d5820e4801"><block label="NoteText"><para>If a patient receiving treatment under the indication short stature due to chronic renal insufficiency undergoes a renal transplant and 12 months post-transplant has an eGFR of equal to or greater than 30mL/min/1.73m<sup>2</sup> prescribers should seek reclassification to the indication short stature and slow growth.</para></block></fragment></section><section id="59697-10458K"><fragment id="59697-10458K"><block label="FormAndStrength">somatropin 6 mg/1.03 mL injection, 1.03 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10458K<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">266.61</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Saizen [SG]<inline label="genericindexfieldbrand"><italic>XE "Saizen(SG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10495J"><fragment id="59697-10495J"><block label="FormAndStrength">somatropin 12 mg/1.5 mL injection, 1.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10495J<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">526.07</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Saizen [SG]<inline label="genericindexfieldbrand"><italic>XE "Saizen(SG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10442N"><fragment id="59697-10442N"><block label="FormAndStrength">somatropin 20 mg/2.5 mL injection, 2.5 mL cartridge</block><table role="GH"><row><cell><block label="DrugItemCode">10442N<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">872.01</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Saizen [SG]<inline label="genericindexfieldbrand"><italic>XE "Saizen(SG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-21295011000036100-17"><fragment id="59697-21295011000036100-17"><block label="DrugName">SOMATROPIN<inline label="genericindexfield">XE "SOMATROPIN"</inline></block></fragment></section><section id="59697-d5839e152"><fragment id="59697-d5839e152"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5839e16"><fragment id="59697-d5839e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature and slow growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5839e144"><fragment id="59697-d5839e144"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5839e253"><fragment id="59697-d5839e253"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with biochemical growth hormone deficiency category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5839e371"><fragment id="59697-d5839e371"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5839e476"><fragment id="59697-d5839e476"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the growth retardation secondary to an intracranial lesion, or cranial irradiation category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5839e594"><fragment id="59697-d5839e594"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5839e699"><fragment id="59697-d5839e699"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a chronological age of 5 years or greater.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5839e814"><fragment id="59697-d5839e814"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5839e917"><fragment id="59697-d5839e917"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the biochemical growth hormone deficiency and precocious puberty category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5839e1042"><fragment id="59697-d5839e1042"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5839e1149"><fragment id="59697-d5839e1149"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5839e1267"><fragment id="59697-d5839e1267"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5839e1372"><fragment id="59697-d5839e1372"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with Turner syndrome category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5839e1494"><fragment id="59697-d5839e1494"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5839e1599"><fragment id="59697-d5839e1599"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature due to short stature homeobox (SHOX) gene disorders category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5839e1737"><fragment id="59697-d5839e1737"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5839e1850"><fragment id="59697-d5839e1850"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with chronic renal insufficiency category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have undergone a renal transplant within the 12 month period immediately prior to the date of application,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an eGFR equal to or greater than 30mL/min/1.73m<sup>2</sup>,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height and weight, not older than three months); AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. Confirmation that the patient has an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> ; AND</para><para>6. If a renal transplant has taken place, confirmation that the patient has undergone a 12 month period of observation following transplantation; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>If a patient receiving treatment under the indication 'short stature associated with chronic renal insufficiency' undergoes a renal transplant and 12 months post-transplant has an eGFR of equal to or greater than 30mL/min/1.73m<sup>2</sup> prescribers should seek reclassification to the indication short stature and slow growth.</para></block></fragment></section><section id="59697-d5839e2009"><fragment id="59697-d5839e2009"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5839e2137"><fragment id="59697-d5839e2137"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and poor body composition due to Prader-Willi syndrome</para><para>Treatment Phase: Recommencement of treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature and poor body composition due to Prader Willi syndrome category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a current bone age below skeletal maturity (15.5 for males and 13.5 for females); OR</para></item><item><para>Patient must have a current bone age at or above skeletal maturity (15.5 for males and 13.5 for females) and treatment must not have lapsed due to failure to respond to growth hormone at a dose of 0.04mg/kg/wk or greater for the most recent treatment period (32 weeks for the initial treatment period or 26 weeks for subsequent treatment periods, whichever applies); OR</para></item><item><para>Patient must have a current bone age at or above skeletal maturity (15.5 for males and 13.5 for females) and treatment must not have lapsed due to failure to respond to growth hormone at a dose of 0.04mg/kg/wk or greater for the most recent treatment period (32 weeks for the initial treatment period or 26 weeks for subsequent treatment periods, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>Patient must have a current bone age at or above skeletal maturity (15.5 for males and 13.5 for females) and treatment must not have lapsed due to failure to respond to growth hormone at a dose of 0.04mg/kg/wk or greater for the most recent treatment period (32 weeks for the initial treatment period or 26 weeks for subsequent treatment periods, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>Patient must have a current bone age at or above skeletal maturity (15.5 for males and 13.5 for females) and treatment must not have lapsed due to failure to respond to growth hormone at a dose of 0.04mg/kg/wk or greater for the most recent treatment period (32 weeks for the initial treatment period or 26 weeks for subsequent treatment periods, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>Patient must have a current bone age at or above skeletal maturity (15.5 for males and 13.5 for females) and treatment must not have lapsed due to failure to respond to growth hormone at a dose of 0.04mg/kg/wk or greater for the most recent treatment period (32 weeks for the initial treatment period or 26 weeks for subsequent treatment periods, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have been re-evaluated via polysomnography for airway obstruction and apnoea during the initial 32 week treatment period and any sleep disorders identified that required treatment must have been addressed,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must not have a chronological age of equal to or greater than 18 years.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must not have developed uncontrolled morbid obesity, defined as a body weight greater than 200% of ideal body weight for height and sex, with ideal body weight derived by calculating the 50th percentile weight for the patient's current height.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment; AND</para><para>3. Recent growth data (height, weight, and waist circumference, not older than three months); AND</para><para>4. The date at which skeletal maturity was achieved (if applicable) [Note: A bone age reading should be performed at least once every 12 months prior to attainment of skeletal maturity.]; AND</para><para>5. Confirmation that during the initial 32 week treatment period, the patient was re-evaluated via polysomnography for airway obstruction and apnoea, and any sleep disorders that were identified have been addressed; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5839e2291"><fragment id="59697-d5839e2291"><block label="NoteText"><para>If recommencement of treatment is sought under a different indication than that under which the patient was previously receiving treatment an application for<bold> recommencement of treatment as a reclassified patient </bold>should be submitted<bold>.</bold></para></block></fragment></section><section id="59697-d5839e2412"><fragment id="59697-d5839e2412"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature and slow growth,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication short stature associated with chronic renal insufficiency, have undergone a renal transplant and a 12 month period of observation following the transplant, and have an estimated glomerular filtration rate of greater than or equal to 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula; OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment; AND</para><para>4. A bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5839e2696"><fragment id="59697-d5839e2696"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and have reached or surpassed 5 years of age (chronological); OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(c) Confirmation that the patient has previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and has reached or surpassed 5 years of age (chronological); AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Biochemical growth hormone deficiency should not be secondary to an intracranial lesion or cranial irradiation for applications under this category.</para></block></fragment></section><section id="59697-d5839e3062"><fragment id="59697-d5839e3062"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than growth retardation secondary to an intracranial lesion, or cranial irradiation,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had an intracranial lesion and have undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para></item><item><para>Patient must have had an intracranial lesion, have received medical advice that it is unsafe to treat the intracranial lesion, and have undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para></item><item><para>Patient must have received cranial irradiation without having had an intracranial lesion, and have undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8cm per year or less in the 12 month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has had an intracranial lesion and has undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para><para>(b) Confirmation that the patient has had an intracranial lesion, has received medical advice that it is unsafe to treat the intracranial lesion, and has undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para><para>(c) Confirmation that the patient has received cranial irradiation without having had an intracranial lesion, and has undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5839e3415"><fragment id="59697-d5839e3415"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a chronological age of less than 2 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a documented clinical risk of hypoglycaemia,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. Confirmation that the patient has a documented clinical risk of hypoglycaemia; AND</para><para>4. Confirmation that the patient has documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5839e3652"><fragment id="59697-d5839e3652"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than biochemical growth hormone deficiency and precocious puberty,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and have commenced puberty (demonstrated by Tanner stage 2 genital or pubic hair development or testicular volumes greater than or equal to 4 mL) before the chronological age of 9 years; OR</para></item><item><para>Patient must be female and have commenced puberty (demonstrated by Tanner stage 2 breast or pubic hair development) before the chronological age of 8 years; OR</para></item><item><para>Patient must be female and menarche occurred before the chronological age of 10 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. Confirmation that the patient has precocious puberty; AND</para><para>4. Confirmation that the patient is undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5839e3938"><fragment id="59697-d5839e3938"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a structural lesion that is not neoplastic; OR</para></item><item><para>Patient must have had a structural lesion that was neoplastic and have undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para></item><item><para>Patient must have a structural lesion that is neoplastic, have received medical advice that it is unsafe to treat the structural lesion, and have undergone a 12 month period of observation since initial diagnosis of the structural lesion,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have other hypothalamic/pituitary hormone deficits (includes ACTH, TSH, GnRH and/or vasopressin/ADH deficiencies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have hypothalamic obesity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity above the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8 cm per year or greater in the twelve month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has a structural lesion that is not neoplastic; OR</para><para>(b) Confirmation that the patient had a structural lesion that was neoplastic and has undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para><para>(c) Confirmation that the patient has a structural lesion that is neoplastic, has received medical advice that it is unsafe to treat the structural lesion, and has undergone a 12 month period of observation since initial diagnosis of the structural lesion; AND</para><para>6. Confirmation that the patient has other hypothalamic/pituitary hormone deficits; AND</para><para>7. Confirmation that the patient has hypothalamic obesity; AND</para><para>8. Recent growth data (height and weight, not older than three months); AND</para><para>9. A bone age result performed within the last 12 months; AND</para><para>10. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5839e4289"><fragment id="59697-d5839e4289"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with Turner syndrome,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a height at or below the 95th percentile for age on the Turner syndrome growth curve for girls immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in all cells (45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in some cells (mosaic 46XX/45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as genetic loss or rearrangement of an X chromosome (such as isochromosome X, ring-chromosome, or partial deletion of an X chromosome), and gender of rearing is female,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. A height measurement from immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with Turner syndrome; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5839e4554"><fragment id="59697-d5839e4554"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature due to short stature homeobox (SHOX) gene disorders,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8 cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with a short stature homeobox (SHOX) gene disorder; AND</para><para>5. If the patient's condition is secondary to mixed gonadal dysgenesis, confirmation that an appropriate plan of management for the patient's increased risk of gonadoblastoma is in place; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5839e4849"><fragment id="59697-d5839e4849"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with chronic renal insufficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, and not have undergone a renal transplant; OR</para></item><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, have undergone a renal transplant, and have undergone a 12 month period of observation following the transplant,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> ; AND</para><para>5. If a renal transplant has taken place, confirmation that the patient has undergone a 12 month period of observation following transplantation; AND</para><para>6. Recent growth data (height and weight, not older than three months); AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5839e5060"><fragment id="59697-d5839e5060"><block label="NoteText"><para>If a patient receiving treatment under the indication short stature due to chronic renal insufficiency undergoes a renal transplant and 12 months post-transplant has an eGFR of equal to or greater than 30mL/min/1.73m<sup>2</sup> prescribers should seek reclassification to the indication short stature and slow growth.</para></block></fragment></section><section id="59697-d5839e5234"><fragment id="59697-d5839e5234"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and poor body composition due to Prader-Willi syndrome</para><para>Treatment Phase: Recommencement of treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature and poor body composition due to Prader-Willi syndrome,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a lapse in growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a current bone age below skeletal maturity (15.5 for males and 13.5 for females); OR</para></item><item><para>Patient must have a current bone age at or above skeletal maturity (15.5 for males and 13.5 for females) and treatment must not have lapsed due to failure to respond to growth hormone at a dose of 0.04mg/kg/wk or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have a current bone age at or above skeletal maturity (15.5 for males and 13.5 for females) and treatment must not have lapsed due to failure to respond to growth hormone at a dose of 0.04mg/kg/wk or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>Patient must have a current bone age at or above skeletal maturity (15.5 for males and 13.5 for females) and treatment must not have lapsed due to failure to respond to growth hormone at a dose of 0.04mg/kg/wk or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>Patient must have a current bone age at or above skeletal maturity (15.5 for males and 13.5 for females) and treatment must not have lapsed due to failure to respond to growth hormone at a dose of 0.04mg/kg/wk or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies) , unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>Patient must have a current bone age at or above skeletal maturity (15.5 for males and 13.5 for females) and treatment must not have lapsed due to failure to respond to growth hormone at a dose of 0.04mg/kg/wk or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with Prader-Willi syndrome (the condition must be genetically proven); OR</para></item><item><para>Patient must have a clinical diagnosis of Prader-Willi syndrome, confirmed by a clinical geneticist,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have been evaluated via polysomnography for airway obstruction and apnoea whilst on growth hormone treatment and any sleep disorders identified that required treatment must have been addressed; OR</para></item><item><para>Patient must have been evaluated via polysomnography for airway obstruction and apnoea within the last 12 months with no sleep disorders identified; OR</para></item><item><para>Patient must have been evaluated via polysomnography for airway obstruction and apnoea within the last 12 months with sleep disorders identified which are not of sufficient severity to require treatment; OR</para></item><item><para>Patient must have been evaluated via polysomnography for airway obstruction and apnoea within the last 12 months with sleep disorders identified for which the patient is currently receiving ameliorative treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have uncontrolled morbid obesity, defined as a body weight greater than 200% of ideal body weight for height and sex, with ideal body weight derived by calculating the 50th percentile weight for the patient's current height,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a chronological age of 18 years or greater.</para></item></list> <para>The maximum duration of each recommencement treatment phase is 32 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for recommencement of treatment as a reclassified patient; AND</para><para>3. (a) Confirmation that the patient has diagnostic results consistent with Prader-Willi syndrome, OR</para><para>(b) Confirmation that the patient has a clinical diagnosis of Prader-Willi syndrome, confirmed by a clinical geneticist; AND</para><para>4. Confirmation that the patient has been evaluated via polysomnography for airway obstruction and apnoea whilst on growth hormone treatment, and any sleep disorders identified via the polysomnography that required treatment have been addressed; AND</para><para>5. Recent growth data (height and weight, not older than three months); AND</para><para>6. The date that skeletal maturity was achieved (if applicable); AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 16 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-10430Y"><fragment id="59697-10430Y"><block label="FormAndStrength">somatropin 1 mg injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10430Y<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">309.85</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10435F"><fragment id="59697-10435F"><block label="FormAndStrength">SOMATROPIN (Recombinant human growth hormone) Powder for injection 5 mg (15 i.u.) with diluent in pre-filled pen (with preservative), 1</block><table role="GH"><row><cell><block label="DrugItemCode">10435F<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">223.37</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin GoQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin GoQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10472E"><fragment id="59697-10472E"><block label="FormAndStrength">somatropin 2 mg injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10472E<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">612.55</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10498M"><fragment id="59697-10498M"><block label="FormAndStrength">somatropin 1.6 mg injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10498M<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">491.48</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10457J"><fragment id="59697-10457J"><block label="FormAndStrength">somatropin 1.2 mg injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10457J<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">370.39</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10426R"><fragment id="59697-10426R"><block label="FormAndStrength">SOMATROPIN (Recombinant human growth hormone) Powder for injection 12 mg (36 i.u.) with diluent in pre-filled pen (with preservative), 1</block><table role="GH"><row><cell><block label="DrugItemCode">10426R<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">526.07</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin GoQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin GoQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10463Q"><fragment id="59697-10463Q"><block label="FormAndStrength">somatropin 800 microgram injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10463Q<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">249.31</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10434E"><fragment id="59697-10434E"><block label="FormAndStrength">somatropin 1.4 mg injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10434E<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">430.93</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10477K"><fragment id="59697-10477K"><block label="FormAndStrength">somatropin 600 microgram injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10477K<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">188.78</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10908D"><fragment id="59697-10908D"><block label="FormAndStrength">somatropin 400 microgram injection, syringe [7] (&amp;) inert substance diluent, syringe [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10908D<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">128.23</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10501Q"><fragment id="59697-10501Q"><block label="FormAndStrength">somatropin 1.8 mg injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10501Q<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">552.02</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10444Q"><fragment id="59697-10444Q"><block label="FormAndStrength">somatropin 12 mg injection [1 cartridge] (&amp;) inert substance diluent [1 mL cartridge], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10444Q<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">526.07</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-21295011000036100-18"><fragment id="59697-21295011000036100-18"><block label="DrugName">SOMATROPIN<inline label="genericindexfield">XE "SOMATROPIN"</inline></block></fragment></section><section id="59697-d5860e16"><fragment id="59697-d5860e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature and slow growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5860e127"><fragment id="59697-d5860e127"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5860e222"><fragment id="59697-d5860e222"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with biochemical growth hormone deficiency category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5860e323"><fragment id="59697-d5860e323"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5860e413"><fragment id="59697-d5860e413"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the growth retardation secondary to an intracranial lesion, or cranial irradiation category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5860e514"><fragment id="59697-d5860e514"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5860e604"><fragment id="59697-d5860e604"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a chronological age of 5 years or greater.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>When a patient receiving treatment under the indication risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants reaches or surpasses 5 years of age (chronological), prescribers should seek reclassification to the indication 'short stature due to biochemical growth hormone deficiency'.</para></block></fragment></section><section id="59697-d5860e705"><fragment id="59697-d5860e705"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5860e795"><fragment id="59697-d5860e795"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the biochemical growth hormone deficiency and precocious puberty category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5860e896"><fragment id="59697-d5860e896"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5860e986"><fragment id="59697-d5860e986"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5860e1087"><fragment id="59697-d5860e1087"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5860e1177"><fragment id="59697-d5860e1177"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with Turner syndrome category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an annualised growth velocity for bone age at or above the mean growth velocity for untreated Turner Syndrome girls (using the Turner Syndrome - Ranke growth velocity chart) while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0 cm.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5860e1282"><fragment id="59697-d5860e1282"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5860e1372"><fragment id="59697-d5860e1372"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature due to short stature homeobox (SHOX) gene disorders category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5860e1483"><fragment id="59697-d5860e1483"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5860e1578"><fragment id="59697-d5860e1578"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature associated with chronic renal insufficiency category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved the 50th percentile growth velocity for bone age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved an increase in height standard deviation score for chronological age and sex while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved a minimum growth velocity of 4cm/year while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have achieved and maintained mid parental height standard deviation score while on the maximum dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have undergone a renal transplant within the 12 month period immediately prior to the date of application,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an eGFR equal to or greater than 30mL/min/1.73m<sup>2</sup>,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7 cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0 cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. A bone age result performed within the last 12 months; AND</para><para>5. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5860e1706"><fragment id="59697-d5860e1706"><block label="NoteText"><para>If a patient receiving treatment under the indication short stature due to chronic renal insufficiency undergoes a renal transplant and 12 months post-transplant has an eGFR of equal to or greater than 30mL/min/1.73m<sup>2</sup> prescribers should seek reclassification to the indication short stature and slow growth.</para></block></fragment></section><section id="59697-d5860e1712"><fragment id="59697-d5860e1712"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5860e1814"><fragment id="59697-d5860e1814"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and poor body composition due to Prader-Willi syndrome</para><para>Treatment Phase: Continuing treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under the short stature and poor body composition due to Prader-Willi syndrome category,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have been re-evaluated via polysomnography for airway obstruction and apnoea during the initial 32 week treatment period and any sleep disorders identified that required treatment must have been addressed,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have been on the maximum dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), and have a bone age below skeletal maturity (15.5 for males and 13.5 for females); OR</para></item><item><para>Patient must have maintained or improved height percentile for age and sex while on the maximum dose of 7.5mg/m2/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), and have a bone age below skeletal maturity (15.5 for males and 13.5 for females); OR</para></item><item><para>Patient must have maintained or improved body mass index SDS for age and sex while on the maximum dose of 7.5mg/m2/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), and have a bone age below skeletal maturity (15.5 for males and 13.5 for females); OR</para></item><item><para>Patient must have maintained or improved waist circumference while on the maximum dose of 7.5mg/m2/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), and have a bone age below skeletal maturity (15.5 for males and 13.5 for females); OR</para></item><item><para>Patient must have maintained or improved waist/height ratio (waist circumference in centimetres divided by height in centimetres) while on the maximum dose of 7.5mg/m2/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), and have a bone age below skeletal maturity (15.5 for males and 13.5 for females); OR</para></item><item><para>Patient must have achieved an increase in height percentile with reference to the untreated Prader-Willi syndrome standards for age and sex while on the maximum dose of 7.5mg/m2/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), and have a bone age below skeletal maturity (15.5 for males and 13.5 for females); OR</para></item><item><para>Patient must not have been on the maximum dose of 0.04mg/kg/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), and have a bone age at or above skeletal maturity (15.5 for males and 13.5 for females); OR</para></item><item><para>Patient must have maintained or improved body mass index while on the maximum dose of 0.04mg/kg/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), and have a bone age at or above skeletal maturity (15.5 for males and 13.5 for females); OR</para></item><item><para>Patient must have maintained or improved body mass index SDS for age and sex while on the maximum dose of 0.04mg/kg/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), and have a bone age at or above skeletal maturity (15.5 for males and 13.5 for females); OR</para></item><item><para>Patient must have maintained or improved waist circumference while on the maximum dose of 0.04mg/kg/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), and have a bone age at or above skeletal maturity (15.5 for males and 13.5 for females); OR</para></item><item><para>Patient must have maintained or improved waist/height ratio (waist circumference in centimetres divided by height in centimetres) while on the maximum dose of 0.04mg/kg/week for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), and have a bone age at or above skeletal maturity (15.5 for males and 13.5 for females); OR</para></item><item><para>Patient must have maintained or improved weight SDS for age and sex while on the maximum dose of 0.04mg/kg/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), and have a bone age at or above skeletal maturity (15.5 for males and 13.5 for females),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must not have a chronological age of equal to or greater than 18 years.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must not have developed uncontrolled morbid obesity, defined as a body weight greater than 200% of ideal body weight for height and sex, with ideal body weight derived by calculating the 50th percentile weight for the patient's current height.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment; AND</para><para>3. Growth data (height, weight and waist circumference) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>4. The date at which skeletal maturity was achieved (if applicable) [Note: A bone age reading should be performed at least once every 12 months prior to attainment of skeletal maturity.]; AND</para><para>5. Confirmation that during the initial 32 week treatment period, the patient was re-evaluated via polysomnography for airway obstruction and apnoea, and any sleep disorders that were identified have been addressed; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Maintenance is defined as a value within a 5% tolerance (this allows for seasonal and other measurement variations).</para></block></fragment></section><section id="59697-d5860e1941"><fragment id="59697-d5860e1941"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5860e2040"><fragment id="59697-d5860e2040"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and slow growth</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature and slow growth,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication short stature associated with chronic renal insufficiency, have undergone a renal transplant and a 12 month period of observation following the transplant, and have an estimated glomerular filtration rate of greater than or equal to 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula; OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months;</para><para>OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment; AND</para><para>4. A bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5860e2195"><fragment id="59697-d5860e2195"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5860e2319"><fragment id="59697-d5860e2319"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with biochemical growth hormone deficiency</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and have reached or surpassed 5 years of age (chronological); OR</para></item><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1<sup>st</sup> percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(c) Confirmation that the patient has previously received treatment under the indication <bold>risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</bold> and has reached or surpassed 5 years of age (chronological); AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para> <para>Biochemical growth hormone deficiency should not be secondary to an intracranial lesion or cranial irradiation for applications under this category.</para></block></fragment></section><section id="59697-d5860e2519"><fragment id="59697-d5860e2519"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5860e2676"><fragment id="59697-d5860e2676"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Growth retardation secondary to an intracranial lesion, or cranial irradiation</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than growth retardation secondary to an intracranial lesion, or cranial irradiation,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had an intracranial lesion and have undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para></item><item><para>Patient must have had an intracranial lesion, have received medical advice that it is unsafe to treat the intracranial lesion, and have undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para></item><item><para>Patient must have received cranial irradiation without having had an intracranial lesion, and have undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8cm per year or less in the 12 month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has had an intracranial lesion and has undergone a 12 month period of observation following completion of treatment for the intracranial lesion (all treatment); OR</para><para>(b) Confirmation that the patient has had an intracranial lesion, has received medical advice that it is unsafe to treat the intracranial lesion, and has undergone a 12 month period of observation since initial diagnosis of the intracranial lesion; OR</para><para>(c) Confirmation that the patient has received cranial irradiation without having had an intracranial lesion, and has undergone a 12 month period of observation following completion of treatment for the condition for which cranial irradiation was received; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5860e2869"><fragment id="59697-d5860e2869"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5860e3020"><fragment id="59697-d5860e3020"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than risk of hypoglycaemia secondary to growth hormone deficiency in neonates/infants,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a chronological age of less than 2 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a documented clinical risk of hypoglycaemia,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. Confirmation that the patient has a documented clinical risk of hypoglycaemia; AND</para><para>4. Confirmation that the patient has documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5860e3144"><fragment id="59697-d5860e3144"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5860e3243"><fragment id="59697-d5860e3243"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Biochemical growth hormone deficiency and precocious puberty</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than biochemical growth hormone deficiency and precocious puberty,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and have commenced puberty (demonstrated by Tanner stage 2 genital or pubic hair development or testicular volumes greater than or equal to 4 mL) before the chronological age of 9 years; OR</para></item><item><para>Patient must be female and have commenced puberty (demonstrated by Tanner stage 2 breast or pubic hair development) before the chronological age of 8 years; OR</para></item><item><para>Patient must be female and menarche occurred before the chronological age of 10 years,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. Confirmation that the patient has precocious puberty; AND</para><para>4. Confirmation that the patient is undergoing Gonadotrophin Releasing Hormone agonist therapy for pubertal suppression; AND</para><para>5. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5860e3400"><fragment id="59697-d5860e3400"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5860e3520"><fragment id="59697-d5860e3520"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a structural lesion that is not neoplastic; OR</para></item><item><para>Patient must have had a structural lesion that was neoplastic and have undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para></item><item><para>Patient must have a structural lesion that is neoplastic, have received medical advice that it is unsafe to treat the structural lesion, and have undergone a 12 month period of observation since initial diagnosis of the structural lesion,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 2 pharmacological growth hormone stimulation tests (e.g. arginine, clonidine, glucagon, insulin); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 pharmacological growth hormone stimulation test (e.g. arginine, clonidine, glucagon, insulin) and 1 physiological growth hormone stimulation test (e.g. sleep, exercise); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) with other evidence of growth hormone deficiency, including septo-optic dysplasia (absent corpus callosum and/or septum pellucidum), midline abnormality including optic nerve hypoplasia, cleft lip and palate, midfacial hypoplasia and central incisor, ectopic and/or absent posterior pituitary bright spot, absent empty sella syndrome , hypoplastic anterior pituitary gland and/or pituitary stalk/infundibulum, and genetically proven biochemical growth hormone deficiency either isolated or as part of hypopituitarism in association with pituitary deficits (ACTH, TSH, GnRH or vasopressin/ADH deficiency); OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGF-1 levels; OR</para></item><item><para>Patient must have evidence of biochemical growth hormone deficiency, with a peak serum growth hormone concentration less than 10mU/L in response to 1 growth hormone stimulation test (pharmacological or physiological e.g. arginine, clonidine, glucagon, insulin, sleep, exercise) and low plasma IGFBP-3 levels,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have other hypothalamic/pituitary hormone deficits (includes ACTH, TSH, GnRH and/or vasopressin/ADH deficiencies),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have hypothalamic obesity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment and a growth velocity above the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity above the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less at commencement of growth hormone treatment and an annual growth velocity of 8 cm per year or greater in the twelve month period immediately prior to commencement of growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Evidence of biochemical growth hormone deficiency, including the type of tests performed and peak growth hormone concentrations; AND</para><para>5. (a) Confirmation that the patient has a structural lesion that is not neoplastic; OR</para><para>(b) Confirmation that the patient had a structural lesion that was neoplastic and has undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment); OR</para><para>(c) Confirmation that the patient has a structural lesion that is neoplastic, has received medical advice that it is unsafe to treat the structural lesion, and has undergone a 12 month period of observation since initial diagnosis of the structural lesion; AND</para><para>6. Confirmation that the patient has other hypothalamic/pituitary hormone deficits; AND</para><para>7. Confirmation that the patient has hypothalamic obesity; AND</para><para>8. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>9. A bone age result performed within the last 12 months; AND</para><para>10. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5860e3717"><fragment id="59697-d5860e3717"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5860e3862"><fragment id="59697-d5860e3862"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with Turner syndrome</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with Turner syndrome,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have had a height at or below the 95th percentile for age on the Turner syndrome growth curve for girls immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in all cells (45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as a loss of a whole X chromosome in some cells (mosaic 46XX/45X), and gender of rearing is female; OR</para></item><item><para>Patient must have diagnostic results consistent with Turner syndrome (the condition must be genetically proven), defined as genetic loss or rearrangement of an X chromosome (such as isochromosome X, ring-chromosome, or partial deletion of an X chromosome), and gender of rearing is female,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 2.5 years or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a bone age of 13.5 years or greater,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a height greater than or equal to 155.0 cm.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. A height measurement from immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with Turner syndrome; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. A bone age result performed within the last 12 months; AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5860e4009"><fragment id="59697-d5860e4009"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5860e4118"><fragment id="59697-d5860e4118"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature due to short stature homeobox (SHOX) gene disorders</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature due to short stature homeobox (SHOX) gene disorders,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis; OR</para></item><item><para>Patient must have diagnostic results consistent with a SHOX mutation/deletion, defined as mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or SRY gene positive by FISH study) and have an appropriate plan of management in place for the patient's increased risk of gonadoblastoma,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity below the 25th percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity below the 25th percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8 cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height below the 1st percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis),</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has diagnostic results consistent with a short stature homeobox (SHOX) gene disorder; AND</para><para>5. If the patient's condition is secondary to mixed gonadal dysgenesis, confirmation that an appropriate plan of management for the patient's increased risk of gonadoblastoma is in place; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>8. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5860e4280"><fragment id="59697-d5860e4280"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5860e4404"><fragment id="59697-d5860e4404"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature associated with chronic renal insufficiency</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature associated with chronic renal insufficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 9.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male, had a chronological age of at least 12 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be male, had a bone age of at least 10 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a chronological age of at least 10 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must be female, had a bone age of at least 8 years at commencement of growth hormone treatment, a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over the 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a growth velocity equal to or less than the 25<sup>th</sup> percentile for bone age and sex measured over both the 12 month and 6 month interval immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment; OR</para></item><item><para>Patient must have had a bone age of 2.5 years or less immediately prior to commencement of growth hormone treatment, an annual growth velocity of 8cm per year or less in the twelve month period immediately prior to commencement of growth hormone treatment, and a height equal to or less than the 25<sup>th</sup> percentile for age and sex immediately prior to commencing growth hormone treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, and not have undergone a renal transplant; OR</para></item><item><para>Patient must have an estimated glomerular filtration rate less than 30mL/minute/1.73m<sup>2</sup> measured by creatinine clearance, excretion of radionuclides such as DTPA, or by the height/creatinine formula, have undergone a renal transplant, and have undergone a 12 month period of observation following the transplant,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a height greater than or equal to 167.7cm; OR</para></item><item><para>Patient must be female and must not have a height greater than or equal to 155.0cm,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be male and must not have a bone age of 15.5 years or more; OR</para></item><item><para>Patient must be female and must not have a bone age of 13.5 years or more.</para></item></list><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) A minimum of 12 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, at intervals no greater than six months, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; OR</para><para>(b) If the patient was an older child (males chronological age 12 and over or bone age 10 and over, females chronological age 10 and over or bone age 8 and over) at the time of commencement of growth hormone treatment, a minimum of 6 months of growth data (height and weight) from immediately prior to commencement of growth hormone treatment, and a bone age result performed within the 12 months immediately prior to commencement of growth hormone treatment; AND</para><para>4. Confirmation that the patient has an estimated glomerular filtration rate less than 30ml/minute/1.73m<sup>2</sup> ; AND</para><para>5. If a renal transplant has taken place, confirmation that the patient has undergone a 12 month period of observation following transplantation; AND</para><para>6. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>7. A bone age result performed within the last 12 months; AND</para><para>The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5860e4608"><fragment id="59697-d5860e4608"><block label="NoteText"><para>If a patient receiving treatment under the indication short stature due to chronic renal insufficiency undergoes a renal transplant and 12 months post-transplant has an eGFR of equal to or greater than 30mL/min/1.73m<sup>2</sup> prescribers should seek reclassification to the indication short stature and slow growth.</para></block></fragment></section><section id="59697-d5860e4614"><fragment id="59697-d5860e4614"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to:</para><para>Department of Human Services </para><para>Prior Written Approval of Complex Drugs</para><para>Reply Paid 9826</para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-d5860e4780"><fragment id="59697-d5860e4780"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Short stature and poor body composition due to Prader-Willi syndrome</para><para>Treatment Phase: Continuing treatment as a reclassified patient</para><para><bold>Treatment criteria:</bold></para><list><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in paediatric endocrinology; OR</para></item><item><para>Must be treated by a medical practitioner in consultation with a nominated specialist or consultant physician in general paediatrics.</para></item></list><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously received treatment under the PBS S100 Growth Hormone Program under a category other than short stature and poor body composition due to Prader-Willi syndrome,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>The treatment must not have lapsed due to failure to respond to growth hormone at a dose of 7.5mg/m<sup>2</sup>/week or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a current bone age below skeletal maturity (15.5 for males and 13.5 for females); OR</para></item><item><para>Patient must have a current bone age at or above skeletal maturity (15.5 for males and 13.5 for females) and treatment must not have lapsed due to failure to respond to growth hormone at a dose of 0.04mg/kg/wk or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies); OR</para></item><item><para>Patient must have a current bone age at or above skeletal maturity (15.5 for males and 13.5 for females) and treatment must not have lapsed due to failure to respond to growth hormone at a dose of 0.04mg/kg/wk or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by a significant medical illness; OR</para></item><item><para>Patient must have a current bone age at or above skeletal maturity (15.5 for males and 13.5 for females) and treatment must not have lapsed due to failure to respond to growth hormone at a dose of 0.04mg/kg/wk or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by major surgery (e.g. renal transplant); OR</para></item><item><para>Patient must have a current bone age at or above skeletal maturity (15.5 for males and 13.5 for females) and treatment must not have lapsed due to failure to respond to growth hormone at a dose of 0.04mg/kg/wk or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies) , unless response was affected by an adverse reaction to growth hormone; OR</para></item><item><para>Patient must have a current bone age at or above skeletal maturity (15.5 for males and 13.5 for females) and treatment must not have lapsed due to failure to respond to growth hormone at a dose of 0.04mg/kg/wk or greater for the most recent treatment period (32 weeks for an initial or recommencement treatment period and 26 weeks for a continuing treatment period, whichever applies), unless response was affected by non-compliance due to social/family problems,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have diagnostic results consistent with Prader-Willi syndrome (the condition must be genetically proven); OR</para></item><item><para>Patient must have a clinical diagnosis of Prader-Willi syndrome, confirmed by a clinical geneticist,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have been evaluated via polysomnography for airway obstruction and apnoea whilst on growth hormone treatment and any sleep disorders identified that required treatment must have been addressed,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have uncontrolled morbid obesity, defined as a body weight greater than 200% of ideal body weight for height and sex, with ideal body weight derived by calculating the 50th percentile weight for the patient's current height,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have diabetes mellitus,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have an active tumour or evidence of tumour growth or activity,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not have a chronological age of 18 years or greater.</para></item></list> <para>The maximum duration of each continuing treatment phase is 26 weeks. Prescribers must determine an appropriate weekly dose in accordance with the dosing arrangements detailed in the <bold>National Health (Growth Hormone Program) Special Arrangement 2015</bold> and request the appropriate number of vials/cartridges required to provide sufficient drug for 13 weeks' worth of treatment (with up to 1 repeat allowed).</para> <para>The authority application must be in writing and must include:</para><para>1. A completed authority prescription form; AND</para><para>2. A completed Growth Hormone Authority Application Supporting Information Form for continuing treatment as a reclassified patient; AND</para><para>3. (a) Confirmation that the patient has diagnostic results consistent with Prader-Willi syndrome, OR</para><para>(b) Confirmation that the patient has a clinical diagnosis of Prader-Willi syndrome, confirmed by a clinical geneticist; AND</para><para>4. Confirmation that the patient has been evaluated via polysomnography for airway obstruction and apnoea whilst on growth hormone treatment, and any sleep disorders identified via the polysomnography that required treatment have been addressed; AND</para><para>5. Growth data (height and weight) for the most recent 6 month treatment period, including data at both the start and end of the treatment period. The most recent data must not be older than three months; AND</para><para>6. The date that skeletal maturity was achieved (if applicable); AND</para><para>7. The proprietary name (brand), form and strength of somatropin requested, and the number of vials/cartridges required to provide sufficient drug for 13 weeks worth of treatment (with up to 1 repeat allowed).</para> <para>Prescribers must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes. These records must be kept for 2 years after the date the prescription to which the records relate is written.</para></block></fragment></section><section id="59697-d5860e4941"><fragment id="59697-d5860e4941"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). </para><para>Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at www.humanservices.gov.au</para><para>Applications for authority to prescribe should be forwarded to: </para><para>Department of Human Services</para><para>Complex Drugs </para><para>Reply Paid 9826 </para><para>HOBART TAS 7001</para></block></fragment></section><section id="59697-10480N"><fragment id="59697-10480N"><block label="FormAndStrength">somatropin 1 mg injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10480N<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">309.85</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10443P"><fragment id="59697-10443P"><block label="FormAndStrength">SOMATROPIN (Recombinant human growth hormone) Powder for injection 5 mg (15 i.u.) with diluent in pre-filled pen (with preservative), 1</block><table role="GH"><row><cell><block label="DrugItemCode">10443P<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">223.37</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin GoQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin GoQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10428W"><fragment id="59697-10428W"><block label="FormAndStrength">somatropin 2 mg injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10428W<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">612.55</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10454F"><fragment id="59697-10454F"><block label="FormAndStrength">somatropin 1.6 mg injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10454F<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">491.48</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10453E"><fragment id="59697-10453E"><block label="FormAndStrength">somatropin 1.2 mg injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10453E<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">370.39</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10431B"><fragment id="59697-10431B"><block label="FormAndStrength">SOMATROPIN (Recombinant human growth hormone) Powder for injection 12 mg (36 i.u.) with diluent in pre-filled pen (with preservative), 1</block><table role="GH"><row><cell><block label="DrugItemCode">10431B<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">526.07</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin GoQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin GoQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10479M"><fragment id="59697-10479M"><block label="FormAndStrength">somatropin 800 microgram injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10479M<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">249.31</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10488B"><fragment id="59697-10488B"><block label="FormAndStrength">somatropin 1.4 mg injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10488B<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">430.93</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10456H"><fragment id="59697-10456H"><block label="FormAndStrength">somatropin 600 microgram injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10456H<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">188.78</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10891F"><fragment id="59697-10891F"><block label="FormAndStrength">somatropin 400 microgram injection, syringe [7] (&amp;) inert substance diluent, syringe [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10891F<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">128.23</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10500P"><fragment id="59697-10500P"><block label="FormAndStrength">somatropin 1.8 mg injection [7] (&amp;) inert substance diluent [7 x 0.25 mL syringes], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10500P<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">552.02</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin MiniQuick [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin MiniQuick(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59697-10499N"><fragment id="59697-10499N"><block label="FormAndStrength">somatropin 12 mg injection [1 cartridge] (&amp;) inert substance diluent [1 mL cartridge], 1 pack</block><table role="GH"><row><cell><block label="DrugItemCode">10499N<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">526.07</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Genotropin [PF]<inline label="genericindexfieldbrand"><italic>XE "Genotropin(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref></xref-fragment></section></document></blockxref>
<blockxref id="107709" title="therapeuticindex-IF.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="59964" href="dynamic/IF/therapeuticindex-IF.psml" urititle="Therapeutic Index - IVF Treatment Program - IF" mediatype="application/vnd.pageseeder.psml+xml"><document id="59964" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="59964" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/IF/therapeuticindex-IF.psml" decodedpath="/ps/test/local3/books/dynamic/IF/therapeuticindex-IF.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:23+10:00" modified="2018-06-15T10:34:32+10:00" title="Therapeutic Index - IVF Treatment Program - IF"><displaytitle>Therapeutic Index - IVF Treatment Program - IF</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107709" title="" type="none" forwardtype="embed" forwardtitle="therapeuticindex-IF.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="43069" fragment="59964-2" editid="105994" modified="2018-06-15T10:34:23+10:00"></locator></fragmentinfo><metadata></metadata><section id="59964-1"><fragment id="59964-1"><block label="mps3indexsectionbreak">IF</block><block label="schedule-heading">IVF Treatment Program</block></fragment><fragment id="59964-2"><block label="index"><para>GENITO URINARY SYSTEM AND SEX HORMONES<inline label="indexpageref"><xref id="105984" title="GENITO URINARY SYSTEM AND SEX HORMONES" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59858" href="#59858" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml">GENITO URINARY SYSTEM AND SEX HORMONES</xref></inline></para></block><block label="index2"><para indent="1">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM<inline label="indexpageref"><xref id="105985" title="SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM" frag="G03" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59858" href="#59858-G03" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml">GENITO URINARY SYSTEM AND SEX HORMONES</xref></inline></para></block><block label="index3"><para indent="2">PROGESTOGENS<inline label="indexpageref"><xref id="105986" title="PROGESTOGENS" frag="G03D" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59858" href="#59858-G03D" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml">GENITO URINARY SYSTEM AND SEX HORMONES</xref></inline></para></block><block label="index3"><para indent="2">GONADOTROPINS AND OTHER OVULATION STIMULANTS<inline label="indexpageref"><xref id="105987" title="GONADOTROPINS AND OTHER OVULATION STIMULANTS" frag="G03G" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59858" href="#59858-G03G" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml">GENITO URINARY SYSTEM AND SEX HORMONES</xref></inline></para></block><block label="index"><para>SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS<inline label="indexpageref"><xref id="105988" title="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60828" href="#60828" urititle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" mediatype="application/vnd.pageseeder.psml+xml">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</xref></inline></para></block><block label="index2"><para indent="1">PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES<inline label="indexpageref"><xref id="105989" title="PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES" frag="H01" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60828" href="#60828-H01" urititle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" mediatype="application/vnd.pageseeder.psml+xml">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</xref></inline></para></block><block label="index3"><para indent="2">HYPOTHALAMIC HORMONES<inline label="indexpageref"><xref id="105990" title="HYPOTHALAMIC HORMONES" frag="H01C" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60828" href="#60828-H01C" urititle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" mediatype="application/vnd.pageseeder.psml+xml">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</xref></inline></para></block><block label="index"><para>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS<inline label="indexpageref"><xref id="105991" title="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60679" href="#60679" urititle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" mediatype="application/vnd.pageseeder.psml+xml">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</xref></inline></para></block><block label="index2"><para indent="1">ENDOCRINE THERAPY<inline label="indexpageref"><xref id="105992" title="ENDOCRINE THERAPY" frag="L02" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60679" href="#60679-L02" urititle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" mediatype="application/vnd.pageseeder.psml+xml">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</xref></inline></para></block><block label="index3"><para indent="2">HORMONES AND RELATED AGENTS<inline label="indexpageref"><xref id="105993" title="HORMONES AND RELATED AGENTS" frag="L02A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60679" href="#60679-L02A" urititle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" mediatype="application/vnd.pageseeder.psml+xml">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</xref></inline></para></block></fragment></section></document></blockxref>
<blockxref id="107710" title="IF.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="60524" href="dynamic/IF.psml" urititle="IVF Treatment Program" mediatype="application/vnd.pageseeder.psml+xml"><document id="60524" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="60524" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/IF.psml" decodedpath="/ps/test/local3/books/dynamic/IF.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:29+10:00" modified="2018-06-15T10:34:32+10:00" title="IVF Treatment Program"><displaytitle>IVF Treatment Program</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107710" title="" type="none" forwardtype="embed" forwardtitle="IF.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="44156" fragment="60524-d114e908155" editid="107080" modified="2018-06-15T10:34:29+10:00"></locator></fragmentinfo><metadata></metadata><section id="60524-1"><fragment id="60524-1"><block label="mps3sectionbreak">IF</block></fragment></section><section id="60524-d114e908155"><xref-fragment id="60524-d114e908155"><blockxref id="107077" title="GENITO URINARY SYSTEM AND SEX HORMONES" frag="default" reversefrag="d114e908155" reversetitle="IF" reverselink="true" reversetype="none" display="document" type="embed" uriid="59858" href="dynamic/IF/atc/G.psml" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml"><document id="59858" schemaversion="0.12" date="2018-06-15T10:34:29+10:00" version="current" level="processed"><documentinfo><uri id="59858" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/IF/atc/G.psml" decodedpath="/ps/test/local3/books/dynamic/IF/atc/G.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:29+10:00" title="GENITO URINARY SYSTEM AND SEX HORMONES"><displaytitle>GENITO URINARY SYSTEM AND SEX HORMONES</displaytitle></uri><reversexrefs><reversexref uriid="59964" href="dynamic/IF/therapeuticindex-IF.psml" frag="2" urititle="Therapeutic Index - IVF Treatment Program - IF" mediatype="application/vnd.pageseeder.psml+xml" id="105984" title="Untitled" type="none" forwardtype="none" forwardtitle="GENITO URINARY SYSTEM AND SEX HORMONES" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60524" href="dynamic/IF.psml" frag="d114e908155" urititle="IVF Treatment Program" mediatype="application/vnd.pageseeder.psml+xml" id="107077" title="IF" type="none" forwardtype="embed" forwardtitle="GENITO URINARY SYSTEM AND SEX HORMONES" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="42626" fragment="59858-G03GA21430011000036104" editid="105540" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42632" fragment="59858-G03GA925370011000036105" editid="105543" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42620" fragment="59858-G03GA33633011000036101" editid="105537" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42624" fragment="59858-G03GA44973011000036102" editid="105539" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42618" fragment="59858-G03GA74621000036103" editid="105536" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42628" fragment="59858-G03GA21352011000036107" editid="105541" modified="2018-06-15T10:34:22+10:00"></locator><locator id="43072" fragment="59858-G03G"><reversexrefs><reversexref uriid="59964" href="dynamic/IF/therapeuticindex-IF.psml" frag="2" urititle="Therapeutic Index - IVF Treatment Program - IF" mediatype="application/vnd.pageseeder.psml+xml" id="105987" title="Untitled" type="none" forwardtype="none" forwardtitle="GONADOTROPINS AND OTHER OVULATION STIMULANTS" forwarddisplay="document" forwardfrag="G03G"></reversexref></reversexrefs></locator><locator id="42616" fragment="59858-G03GA21333011000036104" editid="105535" modified="2018-06-15T10:34:22+10:00"></locator><locator id="43070" fragment="59858-G03"><reversexrefs><reversexref uriid="59964" href="dynamic/IF/therapeuticindex-IF.psml" frag="2" urititle="Therapeutic Index - IVF Treatment Program - IF" mediatype="application/vnd.pageseeder.psml+xml" id="105985" title="Untitled" type="none" forwardtype="none" forwardtitle="SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM" forwarddisplay="document" forwardfrag="G03"></reversexref></reversexrefs></locator><locator id="43071" fragment="59858-G03D"><reversexrefs><reversexref uriid="59964" href="dynamic/IF/therapeuticindex-IF.psml" frag="2" urititle="Therapeutic Index - IVF Treatment Program - IF" mediatype="application/vnd.pageseeder.psml+xml" id="105986" title="Untitled" type="none" forwardtype="none" forwardtitle="PROGESTOGENS" forwarddisplay="document" forwardfrag="G03D"></reversexref></reversexrefs></locator><locator id="42622" fragment="59858-G03DA21412011000036108" editid="105538" modified="2018-06-15T10:34:22+10:00"></locator><locator id="42630" fragment="59858-G03GA319511000144102" editid="105542" modified="2018-06-15T10:34:22+10:00"></locator></fragmentinfo><metadata></metadata><section id="59858-G"><fragment id="59858-G"><block label="ATCLevel1"><para>GENITO URINARY SYSTEM AND SEX HORMONES</para></block></fragment></section><section id="59858-G03"><fragment id="59858-G03"><block label="ATCLevel2"><para>SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</para></block></fragment></section><section id="59858-G03D"><fragment id="59858-G03D"><block label="ATCLevel3"><para>PROGESTOGENS</para></block></fragment></section><section id="59858-G03DA"><fragment id="59858-G03DA"><block label="ATCLevel4"><para>Pregnen (4) derivatives</para></block></fragment></section><section id="59858-G03DA21412011000036108"><xref-fragment id="59858-G03DA21412011000036108"><blockxref id="105529" title="PROGESTERONE" frag="default" reversefrag="G03DA21412011000036108" reversetitle="IF" reverselink="true" reversetype="none" display="document" type="embed" uriid="60764" href="dynamic/IF/drug/21412011000036108-G03DA.psml" urititle="PROGESTERONE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60764" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60764" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/IF/drug/21412011000036108-G03DA.psml" decodedpath="/ps/test/local3/books/dynamic/IF/drug/21412011000036108-G03DA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:31+10:00" modified="2018-06-15T10:34:22+10:00" title="PROGESTERONE"><displaytitle>PROGESTERONE</displaytitle></uri><reversexrefs><reversexref uriid="59858" href="dynamic/IF/atc/G.psml" frag="G03DA21412011000036108" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml" id="105529" title="IF" type="none" forwardtype="embed" forwardtitle="PROGESTERONE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60764-21412011000036108-1"><fragment id="60764-21412011000036108-1"><block label="DrugName">PROGESTERONE<inline label="genericindexfield">XE "PROGESTERONE"</inline></block></fragment></section><section id="60764-d5568e16"><fragment id="60764-d5568e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">4997</block><block label="RestrictionText"><para>Assisted Reproductive Technology</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be for luteal phase support as part of an assisted reproductive technology (ART) treatment cycle for infertile women,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be receiving medical services as described in items 13200 or 13201 of the Medicare Benefits Schedule.</para></item></list> <para>The luteal phase is defined as the time span from embryo transfer until implantation confirmed by positive B-hCG measurement.</para></block></fragment></section><section id="60764-10930G"><fragment id="60764-10930G"><block label="FormAndStrength">progesterone 200 mg capsule, 42</block><table role="IF"><row><cell><block label="DrugItemCode">10930G<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">86.68</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Utrogestan [HB]<inline label="genericindexfieldbrand"><italic>XE "Utrogestan(HB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60764-9609R"><fragment id="60764-9609R"><block label="FormAndStrength">progesterone 200 mg pessary, 15</block><table role="IF"><row><cell><block label="DrugItemCode">9609R<br></br></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>171.94</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Oripro [ON]<inline label="genericindexfieldbrand"><italic>XE "Oripro(ON)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60764-10116K"><fragment id="60764-10116K"><block label="FormAndStrength">progesterone 100 mg pessary, 21</block><table role="IF"><row><cell><block label="DrugItemCode">10116K<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>104.99</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Endometrin [FP]<inline label="genericindexfieldbrand"><italic>XE "Endometrin(FP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60764-9608Q"><fragment id="60764-9608Q"><block label="FormAndStrength">progesterone 100 mg pessary, 15</block><table role="IF"><row><cell><block label="DrugItemCode">9608Q<br></br></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>156.55</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Oripro [ON]<inline label="genericindexfieldbrand"><italic>XE "Oripro(ON)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60764-21412011000036108-2"><fragment id="60764-21412011000036108-2"><block label="DrugName">PROGESTERONE<inline label="genericindexfield">XE "PROGESTERONE"</inline></block></fragment></section><section id="60764-d5570e36"><fragment id="60764-d5570e36"><block label="NoteText"><para>Special Pricing Arrangements apply.</para></block></fragment></section><section id="60764-d5570e16"><fragment id="60764-d5570e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5045</block><block label="RestrictionText"><para>Assisted Reproductive Technology</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be for luteal phase support as part of an assisted reproductive technology (ART) treatment cycle for infertile women,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be receiving medical services as described in items 13200 or 13201 of the Medicare Benefits Schedule.</para></item></list> <para>The luteal phase is defined as the time span from embryo transfer until implantation confirmed by positive B-hCG measurement.</para></block></fragment></section><section id="60764-6366C"><fragment id="60764-6366C"><block label="FormAndStrength">progesterone 8% vaginal gel, 15 applications</block><table role="IF"><row><cell><block label="DrugItemCode">6366C<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>300.59</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Crinone 8% [SG]<inline label="genericindexfieldbrand"><italic>XE "Crinone 8%(SG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59858-G03G"><fragment id="59858-G03G"><block label="ATCLevel3"><para>GONADOTROPINS AND OTHER OVULATION STIMULANTS</para></block></fragment></section><section id="59858-G03GA"><fragment id="59858-G03GA"><block label="ATCLevel4"><para>Gonadotropins</para></block></fragment></section><section id="59858-G03GA21430011000036104"><xref-fragment id="59858-G03GA21430011000036104"><blockxref id="105531" title="CHORIOGONADOTROPIN ALFA" frag="default" reversefrag="G03GA21430011000036104" reversetitle="IF" reverselink="true" reversetype="none" display="document" type="embed" uriid="59982" href="dynamic/IF/drug/21430011000036104-G03GA.psml" urititle="CHORIOGONADOTROPIN ALFA" mediatype="application/vnd.pageseeder.psml+xml"><document id="59982" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="59982" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/IF/drug/21430011000036104-G03GA.psml" decodedpath="/ps/test/local3/books/dynamic/IF/drug/21430011000036104-G03GA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:23+10:00" modified="2018-06-15T10:34:22+10:00" title="CHORIOGONADOTROPIN ALFA"><displaytitle>CHORIOGONADOTROPIN ALFA</displaytitle></uri><reversexrefs><reversexref uriid="59858" href="dynamic/IF/atc/G.psml" frag="G03GA21430011000036104" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml" id="105531" title="IF" type="none" forwardtype="embed" forwardtitle="CHORIOGONADOTROPIN ALFA" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59982-21430011000036104-1"><fragment id="59982-21430011000036104-1"><block label="DrugName">CHORIOGONADOTROPIN ALFA<inline label="genericindexfield">XE "CHORIOGONADOTROPIN ALFA"</inline></block></fragment></section><section id="59982-d5572e26"><fragment id="59982-d5572e26"><block label="NoteText"><para>Special Pricing Arrangements apply.</para></block></fragment></section><section id="59982-d5572e16"><fragment id="59982-d5572e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5019</block><block label="RestrictionText"><para>Assisted Reproductive Technology</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving medical services as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule.</para></item></list></block></fragment></section><section id="59982-6182J"><fragment id="59982-6182J"><block label="FormAndStrength">choriogonadotropin alfa 250 microgram/0.5 mL injection, 1 dose</block><table role="IF"><row><cell><block label="DrugItemCode">6182J<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">63.21</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Ovidrel [SG]<inline label="genericindexfieldbrand"><italic>XE "Ovidrel(SG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59858-G03GA925370011000036105"><xref-fragment id="59858-G03GA925370011000036105"><blockxref id="105534" title="CORIFOLLITROPIN ALFA" frag="default" reversefrag="G03GA925370011000036105" reversetitle="IF" reverselink="true" reversetype="none" display="document" type="embed" uriid="60557" href="dynamic/IF/drug/925370011000036105-G03GA.psml" urititle="CORIFOLLITROPIN ALFA" mediatype="application/vnd.pageseeder.psml+xml"><document id="60557" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60557" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/IF/drug/925370011000036105-G03GA.psml" decodedpath="/ps/test/local3/books/dynamic/IF/drug/925370011000036105-G03GA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:29+10:00" modified="2018-06-15T10:34:22+10:00" title="CORIFOLLITROPIN ALFA"><displaytitle>CORIFOLLITROPIN ALFA</displaytitle></uri><reversexrefs><reversexref uriid="59858" href="dynamic/IF/atc/G.psml" frag="G03GA925370011000036105" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml" id="105534" title="IF" type="none" forwardtype="embed" forwardtitle="CORIFOLLITROPIN ALFA" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60557-925370011000036105-1"><fragment id="60557-925370011000036105-1"><block label="DrugName">CORIFOLLITROPIN ALFA<inline label="genericindexfield">XE "CORIFOLLITROPIN ALFA"</inline></block></fragment></section><section id="60557-d5574e16"><fragment id="60557-d5574e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5009</block><block label="RestrictionText"><para>Assisted Reproductive Technology</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be for controlled ovarian stimulation,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have an antral follicle count of 20 or less,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be receiving medical services as described in items 13200, 13201, or 13202 of the Medicare Benefits Schedule,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing a gonadotrophin releasing antagonist cycle.</para></item></list></block></fragment></section><section id="60557-5816D"><fragment id="60557-5816D"><block label="FormAndStrength">corifollitropin alfa 100 microgram/0.5 mL injection, 0.5 mL syringe</block><table role="IF"><row><cell><block label="DrugItemCode">5816D<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">412.37</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Elonva [MK]<inline label="genericindexfieldbrand"><italic>XE "Elonva(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60557-5817E"><fragment id="60557-5817E"><block label="FormAndStrength">corifollitropin alfa 150 microgram/0.5 mL injection, 0.5 mL syringe</block><table role="IF"><row><cell><block label="DrugItemCode">5817E<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">672.57</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Elonva [MK]<inline label="genericindexfieldbrand"><italic>XE "Elonva(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59858-G03GA21352011000036107"><xref-fragment id="59858-G03GA21352011000036107"><blockxref id="105532" title="FOLLITROPIN ALFA" frag="default" reversefrag="G03GA21352011000036107" reversetitle="IF" reverselink="true" reversetype="none" display="document" type="embed" uriid="60208" href="dynamic/IF/drug/21352011000036107-G03GA.psml" urititle="FOLLITROPIN ALFA" mediatype="application/vnd.pageseeder.psml+xml"><document id="60208" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60208" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/IF/drug/21352011000036107-G03GA.psml" decodedpath="/ps/test/local3/books/dynamic/IF/drug/21352011000036107-G03GA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:26+10:00" modified="2018-06-15T10:34:22+10:00" title="FOLLITROPIN ALFA"><displaytitle>FOLLITROPIN ALFA</displaytitle></uri><reversexrefs><reversexref uriid="59858" href="dynamic/IF/atc/G.psml" frag="G03GA21352011000036107" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml" id="105532" title="IF" type="none" forwardtype="embed" forwardtitle="FOLLITROPIN ALFA" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60208-21352011000036107-1"><fragment id="60208-21352011000036107-1"><block label="DrugName">FOLLITROPIN ALFA<inline label="genericindexfield">XE "FOLLITROPIN ALFA"</inline></block></fragment></section><section id="60208-d5576e16"><fragment id="60208-d5576e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5027</block><block label="RestrictionText"><para>Assisted Reproductive Technology</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving medical services as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule.</para></item></list></block></fragment></section><section id="60208-6433N"><fragment id="60208-6433N"><block label="FormAndStrength">follitropin alfa 900 units (65.52 microgram)/1.5 mL injection, 1.5 mL cartridge</block><table role="IF"><row><cell><block label="DrugItemCode">6433N<br></br></block></cell><cell><block label="MaxQuantity">5</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1684.55</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Gonal-f Pen [SG]<inline label="genericindexfieldbrand"><italic>XE "Gonal-f Pen(SG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60208-10867Y"><fragment id="60208-10867Y"><block label="FormAndStrength">follitropin alfa 450 units (33 microgram)/0.75 mL injection, 5 x 0.75 mL injection devices</block><table role="IF"><row><cell><block label="DrugItemCode">10867Y<br></br></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>2503.24</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Bemfola [FX]<inline label="genericindexfieldbrand"><italic>XE "Bemfola(FX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60208-10873G"><fragment id="60208-10873G"><block label="FormAndStrength">follitropin alfa 150 units (11 microgram)/0.25 mL injection, 5 x 0.25 mL injection devices</block><table role="IF"><row><cell><block label="DrugItemCode">10873G<br></br></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>858.61</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Bemfola [FX]<inline label="genericindexfieldbrand"><italic>XE "Bemfola(FX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60208-10866X"><fragment id="60208-10866X"><block label="FormAndStrength">follitropin alfa 300 units (22 microgram)/0.5 mL injection, 5 x 0.5 mL injection devices</block><table role="IF"><row><cell><block label="DrugItemCode">10866X<br></br></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1684.54</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Bemfola [FX]<inline label="genericindexfieldbrand"><italic>XE "Bemfola(FX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60208-10861P"><fragment id="60208-10861P"><block label="FormAndStrength">follitropin alfa 75 units (5.5 microgram)/0.125 mL injection, 5 x 0.125 mL injection devices</block><table role="IF"><row><cell><block label="DrugItemCode">10861P<br></br></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>432.88</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Bemfola [FX]<inline label="genericindexfieldbrand"><italic>XE "Bemfola(FX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60208-6431L"><fragment id="60208-6431L"><block label="FormAndStrength">follitropin alfa 300 units (21.84 microgram)/0.5 mL injection, 0.5 mL cartridge</block><table role="IF"><row><cell><block label="DrugItemCode">6431L<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>234.21</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Gonal-f Pen [SG]<inline label="genericindexfieldbrand"><italic>XE "Gonal-f Pen(SG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60208-6432M"><fragment id="60208-6432M"><block label="FormAndStrength">follitropin alfa 450 units (32.76 microgram)/0.75 mL injection, 0.75 mL cartridge</block><table role="IF"><row><cell><block label="DrugItemCode">6432M<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>347.73</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Gonal-f Pen [SG]<inline label="genericindexfieldbrand"><italic>XE "Gonal-f Pen(SG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60208-10872F"><fragment id="60208-10872F"><block label="FormAndStrength">follitropin alfa 225 units (16.5 microgram)/0.375 mL injection, 5 x 0.375 mL injection devices</block><table role="IF"><row><cell><block label="DrugItemCode">10872F<br></br></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1275.19</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Bemfola [FX]<inline label="genericindexfieldbrand"><italic>XE "Bemfola(FX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59858-G03GA319511000144102"><xref-fragment id="59858-G03GA319511000144102"><blockxref id="105533" title="FOLLITROPIN ALFA + LUTROPIN ALFA" frag="default" reversefrag="G03GA319511000144102" reversetitle="IF" reverselink="true" reversetype="none" display="document" type="embed" uriid="60393" href="dynamic/IF/drug/319511000144102-G03GA.psml" urititle="FOLLITROPIN ALFA + LUTROPIN ALFA" mediatype="application/vnd.pageseeder.psml+xml"><document id="60393" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60393" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/IF/drug/319511000144102-G03GA.psml" decodedpath="/ps/test/local3/books/dynamic/IF/drug/319511000144102-G03GA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:27+10:00" modified="2018-06-15T10:34:22+10:00" title="FOLLITROPIN ALFA + LUTROPIN ALFA"><displaytitle>FOLLITROPIN ALFA + LUTROPIN ALFA</displaytitle></uri><reversexrefs><reversexref uriid="59858" href="dynamic/IF/atc/G.psml" frag="G03GA319511000144102" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml" id="105533" title="IF" type="none" forwardtype="embed" forwardtitle="FOLLITROPIN ALFA + LUTROPIN ALFA" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60393-319511000144102-1"><fragment id="60393-319511000144102-1"><block label="DrugName">FOLLITROPIN ALFA + LUTROPIN ALFA<inline label="genericindexfield">XE "FOLLITROPIN ALFA + LUTROPIN ALFA"</inline></block></fragment></section><section id="60393-d5578e16"><fragment id="60393-d5578e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5250</block><block label="RestrictionText"><para>Stimulation of follicular development</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have severe LH deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be considered appropriate for treatment with the combination product after titration of FSH and LH after at least one cycle of treatment,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule.</para></item></list></block></fragment></section><section id="60393-10491E"><fragment id="60393-10491E"><block label="FormAndStrength">follitropin alfa 150 units + lutropin alfa 75 units [1 vial] (&amp;) inert substance diluent [1 vial], 1 pack</block><table role="IF"><row><cell><block label="DrugItemCode">10491E<br></br></block></cell><cell><block label="MaxQuantity">14</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>2186.95</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Pergoveris [SG]<inline label="genericindexfieldbrand"><italic>XE "Pergoveris(SG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59858-G03GA21333011000036104"><xref-fragment id="59858-G03GA21333011000036104"><blockxref id="105526" title="FOLLITROPIN BETA" frag="default" reversefrag="G03GA21333011000036104" reversetitle="IF" reverselink="true" reversetype="none" display="document" type="embed" uriid="59836" href="dynamic/IF/drug/21333011000036104-G03GA.psml" urititle="FOLLITROPIN BETA" mediatype="application/vnd.pageseeder.psml+xml"><document id="59836" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="59836" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/IF/drug/21333011000036104-G03GA.psml" decodedpath="/ps/test/local3/books/dynamic/IF/drug/21333011000036104-G03GA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:22+10:00" title="FOLLITROPIN BETA"><displaytitle>FOLLITROPIN BETA</displaytitle></uri><reversexrefs><reversexref uriid="59858" href="dynamic/IF/atc/G.psml" frag="G03GA21333011000036104" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml" id="105526" title="IF" type="none" forwardtype="embed" forwardtitle="FOLLITROPIN BETA" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59836-21333011000036104-1"><fragment id="59836-21333011000036104-1"><block label="DrugName">FOLLITROPIN BETA<inline label="genericindexfield">XE "FOLLITROPIN BETA"</inline></block></fragment></section><section id="59836-d5580e16"><fragment id="59836-d5580e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5027</block><block label="RestrictionText"><para>Assisted Reproductive Technology</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving medical services as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule.</para></item></list></block></fragment></section><section id="59836-6335K"><fragment id="59836-6335K"><block label="FormAndStrength">follitropin beta 300 units/0.36 mL injection, 0.36 mL cartridge</block><table role="IF"><row><cell><block label="DrugItemCode">6335K<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>303.55</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Puregon 300 IU/0.36 mL [MK]<inline label="genericindexfieldbrand"><italic>XE "Puregon 300 IU/0.36 mL(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59836-6464F"><fragment id="59836-6464F"><block label="FormAndStrength">follitropin beta 900 units/1.08 mL injection, 1.08 mL cartridge</block><table role="IF"><row><cell><block label="DrugItemCode">6464F<br></br></block></cell><cell><block label="MaxQuantity">5</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>2114.10</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Puregon 900 IU/1.08 mL [MK]<inline label="genericindexfieldbrand"><italic>XE "Puregon 900 IU/1.08 mL(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59836-6336L"><fragment id="59836-6336L"><block label="FormAndStrength">follitropin beta 600 units/0.72 mL injection, 0.72 mL cartridge</block><table role="IF"><row><cell><block label="DrugItemCode">6336L<br></br></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1159.47</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Puregon 600 IU/0.72 mL [MK]<inline label="genericindexfieldbrand"><italic>XE "Puregon 600 IU/0.72 mL(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59858-G03GA33633011000036101"><xref-fragment id="59858-G03GA33633011000036101"><blockxref id="105528" title="HUMAN CHORIONIC GONADOTROPHIN" frag="default" reversefrag="G03GA33633011000036101" reversetitle="IF" reverselink="true" reversetype="none" display="document" type="embed" uriid="59930" href="dynamic/IF/drug/33633011000036101-G03GA.psml" urititle="HUMAN CHORIONIC GONADOTROPHIN" mediatype="application/vnd.pageseeder.psml+xml"><document id="59930" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="59930" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/IF/drug/33633011000036101-G03GA.psml" decodedpath="/ps/test/local3/books/dynamic/IF/drug/33633011000036101-G03GA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:22+10:00" title="HUMAN CHORIONIC GONADOTROPHIN"><displaytitle>HUMAN CHORIONIC GONADOTROPHIN</displaytitle></uri><reversexrefs><reversexref uriid="59858" href="dynamic/IF/atc/G.psml" frag="G03GA33633011000036101" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml" id="105528" title="IF" type="none" forwardtype="embed" forwardtitle="HUMAN CHORIONIC GONADOTROPHIN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59930-33633011000036101-1"><fragment id="59930-33633011000036101-1"><block label="DrugName">HUMAN CHORIONIC GONADOTROPHIN<inline label="genericindexfield">XE "HUMAN CHORIONIC GONADOTROPHIN"</inline></block></fragment></section><section id="59930-d5582e16"><fragment id="59930-d5582e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">6991</block><block label="RestrictionText"><para>Assisted Reproductive Technology</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving medical services as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule.</para></item></list></block></fragment></section><section id="59930-11154C"><fragment id="59930-11154C"><block label="FormAndStrength">human chorionic gonadotrophin 1500 units injection [3 vials] (&amp;) inert substance diluent [3 x 1 mL vials], 1 pack</block><table role="IF"><row><cell><block label="DrugItemCode">11154C<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">41.89</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Pregnyl [MK]<inline label="genericindexfieldbrand"><italic>XE "Pregnyl(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59930-11156E"><fragment id="59930-11156E"><block label="FormAndStrength">human chorionic gonadotrophin 5000 units injection [1 vial] (&amp;) inert substance diluent [1 mL vial], 1 pack</block><table role="IF"><row><cell><block label="DrugItemCode">11156E<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>27.33</block></cell><cell><block label="MRVSN">28.54</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Pregnyl [MK]<inline label="genericindexfieldbrand"><italic>XE "Pregnyl(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59858-G03GA74621000036103"><xref-fragment id="59858-G03GA74621000036103"><blockxref id="105527" title="HUMAN MENOPAUSAL GONADOTROPHIN" frag="default" reversefrag="G03GA74621000036103" reversetitle="IF" reverselink="true" reversetype="none" display="document" type="embed" uriid="60394" href="dynamic/IF/drug/74621000036103-G03GA.psml" urititle="HUMAN MENOPAUSAL GONADOTROPHIN" mediatype="application/vnd.pageseeder.psml+xml"><document id="60394" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60394" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/IF/drug/74621000036103-G03GA.psml" decodedpath="/ps/test/local3/books/dynamic/IF/drug/74621000036103-G03GA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:27+10:00" modified="2018-06-15T10:34:22+10:00" title="HUMAN MENOPAUSAL GONADOTROPHIN"><displaytitle>HUMAN MENOPAUSAL GONADOTROPHIN</displaytitle></uri><reversexrefs><reversexref uriid="59858" href="dynamic/IF/atc/G.psml" frag="G03GA74621000036103" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml" id="105527" title="IF" type="none" forwardtype="embed" forwardtitle="HUMAN MENOPAUSAL GONADOTROPHIN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60394-74621000036103-1"><fragment id="60394-74621000036103-1"><block label="DrugName">HUMAN MENOPAUSAL GONADOTROPHIN<inline label="genericindexfield">XE "HUMAN MENOPAUSAL GONADOTROPHIN"</inline></block></fragment></section><section id="60394-d5584e16"><fragment id="60394-d5584e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5027</block><block label="RestrictionText"><para>Assisted Reproductive Technology</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be receiving medical services as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule.</para></item></list></block></fragment></section><section id="60394-2036E"><fragment id="60394-2036E"><block label="FormAndStrength">human menopausal gonadotrophin 600 units injection [1 vial] (&amp;) inert substance diluent [1 mL syringe], 1 pack</block><table role="IF"><row><cell><block label="DrugItemCode">2036E<br></br></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>794.35</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Menopur 600 [FP]<inline label="genericindexfieldbrand"><italic>XE "Menopur 600(FP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60394-2038G"><fragment id="60394-2038G"><block label="FormAndStrength">human menopausal gonadotrophin 1200 units injection [1 vial] (&amp;) inert substance diluent [2 x 1 mL syringes], 1 pack</block><table role="IF"><row><cell><block label="DrugItemCode">2038G<br></br></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>2065.63</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Menopur 1200 [FP]<inline label="genericindexfieldbrand"><italic>XE "Menopur 1200(FP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59858-G03GA44973011000036102"><xref-fragment id="59858-G03GA44973011000036102"><blockxref id="105530" title="LUTROPIN ALFA" frag="default" reversefrag="G03GA44973011000036102" reversetitle="IF" reverselink="true" reversetype="none" display="document" type="embed" uriid="60507" href="dynamic/IF/drug/44973011000036102-G03GA.psml" urititle="LUTROPIN ALFA" mediatype="application/vnd.pageseeder.psml+xml"><document id="60507" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="60507" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/IF/drug/44973011000036102-G03GA.psml" decodedpath="/ps/test/local3/books/dynamic/IF/drug/44973011000036102-G03GA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:22+10:00" title="LUTROPIN ALFA"><displaytitle>LUTROPIN ALFA</displaytitle></uri><reversexrefs><reversexref uriid="59858" href="dynamic/IF/atc/G.psml" frag="G03GA44973011000036102" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml" id="105530" title="IF" type="none" forwardtype="embed" forwardtitle="LUTROPIN ALFA" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60507-44973011000036102-1"><fragment id="60507-44973011000036102-1"><block label="DrugName">LUTROPIN ALFA<inline label="genericindexfield">XE "LUTROPIN ALFA"</inline></block></fragment></section><section id="60507-d5586e16"><fragment id="60507-d5586e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5251</block><block label="RestrictionText"><para>Stimulation of follicular development</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have severe LH deficiency,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule.</para></item></list></block></fragment></section><section id="60507-10465T"><fragment id="60507-10465T"><block label="FormAndStrength">lutropin alfa 75 units injection [1 vial] (&amp;) inert substance diluent [1 mL vial], 1 pack</block><table role="IF"><row><cell><block label="DrugItemCode">10465T<br></br></block></cell><cell><block label="MaxQuantity">14</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>1422.69</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Luveris [SG]<inline label="genericindexfieldbrand"><italic>XE "Luveris(SG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref><blockxref id="107078" title="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" frag="default" reversefrag="d114e908155" reversetitle="IF" reverselink="true" reversetype="none" display="document" type="embed" uriid="60828" href="dynamic/IF/atc/H.psml" urititle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" mediatype="application/vnd.pageseeder.psml+xml"><document id="60828" schemaversion="0.12" date="2018-06-15T10:35:15+10:00" version="current" level="processed"><documentinfo><uri id="60828" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/IF/atc/H.psml" decodedpath="/ps/test/local3/books/dynamic/IF/atc/H.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:35:15+10:00" title="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS"><displaytitle>SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</displaytitle></uri><reversexrefs><reversexref uriid="59964" href="dynamic/IF/therapeuticindex-IF.psml" frag="2" urititle="Therapeutic Index - IVF Treatment Program - IF" mediatype="application/vnd.pageseeder.psml+xml" id="105988" title="Untitled" type="none" forwardtype="none" forwardtitle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60524" href="dynamic/IF.psml" frag="d114e908155" urititle="IVF Treatment Program" mediatype="application/vnd.pageseeder.psml+xml" id="107078" title="IF" type="none" forwardtype="embed" forwardtitle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="44803" fragment="60828-H01CA21756011000036105" editid="107745" modified="2018-06-15T10:34:32+10:00"></locator><locator id="44801" fragment="60828-H01CC44862011000036109" editid="107744" modified="2018-06-15T10:34:32+10:00"></locator><locator id="44805" fragment="60828-H01CC44872011000036102" editid="107746" modified="2018-06-15T10:34:32+10:00"></locator><locator id="43074" fragment="60828-H01"><reversexrefs><reversexref uriid="59964" href="dynamic/IF/therapeuticindex-IF.psml" frag="2" urititle="Therapeutic Index - IVF Treatment Program - IF" mediatype="application/vnd.pageseeder.psml+xml" id="105989" title="Untitled" type="none" forwardtype="none" forwardtitle="PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES" forwarddisplay="document" forwardfrag="H01"></reversexref></reversexrefs></locator><locator id="43075" fragment="60828-H01C"><reversexrefs><reversexref uriid="59964" href="dynamic/IF/therapeuticindex-IF.psml" frag="2" urititle="Therapeutic Index - IVF Treatment Program - IF" mediatype="application/vnd.pageseeder.psml+xml" id="105990" title="Untitled" type="none" forwardtype="none" forwardtitle="HYPOTHALAMIC HORMONES" forwarddisplay="document" forwardfrag="H01C"></reversexref></reversexrefs></locator></fragmentinfo><metadata></metadata><section id="60828-H"><fragment id="60828-H"><block label="ATCLevel1"><para>SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</para></block></fragment></section><section id="60828-H01"><fragment id="60828-H01"><block label="ATCLevel2"><para>PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES</para></block></fragment></section><section id="60828-H01C"><fragment id="60828-H01C"><block label="ATCLevel3"><para>HYPOTHALAMIC HORMONES</para></block></fragment></section><section id="60828-H01CA"><fragment id="60828-H01CA"><block label="ATCLevel4"><para>Gonadotropin-releasing hormones</para></block></fragment></section><section id="60828-H01CA21756011000036105"><xref-fragment id="60828-H01CA21756011000036105"><blockxref id="107742" title="NAFARELIN" frag="default" reversefrag="H01CA21756011000036105" reversetitle="IF" reverselink="true" reversetype="none" display="document" type="embed" uriid="59590" href="dynamic/IF/drug/21756011000036105-H01CA.psml" urititle="NAFARELIN" mediatype="application/vnd.pageseeder.psml+xml"><document id="59590" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="59590" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/IF/drug/21756011000036105-H01CA.psml" decodedpath="/ps/test/local3/books/dynamic/IF/drug/21756011000036105-H01CA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:18+10:00" modified="2018-06-15T10:34:32+10:00" title="NAFARELIN"><displaytitle>NAFARELIN</displaytitle></uri><reversexrefs><reversexref uriid="60828" href="dynamic/IF/atc/H.psml" frag="H01CA21756011000036105" urititle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" mediatype="application/vnd.pageseeder.psml+xml" id="107742" title="IF" type="none" forwardtype="embed" forwardtitle="NAFARELIN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59590-21756011000036105-1"><fragment id="59590-21756011000036105-1"><block label="DrugName">NAFARELIN<inline label="genericindexfield">XE "NAFARELIN"</inline></block></fragment></section><section id="59590-d5588e16"><fragment id="59590-d5588e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5046</block><block label="RestrictionText"><para>Assisted Reproductive Technology</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be for prevention of premature luteinisation and ovulation,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing controlled ovarian stimulation,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be receiving medical services as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule.</para></item></list></block></fragment></section><section id="59590-5815C"><fragment id="59590-5815C"><block label="FormAndStrength">nafarelin 200 microgram/actuation nasal spray, 60 actuations</block><table role="IF"><row><cell><block label="DrugItemCode">5815C<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>227.63</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Synarel [PF]<inline label="genericindexfieldbrand"><italic>XE "Synarel(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60828-H01CC"><fragment id="60828-H01CC"><block label="ATCLevel4"><para>Anti-gonadotropin-releasing hormones</para></block></fragment></section><section id="60828-H01CC44872011000036102"><xref-fragment id="60828-H01CC44872011000036102"><blockxref id="107743" title="CETRORELIX" frag="default" reversefrag="H01CC44872011000036102" reversetitle="IF" reverselink="true" reversetype="none" display="document" type="embed" uriid="59658" href="dynamic/IF/drug/44872011000036102-H01CC.psml" urititle="CETRORELIX" mediatype="application/vnd.pageseeder.psml+xml"><document id="59658" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="59658" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/IF/drug/44872011000036102-H01CC.psml" decodedpath="/ps/test/local3/books/dynamic/IF/drug/44872011000036102-H01CC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:19+10:00" modified="2018-06-15T10:34:32+10:00" title="CETRORELIX"><displaytitle>CETRORELIX</displaytitle></uri><reversexrefs><reversexref uriid="60828" href="dynamic/IF/atc/H.psml" frag="H01CC44872011000036102" urititle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" mediatype="application/vnd.pageseeder.psml+xml" id="107743" title="IF" type="none" forwardtype="embed" forwardtitle="CETRORELIX" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59658-44872011000036102-1"><fragment id="59658-44872011000036102-1"><block label="DrugName">CETRORELIX<inline label="genericindexfield">XE "CETRORELIX"</inline></block></fragment></section><section id="59658-d5590e16"><fragment id="59658-d5590e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5046</block><block label="RestrictionText"><para>Assisted Reproductive Technology</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be for prevention of premature luteinisation and ovulation,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing controlled ovarian stimulation,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be receiving medical services as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule.</para></item></list></block></fragment></section><section id="59658-9599F"><fragment id="59658-9599F"><block label="FormAndStrength">cetrorelix 250 microgram injection [1 vial] (&amp;) inert substance diluent [1 mL syringe], 1 pack</block><table role="IF"><row><cell><block label="DrugItemCode">9599F<br></br></block></cell><cell><block label="MaxQuantity">10</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>462.45</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Cetrotide [SG]<inline label="genericindexfieldbrand"><italic>XE "Cetrotide(SG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60828-H01CC44862011000036109"><xref-fragment id="60828-H01CC44862011000036109"><blockxref id="107741" title="GANIRELIX" frag="default" reversefrag="H01CC44862011000036109" reversetitle="IF" reverselink="true" reversetype="none" display="document" type="embed" uriid="60806" href="dynamic/IF/drug/44862011000036109-H01CC.psml" urititle="GANIRELIX" mediatype="application/vnd.pageseeder.psml+xml"><document id="60806" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="60806" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/IF/drug/44862011000036109-H01CC.psml" decodedpath="/ps/test/local3/books/dynamic/IF/drug/44862011000036109-H01CC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:32+10:00" title="GANIRELIX"><displaytitle>GANIRELIX</displaytitle></uri><reversexrefs><reversexref uriid="60828" href="dynamic/IF/atc/H.psml" frag="H01CC44862011000036109" urititle="SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS" mediatype="application/vnd.pageseeder.psml+xml" id="107741" title="IF" type="none" forwardtype="embed" forwardtitle="GANIRELIX" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60806-44862011000036109-1"><fragment id="60806-44862011000036109-1"><block label="DrugName">GANIRELIX<inline label="genericindexfield">XE "GANIRELIX"</inline></block></fragment></section><section id="60806-d5592e16"><fragment id="60806-d5592e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5046</block><block label="RestrictionText"><para>Assisted Reproductive Technology</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be for prevention of premature luteinisation and ovulation,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing controlled ovarian stimulation,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be receiving medical services as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule.</para></item></list></block></fragment></section><section id="60806-9584K"><fragment id="60806-9584K"><block label="FormAndStrength">ganirelix 250 microgram/0.5 mL injection, 5 x 0.5 mL syringes</block><table role="IF"><row><cell><block label="DrugItemCode">9584K<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>462.47</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Orgalutran [MK]<inline label="genericindexfieldbrand"><italic>XE "Orgalutran(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60806-9583J"><fragment id="60806-9583J"><block label="FormAndStrength">ganirelix 250 microgram/0.5 mL injection, 0.5 mL syringe</block><table role="IF"><row><cell><block label="DrugItemCode">9583J<br></br></block></cell><cell><block label="MaxQuantity">10</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>462.45</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Orgalutran [MK]<inline label="genericindexfieldbrand"><italic>XE "Orgalutran(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref><blockxref id="107079" title="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" frag="default" reversefrag="d114e908155" reversetitle="IF" reverselink="true" reversetype="none" display="document" type="embed" uriid="60679" href="dynamic/IF/atc/L.psml" urititle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" mediatype="application/vnd.pageseeder.psml+xml"><document id="60679" schemaversion="0.12" date="2018-06-15T10:35:08+10:00" version="current" level="processed"><documentinfo><uri id="60679" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/IF/atc/L.psml" decodedpath="/ps/test/local3/books/dynamic/IF/atc/L.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:30+10:00" modified="2018-06-15T10:35:08+10:00" title="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"><displaytitle>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</displaytitle></uri><reversexrefs><reversexref uriid="59964" href="dynamic/IF/therapeuticindex-IF.psml" frag="2" urititle="Therapeutic Index - IVF Treatment Program - IF" mediatype="application/vnd.pageseeder.psml+xml" id="105991" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60524" href="dynamic/IF.psml" frag="d114e908155" urititle="IVF Treatment Program" mediatype="application/vnd.pageseeder.psml+xml" id="107079" title="IF" type="none" forwardtype="embed" forwardtitle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="43077" fragment="60679-L02"><reversexrefs><reversexref uriid="59964" href="dynamic/IF/therapeuticindex-IF.psml" frag="2" urititle="Therapeutic Index - IVF Treatment Program - IF" mediatype="application/vnd.pageseeder.psml+xml" id="105992" title="Untitled" type="none" forwardtype="none" forwardtitle="ENDOCRINE THERAPY" forwarddisplay="document" forwardfrag="L02"></reversexref></reversexrefs></locator><locator id="43078" fragment="60679-L02A"><reversexrefs><reversexref uriid="59964" href="dynamic/IF/therapeuticindex-IF.psml" frag="2" urititle="Therapeutic Index - IVF Treatment Program - IF" mediatype="application/vnd.pageseeder.psml+xml" id="105993" title="Untitled" type="none" forwardtype="none" forwardtitle="HORMONES AND RELATED AGENTS" forwarddisplay="document" forwardfrag="L02A"></reversexref></reversexrefs></locator><locator id="44285" fragment="60679-L02AE52800011000036105" editid="107210" modified="2018-06-15T10:34:30+10:00"></locator></fragmentinfo><metadata></metadata><section id="60679-L"><fragment id="60679-L"><block label="ATCLevel1"><para>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</para></block></fragment></section><section id="60679-L02"><fragment id="60679-L02"><block label="ATCLevel2"><para>ENDOCRINE THERAPY</para></block></fragment></section><section id="60679-L02A"><fragment id="60679-L02A"><block label="ATCLevel3"><para>HORMONES AND RELATED AGENTS</para></block></fragment></section><section id="60679-L02AE"><fragment id="60679-L02AE"><block label="ATCLevel4"><para>Gonadotropin releasing hormone analogues</para></block></fragment></section><section id="60679-L02AE52800011000036105"><xref-fragment id="60679-L02AE52800011000036105"><blockxref id="107209" title="TRIPTORELIN" frag="default" reversefrag="L02AE52800011000036105" reversetitle="IF" reverselink="true" reversetype="none" display="document" type="embed" uriid="60861" href="dynamic/IF/drug/52800011000036105-L02AE.psml" urititle="TRIPTORELIN" mediatype="application/vnd.pageseeder.psml+xml"><document id="60861" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60861" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/IF/drug/52800011000036105-L02AE.psml" decodedpath="/ps/test/local3/books/dynamic/IF/drug/52800011000036105-L02AE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:30+10:00" title="TRIPTORELIN"><displaytitle>TRIPTORELIN</displaytitle></uri><reversexrefs><reversexref uriid="60679" href="dynamic/IF/atc/L.psml" frag="L02AE52800011000036105" urititle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" mediatype="application/vnd.pageseeder.psml+xml" id="107209" title="IF" type="none" forwardtype="embed" forwardtitle="TRIPTORELIN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60861-52800011000036105-1"><fragment id="60861-52800011000036105-1"><block label="DrugName">TRIPTORELIN<inline label="genericindexfield">XE "TRIPTORELIN"</inline></block></fragment></section><section id="60861-d5594e16"><fragment id="60861-d5594e16"><block label="RestrictionHead"><para>Authority required (STREAMLINED)</para></block><block label="RestrictionNumber">5046</block><block label="RestrictionText"><para>Assisted Reproductive Technology</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be for prevention of premature luteinisation and ovulation,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing controlled ovarian stimulation,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be receiving medical services as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule.</para></item></list></block></fragment></section><section id="60861-10907C"><fragment id="60861-10907C"><block label="FormAndStrength">triptorelin acetate 100 microgram/mL injection, 7 x 1 mL syringes</block><table role="IF"><row><cell><block label="DrugItemCode">10907C<br></br></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>216.59</block></cell><cell><block label="MRVSN">39.50</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Decapeptyl [FP]<inline label="genericindexfieldbrand"><italic>XE "Decapeptyl(FP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref></xref-fragment></section></document></blockxref>
<blockxref id="107711" title="therapeuticindex-MD.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="59934" href="dynamic/MD/therapeuticindex-MD.psml" urititle="Therapeutic Index - Opiate Dependence Treatment Program - MD" mediatype="application/vnd.pageseeder.psml+xml"><document id="59934" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="59934" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/MD/therapeuticindex-MD.psml" decodedpath="/ps/test/local3/books/dynamic/MD/therapeuticindex-MD.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:32+10:00" title="Therapeutic Index - Opiate Dependence Treatment Program - MD"><displaytitle>Therapeutic Index - Opiate Dependence Treatment Program - MD</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107711" title="" type="none" forwardtype="embed" forwardtitle="therapeuticindex-MD.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="43027" fragment="59934-2" editid="105941" modified="2018-06-15T10:34:22+10:00"></locator></fragmentinfo><metadata></metadata><section id="59934-1"><fragment id="59934-1"><block label="mps3indexsectionbreak">MD</block><block label="schedule-heading">Opiate Dependence Treatment Program</block></fragment><fragment id="59934-2"><block label="index"><para>NERVOUS SYSTEM<inline label="indexpageref"><xref id="105938" title="NERVOUS SYSTEM" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60437" href="#60437" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block><block label="index2"><para indent="1">OTHER NERVOUS SYSTEM DRUGS<inline label="indexpageref"><xref id="105939" title="OTHER NERVOUS SYSTEM DRUGS" frag="N07" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60437" href="#60437-N07" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block><block label="index3"><para indent="2">DRUGS USED IN ADDICTIVE DISORDERS<inline label="indexpageref"><xref id="105940" title="DRUGS USED IN ADDICTIVE DISORDERS" frag="N07B" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60437" href="#60437-N07B" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block></fragment></section></document></blockxref>
<blockxref id="107712" title="MD.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="59819" href="dynamic/MD.psml" urititle="Opiate Dependence Treatment Program" mediatype="application/vnd.pageseeder.psml+xml"><document id="59819" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="59819" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/MD.psml" decodedpath="/ps/test/local3/books/dynamic/MD.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:32+10:00" title="Opiate Dependence Treatment Program"><displaytitle>Opiate Dependence Treatment Program</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107712" title="" type="none" forwardtype="embed" forwardtitle="MD.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="42347" fragment="59819-d114e907011" editid="105258" modified="2018-06-15T10:34:21+10:00"></locator></fragmentinfo><metadata></metadata><section id="59819-1"><fragment id="59819-1"><block label="mps3sectionbreak">MD</block></fragment></section><section id="59819-d114e907011"><xref-fragment id="59819-d114e907011"><blockxref id="105257" title="NERVOUS SYSTEM" frag="default" reversefrag="d114e907011" reversetitle="MD" reverselink="true" reversetype="none" display="document" type="embed" uriid="60437" href="dynamic/MD/atc/N.psml" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml"><document id="60437" schemaversion="0.12" date="2018-06-15T10:34:59+10:00" version="current" level="processed"><documentinfo><uri id="60437" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/MD/atc/N.psml" decodedpath="/ps/test/local3/books/dynamic/MD/atc/N.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:59+10:00" title="NERVOUS SYSTEM"><displaytitle>NERVOUS SYSTEM</displaytitle></uri><reversexrefs><reversexref uriid="59819" href="dynamic/MD.psml" frag="d114e907011" urititle="Opiate Dependence Treatment Program" mediatype="application/vnd.pageseeder.psml+xml" id="105257" title="MD" type="none" forwardtype="embed" forwardtitle="NERVOUS SYSTEM" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="59934" href="dynamic/MD/therapeuticindex-MD.psml" frag="2" urititle="Therapeutic Index - Opiate Dependence Treatment Program - MD" mediatype="application/vnd.pageseeder.psml+xml" id="105938" title="Untitled" type="none" forwardtype="none" forwardtitle="NERVOUS SYSTEM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="43627" fragment="60437-N07BC21232011000036101" editid="106544" modified="2018-06-15T10:34:28+10:00"></locator><locator id="43623" fragment="60437-N07BC21739011000036100" editid="106542" modified="2018-06-15T10:34:28+10:00"></locator><locator id="43028" fragment="60437-N07"><reversexrefs><reversexref uriid="59934" href="dynamic/MD/therapeuticindex-MD.psml" frag="2" urititle="Therapeutic Index - Opiate Dependence Treatment Program - MD" mediatype="application/vnd.pageseeder.psml+xml" id="105939" title="Untitled" type="none" forwardtype="none" forwardtitle="OTHER NERVOUS SYSTEM DRUGS" forwarddisplay="document" forwardfrag="N07"></reversexref></reversexrefs></locator><locator id="43029" fragment="60437-N07B"><reversexrefs><reversexref uriid="59934" href="dynamic/MD/therapeuticindex-MD.psml" frag="2" urititle="Therapeutic Index - Opiate Dependence Treatment Program - MD" mediatype="application/vnd.pageseeder.psml+xml" id="105940" title="Untitled" type="none" forwardtype="none" forwardtitle="DRUGS USED IN ADDICTIVE DISORDERS" forwarddisplay="document" forwardfrag="N07B"></reversexref></reversexrefs></locator><locator id="43625" fragment="60437-N07BC21357011000036109" editid="106543" modified="2018-06-15T10:34:28+10:00"></locator></fragmentinfo><metadata></metadata><section id="60437-N"><fragment id="60437-N"><block label="ATCLevel1"><para>NERVOUS SYSTEM</para></block></fragment></section><section id="60437-N07"><fragment id="60437-N07"><block label="ATCLevel2"><para>OTHER NERVOUS SYSTEM DRUGS</para></block></fragment></section><section id="60437-N07B"><fragment id="60437-N07B"><block label="ATCLevel3"><para>DRUGS USED IN ADDICTIVE DISORDERS</para></block></fragment></section><section id="60437-N07BC"><fragment id="60437-N07BC"><block label="ATCLevel4"><para>Drugs used in opioid dependence</para></block></fragment></section><section id="60437-N07BC21232011000036101"><xref-fragment id="60437-N07BC21232011000036101"><blockxref id="106541" title="BUPRENORPHINE" frag="default" reversefrag="N07BC21232011000036101" reversetitle="MD" reverselink="true" reversetype="none" display="document" type="embed" uriid="60871" href="dynamic/MD/drug/21232011000036101-N07BC.psml" urititle="BUPRENORPHINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60871" schemaversion="0.12" date="2018-06-15T10:34:28+10:00" version="current" level="processed"><documentinfo><uri id="60871" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/MD/drug/21232011000036101-N07BC.psml" decodedpath="/ps/test/local3/books/dynamic/MD/drug/21232011000036101-N07BC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:28+10:00" title="BUPRENORPHINE"><displaytitle>BUPRENORPHINE</displaytitle></uri><reversexrefs><reversexref uriid="60437" href="dynamic/MD/atc/N.psml" frag="N07BC21232011000036101" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="106541" title="MD" type="none" forwardtype="embed" forwardtitle="BUPRENORPHINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60871-21232011000036101-1"><fragment id="60871-21232011000036101-1"><block label="DrugName">BUPRENORPHINE<inline label="genericindexfield">XE "BUPRENORPHINE:.Opiate Dependence Treatment Program"</inline></block></fragment></section><section id="60871-d5562e28"><fragment id="60871-d5562e28"><block label="NoteText"><para>Care must be taken to comply with the provisions of State/Territory law when prescribing this drug.</para></block></fragment></section><section id="60871-d5562e31"><fragment id="60871-d5562e31"><block label="NoteText"><para><bold>Shared Care Model</bold>:</para><para>For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.</para></block></fragment></section><section id="60871-d5562e16"><fragment id="60871-d5562e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Opiate dependence</para><para>Treatment Phase: Maintenance and detoxification (withdrawal)</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be within a framework of medical, social and psychological treatment.</para></item></list></block></fragment></section><section id="60871-6308B"><fragment id="60871-6308B"><block label="FormAndStrength">buprenorphine 2 mg sublingual tablet, 7</block><table role="MD"><row><cell><block label="DrugItemCode">6308B<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="DPMQ">9.98</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Subutex [IR]<inline label="genericindexfieldbrand"><italic>XE "Subutex(IR)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60871-6309C"><fragment id="60871-6309C"><block label="FormAndStrength">buprenorphine 8 mg tablet, 7</block><table role="MD"><row><cell><block label="DrugItemCode">6309C<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="DPMQ">28.60</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Subutex [IR]<inline label="genericindexfieldbrand"><italic>XE "Subutex(IR)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60871-6307Y"><fragment id="60871-6307Y"><block label="FormAndStrength">buprenorphine 400 microgram sublingual tablet, 7</block><table role="MD"><row><cell><block label="DrugItemCode">6307Y<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="DPMQ">5.85</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Subutex [IR]<inline label="genericindexfieldbrand"><italic>XE "Subutex(IR)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60437-N07BC21739011000036100"><xref-fragment id="60437-N07BC21739011000036100"><blockxref id="106539" title="BUPRENORPHINE + NALOXONE" frag="default" reversefrag="N07BC21739011000036100" reversetitle="MD" reverselink="true" reversetype="none" display="document" type="embed" uriid="60454" href="dynamic/MD/drug/21739011000036100-N07BC.psml" urititle="BUPRENORPHINE + NALOXONE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60454" schemaversion="0.12" date="2018-06-15T10:34:28+10:00" version="current" level="processed"><documentinfo><uri id="60454" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/MD/drug/21739011000036100-N07BC.psml" decodedpath="/ps/test/local3/books/dynamic/MD/drug/21739011000036100-N07BC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:28+10:00" title="BUPRENORPHINE + NALOXONE"><displaytitle>BUPRENORPHINE + NALOXONE</displaytitle></uri><reversexrefs><reversexref uriid="60437" href="dynamic/MD/atc/N.psml" frag="N07BC21739011000036100" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="106539" title="MD" type="none" forwardtype="embed" forwardtitle="BUPRENORPHINE + NALOXONE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60454-21739011000036100-1"><fragment id="60454-21739011000036100-1"><block label="DrugName">BUPRENORPHINE + NALOXONE<inline label="genericindexfield">XE "BUPRENORPHINE + NALOXONE"</inline></block></fragment></section><section id="60454-d5564e26"><fragment id="60454-d5564e26"><block label="NoteText"><para>Buprenorphine with naloxone soluble film and buprenorphine with naloxone sublingual tablet do not meet all the criteria for bioequivalence. Patients being switched between sublingual tablets and soluble films may therefore require a dosage adjustment.</para></block></fragment></section><section id="60454-d5564e29"><fragment id="60454-d5564e29"><block label="NoteText"><para>Care must be taken to comply with the provisions of State/Territory law when prescribing this drug.</para></block></fragment></section><section id="60454-d5564e32"><fragment id="60454-d5564e32"><block label="NoteText"><para><bold>Shared Care Model</bold>:</para><para>For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.</para></block></fragment></section><section id="60454-d5564e16"><fragment id="60454-d5564e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Opiate dependence</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be within a framework of medical, social and psychological treatment.</para></item></list></block></fragment></section><section id="60454-9749D"><fragment id="60454-9749D"><block label="FormAndStrength">buprenorphine 2 mg + naloxone 500 microgram sublingual film, 28</block><table role="MD"><row><cell><block label="DrugItemCode">9749D<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="DPMQ">46.20</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Suboxone Film 2/0.5 [IR]<inline label="genericindexfieldbrand"><italic>XE "Suboxone Film 2/0.5(IR)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60454-9750E"><fragment id="60454-9750E"><block label="FormAndStrength">buprenorphine 8 mg + naloxone 2 mg sublingual film, 28</block><table role="MD"><row><cell><block label="DrugItemCode">9750E<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="DPMQ">132.44</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Suboxone Film 8/2 [IR]<inline label="genericindexfieldbrand"><italic>XE "Suboxone Film 8/2(IR)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60437-N07BC21357011000036109"><xref-fragment id="60437-N07BC21357011000036109"><blockxref id="106540" title="METHADONE" frag="default" reversefrag="N07BC21357011000036109" reversetitle="MD" reverselink="true" reversetype="none" display="document" type="embed" uriid="60800" href="dynamic/MD/drug/21357011000036109-N07BC.psml" urititle="METHADONE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60800" schemaversion="0.12" date="2018-06-15T10:34:28+10:00" version="current" level="processed"><documentinfo><uri id="60800" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/MD/drug/21357011000036109-N07BC.psml" decodedpath="/ps/test/local3/books/dynamic/MD/drug/21357011000036109-N07BC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:28+10:00" title="METHADONE"><displaytitle>METHADONE</displaytitle></uri><reversexrefs><reversexref uriid="60437" href="dynamic/MD/atc/N.psml" frag="N07BC21357011000036109" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="106540" title="MD" type="none" forwardtype="embed" forwardtitle="METHADONE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60800-21357011000036109-1"><fragment id="60800-21357011000036109-1"><block label="DrugName">METHADONE<inline label="genericindexfield">XE "METHADONE:.Opiate Dependence Treatment Program"</inline></block></fragment></section><section id="60800-d5566e15"><fragment id="60800-d5566e15"><block label="CautionText"><para>The risk of drug dependence is high.</para></block></fragment></section><section id="60800-d5566e22"><fragment id="60800-d5566e22"><block label="NoteText"><para>Care must be taken to comply with the provisions of State/Territory law when prescribing this drug.</para></block></fragment></section><section id="60800-d5566e25"><fragment id="60800-d5566e25"><block label="NoteText"><para><bold>Shared Care Model</bold>:</para><para>For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.</para></block></fragment></section><section id="60800-d5566e19"><fragment id="60800-d5566e19"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Opiate dependence</para></block></fragment></section><section id="60800-6172W"><fragment id="60800-6172W"><block label="FormAndStrength">methadone hydrochloride 5 mg/mL oral liquid, 1 L</block><table role="MD"><row><cell><block label="DrugItemCode">6172W<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="DPMQ">33.20</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Aspen Methadone Syrup [QA]<inline label="genericindexfieldbrand"><italic>XE "Aspen Methadone Syrup(QA):.Opiate Dependence Treatment Program" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Biodone Forte [MW]<inline label="genericindexfieldbrand"><italic>XE "Biodone Forte (MW)" \i </italic></inline></block></cell></row></table></fragment></section><section id="60800-6171T"><fragment id="60800-6171T"><block label="FormAndStrength">methadone hydrochloride 5 mg/mL oral liquid, 200 mL</block><table role="MD"><row><cell><block label="DrugItemCode">6171T<br></br><inline label="Nurse">NP</inline></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="DPMQ">7.91</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Aspen Methadone Syrup [QA]<inline label="genericindexfieldbrand"><italic>XE "Aspen Methadone Syrup(QA):.Opiate Dependence Treatment Program" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Biodone Forte [MW]<inline label="genericindexfieldbrand"><italic>XE "Biodone Forte (MW)" \i </italic></inline></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref></xref-fragment></section></document></blockxref>
<blockxref id="107713" title="book-main-rpbs-title-page.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="60073" href="static/book-main-rpbs-title-page.psml" urititle="(Book main) RPBS Title Page" mediatype="application/vnd.pageseeder.psml+xml"><document id="60073" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed">

  <documentinfo><uri id="60073" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/static/book-main-rpbs-title-page.psml" decodedpath="/ps/test/local3/books/static/book-main-rpbs-title-page.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:24+10:00" modified="2018-06-15T10:34:32+10:00" title="(Book main) RPBS Title Page"><displaytitle>(Book main) RPBS Title Page</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107713" title="" type="none" forwardtype="embed" forwardtitle="book-main-rpbs-title-page.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60073-title">
    <fragment id="60073-1"><block label="mps3sectionbreak">R1</block><block label="schedule-heading">Repatriation Pharmaceutical Benefits Scheme</block></fragment>
  </section>

  
  <section id="60073-content">
    <fragment id="60073-2">
      <para></para>
    </fragment>
  </section>

</document></blockxref>
<blockxref id="107714" title="book-main-rpbs-cards.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="60017" href="static/book-main-rpbs-cards.psml" urititle="(Book main) Beneficiaries' Entitlement Cards" mediatype="application/vnd.pageseeder.psml+xml"><document id="60017" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="60017" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/static/book-main-rpbs-cards.psml" decodedpath="/ps/test/local3/books/static/book-main-rpbs-cards.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:23+10:00" modified="2018-06-15T10:34:32+10:00" title="(Book main) Beneficiaries' Entitlement Cards"><displaytitle>(Book main) Beneficiaries' Entitlement Cards</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107714" title="" type="none" forwardtype="embed" forwardtitle="book-main-rpbs-cards.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60017-2"><fragment id="60017-2"><block label="titlePage2">BENEFICIARIES' ENTITLEMENT CARDS AND ELIGIBILITY FOR REPATRIATION PHARMACEUTICAL BENEFITS</block><para> </para><table><row><cell>
<para><bold>Gold card</bold></para>
<para>This card is issued to those veterans of Australia's defence force, their widows/widowers and dependants entitled to treatment for all medical conditions.</para>
</cell><cell></cell></row></table><table><row><cell>
<para><bold>White card</bold></para>
<para>A White Card is issued to Australian veterans or mariners under the Veterans’ Entitlements Act 1986 with:</para>
<list><item>an accepted war or service-caused injury or disease;</item><item>malignant cancer (neoplasia) whether war-caused or not;</item><item>pulmonary tuberculosis whether war-caused or not;</item><item>post-traumatic stress disorder whether war-caused or not; or</item><item>anxiety and/or depression whether war-caused or not.</item></list>
</cell><cell></cell></row></table><table><row><cell>
<para><bold>Orange card</bold></para>
<para>Orange Repatriation pharmaceutical benefits cards are issued to Commonwealth and allied veterans and mariners who:</para>
<list><item>have qualifying service from World War I or II and</item><item>are aged 70 or over and</item><item>have been resident in Australia for 10 years or more.</item></list>
</cell><cell></cell></row></table><para> </para><block label="normalcenter">For more information go to the <link href="http://www.dva.gov.au/service_providers/treatment_cards/Pages/index.aspx">Department of Veterans' Affairs</link> website:<br></br>
<link href="http://www.dva.gov.au">http://www.dva.gov.au</link></block></fragment></section></document></blockxref>
<blockxref id="107715" title="book-main-rpbs-explanatorynotes.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="59793" href="static/book-main-rpbs-explanatorynotes.psml" urititle="(Book main) RPBS Explanatory Notes" mediatype="application/vnd.pageseeder.psml+xml"><document id="59793" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="59793" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/static/book-main-rpbs-explanatorynotes.psml" decodedpath="/ps/test/local3/books/static/book-main-rpbs-explanatorynotes.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:32+10:00" title="(Book main) RPBS Explanatory Notes"><displaytitle>(Book main) RPBS Explanatory Notes</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107715" title="" type="none" forwardtype="embed" forwardtitle="book-main-rpbs-explanatorynotes.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59793-2"><fragment id="59793-2"><block label="pagebreak">pagebreak</block><heading level="1">RPBS Explanatory Notes</heading><heading level="2">Introduction</heading><heading level="3">The Australian Repatriation System</heading><list><item>The Australian Repatriation system is based primarily on the principle of compensation to veterans and eligible dependants for injury or death related to war service. In certain cases, treatment is also provided for accepted injuries or conditions that are not service-related or have occurred as a result of other than war service.</item><item>Through the <italic>Veterans' Entitlements Act 1986</italic> the Department of Veterans' Affairs provides programs of compensation, income support and treatment for eligible veterans and their dependants. One of the defined benefits for eligible veterans is the Repatriation Pharmaceutical Benefits Scheme. This range of medications and dressings is more comprehensive than is available through the Pharmaceutical Benefits Scheme.</item></list><heading level="2">RPBS prescribing provisions</heading><list><item>Unless otherwise stated, Repatriation Pharmaceutical Benefits Scheme (RPBS) prescriptions must conform with the requirements of Pharmaceutical Benefits Scheme (PBS) prescriptions, as detailed in Section 1 – Explanatory Notes in the <italic>Schedule of Pharmaceutical Benefits</italic> book. The prescriber shall ensure that a prescription contains the following details: 
<list><item>the category of benefit, i.e., RPBS, by placing a cross in the relevant box;</item><item>the patient's full name and address;</item><item>the prescription date;</item><item>the DVA file number of the patient as evidence of entitlement;</item><item>in the case of authority prescriptions, the Authority approval number or the four digit streamlined authority code;</item><item>the item, form, strength, quantity and directions;</item><item>the number of repeats, if applicable;</item><item>indicate when brand substitution is not permitted; and</item><item>the name, signature, the prescriber number and address of the prescriber.</item></list>
</item></list><heading level="3">Prior Approval Arrangements</heading><list><item>The prior approval of the Department is required to prescribe the following: 
<list><item>‘Authority required’ items (excluding ‘Authority required (STREAMLINED)’ items) listed in either the PBS or RPBS Schedule;</item><item>increased quantities and/or repeats of items listed in either the PBS or RPBS Schedule;</item><item>items listed under section 100 of the <italic>National Health Act 1953</italic>; and</item><item>other items not listed in either Schedule (non-Schedule items).</item></list>
</item><item>The above items are to be prescribed on the common PBS/RPBS authority prescription form in accordance with the directions stated in the Explanatory Notes in the <italic>Schedule of Pharmaceutical Benefits</italic> (See also information regarding dental prescribing and prescribing by optometrists under the RPBS in these Notes.)</item><item>All Authority required prescriptions and requests for non-Schedule items must receive prior approval from the Department. This can be achieved by either: 
<list><item>using the Department's national free call number 1800 552 580; or</item><item>by mailing the written authority prescription to the Veterans' Affairs Pharmaceutical Advisory Centre (VAPAC) at the reply paid address shown at the end of these RPBS Explanatory Notes.</item></list>
</item></list><para>Prior approval is not required from DVA to prescribe an Authority required (STREAMLINED) item (except where increased quantities and/or repeats are required). Instead the authority prescription form must include a four digit streamlined authority code.</para><list><item>Some requests for prior approval (including some non-Schedule items) need to be referred by VAPAC to the Repatriation Pharmaceutical Reference Committee for consideration. In such cases a VAPAC pharmacist will advise the prescriber to submit a request in writing that provides the following information: 
<list><item>A current clinical report on the patient's condition (such as age, co-morbidities, renal, liver failure) and clinical reports including pathology, biochemistry, diagnostic and other investigations if appropriate.</item><item>Details of past and current therapy for the condition. Include details of PBS, RPBS and non-Schedule items utilised, and the results of those therapies.</item><item>Details of the proposed treatment regimen. Include intended dose and duration of treatment and objective measures of response.</item><item>When the proposed use of the item is outside the TGA-approved indications for use in Australia, provide copies of articles from peer reviewed publications supporting the proposed treatment.</item><item>Signed, informed patient consent where the item is to be used for a non-TGA-approved indication.</item><item>For items without Australian marketing approval, a copy of the TGA Special Access Scheme approval to prescribe the drug.</item></list>
</item><item>Requests for prior approval to prescribe a non-Schedule (PBS or RPBS) item that is of the same therapeutic class (ATC level 3) as an item that is listed on the Schedule, will not be approved unless unequivocal clinical evidence is presented to demonstrate that the requested item is essential for effective treatment of the nominated patient.</item><item>A pharmacist should not supply an item prescribed on an RPBS Authority Prescription Form unless the form has been approved and stamped by VAPAC, or has been endorsed by the prescriber with a telephone Authority approval number provided by VAPAC. Medicare Australia will not accept RPBS Authority prescriptions that have not been approved by the Department of Veterans' Affairs for payment.</item></list><heading level="3">Palliative Care Drugs</heading><list><item>The following medications may be available, or made available in increased quantities or doses under prior approval arrangements for use only in the palliative care of terminal disease: 
<list><item>clonazepam</item><item>cyclizine</item><item>dexamethasone</item><item>disodium pamidronate</item><item>fentanyl</item><item>glycopyrrolate</item><item>hyoscine butylbromide</item><item>hyoscine hydrobromide</item><item>ketamine</item><item>midazolam</item><item>octreotide</item></list>
</item><item>For further information telephone VAPAC on 1800 552 580.</item></list><heading level="3">Dental Prescribing</heading><list><item>Under Department of Veterans' Affairs arrangements, financial responsibility for pharmaceutical benefits prescribed by a Local Dental Officer (LDO) is limited to treatment to which holders of the following cards are entitled: Where possible the LDO shall prescribe in accordance with the provisions governing dental prescribing under the Pharmaceutical Benefits Scheme (PBS). 
<list><item>a Gold Repatriation Health Card – For All Conditions; or</item><item>a White Repatriation Health Card – For Specific Conditions; or</item><item>an Orange Repatriation Pharmaceutical Benefits Card.</item></list>
</item><item>Prescriptions for PBS Dental Schedule items for Gold, White and Orange Card holders are to be dispensed at the PBS concessional rate. Claims for payment by the dispensing pharmacist are to be included with other Repatriation prescriptions. The card holder is required to meet the cost of any applicable brand premium.</item><item>When a non-PBS Dental Schedule item is prescribed for an eligible card holder, the LDO's private prescription form should be used. The dispensing pharmacist may charge the patient the full cost of the prescription. The patient may claim a refund for the full cost of a non-Schedule item from the Department if an itemised receipt (not a cash register receipt) and a copy of the prescription are provided.</item></list><heading level="3">Prescribing by optometrists</heading><list><item>Optometrists approved as ‘PBS prescribers’ may write RPBS prescriptions as outlined in Section 1 for medicines listed in Section 2 of the PBS Schedule as pharmaceutical benefits for optometrical use.</item><item>Medicines in the optometrist list include non-Authority and Authority required items.  Procedures for obtaining VAPAC approval to prescribe ‘Authority required’ optometrist items or increased quantities and/or repeats of optometrist items under the RPBS are the same as indicated under prior approval arrangements above.</item><item>The list of medicines for prescribing by optometrists under the RPBS is the same as applies under the PBS. There are no optometrist listings in the RPBS Schedule for prescribing for veterans only. There is no provision for optometrist prescribers to request approval to prescribe items that are not included in the PBS optometrist list (non-Schedule items).</item><item>Optometrist PBS/RPBS prescription forms are for use for prescribing non-Authority or Authority required optometrist items under the RPBS with one item per form only.    </item></list><heading level="2">Provisions governing pricing and payment for RPBS benefits</heading><heading level="3">Introduction</heading><list><item>Unless otherwise stated, the pricing and payment principles and arrangements for approved pharmacists supplying pharmaceutical benefits under the RPBS will be the same as those arrangements applying under the PBS.</item><item>Where a pharmaceutical benefit that is not listed on the PBS or RPBS Schedule is dispensed on an RPBS Authority prescription, a pharmacist will price the benefit and enter the serial number, prescription identifying number and price on the sticker or stamp imprint affixed to the prescription.</item></list><heading level="3">Pricing of Schedule Items</heading><list><item>Items supplied under the RPBS from the PBS Schedule, both ready-prepared and extemporaneously-prepared, will be paid on the same basis as benefits supplied under the PBS. Items supplied under the RPBS from the Repatriation Schedule, including wound dressings, will be paid on the basis of the price as given in the Repatriation Pharmaceutical Benefits section (Section 1 – RPBS Schedule, Drugs, Medicines and Dressings) of the <italic>Schedule of Pharmaceutical Benefits</italic>.</item></list><heading level="3">Pricing of Non-Schedule Ready Prepared Items</heading><list><item>Non-Schedule ready-prepared items are to be priced on the basis of the invoiced, GST-exclusive wholesale price to pharmacists plus the appropriate PBS mark-up and the PBS dispensing fee. Where the item price to pharmacists is greater than $100.00, a copy of the invoice pertaining to the supply of that item is to be submitted together with the appropriate copy of the authority prescription as part of the claim for payment.</item></list><heading level="3">Pricing of Non-Schedule Extemporaneously Prepared Items</heading><list><item>When an ingredient drug is not listed in the PBS Drug Tariff, the recovery price will be based on the invoiced wholesale price to pharmacists, increased by a mark-up of 100%, calculated in accordance with the directions contained in the pricing instructions for pricing of PBS extemporaneously-prepared benefits in this Schedule. The price paid by the pharmacist for the commercial pack from which the ingredient is used shall be endorsed on the prescription form.</item></list><heading level="3">Miscellaneous Pricing Rules</heading><list><item>The price to pharmacists used as the basis of pricing will be the invoiced, GST-exclusive price from the wholesaler.</item><item>If multiple quantities of a manufacturer's original pack are supplied, the PBS mark-up is applied to the price to pharmacist of each pack and then totalled. The PBS dispensing fee, and the PBS dangerous drug fee if applicable, are then added to the total of the marked-up prices.</item><item>When the quantity prescribed corresponds with the quantity of a manufacturer's original pack, in no circumstances will the price payable for one pack exceed that payable for multiples or combinations of packs to supply the quantity prescribed.</item><item>The list of ingredient drugs and prices included in the PBS Drug Tariff are common to both the PBS and RPBS. Certain restrictions apply regarding the prescribing and dispensing of some of these ingredient drugs as pharmaceutical benefits, e.g., use as additive only.</item><item>For items prescribed generically, including non-Schedule and wound dressings, the pharmacist should indicate on the prescription the quantity and brand supplied. If prescriptions are not endorsed, the Department will pay the lowest priced acceptable product available.</item></list><heading level="2">General</heading><heading level="3">Packaging Material, Postage or Freight</heading><list><item>Payment to a pharmacist for the costs of packaging materials, postage or freight required to supply a pharmaceutical benefit is to be paid by the patient, who may then claim reimbursement from the Department through the provision of a pharmacists itemised receipt.</item></list><heading level="3">Payment for Items Supplied at Short Intervals</heading><list><item>For all items dispensed at specific short intervals of time, the Department will pay a separate PBS dispensing fee for each occasion that the drug is supplied and which is acknowledged on receipt by the patient or agent.</item><item>The price payable on the items supplied will be based on the individual dose quantity supplied. Where applicable, a PBS dangerous drug fee and a minimum container charge will be payable for each supply.</item></list><heading level="3">Receipts for Patient Charges</heading><list><item>Where a charge is paid by a patient in any of the circumstances of paragraphs 13 or 24, the pharmacist is required to provide a printed receipt to the patient with the details of the items or services provided, the amount paid, date of supply and the patients name and address. The patient may apply for reimbursement from the Department.</item></list><heading level="3">Special Patient Contributions</heading><list><item>The Special Patient Contribution for items listed as Special Pharmaceutical Benefits in the PBS Schedule is not payable by veterans entitled to pharmaceutical benefits under the RPBS. Eligible veterans receiving Special Pharmaceutical Benefits under the RPBS are required to pay only the concessional patient contribution and any applicable brand premium. If a Safety Net Entitlement card is held, the veteran should receive a Special Pharmaceutical Benefit free of charge, subject to any brand premium applicable. Medicare Australia will reimburse the dispensing pharmacist the total dispensed price, less the concessional patient contribution and/or brand premium if applicable.</item></list><heading level="3">Therapeutic Group Premiums — Authority Processing</heading><list><item>Items attracting a therapeutic group premium are dual listed. Dispensing pharmacists are therefore required to select the appropriate code for those items that are dual listed as authority and non-authority items, in order to correctly charge the patient and claim from Medicare Australia. Those authority prescriptions that grant exemption from a therapeutic group premium will have the letters 'TPX' at the beginning of the telephone Authority approval number, or, in the case of a written approval, will be stamped with the words "This prescription does not attract a therapeutic group premium".</item></list></fragment></section></document></blockxref>
<blockxref id="107716" title="book-main-rpbs-veterans.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="60891" href="static/book-main-rpbs-veterans.psml" urititle="(Book main) RPBS Department Veterans Affairs" mediatype="application/vnd.pageseeder.psml+xml"><document id="60891" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="60891" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/static/book-main-rpbs-veterans.psml" decodedpath="/ps/test/local3/books/static/book-main-rpbs-veterans.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:33+10:00" modified="2018-06-15T10:34:32+10:00" title="(Book main) RPBS Department Veterans Affairs"><displaytitle>(Book main) RPBS Department Veterans Affairs</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107716" title="" type="none" forwardtype="embed" forwardtitle="book-main-rpbs-veterans.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60891-2"><fragment id="60891-2"><block label="titlePage2">Contact the Department of Veterans' Affairs</block><para><bold>Authority Prescription Applications</bold></para><para>Applications for authority to prescribe under the Repatriation Pharmaceutical Benefits Scheme (RPBS) should be sent to the Veterans' Affairs Pharmaceutical Advisory Centre (VAPAC) using the free postal service:</para><para>REPLY PAID 9998<br></br>
VAPAC (Veterans' Affairs Pharmaceutical Advisory Centre)<br></br>
Department of Veterens' Affairs<br></br>
GPO Box 9998<br></br>
BRISBANE QLD 4001</para><para><bold>For RPBS enquiries and telephone approvals 24 hours a day the Freecall number is: </bold><bold>1800 552 580</bold></para><para><bold>Departmental pharmacists answer applications for prior approval for non-Schedule items and Authority application calls.</bold></para></fragment></section></document></blockxref>
<blockxref id="107717" title="book-main-rpbs-repatriation-dressings.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="59651" href="static/book-main-rpbs-repatriation-dressings.psml" urititle="(Book main) RPBS Wound Assessment and Dressing Identification" mediatype="application/vnd.pageseeder.psml+xml"><document id="59651" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="59651" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/static/book-main-rpbs-repatriation-dressings.psml" decodedpath="/ps/test/local3/books/static/book-main-rpbs-repatriation-dressings.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:19+10:00" modified="2018-06-15T10:34:32+10:00" title="(Book main) RPBS Wound Assessment and Dressing Identification"><displaytitle>(Book main) RPBS Wound Assessment and Dressing Identification</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107717" title="" type="none" forwardtype="embed" forwardtitle="book-main-rpbs-repatriation-dressings.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59651-0"><fragment id="59651-0"><block label="pagebreak">pagebreak</block><heading level="1">WOUND ASSESSMENT AND DRESSING IDENTIFICATION</heading><para>It is essential to define the aetiology of the wound before selecting a dressing. Recommendations are based on wound type, colour of wound base, depth of wound, and amount of exudate.</para><para>This wound chart adheres to the MOIST WOUND concept of healing and wound dressings are described below as ABSORBING or MOISTURE DONATING.</para><para>Most wound healing products are designed to remain in situ for several days, with the exception of those for infected wounds which should be changed daily. The quantities and repeats listed in the Repatriation Schedule are considered to be adequate to manage the treatment of a wound for two weeks to one month, when an assessment of the wound's healing process should be undertaken.</para></fragment></section><section id="59651-1"><fragment id="59651-1"><heading level="4">DRESSINGS</heading><heading level="5">PINK EPITHELIALISING WOUND</heading><para>Aim: To protect and promote epithelialisation. Epithelialising wounds normally are superficial and only produce a light exudate.</para><table><row><cell>(A) Covering</cell><cell>
<list><item>Film;</item><item>Film Island</item></list>
</cell><cell>
<list><item>Gauze—Paraffin;</item><item>Non-adherent</item></list>
</cell></row><row><cell>(B) Absorbing</cell><cell>
<list><item>Foam (Light Exudate);</item><item>Hydroactive (Superficial Wound—Light Exudate)</item></list>
</cell><cell>
<list><item>Hydrocolloid (Superficial Wound—Light Exudate)</item></list>
</cell></row></table></fragment></section><section id="59651-2"><fragment id="59651-2"><heading level="5">RED GRANULATING WOUND</heading><para>Aims: (1) to protect the granulating tissue; (2) to encourage epithelialisation; (3) to absorb excess exudate.</para><table>
<row part="header"><cell>LIGHT EXUDATE:</cell><cell>Superficial</cell><cell>Cavity</cell></row>
<row><cell>(A) Absorbing</cell><cell>
<list><item>Foam (Light Exudate);</item><item>Hydroactive<br></br>
 (Superficial Wound—Light Exudate);</item><item>Hydrocolloid<br></br>
 (Superficial Wound—Light Exudate) </item></list>
</cell><cell>
<list><item>Hydrocolloid<br></br>
 (Cavity Wound)</item></list>
</cell></row><row><cell>(B) Moisture donating</cell><cell>
<list><item>Hydrogel—Amorphous;</item><item>Hydrogel—Sheet</item></list>
</cell><cell>
<list><item>Hydrogel—Amorphous</item></list>
</cell></row></table><para> </para><table>
<row part="header"><cell>HIGH EXUDATE:</cell><cell>Superficial</cell><cell>Cavity</cell></row>
<row><cell>(A) Absorbing</cell><cell>
<list><item>Alginate (Superficial Wound);</item><item>Foam—Heavy Exudate;</item><item>Hydroactive<br></br>
 (Superficial Wound—Moderate Exudate);</item><item>Hydrocolloid<br></br>
 (Superficial Wound—Moderate/High Exudate)</item></list>
</cell><cell>
<list><item>Alginate (Cavity Wound);</item><item>Foam—Moderate Exudate<br></br>
 (see “cavity conforming” product);</item><item>Hydroactive (Cavity Wound);</item><item>Hydrocolloid (Cavity Wound)</item></list>
</cell></row><row><cell>(B) Moisture donating</cell><cell>NOT APPROPRIATE</cell><cell></cell></row></table></fragment></section><section id="59651-3"><fragment id="59651-3"><heading level="5">YELLOW SLOUGHY WOUND</heading><para>Aims: (1) to remove slough; (2) to encourage granulation; (3) to absorb excess exudate.</para><table>
<row part="header"><cell>LIGHT EXUDATE:</cell><cell>Superficial</cell><cell>Cavity</cell></row>
<row><cell>(A) Absorbing</cell><cell>
<list><item>Cadexomer Iodine;</item><item>Foam—Light Exudate;</item><item>Foam with Charcoal;</item><item>Hydroactive<br></br>
 (Superficial Wound—Moderate Exudate);</item><item>Hydrocolloid<br></br>
 (Superficial Wound—Moderate Exudate)</item></list>
</cell><cell>
<list><item>Cadexomer Iodine;</item><item>Hydrocolloid<br></br>
 (Cavity Wound)</item></list>
</cell></row><row><cell>(B) Moisture Donating</cell><cell>
<list><item>Hydrogel—Amorphous;</item><item>Hydrogel—Sheet</item></list>
</cell><cell>
<list><item>Hydrogel—Amorphous</item></list>
</cell></row></table><table>
<row part="header"><cell>HIGH EXUDATE:</cell><cell>Superficial</cell><cell>Cavity</cell></row>
<row><cell>(A) Absorbing</cell><cell>
<list><item>Alginate (Superficial Wound);</item><item>Cadexomer Iodine;</item><item>Foam—Heavy Exudate;</item><item>Hydroactive<br></br>
 (Superficial Wound—Moderate/High Exudate);</item><item>Hydrocolloid<br></br>
 (Superficial Wound—Moderate/High<br></br>
 Exudate)</item></list>
</cell><cell>
<list><item>Alginate (Cavity Wound);</item><item>Cadexomer Iodine;</item><item>Hydrocolloid<br></br>
 (Cavity Wound)</item></list>
</cell></row><row><cell>(B) Moisture donating</cell><cell>NOT APPROPRIATE</cell><cell></cell></row></table></fragment></section><section id="59651-4"><fragment id="59651-4"><heading level="5">BLACK NECROTIC WOUND</heading><para>Aim: To remove eschar by — (1) sharp debridement, e.g., scissor/scalpel and/or (2) rehydration and autolytic debridement. (These wounds usually produce a LIGHT EXUDATE.)</para><table>
<row part="header"><cell>DRY / LIGHT EXUDATE:</cell><cell>Superficial</cell><cell>Cavity</cell></row>
<row><cell>(A) Absorbing</cell><cell>
<list><item>Hydroactive (Superficial<br></br>
 Wound—Light Exudate);</item><item>Hydrocolloid (Superficial<br></br>
 Wound—Light/Moderate<br></br>
 Exudate)</item></list>
</cell><cell>
<list><item>Hydrocolloid (Cavity Wound)</item></list>
</cell></row><row><cell>(B) Moisture donating</cell><cell>
<list><item>Hydrogel—Amorphous;</item><item>Hydrogel—Sheet</item></list>
</cell><cell>
<list><item>Hydrogel—Amorphous;</item><item>Hydrogel—Sheet</item></list>
</cell></row></table></fragment></section><section id="59651-5"><fragment id="59651-5"><heading level="5">INFECTED WOUNDS</heading><para>Aims: (1) to clear the infection with systemic antibiotics; (2) to absorb excess exudate; (3) to remove slough if present; (4) to decrease bacterial burden - by applying a Silver dressing or Cadexomer Iodine dressing.</para></fragment></section><section id="59651-6"><fragment id="59651-6"><heading level="5">MALODOROUS WOUNDS</heading><para>Aims: (1) to clear infection if present; (2) to remove slough if present; (3) to clear colonising odour-producing bacteria in slough — by applying metronidazole gel, a Silver dressing or a Cadexomer Iodine dressing; (4) to absorb excess exudate.</para><para>Products: Activated Charcoal; Alginate with Charcoal; Foam with Charcoal; Silver dressing; Cadexomer Iodine dressing.</para></fragment></section><section id="59651-7"><fragment id="59651-7"><heading level="5">MINOR SKIN TRAUMA</heading><para>Aims: (1) to stop bleeding; (2) to prevent infection; (3) to minimise the surface defect; (4) to promote epithelialisation.</para></fragment></section><section id="59651-8"><fragment id="59651-8"><heading level="5">ORDERING COLOPLAST PRODUCTS</heading><para>Coloplast dressings are available via a range of distributors. However, Coloplast's principal agreement to ensure correct RPBS Price to Pharmacy, and ready supply has only been secured with Independence Australia on 1300 788 855. Please note that Coloplast are unable to guarantee ready supply or rebate for price differences on purchases outside this distributor.</para><heading level="5">ORDERING HARTMANN PRODUCTS</heading><para>Hartmann wound dressings are available through HARTMANN and Independence Australia only. If you would like to order Hartmann Wound Care products, please call HARTMANN customer service on 1800 805 839 or Independence Australia on 1300 788 855.</para><heading level="5">ORDERING MOLNLYCKE HEALTHCARE PRODUCTS</heading><para>Molnlycke Healthcare products are distributed through leading pharmacy distributors.  To best ensure product availability at RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS).  IAHS orders can be placed on: Tel: 1300 788 855; or Email customerservice@independenceaustralia.com.  Molnlycke Healthcare are not able to ensure product availability or pricing on listed products beyond these two suppliers.</para><heading level="5">ORDERING SMITH &amp; NEPHEW PRODUCTS</heading><para>Smith &amp; Nephew products are distributed via the three major wholesalers, API, SIGMA &amp; Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith &amp; Nephew Customer Service on 13 13 60. Smith &amp; Nephew cannot ensure RPBS agreed pricing from distributors other than those aforementioned.</para><para> </para></fragment></section></document></blockxref>
<blockxref id="107718" title="therapeuticindex-R1.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml"><document id="60793" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="60793" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/therapeuticindex-R1.psml" decodedpath="/ps/test/local3/books/dynamic/R1/therapeuticindex-R1.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:32+10:00" title="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1"><displaytitle>Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107718" title="" type="none" forwardtype="embed" forwardtitle="therapeuticindex-R1.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="44654" fragment="60793-2" editid="107686" modified="2018-06-15T10:34:32+10:00"></locator></fragmentinfo><metadata></metadata><section id="60793-1"><fragment id="60793-1"><block label="pageBreak">pagebreak</block></fragment><fragment id="60793-2"><block label="index"><para>ALIMENTARY TRACT AND METABOLISM<inline label="indexpageref"><xref id="107580" title="ALIMENTARY TRACT AND METABOLISM" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60082" href="#60082" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index2"><para indent="1">STOMATOLOGICAL PREPARATIONS<inline label="indexpageref"><xref id="107581" title="STOMATOLOGICAL PREPARATIONS" frag="A01" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60082" href="#60082-A01" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index3"><para indent="2">STOMATOLOGICAL PREPARATIONS<inline label="indexpageref"><xref id="107582" title="STOMATOLOGICAL PREPARATIONS" frag="A01A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60082" href="#60082-A01A" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index2"><para indent="1">DRUGS FOR ACID RELATED DISORDERS<inline label="indexpageref"><xref id="107583" title="DRUGS FOR ACID RELATED DISORDERS" frag="A02" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60082" href="#60082-A02" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index3"><para indent="2">ANTACIDS<inline label="indexpageref"><xref id="107584" title="ANTACIDS" frag="A02A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60082" href="#60082-A02A" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index2"><para indent="1">DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS<inline label="indexpageref"><xref id="107585" title="DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS" frag="A03" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60082" href="#60082-A03" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index3"><para indent="2">DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS<inline label="indexpageref"><xref id="107586" title="DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS" frag="A03A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60082" href="#60082-A03A" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index3"><para indent="2">BELLADONNA AND DERIVATIVES, PLAIN<inline label="indexpageref"><xref id="107587" title="BELLADONNA AND DERIVATIVES, PLAIN" frag="A03B" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60082" href="#60082-A03B" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index2"><para indent="1">DRUGS FOR CONSTIPATION<inline label="indexpageref"><xref id="107588" title="DRUGS FOR CONSTIPATION" frag="A06" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60082" href="#60082-A06" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index3"><para indent="2">DRUGS FOR CONSTIPATION<inline label="indexpageref"><xref id="107589" title="DRUGS FOR CONSTIPATION" frag="A06A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60082" href="#60082-A06A" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index2"><para indent="1">ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS<inline label="indexpageref"><xref id="107590" title="ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS" frag="A07" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60082" href="#60082-A07" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index3"><para indent="2">ELECTROLYTES WITH CARBOHYDRATES<inline label="indexpageref"><xref id="107591" title="ELECTROLYTES WITH CARBOHYDRATES" frag="A07C" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60082" href="#60082-A07C" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index3"><para indent="2">ANTIPROPULSIVES<inline label="indexpageref"><xref id="107592" title="ANTIPROPULSIVES" frag="A07D" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60082" href="#60082-A07D" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index2"><para indent="1">ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS<inline label="indexpageref"><xref id="107593" title="ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS" frag="A08" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60082" href="#60082-A08" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index3"><para indent="2">ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS<inline label="indexpageref"><xref id="107594" title="ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS" frag="A08A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60082" href="#60082-A08A" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index2"><para indent="1">VITAMINS<inline label="indexpageref"><xref id="107595" title="VITAMINS" frag="A11" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60082" href="#60082-A11" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index3"><para indent="2">VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12<inline label="indexpageref"><xref id="107596" title="VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12" frag="A11D" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60082" href="#60082-A11D" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index3"><para indent="2">VITAMIN B-COMPLEX, INCL. COMBINATIONS<inline label="indexpageref"><xref id="107597" title="VITAMIN B-COMPLEX, INCL. COMBINATIONS" frag="A11E" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60082" href="#60082-A11E" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index2"><para indent="1">MINERAL SUPPLEMENTS<inline label="indexpageref"><xref id="107598" title="MINERAL SUPPLEMENTS" frag="A12" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60082" href="#60082-A12" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index3"><para indent="2">CALCIUM<inline label="indexpageref"><xref id="107599" title="CALCIUM" frag="A12A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60082" href="#60082-A12A" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index3"><para indent="2">OTHER MINERAL SUPPLEMENTS<inline label="indexpageref"><xref id="107600" title="OTHER MINERAL SUPPLEMENTS" frag="A12C" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60082" href="#60082-A12C" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml">ALIMENTARY TRACT AND METABOLISM</xref></inline></para></block><block label="index"><para>BLOOD AND BLOOD FORMING ORGANS<inline label="indexpageref"><xref id="107601" title="BLOOD AND BLOOD FORMING ORGANS" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60034" href="#60034" urititle="BLOOD AND BLOOD FORMING ORGANS" mediatype="application/vnd.pageseeder.psml+xml">BLOOD AND BLOOD FORMING ORGANS</xref></inline></para></block><block label="index2"><para indent="1">ANTITHROMBOTIC AGENTS<inline label="indexpageref"><xref id="107602" title="ANTITHROMBOTIC AGENTS" frag="B01" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60034" href="#60034-B01" urititle="BLOOD AND BLOOD FORMING ORGANS" mediatype="application/vnd.pageseeder.psml+xml">BLOOD AND BLOOD FORMING ORGANS</xref></inline></para></block><block label="index3"><para indent="2">ANTITHROMBOTIC AGENTS<inline label="indexpageref"><xref id="107603" title="ANTITHROMBOTIC AGENTS" frag="B01A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60034" href="#60034-B01A" urititle="BLOOD AND BLOOD FORMING ORGANS" mediatype="application/vnd.pageseeder.psml+xml">BLOOD AND BLOOD FORMING ORGANS</xref></inline></para></block><block label="index2"><para indent="1">ANTIANEMIC PREPARATIONS<inline label="indexpageref"><xref id="107604" title="ANTIANEMIC PREPARATIONS" frag="B03" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60034" href="#60034-B03" urititle="BLOOD AND BLOOD FORMING ORGANS" mediatype="application/vnd.pageseeder.psml+xml">BLOOD AND BLOOD FORMING ORGANS</xref></inline></para></block><block label="index3"><para indent="2">IRON PREPARATIONS<inline label="indexpageref"><xref id="107605" title="IRON PREPARATIONS" frag="B03A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60034" href="#60034-B03A" urititle="BLOOD AND BLOOD FORMING ORGANS" mediatype="application/vnd.pageseeder.psml+xml">BLOOD AND BLOOD FORMING ORGANS</xref></inline></para></block><block label="index3"><para indent="2">VITAMIN B12 AND FOLIC ACID<inline label="indexpageref"><xref id="107606" title="VITAMIN B12 AND FOLIC ACID" frag="B03B" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60034" href="#60034-B03B" urititle="BLOOD AND BLOOD FORMING ORGANS" mediatype="application/vnd.pageseeder.psml+xml">BLOOD AND BLOOD FORMING ORGANS</xref></inline></para></block><block label="index2"><para indent="1">BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS<inline label="indexpageref"><xref id="107607" title="BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS" frag="B05" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60034" href="#60034-B05" urititle="BLOOD AND BLOOD FORMING ORGANS" mediatype="application/vnd.pageseeder.psml+xml">BLOOD AND BLOOD FORMING ORGANS</xref></inline></para></block><block label="index3"><para indent="2">IRRIGATING SOLUTIONS<inline label="indexpageref"><xref id="107608" title="IRRIGATING SOLUTIONS" frag="B05C" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60034" href="#60034-B05C" urititle="BLOOD AND BLOOD FORMING ORGANS" mediatype="application/vnd.pageseeder.psml+xml">BLOOD AND BLOOD FORMING ORGANS</xref></inline></para></block><block label="index"><para>CARDIOVASCULAR SYSTEM<inline label="indexpageref"><xref id="107609" title="CARDIOVASCULAR SYSTEM" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60991" href="#60991" urititle="CARDIOVASCULAR SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">CARDIOVASCULAR SYSTEM</xref></inline></para></block><block label="index2"><para indent="1">VASOPROTECTIVES<inline label="indexpageref"><xref id="107610" title="VASOPROTECTIVES" frag="C05" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60991" href="#60991-C05" urititle="CARDIOVASCULAR SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">CARDIOVASCULAR SYSTEM</xref></inline></para></block><block label="index3"><para indent="2">AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE<inline label="indexpageref"><xref id="107611" title="AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE" frag="C05A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60991" href="#60991-C05A" urititle="CARDIOVASCULAR SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">CARDIOVASCULAR SYSTEM</xref></inline></para></block><block label="index"><para>DERMATOLOGICALS<inline label="indexpageref"><xref id="107612" title="DERMATOLOGICALS" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60616" href="#60616" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml">DERMATOLOGICALS</xref></inline></para></block><block label="index2"><para indent="1">ANTIFUNGALS FOR DERMATOLOGICAL USE<inline label="indexpageref"><xref id="107613" title="ANTIFUNGALS FOR DERMATOLOGICAL USE" frag="D01" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60616" href="#60616-D01" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml">DERMATOLOGICALS</xref></inline></para></block><block label="index3"><para indent="2">ANTIFUNGALS FOR TOPICAL USE<inline label="indexpageref"><xref id="107614" title="ANTIFUNGALS FOR TOPICAL USE" frag="D01A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60616" href="#60616-D01A" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml">DERMATOLOGICALS</xref></inline></para></block><block label="index3"><para indent="2">ANTIFUNGALS FOR SYSTEMIC USE<inline label="indexpageref"><xref id="107615" title="ANTIFUNGALS FOR SYSTEMIC USE" frag="D01B" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60616" href="#60616-D01B" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml">DERMATOLOGICALS</xref></inline></para></block><block label="index2"><para indent="1">EMOLLIENTS AND PROTECTIVES<inline label="indexpageref"><xref id="107616" title="EMOLLIENTS AND PROTECTIVES" frag="D02" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60616" href="#60616-D02" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml">DERMATOLOGICALS</xref></inline></para></block><block label="index3"><para indent="2">EMOLLIENTS AND PROTECTIVES<inline label="indexpageref"><xref id="107617" title="EMOLLIENTS AND PROTECTIVES" frag="D02A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60616" href="#60616-D02A" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml">DERMATOLOGICALS</xref></inline></para></block><block label="index3"><para indent="2">PROTECTIVES AGAINST UV-RADIATION<inline label="indexpageref"><xref id="107618" title="PROTECTIVES AGAINST UV-RADIATION" frag="D02B" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60616" href="#60616-D02B" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml">DERMATOLOGICALS</xref></inline></para></block><block label="index2"><para indent="1">ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.<inline label="indexpageref"><xref id="107619" title="ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC." frag="D04" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60616" href="#60616-D04" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml">DERMATOLOGICALS</xref></inline></para></block><block label="index3"><para indent="2">ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.<inline label="indexpageref"><xref id="107620" title="ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC." frag="D04A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60616" href="#60616-D04A" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml">DERMATOLOGICALS</xref></inline></para></block><block label="index2"><para indent="1">ANTIPSORIATICS<inline label="indexpageref"><xref id="107621" title="ANTIPSORIATICS" frag="D05" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60616" href="#60616-D05" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml">DERMATOLOGICALS</xref></inline></para></block><block label="index3"><para indent="2">ANTIPSORIATICS FOR TOPICAL USE<inline label="indexpageref"><xref id="107622" title="ANTIPSORIATICS FOR TOPICAL USE" frag="D05A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60616" href="#60616-D05A" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml">DERMATOLOGICALS</xref></inline></para></block><block label="index2"><para indent="1">ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE<inline label="indexpageref"><xref id="107623" title="ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE" frag="D06" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60616" href="#60616-D06" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml">DERMATOLOGICALS</xref></inline></para></block><block label="index3"><para indent="2">ANTIBIOTICS FOR TOPICAL USE<inline label="indexpageref"><xref id="107624" title="ANTIBIOTICS FOR TOPICAL USE" frag="D06A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60616" href="#60616-D06A" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml">DERMATOLOGICALS</xref></inline></para></block><block label="index3"><para indent="2">CHEMOTHERAPEUTICS FOR TOPICAL USE<inline label="indexpageref"><xref id="107625" title="CHEMOTHERAPEUTICS FOR TOPICAL USE" frag="D06B" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60616" href="#60616-D06B" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml">DERMATOLOGICALS</xref></inline></para></block><block label="index2"><para indent="1">CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS<inline label="indexpageref"><xref id="107626" title="CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS" frag="D07" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60616" href="#60616-D07" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml">DERMATOLOGICALS</xref></inline></para></block><block label="index3"><para indent="2">CORTICOSTEROIDS, PLAIN<inline label="indexpageref"><xref id="107627" title="CORTICOSTEROIDS, PLAIN" frag="D07A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60616" href="#60616-D07A" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml">DERMATOLOGICALS</xref></inline></para></block><block label="index2"><para indent="1">ANTISEPTICS AND DISINFECTANTS<inline label="indexpageref"><xref id="107628" title="ANTISEPTICS AND DISINFECTANTS" frag="D08" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60616" href="#60616-D08" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml">DERMATOLOGICALS</xref></inline></para></block><block label="index3"><para indent="2">ANTISEPTICS AND DISINFECTANTS<inline label="indexpageref"><xref id="107629" title="ANTISEPTICS AND DISINFECTANTS" frag="D08A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60616" href="#60616-D08A" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml">DERMATOLOGICALS</xref></inline></para></block><block label="index2"><para indent="1">OTHER DERMATOLOGICAL PREPARATIONS<inline label="indexpageref"><xref id="107630" title="OTHER DERMATOLOGICAL PREPARATIONS" frag="D11" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60616" href="#60616-D11" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml">DERMATOLOGICALS</xref></inline></para></block><block label="index3"><para indent="2">OTHER DERMATOLOGICAL PREPARATIONS<inline label="indexpageref"><xref id="107631" title="OTHER DERMATOLOGICAL PREPARATIONS" frag="D11A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60616" href="#60616-D11A" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml">DERMATOLOGICALS</xref></inline></para></block><block label="index"><para>GENITO URINARY SYSTEM AND SEX HORMONES<inline label="indexpageref"><xref id="107632" title="GENITO URINARY SYSTEM AND SEX HORMONES" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59705" href="#59705" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml">GENITO URINARY SYSTEM AND SEX HORMONES</xref></inline></para></block><block label="index2"><para indent="1">GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS<inline label="indexpageref"><xref id="107633" title="GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS" frag="G01" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59705" href="#59705-G01" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml">GENITO URINARY SYSTEM AND SEX HORMONES</xref></inline></para></block><block label="index3"><para indent="2">ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS<inline label="indexpageref"><xref id="107634" title="ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS" frag="G01A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59705" href="#59705-G01A" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml">GENITO URINARY SYSTEM AND SEX HORMONES</xref></inline></para></block><block label="index2"><para indent="1">OTHER GYNECOLOGICALS<inline label="indexpageref"><xref id="107635" title="OTHER GYNECOLOGICALS" frag="G02" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59705" href="#59705-G02" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml">GENITO URINARY SYSTEM AND SEX HORMONES</xref></inline></para></block><block label="index3"><para indent="2">OTHER GYNECOLOGICALS<inline label="indexpageref"><xref id="107636" title="OTHER GYNECOLOGICALS" frag="G02C" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59705" href="#59705-G02C" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml">GENITO URINARY SYSTEM AND SEX HORMONES</xref></inline></para></block><block label="index2"><para indent="1">UROLOGICALS<inline label="indexpageref"><xref id="107637" title="UROLOGICALS" frag="G04" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59705" href="#59705-G04" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml">GENITO URINARY SYSTEM AND SEX HORMONES</xref></inline></para></block><block label="index3"><para indent="2">UROLOGICALS<inline label="indexpageref"><xref id="107638" title="UROLOGICALS" frag="G04B" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59705" href="#59705-G04B" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml">GENITO URINARY SYSTEM AND SEX HORMONES</xref></inline></para></block><block label="index3"><para indent="2">DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY<inline label="indexpageref"><xref id="107639" title="DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY" frag="G04C" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59705" href="#59705-G04C" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml">GENITO URINARY SYSTEM AND SEX HORMONES</xref></inline></para></block><block label="index"><para>ANTIINFECTIVES FOR SYSTEMIC USE<inline label="indexpageref"><xref id="107640" title="ANTIINFECTIVES FOR SYSTEMIC USE" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60922" href="#60922" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml">ANTIINFECTIVES FOR SYSTEMIC USE</xref></inline></para></block><block label="index2"><para indent="1">ANTIBACTERIALS FOR SYSTEMIC USE<inline label="indexpageref"><xref id="107641" title="ANTIBACTERIALS FOR SYSTEMIC USE" frag="J01" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60922" href="#60922-J01" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml">ANTIINFECTIVES FOR SYSTEMIC USE</xref></inline></para></block><block label="index3"><para indent="2">MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS<inline label="indexpageref"><xref id="107642" title="MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS" frag="J01F" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60922" href="#60922-J01F" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml">ANTIINFECTIVES FOR SYSTEMIC USE</xref></inline></para></block><block label="index"><para>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS<inline label="indexpageref"><xref id="107643" title="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60098" href="#60098" urititle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" mediatype="application/vnd.pageseeder.psml+xml">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</xref></inline></para></block><block label="index2"><para indent="1">ANTINEOPLASTIC AGENTS<inline label="indexpageref"><xref id="107644" title="ANTINEOPLASTIC AGENTS" frag="L01" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60098" href="#60098-L01" urititle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" mediatype="application/vnd.pageseeder.psml+xml">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</xref></inline></para></block><block label="index3"><para indent="2">ANTIMETABOLITES<inline label="indexpageref"><xref id="107645" title="ANTIMETABOLITES" frag="L01B" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60098" href="#60098-L01B" urititle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" mediatype="application/vnd.pageseeder.psml+xml">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</xref></inline></para></block><block label="index2"><para indent="1">IMMUNOSUPPRESSANTS<inline label="indexpageref"><xref id="107646" title="IMMUNOSUPPRESSANTS" frag="L04" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60098" href="#60098-L04" urititle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" mediatype="application/vnd.pageseeder.psml+xml">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</xref></inline></para></block><block label="index3"><para indent="2">IMMUNOSUPPRESSANTS<inline label="indexpageref"><xref id="107647" title="IMMUNOSUPPRESSANTS" frag="L04A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60098" href="#60098-L04A" urititle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" mediatype="application/vnd.pageseeder.psml+xml">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</xref></inline></para></block><block label="index"><para>MUSCULO-SKELETAL SYSTEM<inline label="indexpageref"><xref id="107648" title="MUSCULO-SKELETAL SYSTEM" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60874" href="#60874" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">MUSCULO-SKELETAL SYSTEM</xref></inline></para></block><block label="index2"><para indent="1">TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN<inline label="indexpageref"><xref id="107649" title="TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN" frag="M02" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60874" href="#60874-M02" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">MUSCULO-SKELETAL SYSTEM</xref></inline></para></block><block label="index3"><para indent="2">TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN<inline label="indexpageref"><xref id="107650" title="TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN" frag="M02A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60874" href="#60874-M02A" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">MUSCULO-SKELETAL SYSTEM</xref></inline></para></block><block label="index2"><para indent="1">DRUGS FOR TREATMENT OF BONE DISEASES<inline label="indexpageref"><xref id="107651" title="DRUGS FOR TREATMENT OF BONE DISEASES" frag="M05" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60874" href="#60874-M05" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">MUSCULO-SKELETAL SYSTEM</xref></inline></para></block><block label="index3"><para indent="2">DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION<inline label="indexpageref"><xref id="107652" title="DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION" frag="M05B" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60874" href="#60874-M05B" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">MUSCULO-SKELETAL SYSTEM</xref></inline></para></block><block label="index"><para>NERVOUS SYSTEM<inline label="indexpageref"><xref id="107653" title="NERVOUS SYSTEM" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59816" href="#59816" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block><block label="index2"><para indent="1">ANALGESICS<inline label="indexpageref"><xref id="107654" title="ANALGESICS" frag="N02" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59816" href="#59816-N02" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block><block label="index3"><para indent="2">OPIOIDS<inline label="indexpageref"><xref id="107655" title="OPIOIDS" frag="N02A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59816" href="#59816-N02A" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block><block label="index3"><para indent="2">OTHER ANALGESICS AND ANTIPYRETICS<inline label="indexpageref"><xref id="107656" title="OTHER ANALGESICS AND ANTIPYRETICS" frag="N02B" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59816" href="#59816-N02B" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block><block label="index2"><para indent="1">PSYCHOLEPTICS<inline label="indexpageref"><xref id="107657" title="PSYCHOLEPTICS" frag="N05" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59816" href="#59816-N05" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block><block label="index3"><para indent="2">ANXIOLYTICS<inline label="indexpageref"><xref id="107658" title="ANXIOLYTICS" frag="N05B" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59816" href="#59816-N05B" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block><block label="index3"><para indent="2">HYPNOTICS AND SEDATIVES<inline label="indexpageref"><xref id="107659" title="HYPNOTICS AND SEDATIVES" frag="N05C" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59816" href="#59816-N05C" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block><block label="index2"><para indent="1">OTHER NERVOUS SYSTEM DRUGS<inline label="indexpageref"><xref id="107660" title="OTHER NERVOUS SYSTEM DRUGS" frag="N07" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59816" href="#59816-N07" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block><block label="index3"><para indent="2">DRUGS USED IN ADDICTIVE DISORDERS<inline label="indexpageref"><xref id="107661" title="DRUGS USED IN ADDICTIVE DISORDERS" frag="N07B" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59816" href="#59816-N07B" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">NERVOUS SYSTEM</xref></inline></para></block><block label="index"><para>ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS<inline label="indexpageref"><xref id="107662" title="ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59917" href="#59917" urititle="ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS" mediatype="application/vnd.pageseeder.psml+xml">ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS</xref></inline></para></block><block label="index2"><para indent="1">ANTHELMINTICS<inline label="indexpageref"><xref id="107663" title="ANTHELMINTICS" frag="P02" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59917" href="#59917-P02" urititle="ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS" mediatype="application/vnd.pageseeder.psml+xml">ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS</xref></inline></para></block><block label="index3"><para indent="2">ANTINEMATODAL AGENTS<inline label="indexpageref"><xref id="107664" title="ANTINEMATODAL AGENTS" frag="P02C" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="59917" href="#59917-P02C" urititle="ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS" mediatype="application/vnd.pageseeder.psml+xml">ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS</xref></inline></para></block><block label="index"><para>RESPIRATORY SYSTEM<inline label="indexpageref"><xref id="107665" title="RESPIRATORY SYSTEM" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60371" href="#60371" urititle="RESPIRATORY SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">RESPIRATORY SYSTEM</xref></inline></para></block><block label="index2"><para indent="1">NASAL PREPARATIONS<inline label="indexpageref"><xref id="107666" title="NASAL PREPARATIONS" frag="R01" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60371" href="#60371-R01" urititle="RESPIRATORY SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">RESPIRATORY SYSTEM</xref></inline></para></block><block label="index3"><para indent="2">DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE<inline label="indexpageref"><xref id="107667" title="DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE" frag="R01A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60371" href="#60371-R01A" urititle="RESPIRATORY SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">RESPIRATORY SYSTEM</xref></inline></para></block><block label="index3"><para indent="2">NASAL DECONGESTANTS FOR SYSTEMIC USE<inline label="indexpageref"><xref id="107668" title="NASAL DECONGESTANTS FOR SYSTEMIC USE" frag="R01B" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60371" href="#60371-R01B" urititle="RESPIRATORY SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">RESPIRATORY SYSTEM</xref></inline></para></block><block label="index2"><para indent="1">COUGH AND COLD PREPARATIONS<inline label="indexpageref"><xref id="107669" title="COUGH AND COLD PREPARATIONS" frag="R05" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60371" href="#60371-R05" urititle="RESPIRATORY SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">RESPIRATORY SYSTEM</xref></inline></para></block><block label="index3"><para indent="2">EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS<inline label="indexpageref"><xref id="107670" title="EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS" frag="R05C" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60371" href="#60371-R05C" urititle="RESPIRATORY SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">RESPIRATORY SYSTEM</xref></inline></para></block><block label="index3"><para indent="2">COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS<inline label="indexpageref"><xref id="107671" title="COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS" frag="R05D" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60371" href="#60371-R05D" urititle="RESPIRATORY SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">RESPIRATORY SYSTEM</xref></inline></para></block><block label="index2"><para indent="1">ANTIHISTAMINES FOR SYSTEMIC USE<inline label="indexpageref"><xref id="107672" title="ANTIHISTAMINES FOR SYSTEMIC USE" frag="R06" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60371" href="#60371-R06" urititle="RESPIRATORY SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">RESPIRATORY SYSTEM</xref></inline></para></block><block label="index3"><para indent="2">ANTIHISTAMINES FOR SYSTEMIC USE<inline label="indexpageref"><xref id="107673" title="ANTIHISTAMINES FOR SYSTEMIC USE" frag="R06A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60371" href="#60371-R06A" urititle="RESPIRATORY SYSTEM" mediatype="application/vnd.pageseeder.psml+xml">RESPIRATORY SYSTEM</xref></inline></para></block><block label="index"><para>SENSORY ORGANS<inline label="indexpageref"><xref id="107674" title="SENSORY ORGANS" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60497" href="#60497" urititle="SENSORY ORGANS" mediatype="application/vnd.pageseeder.psml+xml">SENSORY ORGANS</xref></inline></para></block><block label="index2"><para indent="1">OPHTHALMOLOGICALS<inline label="indexpageref"><xref id="107675" title="OPHTHALMOLOGICALS" frag="S01" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60497" href="#60497-S01" urititle="SENSORY ORGANS" mediatype="application/vnd.pageseeder.psml+xml">SENSORY ORGANS</xref></inline></para></block><block label="index3"><para indent="2">DECONGESTANTS AND ANTIALLERGICS<inline label="indexpageref"><xref id="107676" title="DECONGESTANTS AND ANTIALLERGICS" frag="S01G" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60497" href="#60497-S01G" urititle="SENSORY ORGANS" mediatype="application/vnd.pageseeder.psml+xml">SENSORY ORGANS</xref></inline></para></block><block label="index2"><para indent="1">OTOLOGICALS<inline label="indexpageref"><xref id="107677" title="OTOLOGICALS" frag="S02" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60497" href="#60497-S02" urititle="SENSORY ORGANS" mediatype="application/vnd.pageseeder.psml+xml">SENSORY ORGANS</xref></inline></para></block><block label="index3"><para indent="2">OTHER OTOLOGICALS<inline label="indexpageref"><xref id="107678" title="OTHER OTOLOGICALS" frag="S02D" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60497" href="#60497-S02D" urititle="SENSORY ORGANS" mediatype="application/vnd.pageseeder.psml+xml">SENSORY ORGANS</xref></inline></para></block><block label="index"><para>VARIOUS<inline label="indexpageref"><xref id="107679" title="VARIOUS" frag="default" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60316" href="#60316" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml">VARIOUS</xref></inline></para></block><block label="index2"><para indent="1">ALL OTHER THERAPEUTIC PRODUCTS<inline label="indexpageref"><xref id="107680" title="ALL OTHER THERAPEUTIC PRODUCTS" frag="V03" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60316" href="#60316-V03" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml">VARIOUS</xref></inline></para></block><block label="index3"><para indent="2">ALL OTHER THERAPEUTIC PRODUCTS<inline label="indexpageref"><xref id="107681" title="ALL OTHER THERAPEUTIC PRODUCTS" frag="V03A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60316" href="#60316-V03A" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml">VARIOUS</xref></inline></para></block><block label="index2"><para indent="1">GENERAL NUTRIENTS<inline label="indexpageref"><xref id="107682" title="GENERAL NUTRIENTS" frag="V06" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60316" href="#60316-V06" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml">VARIOUS</xref></inline></para></block><block label="index3"><para indent="2">OTHER NUTRIENTS<inline label="indexpageref"><xref id="107683" title="OTHER NUTRIENTS" frag="V06D" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60316" href="#60316-V06D" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml">VARIOUS</xref></inline></para></block><block label="index2"><para indent="1">ALL OTHER NON-THERAPEUTIC PRODUCTS<inline label="indexpageref"><xref id="107684" title="ALL OTHER NON-THERAPEUTIC PRODUCTS" frag="V07" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60316" href="#60316-V07" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml">VARIOUS</xref></inline></para></block><block label="index3"><para indent="2">ALL OTHER NON-THERAPEUTIC PRODUCTS<inline label="indexpageref"><xref id="107685" title="ALL OTHER NON-THERAPEUTIC PRODUCTS" frag="V07A" reversefrag="2" reversetitle="Untitled" reverselink="true" reversetype="none" display="document" type="none" uriid="60316" href="#60316-V07A" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml">VARIOUS</xref></inline></para></block><block label="mps3indexsectionbreak">R1</block></fragment></section></document></blockxref>
<blockxref id="107719" title="R1.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="60526" href="dynamic/R1.psml" urititle="Repatriation Pharmaceutical Benefits Scheme" mediatype="application/vnd.pageseeder.psml+xml"><document id="60526" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="60526" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1.psml" decodedpath="/ps/test/local3/books/dynamic/R1.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:29+10:00" modified="2018-06-15T10:34:32+10:00" title="Repatriation Pharmaceutical Benefits Scheme"><displaytitle>Repatriation Pharmaceutical Benefits Scheme</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107719" title="" type="none" forwardtype="embed" forwardtitle="R1.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="44158" fragment="60526-d114e761780" editid="107094" modified="2018-06-15T10:34:29+10:00"></locator></fragmentinfo><metadata></metadata><section id="60526-1"><fragment id="60526-1"></fragment></section><section id="60526-d114e761780"><xref-fragment id="60526-d114e761780"><blockxref id="107081" title="ALIMENTARY TRACT AND METABOLISM" frag="default" reversefrag="d114e761780" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60082" href="dynamic/R1/atc/A.psml" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml"><document id="60082" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="60082" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/atc/A.psml" decodedpath="/ps/test/local3/books/dynamic/R1/atc/A.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:24+10:00" modified="2018-06-15T10:34:32+10:00" title="ALIMENTARY TRACT AND METABOLISM"><displaytitle>ALIMENTARY TRACT AND METABOLISM</displaytitle></uri><reversexrefs><reversexref uriid="60526" href="dynamic/R1.psml" frag="d114e761780" urititle="Repatriation Pharmaceutical Benefits Scheme" mediatype="application/vnd.pageseeder.psml+xml" id="107081" title="R1" type="none" forwardtype="embed" forwardtitle="ALIMENTARY TRACT AND METABOLISM" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107580" title="Untitled" type="none" forwardtype="none" forwardtitle="ALIMENTARY TRACT AND METABOLISM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="44664" fragment="60082-A07"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107590" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS" forwarddisplay="document" forwardfrag="A07"></reversexref></reversexrefs></locator><locator id="43181" fragment="60082-A06AB156331000144109" editid="106098" modified="2018-06-15T10:34:24+10:00"></locator><locator id="44672" fragment="60082-A12"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107598" title="Untitled" type="none" forwardtype="none" forwardtitle="MINERAL SUPPLEMENTS" forwarddisplay="document" forwardfrag="A12"></reversexref></reversexrefs></locator><locator id="44658" fragment="60082-A02A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107584" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTACIDS" forwarddisplay="document" forwardfrag="A02A"></reversexref></reversexrefs></locator><locator id="44660" fragment="60082-A03A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107586" title="Untitled" type="none" forwardtype="none" forwardtitle="DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS" forwarddisplay="document" forwardfrag="A03A"></reversexref></reversexrefs></locator><locator id="44669" fragment="60082-A11"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107595" title="Untitled" type="none" forwardtype="none" forwardtitle="VITAMINS" forwarddisplay="document" forwardfrag="A11"></reversexref></reversexrefs></locator><locator id="43175" fragment="60082-A02AC21538011000036107" editid="106095" modified="2018-06-15T10:34:24+10:00"></locator><locator id="44665" fragment="60082-A07C"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107591" title="Untitled" type="none" forwardtype="none" forwardtitle="ELECTROLYTES WITH CARBOHYDRATES" forwarddisplay="document" forwardfrag="A07C"></reversexref></reversexrefs></locator><locator id="43151" fragment="60082-A11DA21789011000036109" editid="106083" modified="2018-06-15T10:34:24+10:00"></locator><locator id="43177" fragment="60082-A06AB21264011000036101" editid="106096" modified="2018-06-15T10:34:24+10:00"></locator><locator id="44659" fragment="60082-A03"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107585" title="Untitled" type="none" forwardtype="none" forwardtitle="DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS" forwarddisplay="document" forwardfrag="A03"></reversexref></reversexrefs></locator><locator id="43141" fragment="60082-A07CA7861000144106" editid="106078" modified="2018-06-15T10:34:24+10:00"></locator><locator id="43149" fragment="60082-A01AB21404011000036101" editid="106082" modified="2018-06-15T10:34:24+10:00"></locator><locator id="44670" fragment="60082-A11D"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107596" title="Untitled" type="none" forwardtype="none" forwardtitle="VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12" forwarddisplay="document" forwardfrag="A11D"></reversexref></reversexrefs></locator><locator id="43155" fragment="60082-A08AB21581011000036109" editid="106085" modified="2018-06-15T10:34:24+10:00"></locator><locator id="44674" fragment="60082-A12C"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107600" title="Untitled" type="none" forwardtype="none" forwardtitle="OTHER MINERAL SUPPLEMENTS" forwarddisplay="document" forwardfrag="A12C"></reversexref></reversexrefs></locator><locator id="43171" fragment="60082-A03BB21580011000036102" editid="106093" modified="2018-06-15T10:34:24+10:00"></locator><locator id="43183" fragment="60082-A07DA21760011000036100" editid="106099" modified="2018-06-15T10:34:24+10:00"></locator><locator id="44657" fragment="60082-A02"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107583" title="Untitled" type="none" forwardtype="none" forwardtitle="DRUGS FOR ACID RELATED DISORDERS" forwarddisplay="document" forwardfrag="A02"></reversexref></reversexrefs></locator><locator id="43163" fragment="60082-A06AG21630011000036102" editid="106089" modified="2018-06-15T10:34:24+10:00"></locator><locator id="43153" fragment="60082-A06AC21778011000036106" editid="106084" modified="2018-06-15T10:34:24+10:00"></locator><locator id="44656" fragment="60082-A01A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107582" title="Untitled" type="none" forwardtype="none" forwardtitle="STOMATOLOGICAL PREPARATIONS" forwarddisplay="document" forwardfrag="A01A"></reversexref></reversexrefs></locator><locator id="44667" fragment="60082-A08"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107593" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS" forwarddisplay="document" forwardfrag="A08"></reversexref></reversexrefs></locator><locator id="43147" fragment="60082-A06AX21770011000036109" editid="106081" modified="2018-06-15T10:34:24+10:00"></locator><locator id="43179" fragment="60082-A06AB33647011000036109" editid="106097" modified="2018-06-15T10:34:24+10:00"></locator><locator id="43143" fragment="60082-A02AD6411000144105" editid="106079" modified="2018-06-15T10:34:24+10:00"></locator><locator id="44673" fragment="60082-A12A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107599" title="Untitled" type="none" forwardtype="none" forwardtitle="CALCIUM" forwarddisplay="document" forwardfrag="A12A"></reversexref></reversexrefs></locator><locator id="43157" fragment="60082-A03AA21801011000036109" editid="106086" modified="2018-06-15T10:34:24+10:00"></locator><locator id="44655" fragment="60082-A01"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107581" title="Untitled" type="none" forwardtype="none" forwardtitle="STOMATOLOGICAL PREPARATIONS" forwarddisplay="document" forwardfrag="A01"></reversexref></reversexrefs></locator><locator id="44671" fragment="60082-A11E"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107597" title="Untitled" type="none" forwardtype="none" forwardtitle="VITAMIN B-COMPLEX, INCL. COMBINATIONS" forwarddisplay="document" forwardfrag="A11E"></reversexref></reversexrefs></locator><locator id="43139" fragment="60082-A11EA21693011000036103" editid="106077" modified="2018-06-15T10:34:24+10:00"></locator><locator id="43167" fragment="60082-A06AB21718011000036104" editid="106091" modified="2018-06-15T10:34:24+10:00"></locator><locator id="43173" fragment="60082-A12CC52798011000036107" editid="106094" modified="2018-06-15T10:34:24+10:00"></locator><locator id="43169" fragment="60082-A06AC21835011000036100" editid="106092" modified="2018-06-15T10:34:24+10:00"></locator><locator id="44666" fragment="60082-A07D"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107592" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIPROPULSIVES" forwarddisplay="document" forwardfrag="A07D"></reversexref></reversexrefs></locator><locator id="44663" fragment="60082-A06A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107589" title="Untitled" type="none" forwardtype="none" forwardtitle="DRUGS FOR CONSTIPATION" forwarddisplay="document" forwardfrag="A06A"></reversexref></reversexrefs></locator><locator id="44662" fragment="60082-A06"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107588" title="Untitled" type="none" forwardtype="none" forwardtitle="DRUGS FOR CONSTIPATION" forwarddisplay="document" forwardfrag="A06"></reversexref></reversexrefs></locator><locator id="43165" fragment="60082-A12AA1931000144104" editid="106090" modified="2018-06-15T10:34:24+10:00"></locator><locator id="43161" fragment="60082-A06AC21683011000036102" editid="106088" modified="2018-06-15T10:34:24+10:00"></locator><locator id="44661" fragment="60082-A03B"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107587" title="Untitled" type="none" forwardtype="none" forwardtitle="BELLADONNA AND DERIVATIVES, PLAIN" forwarddisplay="document" forwardfrag="A03B"></reversexref></reversexrefs></locator><locator id="44668" fragment="60082-A08A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107594" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS" forwarddisplay="document" forwardfrag="A08A"></reversexref></reversexrefs></locator><locator id="43145" fragment="60082-A01AB21669011000036102" editid="106080" modified="2018-06-15T10:34:24+10:00"></locator><locator id="43159" fragment="60082-A06AA21872011000036106" editid="106087" modified="2018-06-15T10:34:24+10:00"></locator></fragmentinfo><metadata></metadata><section id="60082-A"><fragment id="60082-A"><block label="ATCLevel1"><para>ALIMENTARY TRACT AND METABOLISM</para></block></fragment></section><section id="60082-A01"><fragment id="60082-A01"><block label="ATCLevel2"><para>STOMATOLOGICAL PREPARATIONS</para></block></fragment></section><section id="60082-A01A"><fragment id="60082-A01A"><block label="ATCLevel3"><para>STOMATOLOGICAL PREPARATIONS</para></block></fragment></section><section id="60082-A01AB"><fragment id="60082-A01AB"><block label="ATCLevel4"><para>Antiinfectives and antiseptics for local oral treatment</para></block></fragment></section><section id="60082-A01AB21404011000036101"><xref-fragment id="60082-A01AB21404011000036101"><blockxref id="106059" title="CHLORHEXIDINE" frag="default" reversefrag="A01AB21404011000036101" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60681" href="dynamic/R1/drug/21404011000036101-A01AB.psml" urititle="CHLORHEXIDINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60681" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="60681" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21404011000036101-A01AB.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21404011000036101-A01AB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:30+10:00" modified="2018-06-15T10:34:24+10:00" title="CHLORHEXIDINE"><displaytitle>CHLORHEXIDINE</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A01AB21404011000036101" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106059" title="R1" type="none" forwardtype="embed" forwardtitle="CHLORHEXIDINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60681-21404011000036101-1"><fragment id="60681-21404011000036101-1"><block label="DrugName">CHLORHEXIDINE<inline label="genericindexfield">XE "CHLORHEXIDINE"</inline></block></fragment></section><section id="60681-4204G"><fragment id="60681-4204G"><block label="FormAndStrength">chlorhexidine gluconate 0.2% mouthwash, 300 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4204G<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.79</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Savacol Mouth and Throat Rinse [OM]<inline label="genericindexfieldbrand"><italic>XE "Savacol Mouth and Throat Rinse(OM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60681-4161B"><fragment id="60681-4161B"><block label="FormAndStrength">chlorhexidine gluconate 0.2% mouthwash, 250 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4161B<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">15.85</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Plaqacide [OB]<inline label="genericindexfieldbrand"><italic>XE "Plaqacide(OB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60082-A01AB21669011000036102"><xref-fragment id="60082-A01AB21669011000036102"><blockxref id="106057" title="NYSTATIN" frag="default" reversefrag="A01AB21669011000036102" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59925" href="dynamic/R1/drug/21669011000036102-A01AB.psml" urititle="NYSTATIN" mediatype="application/vnd.pageseeder.psml+xml"><document id="59925" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="59925" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21669011000036102-A01AB.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21669011000036102-A01AB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:24+10:00" title="NYSTATIN"><displaytitle>NYSTATIN</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A01AB21669011000036102" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106057" title="R1" type="none" forwardtype="embed" forwardtitle="NYSTATIN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59925-21669011000036102-1"><fragment id="59925-21669011000036102-1"><block label="DrugName">NYSTATIN<inline label="genericindexfield">XE "NYSTATIN:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="59925-10854G"><fragment id="59925-10854G"><block label="FormAndStrength">nystatin 100 000 units/mL oral liquid, 24 mL</block><table role="R1"><row><cell><block label="DrugItemCode">10854G<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.57</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Pharmacy Action Nystatin Oral Drops [GQ]<inline label="genericindexfieldbrand"><italic>XE "Pharmacy Action Nystatin Oral Drops(GQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.81</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Mycostatin Oral Drops [QA]<inline label="genericindexfieldbrand"><italic>XE "Mycostatin Oral Drops(QA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60082-A02"><fragment id="60082-A02"><block label="ATCLevel2"><para>DRUGS FOR ACID RELATED DISORDERS</para></block></fragment></section><section id="60082-A02A"><fragment id="60082-A02A"><block label="ATCLevel3"><para>ANTACIDS</para></block></fragment></section><section id="60082-A02AC"><fragment id="60082-A02AC"><block label="ATCLevel4"><para>Calcium compounds</para></block></fragment></section><section id="60082-A02AC21538011000036107"><xref-fragment id="60082-A02AC21538011000036107"><blockxref id="106072" title="CALCIUM CARBONATE + GLYCINE" frag="default" reversefrag="A02AC21538011000036107" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60498" href="dynamic/R1/drug/21538011000036107-A02AC.psml" urititle="CALCIUM CARBONATE + GLYCINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60498" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="60498" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21538011000036107-A02AC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21538011000036107-A02AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:24+10:00" title="CALCIUM CARBONATE + GLYCINE"><displaytitle>CALCIUM CARBONATE + GLYCINE</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A02AC21538011000036107" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106072" title="R1" type="none" forwardtype="embed" forwardtitle="CALCIUM CARBONATE + GLYCINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60498-21538011000036107-1"><fragment id="60498-21538011000036107-1"><block label="DrugName">CALCIUM CARBONATE + GLYCINE<inline label="genericindexfield">XE "CALCIUM CARBONATE + GLYCINE"</inline></block></fragment></section><section id="60498-d4580e17"><fragment id="60498-d4580e17"><block label="NoteText"><para>For patients with chronic renal failure.</para></block></fragment></section><section id="60498-4055K"><fragment id="60498-4055K"><block label="FormAndStrength">calcium carbonate 420 mg + glycine 180 mg chewable tablet, 100</block><table role="R1"><row><cell><block label="DrugItemCode">4055K<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>25.67</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Titralac [MM]<inline label="genericindexfieldbrand"><italic>XE "Titralac(MM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60082-A02AD"><fragment id="60082-A02AD"><block label="ATCLevel4"><para>Combinations and complexes of aluminium, calcium and magnesium compounds</para></block></fragment></section><section id="60082-A02AD6411000144105"><xref-fragment id="60082-A02AD6411000144105"><blockxref id="106056" title="ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND SIMETHICONE" frag="default" reversefrag="A02AD6411000144105" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59618" href="dynamic/R1/drug/6411000144105-A02AD.psml" urititle="ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND SIMETHICONE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59618" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="59618" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/6411000144105-A02AD.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/6411000144105-A02AD.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:19+10:00" modified="2018-06-15T10:34:24+10:00" title="ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND SIMETHICONE"><displaytitle>ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND SIMETHICONE</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A02AD6411000144105" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106056" title="R1" type="none" forwardtype="embed" forwardtitle="ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND SIMETHICONE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59618-6411000144105-1"><fragment id="59618-6411000144105-1"><block label="DrugName">ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND SIMETHICONE<inline label="genericindexfield">XE "ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND SIMETHICONE"</inline></block></fragment></section><section id="59618-4118R"><fragment id="59618-4118R"><block label="FormAndStrength">ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE and SIMETHICONE Oral suspension 400 mg-400 mg-30 mg per 5 mL, 500 mL, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4118R<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>25.19</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Mylanta Double Strength [JT]<inline label="genericindexfieldbrand"><italic>XE "Mylanta Double Strength(JT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60082-A03"><fragment id="60082-A03"><block label="ATCLevel2"><para>DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS</para></block></fragment></section><section id="60082-A03A"><fragment id="60082-A03A"><block label="ATCLevel3"><para>DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS</para></block></fragment></section><section id="60082-A03AA"><fragment id="60082-A03AA"><block label="ATCLevel4"><para>Synthetic anticholinergics, esters with tertiary amino group</para></block></fragment></section><section id="60082-A03AA21801011000036109"><xref-fragment id="60082-A03AA21801011000036109"><blockxref id="106063" title="MEBEVERINE" frag="default" reversefrag="A03AA21801011000036109" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60142" href="dynamic/R1/drug/21801011000036109-A03AA.psml" urititle="MEBEVERINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60142" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="60142" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21801011000036109-A03AA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21801011000036109-A03AA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:25+10:00" modified="2018-06-15T10:34:24+10:00" title="MEBEVERINE"><displaytitle>MEBEVERINE</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A03AA21801011000036109" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106063" title="R1" type="none" forwardtype="embed" forwardtitle="MEBEVERINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60142-21801011000036109-1"><fragment id="60142-21801011000036109-1"><block label="DrugName">MEBEVERINE<inline label="genericindexfield">XE "MEBEVERINE"</inline></block></fragment></section><section id="60142-4328T"><fragment id="60142-4328T"><block label="FormAndStrength">mebeverine hydrochloride 135 mg tablet, 90</block><table role="R1"><row><cell><block label="DrugItemCode">4328T<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">28.91</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Colese [AF]<inline label="genericindexfieldbrand"><italic>XE "Colese(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">33.41</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Colofac [GO]<inline label="genericindexfieldbrand"><italic>XE "Colofac(GO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60082-A03B"><fragment id="60082-A03B"><block label="ATCLevel3"><para>BELLADONNA AND DERIVATIVES, PLAIN</para></block></fragment></section><section id="60082-A03BB"><fragment id="60082-A03BB"><block label="ATCLevel4"><para>Belladonna alkaloids, semisynthetic, quaternary ammonium compounds</para></block></fragment></section><section id="60082-A03BB21580011000036102"><xref-fragment id="60082-A03BB21580011000036102"><blockxref id="106070" title="HYOSCINE BUTYLBROMIDE" frag="default" reversefrag="A03BB21580011000036102" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59706" href="dynamic/R1/drug/21580011000036102-A03BB.psml" urititle="HYOSCINE BUTYLBROMIDE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59706" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="59706" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21580011000036102-A03BB.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21580011000036102-A03BB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:20+10:00" modified="2018-06-15T10:34:24+10:00" title="HYOSCINE BUTYLBROMIDE"><displaytitle>HYOSCINE BUTYLBROMIDE</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A03BB21580011000036102" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106070" title="R1" type="none" forwardtype="embed" forwardtitle="HYOSCINE BUTYLBROMIDE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59706-21580011000036102-1"><fragment id="59706-21580011000036102-1"><block label="DrugName">HYOSCINE BUTYLBROMIDE<inline label="genericindexfield">XE "HYOSCINE BUTYLBROMIDE"</inline></block></fragment></section><section id="59706-4279F"><fragment id="59706-4279F"><block label="FormAndStrength">hyoscine butylbromide 20 mg/mL injection, 5 x 1 mL ampoules</block><table role="R1"><row><cell><block label="DrugItemCode">4279F<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">23.43</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Buscopan [VZ]<inline label="genericindexfieldbrand"><italic>XE "Buscopan(VZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60082-A06"><fragment id="60082-A06"><block label="ATCLevel2"><para>DRUGS FOR CONSTIPATION</para></block></fragment></section><section id="60082-A06A"><fragment id="60082-A06A"><block label="ATCLevel3"><para>DRUGS FOR CONSTIPATION</para></block></fragment></section><section id="60082-A06AA"><fragment id="60082-A06AA"><block label="ATCLevel4"><para>Softeners, emollients</para></block></fragment></section><section id="60082-A06AA21872011000036106"><xref-fragment id="60082-A06AA21872011000036106"><blockxref id="106064" title="DOCUSATE" frag="default" reversefrag="A06AA21872011000036106" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60823" href="dynamic/R1/drug/21872011000036106-A06AA.psml" urititle="DOCUSATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60823" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="60823" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21872011000036106-A06AA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21872011000036106-A06AA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:24+10:00" title="DOCUSATE"><displaytitle>DOCUSATE</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A06AA21872011000036106" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106064" title="R1" type="none" forwardtype="embed" forwardtitle="DOCUSATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60823-21872011000036106-1"><fragment id="60823-21872011000036106-1"><block label="DrugName">DOCUSATE<inline label="genericindexfield">XE "DOCUSATE:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="60823-4200C"><fragment id="60823-4200C"><block label="FormAndStrength">docusate sodium 50 mg tablet, 100</block><table role="R1"><row><cell><block label="DrugItemCode">4200C<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.95</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Coloxyl 50 [FM]<inline label="genericindexfieldbrand"><italic>XE "Coloxyl 50(FM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60082-A06AB"><fragment id="60082-A06AB"><block label="ATCLevel4"><para>Contact laxatives</para></block></fragment></section><section id="60082-A06AB21264011000036101"><xref-fragment id="60082-A06AB21264011000036101"><blockxref id="106073" title="BISACODYL" frag="default" reversefrag="A06AB21264011000036101" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59803" href="dynamic/R1/drug/21264011000036101-A06AB.psml" urititle="BISACODYL" mediatype="application/vnd.pageseeder.psml+xml"><document id="59803" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="59803" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21264011000036101-A06AB.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21264011000036101-A06AB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:24+10:00" title="BISACODYL"><displaytitle>BISACODYL</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A06AB21264011000036101" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106073" title="R1" type="none" forwardtype="embed" forwardtitle="BISACODYL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59803-21264011000036101-1"><fragment id="59803-21264011000036101-1"><block label="DrugName">BISACODYL<inline label="genericindexfield">XE "BISACODYL:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="59803-10578R"><fragment id="59803-10578R"><block label="FormAndStrength">bisacodyl 10 mg suppository, 10</block><table role="R1"><row><cell><block label="DrugItemCode">10578R<br></br></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>23.71</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Petrus Bisacodyl Suppositories [PP]<inline label="genericindexfieldbrand"><italic>XE "Petrus Bisacodyl Suppositories(PP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>25.00</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Dulcolax [VZ]<inline label="genericindexfieldbrand"><italic>XE "Dulcolax(VZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59803-10580W"><fragment id="59803-10580W"><block label="FormAndStrength">bisacodyl 10 mg suppository, 12</block><table role="R1"><row><cell><block label="DrugItemCode">10580W<br></br></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">4</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>21.43</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Petrus Bisacodyl Suppositories [PP]<inline label="genericindexfieldbrand"><italic>XE "Petrus Bisacodyl Suppositories(PP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60082-A06AB33647011000036109"><xref-fragment id="60082-A06AB33647011000036109"><blockxref id="106074" title="DOCUSATE + SENNOSIDE B" frag="default" reversefrag="A06AB33647011000036109" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59624" href="dynamic/R1/drug/33647011000036109-A06AB.psml" urititle="DOCUSATE + SENNOSIDE B" mediatype="application/vnd.pageseeder.psml+xml"><document id="59624" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="59624" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/33647011000036109-A06AB.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/33647011000036109-A06AB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:19+10:00" modified="2018-06-15T10:34:24+10:00" title="DOCUSATE + SENNOSIDE B"><displaytitle>DOCUSATE + SENNOSIDE B</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A06AB33647011000036109" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106074" title="R1" type="none" forwardtype="embed" forwardtitle="DOCUSATE + SENNOSIDE B" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59624-33647011000036109-1"><fragment id="59624-33647011000036109-1"><block label="DrugName">DOCUSATE + SENNOSIDE B<inline label="genericindexfield">XE "DOCUSATE + SENNOSIDE B"</inline></block></fragment></section><section id="59624-10177P"><fragment id="59624-10177P"><block label="FormAndStrength">docusate sodium 50 mg + sennoside B 8 mg tablet, 90</block><table role="R1"><row><cell><block label="DrugItemCode">10177P<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">16.93</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Pharmacy Action Laxative with Senna [GQ]<inline label="genericindexfieldbrand"><italic>XE "Pharmacy Action Laxative with Senna(GQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59624-4028B"><fragment id="59624-4028B"><block label="FormAndStrength">docusate sodium 50 mg + sennoside B 8 mg tablet, 100</block><table role="R1"><row><cell><block label="DrugItemCode">4028B<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.04</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Soflax [EA]<inline label="genericindexfieldbrand"><italic>XE "Soflax(EA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60082-A06AB156331000144109"><xref-fragment id="60082-A06AB156331000144109"><blockxref id="106075" title="DOCUSATE + SENNOSIDES" frag="default" reversefrag="A06AB156331000144109" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60694" href="dynamic/R1/drug/156331000144109-A06AB.psml" urititle="DOCUSATE + SENNOSIDES" mediatype="application/vnd.pageseeder.psml+xml"><document id="60694" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="60694" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/156331000144109-A06AB.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/156331000144109-A06AB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:31+10:00" modified="2018-06-15T10:34:24+10:00" title="DOCUSATE + SENNOSIDES"><displaytitle>DOCUSATE + SENNOSIDES</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A06AB156331000144109" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106075" title="R1" type="none" forwardtype="embed" forwardtitle="DOCUSATE + SENNOSIDES" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60694-156331000144109-1"><fragment id="60694-156331000144109-1"><block label="DrugName">DOCUSATE + SENNOSIDES<inline label="genericindexfield">XE "DOCUSATE + SENNOSIDES"</inline></block></fragment></section><section id="60694-4198Y"><fragment id="60694-4198Y"><block label="FormAndStrength">docusate sodium 50 mg + sennosides 11.27 mg tablet, 90</block><table role="R1"><row><cell><block label="DrugItemCode">4198Y<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">16.97</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Chemists' Own Laxative with Senna [RW]<inline label="genericindexfieldbrand"><italic>XE "Chemists' Own Laxative with Senna(RW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Colaxsen [QA]<inline label="genericindexfieldbrand"><italic>XE "Colaxsen (QA)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Co-Senna [PP]<inline label="genericindexfieldbrand"><italic>XE "Co-Senna(PP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">20.02</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Coloxyl with Senna [FM]<inline label="genericindexfieldbrand"><italic>XE "Coloxyl with Senna(FM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60082-A06AB21718011000036104"><xref-fragment id="60082-A06AB21718011000036104"><blockxref id="106068" title="SENNOSIDE B" frag="default" reversefrag="A06AB21718011000036104" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60320" href="dynamic/R1/drug/21718011000036104-A06AB.psml" urititle="SENNOSIDE B" mediatype="application/vnd.pageseeder.psml+xml"><document id="60320" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="60320" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21718011000036104-A06AB.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21718011000036104-A06AB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:27+10:00" modified="2018-06-15T10:34:24+10:00" title="SENNOSIDE B"><displaytitle>SENNOSIDE B</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A06AB21718011000036104" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106068" title="R1" type="none" forwardtype="embed" forwardtitle="SENNOSIDE B" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60320-21718011000036104-1"><fragment id="60320-21718011000036104-1"><block label="DrugName">SENNOSIDE B<inline label="genericindexfield">XE "SENNOSIDE B"</inline></block></fragment></section><section id="60320-4455L"><fragment id="60320-4455L"><block label="FormAndStrength">sennoside B 7.5 mg tablet, 100</block><table role="R1"><row><cell><block label="DrugItemCode">4455L<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">16.46</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Senna-Gen [PP]<inline label="genericindexfieldbrand"><italic>XE "Senna-Gen(PP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.56</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Senokot [RC]<inline label="genericindexfieldbrand"><italic>XE "Senokot(RC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60082-A06AC"><fragment id="60082-A06AC"><block label="ATCLevel4"><para>Bulk-forming laxatives</para></block></fragment></section><section id="60082-A06AC21835011000036100"><xref-fragment id="60082-A06AC21835011000036100"><blockxref id="106069" title="DRY PSYLLIUM HUSK" frag="default" reversefrag="A06AC21835011000036100" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60853" href="dynamic/R1/drug/21835011000036100-A06AC.psml" urititle="DRY PSYLLIUM HUSK" mediatype="application/vnd.pageseeder.psml+xml"><document id="60853" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="60853" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21835011000036100-A06AC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21835011000036100-A06AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:24+10:00" title="DRY PSYLLIUM HUSK"><displaytitle>DRY PSYLLIUM HUSK</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A06AC21835011000036100" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106069" title="R1" type="none" forwardtype="embed" forwardtitle="DRY PSYLLIUM HUSK" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60853-21835011000036100-1"><fragment id="60853-21835011000036100-1"><block label="DrugName">DRY PSYLLIUM HUSK<inline label="genericindexfield">XE "DRY PSYLLIUM HUSK"</inline></block></fragment></section><section id="60853-4285M"><fragment id="60853-4285M"><block label="FormAndStrength">dry psyllium husk 3.5 g powder for oral liquid, 30 sachets</block><table role="R1"><row><cell><block label="DrugItemCode">4285M<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">20.85</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Fybogel [RC]<inline label="genericindexfieldbrand"><italic>XE "Fybogel(RC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60082-A06AC21683011000036102"><xref-fragment id="60082-A06AC21683011000036102"><blockxref id="106065" title="PSYLLIUM HUSK POWDER" frag="default" reversefrag="A06AC21683011000036102" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60856" href="dynamic/R1/drug/21683011000036102-A06AC.psml" urititle="PSYLLIUM HUSK POWDER" mediatype="application/vnd.pageseeder.psml+xml"><document id="60856" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="60856" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21683011000036102-A06AC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21683011000036102-A06AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:24+10:00" title="PSYLLIUM HUSK POWDER"><displaytitle>PSYLLIUM HUSK POWDER</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A06AC21683011000036102" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106065" title="R1" type="none" forwardtype="embed" forwardtitle="PSYLLIUM HUSK POWDER" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60856-21683011000036102-1"><fragment id="60856-21683011000036102-1"><block label="DrugName">PSYLLIUM HUSK POWDER<inline label="genericindexfield">XE "PSYLLIUM HUSK POWDER"</inline></block></fragment></section><section id="60856-4422R"><fragment id="60856-4422R"><block label="FormAndStrength">PSYLLIUM HYDROPHILIC MUCILLOID Oral powder (non-flavoured) 336 g, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4422R<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">21.18</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Fibre Health Natural Granular [PP]<inline label="genericindexfieldbrand"><italic>XE "Fibre Health Natural Granular(PP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">24.35</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Metamucil Natural Granular [PY]<inline label="genericindexfieldbrand"><italic>XE "Metamucil Natural Granular(PY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60856-4419N"><fragment id="60856-4419N"><block label="FormAndStrength">PSYLLIUM HYDROPHILIC MUCILLOID Oral powder (orange-flavoured, sugar-free) 283 g, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4419N<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">24.35</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Metamucil Orange Smooth [PY]<inline label="genericindexfieldbrand"><italic>XE "Metamucil Orange Smooth(PY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60082-A06AC21778011000036106"><xref-fragment id="60082-A06AC21778011000036106"><blockxref id="106061" title="RHAMNUS FRANGULA + STERCULIA" frag="default" reversefrag="A06AC21778011000036106" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60952" href="dynamic/R1/drug/21778011000036106-A06AC.psml" urititle="RHAMNUS FRANGULA + STERCULIA" mediatype="application/vnd.pageseeder.psml+xml"><document id="60952" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="60952" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21778011000036106-A06AC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21778011000036106-A06AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:33+10:00" modified="2018-06-15T10:34:24+10:00" title="RHAMNUS FRANGULA + STERCULIA"><displaytitle>RHAMNUS FRANGULA + STERCULIA</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A06AC21778011000036106" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106061" title="R1" type="none" forwardtype="embed" forwardtitle="RHAMNUS FRANGULA + STERCULIA" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60952-21778011000036106-1"><fragment id="60952-21778011000036106-1"><block label="DrugName">RHAMNUS FRANGULA + STERCULIA<inline label="genericindexfield">XE "RHAMNUS FRANGULA + STERCULIA"</inline></block></fragment></section><section id="60952-4558X"><fragment id="60952-4558X"><block label="FormAndStrength">rhamnus frangula 80 mg/g + sterculia 620 mg/g granules, 500 g</block><table role="R1"><row><cell><block label="DrugItemCode">4558X<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">27.57</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Normacol Plus [NE]<inline label="genericindexfieldbrand"><italic>XE "Normacol Plus(NE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60082-A06AG"><fragment id="60082-A06AG"><block label="ATCLevel4"><para>Enemas</para></block></fragment></section><section id="60082-A06AG21630011000036102"><xref-fragment id="60082-A06AG21630011000036102"><blockxref id="106066" title="CITRIC ACID + LAURYL SULFOACETATE SODIUM + SORBITOL" frag="default" reversefrag="A06AG21630011000036102" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60302" href="dynamic/R1/drug/21630011000036102-A06AG.psml" urititle="CITRIC ACID + LAURYL SULFOACETATE SODIUM + SORBITOL" mediatype="application/vnd.pageseeder.psml+xml"><document id="60302" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="60302" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21630011000036102-A06AG.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21630011000036102-A06AG.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:26+10:00" modified="2018-06-15T10:34:24+10:00" title="CITRIC ACID + LAURYL SULFOACETATE SODIUM + SORBITOL"><displaytitle>CITRIC ACID + LAURYL SULFOACETATE SODIUM + SORBITOL</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A06AG21630011000036102" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106066" title="R1" type="none" forwardtype="embed" forwardtitle="CITRIC ACID + LAURYL SULFOACETATE SODIUM + SORBITOL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60302-21630011000036102-1"><fragment id="60302-21630011000036102-1"><block label="DrugName">CITRIC ACID + LAURYL SULFOACETATE SODIUM + SORBITOL<inline label="genericindexfield">XE "CITRIC ACID + LAURYL SULFOACETATE SODIUM + SORBITOL"</inline></block></fragment></section><section id="60302-4462W"><fragment id="60302-4462W"><block label="FormAndStrength">sodium citrate dihydrate 450 mg/5 mL + lauryl sulfoacetate sodium 45 mg/5 mL + sorbitol 3.125 g/5 mL enema, 4 x 5 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4462W<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">16.03</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Micolette [AE]<inline label="genericindexfieldbrand"><italic>XE "Micolette(AE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60082-A06AX"><fragment id="60082-A06AX"><block label="ATCLevel4"><para>Other drugs for constipation</para></block></fragment></section><section id="60082-A06AX21770011000036109"><xref-fragment id="60082-A06AX21770011000036109"><blockxref id="106058" title="GLYCEROL" frag="default" reversefrag="A06AX21770011000036109" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60826" href="dynamic/R1/drug/21770011000036109-A06AX.psml" urititle="GLYCEROL" mediatype="application/vnd.pageseeder.psml+xml"><document id="60826" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="60826" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21770011000036109-A06AX.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21770011000036109-A06AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:24+10:00" title="GLYCEROL"><displaytitle>GLYCEROL</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A06AX21770011000036109" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106058" title="R1" type="none" forwardtype="embed" forwardtitle="GLYCEROL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60826-21770011000036109-1"><fragment id="60826-21770011000036109-1"><block label="DrugName">GLYCEROL<inline label="genericindexfield">XE "GLYCEROL"</inline></block></fragment></section><section id="60826-10596Q"><fragment id="60826-10596Q"><block label="FormAndStrength">glycerol 1.4 g suppository, 12</block><table role="R1"><row><cell><block label="DrugItemCode">10596Q<br></br></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>23.32</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Petrus Pharmaceuticals Pty Ltd [PP]<inline label="genericindexfieldbrand"><italic>XE "Petrus Pharmaceuticals Pty Ltd(PP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60826-4246L"><fragment id="60826-4246L"><block label="FormAndStrength">glycerol 2.8 g suppository, 12</block><table role="R1"><row><cell><block label="DrugItemCode">4246L<br></br></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>23.80</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Petrus Pharmaceuticals Pty Ltd [PP]<inline label="genericindexfieldbrand"><italic>XE "Petrus Pharmaceuticals Pty Ltd(PP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60826-10586E"><fragment id="60826-10586E"><block label="FormAndStrength">glycerol 700 mg suppository, 12</block><table role="R1"><row><cell><block label="DrugItemCode">10586E<br></br></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>22.96</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Petrus Pharmaceuticals Pty Ltd [PP]<inline label="genericindexfieldbrand"><italic>XE "Petrus Pharmaceuticals Pty Ltd(PP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60082-A07"><fragment id="60082-A07"><block label="ATCLevel2"><para>ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS</para></block></fragment></section><section id="60082-A07C"><fragment id="60082-A07C"><block label="ATCLevel3"><para>ELECTROLYTES WITH CARBOHYDRATES</para></block></fragment></section><section id="60082-A07CA"><fragment id="60082-A07CA"><block label="ATCLevel4"><para>Oral rehydration salt formulations</para></block></fragment></section><section id="60082-A07CA7861000144106"><xref-fragment id="60082-A07CA7861000144106"><blockxref id="106055" title="SODIUM CHLORIDE + POTASSIUM CHLORIDE + GLUCOSE MONOHYDRATE + CITRIC ACID" frag="default" reversefrag="A07CA7861000144106" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60607" href="dynamic/R1/drug/7861000144106-A07CA.psml" urititle="SODIUM CHLORIDE + POTASSIUM CHLORIDE + GLUCOSE MONOHYDRATE + CITRIC ACID" mediatype="application/vnd.pageseeder.psml+xml"><document id="60607" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="60607" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/7861000144106-A07CA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/7861000144106-A07CA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:30+10:00" modified="2018-06-15T10:34:24+10:00" title="SODIUM CHLORIDE + POTASSIUM CHLORIDE + GLUCOSE MONOHYDRATE + CITRIC ACID"><displaytitle>SODIUM CHLORIDE + POTASSIUM CHLORIDE + GLUCOSE MONOHYDRATE + CITRIC ACID</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A07CA7861000144106" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106055" title="R1" type="none" forwardtype="embed" forwardtitle="SODIUM CHLORIDE + POTASSIUM CHLORIDE + GLUCOSE MONOHYDRATE + CITRIC ACID" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60607-7861000144106-1"><fragment id="60607-7861000144106-1"><block label="DrugName">SODIUM CHLORIDE + POTASSIUM CHLORIDE + GLUCOSE MONOHYDRATE + CITRIC ACID<inline label="genericindexfield">XE "SODIUM CHLORIDE + POTASSIUM CHLORIDE + GLUCOSE MONOHYDRATE + CITRIC ACID"</inline></block></fragment></section><section id="60607-10574M"><fragment id="60607-10574M"><block label="FormAndStrength">sodium chloride 470 mg + potassium chloride 300 mg + glucose monohydrate 3.56 g + sodium acid citrate 530 mg powder for oral liquid, 10 x 4.9 g sachets</block><table role="R1"><row><cell><block label="DrugItemCode">10574M<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">15.90</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">restore O.R.S. [EA]<inline label="genericindexfieldbrand"><italic>XE "restore O.R.S.(EA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60082-A07D"><fragment id="60082-A07D"><block label="ATCLevel3"><para>ANTIPROPULSIVES</para></block></fragment></section><section id="60082-A07DA"><fragment id="60082-A07DA"><block label="ATCLevel4"><para>Antipropulsives</para></block></fragment></section><section id="60082-A07DA21760011000036100"><xref-fragment id="60082-A07DA21760011000036100"><blockxref id="106076" title="LOPERAMIDE" frag="default" reversefrag="A07DA21760011000036100" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59642" href="dynamic/R1/drug/21760011000036100-A07DA.psml" urititle="LOPERAMIDE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59642" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="59642" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21760011000036100-A07DA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21760011000036100-A07DA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:19+10:00" modified="2018-06-15T10:34:24+10:00" title="LOPERAMIDE"><displaytitle>LOPERAMIDE</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A07DA21760011000036100" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106076" title="R1" type="none" forwardtype="embed" forwardtitle="LOPERAMIDE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59642-21760011000036100-1"><fragment id="59642-21760011000036100-1"><block label="DrugName">LOPERAMIDE<inline label="genericindexfield">XE "LOPERAMIDE"</inline></block></fragment></section><section id="59642-10592L"><fragment id="59642-10592L"><block label="FormAndStrength">loperamide hydrochloride 2 mg capsule, 12</block><table role="R1"><row><cell><block label="DrugItemCode">10592L<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">12.58</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Gastrex [CR]<inline label="genericindexfieldbrand"><italic>XE "Gastrex(CR)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59642-11135C"><fragment id="59642-11135C"><block label="FormAndStrength">loperamide hydrochloride 2 mg capsule, 20</block><table role="R1"><row><cell><block label="DrugItemCode">11135C<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">12.58</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Pharmacy Action Diarrhoea Relief [GQ]<inline label="genericindexfieldbrand"><italic>XE "Pharmacy Action Diarrhoea Relief(GQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60082-A08"><fragment id="60082-A08"><block label="ATCLevel2"><para>ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS</para></block></fragment></section><section id="60082-A08A"><fragment id="60082-A08A"><block label="ATCLevel3"><para>ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS</para></block></fragment></section><section id="60082-A08AB"><fragment id="60082-A08AB"><block label="ATCLevel4"><para>Peripherally acting antiobesity products</para></block></fragment></section><section id="60082-A08AB21581011000036109"><xref-fragment id="60082-A08AB21581011000036109"><blockxref id="106062" title="ORLISTAT" frag="default" reversefrag="A08AB21581011000036109" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60892" href="dynamic/R1/drug/21581011000036109-A08AB.psml" urititle="ORLISTAT" mediatype="application/vnd.pageseeder.psml+xml"><document id="60892" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="60892" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21581011000036109-A08AB.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21581011000036109-A08AB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:33+10:00" modified="2018-06-15T10:34:24+10:00" title="ORLISTAT"><displaytitle>ORLISTAT</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A08AB21581011000036109" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106062" title="R1" type="none" forwardtype="embed" forwardtitle="ORLISTAT" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60892-21581011000036109-1"><fragment id="60892-21581011000036109-1"><block label="DrugName">ORLISTAT<inline label="genericindexfield">XE "ORLISTAT"</inline></block></fragment></section><section id="60892-d4597e56"><fragment id="60892-d4597e56"><block label="NoteText"><para>The patient should be ideally enrolled in an exercise program and be receiving supplemental vitamins.</para></block></fragment></section><section id="60892-d4597e16"><fragment id="60892-d4597e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Obesity</para><para>Treatment Phase: Initial treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a Body Mass Index (BMI) greater than or equal to 35 with no known co-morbidities; OR</para></item><item><para>Patient must have a BMI greater than or equal to 30 with 1 or more of the following co-morbidities;(i) diabetes;(ii) ischaemic heart disease;(iii) psychiatric conditions;(iv) hypertension,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be receiving, or enrolled to receive, professional dietetic and weight management advice (where this is available),</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not exceed 12 months in total from initial application,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not receive more than 1 continuous treatment in a lifetime.</para></item></list> <para>The prescriber must provide the patient's initial body weight and BMI at the time of application.</para></block></fragment></section><section id="60892-d4597e92"><fragment id="60892-d4597e92"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Obesity</para><para>Treatment Phase: Continuing treatment (3 to 6 months following commencement)</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously been issued with an authority prescription for this drug,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have reduced their inital body weight by 2.5 kg or 2.5% (whichever is the lesser) during the period 3 to 6 months following commencement of treatment with this drug,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not exceed 12 months in total from initial application,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not receive more than 1 continuous treatment in a lifetime,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be receiving, or enrolled to receive, professional dietetic and weight management advice (where this is available).</para></item></list></block></fragment></section><section id="60892-d4597e167"><fragment id="60892-d4597e167"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Obesity</para><para>Treatment Phase: Continuing treatment (6 to 12 months following commencement)</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have previously been issued with an authority prescription for this drug,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have reduced their inital body weight by 5 kg or 5% (whichever is the lesser) during the period 6 to 12 months following commencement of treatment with this drug,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must not exceed 12 months in total from initial application,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must not receive more than 1 continuous treatment in a lifetime,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be receiving, or enrolled to receive, professional dietetic and weight management advice (where this is available).</para></item></list></block></fragment></section><section id="60892-4570M"><fragment id="60892-4570M"><block label="FormAndStrength">orlistat 120 mg capsule, 84</block><table role="R1"><row><cell><block label="DrugItemCode">4570M<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">132.67</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Xenical [RO]<inline label="genericindexfieldbrand"><italic>XE "Xenical(RO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60082-A11"><fragment id="60082-A11"><block label="ATCLevel2"><para>VITAMINS</para></block></fragment></section><section id="60082-A11D"><fragment id="60082-A11D"><block label="ATCLevel3"><para>VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12</para></block></fragment></section><section id="60082-A11DA"><fragment id="60082-A11DA"><block label="ATCLevel4"><para>Vitamin B1, plain</para></block></fragment></section><section id="60082-A11DA21789011000036109"><xref-fragment id="60082-A11DA21789011000036109"><blockxref id="106060" title="THIAMINE" frag="default" reversefrag="A11DA21789011000036109" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60537" href="dynamic/R1/drug/21789011000036109-A11DA.psml" urititle="THIAMINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60537" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="60537" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21789011000036109-A11DA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21789011000036109-A11DA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:29+10:00" modified="2018-06-15T10:34:24+10:00" title="THIAMINE"><displaytitle>THIAMINE</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A11DA21789011000036109" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106060" title="R1" type="none" forwardtype="embed" forwardtitle="THIAMINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60537-21789011000036109-1"><fragment id="60537-21789011000036109-1"><block label="DrugName">THIAMINE<inline label="genericindexfield">XE "THIAMINE"</inline></block></fragment></section><section id="60537-4043T"><fragment id="60537-4043T"><block label="FormAndStrength">thiamine hydrochloride 100 mg tablet, 100</block><table role="R1"><row><cell><block label="DrugItemCode">4043T<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">14.98</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Betavit [PP]<inline label="genericindexfieldbrand"><italic>XE "Betavit(PP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60082-A11E"><fragment id="60082-A11E"><block label="ATCLevel3"><para>VITAMIN B-COMPLEX, INCL. COMBINATIONS</para></block></fragment></section><section id="60082-A11EA"><fragment id="60082-A11EA"><block label="ATCLevel4"><para>Vitamin B-complex, plain</para></block></fragment></section><section id="60082-A11EA21693011000036103"><xref-fragment id="60082-A11EA21693011000036103"><blockxref id="106054" title="LYSINE + THIAMINE + PYRIDOXINE + CYANOCOBALAMIN + FERRIC PYROPHOSPHATE" frag="default" reversefrag="A11EA21693011000036103" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60825" href="dynamic/R1/drug/21693011000036103-A11EA.psml" urititle="LYSINE + THIAMINE + PYRIDOXINE + CYANOCOBALAMIN + FERRIC PYROPHOSPHATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60825" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="60825" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21693011000036103-A11EA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21693011000036103-A11EA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:24+10:00" title="LYSINE + THIAMINE + PYRIDOXINE + CYANOCOBALAMIN + FERRIC PYROPHOSPHATE"><displaytitle>LYSINE + THIAMINE + PYRIDOXINE + CYANOCOBALAMIN + FERRIC PYROPHOSPHATE</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A11EA21693011000036103" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106054" title="R1" type="none" forwardtype="embed" forwardtitle="LYSINE + THIAMINE + PYRIDOXINE + CYANOCOBALAMIN + FERRIC PYROPHOSPHATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60825-21693011000036103-1"><fragment id="60825-21693011000036103-1"><block label="DrugName">LYSINE + THIAMINE + PYRIDOXINE + CYANOCOBALAMIN + FERRIC PYROPHOSPHATE<inline label="genericindexfield">XE "LYSINE + THIAMINE + PYRIDOXINE + CYANOCOBALAMIN + FERRIC PYROPHOSPHATE"</inline></block></fragment></section><section id="60825-4493L"><fragment id="60825-4493L"><block label="FormAndStrength">lysine hydrochloride 300 mg/10 mL + thiamine hydrochloride 10 mg/10 mL + pyridoxine hydrochloride 5 mg/10 mL + cyanocobalamin 25 microgram/10 mL + iron (as ferric pyrophosphate) 10 mg/10 mL oral liquid, 200 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4493L<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.11</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Accomin Adult Tonic [PF]<inline label="genericindexfieldbrand"><italic>XE "Accomin Adult Tonic(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60082-A12"><fragment id="60082-A12"><block label="ATCLevel2"><para>MINERAL SUPPLEMENTS</para></block></fragment></section><section id="60082-A12A"><fragment id="60082-A12A"><block label="ATCLevel3"><para>CALCIUM</para></block></fragment></section><section id="60082-A12AA"><fragment id="60082-A12AA"><block label="ATCLevel4"><para>Calcium</para></block></fragment></section><section id="60082-A12AA1931000144104"><xref-fragment id="60082-A12AA1931000144104"><blockxref id="106067" title="CALCIUM" frag="default" reversefrag="A12AA1931000144104" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60652" href="dynamic/R1/drug/1931000144104-A12AA.psml" urititle="CALCIUM" mediatype="application/vnd.pageseeder.psml+xml"><document id="60652" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="60652" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/1931000144104-A12AA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/1931000144104-A12AA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:30+10:00" modified="2018-06-15T10:34:24+10:00" title="CALCIUM"><displaytitle>CALCIUM</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A12AA1931000144104" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106067" title="R1" type="none" forwardtype="embed" forwardtitle="CALCIUM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60652-1931000144104-1"><fragment id="60652-1931000144104-1"><block label="DrugName">CALCIUM<inline label="genericindexfield">XE "CALCIUM"</inline></block></fragment></section><section id="60652-d4603e16"><fragment id="60652-d4603e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Hyperphosphataemia</para><para><bold>Clinical criteria:</bold></para><list><item><para>The condition must be associated with chronic renal failure.</para></item></list></block></fragment></section><section id="60652-4094L"><fragment id="60652-4094L"><block label="FormAndStrength">CALCIUM Tablet (chewable) 500 mg (as carbonate), 60</block><table role="R1"><row><cell><block label="DrugItemCode">4094L<br></br></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>29.67</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Cal-500 [PP]<inline label="genericindexfieldbrand"><italic>XE "Cal-500(PP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60652-4142B"><fragment id="60652-4142B"><block label="FormAndStrength">CALCIUM Tablet 600 mg (as carbonate), 120</block><table role="R1"><row><cell><block label="DrugItemCode">4142B<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>24.13</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">CAL-600 [PP]<inline label="genericindexfieldbrand"><italic>XE "CAL-600(PP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60652-1931000144104-2"><fragment id="60652-1931000144104-2"><block label="DrugName">CALCIUM<inline label="genericindexfield">XE "CALCIUM"</inline></block></fragment></section><section id="60652-d4605e16"><fragment id="60652-d4605e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Hypocalcaemia</para></block></fragment></section><section id="60652-d4605e38"><fragment id="60652-d4605e38"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Osteoporosis</para></block></fragment></section><section id="60652-d4605e60"><fragment id="60652-d4605e60"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Proven calcium malabsorption</para></block></fragment></section><section id="60652-4333C"><fragment id="60652-4333C"><block label="FormAndStrength">CALCIUM Tablet (chewable) 500 mg (as carbonate), 60</block><table role="R1"><row><cell><block label="DrugItemCode">4333C<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>20.37</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Cal-500 [PP]<inline label="genericindexfieldbrand"><italic>XE "Cal-500(PP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60652-4082W"><fragment id="60652-4082W"><block label="FormAndStrength">CALCIUM Tablet 600 mg (as carbonate), 120</block><table role="R1"><row><cell><block label="DrugItemCode">4082W<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.61</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">CAL-600 [PP]<inline label="genericindexfieldbrand"><italic>XE "CAL-600(PP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60082-A12C"><fragment id="60082-A12C"><block label="ATCLevel3"><para>OTHER MINERAL SUPPLEMENTS</para></block></fragment></section><section id="60082-A12CC"><fragment id="60082-A12CC"><block label="ATCLevel4"><para>Magnesium</para></block></fragment></section><section id="60082-A12CC52798011000036107"><xref-fragment id="60082-A12CC52798011000036107"><blockxref id="106071" title="MAGNESIUM ASPARTATE DIHYDRATE" frag="default" reversefrag="A12CC52798011000036107" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60546" href="dynamic/R1/drug/52798011000036107-A12CC.psml" urititle="MAGNESIUM ASPARTATE DIHYDRATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60546" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="60546" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/52798011000036107-A12CC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/52798011000036107-A12CC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:29+10:00" modified="2018-06-15T10:34:24+10:00" title="MAGNESIUM ASPARTATE DIHYDRATE"><displaytitle>MAGNESIUM ASPARTATE DIHYDRATE</displaytitle></uri><reversexrefs><reversexref uriid="60082" href="dynamic/R1/atc/A.psml" frag="A12CC52798011000036107" urititle="ALIMENTARY TRACT AND METABOLISM" mediatype="application/vnd.pageseeder.psml+xml" id="106071" title="R1" type="none" forwardtype="embed" forwardtitle="MAGNESIUM ASPARTATE DIHYDRATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60546-52798011000036107-1"><fragment id="60546-52798011000036107-1"><block label="DrugName">MAGNESIUM ASPARTATE DIHYDRATE<inline label="genericindexfield">XE "MAGNESIUM ASPARTATE DIHYDRATE"</inline></block></fragment></section><section id="60546-d4609e16"><fragment id="60546-d4609e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Hypomagnesaemia</para> <para>The condition must be documented in the patient's medical records.</para></block></fragment></section><section id="60546-4321K"><fragment id="60546-4321K"><block label="FormAndStrength">magnesium aspartate dihydrate 500 mg (magnesium 37.4 mg) tablet, 50</block><table role="R1"><row><cell><block label="DrugItemCode">4321K<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.11</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Mag-Sup [PP]<inline label="genericindexfieldbrand"><italic>XE "Mag-Sup(PP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.68</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Magmin [BB]<inline label="genericindexfieldbrand"><italic>XE "Magmin(BB)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref><blockxref id="107082" title="BLOOD AND BLOOD FORMING ORGANS" frag="default" reversefrag="d114e761780" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60034" href="dynamic/R1/atc/B.psml" urititle="BLOOD AND BLOOD FORMING ORGANS" mediatype="application/vnd.pageseeder.psml+xml"><document id="60034" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="60034" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/atc/B.psml" decodedpath="/ps/test/local3/books/dynamic/R1/atc/B.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:24+10:00" modified="2018-06-15T10:34:32+10:00" title="BLOOD AND BLOOD FORMING ORGANS"><displaytitle>BLOOD AND BLOOD FORMING ORGANS</displaytitle></uri><reversexrefs><reversexref uriid="60526" href="dynamic/R1.psml" frag="d114e761780" urititle="Repatriation Pharmaceutical Benefits Scheme" mediatype="application/vnd.pageseeder.psml+xml" id="107082" title="R1" type="none" forwardtype="embed" forwardtitle="BLOOD AND BLOOD FORMING ORGANS" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107601" title="Untitled" type="none" forwardtype="none" forwardtitle="BLOOD AND BLOOD FORMING ORGANS" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="43096" fragment="60034-B03BA21828011000036108" editid="106013" modified="2018-06-15T10:34:24+10:00"></locator><locator id="43088" fragment="60034-B03BB21654011000036106" editid="106009" modified="2018-06-15T10:34:24+10:00"></locator><locator id="44679" fragment="60034-B03B"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107606" title="Untitled" type="none" forwardtype="none" forwardtitle="VITAMIN B12 AND FOLIC ACID" forwarddisplay="document" forwardfrag="B03B"></reversexref></reversexrefs></locator><locator id="44681" fragment="60034-B05C"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107608" title="Untitled" type="none" forwardtype="none" forwardtitle="IRRIGATING SOLUTIONS" forwarddisplay="document" forwardfrag="B05C"></reversexref></reversexrefs></locator><locator id="44678" fragment="60034-B03A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107605" title="Untitled" type="none" forwardtype="none" forwardtitle="IRON PREPARATIONS" forwarddisplay="document" forwardfrag="B03A"></reversexref></reversexrefs></locator><locator id="43086" fragment="60034-B05CB21308011000036103" editid="106008" modified="2018-06-15T10:34:24+10:00"></locator><locator id="43098" fragment="60034-B01AC21719011000036107" editid="106014" modified="2018-06-15T10:34:24+10:00"></locator><locator id="44677" fragment="60034-B03"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107604" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIANEMIC PREPARATIONS" forwarddisplay="document" forwardfrag="B03"></reversexref></reversexrefs></locator><locator id="44676" fragment="60034-B01A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107603" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTITHROMBOTIC AGENTS" forwarddisplay="document" forwardfrag="B01A"></reversexref></reversexrefs></locator><locator id="44675" fragment="60034-B01"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107602" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTITHROMBOTIC AGENTS" forwarddisplay="document" forwardfrag="B01"></reversexref></reversexrefs></locator><locator id="43090" fragment="60034-B03AA933232111000036107" editid="106010" modified="2018-06-15T10:34:24+10:00"></locator><locator id="43094" fragment="60034-B03AD21667011000036109" editid="106012" modified="2018-06-15T10:34:24+10:00"></locator><locator id="43092" fragment="60034-B01AC21802011000036103" editid="106011" modified="2018-06-15T10:34:24+10:00"></locator><locator id="44680" fragment="60034-B05"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107607" title="Untitled" type="none" forwardtype="none" forwardtitle="BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS" forwarddisplay="document" forwardfrag="B05"></reversexref></reversexrefs></locator></fragmentinfo><metadata></metadata><section id="60034-B"><fragment id="60034-B"><block label="ATCLevel1"><para>BLOOD AND BLOOD FORMING ORGANS</para></block></fragment></section><section id="60034-B01"><fragment id="60034-B01"><block label="ATCLevel2"><para>ANTITHROMBOTIC AGENTS</para></block></fragment></section><section id="60034-B01A"><fragment id="60034-B01A"><block label="ATCLevel3"><para>ANTITHROMBOTIC AGENTS</para></block></fragment></section><section id="60034-B01AC"><fragment id="60034-B01AC"><block label="ATCLevel4"><para>Platelet aggregation inhibitors excl. heparin</para></block></fragment></section><section id="60034-B01AC21719011000036107"><xref-fragment id="60034-B01AC21719011000036107"><blockxref id="106007" title="ASPIRIN" frag="default" reversefrag="B01AC21719011000036107" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59937" href="dynamic/R1/drug/21719011000036107-B01AC.psml" urititle="ASPIRIN" mediatype="application/vnd.pageseeder.psml+xml"><document id="59937" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="59937" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21719011000036107-B01AC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21719011000036107-B01AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:23+10:00" modified="2018-06-15T10:34:24+10:00" title="ASPIRIN"><displaytitle>ASPIRIN</displaytitle></uri><reversexrefs><reversexref uriid="60034" href="dynamic/R1/atc/B.psml" frag="B01AC21719011000036107" urititle="BLOOD AND BLOOD FORMING ORGANS" mediatype="application/vnd.pageseeder.psml+xml" id="106007" title="R1" type="none" forwardtype="embed" forwardtitle="ASPIRIN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59937-21719011000036107-1"><fragment id="59937-21719011000036107-1"><block label="DrugName">ASPIRIN<inline label="genericindexfield">XE "ASPIRIN:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="59937-10590J"><fragment id="59937-10590J"><block label="FormAndStrength">aspirin 100 mg tablet, 112</block><table role="R1"><row><cell><block label="DrugItemCode">10590J<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">12.93</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Spren 100 [OW]<inline label="genericindexfieldbrand"><italic>XE "Spren 100(OW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59937-4076M"><fragment id="59937-4076M"><block label="FormAndStrength">aspirin 100 mg tablet, 90</block><table role="R1"><row><cell><block label="DrugItemCode">4076M<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">19.13</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Cardiprin 100 [RC]<inline label="genericindexfieldbrand"><italic>XE "Cardiprin 100(RC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59937-21719011000036107-2"><fragment id="59937-21719011000036107-2"><block label="DrugName">ASPIRIN<inline label="genericindexfield">XE "ASPIRIN:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="59937-d4612e17"><fragment id="59937-d4612e17"><block label="NoteText"><para>The enteric coated preparations are for patients with a significant risk of gastrointestinal bleeding.</para></block></fragment></section><section id="59937-4077N"><fragment id="59937-4077N"><block label="FormAndStrength">aspirin 100 mg enteric tablet, 84</block><table role="R1"><row><cell><block label="DrugItemCode">4077N<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.43</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Cardasa [AF]<inline label="genericindexfieldbrand"><italic>XE "Cardasa(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Cartia [AS]<inline label="genericindexfieldbrand"><italic>XE "Cartia(AS)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Pharmacy Action Low Dose Aspirin [GQ]<inline label="genericindexfieldbrand"><italic>XE "Pharmacy Action Low Dose Aspirin (GQ)" \i </italic></inline></block></cell></row></table></fragment></section><section id="59937-4078P"><fragment id="59937-4078P"><block label="FormAndStrength">aspirin 100 mg enteric capsule, 84</block><table role="R1"><row><cell><block label="DrugItemCode">4078P<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.22</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Astrix [YN]<inline label="genericindexfieldbrand"><italic>XE "Astrix(YN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60034-B01AC21802011000036103"><xref-fragment id="60034-B01AC21802011000036103"><blockxref id="106004" title="CLOPIDOGREL" frag="default" reversefrag="B01AC21802011000036103" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60441" href="dynamic/R1/drug/21802011000036103-B01AC.psml" urititle="CLOPIDOGREL" mediatype="application/vnd.pageseeder.psml+xml"><document id="60441" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="60441" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21802011000036103-B01AC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21802011000036103-B01AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:24+10:00" title="CLOPIDOGREL"><displaytitle>CLOPIDOGREL</displaytitle></uri><reversexrefs><reversexref uriid="60034" href="dynamic/R1/atc/B.psml" frag="B01AC21802011000036103" urititle="BLOOD AND BLOOD FORMING ORGANS" mediatype="application/vnd.pageseeder.psml+xml" id="106004" title="R1" type="none" forwardtype="embed" forwardtitle="CLOPIDOGREL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60441-21802011000036103-1"><fragment id="60441-21802011000036103-1"><block label="DrugName">CLOPIDOGREL<inline label="genericindexfield">XE "CLOPIDOGREL"</inline></block></fragment></section><section id="60441-d4614e19"><fragment id="60441-d4614e19"><block label="NoteText"><para>Pharmaceutical benefits that have the forms clopidogrel tablet 75 mg (as besilate) and clopidogrel tablet 75 mg (as hydrogen sulfate) are equivalent for the purposes of substitution.</para></block></fragment></section><section id="60441-d4614e16"><fragment id="60441-d4614e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>For use in patients pre- and post-angioplasty</para></block></fragment></section><section id="60441-10169F"><fragment id="60441-10169F"><block label="FormAndStrength">clopidogrel 75 mg tablet, 28</block><table role="R1"><row><cell><block label="DrugItemCode">10169F<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">15.18</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Clopidogrel GH [GQ]<inline label="genericindexfieldbrand"><italic>XE "Clopidogrel GH(GQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Plidogrel [RF]<inline label="genericindexfieldbrand"><italic>XE "Plidogrel (RF)" \i </italic></inline></block></cell></row></table></fragment></section><section id="60441-4179Y"><fragment id="60441-4179Y"><block label="FormAndStrength">clopidogrel 75 mg tablet, 28</block><table role="R1"><row><cell><block label="DrugItemCode">4179Y<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">15.18</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Clopidogrel [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Clopidogrel(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Blooms the Chemist Clopidogrel [IB]<inline label="genericindexfieldbrand"><italic>XE "Blooms the Chemist Clopidogrel (IB)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Chem mart Clopidogrel [CH]<inline label="genericindexfieldbrand"><italic>XE "Chem mart Clopidogrel(CH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Clopidogrel AN [EA]<inline label="genericindexfieldbrand"><italic>XE "Clopidogrel AN (EA)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Iscover [AV]<inline label="genericindexfieldbrand"><italic>XE "Iscover(AV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Piax [AF]<inline label="genericindexfieldbrand"><italic>XE "Piax (AF)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Plavix [SW]<inline label="genericindexfieldbrand"><italic>XE "Plavix(SW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Terry White Chemists Clopidogrel [TW]<inline label="genericindexfieldbrand"><italic>XE "Terry White Chemists Clopidogrel (TW)" \i </italic></inline></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60034-B03"><fragment id="60034-B03"><block label="ATCLevel2"><para>ANTIANEMIC PREPARATIONS</para></block></fragment></section><section id="60034-B03A"><fragment id="60034-B03A"><block label="ATCLevel3"><para>IRON PREPARATIONS</para></block></fragment></section><section id="60034-B03AA"><fragment id="60034-B03AA"><block label="ATCLevel4"><para>Iron bivalent, oral preparations</para></block></fragment></section><section id="60034-B03AA933232111000036107"><xref-fragment id="60034-B03AA933232111000036107"><blockxref id="106003" title="FERROUS FUMARATE" frag="default" reversefrag="B03AA933232111000036107" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60300" href="dynamic/R1/drug/933232111000036107-B03AA.psml" urititle="FERROUS FUMARATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60300" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="60300" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/933232111000036107-B03AA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/933232111000036107-B03AA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:26+10:00" modified="2018-06-15T10:34:24+10:00" title="FERROUS FUMARATE"><displaytitle>FERROUS FUMARATE</displaytitle></uri><reversexrefs><reversexref uriid="60034" href="dynamic/R1/atc/B.psml" frag="B03AA933232111000036107" urititle="BLOOD AND BLOOD FORMING ORGANS" mediatype="application/vnd.pageseeder.psml+xml" id="106003" title="R1" type="none" forwardtype="embed" forwardtitle="FERROUS FUMARATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60300-933232111000036107-1"><fragment id="60300-933232111000036107-1"><block label="DrugName">FERROUS FUMARATE<inline label="genericindexfield">XE "FERROUS FUMARATE"</inline></block></fragment></section><section id="60300-10594N"><fragment id="60300-10594N"><block label="FormAndStrength">ferrous fumarate 200 mg (iron 65.7 mg) tablet, 60</block><table role="R1"><row><cell><block label="DrugItemCode">10594N<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.76</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Ferro-tab [AE]<inline label="genericindexfieldbrand"><italic>XE "Ferro-tab(AE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60034-B03AD"><fragment id="60034-B03AD"><block label="ATCLevel4"><para>Iron in combination with folic acid</para></block></fragment></section><section id="60034-B03AD21667011000036109"><xref-fragment id="60034-B03AD21667011000036109"><blockxref id="106005" title="FERROUS FUMARATE + FOLIC ACID" frag="default" reversefrag="B03AD21667011000036109" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59592" href="dynamic/R1/drug/21667011000036109-B03AD.psml" urititle="FERROUS FUMARATE + FOLIC ACID" mediatype="application/vnd.pageseeder.psml+xml"><document id="59592" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="59592" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21667011000036109-B03AD.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21667011000036109-B03AD.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:18+10:00" modified="2018-06-15T10:34:24+10:00" title="FERROUS FUMARATE + FOLIC ACID"><displaytitle>FERROUS FUMARATE + FOLIC ACID</displaytitle></uri><reversexrefs><reversexref uriid="60034" href="dynamic/R1/atc/B.psml" frag="B03AD21667011000036109" urititle="BLOOD AND BLOOD FORMING ORGANS" mediatype="application/vnd.pageseeder.psml+xml" id="106005" title="R1" type="none" forwardtype="embed" forwardtitle="FERROUS FUMARATE + FOLIC ACID" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59592-21667011000036109-1"><fragment id="59592-21667011000036109-1"><block label="DrugName">FERROUS FUMARATE + FOLIC ACID<inline label="genericindexfield">XE "FERROUS FUMARATE + FOLIC ACID"</inline></block></fragment></section><section id="59592-10579T"><fragment id="59592-10579T"><block label="FormAndStrength">ferrous fumarate 310 mg (iron 100 mg) + folic acid 350 microgram tablet, 60</block><table role="R1"><row><cell><block label="DrugItemCode">10579T<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.78</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Ferro-f-tab [AE]<inline label="genericindexfieldbrand"><italic>XE "Ferro-f-tab(AE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60034-B03B"><fragment id="60034-B03B"><block label="ATCLevel3"><para>VITAMIN B12 AND FOLIC ACID</para></block></fragment></section><section id="60034-B03BA"><fragment id="60034-B03BA"><block label="ATCLevel4"><para>Vitamin B12 (cyanocobalamin and analogues)</para></block></fragment></section><section id="60034-B03BA21828011000036108"><xref-fragment id="60034-B03BA21828011000036108"><blockxref id="106006" title="HYDROXOCOBALAMIN" frag="default" reversefrag="B03BA21828011000036108" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60008" href="dynamic/R1/drug/21828011000036108-B03BA.psml" urititle="HYDROXOCOBALAMIN" mediatype="application/vnd.pageseeder.psml+xml"><document id="60008" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="60008" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21828011000036108-B03BA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21828011000036108-B03BA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:23+10:00" modified="2018-06-15T10:34:24+10:00" title="HYDROXOCOBALAMIN"><displaytitle>HYDROXOCOBALAMIN</displaytitle></uri><reversexrefs><reversexref uriid="60034" href="dynamic/R1/atc/B.psml" frag="B03BA21828011000036108" urititle="BLOOD AND BLOOD FORMING ORGANS" mediatype="application/vnd.pageseeder.psml+xml" id="106006" title="R1" type="none" forwardtype="embed" forwardtitle="HYDROXOCOBALAMIN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60008-21828011000036108-1"><fragment id="60008-21828011000036108-1"><block label="DrugName">HYDROXOCOBALAMIN<inline label="genericindexfield">XE "HYDROXOCOBALAMIN"</inline></block></fragment></section><section id="60008-d4618e19"><fragment id="60008-d4618e19"><block label="NoteText"><para>One injection of hydroxocobalamin 1 mg every three months provides appropriate maintenance therapy in vitamin B<sub>12</sub> deficiencies.</para></block></fragment></section><section id="60008-d4618e25"><fragment id="60008-d4618e25"><block label="NoteText"><para>Pharmaceutical benefits that have the form hydroxocobalamin injection 1 mg (as acetate) in 1 mL and pharmaceutical benefits that have the form hydroxocobalamin injection 1 mg (as chloride) in 1 mL are equivalent for the purposes of substitution.</para></block></fragment></section><section id="60008-d4618e16"><fragment id="60008-d4618e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Pernicious anaemia</para></block></fragment></section><section id="60008-d4618e47"><fragment id="60008-d4618e47"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Proven vitamin B12 deficiencies other than pernicious anaemia</para></block></fragment></section><section id="60008-d4618e78"><fragment id="60008-d4618e78"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Anaemias associated with vitamin B12 deficiency</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have had a gastrectomy,</para></item></list><para><bold>AND</bold></para><list><item><para>The treatment must be for prophylaxis.</para></item></list></block></fragment></section><section id="60008-10577Q"><fragment id="60008-10577Q"><block label="FormAndStrength">hydroxocobalamin 1 mg/mL injection, 3 x 1 mL ampoules</block><table role="R1"><row><cell><block label="DrugItemCode">10577Q<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">15.36</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Vita-B12 [GH]<inline label="genericindexfieldbrand"><italic>XE "Vita-B12(GH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60008-10587F"><fragment id="60008-10587F"><block label="FormAndStrength">hydroxocobalamin 1 mg/mL injection, 3 x 1 mL ampoules</block><table role="R1"><row><cell><block label="DrugItemCode">10587F<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">15.36</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Neo-B12 [PF]<inline label="genericindexfieldbrand"><italic>XE "Neo-B12(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60034-B03BB"><fragment id="60034-B03BB"><block label="ATCLevel4"><para>Folic acid and derivatives</para></block></fragment></section><section id="60034-B03BB21654011000036106"><xref-fragment id="60034-B03BB21654011000036106"><blockxref id="106002" title="FOLIC ACID" frag="default" reversefrag="B03BB21654011000036106" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60717" href="dynamic/R1/drug/21654011000036106-B03BB.psml" urititle="FOLIC ACID" mediatype="application/vnd.pageseeder.psml+xml"><document id="60717" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="60717" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21654011000036106-B03BB.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21654011000036106-B03BB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:31+10:00" modified="2018-06-15T10:34:24+10:00" title="FOLIC ACID"><displaytitle>FOLIC ACID</displaytitle></uri><reversexrefs><reversexref uriid="60034" href="dynamic/R1/atc/B.psml" frag="B03BB21654011000036106" urititle="BLOOD AND BLOOD FORMING ORGANS" mediatype="application/vnd.pageseeder.psml+xml" id="106002" title="R1" type="none" forwardtype="embed" forwardtitle="FOLIC ACID" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60717-21654011000036106-1"><fragment id="60717-21654011000036106-1"><block label="DrugName">FOLIC ACID<inline label="genericindexfield">XE "FOLIC ACID"</inline></block></fragment></section><section id="60717-10584C"><fragment id="60717-10584C"><block label="FormAndStrength">folic acid 500 microgram tablet, 100</block><table role="R1"><row><cell><block label="DrugItemCode">10584C<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>15.15</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Foltabs 500 [PP]<inline label="genericindexfieldbrand"><italic>XE "Foltabs 500(PP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Megafol 0.5 [AF]<inline label="genericindexfieldbrand"><italic>XE "Megafol 0.5 (AF)" \i </italic></inline></block></cell></row></table></fragment></section><section id="60717-21654011000036106-2"><fragment id="60717-21654011000036106-2"><block label="DrugName">FOLIC ACID<inline label="genericindexfield">XE "FOLIC ACID"</inline></block></fragment></section><section id="60717-d4623e17"><fragment id="60717-d4623e17"><block label="NoteText"><para>The 5 mg strength tablet should be used in malabsorption states only.</para></block></fragment></section><section id="60717-10573L"><fragment id="60717-10573L"><block label="FormAndStrength">folic acid 5 mg tablet, 100</block><table role="R1"><row><cell><block label="DrugItemCode">10573L<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>17.37</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Megafol 5 [AF]<inline label="genericindexfieldbrand"><italic>XE "Megafol 5(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60034-B05"><fragment id="60034-B05"><block label="ATCLevel2"><para>BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS</para></block></fragment></section><section id="60034-B05C"><fragment id="60034-B05C"><block label="ATCLevel3"><para>IRRIGATING SOLUTIONS</para></block></fragment></section><section id="60034-B05CB"><fragment id="60034-B05CB"><block label="ATCLevel4"><para>Salt solutions</para></block></fragment></section><section id="60034-B05CB21308011000036103"><xref-fragment id="60034-B05CB21308011000036103"><blockxref id="106001" title="SODIUM CHLORIDE" frag="default" reversefrag="B05CB21308011000036103" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59766" href="dynamic/R1/drug/21308011000036103-B05CB.psml" urititle="SODIUM CHLORIDE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59766" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="59766" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21308011000036103-B05CB.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21308011000036103-B05CB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:24+10:00" title="SODIUM CHLORIDE"><displaytitle>SODIUM CHLORIDE</displaytitle></uri><reversexrefs><reversexref uriid="60034" href="dynamic/R1/atc/B.psml" frag="B05CB21308011000036103" urititle="BLOOD AND BLOOD FORMING ORGANS" mediatype="application/vnd.pageseeder.psml+xml" id="106001" title="R1" type="none" forwardtype="embed" forwardtitle="SODIUM CHLORIDE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59766-21308011000036103-1"><fragment id="59766-21308011000036103-1"><block label="DrugName">SODIUM CHLORIDE<inline label="genericindexfield">XE "SODIUM CHLORIDE"</inline></block></fragment></section><section id="59766-4461T"><fragment id="59766-4461T"><block label="FormAndStrength">sodium chloride 0.9% (9 g/L) solution, 1 L bottle</block><table role="R1"><row><cell><block label="DrugItemCode">4461T<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">14.77</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Baxter Healthcare Pty Ltd [BX]<inline label="genericindexfieldbrand"><italic>XE "Baxter Healthcare Pty Ltd(BX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59766-4460R"><fragment id="59766-4460R"><block label="FormAndStrength">sodium chloride 0.9% (4.5 g/500 mL) solution, 500 mL bottle</block><table role="R1"><row><cell><block label="DrugItemCode">4460R<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">14.49</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Baxter Healthcare Pty Ltd [BX]<inline label="genericindexfieldbrand"><italic>XE "Baxter Healthcare Pty Ltd(BX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref><blockxref id="107083" title="CARDIOVASCULAR SYSTEM" frag="default" reversefrag="d114e761780" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60991" href="dynamic/R1/atc/C.psml" urititle="CARDIOVASCULAR SYSTEM" mediatype="application/vnd.pageseeder.psml+xml"><document id="60991" schemaversion="0.12" date="2018-06-15T10:35:19+10:00" version="current" level="processed"><documentinfo><uri id="60991" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/atc/C.psml" decodedpath="/ps/test/local3/books/dynamic/R1/atc/C.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:34+10:00" modified="2018-06-15T10:35:19+10:00" title="CARDIOVASCULAR SYSTEM"><displaytitle>CARDIOVASCULAR SYSTEM</displaytitle></uri><reversexrefs><reversexref uriid="60526" href="dynamic/R1.psml" frag="d114e761780" urititle="Repatriation Pharmaceutical Benefits Scheme" mediatype="application/vnd.pageseeder.psml+xml" id="107083" title="R1" type="none" forwardtype="embed" forwardtitle="CARDIOVASCULAR SYSTEM" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107609" title="Untitled" type="none" forwardtype="none" forwardtitle="CARDIOVASCULAR SYSTEM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="45026" fragment="60991-C05AX21666011000036106" editid="107988" modified="2018-06-15T10:34:34+10:00"></locator><locator id="44683" fragment="60991-C05A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107611" title="Untitled" type="none" forwardtype="none" forwardtitle="AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE" forwarddisplay="document" forwardfrag="C05A"></reversexref></reversexrefs></locator><locator id="44682" fragment="60991-C05"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107610" title="Untitled" type="none" forwardtype="none" forwardtitle="VASOPROTECTIVES" forwarddisplay="document" forwardfrag="C05"></reversexref></reversexrefs></locator></fragmentinfo><metadata></metadata><section id="60991-C"><fragment id="60991-C"><block label="ATCLevel1"><para>CARDIOVASCULAR SYSTEM</para></block></fragment></section><section id="60991-C05"><fragment id="60991-C05"><block label="ATCLevel2"><para>VASOPROTECTIVES</para></block></fragment></section><section id="60991-C05A"><fragment id="60991-C05A"><block label="ATCLevel3"><para>AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE</para></block></fragment></section><section id="60991-C05AX"><fragment id="60991-C05AX"><block label="ATCLevel4"><para>Other agents for treatment of hemorrhoids and anal fissures for topical use</para></block></fragment></section><section id="60991-C05AX21666011000036106"><xref-fragment id="60991-C05AX21666011000036106"><blockxref id="107987" title="ZINC OXIDE + PERU BALSAM + BENZYL BENZOATE" frag="default" reversefrag="C05AX21666011000036106" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60580" href="dynamic/R1/drug/21666011000036106-C05AX.psml" urititle="ZINC OXIDE + PERU BALSAM + BENZYL BENZOATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60580" schemaversion="0.12" date="2018-06-15T10:34:34+10:00" version="current" level="processed"><documentinfo><uri id="60580" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21666011000036106-C05AX.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21666011000036106-C05AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:29+10:00" modified="2018-06-15T10:34:34+10:00" title="ZINC OXIDE + PERU BALSAM + BENZYL BENZOATE"><displaytitle>ZINC OXIDE + PERU BALSAM + BENZYL BENZOATE</displaytitle></uri><reversexrefs><reversexref uriid="60991" href="dynamic/R1/atc/C.psml" frag="C05AX21666011000036106" urititle="CARDIOVASCULAR SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107987" title="R1" type="none" forwardtype="embed" forwardtitle="ZINC OXIDE + PERU BALSAM + BENZYL BENZOATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60580-21666011000036106-1"><fragment id="60580-21666011000036106-1"><block label="DrugName">ZINC OXIDE + PERU BALSAM + BENZYL BENZOATE<inline label="genericindexfield">XE "ZINC OXIDE + PERU BALSAM + BENZYL BENZOATE"</inline></block></fragment></section><section id="60580-4039N"><fragment id="60580-4039N"><block label="FormAndStrength">zinc oxide 10.75% + peru balsam 1.88% + benzyl benzoate 1.25% ointment, 50 g</block><table role="R1"><row><cell><block label="DrugItemCode">4039N<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.06</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Anusol [JT]<inline label="genericindexfieldbrand"><italic>XE "Anusol(JT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60580-4040P"><fragment id="60580-4040P"><block label="FormAndStrength">zinc oxide 300 mg + peru balsam 50 mg + benzyl benzoate 33 mg suppository, 12</block><table role="R1"><row><cell><block label="DrugItemCode">4040P<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.12</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Anusol [JT]<inline label="genericindexfieldbrand"><italic>XE "Anusol(JT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref><blockxref id="107084" title="DERMATOLOGICALS" frag="default" reversefrag="d114e761780" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60616" href="dynamic/R1/atc/D.psml" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml"><document id="60616" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="60616" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/atc/D.psml" decodedpath="/ps/test/local3/books/dynamic/R1/atc/D.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:30+10:00" modified="2018-06-15T10:34:32+10:00" title="DERMATOLOGICALS"><displaytitle>DERMATOLOGICALS</displaytitle></uri><reversexrefs><reversexref uriid="60526" href="dynamic/R1.psml" frag="d114e761780" urititle="Repatriation Pharmaceutical Benefits Scheme" mediatype="application/vnd.pageseeder.psml+xml" id="107084" title="R1" type="none" forwardtype="embed" forwardtitle="DERMATOLOGICALS" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107612" title="Untitled" type="none" forwardtype="none" forwardtitle="DERMATOLOGICALS" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="44198" fragment="60616-D01AC21500011000036103" editid="107153" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44222" fragment="60616-D02AX6431000144102" editid="107165" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44218" fragment="60616-D01AC21454011000036108" editid="107163" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44702" fragment="60616-D11A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107631" title="Untitled" type="none" forwardtype="none" forwardtitle="OTHER DERMATOLOGICAL PREPARATIONS" forwarddisplay="document" forwardfrag="D11A"></reversexref></reversexrefs></locator><locator id="44684" fragment="60616-D01"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107613" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIFUNGALS FOR DERMATOLOGICAL USE" forwarddisplay="document" forwardfrag="D01"></reversexref></reversexrefs></locator><locator id="44260" fragment="60616-D06BB21864011000036108" editid="107184" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44700" fragment="60616-D08A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107629" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTISEPTICS AND DISINFECTANTS" forwarddisplay="document" forwardfrag="D08A"></reversexref></reversexrefs></locator><locator id="44258" fragment="60616-D11AF61753011000036105" editid="107183" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44234" fragment="60616-D01AE21846011000036106" editid="107171" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44690" fragment="60616-D04"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107619" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC." forwarddisplay="document" forwardfrag="D04"></reversexref></reversexrefs></locator><locator id="44701" fragment="60616-D11"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107630" title="Untitled" type="none" forwardtype="none" forwardtitle="OTHER DERMATOLOGICAL PREPARATIONS" forwarddisplay="document" forwardfrag="D11"></reversexref></reversexrefs></locator><locator id="44694" fragment="60616-D06"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107623" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE" forwarddisplay="document" forwardfrag="D06"></reversexref></reversexrefs></locator><locator id="44204" fragment="60616-D11AX21657011000036100" editid="107156" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44226" fragment="60616-D02AE21561011000036106" editid="107167" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44698" fragment="60616-D07A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107627" title="Untitled" type="none" forwardtype="none" forwardtitle="CORTICOSTEROIDS, PLAIN" forwarddisplay="document" forwardfrag="D07A"></reversexref></reversexrefs></locator><locator id="44228" fragment="60616-D07AC21366011000036103" editid="107168" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44244" fragment="60616-D01BA21575011000036104" editid="107176" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44232" fragment="60616-D08AG21660011000036108" editid="107170" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44230" fragment="60616-D06BX111241000036107" editid="107169" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44686" fragment="60616-D01B"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107615" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIFUNGALS FOR SYSTEMIC USE" forwarddisplay="document" forwardfrag="D01B"></reversexref></reversexrefs></locator><locator id="44236" fragment="60616-D11AX33625011000036102" editid="107172" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44200" fragment="60616-D01AE21680011000036105" editid="107154" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44210" fragment="60616-D07AA21231011000036107" editid="107159" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44248" fragment="60616-D01AC21684011000036100" editid="107178" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44685" fragment="60616-D01A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107614" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIFUNGALS FOR TOPICAL USE" forwarddisplay="document" forwardfrag="D01A"></reversexref></reversexrefs></locator><locator id="44216" fragment="60616-D05AA32630011000036102" editid="107162" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44256" fragment="60616-D11AC7031000144109" editid="107182" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44242" fragment="60616-D01AA21669011000036102" editid="107175" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44254" fragment="60616-D02BA7131000144108" editid="107181" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44214" fragment="60616-D11AC922057011000036107" editid="107161" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44192" fragment="60616-D11AX32624011000036105" editid="107150" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44196" fragment="60616-D11AX21715011000036105" editid="107152" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44220" fragment="60616-D04AB21572011000036107" editid="107164" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44240" fragment="60616-D11AX21288011000036105" editid="107174" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44238" fragment="60616-D11AX933232101000036105" editid="107173" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44252" fragment="60616-D07AC21409011000036100" editid="107180" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44692" fragment="60616-D05"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107621" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIPSORIATICS" forwarddisplay="document" forwardfrag="D05"></reversexref></reversexrefs></locator><locator id="44689" fragment="60616-D02B"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107618" title="Untitled" type="none" forwardtype="none" forwardtitle="PROTECTIVES AGAINST UV-RADIATION" forwarddisplay="document" forwardfrag="D02B"></reversexref></reversexrefs></locator><locator id="44190" fragment="60616-D04AX21598011000036104" editid="107149" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44208" fragment="60616-D11AC6941000144104" editid="107158" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44206" fragment="60616-D02AX86902011000036102" editid="107157" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44696" fragment="60616-D06B"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107625" title="Untitled" type="none" forwardtype="none" forwardtitle="CHEMOTHERAPEUTICS FOR TOPICAL USE" forwarddisplay="document" forwardfrag="D06B"></reversexref></reversexrefs></locator><locator id="44687" fragment="60616-D02"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107616" title="Untitled" type="none" forwardtype="none" forwardtitle="EMOLLIENTS AND PROTECTIVES" forwarddisplay="document" forwardfrag="D02"></reversexref></reversexrefs></locator><locator id="44693" fragment="60616-D05A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107622" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIPSORIATICS FOR TOPICAL USE" forwarddisplay="document" forwardfrag="D05A"></reversexref></reversexrefs></locator><locator id="44194" fragment="60616-D11AC21422011000036103" editid="107151" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44691" fragment="60616-D04A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107620" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC." forwarddisplay="document" forwardfrag="D04A"></reversexref></reversexrefs></locator><locator id="44688" fragment="60616-D02A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107617" title="Untitled" type="none" forwardtype="none" forwardtitle="EMOLLIENTS AND PROTECTIVES" forwarddisplay="document" forwardfrag="D02A"></reversexref></reversexrefs></locator><locator id="44697" fragment="60616-D07"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107626" title="Untitled" type="none" forwardtype="none" forwardtitle="CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS" forwarddisplay="document" forwardfrag="D07"></reversexref></reversexrefs></locator><locator id="44224" fragment="60616-D01AE21575011000036104" editid="107166" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44212" fragment="60616-D02AA32614011000036102" editid="107160" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44202" fragment="60616-D06AX21590011000036101" editid="107155" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44695" fragment="60616-D06A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107624" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIBIOTICS FOR TOPICAL USE" forwarddisplay="document" forwardfrag="D06A"></reversexref></reversexrefs></locator><locator id="44246" fragment="60616-D02AC21752011000036106" editid="107177" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44250" fragment="60616-D11AX21816011000036101" editid="107179" modified="2018-06-15T10:34:30+10:00"></locator><locator id="44699" fragment="60616-D08"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107628" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTISEPTICS AND DISINFECTANTS" forwarddisplay="document" forwardfrag="D08"></reversexref></reversexrefs></locator></fragmentinfo><metadata></metadata><section id="60616-D"><fragment id="60616-D"><block label="ATCLevel1"><para>DERMATOLOGICALS</para></block></fragment></section><section id="60616-D01"><fragment id="60616-D01"><block label="ATCLevel2"><para>ANTIFUNGALS FOR DERMATOLOGICAL USE</para></block></fragment></section><section id="60616-D01A"><fragment id="60616-D01A"><block label="ATCLevel3"><para>ANTIFUNGALS FOR TOPICAL USE</para></block></fragment></section><section id="60616-D01AA"><fragment id="60616-D01AA"><block label="ATCLevel4"><para>Antibiotics</para></block></fragment></section><section id="60616-D01AA21669011000036102"><xref-fragment id="60616-D01AA21669011000036102"><blockxref id="107139" title="NYSTATIN" frag="default" reversefrag="D01AA21669011000036102" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60138" href="dynamic/R1/drug/21669011000036102-D01AA.psml" urititle="NYSTATIN" mediatype="application/vnd.pageseeder.psml+xml"><document id="60138" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60138" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21669011000036102-D01AA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21669011000036102-D01AA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:25+10:00" modified="2018-06-15T10:34:30+10:00" title="NYSTATIN"><displaytitle>NYSTATIN</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D01AA21669011000036102" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107139" title="R1" type="none" forwardtype="embed" forwardtitle="NYSTATIN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60138-21669011000036102-1"><fragment id="60138-21669011000036102-1"><block label="DrugName">NYSTATIN<inline label="genericindexfield">XE "NYSTATIN:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="60138-4001N"><fragment id="60138-4001N"><block label="FormAndStrength">nystatin 100 000 units/g cream, 15 g</block><table role="R1"><row><cell><block label="DrugItemCode">4001N<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">16.10</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Mycostatin [FM]<inline label="genericindexfieldbrand"><italic>XE "Mycostatin(FM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D01AC"><fragment id="60616-D01AC"><block label="ATCLevel4"><para>Imidazole and triazole derivatives</para></block></fragment></section><section id="60616-D01AC21684011000036100"><xref-fragment id="60616-D01AC21684011000036100"><blockxref id="107142" title="CLOTRIMAZOLE" frag="default" reversefrag="D01AC21684011000036100" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59804" href="dynamic/R1/drug/21684011000036100-D01AC.psml" urititle="CLOTRIMAZOLE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59804" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="59804" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21684011000036100-D01AC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21684011000036100-D01AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:30+10:00" title="CLOTRIMAZOLE"><displaytitle>CLOTRIMAZOLE</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D01AC21684011000036100" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107142" title="R1" type="none" forwardtype="embed" forwardtitle="CLOTRIMAZOLE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59804-21684011000036100-1"><fragment id="59804-21684011000036100-1"><block label="DrugName">CLOTRIMAZOLE<inline label="genericindexfield">XE "CLOTRIMAZOLE:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="59804-4004R"><fragment id="59804-4004R"><block label="FormAndStrength">clotrimazole 1% cream, 20 g</block><table role="R1"><row><cell><block label="DrugItemCode">4004R<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">12.85</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Pharmacy Action Anti-Fungal Cream [GQ]<inline label="genericindexfieldbrand"><italic>XE "Pharmacy Action Anti-Fungal Cream(GQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">13.19</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Clonea [AF]<inline label="genericindexfieldbrand"><italic>XE "Clonea(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D01AC21500011000036103"><xref-fragment id="60616-D01AC21500011000036103"><blockxref id="107117" title="KETOCONAZOLE" frag="default" reversefrag="D01AC21500011000036103" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60985" href="dynamic/R1/drug/21500011000036103-D01AC.psml" urititle="KETOCONAZOLE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60985" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60985" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21500011000036103-D01AC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21500011000036103-D01AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:34+10:00" modified="2018-06-15T10:34:30+10:00" title="KETOCONAZOLE"><displaytitle>KETOCONAZOLE</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D01AC21500011000036103" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107117" title="R1" type="none" forwardtype="embed" forwardtitle="KETOCONAZOLE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60985-21500011000036103-1"><fragment id="60985-21500011000036103-1"><block label="DrugName">KETOCONAZOLE<inline label="genericindexfield">XE "KETOCONAZOLE"</inline></block></fragment></section><section id="60985-d4629e16"><fragment id="60985-d4629e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Severe seborrhoeic dermatitis</para></block></fragment></section><section id="60985-4007X"><fragment id="60985-4007X"><block label="FormAndStrength">ketoconazole 2% shampoo, 100 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4007X<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">22.35</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Sebizole [EA]<inline label="genericindexfieldbrand"><italic>XE "Sebizole(EA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D01AC21454011000036108"><xref-fragment id="60616-D01AC21454011000036108"><blockxref id="107127" title="MICONAZOLE" frag="default" reversefrag="D01AC21454011000036108" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59799" href="dynamic/R1/drug/21454011000036108-D01AC.psml" urititle="MICONAZOLE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59799" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="59799" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21454011000036108-D01AC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21454011000036108-D01AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:30+10:00" title="MICONAZOLE"><displaytitle>MICONAZOLE</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D01AC21454011000036108" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107127" title="R1" type="none" forwardtype="embed" forwardtitle="MICONAZOLE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59799-21454011000036108-1"><fragment id="59799-21454011000036108-1"><block label="DrugName">MICONAZOLE<inline label="genericindexfield">XE "MICONAZOLE"</inline></block></fragment></section><section id="59799-3400Y"><fragment id="59799-3400Y"><block label="FormAndStrength">miconazole nitrate 2% cream, 40 g</block><table role="R1"><row><cell><block label="DrugItemCode">3400Y<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.40</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Resolve Thrush [EO]<inline label="genericindexfieldbrand"><italic>XE "Resolve Thrush(EO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D01AE"><fragment id="60616-D01AE"><block label="ATCLevel4"><para>Other antifungals for topical use</para></block></fragment></section><section id="60616-D01AE21846011000036106"><xref-fragment id="60616-D01AE21846011000036106"><blockxref id="107135" title="AMOROLFINE" frag="default" reversefrag="D01AE21846011000036106" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60385" href="dynamic/R1/drug/21846011000036106-D01AE.psml" urititle="AMOROLFINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60385" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60385" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21846011000036106-D01AE.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21846011000036106-D01AE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:27+10:00" modified="2018-06-15T10:34:30+10:00" title="AMOROLFINE"><displaytitle>AMOROLFINE</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D01AE21846011000036106" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107135" title="R1" type="none" forwardtype="embed" forwardtitle="AMOROLFINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60385-21846011000036106-1"><fragment id="60385-21846011000036106-1"><block label="DrugName">AMOROLFINE<inline label="genericindexfield">XE "AMOROLFINE"</inline></block></fragment></section><section id="60385-d4632e16"><fragment id="60385-d4632e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Onychomycosis</para></block></fragment></section><section id="60385-4010C"><fragment id="60385-4010C"><block label="FormAndStrength">amorolfine 5% application, 5 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4010C<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">47.65</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Myconail [AE]<inline label="genericindexfieldbrand"><italic>XE "Myconail(AE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">61.08</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Sandoz Nail Repair [SZ]<inline label="genericindexfieldbrand"><italic>XE "Sandoz Nail Repair(SZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">67.73</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Pharmacy Action Anti-Fungal Nail Treatment [GQ]<inline label="genericindexfieldbrand"><italic>XE "Pharmacy Action Anti-Fungal Nail Treatment(GQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">83.90</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Aporyl [TX]<inline label="genericindexfieldbrand"><italic>XE "Aporyl(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">92.65</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Loceryl [GA]<inline label="genericindexfieldbrand"><italic>XE "Loceryl(GA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D01AE21575011000036104"><xref-fragment id="60616-D01AE21575011000036104"><blockxref id="107130" title="TERBINAFINE" frag="default" reversefrag="D01AE21575011000036104" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="61091" href="dynamic/R1/drug/21575011000036104-D01AE.psml" urititle="TERBINAFINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="61091" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="61091" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21575011000036104-D01AE.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21575011000036104-D01AE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:35+10:00" modified="2018-06-15T10:34:30+10:00" title="TERBINAFINE"><displaytitle>TERBINAFINE</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D01AE21575011000036104" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107130" title="R1" type="none" forwardtype="embed" forwardtitle="TERBINAFINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="61091-21575011000036104-1"><fragment id="61091-21575011000036104-1"><block label="DrugName">TERBINAFINE<inline label="genericindexfield">XE "TERBINAFINE:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="61091-d4634e16"><fragment id="61091-d4634e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Tinea pedis</para></block></fragment></section><section id="61091-4463X"><fragment id="61091-4463X"><block label="FormAndStrength">terbinafine 1% gel, 15 g</block><table role="R1"><row><cell><block label="DrugItemCode">4463X<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">25.81</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Lamisil DermGel [GK]<inline label="genericindexfieldbrand"><italic>XE "Lamisil DermGel(GK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="61091-4473K"><fragment id="61091-4473K"><block label="FormAndStrength">terbinafine hydrochloride 1% cream, 15 g</block><table role="R1"><row><cell><block label="DrugItemCode">4473K<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">24.54</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Lamisil [GK]<inline label="genericindexfieldbrand"><italic>XE "Lamisil(GK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Pharmacy Action Pharmisil [GQ]<inline label="genericindexfieldbrand"><italic>XE "Pharmacy Action Pharmisil (GQ)" \i </italic></inline></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D01AE21680011000036105"><xref-fragment id="60616-D01AE21680011000036105"><blockxref id="107118" title="TOLNAFTATE" frag="default" reversefrag="D01AE21680011000036105" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60049" href="dynamic/R1/drug/21680011000036105-D01AE.psml" urititle="TOLNAFTATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60049" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60049" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21680011000036105-D01AE.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21680011000036105-D01AE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:24+10:00" modified="2018-06-15T10:34:30+10:00" title="TOLNAFTATE"><displaytitle>TOLNAFTATE</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D01AE21680011000036105" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107118" title="R1" type="none" forwardtype="embed" forwardtitle="TOLNAFTATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60049-21680011000036105-1"><fragment id="60049-21680011000036105-1"><block label="DrugName">TOLNAFTATE<inline label="genericindexfield">XE "TOLNAFTATE"</inline></block></fragment></section><section id="60049-4481W"><fragment id="60049-4481W"><block label="FormAndStrength">tolnaftate 0.07% spray, 100 g</block><table role="R1"><row><cell><block label="DrugItemCode">4481W<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.63</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tinaderm [BN]<inline label="genericindexfieldbrand"><italic>XE "Tinaderm(BN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D01B"><fragment id="60616-D01B"><block label="ATCLevel3"><para>ANTIFUNGALS FOR SYSTEMIC USE</para></block></fragment></section><section id="60616-D01BA"><fragment id="60616-D01BA"><block label="ATCLevel4"><para>Antifungals for systemic use</para></block></fragment></section><section id="60616-D01BA21575011000036104"><xref-fragment id="60616-D01BA21575011000036104"><blockxref id="107140" title="TERBINAFINE" frag="default" reversefrag="D01BA21575011000036104" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60867" href="dynamic/R1/drug/21575011000036104-D01BA.psml" urititle="TERBINAFINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60867" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60867" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21575011000036104-D01BA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21575011000036104-D01BA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:30+10:00" title="TERBINAFINE"><displaytitle>TERBINAFINE</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D01BA21575011000036104" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107140" title="R1" type="none" forwardtype="embed" forwardtitle="TERBINAFINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60867-21575011000036104-1"><fragment id="60867-21575011000036104-1"><block label="DrugName">TERBINAFINE<inline label="genericindexfield">XE "TERBINAFINE:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="60867-d4637e16"><fragment id="60867-d4637e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Onychomycosis</para><para><bold>Clinical criteria:</bold></para><list><item><para>The condition must be due to dermatophyte infection proven by microscopy and confirmed by an Approved Pathology Provider; OR</para></item><item><para>The condition must be due to dermatophyte infection proven by culture and confirmed by an Approved Pathology Provider.</para></item></list></block></fragment></section><section id="60867-4011D"><fragment id="60867-4011D"><block label="FormAndStrength">terbinafine 250 mg tablet, 42</block><table role="R1"><row><cell><block label="DrugItemCode">4011D<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">30.00</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">GenRx Terbinafine [GX]<inline label="genericindexfieldbrand"><italic>XE "GenRx Terbinafine(GX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Lamisil (Novartis Pharmaceuticals Australia Pty Limited) [NV]<inline label="genericindexfieldbrand"><italic>XE "Lamisil (Novartis Pharmaceuticals Australia Pty Limited) (NV)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Tamsil [RW]<inline label="genericindexfieldbrand"><italic>XE "Tamsil(RW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Terbinafine GH [GQ]<inline label="genericindexfieldbrand"><italic>XE "Terbinafine GH (GQ)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Terbinafine Sandoz [SZ]<inline label="genericindexfieldbrand"><italic>XE "Terbinafine Sandoz(SZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Tinasil [AF]<inline label="genericindexfieldbrand"><italic>XE "Tinasil (AF)" \i </italic></inline></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D02"><fragment id="60616-D02"><block label="ATCLevel2"><para>EMOLLIENTS AND PROTECTIVES</para></block></fragment></section><section id="60616-D02A"><fragment id="60616-D02A"><block label="ATCLevel3"><para>EMOLLIENTS AND PROTECTIVES</para></block></fragment></section><section id="60616-D02AA"><fragment id="60616-D02AA"><block label="ATCLevel4"><para>Silicone products</para></block></fragment></section><section id="60616-D02AA32614011000036102"><xref-fragment id="60616-D02AA32614011000036102"><blockxref id="107124" title="DIMETICONE-350 + GLYCEROL" frag="default" reversefrag="D02AA32614011000036102" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60792" href="dynamic/R1/drug/32614011000036102-D02AA.psml" urititle="DIMETICONE-350 + GLYCEROL" mediatype="application/vnd.pageseeder.psml+xml"><document id="60792" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60792" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/32614011000036102-D02AA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/32614011000036102-D02AA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:30+10:00" title="DIMETICONE-350 + GLYCEROL"><displaytitle>DIMETICONE-350 + GLYCEROL</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D02AA32614011000036102" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107124" title="R1" type="none" forwardtype="embed" forwardtitle="DIMETICONE-350 + GLYCEROL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60792-32614011000036102-1"><fragment id="60792-32614011000036102-1"><block label="DrugName">DIMETICONE-350 + GLYCEROL<inline label="genericindexfield">XE "DIMETICONE-350 + GLYCEROL"</inline></block></fragment></section><section id="60792-d4639e16"><fragment id="60792-d4639e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>For colostomy and ileostomy use</para></block></fragment></section><section id="60792-d4639e38"><fragment id="60792-d4639e38"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>For use by paraplegic and quadriplegic patients</para></block></fragment></section><section id="60792-d4639e60"><fragment id="60792-d4639e60"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>For use with surgical appliances</para></block></fragment></section><section id="60792-4556T"><fragment id="60792-4556T"><block label="FormAndStrength">dimeticone-350 15% + glycerol 2% cream, 75 g</block><table role="R1"><row><cell><block label="DrugItemCode">4556T<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">16.40</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Silic 15 [EO]<inline label="genericindexfieldbrand"><italic>XE "Silic 15(EO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60792-4551M"><fragment id="60792-4551M"><block label="FormAndStrength">dimeticone-350 15% + glycerol 2% cream, 500 g</block><table role="R1"><row><cell><block label="DrugItemCode">4551M<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">28.47</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Silic 15 [EO]<inline label="genericindexfieldbrand"><italic>XE "Silic 15(EO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D02AC"><fragment id="60616-D02AC"><block label="ATCLevel4"><para>Soft paraffin and fat products</para></block></fragment></section><section id="60616-D02AC21752011000036106"><xref-fragment id="60616-D02AC21752011000036106"><blockxref id="107141" title="WOOL ALCOHOLS" frag="default" reversefrag="D02AC21752011000036106" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59737" href="dynamic/R1/drug/21752011000036106-D02AC.psml" urititle="WOOL ALCOHOLS" mediatype="application/vnd.pageseeder.psml+xml"><document id="59737" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="59737" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21752011000036106-D02AC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21752011000036106-D02AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:20+10:00" modified="2018-06-15T10:34:30+10:00" title="WOOL ALCOHOLS"><displaytitle>WOOL ALCOHOLS</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D02AC21752011000036106" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107141" title="R1" type="none" forwardtype="embed" forwardtitle="WOOL ALCOHOLS" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59737-21752011000036106-1"><fragment id="59737-21752011000036106-1"><block label="DrugName">WOOL ALCOHOLS<inline label="genericindexfield">XE "WOOL ALCOHOLS"</inline></block></fragment></section><section id="59737-4041Q"><fragment id="59737-4041Q"><block label="FormAndStrength">wool alcohols 6% ointment, 100 g</block><table role="R1"><row><cell><block label="DrugItemCode">4041Q<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.84</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Eucerin [BE]<inline label="genericindexfieldbrand"><italic>XE "Eucerin(BE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D02AE"><fragment id="60616-D02AE"><block label="ATCLevel4"><para>Carbamide products</para></block></fragment></section><section id="60616-D02AE21561011000036106"><xref-fragment id="60616-D02AE21561011000036106"><blockxref id="107131" title="UREA" frag="default" reversefrag="D02AE21561011000036106" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59902" href="dynamic/R1/drug/21561011000036106-D02AE.psml" urititle="UREA" mediatype="application/vnd.pageseeder.psml+xml"><document id="59902" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="59902" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21561011000036106-D02AE.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21561011000036106-D02AE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:30+10:00" title="UREA"><displaytitle>UREA</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D02AE21561011000036106" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107131" title="R1" type="none" forwardtype="embed" forwardtitle="UREA" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59902-21561011000036106-1"><fragment id="59902-21561011000036106-1"><block label="DrugName">UREA<inline label="genericindexfield">XE "UREA"</inline></block></fragment></section><section id="59902-4042R"><fragment id="59902-4042R"><block label="FormAndStrength">urea 10% cream, 100 g</block><table role="R1"><row><cell><block label="DrugItemCode">4042R<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">16.11</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Aquacare H.P. [AG]<inline label="genericindexfieldbrand"><italic>XE "Aquacare H.P.(AG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">16.33</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Urederm [KY]<inline label="genericindexfieldbrand"><italic>XE "Urederm(KY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">16.61</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Calmurid [OL]<inline label="genericindexfieldbrand"><italic>XE "Calmurid(OL)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D02AX"><fragment id="60616-D02AX"><block label="ATCLevel4"><para>Other emollients and protectives</para></block></fragment></section><section id="60616-D02AX86902011000036102"><xref-fragment id="60616-D02AX86902011000036102"><blockxref id="107121" title="CARMELLOSE SODIUM + GELATIN + PECTIN" frag="default" reversefrag="D02AX86902011000036102" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60460" href="dynamic/R1/drug/86902011000036102-D02AX.psml" urititle="CARMELLOSE SODIUM + GELATIN + PECTIN" mediatype="application/vnd.pageseeder.psml+xml"><document id="60460" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60460" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/86902011000036102-D02AX.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/86902011000036102-D02AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:30+10:00" title="CARMELLOSE SODIUM + GELATIN + PECTIN"><displaytitle>CARMELLOSE SODIUM + GELATIN + PECTIN</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D02AX86902011000036102" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107121" title="R1" type="none" forwardtype="embed" forwardtitle="CARMELLOSE SODIUM + GELATIN + PECTIN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60460-86902011000036102-1"><fragment id="60460-86902011000036102-1"><block label="DrugName">CARMELLOSE SODIUM + GELATIN + PECTIN<inline label="genericindexfield">XE "CARMELLOSE SODIUM + GELATIN + PECTIN"</inline></block></fragment></section><section id="60460-4518T"><fragment id="60460-4518T"><block label="FormAndStrength">carmellose sodium 16.7% + gelatin 16.7% + pectin 16.7% oromucosal paste, 5 g</block><table role="R1"><row><cell><block label="DrugItemCode">4518T<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">15.81</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Orabase [QA]<inline label="genericindexfieldbrand"><italic>XE "Orabase(QA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D02AX6431000144102"><xref-fragment id="60616-D02AX6431000144102"><blockxref id="107129" title="SKIN EMOLLIENT" frag="default" reversefrag="D02AX6431000144102" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59615" href="dynamic/R1/drug/6431000144102-D02AX.psml" urititle="SKIN EMOLLIENT" mediatype="application/vnd.pageseeder.psml+xml"><document id="59615" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="59615" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/6431000144102-D02AX.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/6431000144102-D02AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:19+10:00" modified="2018-06-15T10:34:30+10:00" title="SKIN EMOLLIENT"><displaytitle>SKIN EMOLLIENT</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D02AX6431000144102" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107129" title="R1" type="none" forwardtype="embed" forwardtitle="SKIN EMOLLIENT" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59615-6431000144102-1"><fragment id="59615-6431000144102-1"><block label="DrugName">SKIN EMOLLIENT<inline label="genericindexfield">XE "SKIN EMOLLIENT"</inline></block></fragment></section><section id="59615-4107E"><fragment id="59615-4107E"><block label="FormAndStrength">SKIN EMOLLIENT Lotion 500 mL, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4107E<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">20.59</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Alpha Keri Lotion [MT]<inline label="genericindexfieldbrand"><italic>XE "Alpha Keri Lotion(MT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59615-4122Y"><fragment id="59615-4122Y"><block label="FormAndStrength">SKIN EMOLLIENT Bath oil 500 mL, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4122Y<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">20.59</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Alpha Keri Bath Oil [MT]<inline label="genericindexfieldbrand"><italic>XE "Alpha Keri Bath Oil(MT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">22.69</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">QV Bath Oil [EO]<inline label="genericindexfieldbrand"><italic>XE "QV Bath Oil(EO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">22.77</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Hamilton Skin Therapy Oil [KY]<inline label="genericindexfieldbrand"><italic>XE "Hamilton Skin Therapy Oil(KY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D02B"><fragment id="60616-D02B"><block label="ATCLevel3"><para>PROTECTIVES AGAINST UV-RADIATION</para></block></fragment></section><section id="60616-D02BA"><fragment id="60616-D02BA"><block label="ATCLevel4"><para>Protectives against UV-radiation for topical use</para></block></fragment></section><section id="60616-D02BA7131000144108"><xref-fragment id="60616-D02BA7131000144108"><blockxref id="107145" title="SUNSCREENS" frag="default" reversefrag="D02BA7131000144108" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59718" href="dynamic/R1/drug/7131000144108-D02BA.psml" urititle="SUNSCREENS" mediatype="application/vnd.pageseeder.psml+xml"><document id="59718" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="59718" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/7131000144108-D02BA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/7131000144108-D02BA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:20+10:00" modified="2018-06-15T10:34:30+10:00" title="SUNSCREENS"><displaytitle>SUNSCREENS</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D02BA7131000144108" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107145" title="R1" type="none" forwardtype="embed" forwardtitle="SUNSCREENS" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59718-7131000144108-1"><fragment id="59718-7131000144108-1"><block label="DrugName">SUNSCREENS<inline label="genericindexfield">XE "SUNSCREENS"</inline></block></fragment></section><section id="59718-4546G"><fragment id="59718-4546G"><block label="FormAndStrength">SUNSCREENS Lotion (non-alcoholic) 125 mL, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4546G<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">19.40</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Aquasun Lotion SPF 18 [PF]<inline label="genericindexfieldbrand"><italic>XE "Aquasun Lotion SPF 18(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">21.20</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Sunsense Ultra SPF 50+ [EO]<inline label="genericindexfieldbrand"><italic>XE "Sunsense Ultra SPF 50+(EO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59718-4307Q"><fragment id="59718-4307Q"><block label="FormAndStrength">SUNSCREENS Cream 75 g, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4307Q<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">21.20</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Sunsense Sensitive SPF 50+ [EO]<inline label="genericindexfieldbrand"><italic>XE "Sunsense Sensitive SPF 50+(EO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D04"><fragment id="60616-D04"><block label="ATCLevel2"><para>ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.</para></block></fragment></section><section id="60616-D04A"><fragment id="60616-D04A"><block label="ATCLevel3"><para>ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.</para></block></fragment></section><section id="60616-D04AB"><fragment id="60616-D04AB"><block label="ATCLevel4"><para>Anesthetics for topical use</para></block></fragment></section><section id="60616-D04AB21572011000036107"><xref-fragment id="60616-D04AB21572011000036107"><blockxref id="107128" title="LIDOCAINE (LIGNOCAINE)" frag="default" reversefrag="D04AB21572011000036107" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59892" href="dynamic/R1/drug/21572011000036107-D04AB.psml" urititle="LIDOCAINE (LIGNOCAINE)" mediatype="application/vnd.pageseeder.psml+xml"><document id="59892" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="59892" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21572011000036107-D04AB.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21572011000036107-D04AB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:30+10:00" title="LIDOCAINE (LIGNOCAINE)"><displaytitle>LIDOCAINE (LIGNOCAINE)</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D04AB21572011000036107" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107128" title="R1" type="none" forwardtype="embed" forwardtitle="LIDOCAINE (LIGNOCAINE)" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59892-21572011000036107-1"><fragment id="59892-21572011000036107-1"><block label="DrugName">LIDOCAINE (LIGNOCAINE)<inline label="genericindexfield">XE "LIDOCAINE (LIGNOCAINE):.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="59892-4308R"><fragment id="59892-4308R"><block label="FormAndStrength">lidocaine (lignocaine) hydrochloride 2% oral liquid, 200 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4308R<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">103.21</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Xylocaine Viscous [QA]<inline label="genericindexfieldbrand"><italic>XE "Xylocaine Viscous(QA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D04AX"><fragment id="60616-D04AX"><block label="ATCLevel4"><para>Other antipruritics</para></block></fragment></section><section id="60616-D04AX21598011000036104"><xref-fragment id="60616-D04AX21598011000036104"><blockxref id="107113" title="TAR + TROLAMINE LAURIL SULFATE" frag="default" reversefrag="D04AX21598011000036104" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59820" href="dynamic/R1/drug/21598011000036104-D04AX.psml" urititle="TAR + TROLAMINE LAURIL SULFATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59820" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="59820" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21598011000036104-D04AX.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21598011000036104-D04AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:30+10:00" title="TAR + TROLAMINE LAURIL SULFATE"><displaytitle>TAR + TROLAMINE LAURIL SULFATE</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D04AX21598011000036104" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107113" title="R1" type="none" forwardtype="embed" forwardtitle="TAR + TROLAMINE LAURIL SULFATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59820-21598011000036104-1"><fragment id="59820-21598011000036104-1"><block label="DrugName">TAR + TROLAMINE LAURIL SULFATE<inline label="genericindexfield">XE "TAR + TROLAMINE LAURIL SULFATE"</inline></block></fragment></section><section id="59820-d4649e17"><fragment id="59820-d4649e17"><block label="NoteText"><para>For patients who have failed to respond to simple moisturising agents.</para></block></fragment></section><section id="59820-4408B"><fragment id="59820-4408B"><block label="FormAndStrength">tar 2.3% + trolamine lauril sulfate 6% solution, 500 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4408B<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">25.44</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Pinetarsol [EO]<inline label="genericindexfieldbrand"><italic>XE "Pinetarsol(EO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D05"><fragment id="60616-D05"><block label="ATCLevel2"><para>ANTIPSORIATICS</para></block></fragment></section><section id="60616-D05A"><fragment id="60616-D05A"><block label="ATCLevel3"><para>ANTIPSORIATICS FOR TOPICAL USE</para></block></fragment></section><section id="60616-D05AA"><fragment id="60616-D05AA"><block label="ATCLevel4"><para>Tars</para></block></fragment></section><section id="60616-D05AA32630011000036102"><xref-fragment id="60616-D05AA32630011000036102"><blockxref id="107126" title="COAL TAR SOLUTION + PHENOL + PRECIPITATED SULFUR" frag="default" reversefrag="D05AA32630011000036102" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60212" href="dynamic/R1/drug/32630011000036102-D05AA.psml" urititle="COAL TAR SOLUTION + PHENOL + PRECIPITATED SULFUR" mediatype="application/vnd.pageseeder.psml+xml"><document id="60212" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60212" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/32630011000036102-D05AA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/32630011000036102-D05AA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:26+10:00" modified="2018-06-15T10:34:30+10:00" title="COAL TAR SOLUTION + PHENOL + PRECIPITATED SULFUR"><displaytitle>COAL TAR SOLUTION + PHENOL + PRECIPITATED SULFUR</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D05AA32630011000036102" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107126" title="R1" type="none" forwardtype="embed" forwardtitle="COAL TAR SOLUTION + PHENOL + PRECIPITATED SULFUR" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60212-32630011000036102-1"><fragment id="60212-32630011000036102-1"><block label="DrugName">COAL TAR SOLUTION + PHENOL + PRECIPITATED SULFUR<inline label="genericindexfield">XE "COAL TAR SOLUTION + PHENOL + PRECIPITATED SULFUR"</inline></block></fragment></section><section id="60212-4505D"><fragment id="60212-4505D"><block label="FormAndStrength">coal tar solution 5% + phenol 0.5% + precipitated sulfur 0.5% gel, 30 g</block><table role="R1"><row><cell><block label="DrugItemCode">4505D<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">19.44</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Egopsoryl-TA [EO]<inline label="genericindexfieldbrand"><italic>XE "Egopsoryl-TA(EO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D06"><fragment id="60616-D06"><block label="ATCLevel2"><para>ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE</para></block></fragment></section><section id="60616-D06A"><fragment id="60616-D06A"><block label="ATCLevel3"><para>ANTIBIOTICS FOR TOPICAL USE</para></block></fragment></section><section id="60616-D06AX"><fragment id="60616-D06AX"><block label="ATCLevel4"><para>Other antibiotics for topical use</para></block></fragment></section><section id="60616-D06AX21590011000036101"><xref-fragment id="60616-D06AX21590011000036101"><blockxref id="107119" title="MUPIROCIN" frag="default" reversefrag="D06AX21590011000036101" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60848" href="dynamic/R1/drug/21590011000036101-D06AX.psml" urititle="MUPIROCIN" mediatype="application/vnd.pageseeder.psml+xml"><document id="60848" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60848" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21590011000036101-D06AX.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21590011000036101-D06AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:30+10:00" title="MUPIROCIN"><displaytitle>MUPIROCIN</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D06AX21590011000036101" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107119" title="R1" type="none" forwardtype="embed" forwardtitle="MUPIROCIN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60848-21590011000036101-1"><fragment id="60848-21590011000036101-1"><block label="DrugName">MUPIROCIN<inline label="genericindexfield">XE "MUPIROCIN:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="60848-d4652e16"><fragment id="60848-d4652e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Secondarily infected traumatic skin lesions</para></block></fragment></section><section id="60848-4350Y"><fragment id="60848-4350Y"><block label="FormAndStrength">mupirocin 2% ointment, 15 g</block><table role="R1"><row><cell><block label="DrugItemCode">4350Y<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">20.51</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Bactroban [GK]<inline label="genericindexfieldbrand"><italic>XE "Bactroban(GK):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60848-4348W"><fragment id="60848-4348W"><block label="FormAndStrength">mupirocin 2% cream, 15 g</block><table role="R1"><row><cell><block label="DrugItemCode">4348W<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">20.51</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Bactroban [GK]<inline label="genericindexfieldbrand"><italic>XE "Bactroban(GK):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D06B"><fragment id="60616-D06B"><block label="ATCLevel3"><para>CHEMOTHERAPEUTICS FOR TOPICAL USE</para></block></fragment></section><section id="60616-D06BB"><fragment id="60616-D06BB"><block label="ATCLevel4"><para>Antivirals</para></block></fragment></section><section id="60616-D06BB21864011000036108"><xref-fragment id="60616-D06BB21864011000036108"><blockxref id="107148" title="PODOPHYLLOTOXIN" frag="default" reversefrag="D06BB21864011000036108" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="61089" href="dynamic/R1/drug/21864011000036108-D06BB.psml" urititle="PODOPHYLLOTOXIN" mediatype="application/vnd.pageseeder.psml+xml"><document id="61089" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="61089" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21864011000036108-D06BB.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21864011000036108-D06BB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:35+10:00" modified="2018-06-15T10:34:30+10:00" title="PODOPHYLLOTOXIN"><displaytitle>PODOPHYLLOTOXIN</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D06BB21864011000036108" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107148" title="R1" type="none" forwardtype="embed" forwardtitle="PODOPHYLLOTOXIN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="61089-21864011000036108-1"><fragment id="61089-21864011000036108-1"><block label="DrugName">PODOPHYLLOTOXIN<inline label="genericindexfield">XE "PODOPHYLLOTOXIN"</inline></block></fragment></section><section id="61089-d4654e16"><fragment id="61089-d4654e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Ano-genital warts</para></block></fragment></section><section id="61089-4390C"><fragment id="61089-4390C"><block label="FormAndStrength">podophyllotoxin 0.15% cream, 5 g</block><table role="R1"><row><cell><block label="DrugItemCode">4390C<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">52.83</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Wartec Cream [GK]<inline label="genericindexfieldbrand"><italic>XE "Wartec Cream(GK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D06BX"><fragment id="60616-D06BX"><block label="ATCLevel4"><para>Other chemotherapeutics</para></block></fragment></section><section id="60616-D06BX111241000036107"><xref-fragment id="60616-D06BX111241000036107"><blockxref id="107133" title="INGENOL MEBUTATE" frag="default" reversefrag="D06BX111241000036107" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60640" href="dynamic/R1/drug/111241000036107-D06BX.psml" urititle="INGENOL MEBUTATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60640" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60640" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/111241000036107-D06BX.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/111241000036107-D06BX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:30+10:00" modified="2018-06-15T10:34:30+10:00" title="INGENOL MEBUTATE"><displaytitle>INGENOL MEBUTATE</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D06BX111241000036107" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107133" title="R1" type="none" forwardtype="embed" forwardtitle="INGENOL MEBUTATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60640-111241000036107-1"><fragment id="60640-111241000036107-1"><block label="DrugName">INGENOL MEBUTATE<inline label="genericindexfield">XE "INGENOL MEBUTATE"</inline></block></fragment></section><section id="60640-d4656e16"><fragment id="60640-d4656e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Solar keratosis</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must require topical drug therapy on the face and scalp as field treatment for clinically visible and subclinical lesions where other standard treatments are inappropriate.</para></item></list></block></fragment></section><section id="60640-2464Q"><fragment id="60640-2464Q"><block label="FormAndStrength">ingenol mebutate 0.015% gel, 3 x 470 mg</block><table role="R1"><row><cell><block label="DrugItemCode">2464Q<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">138.90</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Picato [LO]<inline label="genericindexfieldbrand"><italic>XE "Picato(LO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60640-111241000036107-2"><fragment id="60640-111241000036107-2"><block label="DrugName">INGENOL MEBUTATE<inline label="genericindexfield">XE "INGENOL MEBUTATE"</inline></block></fragment></section><section id="60640-d4658e16"><fragment id="60640-d4658e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Solar (actinic) keratosis</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must require topical drug therapy as field treatment for clinically visible and subclinical lesions where other standard treatments are inappropriate.</para></item></list></block></fragment></section><section id="60640-2468X"><fragment id="60640-2468X"><block label="FormAndStrength">ingenol mebutate 0.05% gel, 2 x 470 mg</block><table role="R1"><row><cell><block label="DrugItemCode">2468X<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">138.90</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Picato [LO]<inline label="genericindexfieldbrand"><italic>XE "Picato(LO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D07"><fragment id="60616-D07"><block label="ATCLevel2"><para>CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS</para></block></fragment></section><section id="60616-D07A"><fragment id="60616-D07A"><block label="ATCLevel3"><para>CORTICOSTEROIDS, PLAIN</para></block></fragment></section><section id="60616-D07AA"><fragment id="60616-D07AA"><block label="ATCLevel4"><para>Corticosteroids, weak (group I)</para></block></fragment></section><section id="60616-D07AA21231011000036107"><xref-fragment id="60616-D07AA21231011000036107"><blockxref id="107123" title="HYDROCORTISONE ACETATE" frag="default" reversefrag="D07AA21231011000036107" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60170" href="dynamic/R1/drug/21231011000036107-D07AA.psml" urititle="HYDROCORTISONE ACETATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60170" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60170" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21231011000036107-D07AA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21231011000036107-D07AA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:25+10:00" modified="2018-06-15T10:34:30+10:00" title="HYDROCORTISONE ACETATE"><displaytitle>HYDROCORTISONE ACETATE</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D07AA21231011000036107" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107123" title="R1" type="none" forwardtype="embed" forwardtitle="HYDROCORTISONE ACETATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60170-21231011000036107-1"><fragment id="60170-21231011000036107-1"><block label="DrugName">HYDROCORTISONE ACETATE<inline label="genericindexfield">XE "HYDROCORTISONE ACETATE:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="60170-d4660e16"><fragment id="60170-d4660e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Corticosteroid-responsive dermatoses</para></block></fragment></section><section id="60170-10831C"><fragment id="60170-10831C"><block label="FormAndStrength">hydrocortisone acetate 1% ointment, 30 g</block><table role="R1"><row><cell><block label="DrugItemCode">10831C<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">16.26</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Cortic-DS 1% [QA]<inline label="genericindexfieldbrand"><italic>XE "Cortic-DS 1%(QA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D07AC"><fragment id="60616-D07AC"><block label="ATCLevel4"><para>Corticosteroids, potent (group III)</para></block></fragment></section><section id="60616-D07AC21366011000036103"><xref-fragment id="60616-D07AC21366011000036103"><blockxref id="107132" title="BETAMETHASONE VALERATE" frag="default" reversefrag="D07AC21366011000036103" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60023" href="dynamic/R1/drug/21366011000036103-D07AC.psml" urititle="BETAMETHASONE VALERATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60023" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60023" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21366011000036103-D07AC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21366011000036103-D07AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:24+10:00" modified="2018-06-15T10:34:30+10:00" title="BETAMETHASONE VALERATE"><displaytitle>BETAMETHASONE VALERATE</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D07AC21366011000036103" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107132" title="R1" type="none" forwardtype="embed" forwardtitle="BETAMETHASONE VALERATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60023-21366011000036103-1"><fragment id="60023-21366011000036103-1"><block label="DrugName">BETAMETHASONE VALERATE<inline label="genericindexfield">XE "BETAMETHASONE VALERATE"</inline></block></fragment></section><section id="60023-4131K"><fragment id="60023-4131K"><block label="FormAndStrength">betamethasone (as valerate) 0.1% cream, 30 g</block><table role="R1"><row><cell><block label="DrugItemCode">4131K<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">25.01</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Betnovate [QA]<inline label="genericindexfieldbrand"><italic>XE "Betnovate(QA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60023-4132L"><fragment id="60023-4132L"><block label="FormAndStrength">betamethasone (as valerate) 0.1% ointment, 30 g</block><table role="R1"><row><cell><block label="DrugItemCode">4132L<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">25.01</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Betnovate [QA]<inline label="genericindexfieldbrand"><italic>XE "Betnovate(QA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D07AC21409011000036100"><xref-fragment id="60616-D07AC21409011000036100"><blockxref id="107144" title="MOMETASONE" frag="default" reversefrag="D07AC21409011000036100" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60682" href="dynamic/R1/drug/21409011000036100-D07AC.psml" urititle="MOMETASONE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60682" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60682" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21409011000036100-D07AC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21409011000036100-D07AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:30+10:00" modified="2018-06-15T10:34:30+10:00" title="MOMETASONE"><displaytitle>MOMETASONE</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D07AC21409011000036100" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107144" title="R1" type="none" forwardtype="embed" forwardtitle="MOMETASONE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60682-21409011000036100-1"><fragment id="60682-21409011000036100-1"><block label="DrugName">MOMETASONE<inline label="genericindexfield">XE "MOMETASONE"</inline></block></fragment></section><section id="60682-d4663e17"><fragment id="60682-d4663e17"><block label="NoteText"><para>Application to large areas of skin for longer than four weeks is not recommended.</para></block></fragment></section><section id="60682-4343N"><fragment id="60682-4343N"><block label="FormAndStrength">mometasone furoate 0.1% ointment, 50 g</block><table role="R1"><row><cell><block label="DrugItemCode">4343N<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">34.62</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Elocon [MK]<inline label="genericindexfieldbrand"><italic>XE "Elocon(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60682-4342M"><fragment id="60682-4342M"><block label="FormAndStrength">mometasone furoate 0.1% cream, 50 g</block><table role="R1"><row><cell><block label="DrugItemCode">4342M<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">34.62</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Elocon [MK]<inline label="genericindexfieldbrand"><italic>XE "Elocon(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D08"><fragment id="60616-D08"><block label="ATCLevel2"><para>ANTISEPTICS AND DISINFECTANTS</para></block></fragment></section><section id="60616-D08A"><fragment id="60616-D08A"><block label="ATCLevel3"><para>ANTISEPTICS AND DISINFECTANTS</para></block></fragment></section><section id="60616-D08AG"><fragment id="60616-D08AG"><block label="ATCLevel4"><para>Iodine products</para></block></fragment></section><section id="60616-D08AG21660011000036108"><xref-fragment id="60616-D08AG21660011000036108"><blockxref id="107134" title="POVIDONE-IODINE" frag="default" reversefrag="D08AG21660011000036108" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60739" href="dynamic/R1/drug/21660011000036108-D08AG.psml" urititle="POVIDONE-IODINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60739" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60739" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21660011000036108-D08AG.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21660011000036108-D08AG.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:31+10:00" modified="2018-06-15T10:34:30+10:00" title="POVIDONE-IODINE"><displaytitle>POVIDONE-IODINE</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D08AG21660011000036108" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107134" title="R1" type="none" forwardtype="embed" forwardtitle="POVIDONE-IODINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60739-21660011000036108-1"><fragment id="60739-21660011000036108-1"><block label="DrugName">POVIDONE-IODINE<inline label="genericindexfield">XE "POVIDONE-IODINE:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="60739-4411E"><fragment id="60739-4411E"><block label="FormAndStrength">povidone-iodine 10% solution, 100 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4411E<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">24.73</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Betadine Antiseptic Liquid [SW]<inline label="genericindexfieldbrand"><italic>XE "Betadine Antiseptic Liquid(SW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D11"><fragment id="60616-D11"><block label="ATCLevel2"><para>OTHER DERMATOLOGICAL PREPARATIONS</para></block></fragment></section><section id="60616-D11A"><fragment id="60616-D11A"><block label="ATCLevel3"><para>OTHER DERMATOLOGICAL PREPARATIONS</para></block></fragment></section><section id="60616-D11AC"><fragment id="60616-D11AC"><block label="ATCLevel4"><para>Medicated shampoos</para></block></fragment></section><section id="60616-D11AC7031000144109"><xref-fragment id="60616-D11AC7031000144109"><blockxref id="107146" title="SALICYLIC ACID + BENZALKONIUM CHLORIDE + ALCOHOL + COAL TAR SOLUTION + POLYOXYETHYLENE ETHERS" frag="default" reversefrag="D11AC7031000144109" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60582" href="dynamic/R1/drug/7031000144109-D11AC.psml" urititle="SALICYLIC ACID + BENZALKONIUM CHLORIDE + ALCOHOL + COAL TAR SOLUTION + POLYOXYETHYLENE ETHERS" mediatype="application/vnd.pageseeder.psml+xml"><document id="60582" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60582" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/7031000144109-D11AC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/7031000144109-D11AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:29+10:00" modified="2018-06-15T10:34:30+10:00" title="SALICYLIC ACID + BENZALKONIUM CHLORIDE + ALCOHOL + COAL TAR SOLUTION + POLYOXYETHYLENE ETHERS"><displaytitle>SALICYLIC ACID + BENZALKONIUM CHLORIDE + ALCOHOL + COAL TAR SOLUTION + POLYOXYETHYLENE ETHERS</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D11AC7031000144109" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107146" title="R1" type="none" forwardtype="embed" forwardtitle="SALICYLIC ACID + BENZALKONIUM CHLORIDE + ALCOHOL + COAL TAR SOLUTION + POLYOXYETHYLENE ETHERS" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60582-7031000144109-1"><fragment id="60582-7031000144109-1"><block label="DrugName">SALICYLIC ACID + BENZALKONIUM CHLORIDE + ALCOHOL + COAL TAR SOLUTION + POLYOXYETHYLENE ETHERS<inline label="genericindexfield">XE "SALICYLIC ACID + BENZALKONIUM CHLORIDE + ALCOHOL + COAL TAR SOLUTION + POLYOXYETHYLENE ETHERS"</inline></block></fragment></section><section id="60582-4560B"><fragment id="60582-4560B"><block label="FormAndStrength">SALICYLIC ACID with COAL TAR SOLUTION Scalp cleanser 20 mg-50 mg per mL (2%-5%), 200 mL, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4560B<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">23.23</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Ionil-T [GA]<inline label="genericindexfieldbrand"><italic>XE "Ionil-T(GA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D11AC21422011000036103"><xref-fragment id="60616-D11AC21422011000036103"><blockxref id="107115" title="SELENIUM SULFIDE" frag="default" reversefrag="D11AC21422011000036103" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60678" href="dynamic/R1/drug/21422011000036103-D11AC.psml" urititle="SELENIUM SULFIDE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60678" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60678" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21422011000036103-D11AC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21422011000036103-D11AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:30+10:00" modified="2018-06-15T10:34:30+10:00" title="SELENIUM SULFIDE"><displaytitle>SELENIUM SULFIDE</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D11AC21422011000036103" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107115" title="R1" type="none" forwardtype="embed" forwardtitle="SELENIUM SULFIDE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60678-21422011000036103-1"><fragment id="60678-21422011000036103-1"><block label="DrugName">SELENIUM SULFIDE<inline label="genericindexfield">XE "SELENIUM SULFIDE"</inline></block></fragment></section><section id="60678-4452H"><fragment id="60678-4452H"><block label="FormAndStrength">selenium sulfide 2.5% shampoo, 125 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4452H<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.80</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Selsun [DQ]<inline label="genericindexfieldbrand"><italic>XE "Selsun(DQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D11AC6941000144104"><xref-fragment id="60616-D11AC6941000144104"><blockxref id="107122" title="TAR + CADE OIL + COAL TAR + ARACHIS OIL EXTRACT OF COAL TAR" frag="default" reversefrag="D11AC6941000144104" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59851" href="dynamic/R1/drug/6941000144104-D11AC.psml" urititle="TAR + CADE OIL + COAL TAR + ARACHIS OIL EXTRACT OF COAL TAR" mediatype="application/vnd.pageseeder.psml+xml"><document id="59851" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="59851" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/6941000144104-D11AC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/6941000144104-D11AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:30+10:00" title="TAR + CADE OIL + COAL TAR + ARACHIS OIL EXTRACT OF COAL TAR"><displaytitle>TAR + CADE OIL + COAL TAR + ARACHIS OIL EXTRACT OF COAL TAR</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D11AC6941000144104" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107122" title="R1" type="none" forwardtype="embed" forwardtitle="TAR + CADE OIL + COAL TAR + ARACHIS OIL EXTRACT OF COAL TAR" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59851-6941000144104-1"><fragment id="59851-6941000144104-1"><block label="DrugName">TAR + CADE OIL + COAL TAR + ARACHIS OIL EXTRACT OF COAL TAR<inline label="genericindexfield">XE "TAR + CADE OIL + COAL TAR + ARACHIS OIL EXTRACT OF COAL TAR"</inline></block></fragment></section><section id="59851-4405W"><fragment id="59851-4405W"><block label="FormAndStrength">tar 0.3% (300 microgram/mL) + cade oil 0.03% (300 microgram/mL) + coal tar 0.01% (100 microgram/mL) + arachis oil extract of coal tar 0.3% (3 mg/mL) lotion, 300 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4405W<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">26.50</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Polytar [GK]<inline label="genericindexfieldbrand"><italic>XE "Polytar(GK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D11AC922057011000036107"><xref-fragment id="60616-D11AC922057011000036107"><blockxref id="107125" title="TAR + COAL TAR SOLUTION + SALICYLIC ACID" frag="default" reversefrag="D11AC922057011000036107" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59769" href="dynamic/R1/drug/922057011000036107-D11AC.psml" urititle="TAR + COAL TAR SOLUTION + SALICYLIC ACID" mediatype="application/vnd.pageseeder.psml+xml"><document id="59769" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="59769" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/922057011000036107-D11AC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/922057011000036107-D11AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:30+10:00" title="TAR + COAL TAR SOLUTION + SALICYLIC ACID"><displaytitle>TAR + COAL TAR SOLUTION + SALICYLIC ACID</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D11AC922057011000036107" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107125" title="R1" type="none" forwardtype="embed" forwardtitle="TAR + COAL TAR SOLUTION + SALICYLIC ACID" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59769-922057011000036107-1"><fragment id="59769-922057011000036107-1"><block label="DrugName">TAR + COAL TAR SOLUTION + SALICYLIC ACID<inline label="genericindexfield">XE "TAR + COAL TAR SOLUTION + SALICYLIC ACID"</inline></block></fragment></section><section id="59769-4447C"><fragment id="59769-4447C"><block label="FormAndStrength">tar 1% + coal tar solution 1% + salicylic acid 2% solution, 250 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4447C<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">21.89</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Sebitar [EO]<inline label="genericindexfieldbrand"><italic>XE "Sebitar(EO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D11AF"><fragment id="60616-D11AF"><block label="ATCLevel4"><para>Wart and anti-corn preparations</para></block></fragment></section><section id="60616-D11AF61753011000036105"><xref-fragment id="60616-D11AF61753011000036105"><blockxref id="107147" title="SALICYLIC ACID + LACTIC ACID" frag="default" reversefrag="D11AF61753011000036105" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59754" href="dynamic/R1/drug/61753011000036105-D11AF.psml" urititle="SALICYLIC ACID + LACTIC ACID" mediatype="application/vnd.pageseeder.psml+xml"><document id="59754" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="59754" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/61753011000036105-D11AF.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/61753011000036105-D11AF.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:20+10:00" modified="2018-06-15T10:34:30+10:00" title="SALICYLIC ACID + LACTIC ACID"><displaytitle>SALICYLIC ACID + LACTIC ACID</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D11AF61753011000036105" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107147" title="R1" type="none" forwardtype="embed" forwardtitle="SALICYLIC ACID + LACTIC ACID" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59754-61753011000036105-1"><fragment id="59754-61753011000036105-1"><block label="DrugName">SALICYLIC ACID + LACTIC ACID<inline label="genericindexfield">XE "SALICYLIC ACID + LACTIC ACID"</inline></block></fragment></section><section id="59754-4386W"><fragment id="59754-4386W"><block label="FormAndStrength">salicylic acid 16.7% + lactic acid 16.7% application, 15 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4386W<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">21.29</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Duofilm Solution [GK]<inline label="genericindexfieldbrand"><italic>XE "Duofilm Solution(GK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D11AX"><fragment id="60616-D11AX"><block label="ATCLevel4"><para>Other dermatologicals</para></block></fragment></section><section id="60616-D11AX21288011000036105"><xref-fragment id="60616-D11AX21288011000036105"><blockxref id="107138" title="DICLOFENAC" frag="default" reversefrag="D11AX21288011000036105" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60794" href="dynamic/R1/drug/21288011000036105-D11AX.psml" urititle="DICLOFENAC" mediatype="application/vnd.pageseeder.psml+xml"><document id="60794" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60794" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21288011000036105-D11AX.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21288011000036105-D11AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:30+10:00" title="DICLOFENAC"><displaytitle>DICLOFENAC</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D11AX21288011000036105" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107138" title="R1" type="none" forwardtype="embed" forwardtitle="DICLOFENAC" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60794-21288011000036105-1"><fragment id="60794-21288011000036105-1"><block label="DrugName">DICLOFENAC<inline label="genericindexfield">XE "DICLOFENAC:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="60794-d4671e28"><fragment id="60794-d4671e28"><block label="NoteText"><para>Maximum quantity of four tubes (original + 3 repeats) in 12 months.</para></block></fragment></section><section id="60794-d4671e16"><fragment id="60794-d4671e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Solar (actinic) keratosis</para><para>Treatment Phase: Management</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must require topical drug therapy as field treatment for clinically visible and subclinical lesions where other standard treatments are inappropriate.</para></item></list></block></fragment></section><section id="60794-4046Y"><fragment id="60794-4046Y"><block label="FormAndStrength">diclofenac sodium 3% gel, 25 g</block><table role="R1"><row><cell><block label="DrugItemCode">4046Y<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">58.15</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Solaraze 3% Gel [FK]<inline label="genericindexfieldbrand"><italic>XE "Solaraze 3% Gel(FK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D11AX21816011000036101"><xref-fragment id="60616-D11AX21816011000036101"><blockxref id="107143" title="ICHTHAMMOL" frag="default" reversefrag="D11AX21816011000036101" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60521" href="dynamic/R1/drug/21816011000036101-D11AX.psml" urititle="ICHTHAMMOL" mediatype="application/vnd.pageseeder.psml+xml"><document id="60521" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60521" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21816011000036101-D11AX.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21816011000036101-D11AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:29+10:00" modified="2018-06-15T10:34:30+10:00" title="ICHTHAMMOL"><displaytitle>ICHTHAMMOL</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D11AX21816011000036101" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107143" title="R1" type="none" forwardtype="embed" forwardtitle="ICHTHAMMOL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60521-21816011000036101-1"><fragment id="60521-21816011000036101-1"><block label="DrugName">ICHTHAMMOL<inline label="genericindexfield">XE "ICHTHAMMOL"</inline></block></fragment></section><section id="60521-d4673e17"><fragment id="60521-d4673e17"><block label="NoteText"><para>For patients who have failed to respond to simple moisturising agents.</para></block></fragment></section><section id="60521-4281H"><fragment id="60521-4281H"><block label="FormAndStrength">ichthammol Cream 5 mg-10 mg-10 mg per g (0.5%-1%-1%), 50 g, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4281H<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">21.25</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Egoderm Cream [EO]<inline label="genericindexfieldbrand"><italic>XE "Egoderm Cream(EO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D11AX21657011000036100"><xref-fragment id="60616-D11AX21657011000036100"><blockxref id="107120" title="ICHTHAMMOL + ZINC OXIDE" frag="default" reversefrag="D11AX21657011000036100" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60221" href="dynamic/R1/drug/21657011000036100-D11AX.psml" urititle="ICHTHAMMOL + ZINC OXIDE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60221" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60221" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21657011000036100-D11AX.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21657011000036100-D11AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:26+10:00" modified="2018-06-15T10:34:30+10:00" title="ICHTHAMMOL + ZINC OXIDE"><displaytitle>ICHTHAMMOL + ZINC OXIDE</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D11AX21657011000036100" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107120" title="R1" type="none" forwardtype="embed" forwardtitle="ICHTHAMMOL + ZINC OXIDE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60221-21657011000036100-1"><fragment id="60221-21657011000036100-1"><block label="DrugName">ICHTHAMMOL + ZINC OXIDE<inline label="genericindexfield">XE "ICHTHAMMOL + ZINC OXIDE"</inline></block></fragment></section><section id="60221-d4675e17"><fragment id="60221-d4675e17"><block label="NoteText"><para>For patients who have failed to respond to simple moisturising agents.</para></block></fragment></section><section id="60221-4280G"><fragment id="60221-4280G"><block label="FormAndStrength">ichthammol 1% + zinc oxide 15% ointment, 50 g</block><table role="R1"><row><cell><block label="DrugItemCode">4280G<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">21.25</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Egoderm Ointment [EO]<inline label="genericindexfieldbrand"><italic>XE "Egoderm Ointment(EO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D11AX21715011000036105"><xref-fragment id="60616-D11AX21715011000036105"><blockxref id="107116" title="IMIQUIMOD" frag="default" reversefrag="D11AX21715011000036105" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60813" href="dynamic/R1/drug/21715011000036105-D11AX.psml" urititle="IMIQUIMOD" mediatype="application/vnd.pageseeder.psml+xml"><document id="60813" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60813" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21715011000036105-D11AX.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21715011000036105-D11AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:30+10:00" title="IMIQUIMOD"><displaytitle>IMIQUIMOD</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D11AX21715011000036105" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107116" title="R1" type="none" forwardtype="embed" forwardtitle="IMIQUIMOD" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60813-21715011000036105-1"><fragment id="60813-21715011000036105-1"><block label="DrugName">IMIQUIMOD<inline label="genericindexfield">XE "IMIQUIMOD"</inline></block></fragment></section><section id="60813-d4677e16"><fragment id="60813-d4677e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Superficial basal cell carcinoma</para><para>Treatment Phase: Primary treatment</para><para><bold>Clinical criteria:</bold></para><list><item><para>The condition must be confirmed by a histological diagnosis,</para></item></list><para><bold>AND</bold></para><list><item><para>The condition must be one where other standard treatments are inappropriate,</para></item></list><para><bold>AND</bold></para><list><item><para>The condition must require topical drug therapy.</para></item></list></block></fragment></section><section id="60813-4559Y"><fragment id="60813-4559Y"><block label="FormAndStrength">imiquimod 5% cream, 12 x 250 mg sachets</block><table role="R1"><row><cell><block label="DrugItemCode">4559Y<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">86.62</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Aldiq [QA]<inline label="genericindexfieldbrand"><italic>XE "Aldiq(QA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Imiquimod [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Imiquimod (TX)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">88.90</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Aldara [IL]<inline label="genericindexfieldbrand"><italic>XE "Aldara(IL)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60813-21715011000036105-2"><fragment id="60813-21715011000036105-2"><block label="DrugName">IMIQUIMOD<inline label="genericindexfield">XE "IMIQUIMOD"</inline></block></fragment></section><section id="60813-d4679e26"><fragment id="60813-d4679e26"><block label="NoteText"><para>Pharmaceutical benefits that have the form imiquimod single use sachets and pharmaceutical benefits that have the form imiquimod multi-use pump are equivalent for the purposes of substitution.</para></block></fragment></section><section id="60813-d4679e16"><fragment id="60813-d4679e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Solar keratosis</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must require topical drug therapy on the face and scalp as field treatment for clinically visible and subclinical lesions where other standard treatments are inappropriate.</para></item></list></block></fragment></section><section id="60813-4134N"><fragment id="60813-4134N"><block label="FormAndStrength">imiquimod 5% cream, 12 x 250 mg sachets</block><table role="R1"><row><cell><block label="DrugItemCode">4134N<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">86.62</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Aldiq [QA]<inline label="genericindexfieldbrand"><italic>XE "Aldiq(QA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Imiquimod [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Imiquimod (TX)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">88.90</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Aldara [IL]<inline label="genericindexfieldbrand"><italic>XE "Aldara(IL)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60813-10106X"><fragment id="60813-10106X"><block label="FormAndStrength">imiquimod 5% cream, 2 x 2 g</block><table role="R1"><row><cell><block label="DrugItemCode">10106X<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">91.17</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Aldara Pump [IL]<inline label="genericindexfieldbrand"><italic>XE "Aldara Pump(IL)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D11AX33625011000036102"><xref-fragment id="60616-D11AX33625011000036102"><blockxref id="107136" title="LIGHT LIQUID PARAFFIN + COCOAMPHODIACETATE DISODIUM" frag="default" reversefrag="D11AX33625011000036102" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60795" href="dynamic/R1/drug/33625011000036102-D11AX.psml" urititle="LIGHT LIQUID PARAFFIN + COCOAMPHODIACETATE DISODIUM" mediatype="application/vnd.pageseeder.psml+xml"><document id="60795" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="60795" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/33625011000036102-D11AX.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/33625011000036102-D11AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:30+10:00" title="LIGHT LIQUID PARAFFIN + COCOAMPHODIACETATE DISODIUM"><displaytitle>LIGHT LIQUID PARAFFIN + COCOAMPHODIACETATE DISODIUM</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D11AX33625011000036102" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107136" title="R1" type="none" forwardtype="embed" forwardtitle="LIGHT LIQUID PARAFFIN + COCOAMPHODIACETATE DISODIUM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60795-33625011000036102-1"><fragment id="60795-33625011000036102-1"><block label="DrugName">LIGHT LIQUID PARAFFIN + COCOAMPHODIACETATE DISODIUM<inline label="genericindexfield">XE "LIGHT LIQUID PARAFFIN + COCOAMPHODIACETATE DISODIUM"</inline></block></fragment></section><section id="60795-4549K"><fragment id="60795-4549K"><block label="FormAndStrength">light liquid paraffin 3.5% + cocoamphodiacetate disodium 3% lotion, 500 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4549K<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">23.54</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Hamilton Skin Therapy Wash [KY]<inline label="genericindexfieldbrand"><italic>XE "Hamilton Skin Therapy Wash(KY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D11AX933232101000036105"><xref-fragment id="60616-D11AX933232101000036105"><blockxref id="107137" title="PANTHENOL" frag="default" reversefrag="D11AX933232101000036105" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59976" href="dynamic/R1/drug/933232101000036105-D11AX.psml" urititle="PANTHENOL" mediatype="application/vnd.pageseeder.psml+xml"><document id="59976" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="59976" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/933232101000036105-D11AX.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/933232101000036105-D11AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:23+10:00" modified="2018-06-15T10:34:30+10:00" title="PANTHENOL"><displaytitle>PANTHENOL</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D11AX933232101000036105" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107137" title="R1" type="none" forwardtype="embed" forwardtitle="PANTHENOL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59976-933232101000036105-1"><fragment id="59976-933232101000036105-1"><block label="DrugName">PANTHENOL<inline label="genericindexfield">XE "PANTHENOL"</inline></block></fragment></section><section id="59976-d4682e17"><fragment id="59976-d4682e17"><block label="NoteText"><para>To be used in conjunction with the scalp cleanser salicylic acid with coal tar solution and pine tar (code 4447C).</para></block></fragment></section><section id="59976-4510J"><fragment id="59976-4510J"><block label="FormAndStrength">panthenol conditioner, 200 g</block><table role="R1"><row><cell><block label="DrugItemCode">4510J<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.90</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">SebiRinse [EO]<inline label="genericindexfieldbrand"><italic>XE "SebiRinse(EO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60616-D11AX32624011000036105"><xref-fragment id="60616-D11AX32624011000036105"><blockxref id="107114" title="ZINC OXIDE + MAIZE STARCH + PURIFIED TALC + CHLORPHENESIN" frag="default" reversefrag="D11AX32624011000036105" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59700" href="dynamic/R1/drug/32624011000036105-D11AX.psml" urititle="ZINC OXIDE + MAIZE STARCH + PURIFIED TALC + CHLORPHENESIN" mediatype="application/vnd.pageseeder.psml+xml"><document id="59700" schemaversion="0.12" date="2018-06-15T10:34:30+10:00" version="current" level="processed"><documentinfo><uri id="59700" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/32624011000036105-D11AX.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/32624011000036105-D11AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:20+10:00" modified="2018-06-15T10:34:30+10:00" title="ZINC OXIDE + MAIZE STARCH + PURIFIED TALC + CHLORPHENESIN"><displaytitle>ZINC OXIDE + MAIZE STARCH + PURIFIED TALC + CHLORPHENESIN</displaytitle></uri><reversexrefs><reversexref uriid="60616" href="dynamic/R1/atc/D.psml" frag="D11AX32624011000036105" urititle="DERMATOLOGICALS" mediatype="application/vnd.pageseeder.psml+xml" id="107114" title="R1" type="none" forwardtype="embed" forwardtitle="ZINC OXIDE + MAIZE STARCH + PURIFIED TALC + CHLORPHENESIN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59700-32624011000036105-1"><fragment id="59700-32624011000036105-1"><block label="DrugName">ZINC OXIDE + MAIZE STARCH + PURIFIED TALC + CHLORPHENESIN<inline label="genericindexfield">XE "ZINC OXIDE + MAIZE STARCH + PURIFIED TALC + CHLORPHENESIN"</inline></block></fragment></section><section id="59700-4497Q"><fragment id="59700-4497Q"><block label="FormAndStrength">zinc oxide 25% + maize starch 55.85% + purified talc 18.07% + chlorphenesin 1% dusting powder, 100 g</block><table role="R1"><row><cell><block label="DrugItemCode">4497Q<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">16.16</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Z.S.C. [RW]<inline label="genericindexfieldbrand"><italic>XE "Z.S.C.(RW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref><blockxref id="107085" title="GENITO URINARY SYSTEM AND SEX HORMONES" frag="default" reversefrag="d114e761780" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59705" href="dynamic/R1/atc/G.psml" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml"><document id="59705" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="59705" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/atc/G.psml" decodedpath="/ps/test/local3/books/dynamic/R1/atc/G.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:20+10:00" modified="2018-06-15T10:34:32+10:00" title="GENITO URINARY SYSTEM AND SEX HORMONES"><displaytitle>GENITO URINARY SYSTEM AND SEX HORMONES</displaytitle></uri><reversexrefs><reversexref uriid="60526" href="dynamic/R1.psml" frag="d114e761780" urititle="Repatriation Pharmaceutical Benefits Scheme" mediatype="application/vnd.pageseeder.psml+xml" id="107085" title="R1" type="none" forwardtype="embed" forwardtitle="GENITO URINARY SYSTEM AND SEX HORMONES" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107632" title="Untitled" type="none" forwardtype="none" forwardtitle="GENITO URINARY SYSTEM AND SEX HORMONES" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="42233" fragment="59705-G04BE21478011000036104" editid="105156" modified="2018-06-15T10:34:20+10:00"></locator><locator id="44707" fragment="59705-G04"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107637" title="Untitled" type="none" forwardtype="none" forwardtitle="UROLOGICALS" forwarddisplay="document" forwardfrag="G04"></reversexref></reversexrefs></locator><locator id="42251" fragment="59705-G04BX21568011000036102" editid="105165" modified="2018-06-15T10:34:20+10:00"></locator><locator id="44703" fragment="59705-G01"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107633" title="Untitled" type="none" forwardtype="none" forwardtitle="GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS" forwarddisplay="document" forwardfrag="G01"></reversexref></reversexrefs></locator><locator id="44705" fragment="59705-G02"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107635" title="Untitled" type="none" forwardtype="none" forwardtitle="OTHER GYNECOLOGICALS" forwarddisplay="document" forwardfrag="G02"></reversexref></reversexrefs></locator><locator id="44704" fragment="59705-G01A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107634" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS" forwarddisplay="document" forwardfrag="G01A"></reversexref></reversexrefs></locator><locator id="42249" fragment="59705-G04CA33648011000036105" editid="105164" modified="2018-06-15T10:34:20+10:00"></locator><locator id="42235" fragment="59705-G04CA926977011000036100" editid="105157" modified="2018-06-15T10:34:20+10:00"></locator><locator id="44709" fragment="59705-G04C"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107639" title="Untitled" type="none" forwardtype="none" forwardtitle="DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY" forwarddisplay="document" forwardfrag="G04C"></reversexref></reversexrefs></locator><locator id="42257" fragment="59705-G04BE21529011000036101" editid="105168" modified="2018-06-15T10:34:20+10:00"></locator><locator id="42245" fragment="59705-G04CA931811011000036106" editid="105162" modified="2018-06-15T10:34:20+10:00"></locator><locator id="42241" fragment="59705-G04BE21725011000036104" editid="105160" modified="2018-06-15T10:34:20+10:00"></locator><locator id="42247" fragment="59705-G01AA21669011000036102" editid="105163" modified="2018-06-15T10:34:20+10:00"></locator><locator id="44708" fragment="59705-G04B"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107638" title="Untitled" type="none" forwardtype="none" forwardtitle="UROLOGICALS" forwarddisplay="document" forwardfrag="G04B"></reversexref></reversexrefs></locator><locator id="42243" fragment="59705-G04BE44856011000036100" editid="105161" modified="2018-06-15T10:34:20+10:00"></locator><locator id="44706" fragment="59705-G02C"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107636" title="Untitled" type="none" forwardtype="none" forwardtitle="OTHER GYNECOLOGICALS" forwarddisplay="document" forwardfrag="G02C"></reversexref></reversexrefs></locator><locator id="42237" fragment="59705-G02C21876011000036105" editid="105158" modified="2018-06-15T10:34:20+10:00"></locator><locator id="42239" fragment="59705-G04CB21896011000036102" editid="105159" modified="2018-06-15T10:34:20+10:00"></locator><locator id="42255" fragment="59705-G01AF21684011000036100" editid="105167" modified="2018-06-15T10:34:20+10:00"></locator><locator id="42253" fragment="59705-G04CB920821011000036105" editid="105166" modified="2018-06-15T10:34:20+10:00"></locator></fragmentinfo><metadata></metadata><section id="59705-G"><fragment id="59705-G"><block label="ATCLevel1"><para>GENITO URINARY SYSTEM AND SEX HORMONES</para></block></fragment></section><section id="59705-G01"><fragment id="59705-G01"><block label="ATCLevel2"><para>GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS</para></block></fragment></section><section id="59705-G01A"><fragment id="59705-G01A"><block label="ATCLevel3"><para>ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS</para></block></fragment></section><section id="59705-G01AA"><fragment id="59705-G01AA"><block label="ATCLevel4"><para>Antibiotics</para></block></fragment></section><section id="59705-G01AA21669011000036102"><xref-fragment id="59705-G01AA21669011000036102"><blockxref id="105150" title="NYSTATIN" frag="default" reversefrag="G01AA21669011000036102" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60246" href="dynamic/R1/drug/21669011000036102-G01AA.psml" urititle="NYSTATIN" mediatype="application/vnd.pageseeder.psml+xml"><document id="60246" schemaversion="0.12" date="2018-06-15T10:34:20+10:00" version="current" level="processed"><documentinfo><uri id="60246" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21669011000036102-G01AA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21669011000036102-G01AA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:26+10:00" modified="2018-06-15T10:34:20+10:00" title="NYSTATIN"><displaytitle>NYSTATIN</displaytitle></uri><reversexrefs><reversexref uriid="59705" href="dynamic/R1/atc/G.psml" frag="G01AA21669011000036102" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml" id="105150" title="R1" type="none" forwardtype="embed" forwardtitle="NYSTATIN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60246-21669011000036102-1"><fragment id="60246-21669011000036102-1"><block label="DrugName">NYSTATIN<inline label="genericindexfield">XE "NYSTATIN:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="60246-4013F"><fragment id="60246-4013F"><block label="FormAndStrength">nystatin 20 000 units/g vaginal cream, 75 g</block><table role="R1"><row><cell><block label="DrugItemCode">4013F<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.50</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Nilstat [QA]<inline label="genericindexfieldbrand"><italic>XE "Nilstat(QA):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59705-G01AF"><fragment id="59705-G01AF"><block label="ATCLevel4"><para>Imidazole derivatives</para></block></fragment></section><section id="59705-G01AF21684011000036100"><xref-fragment id="59705-G01AF21684011000036100"><blockxref id="105154" title="CLOTRIMAZOLE" frag="default" reversefrag="G01AF21684011000036100" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60691" href="dynamic/R1/drug/21684011000036100-G01AF.psml" urititle="CLOTRIMAZOLE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60691" schemaversion="0.12" date="2018-06-15T10:34:20+10:00" version="current" level="processed"><documentinfo><uri id="60691" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21684011000036100-G01AF.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21684011000036100-G01AF.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:31+10:00" modified="2018-06-15T10:34:20+10:00" title="CLOTRIMAZOLE"><displaytitle>CLOTRIMAZOLE</displaytitle></uri><reversexrefs><reversexref uriid="59705" href="dynamic/R1/atc/G.psml" frag="G01AF21684011000036100" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml" id="105154" title="R1" type="none" forwardtype="embed" forwardtitle="CLOTRIMAZOLE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60691-21684011000036100-1"><fragment id="60691-21684011000036100-1"><block label="DrugName">CLOTRIMAZOLE<inline label="genericindexfield">XE "CLOTRIMAZOLE:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="60691-4017K"><fragment id="60691-4017K"><block label="FormAndStrength">clotrimazole 2% vaginal cream, 20 g</block><table role="R1"><row><cell><block label="DrugItemCode">4017K<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.62</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">APO-Clotrimazole 3 Day Cream [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Clotrimazole 3 Day Cream(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Clonea 3 Day Cream [AF]<inline label="genericindexfieldbrand"><italic>XE "Clonea 3 Day Cream (AF)" \i </italic></inline></block></cell></row></table></fragment></section><section id="60691-4016J"><fragment id="60691-4016J"><block label="FormAndStrength">clotrimazole 1% vaginal cream, 35 g</block><table role="R1"><row><cell><block label="DrugItemCode">4016J<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.41</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Clonea 6 Day Cream [AF]<inline label="genericindexfieldbrand"><italic>XE "Clonea 6 Day Cream(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Pharmacy Action FemCream [GQ]<inline label="genericindexfieldbrand"><italic>XE "Pharmacy Action FemCream (GQ)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.62</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Clotrimazole 6 Day Cream [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Clotrimazole 6 Day Cream(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59705-G02"><fragment id="59705-G02"><block label="ATCLevel2"><para>OTHER GYNECOLOGICALS</para></block></fragment></section><section id="59705-G02C"><fragment id="59705-G02C"><block label="ATCLevel3"><para>OTHER GYNECOLOGICALS</para></block></fragment></section><section id="59705-G02C21876011000036105"><xref-fragment id="59705-G02C21876011000036105"><blockxref id="105145" title="ACETIC ACID + HYDROXYQUINOLINE + RICINOLEIC ACID" frag="default" reversefrag="G02C21876011000036105" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60006" href="dynamic/R1/drug/21876011000036105-G02C.psml" urititle="ACETIC ACID + HYDROXYQUINOLINE + RICINOLEIC ACID" mediatype="application/vnd.pageseeder.psml+xml"><document id="60006" schemaversion="0.12" date="2018-06-15T10:34:20+10:00" version="current" level="processed"><documentinfo><uri id="60006" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21876011000036105-G02C.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21876011000036105-G02C.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:23+10:00" modified="2018-06-15T10:34:20+10:00" title="ACETIC ACID + HYDROXYQUINOLINE + RICINOLEIC ACID"><displaytitle>ACETIC ACID + HYDROXYQUINOLINE + RICINOLEIC ACID</displaytitle></uri><reversexrefs><reversexref uriid="59705" href="dynamic/R1/atc/G.psml" frag="G02C21876011000036105" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml" id="105145" title="R1" type="none" forwardtype="embed" forwardtitle="ACETIC ACID + HYDROXYQUINOLINE + RICINOLEIC ACID" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60006-21876011000036105-1"><fragment id="60006-21876011000036105-1"><block label="DrugName">ACETIC ACID + HYDROXYQUINOLINE + RICINOLEIC ACID<inline label="genericindexfield">XE "ACETIC ACID + HYDROXYQUINOLINE + RICINOLEIC ACID"</inline></block></fragment></section><section id="60006-4434J"><fragment id="60006-4434J"><block label="FormAndStrength">acetic acid 0.94% + oxyquinoline sulfate 0.025% + ricinoleic acid 0.75% vaginal gel, 100 g</block><table role="R1"><row><cell><block label="DrugItemCode">4434J<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">34.12</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Aci-Jel [CU]<inline label="genericindexfieldbrand"><italic>XE "Aci-Jel(CU)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59705-G04"><fragment id="59705-G04"><block label="ATCLevel2"><para>UROLOGICALS</para></block></fragment></section><section id="59705-G04B"><fragment id="59705-G04B"><block label="ATCLevel3"><para>UROLOGICALS</para></block></fragment></section><section id="59705-G04BE"><fragment id="59705-G04BE"><block label="ATCLevel4"><para>Drugs used in erectile dysfunction</para></block></fragment></section><section id="59705-G04BE21478011000036104"><xref-fragment id="59705-G04BE21478011000036104"><blockxref id="105143" title="ALPROSTADIL" frag="default" reversefrag="G04BE21478011000036104" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59785" href="dynamic/R1/drug/21478011000036104-G04BE.psml" urititle="ALPROSTADIL" mediatype="application/vnd.pageseeder.psml+xml"><document id="59785" schemaversion="0.12" date="2018-06-15T10:34:20+10:00" version="current" level="processed"><documentinfo><uri id="59785" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21478011000036104-G04BE.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21478011000036104-G04BE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:20+10:00" title="ALPROSTADIL"><displaytitle>ALPROSTADIL</displaytitle></uri><reversexrefs><reversexref uriid="59705" href="dynamic/R1/atc/G.psml" frag="G04BE21478011000036104" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml" id="105143" title="R1" type="none" forwardtype="embed" forwardtitle="ALPROSTADIL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59785-21478011000036104-1"><fragment id="59785-21478011000036104-1"><block label="DrugName">ALPROSTADIL<inline label="genericindexfield">XE "ALPROSTADIL"</inline></block></fragment></section><section id="59785-d4688e16"><fragment id="59785-d4688e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Erectile dysfunction</para><para><bold>Clinical criteria:</bold></para><list><item><para>The condition must be vasculogenic; OR</para></item><item><para>The condition must be psychogenic; OR</para></item><item><para>The condition must be neurogenic,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a specific accepted war-caused or service-related disability.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be male.</para></item></list> <para>Authorisation will not be given for any additional prescriptions within 6 months or for any increased quantities or repeats.</para></block></fragment></section><section id="59785-4580C"><fragment id="59785-4580C"><block label="FormAndStrength">alprostadil 20 microgram injection [2] (&amp;) inert substance diluent [2 x 0.6 mL syringes], 1 pack</block><table role="R1"><row><cell><block label="DrugItemCode">4580C<br></br></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>125.98</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Caverject Impulse [PF]<inline label="genericindexfieldbrand"><italic>XE "Caverject Impulse(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59785-4579B"><fragment id="59785-4579B"><block label="FormAndStrength">alprostadil 10 microgram injection [2] (&amp;) inert substance diluent [2 x 0.6 mL syringes], 1 pack</block><table role="R1"><row><cell><block label="DrugItemCode">4579B<br></br></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>101.14</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Caverject Impulse [PF]<inline label="genericindexfieldbrand"><italic>XE "Caverject Impulse(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59705-G04BE21529011000036101"><xref-fragment id="59705-G04BE21529011000036101"><blockxref id="105155" title="SILDENAFIL" frag="default" reversefrag="G04BE21529011000036101" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60129" href="dynamic/R1/drug/21529011000036101-G04BE.psml" urititle="SILDENAFIL" mediatype="application/vnd.pageseeder.psml+xml"><document id="60129" schemaversion="0.12" date="2018-06-15T10:34:20+10:00" version="current" level="processed"><documentinfo><uri id="60129" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21529011000036101-G04BE.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21529011000036101-G04BE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:25+10:00" modified="2018-06-15T10:34:20+10:00" title="SILDENAFIL"><displaytitle>SILDENAFIL</displaytitle></uri><reversexrefs><reversexref uriid="59705" href="dynamic/R1/atc/G.psml" frag="G04BE21529011000036101" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml" id="105155" title="R1" type="none" forwardtype="embed" forwardtitle="SILDENAFIL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60129-21529011000036101-1"><fragment id="60129-21529011000036101-1"><block label="DrugName">SILDENAFIL<inline label="genericindexfield">XE "SILDENAFIL:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="60129-d4690e16"><fragment id="60129-d4690e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Erectile dysfunction</para><para><bold>Clinical criteria:</bold></para><list><item><para>The condition must be vasculogenic; OR</para></item><item><para>The condition must be psychogenic; OR</para></item><item><para>The condition must be neurogenic,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a specific accepted war-caused or service-related disability.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be male.</para></item></list> <para>Authorisation will not be given for any additional prescriptions within 6 months or for any increased quantities or repeats.</para></block></fragment></section><section id="60129-4585H"><fragment id="60129-4585H"><block label="FormAndStrength">sildenafil 50 mg tablet, 4</block><table role="R1"><row><cell><block label="DrugItemCode">4585H<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">67.04</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Sildenafil [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Sildenafil(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Sildenafil Actavis [EA]<inline label="genericindexfieldbrand"><italic>XE "Sildenafil Actavis (EA)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Vasafil 50 [RW]<inline label="genericindexfieldbrand"><italic>XE "Vasafil 50(RW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Vedafil [AF]<inline label="genericindexfieldbrand"><italic>XE "Vedafil (AF)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">77.70</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Viagra [PF]<inline label="genericindexfieldbrand"><italic>XE "Viagra(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60129-4586J"><fragment id="60129-4586J"><block label="FormAndStrength">sildenafil 100 mg tablet, 4</block><table role="R1"><row><cell><block label="DrugItemCode">4586J<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">71.61</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Sildenafil [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Sildenafil(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Chem mart Sildenafil [CH]<inline label="genericindexfieldbrand"><italic>XE "Chem mart Sildenafil (CH)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Sildenafil Actavis [EA]<inline label="genericindexfieldbrand"><italic>XE "Sildenafil Actavis(EA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Sildenafil generichealth [GQ]<inline label="genericindexfieldbrand"><italic>XE "Sildenafil generichealth (GQ)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Terry White Chemists Sildenafil [TW]<inline label="genericindexfieldbrand"><italic>XE "Terry White Chemists Sildenafil(TW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Vasafil 100 [RW]<inline label="genericindexfieldbrand"><italic>XE "Vasafil 100 (RW)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Vedafil [AF]<inline label="genericindexfieldbrand"><italic>XE "Vedafil(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">83.14</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Silaran [RA]<inline label="genericindexfieldbrand"><italic>XE "Silaran(RA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Viagra [PF]<inline label="genericindexfieldbrand"><italic>XE "Viagra (PF)" \i </italic></inline></block></cell></row></table></fragment></section><section id="60129-4584G"><fragment id="60129-4584G"><block label="FormAndStrength">sildenafil 25 mg tablet, 4</block><table role="R1"><row><cell><block label="DrugItemCode">4584G<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">55.04</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Sildenafil Actavis [EA]<inline label="genericindexfieldbrand"><italic>XE "Sildenafil Actavis(EA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Vasafil 25 [RW]<inline label="genericindexfieldbrand"><italic>XE "Vasafil 25 (RW)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Vedafil [AF]<inline label="genericindexfieldbrand"><italic>XE "Vedafil(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">55.05</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Sildenafil [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Sildenafil(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">63.42</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Viagra [PF]<inline label="genericindexfieldbrand"><italic>XE "Viagra(PF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59705-G04BE21725011000036104"><xref-fragment id="59705-G04BE21725011000036104"><blockxref id="105147" title="TADALAFIL" frag="default" reversefrag="G04BE21725011000036104" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60054" href="dynamic/R1/drug/21725011000036104-G04BE.psml" urititle="TADALAFIL" mediatype="application/vnd.pageseeder.psml+xml"><document id="60054" schemaversion="0.12" date="2018-06-15T10:34:20+10:00" version="current" level="processed"><documentinfo><uri id="60054" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21725011000036104-G04BE.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21725011000036104-G04BE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:24+10:00" modified="2018-06-15T10:34:20+10:00" title="TADALAFIL"><displaytitle>TADALAFIL</displaytitle></uri><reversexrefs><reversexref uriid="59705" href="dynamic/R1/atc/G.psml" frag="G04BE21725011000036104" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml" id="105147" title="R1" type="none" forwardtype="embed" forwardtitle="TADALAFIL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60054-21725011000036104-1"><fragment id="60054-21725011000036104-1"><block label="DrugName">TADALAFIL<inline label="genericindexfield">XE "TADALAFIL:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="60054-d4692e16"><fragment id="60054-d4692e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Erectile dysfunction</para><para><bold>Clinical criteria:</bold></para><list><item><para>The condition must be vasculogenic; OR</para></item><item><para>The condition must be psychogenic; OR</para></item><item><para>The condition must be neurogenic,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a specific accepted war-caused or service-related disability.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be male.</para></item></list> <para>Authorisation will not be given for any additional prescriptions within 6 months or for any increased quantities or repeats.</para></block></fragment></section><section id="60054-4596X"><fragment id="60054-4596X"><block label="FormAndStrength">tadalafil 10 mg tablet, 4</block><table role="R1"><row><cell><block label="DrugItemCode">4596X<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">103.85</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Cialis [LY]<inline label="genericindexfieldbrand"><italic>XE "Cialis(LY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60054-4597Y"><fragment id="60054-4597Y"><block label="FormAndStrength">tadalafil 20 mg tablet, 4</block><table role="R1"><row><cell><block label="DrugItemCode">4597Y<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">103.85</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Cialis [LY]<inline label="genericindexfieldbrand"><italic>XE "Cialis(LY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59705-G04BE44856011000036100"><xref-fragment id="59705-G04BE44856011000036100"><blockxref id="105148" title="VARDENAFIL" frag="default" reversefrag="G04BE44856011000036100" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60750" href="dynamic/R1/drug/44856011000036100-G04BE.psml" urititle="VARDENAFIL" mediatype="application/vnd.pageseeder.psml+xml"><document id="60750" schemaversion="0.12" date="2018-06-15T10:34:20+10:00" version="current" level="processed"><documentinfo><uri id="60750" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/44856011000036100-G04BE.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/44856011000036100-G04BE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:31+10:00" modified="2018-06-15T10:34:20+10:00" title="VARDENAFIL"><displaytitle>VARDENAFIL</displaytitle></uri><reversexrefs><reversexref uriid="59705" href="dynamic/R1/atc/G.psml" frag="G04BE44856011000036100" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml" id="105148" title="R1" type="none" forwardtype="embed" forwardtitle="VARDENAFIL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60750-44856011000036100-1"><fragment id="60750-44856011000036100-1"><block label="DrugName">VARDENAFIL<inline label="genericindexfield">XE "VARDENAFIL"</inline></block></fragment></section><section id="60750-d4694e16"><fragment id="60750-d4694e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Erectile dysfunction</para><para><bold>Clinical criteria:</bold></para><list><item><para>The condition must be vasculogenic; OR</para></item><item><para>The condition must be psychogenic; OR</para></item><item><para>The condition must be neurogenic,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have a specific accepted war-caused or service-related disability.</para></item></list><para><bold>Population criteria:</bold></para><list><item><para>Patient must be male.</para></item></list> <para>Authorisation will not be given for any additional prescriptions within 6 months or for any increased quantities or repeats.</para></block></fragment></section><section id="60750-4290T"><fragment id="60750-4290T"><block label="FormAndStrength">vardenafil 10 mg tablet, 4</block><table role="R1"><row><cell><block label="DrugItemCode">4290T<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">71.43</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Levitra [BN]<inline label="genericindexfieldbrand"><italic>XE "Levitra(BN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60750-4302K"><fragment id="60750-4302K"><block label="FormAndStrength">vardenafil 20 mg tablet, 4</block><table role="R1"><row><cell><block label="DrugItemCode">4302K<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">81.18</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Levitra [BN]<inline label="genericindexfieldbrand"><italic>XE "Levitra(BN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59705-G04BX"><fragment id="59705-G04BX"><block label="ATCLevel4"><para>Other urologicals</para></block></fragment></section><section id="59705-G04BX21568011000036102"><xref-fragment id="59705-G04BX21568011000036102"><blockxref id="105152" title="BICARBONATE + CITRIC ACID + TARTARIC ACID" frag="default" reversefrag="G04BX21568011000036102" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="61035" href="dynamic/R1/drug/21568011000036102-G04BX.psml" urititle="BICARBONATE + CITRIC ACID + TARTARIC ACID" mediatype="application/vnd.pageseeder.psml+xml"><document id="61035" schemaversion="0.12" date="2018-06-15T10:34:20+10:00" version="current" level="processed"><documentinfo><uri id="61035" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21568011000036102-G04BX.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21568011000036102-G04BX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:34+10:00" modified="2018-06-15T10:34:20+10:00" title="BICARBONATE + CITRIC ACID + TARTARIC ACID"><displaytitle>BICARBONATE + CITRIC ACID + TARTARIC ACID</displaytitle></uri><reversexrefs><reversexref uriid="59705" href="dynamic/R1/atc/G.psml" frag="G04BX21568011000036102" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml" id="105152" title="R1" type="none" forwardtype="embed" forwardtitle="BICARBONATE + CITRIC ACID + TARTARIC ACID" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="61035-21568011000036102-1"><fragment id="61035-21568011000036102-1"><block label="DrugName">BICARBONATE + CITRIC ACID + TARTARIC ACID<inline label="genericindexfield">XE "BICARBONATE + CITRIC ACID + TARTARIC ACID"</inline></block></fragment></section><section id="61035-d4696e16"><fragment id="61035-d4696e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Urinary symptoms</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be for when antibiotic or other therapy alone is inappropriate.</para></item></list></block></fragment></section><section id="61035-4049D"><fragment id="61035-4049D"><block label="FormAndStrength">sodium bicarbonate 1.76 g + sodium citrate 630 mg + citric acid 720 mg + tartaric acid 890 mg powder for oral liquid, 28 x 4 g sachets</block><table role="R1"><row><cell><block label="DrugItemCode">4049D<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">4</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.29</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Uracol [EA]<inline label="genericindexfieldbrand"><italic>XE "Uracol(EA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Ural Sachets [QA]<inline label="genericindexfieldbrand"><italic>XE "Ural Sachets (QA)" \i </italic></inline></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59705-G04C"><fragment id="59705-G04C"><block label="ATCLevel3"><para>DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY</para></block></fragment></section><section id="59705-G04CA"><fragment id="59705-G04CA"><block label="ATCLevel4"><para>Alpha-adrenoreceptor antagonists</para></block></fragment></section><section id="59705-G04CA926977011000036100"><xref-fragment id="59705-G04CA926977011000036100"><blockxref id="105144" title="ALFUZOSIN" frag="default" reversefrag="G04CA926977011000036100" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60803" href="dynamic/R1/drug/926977011000036100-G04CA.psml" urititle="ALFUZOSIN" mediatype="application/vnd.pageseeder.psml+xml"><document id="60803" schemaversion="0.12" date="2018-06-15T10:34:20+10:00" version="current" level="processed"><documentinfo><uri id="60803" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/926977011000036100-G04CA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/926977011000036100-G04CA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:20+10:00" title="ALFUZOSIN"><displaytitle>ALFUZOSIN</displaytitle></uri><reversexrefs><reversexref uriid="59705" href="dynamic/R1/atc/G.psml" frag="G04CA926977011000036100" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml" id="105144" title="R1" type="none" forwardtype="embed" forwardtitle="ALFUZOSIN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60803-926977011000036100-1"><fragment id="60803-926977011000036100-1"><block label="DrugName">ALFUZOSIN<inline label="genericindexfield">XE "ALFUZOSIN"</inline></block></fragment></section><section id="60803-d4698e16"><fragment id="60803-d4698e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Benign prostatic hyperplasia</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be one in whom surgery is inappropriate; OR</para></item><item><para>Patient must have failed to respond to other drug treatment or other drug treatment must be contraindicated.</para></item></list></block></fragment></section><section id="60803-4277D"><fragment id="60803-4277D"><block label="FormAndStrength">alfuzosin hydrochloride 10 mg modified release tablet, 30</block><table role="R1"><row><cell><block label="DrugItemCode">4277D<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">62.85</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Xatral SR [SW]<inline label="genericindexfieldbrand"><italic>XE "Xatral SR(SW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59705-G04CA931811011000036106"><xref-fragment id="59705-G04CA931811011000036106"><blockxref id="105149" title="DUTASTERIDE + TAMSULOSIN" frag="default" reversefrag="G04CA931811011000036106" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="61063" href="dynamic/R1/drug/931811011000036106-G04CA.psml" urititle="DUTASTERIDE + TAMSULOSIN" mediatype="application/vnd.pageseeder.psml+xml"><document id="61063" schemaversion="0.12" date="2018-06-15T10:34:20+10:00" version="current" level="processed"><documentinfo><uri id="61063" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/931811011000036106-G04CA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/931811011000036106-G04CA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:34+10:00" modified="2018-06-15T10:34:20+10:00" title="DUTASTERIDE + TAMSULOSIN"><displaytitle>DUTASTERIDE + TAMSULOSIN</displaytitle></uri><reversexrefs><reversexref uriid="59705" href="dynamic/R1/atc/G.psml" frag="G04CA931811011000036106" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml" id="105149" title="R1" type="none" forwardtype="embed" forwardtitle="DUTASTERIDE + TAMSULOSIN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="61063-931811011000036106-1"><fragment id="61063-931811011000036106-1"><block label="DrugName">DUTASTERIDE + TAMSULOSIN<inline label="genericindexfield">XE "DUTASTERIDE + TAMSULOSIN"</inline></block></fragment></section><section id="61063-d4700e16"><fragment id="61063-d4700e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Benign prostatic hyperplasia</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be one in whom surgery is inappropriate; OR</para></item><item><para>Patient must have failed to respond to other drug treatment or other drug treatment must be contraindicated.</para></item></list></block></fragment></section><section id="61063-10102Q"><fragment id="61063-10102Q"><block label="FormAndStrength">dutasteride 500 microgram + tamsulosin hydrochloride 400 microgram modified release capsule, 30</block><table role="R1"><row><cell><block label="DrugItemCode">10102Q<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">31.97</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Duodart 500ug/400ug [GK]<inline label="genericindexfieldbrand"><italic>XE "Duodart 500ug/400ug(GK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59705-G04CA33648011000036105"><xref-fragment id="59705-G04CA33648011000036105"><blockxref id="105151" title="TAMSULOSIN" frag="default" reversefrag="G04CA33648011000036105" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60881" href="dynamic/R1/drug/33648011000036105-G04CA.psml" urititle="TAMSULOSIN" mediatype="application/vnd.pageseeder.psml+xml"><document id="60881" schemaversion="0.12" date="2018-06-15T10:34:20+10:00" version="current" level="processed"><documentinfo><uri id="60881" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/33648011000036105-G04CA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/33648011000036105-G04CA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:33+10:00" modified="2018-06-15T10:34:20+10:00" title="TAMSULOSIN"><displaytitle>TAMSULOSIN</displaytitle></uri><reversexrefs><reversexref uriid="59705" href="dynamic/R1/atc/G.psml" frag="G04CA33648011000036105" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml" id="105151" title="R1" type="none" forwardtype="embed" forwardtitle="TAMSULOSIN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60881-33648011000036105-1"><fragment id="60881-33648011000036105-1"><block label="DrugName">TAMSULOSIN<inline label="genericindexfield">XE "TAMSULOSIN"</inline></block></fragment></section><section id="60881-d4702e16"><fragment id="60881-d4702e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Benign prostatic hyperplasia</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be one in whom surgery is inappropriate; OR</para></item><item><para>Patient must have failed to respond to other drug treatment or other drug treatment must be contraindicated.</para></item></list></block></fragment></section><section id="60881-4070F"><fragment id="60881-4070F"><block label="FormAndStrength">tamsulosin hydrochloride 400 microgram modified release tablet, 30</block><table role="R1"><row><cell><block label="DrugItemCode">4070F<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">62.85</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Flomaxtra [LS]<inline label="genericindexfieldbrand"><italic>XE "Flomaxtra(LS)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tamsulosin Sandoz SR [SZ]<inline label="genericindexfieldbrand"><italic>XE "Tamsulosin Sandoz SR (SZ)" \i </italic></inline></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59705-G04CB"><fragment id="59705-G04CB"><block label="ATCLevel4"><para>Testosterone-5-alpha reductase inhibitors</para></block></fragment></section><section id="59705-G04CB920821011000036105"><xref-fragment id="59705-G04CB920821011000036105"><blockxref id="105153" title="DUTASTERIDE" frag="default" reversefrag="G04CB920821011000036105" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60294" href="dynamic/R1/drug/920821011000036105-G04CB.psml" urititle="DUTASTERIDE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60294" schemaversion="0.12" date="2018-06-15T10:34:20+10:00" version="current" level="processed"><documentinfo><uri id="60294" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/920821011000036105-G04CB.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/920821011000036105-G04CB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:26+10:00" modified="2018-06-15T10:34:20+10:00" title="DUTASTERIDE"><displaytitle>DUTASTERIDE</displaytitle></uri><reversexrefs><reversexref uriid="59705" href="dynamic/R1/atc/G.psml" frag="G04CB920821011000036105" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml" id="105153" title="R1" type="none" forwardtype="embed" forwardtitle="DUTASTERIDE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60294-920821011000036105-1"><fragment id="60294-920821011000036105-1"><block label="DrugName">DUTASTERIDE<inline label="genericindexfield">XE "DUTASTERIDE"</inline></block></fragment></section><section id="60294-d4704e16"><fragment id="60294-d4704e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Benign prostatic hyperplasia</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be one in whom surgery is inappropriate; OR</para></item><item><para>Patient must have failed to respond to other drug treatment or other drug treatment must be contraindicated.</para></item></list></block></fragment></section><section id="60294-10095H"><fragment id="60294-10095H"><block label="FormAndStrength">dutasteride 500 microgram capsule, 30</block><table role="R1"><row><cell><block label="DrugItemCode">10095H<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">27.76</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Avodart [GK]<inline label="genericindexfieldbrand"><italic>XE "Avodart(GK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59705-G04CB21896011000036102"><xref-fragment id="59705-G04CB21896011000036102"><blockxref id="105146" title="FINASTERIDE" frag="default" reversefrag="G04CB21896011000036102" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59832" href="dynamic/R1/drug/21896011000036102-G04CB.psml" urititle="FINASTERIDE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59832" schemaversion="0.12" date="2018-06-15T10:34:20+10:00" version="current" level="processed"><documentinfo><uri id="59832" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21896011000036102-G04CB.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21896011000036102-G04CB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:20+10:00" title="FINASTERIDE"><displaytitle>FINASTERIDE</displaytitle></uri><reversexrefs><reversexref uriid="59705" href="dynamic/R1/atc/G.psml" frag="G04CB21896011000036102" urititle="GENITO URINARY SYSTEM AND SEX HORMONES" mediatype="application/vnd.pageseeder.psml+xml" id="105146" title="R1" type="none" forwardtype="embed" forwardtitle="FINASTERIDE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59832-21896011000036102-1"><fragment id="59832-21896011000036102-1"><block label="DrugName">FINASTERIDE<inline label="genericindexfield">XE "FINASTERIDE"</inline></block></fragment></section><section id="59832-d4706e16"><fragment id="59832-d4706e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Benign prostatic hyperplasia</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be one in whom surgery is inappropriate; OR</para></item><item><para>Patient must have failed to respond to other drug treatment or other drug treatment must be contraindicated.</para></item></list></block></fragment></section><section id="59832-4303L"><fragment id="59832-4303L"><block label="FormAndStrength">finasteride 5 mg tablet, 28</block><table role="R1"><row><cell><block label="DrugItemCode">4303L<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">88.22</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Finpro [RZ]<inline label="genericindexfieldbrand"><italic>XE "Finpro(RZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Pharmacy Choice Finasteride [RI]<inline label="genericindexfieldbrand"><italic>XE "Pharmacy Choice Finasteride (RI)" \i </italic></inline></block></cell></row></table></fragment></section><section id="59832-4233T"><fragment id="59832-4233T"><block label="FormAndStrength">finasteride 5 mg tablet, 30</block><table role="R1"><row><cell><block label="DrugItemCode">4233T<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">75.88</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Auro-Finasteride [DO]<inline label="genericindexfieldbrand"><italic>XE "Auro-Finasteride(DO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Finasteride AN [EA]<inline label="genericindexfieldbrand"><italic>XE "Finasteride AN (EA)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Finasteride GH 5 [GQ]<inline label="genericindexfieldbrand"><italic>XE "Finasteride GH 5(GQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Finide [AL]<inline label="genericindexfieldbrand"><italic>XE "Finide (AL)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">93.73</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Finnacar [RW]<inline label="genericindexfieldbrand"><italic>XE "Finnacar(RW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">98.08</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Finasteride [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Finasteride(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Finasta [SZ]<inline label="genericindexfieldbrand"><italic>XE "Finasta (SZ)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Finasteride Alphapharm [AF]<inline label="genericindexfieldbrand"><italic>XE "Finasteride Alphapharm(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Finasteride-GA 5 [GN]<inline label="genericindexfieldbrand"><italic>XE "Finasteride-GA 5 (GN)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Pharmacor Finasteride 5 [CR]<inline label="genericindexfieldbrand"><italic>XE "Pharmacor Finasteride 5(CR)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Proscar [MK]<inline label="genericindexfieldbrand"><italic>XE "Proscar (MK)" \i </italic></inline></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref><blockxref id="107086" title="ANTIINFECTIVES FOR SYSTEMIC USE" frag="default" reversefrag="d114e761780" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60922" href="dynamic/R1/atc/J.psml" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60922" schemaversion="0.12" date="2018-06-15T10:35:17+10:00" version="current" level="processed"><documentinfo><uri id="60922" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/atc/J.psml" decodedpath="/ps/test/local3/books/dynamic/R1/atc/J.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:33+10:00" modified="2018-06-15T10:35:17+10:00" title="ANTIINFECTIVES FOR SYSTEMIC USE"><displaytitle>ANTIINFECTIVES FOR SYSTEMIC USE</displaytitle></uri><reversexrefs><reversexref uriid="60526" href="dynamic/R1.psml" frag="d114e761780" urititle="Repatriation Pharmaceutical Benefits Scheme" mediatype="application/vnd.pageseeder.psml+xml" id="107086" title="R1" type="none" forwardtype="embed" forwardtitle="ANTIINFECTIVES FOR SYSTEMIC USE" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107640" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIINFECTIVES FOR SYSTEMIC USE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="44711" fragment="60922-J01F"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107642" title="Untitled" type="none" forwardtype="none" forwardtitle="MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS" forwarddisplay="document" forwardfrag="J01F"></reversexref></reversexrefs></locator><locator id="44916" fragment="60922-J01FA21518011000036103" editid="107869" modified="2018-06-15T10:34:33+10:00"></locator><locator id="44710" fragment="60922-J01"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107641" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIBACTERIALS FOR SYSTEMIC USE" forwarddisplay="document" forwardfrag="J01"></reversexref></reversexrefs></locator></fragmentinfo><metadata></metadata><section id="60922-J"><fragment id="60922-J"><block label="ATCLevel1"><para>ANTIINFECTIVES FOR SYSTEMIC USE</para></block></fragment></section><section id="60922-J01"><fragment id="60922-J01"><block label="ATCLevel2"><para>ANTIBACTERIALS FOR SYSTEMIC USE</para></block></fragment></section><section id="60922-J01F"><fragment id="60922-J01F"><block label="ATCLevel3"><para>MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS</para></block></fragment></section><section id="60922-J01FA"><fragment id="60922-J01FA"><block label="ATCLevel4"><para>Macrolides</para></block></fragment></section><section id="60922-J01FA21518011000036103"><xref-fragment id="60922-J01FA21518011000036103"><blockxref id="107868" title="AZITHROMYCIN" frag="default" reversefrag="J01FA21518011000036103" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60192" href="dynamic/R1/drug/21518011000036103-J01FA.psml" urititle="AZITHROMYCIN" mediatype="application/vnd.pageseeder.psml+xml"><document id="60192" schemaversion="0.12" date="2018-06-15T10:34:33+10:00" version="current" level="processed"><documentinfo><uri id="60192" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21518011000036103-J01FA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21518011000036103-J01FA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:25+10:00" modified="2018-06-15T10:34:33+10:00" title="AZITHROMYCIN"><displaytitle>AZITHROMYCIN</displaytitle></uri><reversexrefs><reversexref uriid="60922" href="dynamic/R1/atc/J.psml" frag="J01FA21518011000036103" urititle="ANTIINFECTIVES FOR SYSTEMIC USE" mediatype="application/vnd.pageseeder.psml+xml" id="107868" title="R1" type="none" forwardtype="embed" forwardtitle="AZITHROMYCIN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60192-21518011000036103-1"><fragment id="60192-21518011000036103-1"><block label="DrugName">AZITHROMYCIN<inline label="genericindexfield">XE "AZITHROMYCIN:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="60192-d4708e16"><fragment id="60192-d4708e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Upper and lower respiratory tract infections</para></block></fragment></section><section id="60192-4115N"><fragment id="60192-4115N"><block label="FormAndStrength">azithromycin 500 mg tablet, 3</block><table role="R1"><row><cell><block label="DrugItemCode">4115N<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">32.91</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Zedd 500 [RW]<inline label="genericindexfieldbrand"><italic>XE "Zedd 500(RW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Azithromycin [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Azithromycin(TX):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Azithromycin-GA [EA]<inline label="genericindexfieldbrand"><italic>XE "Azithromycin-GA (EA)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Azithromycin Mylan [AF]<inline label="genericindexfieldbrand"><italic>XE "Azithromycin Mylan(AF):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Azithromycin Sandoz [SZ]<inline label="genericindexfieldbrand"><italic>XE "Azithromycin Sandoz (SZ):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Chem mart Azithromycin [CH]<inline label="genericindexfieldbrand"><italic>XE "Chem mart Azithromycin(CH):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Terry White Chemists Azithromycin [TW]<inline label="genericindexfieldbrand"><italic>XE "Terry White Chemists Azithromycin (TW):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Zithromax [PF]<inline label="genericindexfieldbrand"><italic>XE "Zithromax(PF):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Zitrocin [GN]<inline label="genericindexfieldbrand"><italic>XE "Zitrocin (GN):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref><blockxref id="107087" title="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" frag="default" reversefrag="d114e761780" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60098" href="dynamic/R1/atc/L.psml" urititle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" mediatype="application/vnd.pageseeder.psml+xml"><document id="60098" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="60098" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/atc/L.psml" decodedpath="/ps/test/local3/books/dynamic/R1/atc/L.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:24+10:00" modified="2018-06-15T10:34:32+10:00" title="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"><displaytitle>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</displaytitle></uri><reversexrefs><reversexref uriid="60526" href="dynamic/R1.psml" frag="d114e761780" urititle="Repatriation Pharmaceutical Benefits Scheme" mediatype="application/vnd.pageseeder.psml+xml" id="107087" title="R1" type="none" forwardtype="embed" forwardtitle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107643" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="44713" fragment="60098-L01B"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107645" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIMETABOLITES" forwarddisplay="document" forwardfrag="L01B"></reversexref></reversexrefs></locator><locator id="44715" fragment="60098-L04A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107647" title="Untitled" type="none" forwardtype="none" forwardtitle="IMMUNOSUPPRESSANTS" forwarddisplay="document" forwardfrag="L04A"></reversexref></reversexrefs></locator><locator id="43185" fragment="60098-L01BC21481011000036100" editid="106102" modified="2018-06-15T10:34:24+10:00"></locator><locator id="44712" fragment="60098-L01"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107644" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTINEOPLASTIC AGENTS" forwarddisplay="document" forwardfrag="L01"></reversexref></reversexrefs></locator><locator id="43187" fragment="60098-L04AB21926011000036101" editid="106103" modified="2018-06-15T10:34:24+10:00"></locator><locator id="44714" fragment="60098-L04"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107646" title="Untitled" type="none" forwardtype="none" forwardtitle="IMMUNOSUPPRESSANTS" forwarddisplay="document" forwardfrag="L04"></reversexref></reversexrefs></locator></fragmentinfo><metadata></metadata><section id="60098-L"><fragment id="60098-L"><block label="ATCLevel1"><para>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</para></block></fragment></section><section id="60098-L01"><fragment id="60098-L01"><block label="ATCLevel2"><para>ANTINEOPLASTIC AGENTS</para></block></fragment></section><section id="60098-L01B"><fragment id="60098-L01B"><block label="ATCLevel3"><para>ANTIMETABOLITES</para></block></fragment></section><section id="60098-L01BC"><fragment id="60098-L01BC"><block label="ATCLevel4"><para>Pyrimidine analogues</para></block></fragment></section><section id="60098-L01BC21481011000036100"><xref-fragment id="60098-L01BC21481011000036100"><blockxref id="106100" title="FLUOROURACIL" frag="default" reversefrag="L01BC21481011000036100" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59679" href="dynamic/R1/drug/21481011000036100-L01BC.psml" urititle="FLUOROURACIL" mediatype="application/vnd.pageseeder.psml+xml"><document id="59679" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="59679" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21481011000036100-L01BC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21481011000036100-L01BC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:20+10:00" modified="2018-06-15T10:34:24+10:00" title="FLUOROURACIL"><displaytitle>FLUOROURACIL</displaytitle></uri><reversexrefs><reversexref uriid="60098" href="dynamic/R1/atc/L.psml" frag="L01BC21481011000036100" urititle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" mediatype="application/vnd.pageseeder.psml+xml" id="106100" title="R1" type="none" forwardtype="embed" forwardtitle="FLUOROURACIL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59679-21481011000036100-1"><fragment id="59679-21481011000036100-1"><block label="DrugName">FLUOROURACIL<inline label="genericindexfield">XE "FLUOROURACIL"</inline></block></fragment></section><section id="59679-4222F"><fragment id="59679-4222F"><block label="FormAndStrength">fluorouracil 5% cream, 20 g</block><table role="R1"><row><cell><block label="DrugItemCode">4222F<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">65.28</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APOC-5FU [TX]<inline label="genericindexfieldbrand"><italic>XE "APOC-5FU(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Efudix [IL]<inline label="genericindexfieldbrand"><italic>XE "Efudix (IL)" \i </italic></inline></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60098-L04"><fragment id="60098-L04"><block label="ATCLevel2"><para>IMMUNOSUPPRESSANTS</para></block></fragment></section><section id="60098-L04A"><fragment id="60098-L04A"><block label="ATCLevel3"><para>IMMUNOSUPPRESSANTS</para></block></fragment></section><section id="60098-L04AB"><fragment id="60098-L04AB"><block label="ATCLevel4"><para>Tumor necrosis factor alpha (TNF-) inhibitors</para></block></fragment></section><section id="60098-L04AB21926011000036101"><xref-fragment id="60098-L04AB21926011000036101"><blockxref id="106101" title="INFLIXIMAB" frag="default" reversefrag="L04AB21926011000036101" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60304" href="dynamic/R1/drug/21926011000036101-L04AB.psml" urititle="INFLIXIMAB" mediatype="application/vnd.pageseeder.psml+xml"><document id="60304" schemaversion="0.12" date="2018-06-15T10:34:24+10:00" version="current" level="processed"><documentinfo><uri id="60304" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21926011000036101-L04AB.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21926011000036101-L04AB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:26+10:00" modified="2018-06-15T10:34:24+10:00" title="INFLIXIMAB"><displaytitle>INFLIXIMAB</displaytitle></uri><reversexrefs><reversexref uriid="60098" href="dynamic/R1/atc/L.psml" frag="L04AB21926011000036101" urititle="ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS" mediatype="application/vnd.pageseeder.psml+xml" id="106101" title="R1" type="none" forwardtype="embed" forwardtitle="INFLIXIMAB" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60304-21926011000036101-1"><fragment id="60304-21926011000036101-1"><block label="DrugName">INFLIXIMAB<inline label="genericindexfield">XE "INFLIXIMAB"</inline></block></fragment></section><section id="60304-d4711e37"><fragment id="60304-d4711e37"><block label="NoteText"><para>Any queries concerning the arrangements to prescribe infliximab may be directed to the Veterans' Affairs Pharmaceutical Advisory Centre (VAPAC) on 1800 552 580.</para><para> Written applications for authority to prescribe infliximab should be forwarded to:</para><para> Reply Paid 9998</para><para> Veterans' Affairs Pharmaceutical Advisory Centre (VAPAC)</para><para> Department of Veterans' Affairs</para><para> GPO Box 9998</para><para> BRISBANE QLD 4001</para></block></fragment></section><section id="60304-d4711e16"><fragment id="60304-d4711e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Initial treatment, in combination with methotrexate, of specific accepted war-caused or service-related disability of refractory rheumatoid arthritis. Initial treatment may be prescribed by rheumatologists or consultant physicians for the reduction of signs and symptoms and prevention of structural joint damage in adult patients with active rheumatoid arthritis who satisfy all of the following criteria:</para><para> (1) (a) Proven raised erythrocyte sedimentation rate (ESR) and/or C-reactive protein (CRP); and</para><para> (1) (b) Proven erosive rheumatoid arthritis without end-stage disease;</para><para> (2) Failure of an adequate trial of methotrexate and 2 other disease modifying anti-rheumatic drugs (such as sulfasalazine, hydroxychloroquine, leflunomide or cyclosporin) — unless these drugs were contraindicated or intolerance had developed;</para><para> (3) No history of active tuberculosis requiring treatment in the last 3 years;</para><para> (4) No history of opportunistic infection in the last 2 months;</para><para> (5) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.</para><para> Applications for authorisation must be in writing and must include:</para><para> (1) a completed authority prescription form; and</para><para> (2) a completed Infliximab (Remicade) RPBS Authority Application - Supporting Information form (contact the VAPAC on 1800 552 580 for a copy of the form)</para></block></fragment></section><section id="60304-d4711e69"><fragment id="60304-d4711e69"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Continuing treatment, in combination with methotrexate, of specific accepted war-caused or service-related disability of refractory rheumatoid arthritis. Continuing treatment may be prescribed by rheumatologists or consultant physicians, following initial therapy of 3 doses, in patients who satisfy the following criteria:</para><para> (1) There is improvement in ESR and/or CRP; and</para><para> (2) An ACR20 (American College of Rheumatology) response is achieved by 14 weeks after the commencement of therapy.</para><para> Applications for authorisation must be in writing and must include:</para><para> (1) a completed authority prescription form; and</para><para> (2) a completed Infliximab (Remicade) RPBS Authority Application - Supporting Information form (contact the VAPAC on 1800 552 580 for a copy of the form)</para></block></fragment></section><section id="60304-4284L"><fragment id="60304-4284L"><block label="FormAndStrength">infliximab 100 mg injection, 1 vial</block><table role="R1"><row><cell><block label="DrugItemCode">4284L<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">569.47</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Remicade [JC]<inline label="genericindexfieldbrand"><italic>XE "Remicade(JC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref><blockxref id="107088" title="MUSCULO-SKELETAL SYSTEM" frag="default" reversefrag="d114e761780" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60874" href="dynamic/R1/atc/M.psml" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml"><document id="60874" schemaversion="0.12" date="2018-06-15T10:35:16+10:00" version="current" level="processed"><documentinfo><uri id="60874" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/atc/M.psml" decodedpath="/ps/test/local3/books/dynamic/R1/atc/M.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:35:16+10:00" title="MUSCULO-SKELETAL SYSTEM"><displaytitle>MUSCULO-SKELETAL SYSTEM</displaytitle></uri><reversexrefs><reversexref uriid="60526" href="dynamic/R1.psml" frag="d114e761780" urititle="Repatriation Pharmaceutical Benefits Scheme" mediatype="application/vnd.pageseeder.psml+xml" id="107088" title="R1" type="none" forwardtype="embed" forwardtitle="MUSCULO-SKELETAL SYSTEM" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107648" title="Untitled" type="none" forwardtype="none" forwardtitle="MUSCULO-SKELETAL SYSTEM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="44817" fragment="60874-M05BB13681000144105" editid="107763" modified="2018-06-15T10:34:32+10:00"></locator><locator id="44823" fragment="60874-M02AC21251011000036106" editid="107766" modified="2018-06-15T10:34:32+10:00"></locator><locator id="44717" fragment="60874-M02A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107650" title="Untitled" type="none" forwardtype="none" forwardtitle="TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN" forwarddisplay="document" forwardfrag="M02A"></reversexref></reversexrefs></locator><locator id="44719" fragment="60874-M05B"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107652" title="Untitled" type="none" forwardtype="none" forwardtitle="DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION" forwarddisplay="document" forwardfrag="M05B"></reversexref></reversexrefs></locator><locator id="44718" fragment="60874-M05"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107651" title="Untitled" type="none" forwardtype="none" forwardtitle="DRUGS FOR TREATMENT OF BONE DISEASES" forwarddisplay="document" forwardfrag="M05"></reversexref></reversexrefs></locator><locator id="44827" fragment="60874-M05BB12321000144109" editid="107768" modified="2018-06-15T10:34:32+10:00"></locator><locator id="44825" fragment="60874-M02AC21628011000036103" editid="107767" modified="2018-06-15T10:34:32+10:00"></locator><locator id="44821" fragment="60874-M05BB21250011000036104" editid="107765" modified="2018-06-15T10:34:32+10:00"></locator><locator id="44716" fragment="60874-M02"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107649" title="Untitled" type="none" forwardtype="none" forwardtitle="TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN" forwarddisplay="document" forwardfrag="M02"></reversexref></reversexrefs></locator><locator id="44819" fragment="60874-M05BA21476011000036103" editid="107764" modified="2018-06-15T10:34:32+10:00"></locator></fragmentinfo><metadata></metadata><section id="60874-M"><fragment id="60874-M"><block label="ATCLevel1"><para>MUSCULO-SKELETAL SYSTEM</para></block></fragment></section><section id="60874-M02"><fragment id="60874-M02"><block label="ATCLevel2"><para>TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN</para></block></fragment></section><section id="60874-M02A"><fragment id="60874-M02A"><block label="ATCLevel3"><para>TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN</para></block></fragment></section><section id="60874-M02AC"><fragment id="60874-M02AC"><block label="ATCLevel4"><para>Preparations with salicylic acid derivatives</para></block></fragment></section><section id="60874-M02AC21251011000036106"><xref-fragment id="60874-M02AC21251011000036106"><blockxref id="107760" title="METHYL SALICYLATE" frag="default" reversefrag="M02AC21251011000036106" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59890" href="dynamic/R1/drug/21251011000036106-M02AC.psml" urititle="METHYL SALICYLATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59890" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="59890" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21251011000036106-M02AC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21251011000036106-M02AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:32+10:00" title="METHYL SALICYLATE"><displaytitle>METHYL SALICYLATE</displaytitle></uri><reversexrefs><reversexref uriid="60874" href="dynamic/R1/atc/M.psml" frag="M02AC21251011000036106" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107760" title="R1" type="none" forwardtype="embed" forwardtitle="METHYL SALICYLATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59890-21251011000036106-1"><fragment id="59890-21251011000036106-1"><block label="DrugName">METHYL SALICYLATE<inline label="genericindexfield">XE "METHYL SALICYLATE"</inline></block></fragment></section><section id="59890-4026X"><fragment id="59890-4026X"><block label="FormAndStrength">methyl salicylate 25% liniment, 100 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4026X<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">14.15</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Gold Cross [BI]<inline label="genericindexfieldbrand"><italic>XE "Gold Cross(BI):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59890-4023R"><fragment id="59890-4023R"><block label="FormAndStrength">methyl salicylate 50% ointment, 100 g</block><table role="R1"><row><cell><block label="DrugItemCode">4023R<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">16.09</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Gold Cross [BI]<inline label="genericindexfieldbrand"><italic>XE "Gold Cross(BI):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60874-M02AC21628011000036103"><xref-fragment id="60874-M02AC21628011000036103"><blockxref id="107761" title="METHYL SALICYLATE + EUCALYPTUS OIL + MENTHOL" frag="default" reversefrag="M02AC21628011000036103" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60169" href="dynamic/R1/drug/21628011000036103-M02AC.psml" urititle="METHYL SALICYLATE + EUCALYPTUS OIL + MENTHOL" mediatype="application/vnd.pageseeder.psml+xml"><document id="60169" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="60169" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21628011000036103-M02AC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21628011000036103-M02AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:25+10:00" modified="2018-06-15T10:34:32+10:00" title="METHYL SALICYLATE + EUCALYPTUS OIL + MENTHOL"><displaytitle>METHYL SALICYLATE + EUCALYPTUS OIL + MENTHOL</displaytitle></uri><reversexrefs><reversexref uriid="60874" href="dynamic/R1/atc/M.psml" frag="M02AC21628011000036103" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107761" title="R1" type="none" forwardtype="embed" forwardtitle="METHYL SALICYLATE + EUCALYPTUS OIL + MENTHOL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60169-21628011000036103-1"><fragment id="60169-21628011000036103-1"><block label="DrugName">METHYL SALICYLATE + EUCALYPTUS OIL + MENTHOL<inline label="genericindexfield">XE "METHYL SALICYLATE + EUCALYPTUS OIL + MENTHOL"</inline></block></fragment></section><section id="60169-4022Q"><fragment id="60169-4022Q"><block label="FormAndStrength">methyl salicylate 25% + eucalyptus oil 10% + menthol 4% cream, 100 g</block><table role="R1"><row><cell><block label="DrugItemCode">4022Q<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.70</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Gold Cross [BI]<inline label="genericindexfieldbrand"><italic>XE "Gold Cross(BI):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60874-M05"><fragment id="60874-M05"><block label="ATCLevel2"><para>DRUGS FOR TREATMENT OF BONE DISEASES</para></block></fragment></section><section id="60874-M05B"><fragment id="60874-M05B"><block label="ATCLevel3"><para>DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION</para></block></fragment></section><section id="60874-M05BA"><fragment id="60874-M05BA"><block label="ATCLevel4"><para>Bisphosphonates</para></block></fragment></section><section id="60874-M05BA21476011000036103"><xref-fragment id="60874-M05BA21476011000036103"><blockxref id="107758" title="RISEDRONATE" frag="default" reversefrag="M05BA21476011000036103" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59999" href="dynamic/R1/drug/21476011000036103-M05BA.psml" urititle="RISEDRONATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59999" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="59999" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21476011000036103-M05BA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21476011000036103-M05BA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:23+10:00" modified="2018-06-15T10:34:32+10:00" title="RISEDRONATE"><displaytitle>RISEDRONATE</displaytitle></uri><reversexrefs><reversexref uriid="60874" href="dynamic/R1/atc/M.psml" frag="M05BA21476011000036103" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107758" title="R1" type="none" forwardtype="embed" forwardtitle="RISEDRONATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59999-21476011000036103-1"><fragment id="59999-21476011000036103-1"><block label="DrugName">RISEDRONATE<inline label="genericindexfield">XE "RISEDRONATE"</inline></block></fragment></section><section id="59999-d4716e16"><fragment id="59999-d4716e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Preservation of bone mineral density</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be on long-term glucocorticoid therapy,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing continuous treatment with a dose equal to or greater than 7.5 mg of prednisone or equivalent per day,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be osteopenic (bone mineral density t-score of less than -1.0).</para></item></list> <para>Prescribers need to demonstrate that the patient has been on continuous therapy for 3 months or more.</para></block></fragment></section><section id="59999-4444X"><fragment id="59999-4444X"><block label="FormAndStrength">risedronate sodium 35 mg tablet, 4</block><table role="R1"><row><cell><block label="DrugItemCode">4444X<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">35.10</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Acris Once-a-Week [AF]<inline label="genericindexfieldbrand"><italic>XE "Acris Once-a-Week(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Risedronate [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Risedronate (TX)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Risedronate AN [EA]<inline label="genericindexfieldbrand"><italic>XE "Risedronate AN(EA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Risedronate-GA [GN]<inline label="genericindexfieldbrand"><italic>XE "Risedronate-GA (GN)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Risedronate Sandoz [SZ]<inline label="genericindexfieldbrand"><italic>XE "Risedronate Sandoz(SZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Risedro once a week [RW]<inline label="genericindexfieldbrand"><italic>XE "Risedro once a week (RW)" \i </italic></inline></block></cell></row></table></fragment></section><section id="59999-4443W"><fragment id="59999-4443W"><block label="FormAndStrength">risedronate sodium 5 mg tablet, 28</block><table role="R1"><row><cell><block label="DrugItemCode">4443W<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">35.10</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Actonel [UA]<inline label="genericindexfieldbrand"><italic>XE "Actonel(UA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59999-2191H"><fragment id="59999-2191H"><block label="FormAndStrength">RISEDRONATE SODIUM Tablet 35 mg (enteric coated), 4</block><table role="R1"><row><cell><block label="DrugItemCode">2191H<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">35.10</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Actonel EC [UA]<inline label="genericindexfieldbrand"><italic>XE "Actonel EC(UA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60874-M05BB"><fragment id="60874-M05BB"><block label="ATCLevel4"><para>Bisphosphonates, combinations</para></block></fragment></section><section id="60874-M05BB21250011000036104"><xref-fragment id="60874-M05BB21250011000036104"><blockxref id="107759" title="ALENDRONATE + COLECALCIFEROL" frag="default" reversefrag="M05BB21250011000036104" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60056" href="dynamic/R1/drug/21250011000036104-M05BB.psml" urititle="ALENDRONATE + COLECALCIFEROL" mediatype="application/vnd.pageseeder.psml+xml"><document id="60056" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="60056" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21250011000036104-M05BB.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21250011000036104-M05BB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:24+10:00" modified="2018-06-15T10:34:32+10:00" title="ALENDRONATE + COLECALCIFEROL"><displaytitle>ALENDRONATE + COLECALCIFEROL</displaytitle></uri><reversexrefs><reversexref uriid="60874" href="dynamic/R1/atc/M.psml" frag="M05BB21250011000036104" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107759" title="R1" type="none" forwardtype="embed" forwardtitle="ALENDRONATE + COLECALCIFEROL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60056-21250011000036104-1"><fragment id="60056-21250011000036104-1"><block label="DrugName">ALENDRONATE + COLECALCIFEROL<inline label="genericindexfield">XE "ALENDRONATE + COLECALCIFEROL"</inline></block></fragment></section><section id="60056-d4718e16"><fragment id="60056-d4718e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Preservation of bone mineral density</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be on long-term glucocorticoid therapy,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing continuous treatment with a dose equal to or greater than 7.5 mg of prednisone or equivalent per day,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be osteopenic (bone mineral density t-score of less than -1.0).</para></item></list> <para>Prescribers need to demonstrate that the patient has been on continuous therapy for 3 months or more.</para></block></fragment></section><section id="60056-2194L"><fragment id="60056-2194L"><block label="FormAndStrength">alendronate 70 mg + colecalciferol 70 microgram tablet, 4</block><table role="R1"><row><cell><block label="DrugItemCode">2194L<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.94</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Alendronate plus D3-DRLA [RZ]<inline label="genericindexfieldbrand"><italic>XE "Alendronate plus D3-DRLA(RZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Alendronate Plus D3 70 mg/70 mcg [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Alendronate Plus D3 70 mg/70 mcg (TX)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Chem mart Alendronate Plus D3 70 mg/70 mcg [CH]<inline label="genericindexfieldbrand"><italic>XE "Chem mart Alendronate Plus D3 70 mg/70 mcg(CH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">FonatPlus [AF]<inline label="genericindexfieldbrand"><italic>XE "FonatPlus (AF)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Terry White Chemists Alendronate Plus D3 70 mg/70 mcg [TW]<inline label="genericindexfieldbrand"><italic>XE "Terry White Chemists Alendronate Plus D3 70 mg/70 mcg(TW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">21.94</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Fosamax Plus [MK]<inline label="genericindexfieldbrand"><italic>XE "Fosamax Plus(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60056-2224C"><fragment id="60056-2224C"><block label="FormAndStrength">alendronate 70 mg + colecalciferol 140 microgram (5600 units) tablet, 4</block><table role="R1"><row><cell><block label="DrugItemCode">2224C<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.94</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Alendronate plus D3-DRLA [RZ]<inline label="genericindexfieldbrand"><italic>XE "Alendronate plus D3-DRLA(RZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Alendronate Plus D3 70 mg/140 mcg [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Alendronate Plus D3 70 mg/140 mcg (TX)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Chem mart Alendronate Plus D3 70 mg/140 mcg [CH]<inline label="genericindexfieldbrand"><italic>XE "Chem mart Alendronate Plus D3 70 mg/140 mcg(CH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">FonatPlus [AF]<inline label="genericindexfieldbrand"><italic>XE "FonatPlus (AF)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Terry White Chemists Alendronate Plus D3 70 mg/140 mcg [TW]<inline label="genericindexfieldbrand"><italic>XE "Terry White Chemists Alendronate Plus D3 70 mg/140 mcg(TW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">21.94</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Fosamax Plus 70 mg/140 mcg [MK]<inline label="genericindexfieldbrand"><italic>XE "Fosamax Plus 70 mg/140 mcg(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60874-M05BB13681000144105"><xref-fragment id="60874-M05BB13681000144105"><blockxref id="107757" title="ALENDRONATE + COLECALCIFEROL (&amp;) CALCIUM CARBONATE" frag="default" reversefrag="M05BB13681000144105" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60850" href="dynamic/R1/drug/13681000144105-M05BB.psml" urititle="ALENDRONATE + COLECALCIFEROL (&amp;) CALCIUM CARBONATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60850" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="60850" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/13681000144105-M05BB.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/13681000144105-M05BB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:32+10:00" title="ALENDRONATE + COLECALCIFEROL (&amp;) CALCIUM CARBONATE"><displaytitle>ALENDRONATE + COLECALCIFEROL (&amp;) CALCIUM CARBONATE</displaytitle></uri><reversexrefs><reversexref uriid="60874" href="dynamic/R1/atc/M.psml" frag="M05BB13681000144105" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107757" title="R1" type="none" forwardtype="embed" forwardtitle="ALENDRONATE + COLECALCIFEROL (&amp;) CALCIUM CARBONATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60850-13681000144105-1"><fragment id="60850-13681000144105-1"><block label="DrugName">ALENDRONATE + COLECALCIFEROL (&amp;) CALCIUM CARBONATE<inline label="genericindexfield">XE "ALENDRONATE + COLECALCIFEROL (&amp;) CALCIUM CARBONATE"</inline></block></fragment></section><section id="60850-d4720e16"><fragment id="60850-d4720e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Preservation of bone mineral density</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be on long-term glucocorticoid therapy,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing continuous treatment with a dose equal to or greater than 7.5 mg of prednisone or equivalent per day,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be osteopenic (bone mineral density t-score of less than -1.0).</para></item></list> <para>Prescribers need to demonstrate that the patient has been on continuous therapy for 3 months or more.</para></block></fragment></section><section id="60850-2273P"><fragment id="60850-2273P"><block label="FormAndStrength">alendronate 70 mg + colecalciferol 140 microgram tablet [4] (&amp;) calcium (as carbonate) 500 mg tablet [48], 1 pack</block><table role="R1"><row><cell><block label="DrugItemCode">2273P<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">22.83</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Alendronate Plus D3 and Calcium [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Alendronate Plus D3 and Calcium(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">24.71</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Fosamax Plus D-Cal [MK]<inline label="genericindexfieldbrand"><italic>XE "Fosamax Plus D-Cal(MK)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60874-M05BB12321000144109"><xref-fragment id="60874-M05BB12321000144109"><blockxref id="107762" title="RISEDRONATE (&amp;) CALCIUM CARBONATE" frag="default" reversefrag="M05BB12321000144109" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60373" href="dynamic/R1/drug/12321000144109-M05BB.psml" urititle="RISEDRONATE (&amp;) CALCIUM CARBONATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60373" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="60373" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/12321000144109-M05BB.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/12321000144109-M05BB.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:27+10:00" modified="2018-06-15T10:34:32+10:00" title="RISEDRONATE (&amp;) CALCIUM CARBONATE"><displaytitle>RISEDRONATE (&amp;) CALCIUM CARBONATE</displaytitle></uri><reversexrefs><reversexref uriid="60874" href="dynamic/R1/atc/M.psml" frag="M05BB12321000144109" urititle="MUSCULO-SKELETAL SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="107762" title="R1" type="none" forwardtype="embed" forwardtitle="RISEDRONATE (&amp;) CALCIUM CARBONATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60373-12321000144109-1"><fragment id="60373-12321000144109-1"><block label="DrugName">RISEDRONATE (&amp;) CALCIUM CARBONATE<inline label="genericindexfield">XE "RISEDRONATE (&amp;) CALCIUM CARBONATE"</inline></block></fragment></section><section id="60373-d4722e16"><fragment id="60373-d4722e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Preservation of bone mineral density</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must be on long-term glucocorticoid therapy,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be undergoing continuous treatment with a dose equal to or greater than 7.5 mg of prednisone or equivalent per day,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be osteopenic (bone mineral density t-score of less than -1.0).</para></item></list> <para>Prescribers need to demonstrate that the patient has been on continuous therapy for 3 months or more.</para></block></fragment></section><section id="60373-4059P"><fragment id="60373-4059P"><block label="FormAndStrength">risedronate sodium 35 mg tablet [4] (&amp;) calcium (as carbonate) 500 mg tablet [24], 28</block><table role="R1"><row><cell><block label="DrugItemCode">4059P<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">35.10</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Acris Combi [AF]<inline label="genericindexfieldbrand"><italic>XE "Acris Combi(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref><blockxref id="107089" title="NERVOUS SYSTEM" frag="default" reversefrag="d114e761780" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59816" href="dynamic/R1/atc/N.psml" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml"><document id="59816" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="59816" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/atc/N.psml" decodedpath="/ps/test/local3/books/dynamic/R1/atc/N.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:32+10:00" title="NERVOUS SYSTEM"><displaytitle>NERVOUS SYSTEM</displaytitle></uri><reversexrefs><reversexref uriid="60526" href="dynamic/R1.psml" frag="d114e761780" urititle="Repatriation Pharmaceutical Benefits Scheme" mediatype="application/vnd.pageseeder.psml+xml" id="107089" title="R1" type="none" forwardtype="embed" forwardtitle="NERVOUS SYSTEM" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107653" title="Untitled" type="none" forwardtype="none" forwardtitle="NERVOUS SYSTEM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="44725" fragment="59816-N05C"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107659" title="Untitled" type="none" forwardtype="none" forwardtitle="HYPNOTICS AND SEDATIVES" forwarddisplay="document" forwardfrag="N05C"></reversexref></reversexrefs></locator><locator id="42329" fragment="59816-N02AJ21831011000036102" editid="105248" modified="2018-06-15T10:34:21+10:00"></locator><locator id="44724" fragment="59816-N05B"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107658" title="Untitled" type="none" forwardtype="none" forwardtitle="ANXIOLYTICS" forwarddisplay="document" forwardfrag="N05B"></reversexref></reversexrefs></locator><locator id="42327" fragment="59816-N05CF21574011000036103" editid="105247" modified="2018-06-15T10:34:21+10:00"></locator><locator id="44722" fragment="59816-N02B"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107656" title="Untitled" type="none" forwardtype="none" forwardtitle="OTHER ANALGESICS AND ANTIPYRETICS" forwarddisplay="document" forwardfrag="N02B"></reversexref></reversexrefs></locator><locator id="42331" fragment="59816-N05BE21325011000036100" editid="105249" modified="2018-06-15T10:34:21+10:00"></locator><locator id="42337" fragment="59816-N05BA21586011000036104" editid="105252" modified="2018-06-15T10:34:21+10:00"></locator><locator id="44721" fragment="59816-N02A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107655" title="Untitled" type="none" forwardtype="none" forwardtitle="OPIOIDS" forwarddisplay="document" forwardfrag="N02A"></reversexref></reversexrefs></locator><locator id="42345" fragment="59816-N07BA21432011000036100" editid="105256" modified="2018-06-15T10:34:21+10:00"></locator><locator id="44727" fragment="59816-N07B"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107661" title="Untitled" type="none" forwardtype="none" forwardtitle="DRUGS USED IN ADDICTIVE DISORDERS" forwarddisplay="document" forwardfrag="N07B"></reversexref></reversexrefs></locator><locator id="42341" fragment="59816-N02AA21252011000036100" editid="105254" modified="2018-06-15T10:34:21+10:00"></locator><locator id="42335" fragment="59816-N05CD21785011000036107" editid="105251" modified="2018-06-15T10:34:21+10:00"></locator><locator id="44726" fragment="59816-N07"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107660" title="Untitled" type="none" forwardtype="none" forwardtitle="OTHER NERVOUS SYSTEM DRUGS" forwarddisplay="document" forwardfrag="N07"></reversexref></reversexrefs></locator><locator id="44720" fragment="59816-N02"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107654" title="Untitled" type="none" forwardtype="none" forwardtitle="ANALGESICS" forwarddisplay="document" forwardfrag="N02"></reversexref></reversexrefs></locator><locator id="44723" fragment="59816-N05"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107657" title="Untitled" type="none" forwardtype="none" forwardtitle="PSYCHOLEPTICS" forwarddisplay="document" forwardfrag="N05"></reversexref></reversexrefs></locator><locator id="42343" fragment="59816-N02BG21444011000036105" editid="105255" modified="2018-06-15T10:34:21+10:00"></locator><locator id="42339" fragment="59816-N02AJ21286011000036106" editid="105253" modified="2018-06-15T10:34:21+10:00"></locator><locator id="42333" fragment="59816-N02BE21433011000036107" editid="105250" modified="2018-06-15T10:34:21+10:00"></locator></fragmentinfo><metadata></metadata><section id="59816-N"><fragment id="59816-N"><block label="ATCLevel1"><para>NERVOUS SYSTEM</para></block></fragment></section><section id="59816-N02"><fragment id="59816-N02"><block label="ATCLevel2"><para>ANALGESICS</para></block></fragment></section><section id="59816-N02A"><fragment id="59816-N02A"><block label="ATCLevel3"><para>OPIOIDS</para></block></fragment></section><section id="59816-N02AA"><fragment id="59816-N02AA"><block label="ATCLevel4"><para>Natural opium alkaloids</para></block></fragment></section><section id="59816-N02AA21252011000036100"><xref-fragment id="59816-N02AA21252011000036100"><blockxref id="105244" title="MORPHINE" frag="default" reversefrag="N02AA21252011000036100" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60144" href="dynamic/R1/drug/21252011000036100-N02AA.psml" urititle="MORPHINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60144" schemaversion="0.12" date="2018-06-15T10:34:21+10:00" version="current" level="processed"><documentinfo><uri id="60144" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21252011000036100-N02AA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21252011000036100-N02AA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:25+10:00" modified="2018-06-15T10:34:21+10:00" title="MORPHINE"><displaytitle>MORPHINE</displaytitle></uri><reversexrefs><reversexref uriid="59816" href="dynamic/R1/atc/N.psml" frag="N02AA21252011000036100" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="105244" title="R1" type="none" forwardtype="embed" forwardtitle="MORPHINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60144-21252011000036100-1"><fragment id="60144-21252011000036100-1"><block label="DrugName">MORPHINE<inline label="genericindexfield">XE "MORPHINE"</inline></block></fragment></section><section id="60144-d4724e15"><fragment id="60144-d4724e15"><block label="CautionText"><para>The risk of drug dependence is high.</para></block></fragment></section><section id="60144-d4724e29"><fragment id="60144-d4724e29"><block label="NoteText"><para>Authorities for increased maximum quantities and/or repeats will be granted only for:</para><para>(i) chronic severe disabling pain associated with proven malignant neoplasia; or</para><para>(ii) chronic severe disabling pain where treatment has been initiated by a specialist with appropriate expertise in pain management.</para></block></fragment></section><section id="60144-d4724e19"><fragment id="60144-d4724e19"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Chronic severe disabling pain</para><para><bold>Clinical criteria:</bold></para><list><item><para>The condition must be unresponsive to non-opioid analgesics.</para></item></list></block></fragment></section><section id="60144-4349X"><fragment id="60144-4349X"><block label="FormAndStrength">morphine sulfate pentahydrate 200 mg modified release tablet, 28</block><table role="R1"><row><cell><block label="DrugItemCode">4349X<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">116.58</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">MS Contin [MF]<inline label="genericindexfieldbrand"><italic>XE "MS Contin(MF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59816-N02AJ"><fragment id="59816-N02AJ"><block label="ATCLevel4"><para>Opioids in combination with non-opioid analgesics</para></block></fragment></section><section id="59816-N02AJ21831011000036102"><xref-fragment id="59816-N02AJ21831011000036102"><blockxref id="105238" title="ASPIRIN + CODEINE" frag="default" reversefrag="N02AJ21831011000036102" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60099" href="dynamic/R1/drug/21831011000036102-N02AJ.psml" urititle="ASPIRIN + CODEINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60099" schemaversion="0.12" date="2018-06-15T10:34:21+10:00" version="current" level="processed"><documentinfo><uri id="60099" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21831011000036102-N02AJ.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21831011000036102-N02AJ.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:24+10:00" modified="2018-06-15T10:34:21+10:00" title="ASPIRIN + CODEINE"><displaytitle>ASPIRIN + CODEINE</displaytitle></uri><reversexrefs><reversexref uriid="59816" href="dynamic/R1/atc/N.psml" frag="N02AJ21831011000036102" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="105238" title="R1" type="none" forwardtype="embed" forwardtitle="ASPIRIN + CODEINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60099-21831011000036102-1"><fragment id="60099-21831011000036102-1"><block label="DrugName">ASPIRIN + CODEINE<inline label="genericindexfield">XE "ASPIRIN + CODEINE"</inline></block></fragment></section><section id="60099-4286N"><fragment id="60099-4286N"><block label="FormAndStrength">aspirin 300 mg + codeine phosphate hemihydrate 8 mg dispersible tablet, 40</block><table role="R1"><row><cell><block label="DrugItemCode">4286N<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.84</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Aspalgin 40 [QA]<inline label="genericindexfieldbrand"><italic>XE "Aspalgin 40(QA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59816-N02AJ21286011000036106"><xref-fragment id="59816-N02AJ21286011000036106"><blockxref id="105243" title="PARACETAMOL + CODEINE" frag="default" reversefrag="N02AJ21286011000036106" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59774" href="dynamic/R1/drug/21286011000036106-N02AJ.psml" urititle="PARACETAMOL + CODEINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59774" schemaversion="0.12" date="2018-06-15T10:34:21+10:00" version="current" level="processed"><documentinfo><uri id="59774" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21286011000036106-N02AJ.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21286011000036106-N02AJ.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:21+10:00" title="PARACETAMOL + CODEINE"><displaytitle>PARACETAMOL + CODEINE</displaytitle></uri><reversexrefs><reversexref uriid="59816" href="dynamic/R1/atc/N.psml" frag="N02AJ21286011000036106" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="105243" title="R1" type="none" forwardtype="embed" forwardtitle="PARACETAMOL + CODEINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59774-21286011000036106-1"><fragment id="59774-21286011000036106-1"><block label="DrugName">PARACETAMOL + CODEINE<inline label="genericindexfield">XE "PARACETAMOL + CODEINE"</inline></block></fragment></section><section id="59774-4275B"><fragment id="59774-4275B"><block label="FormAndStrength">paracetamol 500 mg + codeine phosphate hemihydrate 8 mg tablet, 40</block><table role="R1"><row><cell><block label="DrugItemCode">4275B<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">14.80</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Panamax Co. 40 [SW]<inline label="genericindexfieldbrand"><italic>XE "Panamax Co. 40(SW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59816-N02B"><fragment id="59816-N02B"><block label="ATCLevel3"><para>OTHER ANALGESICS AND ANTIPYRETICS</para></block></fragment></section><section id="59816-N02BE"><fragment id="59816-N02BE"><block label="ATCLevel4"><para>Anilides</para></block></fragment></section><section id="59816-N02BE21433011000036107"><xref-fragment id="59816-N02BE21433011000036107"><blockxref id="105240" title="PARACETAMOL" frag="default" reversefrag="N02BE21433011000036107" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60048" href="dynamic/R1/drug/21433011000036107-N02BE.psml" urititle="PARACETAMOL" mediatype="application/vnd.pageseeder.psml+xml"><document id="60048" schemaversion="0.12" date="2018-06-15T10:34:21+10:00" version="current" level="processed"><documentinfo><uri id="60048" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21433011000036107-N02BE.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21433011000036107-N02BE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:24+10:00" modified="2018-06-15T10:34:21+10:00" title="PARACETAMOL"><displaytitle>PARACETAMOL</displaytitle></uri><reversexrefs><reversexref uriid="59816" href="dynamic/R1/atc/N.psml" frag="N02BE21433011000036107" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="105240" title="R1" type="none" forwardtype="embed" forwardtitle="PARACETAMOL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60048-21433011000036107-1"><fragment id="60048-21433011000036107-1"><block label="DrugName">PARACETAMOL<inline label="genericindexfield">XE "PARACETAMOL"</inline></block></fragment></section><section id="60048-10582Y"><fragment id="60048-10582Y"><block label="FormAndStrength">paracetamol 500 mg tablet, 100</block><table role="R1"><row><cell><block label="DrugItemCode">10582Y<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">12.74</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Paracetamol [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Paracetamol(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Febridol [EA]<inline label="genericindexfieldbrand"><italic>XE "Febridol (EA)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Generic Health Pty Ltd [GQ]<inline label="genericindexfieldbrand"><italic>XE "Generic Health Pty Ltd(GQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Panamax [SW]<inline label="genericindexfieldbrand"><italic>XE "Panamax (SW)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Paracetamol (Sandoz) [SZ]<inline label="genericindexfieldbrand"><italic>XE "Paracetamol (Sandoz)(SZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Paralgin [OW]<inline label="genericindexfieldbrand"><italic>XE "Paralgin (OW)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Parapane [AF]<inline label="genericindexfieldbrand"><italic>XE "Parapane(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60048-10599W"><fragment id="60048-10599W"><block label="FormAndStrength">paracetamol 240 mg/5 mL oral liquid, 200 mL</block><table role="R1"><row><cell><block label="DrugItemCode">10599W<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">14.79</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Panamax 240 Elixir [SW]<inline label="genericindexfieldbrand"><italic>XE "Panamax 240 Elixir(SW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60048-21433011000036107-2"><fragment id="60048-21433011000036107-2"><block label="DrugName">PARACETAMOL<inline label="genericindexfield">XE "PARACETAMOL"</inline></block></fragment></section><section id="60048-d4729e16"><fragment id="60048-d4729e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Persistent pain</para><para><bold>Clinical criteria:</bold></para><list><item><para>The condition must be associated with osteoarthritis.</para></item></list></block></fragment></section><section id="60048-10598T"><fragment id="60048-10598T"><block label="FormAndStrength">paracetamol 665 mg modified release tablet, 96</block><table role="R1"><row><cell><block label="DrugItemCode">10598T<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>18.55</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Osteomol 665 Paracetamol [CR]<inline label="genericindexfieldbrand"><italic>XE "Osteomol 665 Paracetamol(CR)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60048-21433011000036107-3"><fragment id="60048-21433011000036107-3"><block label="DrugName">PARACETAMOL<inline label="genericindexfield">XE "PARACETAMOL"</inline></block></fragment></section><section id="60048-d4731e16"><fragment id="60048-d4731e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Chronic arthropathies</para></block></fragment></section><section id="60048-10585D"><fragment id="60048-10585D"><block label="FormAndStrength">paracetamol 500 mg tablet, 100</block><table role="R1"><row><cell><block label="DrugItemCode">10585D<br></br></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">4</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>16.03</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Paracetamol [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Paracetamol(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Febridol [EA]<inline label="genericindexfieldbrand"><italic>XE "Febridol (EA)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Generic Health Pty Ltd [GQ]<inline label="genericindexfieldbrand"><italic>XE "Generic Health Pty Ltd(GQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Panamax [SW]<inline label="genericindexfieldbrand"><italic>XE "Panamax (SW)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Paracetamol (Sandoz) [SZ]<inline label="genericindexfieldbrand"><italic>XE "Paracetamol (Sandoz)(SZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Paralgin [OW]<inline label="genericindexfieldbrand"><italic>XE "Paralgin (OW)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Parapane [AF]<inline label="genericindexfieldbrand"><italic>XE "Parapane(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59816-N02BG"><fragment id="59816-N02BG"><block label="ATCLevel4"><para>Other analgesics and antipyretics</para></block></fragment></section><section id="59816-N02BG21444011000036105"><xref-fragment id="59816-N02BG21444011000036105"><blockxref id="105245" title="GABAPENTIN" frag="default" reversefrag="N02BG21444011000036105" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60462" href="dynamic/R1/drug/21444011000036105-N02BG.psml" urititle="GABAPENTIN" mediatype="application/vnd.pageseeder.psml+xml"><document id="60462" schemaversion="0.12" date="2018-06-15T10:34:21+10:00" version="current" level="processed"><documentinfo><uri id="60462" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21444011000036105-N02BG.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21444011000036105-N02BG.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:21+10:00" title="GABAPENTIN"><displaytitle>GABAPENTIN</displaytitle></uri><reversexrefs><reversexref uriid="59816" href="dynamic/R1/atc/N.psml" frag="N02BG21444011000036105" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="105245" title="R1" type="none" forwardtype="embed" forwardtitle="GABAPENTIN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60462-21444011000036105-1"><fragment id="60462-21444011000036105-1"><block label="DrugName">GABAPENTIN<inline label="genericindexfield">XE "GABAPENTIN:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="60462-d4733e16"><fragment id="60462-d4733e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Refractory neuropathic pain</para><para><bold>Clinical criteria:</bold></para><list><item><para>The condition must be unable to be controlled by other drugs.</para></item></list></block></fragment></section><section id="60462-4592Q"><fragment id="60462-4592Q"><block label="FormAndStrength">gabapentin 300 mg capsule, 100</block><table role="R1"><row><cell><block label="DrugItemCode">4592Q<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">24.59</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Gabapentin 300 [CR]<inline label="genericindexfieldbrand"><italic>XE "Gabapentin 300(CR)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Gabapentin Aspen 300 [RW]<inline label="genericindexfieldbrand"><italic>XE "Gabapentin Aspen 300 (RW)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Gabapentin GH [GQ]<inline label="genericindexfieldbrand"><italic>XE "Gabapentin GH(GQ):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Gantin [EA]<inline label="genericindexfieldbrand"><italic>XE "Gantin (EA):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">GenRx Gabapentin [GX]<inline label="genericindexfieldbrand"><italic>XE "GenRx Gabapentin(GX):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Neurontin [PF]<inline label="genericindexfieldbrand"><italic>XE "Neurontin (PF):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Nupentin 300 [AF]<inline label="genericindexfieldbrand"><italic>XE "Nupentin 300(AF):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60462-4594T"><fragment id="60462-4594T"><block label="FormAndStrength">gabapentin 600 mg tablet, 100</block><table role="R1"><row><cell><block label="DrugItemCode">4594T<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">40.31</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Gabapentin AN [EA]<inline label="genericindexfieldbrand"><italic>XE "Gabapentin AN(EA):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Gabapentin Aspen 600 [RW]<inline label="genericindexfieldbrand"><italic>XE "Gabapentin Aspen 600 (RW)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">GenRx Gabapentin [GX]<inline label="genericindexfieldbrand"><italic>XE "GenRx Gabapentin(GX):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Neurontin [PF]<inline label="genericindexfieldbrand"><italic>XE "Neurontin (PF):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Nupentin Tabs [AF]<inline label="genericindexfieldbrand"><italic>XE "Nupentin Tabs(AF):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60462-4593R"><fragment id="60462-4593R"><block label="FormAndStrength">gabapentin 400 mg capsule, 100</block><table role="R1"><row><cell><block label="DrugItemCode">4593R<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">29.50</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Gabapentin 400 [CR]<inline label="genericindexfieldbrand"><italic>XE "Gabapentin 400(CR)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Gabapentin Aspen 400 [RW]<inline label="genericindexfieldbrand"><italic>XE "Gabapentin Aspen 400 (RW)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Gabapentin GH [GQ]<inline label="genericindexfieldbrand"><italic>XE "Gabapentin GH(GQ):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Gantin [EA]<inline label="genericindexfieldbrand"><italic>XE "Gantin (EA):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">GenRx Gabapentin [GX]<inline label="genericindexfieldbrand"><italic>XE "GenRx Gabapentin(GX):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Neurontin [PF]<inline label="genericindexfieldbrand"><italic>XE "Neurontin (PF):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Nupentin 400 [AF]<inline label="genericindexfieldbrand"><italic>XE "Nupentin 400(AF):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60462-4595W"><fragment id="60462-4595W"><block label="FormAndStrength">gabapentin 800 mg tablet, 100</block><table role="R1"><row><cell><block label="DrugItemCode">4595W<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">50.06</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Gabapentin AN [EA]<inline label="genericindexfieldbrand"><italic>XE "Gabapentin AN(EA):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Gabapentin Aspen 800 [RW]<inline label="genericindexfieldbrand"><italic>XE "Gabapentin Aspen 800 (RW)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Gantin [ED]<inline label="genericindexfieldbrand"><italic>XE "Gantin(ED)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">GenRx Gabapentin [GX]<inline label="genericindexfieldbrand"><italic>XE "GenRx Gabapentin (GX)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Neurontin [PF]<inline label="genericindexfieldbrand"><italic>XE "Neurontin(PF):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Nupentin Tabs [AF]<inline label="genericindexfieldbrand"><italic>XE "Nupentin Tabs (AF):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell></row></table></fragment></section><section id="60462-4591P"><fragment id="60462-4591P"><block label="FormAndStrength">gabapentin 100 mg capsule, 100</block><table role="R1"><row><cell><block label="DrugItemCode">4591P<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">15.13</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Gabapentin [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Gabapentin(TX):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Gabapentin Aspen 100 [RW]<inline label="genericindexfieldbrand"><italic>XE "Gabapentin Aspen 100 (RW)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Neurontin [PF]<inline label="genericindexfieldbrand"><italic>XE "Neurontin(PF):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Nupentin 100 [AF]<inline label="genericindexfieldbrand"><italic>XE "Nupentin 100 (AF):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59816-N05"><fragment id="59816-N05"><block label="ATCLevel2"><para>PSYCHOLEPTICS</para></block></fragment></section><section id="59816-N05B"><fragment id="59816-N05B"><block label="ATCLevel3"><para>ANXIOLYTICS</para></block></fragment></section><section id="59816-N05BA"><fragment id="59816-N05BA"><block label="ATCLevel4"><para>Benzodiazepine derivatives</para></block></fragment></section><section id="59816-N05BA21586011000036104"><xref-fragment id="59816-N05BA21586011000036104"><blockxref id="105242" title="BROMAZEPAM" frag="default" reversefrag="N05BA21586011000036104" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60326" href="dynamic/R1/drug/21586011000036104-N05BA.psml" urititle="BROMAZEPAM" mediatype="application/vnd.pageseeder.psml+xml"><document id="60326" schemaversion="0.12" date="2018-06-15T10:34:21+10:00" version="current" level="processed"><documentinfo><uri id="60326" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21586011000036104-N05BA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21586011000036104-N05BA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:27+10:00" modified="2018-06-15T10:34:21+10:00" title="BROMAZEPAM"><displaytitle>BROMAZEPAM</displaytitle></uri><reversexrefs><reversexref uriid="59816" href="dynamic/R1/atc/N.psml" frag="N05BA21586011000036104" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="105242" title="R1" type="none" forwardtype="embed" forwardtitle="BROMAZEPAM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60326-21586011000036104-1"><fragment id="60326-21586011000036104-1"><block label="DrugName">BROMAZEPAM<inline label="genericindexfield">XE "BROMAZEPAM"</inline></block></fragment></section><section id="60326-d4735e33"><fragment id="60326-d4735e33"><block label="NoteText"><para>This drug should not be used as the first line of treatment.</para></block></fragment></section><section id="60326-d4735e36"><fragment id="60326-d4735e36"><block label="NoteText"><para>Other PBS-listed benzodiazepines should have been adequately tried and found to be ineffective or inappropriate.</para></block></fragment></section><section id="60326-d4735e39"><fragment id="60326-d4735e39"><block label="NoteText"><para>Authorities for increased quantities and/or repeats may be granted to patients with terminal disease, and other patients who have been shown to be dependent on this item by an unsuccessful attempt at gradual withdrawal.</para></block></fragment></section><section id="60326-d4735e16"><fragment id="60326-d4735e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Terminal disease</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be for the short-term,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be receiving palliative care.</para></item></list></block></fragment></section><section id="60326-d4735e65"><fragment id="60326-d4735e65"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Refractory phobic or anxiety states</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be for the short-term.</para></item></list></block></fragment></section><section id="60326-4150K"><fragment id="60326-4150K"><block label="FormAndStrength">bromazepam 3 mg tablet, 30</block><table role="R1"><row><cell><block label="DrugItemCode">4150K<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>31.15</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Lexotan [RO]<inline label="genericindexfieldbrand"><italic>XE "Lexotan(RO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60326-4151L"><fragment id="60326-4151L"><block label="FormAndStrength">bromazepam 6 mg tablet, 30</block><table role="R1"><row><cell><block label="DrugItemCode">4151L<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>36.89</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Lexotan [RO]<inline label="genericindexfieldbrand"><italic>XE "Lexotan(RO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59816-N05BE"><fragment id="59816-N05BE"><block label="ATCLevel4"><para>Azaspirodecanedione derivatives</para></block></fragment></section><section id="59816-N05BE21325011000036100"><xref-fragment id="59816-N05BE21325011000036100"><blockxref id="105239" title="BUSPIRONE" frag="default" reversefrag="N05BE21325011000036100" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60046" href="dynamic/R1/drug/21325011000036100-N05BE.psml" urititle="BUSPIRONE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60046" schemaversion="0.12" date="2018-06-15T10:34:21+10:00" version="current" level="processed"><documentinfo><uri id="60046" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21325011000036100-N05BE.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21325011000036100-N05BE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:24+10:00" modified="2018-06-15T10:34:21+10:00" title="BUSPIRONE"><displaytitle>BUSPIRONE</displaytitle></uri><reversexrefs><reversexref uriid="59816" href="dynamic/R1/atc/N.psml" frag="N05BE21325011000036100" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="105239" title="R1" type="none" forwardtype="embed" forwardtitle="BUSPIRONE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60046-21325011000036100-1"><fragment id="60046-21325011000036100-1"><block label="DrugName">BUSPIRONE<inline label="genericindexfield">XE "BUSPIRONE"</inline></block></fragment></section><section id="60046-d4738e16"><fragment id="60046-d4738e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Anxiety</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be for the short-term.</para></item></list></block></fragment></section><section id="60046-4144D"><fragment id="60046-4144D"><block label="FormAndStrength">buspirone hydrochloride 5 mg tablet, 50</block><table role="R1"><row><cell><block label="DrugItemCode">4144D<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">38.54</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Buspar [QA]<inline label="genericindexfieldbrand"><italic>XE "Buspar(QA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60046-4145E"><fragment id="60046-4145E"><block label="FormAndStrength">buspirone hydrochloride 10 mg tablet, 50</block><table role="R1"><row><cell><block label="DrugItemCode">4145E<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">55.01</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Buspar [QA]<inline label="genericindexfieldbrand"><italic>XE "Buspar(QA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59816-N05C"><fragment id="59816-N05C"><block label="ATCLevel3"><para>HYPNOTICS AND SEDATIVES</para></block></fragment></section><section id="59816-N05CD"><fragment id="59816-N05CD"><block label="ATCLevel4"><para>Benzodiazepine derivatives</para></block></fragment></section><section id="59816-N05CD21785011000036107"><xref-fragment id="59816-N05CD21785011000036107"><blockxref id="105241" title="FLUNITRAZEPAM" frag="default" reversefrag="N05CD21785011000036107" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60822" href="dynamic/R1/drug/21785011000036107-N05CD.psml" urititle="FLUNITRAZEPAM" mediatype="application/vnd.pageseeder.psml+xml"><document id="60822" schemaversion="0.12" date="2018-06-15T10:34:21+10:00" version="current" level="processed"><documentinfo><uri id="60822" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21785011000036107-N05CD.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21785011000036107-N05CD.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:21+10:00" title="FLUNITRAZEPAM"><displaytitle>FLUNITRAZEPAM</displaytitle></uri><reversexrefs><reversexref uriid="59816" href="dynamic/R1/atc/N.psml" frag="N05CD21785011000036107" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="105241" title="R1" type="none" forwardtype="embed" forwardtitle="FLUNITRAZEPAM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60822-21785011000036107-1"><fragment id="60822-21785011000036107-1"><block label="DrugName">FLUNITRAZEPAM<inline label="genericindexfield">XE "FLUNITRAZEPAM"</inline></block></fragment></section><section id="60822-d4740e33"><fragment id="60822-d4740e33"><block label="NoteText"><para>This drug should not be used as the first line of treatment.</para></block></fragment></section><section id="60822-d4740e36"><fragment id="60822-d4740e36"><block label="NoteText"><para>Other PBS-listed benzodiazepines should have been adequately tried and found to be ineffective or inappropriate.</para></block></fragment></section><section id="60822-d4740e39"><fragment id="60822-d4740e39"><block label="NoteText"><para>Authorities for increased quantities and/or repeats may be granted to patients with terminal disease, and other patients who have been shown to be dependent on this item by an unsuccessful attempt at gradual withdrawal.</para></block></fragment></section><section id="60822-d4740e16"><fragment id="60822-d4740e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Terminal disease</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be for the short-term,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must be receiving palliative care.</para></item></list></block></fragment></section><section id="60822-d4740e65"><fragment id="60822-d4740e65"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Refractory phobic or anxiety states</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be for the short-term.</para></item></list></block></fragment></section><section id="60822-4216X"><fragment id="60822-4216X"><block label="FormAndStrength">flunitrazepam 1 mg tablet, 30</block><table role="R1"><row><cell><block label="DrugItemCode">4216X<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">19.10</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Hypnodorm [AF]<inline label="genericindexfieldbrand"><italic>XE "Hypnodorm(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59816-N05CF"><fragment id="59816-N05CF"><block label="ATCLevel4"><para>Benzodiazepine related drugs</para></block></fragment></section><section id="59816-N05CF21574011000036103"><xref-fragment id="59816-N05CF21574011000036103"><blockxref id="105237" title="ZOPICLONE" frag="default" reversefrag="N05CF21574011000036103" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60234" href="dynamic/R1/drug/21574011000036103-N05CF.psml" urititle="ZOPICLONE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60234" schemaversion="0.12" date="2018-06-15T10:34:21+10:00" version="current" level="processed"><documentinfo><uri id="60234" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21574011000036103-N05CF.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21574011000036103-N05CF.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:26+10:00" modified="2018-06-15T10:34:21+10:00" title="ZOPICLONE"><displaytitle>ZOPICLONE</displaytitle></uri><reversexrefs><reversexref uriid="59816" href="dynamic/R1/atc/N.psml" frag="N05CF21574011000036103" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="105237" title="R1" type="none" forwardtype="embed" forwardtitle="ZOPICLONE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60234-21574011000036103-1"><fragment id="60234-21574011000036103-1"><block label="DrugName">ZOPICLONE<inline label="genericindexfield">XE "ZOPICLONE"</inline></block></fragment></section><section id="60234-d4743e16"><fragment id="60234-d4743e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Insomnia</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be for the short-term.</para></item></list></block></fragment></section><section id="60234-4522B"><fragment id="60234-4522B"><block label="FormAndStrength">zopiclone 7.5 mg tablet, 30</block><table role="R1"><row><cell><block label="DrugItemCode">4522B<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">24.43</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">APO-Zopiclone [TX]<inline label="genericindexfieldbrand"><italic>XE "APO-Zopiclone(TX)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Chem mart Zopiclone [CH]<inline label="genericindexfieldbrand"><italic>XE "Chem mart Zopiclone (CH)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Imrest [AF]<inline label="genericindexfieldbrand"><italic>XE "Imrest(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Terry White Chemists Zopiclone [TW]<inline label="genericindexfieldbrand"><italic>XE "Terry White Chemists Zopiclone (TW)" \i </italic></inline></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Zopiclone GH [GQ]<inline label="genericindexfieldbrand"><italic>XE "Zopiclone GH(GQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">27.17</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Imovane [SW]<inline label="genericindexfieldbrand"><italic>XE "Imovane(SW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="59816-N07"><fragment id="59816-N07"><block label="ATCLevel2"><para>OTHER NERVOUS SYSTEM DRUGS</para></block></fragment></section><section id="59816-N07B"><fragment id="59816-N07B"><block label="ATCLevel3"><para>DRUGS USED IN ADDICTIVE DISORDERS</para></block></fragment></section><section id="59816-N07BA"><fragment id="59816-N07BA"><block label="ATCLevel4"><para>Drugs used in nicotine dependence</para></block></fragment></section><section id="59816-N07BA21432011000036100"><xref-fragment id="59816-N07BA21432011000036100"><blockxref id="105246" title="NICOTINE" frag="default" reversefrag="N07BA21432011000036100" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60097" href="dynamic/R1/drug/21432011000036100-N07BA.psml" urititle="NICOTINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60097" schemaversion="0.12" date="2018-06-15T10:34:21+10:00" version="current" level="processed"><documentinfo><uri id="60097" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21432011000036100-N07BA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21432011000036100-N07BA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:24+10:00" modified="2018-06-15T10:34:21+10:00" title="NICOTINE"><displaytitle>NICOTINE</displaytitle></uri><reversexrefs><reversexref uriid="59816" href="dynamic/R1/atc/N.psml" frag="N07BA21432011000036100" urititle="NERVOUS SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="105246" title="R1" type="none" forwardtype="embed" forwardtitle="NICOTINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60097-21432011000036100-1"><fragment id="60097-21432011000036100-1"><block label="DrugName">NICOTINE<inline label="genericindexfield">XE "NICOTINE"</inline></block></fragment></section><section id="60097-d4745e33"><fragment id="60097-d4745e33"><block label="NoteText"><para>Studies have shown that successful therapy with this drug is enhanced by patient participation in a support and counselling program.</para></block></fragment></section><section id="60097-d4745e16"><fragment id="60097-d4745e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Nicotine dependence</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have indicated they are ready to cease smoking,</para></item></list><para><bold>AND</bold></para><list><item><para>Patient must have entered a comprehensive support and counselling program.</para></item></list></block></fragment></section><section id="60097-4572P"><fragment id="60097-4572P"><block label="FormAndStrength">nicotine 14 mg/24 hours patch, 7</block><table role="R1"><row><cell><block label="DrugItemCode">4572P<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>54.73</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">QuitX [AF]<inline label="genericindexfieldbrand"><italic>XE "QuitX(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>67.75</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Nicabate CQ 14 [GC]<inline label="genericindexfieldbrand"><italic>XE "Nicabate CQ 14(GC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60097-4578Y"><fragment id="60097-4578Y"><block label="FormAndStrength">nicotine 15 mg/16 hours patch, 7</block><table role="R1"><row><cell><block label="DrugItemCode">4578Y<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>59.77</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Nicorette Patch [JT]<inline label="genericindexfieldbrand"><italic>XE "Nicorette Patch(JT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60097-4573Q"><fragment id="60097-4573Q"><block label="FormAndStrength">nicotine 21 mg/24 hours patch, 7</block><table role="R1"><row><cell><block label="DrugItemCode">4573Q<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>57.69</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">QuitX [AF]<inline label="genericindexfieldbrand"><italic>XE "QuitX(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>67.75</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Nicabate CQ 21 [GC]<inline label="genericindexfieldbrand"><italic>XE "Nicabate CQ 21(GC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60097-4576W"><fragment id="60097-4576W"><block label="FormAndStrength">nicotine 5 mg/16 hours patch, 7</block><table role="R1"><row><cell><block label="DrugItemCode">4576W<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>50.97</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Nicorette Patch [JT]<inline label="genericindexfieldbrand"><italic>XE "Nicorette Patch(JT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60097-4571N"><fragment id="60097-4571N"><block label="FormAndStrength">nicotine 7 mg/24 hours patch, 7</block><table role="R1"><row><cell><block label="DrugItemCode">4571N<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>51.57</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">QuitX [AF]<inline label="genericindexfieldbrand"><italic>XE "QuitX(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60097-4577X"><fragment id="60097-4577X"><block label="FormAndStrength">nicotine 10 mg/16 hours patch, 7</block><table role="R1"><row><cell><block label="DrugItemCode">4577X<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>54.95</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Nicorette Patch [JT]<inline label="genericindexfieldbrand"><italic>XE "Nicorette Patch(JT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref><blockxref id="107090" title="ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS" frag="default" reversefrag="d114e761780" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59917" href="dynamic/R1/atc/P.psml" urititle="ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS" mediatype="application/vnd.pageseeder.psml+xml"><document id="59917" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="59917" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/atc/P.psml" decodedpath="/ps/test/local3/books/dynamic/R1/atc/P.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:32+10:00" title="ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS"><displaytitle>ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS</displaytitle></uri><reversexrefs><reversexref uriid="60526" href="dynamic/R1.psml" frag="d114e761780" urititle="Repatriation Pharmaceutical Benefits Scheme" mediatype="application/vnd.pageseeder.psml+xml" id="107090" title="R1" type="none" forwardtype="embed" forwardtitle="ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107662" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="42758" fragment="59917-P02CA21850011000036105" editid="105669" modified="2018-06-15T10:34:22+10:00"></locator><locator id="44729" fragment="59917-P02C"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107664" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTINEMATODAL AGENTS" forwarddisplay="document" forwardfrag="P02C"></reversexref></reversexrefs></locator><locator id="44728" fragment="59917-P02"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107663" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTHELMINTICS" forwarddisplay="document" forwardfrag="P02"></reversexref></reversexrefs></locator></fragmentinfo><metadata></metadata><section id="59917-P"><fragment id="59917-P"><block label="ATCLevel1"><para>ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS</para></block></fragment></section><section id="59917-P02"><fragment id="59917-P02"><block label="ATCLevel2"><para>ANTHELMINTICS</para></block></fragment></section><section id="59917-P02C"><fragment id="59917-P02C"><block label="ATCLevel3"><para>ANTINEMATODAL AGENTS</para></block></fragment></section><section id="59917-P02CA"><fragment id="59917-P02CA"><block label="ATCLevel4"><para>Benzimidazole derivatives</para></block></fragment></section><section id="59917-P02CA21850011000036105"><xref-fragment id="59917-P02CA21850011000036105"><blockxref id="105668" title="MEBENDAZOLE" frag="default" reversefrag="P02CA21850011000036105" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="61053" href="dynamic/R1/drug/21850011000036105-P02CA.psml" urititle="MEBENDAZOLE" mediatype="application/vnd.pageseeder.psml+xml"><document id="61053" schemaversion="0.12" date="2018-06-15T10:34:22+10:00" version="current" level="processed"><documentinfo><uri id="61053" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21850011000036105-P02CA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21850011000036105-P02CA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:34+10:00" modified="2018-06-15T10:34:22+10:00" title="MEBENDAZOLE"><displaytitle>MEBENDAZOLE</displaytitle></uri><reversexrefs><reversexref uriid="59917" href="dynamic/R1/atc/P.psml" frag="P02CA21850011000036105" urititle="ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS" mediatype="application/vnd.pageseeder.psml+xml" id="105668" title="R1" type="none" forwardtype="embed" forwardtitle="MEBENDAZOLE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="61053-21850011000036105-1"><fragment id="61053-21850011000036105-1"><block label="DrugName">MEBENDAZOLE<inline label="genericindexfield">XE "MEBENDAZOLE"</inline></block></fragment></section><section id="61053-4325P"><fragment id="61053-4325P"><block label="FormAndStrength">mebendazole 100 mg tablet, 6</block><table role="R1"><row><cell><block label="DrugItemCode">4325P<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.29</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Pharmacy Action Worm Treatment [GQ]<inline label="genericindexfieldbrand"><italic>XE "Pharmacy Action Worm Treatment(GQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref><blockxref id="107091" title="RESPIRATORY SYSTEM" frag="default" reversefrag="d114e761780" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60371" href="dynamic/R1/atc/R.psml" urititle="RESPIRATORY SYSTEM" mediatype="application/vnd.pageseeder.psml+xml"><document id="60371" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="60371" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/atc/R.psml" decodedpath="/ps/test/local3/books/dynamic/R1/atc/R.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:27+10:00" modified="2018-06-15T10:34:32+10:00" title="RESPIRATORY SYSTEM"><displaytitle>RESPIRATORY SYSTEM</displaytitle></uri><reversexrefs><reversexref uriid="60526" href="dynamic/R1.psml" frag="d114e761780" urititle="Repatriation Pharmaceutical Benefits Scheme" mediatype="application/vnd.pageseeder.psml+xml" id="107091" title="R1" type="none" forwardtype="embed" forwardtitle="RESPIRATORY SYSTEM" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107665" title="Untitled" type="none" forwardtype="none" forwardtitle="RESPIRATORY SYSTEM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="43621" fragment="60371-R01AD21307011000036104" editid="106538" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43601" fragment="60371-R01AA21364011000036106" editid="106528" modified="2018-06-15T10:34:27+10:00"></locator><locator id="44735" fragment="60371-R05D"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107671" title="Untitled" type="none" forwardtype="none" forwardtitle="COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS" forwarddisplay="document" forwardfrag="R05D"></reversexref></reversexrefs></locator><locator id="43603" fragment="60371-R01AC21253011000036107" editid="106529" modified="2018-06-15T10:34:27+10:00"></locator><locator id="44737" fragment="60371-R06A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107673" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIHISTAMINES FOR SYSTEMIC USE" forwarddisplay="document" forwardfrag="R06A"></reversexref></reversexrefs></locator><locator id="43607" fragment="60371-R05DA21705011000036108" editid="106531" modified="2018-06-15T10:34:27+10:00"></locator><locator id="44736" fragment="60371-R06"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107672" title="Untitled" type="none" forwardtype="none" forwardtitle="ANTIHISTAMINES FOR SYSTEMIC USE" forwarddisplay="document" forwardfrag="R06"></reversexref></reversexrefs></locator><locator id="44732" fragment="60371-R01B"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107668" title="Untitled" type="none" forwardtype="none" forwardtitle="NASAL DECONGESTANTS FOR SYSTEMIC USE" forwarddisplay="document" forwardfrag="R01B"></reversexref></reversexrefs></locator><locator id="43609" fragment="60371-R01BA21540011000036109" editid="106532" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43605" fragment="60371-R05CA21924011000036109" editid="106530" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43619" fragment="60371-R01AX21512011000036101" editid="106537" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43613" fragment="60371-R06AX21394011000036108" editid="106534" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43617" fragment="60371-R06AX21701011000036106" editid="106536" modified="2018-06-15T10:34:27+10:00"></locator><locator id="44731" fragment="60371-R01A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107667" title="Untitled" type="none" forwardtype="none" forwardtitle="DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE" forwarddisplay="document" forwardfrag="R01A"></reversexref></reversexrefs></locator><locator id="44734" fragment="60371-R05C"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107670" title="Untitled" type="none" forwardtype="none" forwardtitle="EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS" forwarddisplay="document" forwardfrag="R05C"></reversexref></reversexrefs></locator><locator id="44730" fragment="60371-R01"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107666" title="Untitled" type="none" forwardtype="none" forwardtitle="NASAL PREPARATIONS" forwarddisplay="document" forwardfrag="R01"></reversexref></reversexrefs></locator><locator id="43615" fragment="60371-R06AE21373011000036102" editid="106535" modified="2018-06-15T10:34:27+10:00"></locator><locator id="44733" fragment="60371-R05"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107669" title="Untitled" type="none" forwardtype="none" forwardtitle="COUGH AND COLD PREPARATIONS" forwarddisplay="document" forwardfrag="R05"></reversexref></reversexrefs></locator><locator id="43611" fragment="60371-R01AC21711011000036108" editid="106533" modified="2018-06-15T10:34:27+10:00"></locator></fragmentinfo><metadata></metadata><section id="60371-R"><fragment id="60371-R"><block label="ATCLevel1"><para>RESPIRATORY SYSTEM</para></block></fragment></section><section id="60371-R01"><fragment id="60371-R01"><block label="ATCLevel2"><para>NASAL PREPARATIONS</para></block></fragment></section><section id="60371-R01A"><fragment id="60371-R01A"><block label="ATCLevel3"><para>DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE</para></block></fragment></section><section id="60371-R01AA"><fragment id="60371-R01AA"><block label="ATCLevel4"><para>Sympathomimetics, plain</para></block></fragment></section><section id="60371-R01AA21364011000036106"><xref-fragment id="60371-R01AA21364011000036106"><blockxref id="106517" title="OXYMETAZOLINE" frag="default" reversefrag="R01AA21364011000036106" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59827" href="dynamic/R1/drug/21364011000036106-R01AA.psml" urititle="OXYMETAZOLINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59827" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="59827" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21364011000036106-R01AA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21364011000036106-R01AA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:27+10:00" title="OXYMETAZOLINE"><displaytitle>OXYMETAZOLINE</displaytitle></uri><reversexrefs><reversexref uriid="60371" href="dynamic/R1/atc/R.psml" frag="R01AA21364011000036106" urititle="RESPIRATORY SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="106517" title="R1" type="none" forwardtype="embed" forwardtitle="OXYMETAZOLINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59827-21364011000036106-1"><fragment id="59827-21364011000036106-1"><block label="DrugName">OXYMETAZOLINE<inline label="genericindexfield">XE "OXYMETAZOLINE"</inline></block></fragment></section><section id="59827-4379L"><fragment id="59827-4379L"><block label="FormAndStrength">oxymetazoline hydrochloride 0.05% nasal spray, 18 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4379L<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">20.08</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Logicin Rapid Relief [QA]<inline label="genericindexfieldbrand"><italic>XE "Logicin Rapid Relief(QA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59827-4378K"><fragment id="59827-4378K"><block label="FormAndStrength">oxymetazoline hydrochloride 0.05% nasal spray, 15 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4378K<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">20.42</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Drixine [BN]<inline label="genericindexfieldbrand"><italic>XE "Drixine(BN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60371-R01AC"><fragment id="60371-R01AC"><block label="ATCLevel4"><para>Antiallergic agents, excl. corticosteroids</para></block></fragment></section><section id="60371-R01AC21253011000036107"><xref-fragment id="60371-R01AC21253011000036107"><blockxref id="106518" title="CROMOGLYCATE" frag="default" reversefrag="R01AC21253011000036107" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59596" href="dynamic/R1/drug/21253011000036107-R01AC.psml" urititle="CROMOGLYCATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59596" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="59596" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21253011000036107-R01AC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21253011000036107-R01AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:18+10:00" modified="2018-06-15T10:34:27+10:00" title="CROMOGLYCATE"><displaytitle>CROMOGLYCATE</displaytitle></uri><reversexrefs><reversexref uriid="60371" href="dynamic/R1/atc/R.psml" frag="R01AC21253011000036107" urititle="RESPIRATORY SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="106518" title="R1" type="none" forwardtype="embed" forwardtitle="CROMOGLYCATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59596-21253011000036107-1"><fragment id="59596-21253011000036107-1"><block label="DrugName">CROMOGLYCATE<inline label="genericindexfield">XE "CROMOGLYCATE:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="59596-4468E"><fragment id="59596-4468E"><block label="FormAndStrength">sodium cromoglycate 2% nasal spray, 26 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4468E<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">25.43</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Rynacrom [SW]<inline label="genericindexfieldbrand"><italic>XE "Rynacrom(SW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60371-R01AC21711011000036108"><xref-fragment id="60371-R01AC21711011000036108"><blockxref id="106522" title="LEVOCABASTINE" frag="default" reversefrag="R01AC21711011000036108" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60585" href="dynamic/R1/drug/21711011000036108-R01AC.psml" urititle="LEVOCABASTINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60585" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60585" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21711011000036108-R01AC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21711011000036108-R01AC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:29+10:00" modified="2018-06-15T10:34:27+10:00" title="LEVOCABASTINE"><displaytitle>LEVOCABASTINE</displaytitle></uri><reversexrefs><reversexref uriid="60371" href="dynamic/R1/atc/R.psml" frag="R01AC21711011000036108" urititle="RESPIRATORY SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="106522" title="R1" type="none" forwardtype="embed" forwardtitle="LEVOCABASTINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60585-21711011000036108-1"><fragment id="60585-21711011000036108-1"><block label="DrugName">LEVOCABASTINE<inline label="genericindexfield">XE "LEVOCABASTINE:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="60585-4311X"><fragment id="60585-4311X"><block label="FormAndStrength">levocabastine 0.05% nasal spray, 100 actuations</block><table role="R1"><row><cell><block label="DrugItemCode">4311X<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">21.37</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Livostin [JT]<inline label="genericindexfieldbrand"><italic>XE "Livostin(JT):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60371-R01AD"><fragment id="60371-R01AD"><block label="ATCLevel4"><para>Corticosteroids</para></block></fragment></section><section id="60371-R01AD21307011000036104"><xref-fragment id="60371-R01AD21307011000036104"><blockxref id="106527" title="BUDESONIDE" frag="default" reversefrag="R01AD21307011000036104" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60076" href="dynamic/R1/drug/21307011000036104-R01AD.psml" urititle="BUDESONIDE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60076" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60076" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21307011000036104-R01AD.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21307011000036104-R01AD.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:24+10:00" modified="2018-06-15T10:34:27+10:00" title="BUDESONIDE"><displaytitle>BUDESONIDE</displaytitle></uri><reversexrefs><reversexref uriid="60371" href="dynamic/R1/atc/R.psml" frag="R01AD21307011000036104" urititle="RESPIRATORY SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="106527" title="R1" type="none" forwardtype="embed" forwardtitle="BUDESONIDE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60076-21307011000036104-1"><fragment id="60076-21307011000036104-1"><block label="DrugName">BUDESONIDE<inline label="genericindexfield">XE "BUDESONIDE:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="60076-d4751e16"><fragment id="60076-d4751e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Severe intractable rhinitis</para></block></fragment></section><section id="60076-4092J"><fragment id="60076-4092J"><block label="FormAndStrength">budesonide 64 microgram/actuation nasal spray, 120 actuations</block><table role="R1"><row><cell><block label="DrugItemCode">4092J<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">41.68</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Budamax Aqueous [PM]<inline label="genericindexfieldbrand"><italic>XE "Budamax Aqueous(PM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60371-R01AX"><fragment id="60371-R01AX"><block label="ATCLevel4"><para>Other nasal preparations</para></block></fragment></section><section id="60371-R01AX21512011000036101"><xref-fragment id="60371-R01AX21512011000036101"><blockxref id="106526" title="IPRATROPIUM" frag="default" reversefrag="R01AX21512011000036101" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60502" href="dynamic/R1/drug/21512011000036101-R01AX.psml" urititle="IPRATROPIUM" mediatype="application/vnd.pageseeder.psml+xml"><document id="60502" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60502" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21512011000036101-R01AX.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21512011000036101-R01AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:27+10:00" title="IPRATROPIUM"><displaytitle>IPRATROPIUM</displaytitle></uri><reversexrefs><reversexref uriid="60371" href="dynamic/R1/atc/R.psml" frag="R01AX21512011000036101" urititle="RESPIRATORY SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="106526" title="R1" type="none" forwardtype="embed" forwardtitle="IPRATROPIUM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60502-21512011000036101-1"><fragment id="60502-21512011000036101-1"><block label="DrugName">IPRATROPIUM<inline label="genericindexfield">XE "IPRATROPIUM:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="60502-d4753e16"><fragment id="60502-d4753e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Severe intractable rhinorrhoea</para><para><bold>Clinical criteria:</bold></para><list><item><para>The condition must be associated with perennial rhinitis,</para></item></list><para><bold>AND</bold></para><list><item><para>The condition must be unresponsive to insufflated nasal steroids.</para></item></list></block></fragment></section><section id="60502-4089F"><fragment id="60502-4089F"><block label="FormAndStrength">ipratropium bromide monohydrate 22 microgram/actuation nasal spray, 180 actuations</block><table role="R1"><row><cell><block label="DrugItemCode">4089F<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">26.48</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Atrovent Nasal Aqueous [VZ]<inline label="genericindexfieldbrand"><italic>XE "Atrovent Nasal Aqueous(VZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60502-4090G"><fragment id="60502-4090G"><block label="FormAndStrength">ipratropium bromide monohydrate 44 microgram/actuation nasal spray, 180 actuations</block><table role="R1"><row><cell><block label="DrugItemCode">4090G<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">32.63</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Atrovent Nasal Forte [VZ]<inline label="genericindexfieldbrand"><italic>XE "Atrovent Nasal Forte(VZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60371-R01B"><fragment id="60371-R01B"><block label="ATCLevel3"><para>NASAL DECONGESTANTS FOR SYSTEMIC USE</para></block></fragment></section><section id="60371-R01BA"><fragment id="60371-R01BA"><block label="ATCLevel4"><para>Sympathomimetics</para></block></fragment></section><section id="60371-R01BA21540011000036109"><xref-fragment id="60371-R01BA21540011000036109"><blockxref id="106521" title="PSEUDOEPHEDRINE" frag="default" reversefrag="R01BA21540011000036109" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59920" href="dynamic/R1/drug/21540011000036109-R01BA.psml" urititle="PSEUDOEPHEDRINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59920" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="59920" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21540011000036109-R01BA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21540011000036109-R01BA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:27+10:00" title="PSEUDOEPHEDRINE"><displaytitle>PSEUDOEPHEDRINE</displaytitle></uri><reversexrefs><reversexref uriid="60371" href="dynamic/R1/atc/R.psml" frag="R01BA21540011000036109" urititle="RESPIRATORY SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="106521" title="R1" type="none" forwardtype="embed" forwardtitle="PSEUDOEPHEDRINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59920-21540011000036109-1"><fragment id="59920-21540011000036109-1"><block label="DrugName">PSEUDOEPHEDRINE<inline label="genericindexfield">XE "PSEUDOEPHEDRINE"</inline></block></fragment></section><section id="59920-4029C"><fragment id="59920-4029C"><block label="FormAndStrength">pseudoephedrine hydrochloride 60 mg tablet, 12</block><table role="R1"><row><cell><block label="DrugItemCode">4029C<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">14.44</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Pharmacy Action Sinus &amp; Nasal Decongestant Relief [GQ]<inline label="genericindexfieldbrand"><italic>XE "Pharmacy Action Sinus &amp; Nasal Decongestant Relief(GQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">15.09</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Logicin Sinus [QA]<inline label="genericindexfieldbrand"><italic>XE "Logicin Sinus(QA)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60371-R05"><fragment id="60371-R05"><block label="ATCLevel2"><para>COUGH AND COLD PREPARATIONS</para></block></fragment></section><section id="60371-R05C"><fragment id="60371-R05C"><block label="ATCLevel3"><para>EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS</para></block></fragment></section><section id="60371-R05CA"><fragment id="60371-R05CA"><block label="ATCLevel4"><para>Expectorants</para></block></fragment></section><section id="60371-R05CA21924011000036109"><xref-fragment id="60371-R05CA21924011000036109"><blockxref id="106519" title="AMMONIUM + SENEGA ROOT" frag="default" reversefrag="R05CA21924011000036109" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59922" href="dynamic/R1/drug/21924011000036109-R05CA.psml" urititle="AMMONIUM + SENEGA ROOT" mediatype="application/vnd.pageseeder.psml+xml"><document id="59922" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="59922" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21924011000036109-R05CA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21924011000036109-R05CA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:27+10:00" title="AMMONIUM + SENEGA ROOT"><displaytitle>AMMONIUM + SENEGA ROOT</displaytitle></uri><reversexrefs><reversexref uriid="60371" href="dynamic/R1/atc/R.psml" frag="R05CA21924011000036109" urititle="RESPIRATORY SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="106519" title="R1" type="none" forwardtype="embed" forwardtitle="AMMONIUM + SENEGA ROOT" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59922-21924011000036109-1"><fragment id="59922-21924011000036109-1"><block label="DrugName">AMMONIUM + SENEGA ROOT<inline label="genericindexfield">XE "AMMONIUM + SENEGA ROOT"</inline></block></fragment></section><section id="59922-4074K"><fragment id="59922-4074K"><block label="FormAndStrength">ammonium bicarbonate 25 mg/mL + senega root 25 mg/mL oral liquid, 200 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4074K<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">4</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">13.49</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Gold Cross [BI]<inline label="genericindexfieldbrand"><italic>XE "Gold Cross(BI):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60371-R05D"><fragment id="60371-R05D"><block label="ATCLevel3"><para>COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS</para></block></fragment></section><section id="60371-R05DA"><fragment id="60371-R05DA"><block label="ATCLevel4"><para>Opium alkaloids and derivatives</para></block></fragment></section><section id="60371-R05DA21705011000036108"><xref-fragment id="60371-R05DA21705011000036108"><blockxref id="106520" title="PHOLCODINE" frag="default" reversefrag="R05DA21705011000036108" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60189" href="dynamic/R1/drug/21705011000036108-R05DA.psml" urititle="PHOLCODINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60189" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60189" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21705011000036108-R05DA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21705011000036108-R05DA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:25+10:00" modified="2018-06-15T10:34:27+10:00" title="PHOLCODINE"><displaytitle>PHOLCODINE</displaytitle></uri><reversexrefs><reversexref uriid="60371" href="dynamic/R1/atc/R.psml" frag="R05DA21705011000036108" urititle="RESPIRATORY SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="106520" title="R1" type="none" forwardtype="embed" forwardtitle="PHOLCODINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60189-21705011000036108-1"><fragment id="60189-21705011000036108-1"><block label="DrugName">PHOLCODINE<inline label="genericindexfield">XE "PHOLCODINE"</inline></block></fragment></section><section id="60189-4071G"><fragment id="60189-4071G"><block label="FormAndStrength">pholcodine 1 mg/mL oral liquid, 100 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4071G<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">13.35</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Gold Cross [BI]<inline label="genericindexfieldbrand"><italic>XE "Gold Cross(BI):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.21</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Duro-Tuss [IL]<inline label="genericindexfieldbrand"><italic>XE "Duro-Tuss(IL)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60371-R06"><fragment id="60371-R06"><block label="ATCLevel2"><para>ANTIHISTAMINES FOR SYSTEMIC USE</para></block></fragment></section><section id="60371-R06A"><fragment id="60371-R06A"><block label="ATCLevel3"><para>ANTIHISTAMINES FOR SYSTEMIC USE</para></block></fragment></section><section id="60371-R06AE"><fragment id="60371-R06AE"><block label="ATCLevel4"><para>Piperazine derivatives</para></block></fragment></section><section id="60371-R06AE21373011000036102"><xref-fragment id="60371-R06AE21373011000036102"><blockxref id="106524" title="CETIRIZINE" frag="default" reversefrag="R06AE21373011000036102" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60545" href="dynamic/R1/drug/21373011000036102-R06AE.psml" urititle="CETIRIZINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60545" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60545" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21373011000036102-R06AE.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21373011000036102-R06AE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:29+10:00" modified="2018-06-15T10:34:27+10:00" title="CETIRIZINE"><displaytitle>CETIRIZINE</displaytitle></uri><reversexrefs><reversexref uriid="60371" href="dynamic/R1/atc/R.psml" frag="R06AE21373011000036102" urititle="RESPIRATORY SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="106524" title="R1" type="none" forwardtype="embed" forwardtitle="CETIRIZINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60545-21373011000036102-1"><fragment id="60545-21373011000036102-1"><block label="DrugName">CETIRIZINE<inline label="genericindexfield">XE "CETIRIZINE"</inline></block></fragment></section><section id="60545-4175R"><fragment id="60545-4175R"><block label="FormAndStrength">cetirizine hydrochloride 10 mg tablet, 30</block><table role="R1"><row><cell><block label="DrugItemCode">4175R<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">28.06</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Pharmacy Action Cetrelief [GQ]<inline label="genericindexfieldbrand"><italic>XE "Pharmacy Action Cetrelief(GQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">31.29</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Alzene [AF]<inline label="genericindexfieldbrand"><italic>XE "Alzene(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">34.09</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Zilarex [SZ]<inline label="genericindexfieldbrand"><italic>XE "Zilarex(SZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">39.81</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Zyrtec [JT]<inline label="genericindexfieldbrand"><italic>XE "Zyrtec(JT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60371-R06AX"><fragment id="60371-R06AX"><block label="ATCLevel4"><para>Other antihistamines for systemic use</para></block></fragment></section><section id="60371-R06AX21394011000036108"><xref-fragment id="60371-R06AX21394011000036108"><blockxref id="106523" title="FEXOFENADINE" frag="default" reversefrag="R06AX21394011000036108" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59817" href="dynamic/R1/drug/21394011000036108-R06AX.psml" urititle="FEXOFENADINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59817" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="59817" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21394011000036108-R06AX.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21394011000036108-R06AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:27+10:00" title="FEXOFENADINE"><displaytitle>FEXOFENADINE</displaytitle></uri><reversexrefs><reversexref uriid="60371" href="dynamic/R1/atc/R.psml" frag="R06AX21394011000036108" urititle="RESPIRATORY SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="106523" title="R1" type="none" forwardtype="embed" forwardtitle="FEXOFENADINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59817-21394011000036108-1"><fragment id="59817-21394011000036108-1"><block label="DrugName">FEXOFENADINE<inline label="genericindexfield">XE "FEXOFENADINE"</inline></block></fragment></section><section id="59817-4237B"><fragment id="59817-4237B"><block label="FormAndStrength">fexofenadine hydrochloride 60 mg tablet, 20</block><table role="R1"><row><cell><block label="DrugItemCode">4237B<br></br></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>55.15</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Telfast [SW]<inline label="genericindexfieldbrand"><italic>XE "Telfast(SW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59817-4238C"><fragment id="59817-4238C"><block label="FormAndStrength">fexofenadine hydrochloride 120 mg tablet, 30</block><table role="R1"><row><cell><block label="DrugItemCode">4238C<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">27.88</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Pharmacy Action Fexorelief 120 [GQ]<inline label="genericindexfieldbrand"><italic>XE "Pharmacy Action Fexorelief 120(GQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">31.09</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Xergic [AF]<inline label="genericindexfieldbrand"><italic>XE "Xergic(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">35.69</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Fexal [SZ]<inline label="genericindexfieldbrand"><italic>XE "Fexal(SZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">47.30</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Telfast 120 [SW]<inline label="genericindexfieldbrand"><italic>XE "Telfast 120(SW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60371-R06AX21701011000036106"><xref-fragment id="60371-R06AX21701011000036106"><blockxref id="106525" title="LORATADINE" frag="default" reversefrag="R06AX21701011000036106" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="61062" href="dynamic/R1/drug/21701011000036106-R06AX.psml" urititle="LORATADINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="61062" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="61062" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21701011000036106-R06AX.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21701011000036106-R06AX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:34+10:00" modified="2018-06-15T10:34:27+10:00" title="LORATADINE"><displaytitle>LORATADINE</displaytitle></uri><reversexrefs><reversexref uriid="60371" href="dynamic/R1/atc/R.psml" frag="R06AX21701011000036106" urititle="RESPIRATORY SYSTEM" mediatype="application/vnd.pageseeder.psml+xml" id="106525" title="R1" type="none" forwardtype="embed" forwardtitle="LORATADINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="61062-21701011000036106-1"><fragment id="61062-21701011000036106-1"><block label="DrugName">LORATADINE<inline label="genericindexfield">XE "LORATADINE"</inline></block></fragment></section><section id="61062-4313B"><fragment id="61062-4313B"><block label="FormAndStrength">loratadine 10 mg tablet, 30</block><table role="R1"><row><cell><block label="DrugItemCode">4313B<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">30.49</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Pharmacy Action Lorastyne [GQ]<inline label="genericindexfieldbrand"><italic>XE "Pharmacy Action Lorastyne(GQ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">34.19</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Allereze [AF]<inline label="genericindexfieldbrand"><italic>XE "Allereze(AF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">43.82</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Lorano [SZ]<inline label="genericindexfieldbrand"><italic>XE "Lorano(SZ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">46.09</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent">a</block></cell><cell><block label="BrandName">Claratyne [BN]<inline label="genericindexfieldbrand"><italic>XE "Claratyne(BN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref><blockxref id="107092" title="SENSORY ORGANS" frag="default" reversefrag="d114e761780" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60497" href="dynamic/R1/atc/S.psml" urititle="SENSORY ORGANS" mediatype="application/vnd.pageseeder.psml+xml"><document id="60497" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="60497" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/atc/S.psml" decodedpath="/ps/test/local3/books/dynamic/R1/atc/S.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:32+10:00" title="SENSORY ORGANS"><displaytitle>SENSORY ORGANS</displaytitle></uri><reversexrefs><reversexref uriid="60526" href="dynamic/R1.psml" frag="d114e761780" urititle="Repatriation Pharmaceutical Benefits Scheme" mediatype="application/vnd.pageseeder.psml+xml" id="107092" title="R1" type="none" forwardtype="embed" forwardtitle="SENSORY ORGANS" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107674" title="Untitled" type="none" forwardtype="none" forwardtitle="SENSORY ORGANS" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="44738" fragment="60497-S01"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107675" title="Untitled" type="none" forwardtype="none" forwardtitle="OPHTHALMOLOGICALS" forwarddisplay="document" forwardfrag="S01"></reversexref></reversexrefs></locator><locator id="44740" fragment="60497-S02"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107677" title="Untitled" type="none" forwardtype="none" forwardtitle="OTOLOGICALS" forwarddisplay="document" forwardfrag="S02"></reversexref></reversexrefs></locator><locator id="44152" fragment="60497-S02DC21872011000036106" editid="107070" modified="2018-06-15T10:34:28+10:00"></locator><locator id="44741" fragment="60497-S02D"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107678" title="Untitled" type="none" forwardtype="none" forwardtitle="OTHER OTOLOGICALS" forwarddisplay="document" forwardfrag="S02D"></reversexref></reversexrefs></locator><locator id="44150" fragment="60497-S01GA21921011000036106" editid="107069" modified="2018-06-15T10:34:28+10:00"></locator><locator id="44146" fragment="60497-S02DC21712011000036102" editid="107067" modified="2018-06-15T10:34:28+10:00"></locator><locator id="44148" fragment="60497-S01GA21810011000036104" editid="107068" modified="2018-06-15T10:34:28+10:00"></locator><locator id="44144" fragment="60497-S01GX21711011000036108" editid="107066" modified="2018-06-15T10:34:28+10:00"></locator><locator id="44154" fragment="60497-S02DC21582011000036103" editid="107071" modified="2018-06-15T10:34:28+10:00"></locator><locator id="44739" fragment="60497-S01G"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107676" title="Untitled" type="none" forwardtype="none" forwardtitle="DECONGESTANTS AND ANTIALLERGICS" forwarddisplay="document" forwardfrag="S01G"></reversexref></reversexrefs></locator></fragmentinfo><metadata></metadata><section id="60497-S"><fragment id="60497-S"><block label="ATCLevel1"><para>SENSORY ORGANS</para></block></fragment></section><section id="60497-S01"><fragment id="60497-S01"><block label="ATCLevel2"><para>OPHTHALMOLOGICALS</para></block></fragment></section><section id="60497-S01G"><fragment id="60497-S01G"><block label="ATCLevel3"><para>DECONGESTANTS AND ANTIALLERGICS</para></block></fragment></section><section id="60497-S01GA"><fragment id="60497-S01GA"><block label="ATCLevel4"><para>Sympathomimetics used as decongestants</para></block></fragment></section><section id="60497-S01GA21921011000036106"><xref-fragment id="60497-S01GA21921011000036106"><blockxref id="107063" title="NAPHAZOLINE" frag="default" reversefrag="S01GA21921011000036106" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59566" href="dynamic/R1/drug/21921011000036106-S01GA.psml" urititle="NAPHAZOLINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59566" schemaversion="0.12" date="2018-06-15T10:34:28+10:00" version="current" level="processed"><documentinfo><uri id="59566" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21921011000036106-S01GA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21921011000036106-S01GA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:18+10:00" modified="2018-06-15T10:34:28+10:00" title="NAPHAZOLINE"><displaytitle>NAPHAZOLINE</displaytitle></uri><reversexrefs><reversexref uriid="60497" href="dynamic/R1/atc/S.psml" frag="S01GA21921011000036106" urititle="SENSORY ORGANS" mediatype="application/vnd.pageseeder.psml+xml" id="107063" title="R1" type="none" forwardtype="embed" forwardtitle="NAPHAZOLINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59566-21921011000036106-1"><fragment id="59566-21921011000036106-1"><block label="DrugName">NAPHAZOLINE<inline label="genericindexfield">XE "NAPHAZOLINE"</inline></block></fragment></section><section id="59566-4035J"><fragment id="59566-4035J"><block label="FormAndStrength">naphazoline hydrochloride 0.1% eye drops, 15 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4035J<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.63</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Albalon Liquifilm [AG]<inline label="genericindexfieldbrand"><italic>XE "Albalon Liquifilm(AG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60497-S01GA21810011000036104"><xref-fragment id="60497-S01GA21810011000036104"><blockxref id="107062" title="NAPHAZOLINE + ANTAZOLINE" frag="default" reversefrag="S01GA21810011000036104" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59910" href="dynamic/R1/drug/21810011000036104-S01GA.psml" urititle="NAPHAZOLINE + ANTAZOLINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59910" schemaversion="0.12" date="2018-06-15T10:34:28+10:00" version="current" level="processed"><documentinfo><uri id="59910" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21810011000036104-S01GA.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21810011000036104-S01GA.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:28+10:00" title="NAPHAZOLINE + ANTAZOLINE"><displaytitle>NAPHAZOLINE + ANTAZOLINE</displaytitle></uri><reversexrefs><reversexref uriid="60497" href="dynamic/R1/atc/S.psml" frag="S01GA21810011000036104" urititle="SENSORY ORGANS" mediatype="application/vnd.pageseeder.psml+xml" id="107062" title="R1" type="none" forwardtype="embed" forwardtitle="NAPHAZOLINE + ANTAZOLINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59910-21810011000036104-1"><fragment id="59910-21810011000036104-1"><block label="DrugName">NAPHAZOLINE + ANTAZOLINE<inline label="genericindexfield">XE "NAPHAZOLINE + ANTAZOLINE"</inline></block></fragment></section><section id="59910-4032F"><fragment id="59910-4032F"><block label="FormAndStrength">naphazoline hydrochloride 0.05% + antazoline phosphate 0.5% eye drops, 15 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4032F<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.38</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Albalon-A [AG]<inline label="genericindexfieldbrand"><italic>XE "Albalon-A(AG)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60497-S01GX"><fragment id="60497-S01GX"><block label="ATCLevel4"><para>Other antiallergics</para></block></fragment></section><section id="60497-S01GX21711011000036108"><xref-fragment id="60497-S01GX21711011000036108"><blockxref id="107060" title="LEVOCABASTINE" frag="default" reversefrag="S01GX21711011000036108" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59730" href="dynamic/R1/drug/21711011000036108-S01GX.psml" urititle="LEVOCABASTINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59730" schemaversion="0.12" date="2018-06-15T10:34:28+10:00" version="current" level="processed"><documentinfo><uri id="59730" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21711011000036108-S01GX.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21711011000036108-S01GX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:20+10:00" modified="2018-06-15T10:34:28+10:00" title="LEVOCABASTINE"><displaytitle>LEVOCABASTINE</displaytitle></uri><reversexrefs><reversexref uriid="60497" href="dynamic/R1/atc/S.psml" frag="S01GX21711011000036108" urititle="SENSORY ORGANS" mediatype="application/vnd.pageseeder.psml+xml" id="107060" title="R1" type="none" forwardtype="embed" forwardtitle="LEVOCABASTINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59730-21711011000036108-1"><fragment id="59730-21711011000036108-1"><block label="DrugName">LEVOCABASTINE<inline label="genericindexfield">XE "LEVOCABASTINE:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="59730-4310W"><fragment id="59730-4310W"><block label="FormAndStrength">levocabastine 0.05% eye drops, 4 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4310W<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">21.37</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Livostin [JT]<inline label="genericindexfieldbrand"><italic>XE "Livostin(JT):.Repatriation Pharmaceutical Benefits Scheme" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60497-S02"><fragment id="60497-S02"><block label="ATCLevel2"><para>OTOLOGICALS</para></block></fragment></section><section id="60497-S02D"><fragment id="60497-S02D"><block label="ATCLevel3"><para>OTHER OTOLOGICALS</para></block></fragment></section><section id="60497-S02DC"><fragment id="60497-S02DC"><block label="ATCLevel4"><para>Indifferent preparations</para></block></fragment></section><section id="60497-S02DC21582011000036103"><xref-fragment id="60497-S02DC21582011000036103"><blockxref id="107065" title="CARBAMIDE PEROXIDE" frag="default" reversefrag="S02DC21582011000036103" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60067" href="dynamic/R1/drug/21582011000036103-S02DC.psml" urititle="CARBAMIDE PEROXIDE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60067" schemaversion="0.12" date="2018-06-15T10:34:28+10:00" version="current" level="processed"><documentinfo><uri id="60067" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21582011000036103-S02DC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21582011000036103-S02DC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:24+10:00" modified="2018-06-15T10:34:28+10:00" title="CARBAMIDE PEROXIDE"><displaytitle>CARBAMIDE PEROXIDE</displaytitle></uri><reversexrefs><reversexref uriid="60497" href="dynamic/R1/atc/S.psml" frag="S02DC21582011000036103" urititle="SENSORY ORGANS" mediatype="application/vnd.pageseeder.psml+xml" id="107065" title="R1" type="none" forwardtype="embed" forwardtitle="CARBAMIDE PEROXIDE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60067-21582011000036103-1"><fragment id="60067-21582011000036103-1"><block label="DrugName">CARBAMIDE PEROXIDE<inline label="genericindexfield">XE "CARBAMIDE PEROXIDE"</inline></block></fragment></section><section id="60067-4176T"><fragment id="60067-4176T"><block label="FormAndStrength">carbamide peroxide 6.5% ear drops, 12 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4176T<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">20.57</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Ear Clear for Ear Wax Removal [KY]<inline label="genericindexfieldbrand"><italic>XE "Ear Clear for Ear Wax Removal(KY)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60497-S02DC21872011000036106"><xref-fragment id="60497-S02DC21872011000036106"><blockxref id="107064" title="DOCUSATE" frag="default" reversefrag="S02DC21872011000036106" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60614" href="dynamic/R1/drug/21872011000036106-S02DC.psml" urititle="DOCUSATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60614" schemaversion="0.12" date="2018-06-15T10:34:28+10:00" version="current" level="processed"><documentinfo><uri id="60614" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21872011000036106-S02DC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21872011000036106-S02DC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:30+10:00" modified="2018-06-15T10:34:28+10:00" title="DOCUSATE"><displaytitle>DOCUSATE</displaytitle></uri><reversexrefs><reversexref uriid="60497" href="dynamic/R1/atc/S.psml" frag="S02DC21872011000036106" urititle="SENSORY ORGANS" mediatype="application/vnd.pageseeder.psml+xml" id="107064" title="R1" type="none" forwardtype="embed" forwardtitle="DOCUSATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60614-21872011000036106-1"><fragment id="60614-21872011000036106-1"><block label="DrugName">DOCUSATE<inline label="genericindexfield">XE "DOCUSATE:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="60614-4199B"><fragment id="60614-4199B"><block label="FormAndStrength">docusate sodium 0.5% ear drops, 10 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4199B<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.09</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Waxsol [GO]<inline label="genericindexfieldbrand"><italic>XE "Waxsol(GO)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60497-S02DC21712011000036102"><xref-fragment id="60497-S02DC21712011000036102"><blockxref id="107061" title="ORTHO-DICHLOROBENZENE + PARA-DICHLOROBENZENE + CHLOROBUTANOL + ARACHIS OIL" frag="default" reversefrag="S02DC21712011000036102" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59843" href="dynamic/R1/drug/21712011000036102-S02DC.psml" urititle="ORTHO-DICHLOROBENZENE + PARA-DICHLOROBENZENE + CHLOROBUTANOL + ARACHIS OIL" mediatype="application/vnd.pageseeder.psml+xml"><document id="59843" schemaversion="0.12" date="2018-06-15T10:34:28+10:00" version="current" level="processed"><documentinfo><uri id="59843" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21712011000036102-S02DC.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21712011000036102-S02DC.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:28+10:00" title="ORTHO-DICHLOROBENZENE + PARA-DICHLOROBENZENE + CHLOROBUTANOL + ARACHIS OIL"><displaytitle>ORTHO-DICHLOROBENZENE + PARA-DICHLOROBENZENE + CHLOROBUTANOL + ARACHIS OIL</displaytitle></uri><reversexrefs><reversexref uriid="60497" href="dynamic/R1/atc/S.psml" frag="S02DC21712011000036102" urititle="SENSORY ORGANS" mediatype="application/vnd.pageseeder.psml+xml" id="107061" title="R1" type="none" forwardtype="embed" forwardtitle="ORTHO-DICHLOROBENZENE + PARA-DICHLOROBENZENE + CHLOROBUTANOL + ARACHIS OIL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59843-21712011000036102-1"><fragment id="59843-21712011000036102-1"><block label="DrugName">ORTHO-DICHLOROBENZENE + PARA-DICHLOROBENZENE + CHLOROBUTANOL + ARACHIS OIL<inline label="genericindexfield">XE "ORTHO-DICHLOROBENZENE + PARA-DICHLOROBENZENE + CHLOROBUTANOL + ARACHIS OIL"</inline></block></fragment></section><section id="59843-4180B"><fragment id="59843-4180B"><block label="FormAndStrength">ortho-dichlorobenzene 14% + para-dichlorobenzene 2% + chlorobutanol hemihydrate 5% + arachis oil 57% ear drops, 10 mL</block><table role="R1"><row><cell><block label="DrugItemCode">4180B<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.75</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Cerumol [UN]<inline label="genericindexfieldbrand"><italic>XE "Cerumol(UN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref><blockxref id="107093" title="VARIOUS" frag="default" reversefrag="d114e761780" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60316" href="dynamic/R1/atc/V.psml" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml"><document id="60316" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="60316" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/atc/V.psml" decodedpath="/ps/test/local3/books/dynamic/R1/atc/V.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:27+10:00" modified="2018-06-15T10:34:32+10:00" title="VARIOUS"><displaytitle>VARIOUS</displaytitle></uri><reversexrefs><reversexref uriid="60526" href="dynamic/R1.psml" frag="d114e761780" urititle="Repatriation Pharmaceutical Benefits Scheme" mediatype="application/vnd.pageseeder.psml+xml" id="107093" title="R1" type="none" forwardtype="embed" forwardtitle="VARIOUS" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107679" title="Untitled" type="none" forwardtype="none" forwardtitle="VARIOUS" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo><locator id="43483" fragment="60316-V07AY50714011000036106" editid="106454" modified="2018-06-15T10:34:27+10:00"></locator><locator id="44747" fragment="60316-V07A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107685" title="Untitled" type="none" forwardtype="none" forwardtitle="ALL OTHER NON-THERAPEUTIC PRODUCTS" forwarddisplay="document" forwardfrag="V07A"></reversexref></reversexrefs></locator><locator id="43541" fragment="60316-V07AY111251000036105" editid="106483" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43553" fragment="60316-V07AY50703011000036107" editid="106489" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43543" fragment="60316-V07AY50771011000036102" editid="106484" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43491" fragment="60316-V07AY7601000144108" editid="106458" modified="2018-06-15T10:34:27+10:00"></locator><locator id="44744" fragment="60316-V06"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107682" title="Untitled" type="none" forwardtype="none" forwardtitle="GENERAL NUTRIENTS" forwarddisplay="document" forwardfrag="V06"></reversexref></reversexrefs></locator><locator id="43557" fragment="60316-V07AY50754011000036102" editid="106491" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43583" fragment="60316-V07AY50744011000036100" editid="106504" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43579" fragment="60316-V07AY50720011000036108" editid="106502" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43513" fragment="60316-V06DX733691000168107" editid="106469" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43565" fragment="60316-V07AY50731011000036104" editid="106495" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43473" fragment="60316-V07AY157031000036107" editid="106449" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43569" fragment="60316-V07AY50775011000036100" editid="106497" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43573" fragment="60316-V07AY50777011000036105" editid="106499" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43503" fragment="60316-V07AY21660011000036108" editid="106464" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43577" fragment="60316-V07AY430321000144107" editid="106501" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43505" fragment="60316-V07AY282941000144106" editid="106465" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43481" fragment="60316-V07AY50715011000036105" editid="106453" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43511" fragment="60316-V07AY50768011000036103" editid="106468" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43499" fragment="60316-V07AY21550011000036106" editid="106462" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43527" fragment="60316-V07AY50697011000036107" editid="106476" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43567" fragment="60316-V07AY50701011000036106" editid="106496" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43589" fragment="60316-V07AY50700011000036104" editid="106507" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43561" fragment="60316-V07AY50724011000036103" editid="106493" modified="2018-06-15T10:34:27+10:00"></locator><locator id="44746" fragment="60316-V07"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107684" title="Untitled" type="none" forwardtype="none" forwardtitle="ALL OTHER NON-THERAPEUTIC PRODUCTS" forwarddisplay="document" forwardfrag="V07"></reversexref></reversexrefs></locator><locator id="43551" fragment="60316-V07AY50713011000036109" editid="106488" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43515" fragment="60316-V07AY933247641000036101" editid="106470" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43531" fragment="60316-V07AY50728011000036105" editid="106478" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43587" fragment="60316-V07AY85068011000036107" editid="106506" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43555" fragment="60316-V07AY50721011000036101" editid="106490" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43501" fragment="60316-V07A50706011000036101" editid="106463" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43571" fragment="60316-V07AY50765011000036109" editid="106498" modified="2018-06-15T10:34:27+10:00"></locator><locator id="44743" fragment="60316-V03A"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107681" title="Untitled" type="none" forwardtype="none" forwardtitle="ALL OTHER THERAPEUTIC PRODUCTS" forwarddisplay="document" forwardfrag="V03A"></reversexref></reversexrefs></locator><locator id="43485" fragment="60316-V07AY50757011000036108" editid="106455" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43529" fragment="60316-V07AY50760011000036100" editid="106477" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43575" fragment="60316-V07AY50763011000036108" editid="106500" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43537" fragment="60316-V07AY50699011000036100" editid="106481" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43559" fragment="60316-V07AY50710011000036101" editid="106492" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43521" fragment="60316-V07AY50698011000036108" editid="106473" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43591" fragment="60316-V07AY50742011000036109" editid="106508" modified="2018-06-15T10:34:27+10:00"></locator><locator id="44745" fragment="60316-V06D"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107683" title="Untitled" type="none" forwardtype="none" forwardtitle="OTHER NUTRIENTS" forwarddisplay="document" forwardfrag="V06D"></reversexref></reversexrefs></locator><locator id="43495" fragment="60316-V06DX733191000168102" editid="106460" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43475" fragment="60316-V07AY50779011000036103" editid="106450" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43493" fragment="60316-V07AY733051000168108" editid="106459" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43471" fragment="60316-V07AY50717011000036100" editid="106448" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43517" fragment="60316-V07AY50725011000036104" editid="106471" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43549" fragment="60316-V07AY50761011000036107" editid="106487" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43585" fragment="60316-V07AY50734011000036101" editid="106505" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43477" fragment="60316-V07AY111261000036108" editid="106451" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43507" fragment="60316-V07AY50749011000036104" editid="106466" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43539" fragment="60316-V07AY50730011000036106" editid="106482" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43525" fragment="60316-V07AY50748011000036107" editid="106475" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43545" fragment="60316-V07AY171041000036105" editid="106485" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43479" fragment="60316-V07AY50716011000036103" editid="106452" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43509" fragment="60316-V07AY282751000144107" editid="106467" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43563" fragment="60316-V07AY50767011000036104" editid="106494" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43523" fragment="60316-V07AY50727011000036109" editid="106474" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43533" fragment="60316-V07AY12941000144101" editid="106479" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43519" fragment="60316-V07AY50704011000036109" editid="106472" modified="2018-06-15T10:34:27+10:00"></locator><locator id="44742" fragment="60316-V03"><reversexrefs><reversexref uriid="60793" href="dynamic/R1/therapeuticindex-R1.psml" frag="2" urititle="Therapeutic Index - Repatriation Pharmaceutical Benefits Scheme - R1" mediatype="application/vnd.pageseeder.psml+xml" id="107680" title="Untitled" type="none" forwardtype="none" forwardtitle="ALL OTHER THERAPEUTIC PRODUCTS" forwarddisplay="document" forwardfrag="V03"></reversexref></reversexrefs></locator><locator id="43489" fragment="60316-V07AY50718011000036104" editid="106457" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43581" fragment="60316-V07AY50711011000036108" editid="106503" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43535" fragment="60316-V07AY111231000036102" editid="106480" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43547" fragment="60316-V07AY50740011000036105" editid="106486" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43497" fragment="60316-V03AE21477011000036100" editid="106461" modified="2018-06-15T10:34:27+10:00"></locator><locator id="43487" fragment="60316-V07AY282011000144106" editid="106456" modified="2018-06-15T10:34:27+10:00"></locator></fragmentinfo><metadata></metadata><section id="60316-V"><fragment id="60316-V"><block label="ATCLevel1"><para>VARIOUS</para></block></fragment></section><section id="60316-V03"><fragment id="60316-V03"><block label="ATCLevel2"><para>ALL OTHER THERAPEUTIC PRODUCTS</para></block></fragment></section><section id="60316-V03A"><fragment id="60316-V03A"><block label="ATCLevel3"><para>ALL OTHER THERAPEUTIC PRODUCTS</para></block></fragment></section><section id="60316-V03AE"><fragment id="60316-V03AE"><block label="ATCLevel4"><para>Drugs for treatment of hyperkalemia and hyperphosphatemia</para></block></fragment></section><section id="60316-V03AE21477011000036100"><xref-fragment id="60316-V03AE21477011000036100"><blockxref id="106400" title="SODIUM POLYSTYRENE SULFONATE" frag="default" reversefrag="V03AE21477011000036100" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60927" href="dynamic/R1/drug/21477011000036100-V03AE.psml" urititle="SODIUM POLYSTYRENE SULFONATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60927" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60927" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21477011000036100-V03AE.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21477011000036100-V03AE.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:33+10:00" modified="2018-06-15T10:34:27+10:00" title="SODIUM POLYSTYRENE SULFONATE"><displaytitle>SODIUM POLYSTYRENE SULFONATE</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V03AE21477011000036100" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106400" title="R1" type="none" forwardtype="embed" forwardtitle="SODIUM POLYSTYRENE SULFONATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60927-21477011000036100-1"><fragment id="60927-21477011000036100-1"><block label="DrugName">SODIUM POLYSTYRENE SULFONATE<inline label="genericindexfield">XE "SODIUM POLYSTYRENE SULFONATE"</inline></block></fragment></section><section id="60927-4470G"><fragment id="60927-4470G"><block label="FormAndStrength">sodium polystyrene sulfonate 999.3 mg/g powder, 454 g</block><table role="R1"><row><cell><block label="DrugItemCode">4470G<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">69.91</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Resonium-A [SW]<inline label="genericindexfieldbrand"><italic>XE "Resonium-A(SW)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V06"><fragment id="60316-V06"><block label="ATCLevel2"><para>GENERAL NUTRIENTS</para></block></fragment></section><section id="60316-V06D"><fragment id="60316-V06D"><block label="ATCLevel3"><para>OTHER NUTRIENTS</para></block></fragment></section><section id="60316-V06DX"><fragment id="60316-V06DX"><block label="ATCLevel4"><para>Other combinations of nutrients</para></block></fragment></section><section id="60316-V06DX733191000168102"><xref-fragment id="60316-V06DX733191000168102"><blockxref id="106399" title="PROTEIN FORMULA WITH ARGININE, VITAMIN C AND E" frag="default" reversefrag="V06DX733191000168102" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60152" href="dynamic/R1/drug/733191000168102-V06DX.psml" urititle="PROTEIN FORMULA WITH ARGININE, VITAMIN C AND E" mediatype="application/vnd.pageseeder.psml+xml"><document id="60152" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60152" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/733191000168102-V06DX.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/733191000168102-V06DX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:25+10:00" modified="2018-06-15T10:34:27+10:00" title="PROTEIN FORMULA WITH ARGININE, VITAMIN C AND E"><displaytitle>PROTEIN FORMULA WITH ARGININE, VITAMIN C AND E</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V06DX733191000168102" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106399" title="R1" type="none" forwardtype="embed" forwardtitle="PROTEIN FORMULA WITH ARGININE, VITAMIN C AND E" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60152-733191000168102-1"><fragment id="60152-733191000168102-1"><block label="DrugName">PROTEIN FORMULA WITH ARGININE, VITAMIN C AND E<inline label="genericindexfield">XE "PROTEIN FORMULA WITH ARGININE, VITAMIN C AND E"</inline></block></fragment></section><section id="60152-d4768e16"><fragment id="60152-d4768e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Stage 2 and above pressure injury</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be for special medical purposes to support healing of pressure injuries.</para></item></list></block></fragment></section><section id="60152-10850C"><fragment id="60152-10850C"><block label="FormAndStrength">protein formula with arginine, vitamin C and E powder for oral liquid, 14 x 9.2 g sachets</block><table role="R1"><row><cell><block label="DrugItemCode">10850C<br></br></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>158.63</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Arginaid [NT]<inline label="genericindexfieldbrand"><italic>XE "Arginaid(NT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V06DX733691000168107"><xref-fragment id="60316-V06DX733691000168107"><blockxref id="106408" title="PROTEIN FORMULA WITH ARGININE, VITAMIN C, E AND ZINC" frag="default" reversefrag="V06DX733691000168107" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59828" href="dynamic/R1/drug/733691000168107-V06DX.psml" urititle="PROTEIN FORMULA WITH ARGININE, VITAMIN C, E AND ZINC" mediatype="application/vnd.pageseeder.psml+xml"><document id="59828" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="59828" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/733691000168107-V06DX.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/733691000168107-V06DX.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:27+10:00" title="PROTEIN FORMULA WITH ARGININE, VITAMIN C, E AND ZINC"><displaytitle>PROTEIN FORMULA WITH ARGININE, VITAMIN C, E AND ZINC</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V06DX733691000168107" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106408" title="R1" type="none" forwardtype="embed" forwardtitle="PROTEIN FORMULA WITH ARGININE, VITAMIN C, E AND ZINC" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59828-733691000168107-1"><fragment id="59828-733691000168107-1"><block label="DrugName">PROTEIN FORMULA WITH ARGININE, VITAMIN C, E AND ZINC<inline label="genericindexfield">XE "PROTEIN FORMULA WITH ARGININE, VITAMIN C, E AND ZINC"</inline></block></fragment></section><section id="59828-d4770e16"><fragment id="59828-d4770e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Stage 2 and above pressure injury</para><para><bold>Clinical criteria:</bold></para><list><item><para>The treatment must be for special medical purposes to support healing of pressure injuries.</para></item></list></block></fragment></section><section id="59828-10841N"><fragment id="59828-10841N"><block label="FormAndStrength">protein formula with arginine, vitamin C, E and zinc oral liquid, 27 x 237 mL cartons</block><table role="R1"><row><cell><block label="DrugItemCode">10841N<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">5</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>263.19</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Arginaid Extra [NT]<inline label="genericindexfieldbrand"><italic>XE "Arginaid Extra(NT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07"><fragment id="60316-V07"><block label="ATCLevel2"><para>ALL OTHER NON-THERAPEUTIC PRODUCTS</para></block></fragment></section><section id="60316-V07A"><fragment id="60316-V07A"><block label="ATCLevel3"><para>ALL OTHER NON-THERAPEUTIC PRODUCTS</para></block></fragment></section><section id="60316-V07A50706011000036101"><xref-fragment id="60316-V07A50706011000036101"><blockxref id="106402" title="LUBRICATING AGENT" frag="default" reversefrag="V07A50706011000036101" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60798" href="dynamic/R1/drug/50706011000036101-V07A.psml" urititle="LUBRICATING AGENT" mediatype="application/vnd.pageseeder.psml+xml"><document id="60798" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60798" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50706011000036101-V07A.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50706011000036101-V07A.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:27+10:00" title="LUBRICATING AGENT"><displaytitle>LUBRICATING AGENT</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07A50706011000036101" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106402" title="R1" type="none" forwardtype="embed" forwardtitle="LUBRICATING AGENT" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60798-50706011000036101-1"><fragment id="60798-50706011000036101-1"><block label="DrugName">LUBRICATING AGENT<inline label="genericindexfield">XE "LUBRICATING AGENT"</inline></block></fragment></section><section id="60798-4306P"><fragment id="60798-4306P"><block label="FormAndStrength">lubricating agent jelly, 100 g</block><table role="R1"><row><cell><block label="DrugItemCode">4306P<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">14.32</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Lubri-Gel [PP]<inline label="genericindexfieldbrand"><italic>XE "Lubri-Gel(PP)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY"><fragment id="60316-V07AY"><block label="ATCLevel4"><para>Other non-therapeutic auxiliary products</para></block></fragment></section><section id="60316-V07AY50749011000036104"><xref-fragment id="60316-V07AY50749011000036104"><blockxref id="106405" title="BANDAGE ABSORBENT WOOL" frag="default" reversefrag="V07AY50749011000036104" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60175" href="dynamic/R1/drug/50749011000036104-V07AY.psml" urititle="BANDAGE ABSORBENT WOOL" mediatype="application/vnd.pageseeder.psml+xml"><document id="60175" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60175" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50749011000036104-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50749011000036104-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:25+10:00" modified="2018-06-15T10:34:27+10:00" title="BANDAGE ABSORBENT WOOL"><displaytitle>BANDAGE ABSORBENT WOOL</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50749011000036104" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106405" title="R1" type="none" forwardtype="embed" forwardtitle="BANDAGE ABSORBENT WOOL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60175-50749011000036104-1"><fragment id="60175-50749011000036104-1"><block label="DrugName">BANDAGE ABSORBENT WOOL<inline label="genericindexfield">XE "BANDAGE ABSORBENT WOOL"</inline></block></fragment></section><section id="60175-4653X"><fragment id="60175-4653X"><block label="FormAndStrength">bandage absorbent wool 10 cm x 3 m bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4653X<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">23.18</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Surepress 650948 [CC]<inline label="genericindexfieldbrand"><italic>XE "Surepress 650948(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50775011000036100"><xref-fragment id="60316-V07AY50775011000036100"><blockxref id="106436" title="BANDAGE CALICO" frag="default" reversefrag="V07AY50775011000036100" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60981" href="dynamic/R1/drug/50775011000036100-V07AY.psml" urititle="BANDAGE CALICO" mediatype="application/vnd.pageseeder.psml+xml"><document id="60981" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60981" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50775011000036100-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50775011000036100-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:34+10:00" modified="2018-06-15T10:34:27+10:00" title="BANDAGE CALICO"><displaytitle>BANDAGE CALICO</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50775011000036100" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106436" title="R1" type="none" forwardtype="embed" forwardtitle="BANDAGE CALICO" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60981-50775011000036100-1"><fragment id="60981-50775011000036100-1"><block label="DrugName">BANDAGE CALICO<inline label="genericindexfield">XE "BANDAGE CALICO"</inline></block></fragment></section><section id="60981-4717G"><fragment id="60981-4717G"><block label="FormAndStrength">bandage calico large triangular bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4717G<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.10</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Handy 36361414 [BV]<inline label="genericindexfieldbrand"><italic>XE "Handy 36361414(BV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50716011000036103"><xref-fragment id="60316-V07AY50716011000036103"><blockxref id="106391" title="BANDAGE COMPRESSION" frag="default" reversefrag="V07AY50716011000036103" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60024" href="dynamic/R1/drug/50716011000036103-V07AY.psml" urititle="BANDAGE COMPRESSION" mediatype="application/vnd.pageseeder.psml+xml"><document id="60024" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60024" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50716011000036103-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50716011000036103-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:24+10:00" modified="2018-06-15T10:34:27+10:00" title="BANDAGE COMPRESSION"><displaytitle>BANDAGE COMPRESSION</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50716011000036103" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106391" title="R1" type="none" forwardtype="embed" forwardtitle="BANDAGE COMPRESSION" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60024-50716011000036103-1"><fragment id="60024-50716011000036103-1"><block label="DrugName">BANDAGE COMPRESSION<inline label="genericindexfield">XE "BANDAGE COMPRESSION"</inline></block></fragment></section><section id="60024-d4775e17"><fragment id="60024-d4775e17"><block label="NoteText"><para>Treatment of varices and oedema associated with venous disease and lymphoedema; contraindicated in arterial disease.</para></block></fragment></section><section id="60024-4748X"><fragment id="60024-4748X"><block label="FormAndStrength">bandage compression 10 cm x 3 m high stretch bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4748X<br></br></block></cell><cell><block label="MaxQuantity">5</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>71.55</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Surepress 650947 [CC]<inline label="genericindexfieldbrand"><italic>XE "Surepress 650947(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>149.85</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tensopress 71723-00 [BV]<inline label="genericindexfieldbrand"><italic>XE "Tensopress 71723-00(BV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60024-4654Y"><fragment id="60024-4654Y"><block label="FormAndStrength">BANDAGE-COMPRESSION Bandage, short stretch, 8 cm x 2.6 m, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4654Y<br></br></block></cell><cell><block label="MaxQuantity">5</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>76.90</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Comprilan 01027-00 [BV]<inline label="genericindexfieldbrand"><italic>XE "Comprilan 01027-00(BV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60024-50716011000036103-2"><fragment id="60024-50716011000036103-2"><block label="DrugName">BANDAGE COMPRESSION<inline label="genericindexfield">XE "BANDAGE COMPRESSION"</inline></block></fragment></section><section id="60024-d4777e17"><fragment id="60024-d4777e17"><block label="NoteText"><para>Treatment of varices and oedema associated with venous disease and lymphoedema; contraindicated in arterial disease.</para></block></fragment></section><section id="60024-d4777e20"><fragment id="60024-d4777e20"><block label="NoteText"><para>Smith &amp; Nephew products are distributed via the three major wholesalers, API, Sigma &amp; Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith &amp; Nephew Customer Service on 13 13 60. Smith &amp; Nephew cannot ensure RPBS pricing from distributors other than those aforementioned.</para></block></fragment></section><section id="60024-4598B"><fragment id="60024-4598B"><block label="FormAndStrength">bandage compression four layer bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4598B<br></br></block></cell><cell><block label="MaxQuantity">5</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>169.75</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Profore Lite 66050415 [SN]<inline label="genericindexfieldbrand"><italic>XE "Profore Lite 66050415(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60024-4658E"><fragment id="60024-4658E"><block label="FormAndStrength">bandage compression four layer bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4658E<br></br></block></cell><cell><block label="MaxQuantity">5</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>253.40</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Profore 66050016 [SN]<inline label="genericindexfieldbrand"><italic>XE "Profore 66050016(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60024-50716011000036103-3"><fragment id="60024-50716011000036103-3"><block label="DrugName">BANDAGE COMPRESSION<inline label="genericindexfield">XE "BANDAGE COMPRESSION"</inline></block></fragment></section><section id="60024-d4779e17"><fragment id="60024-d4779e17"><block label="NoteText"><para>Treatment of varices and oedema associated with venous disease and lymphoedema; contraindicated in arterial disease.</para></block></fragment></section><section id="60024-d4779e20"><fragment id="60024-d4779e20"><block label="NoteText"><para>Molnlycke Health Care products are distributed through leading pharmacy distributors. To best ensure product availability at the RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email: customerservice@independenceaustralia.com. Molnlycke Health Care is not able to ensure product availability or pricing on listed products beyond these two suppliers.</para></block></fragment></section><section id="60024-4657D"><fragment id="60024-4657D"><block label="FormAndStrength">bandage compression 10 cm x 3.5 m high stretch bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4657D<br></br></block></cell><cell><block label="MaxQuantity">5</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>76.70</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Setopress 3505 [MH]<inline label="genericindexfieldbrand"><italic>XE "Setopress 3505(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60024-50716011000036103-4"><fragment id="60024-50716011000036103-4"><block label="DrugName">BANDAGE COMPRESSION<inline label="genericindexfield">XE "BANDAGE COMPRESSION"</inline></block></fragment></section><section id="60024-d4781e21"><fragment id="60024-d4781e21"><block label="NoteText"><para>Treatment of varices and oedema associated with venous disease and lymphoedema; contraindicated in arterial disease.</para></block></fragment></section><section id="60024-d4781e24"><fragment id="60024-d4781e24"><block label="NoteText"><para>Bandage can be left in situ for up to 7 days as per manufacturer's instructions.</para></block></fragment></section><section id="60024-d4781e16"><fragment id="60024-d4781e16"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Venous ulcer</para><para>Treatment Phase: Initial treatment</para></block></fragment></section><section id="60024-d4781e48"><fragment id="60024-d4781e48"><block label="RestrictionHead"><para>Restricted benefit</para></block><block label="RestrictionText"><para>Venous ulcer</para><para>Treatment Phase: Continuing treatment</para></block></fragment></section><section id="60024-4050E"><fragment id="60024-4050E"><block label="FormAndStrength">bandage compression two layer bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4050E<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">42.85</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Coban 2 [MM]<inline label="genericindexfieldbrand"><italic>XE "Coban 2(MM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50704011000036109"><xref-fragment id="60316-V07AY50704011000036109"><blockxref id="106411" title="BANDAGE RETENTION COHESIVE HEAVY" frag="default" reversefrag="V07AY50704011000036109" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59946" href="dynamic/R1/drug/50704011000036109-V07AY.psml" urititle="BANDAGE RETENTION COHESIVE HEAVY" mediatype="application/vnd.pageseeder.psml+xml"><document id="59946" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="59946" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50704011000036109-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50704011000036109-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:23+10:00" modified="2018-06-15T10:34:27+10:00" title="BANDAGE RETENTION COHESIVE HEAVY"><displaytitle>BANDAGE RETENTION COHESIVE HEAVY</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50704011000036109" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106411" title="R1" type="none" forwardtype="embed" forwardtitle="BANDAGE RETENTION COHESIVE HEAVY" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59946-50704011000036109-1"><fragment id="59946-50704011000036109-1"><block label="DrugName">BANDAGE RETENTION COHESIVE HEAVY<inline label="genericindexfield">XE "BANDAGE RETENTION COHESIVE HEAVY"</inline></block></fragment></section><section id="59946-4813H"><fragment id="59946-4813H"><block label="FormAndStrength">bandage retention cohesive heavy 10 cm x 1.3 m bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4813H<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>23.83</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Peg 7423 [MM]<inline label="genericindexfieldbrand"><italic>XE "Peg 7423(MM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59946-4811F"><fragment id="59946-4811F"><block label="FormAndStrength">bandage retention cohesive heavy 5 cm x 1.3 m bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4811F<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>17.69</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Peg 7420 [MM]<inline label="genericindexfieldbrand"><italic>XE "Peg 7420(MM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59946-4814J"><fragment id="59946-4814J"><block label="FormAndStrength">bandage retention cohesive heavy 15 cm x 1.3 m bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4814J<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>30.01</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Peg 7425 [MM]<inline label="genericindexfieldbrand"><italic>XE "Peg 7425(MM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59946-4812G"><fragment id="59946-4812G"><block label="FormAndStrength">bandage retention cohesive heavy 7.5 cm x 1.3 m bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4812G<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>20.55</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Peg 7422 [MM]<inline label="genericindexfieldbrand"><italic>XE "Peg 7422(MM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59946-4660G"><fragment id="59946-4660G"><block label="FormAndStrength">bandage retention cohesive heavy 10 cm x 2 m bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4660G<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>22.35</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Coban 1584 [MM]<inline label="genericindexfieldbrand"><italic>XE "Coban 1584(MM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50748011000036107"><xref-fragment id="60316-V07AY50748011000036107"><blockxref id="106414" title="BANDAGE RETENTION COHESIVE LIGHT" frag="default" reversefrag="V07AY50748011000036107" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60889" href="dynamic/R1/drug/50748011000036107-V07AY.psml" urititle="BANDAGE RETENTION COHESIVE LIGHT" mediatype="application/vnd.pageseeder.psml+xml"><document id="60889" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60889" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50748011000036107-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50748011000036107-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:33+10:00" modified="2018-06-15T10:34:27+10:00" title="BANDAGE RETENTION COHESIVE LIGHT"><displaytitle>BANDAGE RETENTION COHESIVE LIGHT</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50748011000036107" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106414" title="R1" type="none" forwardtype="embed" forwardtitle="BANDAGE RETENTION COHESIVE LIGHT" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60889-50748011000036107-1"><fragment id="60889-50748011000036107-1"><block label="DrugName">BANDAGE RETENTION COHESIVE LIGHT<inline label="genericindexfield">XE "BANDAGE RETENTION COHESIVE LIGHT"</inline></block></fragment></section><section id="60889-4662J"><fragment id="60889-4662J"><block label="FormAndStrength">bandage retention cohesive light 10 cm x 2 m bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4662J<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>33.47</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Handygauze Cohesive 8635 [BV]<inline label="genericindexfieldbrand"><italic>XE "Handygauze Cohesive 8635(BV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60889-4718H"><fragment id="60889-4718H"><block label="FormAndStrength">bandage retention cohesive light 2.5 cm x 2 m bandage, 2</block><table role="R1"><row><cell><block label="DrugItemCode">4718H<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.23</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Handygauze Cohesive 8631 [BV]<inline label="genericindexfieldbrand"><italic>XE "Handygauze Cohesive 8631(BV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60889-4719J"><fragment id="60889-4719J"><block label="FormAndStrength">bandage retention cohesive light 6 cm x 2 m bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4719J<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>19.61</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Handygauze Cohesive 8633 [BV]<inline label="genericindexfieldbrand"><italic>XE "Handygauze Cohesive 8633(BV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50725011000036104"><xref-fragment id="60316-V07AY50725011000036104"><blockxref id="106410" title="BANDAGE RETENTION COTTON CREPE" frag="default" reversefrag="V07AY50725011000036104" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60697" href="dynamic/R1/drug/50725011000036104-V07AY.psml" urititle="BANDAGE RETENTION COTTON CREPE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60697" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60697" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50725011000036104-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50725011000036104-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:31+10:00" modified="2018-06-15T10:34:27+10:00" title="BANDAGE RETENTION COTTON CREPE"><displaytitle>BANDAGE RETENTION COTTON CREPE</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50725011000036104" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106410" title="R1" type="none" forwardtype="embed" forwardtitle="BANDAGE RETENTION COTTON CREPE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60697-50725011000036104-1"><fragment id="60697-50725011000036104-1"><block label="DrugName">BANDAGE RETENTION COTTON CREPE<inline label="genericindexfield">XE "BANDAGE RETENTION COTTON CREPE"</inline></block></fragment></section><section id="60697-4729X"><fragment id="60697-4729X"><block label="FormAndStrength">bandage retention cotton crepe 10 cm x 2.3 m bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4729X<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>27.57</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Telfa 8254F [KE]<inline label="genericindexfieldbrand"><italic>XE "Telfa 8254F(KE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>33.01</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tensocrepe 36301001 [BV]<inline label="genericindexfieldbrand"><italic>XE "Tensocrepe 36301001(BV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60697-4728W"><fragment id="60697-4728W"><block label="FormAndStrength">bandage retention cotton crepe 7.5 cm x 2.3 m bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4728W<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>24.83</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Telfa 8253F [KE]<inline label="genericindexfieldbrand"><italic>XE "Telfa 8253F(KE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>27.87</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tensocrepe 36307501 [BV]<inline label="genericindexfieldbrand"><italic>XE "Tensocrepe 36307501(BV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60697-4727T"><fragment id="60697-4727T"><block label="FormAndStrength">bandage retention cotton crepe 5 cm x 2.3 m bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4727T<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>20.65</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Telfa 8252F [KE]<inline label="genericindexfieldbrand"><italic>XE "Telfa 8252F(KE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>23.31</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tensocrepe 36300501 [BV]<inline label="genericindexfieldbrand"><italic>XE "Tensocrepe 36300501(BV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50697011000036107"><xref-fragment id="60316-V07AY50697011000036107"><blockxref id="106415" title="BANDAGE TUBULAR" frag="default" reversefrag="V07AY50697011000036107" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60865" href="dynamic/R1/drug/50697011000036107-V07AY.psml" urititle="BANDAGE TUBULAR" mediatype="application/vnd.pageseeder.psml+xml"><document id="60865" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60865" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50697011000036107-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50697011000036107-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:27+10:00" title="BANDAGE TUBULAR"><displaytitle>BANDAGE TUBULAR</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50697011000036107" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106415" title="R1" type="none" forwardtype="embed" forwardtitle="BANDAGE TUBULAR" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60865-50697011000036107-1"><fragment id="60865-50697011000036107-1"><block label="DrugName">BANDAGE TUBULAR<inline label="genericindexfield">XE "BANDAGE TUBULAR"</inline></block></fragment></section><section id="60865-4665M"><fragment id="60865-4665M"><block label="FormAndStrength">bandage tubular size E (35 cm to 45 cm) straight bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4665M<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.89</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Elastoplast 2227 [BE]<inline label="genericindexfieldbrand"><italic>XE "Elastoplast 2227(BE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60865-4664L"><fragment id="60865-4664L"><block label="FormAndStrength">bandage tubular size D (25 cm to 43 cm) straight bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4664L<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.89</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Elastoplast 2226 [BE]<inline label="genericindexfieldbrand"><italic>XE "Elastoplast 2226(BE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60865-4663K"><fragment id="60865-4663K"><block label="FormAndStrength">bandage tubular size C (15 cm to 25 cm) straight bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4663K<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.89</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Elastoplast 2225 [BE]<inline label="genericindexfieldbrand"><italic>XE "Elastoplast 2225(BE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60865-50697011000036107-2"><fragment id="60865-50697011000036107-2"><block label="DrugName">BANDAGE TUBULAR<inline label="genericindexfield">XE "BANDAGE TUBULAR"</inline></block></fragment></section><section id="60865-d4788e17"><fragment id="60865-d4788e17"><block label="NoteText"><para>Molnlycke Health Care products are distributed through leading pharmacy distributors. To best ensure product availability at the RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email: customerservice@independenceaustralia.com. Molnlycke Health Care is not able to ensure product availability or pricing on listed products beyond these two suppliers.</para></block></fragment></section><section id="60865-4858Q"><fragment id="60865-4858Q"><block label="FormAndStrength">bandage tubular 8.75 cm x 1 m bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4858Q<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.53</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tubigrip E 1547 [MH]<inline label="genericindexfieldbrand"><italic>XE "Tubigrip E 1547(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60865-4855M"><fragment id="60865-4855M"><block label="FormAndStrength">bandage tubular 6.25 cm x 1 m bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4855M<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.53</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tubigrip B 1520 [MH]<inline label="genericindexfieldbrand"><italic>XE "Tubigrip B 1520(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60865-4856N"><fragment id="60865-4856N"><block label="FormAndStrength">bandage tubular 6.75 cm x 1 m bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4856N<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.53</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tubigrip C 1545 [MH]<inline label="genericindexfieldbrand"><italic>XE "Tubigrip C 1545(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60865-4857P"><fragment id="60865-4857P"><block label="FormAndStrength">bandage tubular 7.5 cm x 1 m bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4857P<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.53</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tubigrip D 1546 [MH]<inline label="genericindexfieldbrand"><italic>XE "Tubigrip D 1546(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60865-4859R"><fragment id="60865-4859R"><block label="FormAndStrength">bandage tubular 10 cm x 1 m bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4859R<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.53</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tubigrip F 1548 [MH]<inline label="genericindexfieldbrand"><italic>XE "Tubigrip F 1548(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50768011000036103"><xref-fragment id="60316-V07AY50768011000036103"><blockxref id="106407" title="BANDAGE TUBULAR FINGER" frag="default" reversefrag="V07AY50768011000036103" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60469" href="dynamic/R1/drug/50768011000036103-V07AY.psml" urititle="BANDAGE TUBULAR FINGER" mediatype="application/vnd.pageseeder.psml+xml"><document id="60469" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60469" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50768011000036103-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50768011000036103-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:27+10:00" title="BANDAGE TUBULAR FINGER"><displaytitle>BANDAGE TUBULAR FINGER</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50768011000036103" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106407" title="R1" type="none" forwardtype="embed" forwardtitle="BANDAGE TUBULAR FINGER" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60469-50768011000036103-1"><fragment id="60469-50768011000036103-1"><block label="DrugName">BANDAGE TUBULAR FINGER<inline label="genericindexfield">XE "BANDAGE TUBULAR FINGER"</inline></block></fragment></section><section id="60469-4798M"><fragment id="60469-4798M"><block label="FormAndStrength">BANDAGE-TUBULAR (FINGER) Complete pack including applicator, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4798M<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">20.96</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tubegauz 0501633 [SS]<inline label="genericindexfieldbrand"><italic>XE "Tubegauz 0501633(SS)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50703011000036107"><xref-fragment id="60316-V07AY50703011000036107"><blockxref id="106428" title="BANDAGE TUBULAR LIGHT WEIGHT" frag="default" reversefrag="V07AY50703011000036107" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59891" href="dynamic/R1/drug/50703011000036107-V07AY.psml" urititle="BANDAGE TUBULAR LIGHT WEIGHT" mediatype="application/vnd.pageseeder.psml+xml"><document id="59891" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="59891" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50703011000036107-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50703011000036107-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:27+10:00" title="BANDAGE TUBULAR LIGHT WEIGHT"><displaytitle>BANDAGE TUBULAR LIGHT WEIGHT</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50703011000036107" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106428" title="R1" type="none" forwardtype="embed" forwardtitle="BANDAGE TUBULAR LIGHT WEIGHT" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59891-50703011000036107-1"><fragment id="59891-50703011000036107-1"><block label="DrugName">BANDAGE TUBULAR LIGHT WEIGHT<inline label="genericindexfield">XE "BANDAGE TUBULAR LIGHT WEIGHT"</inline></block></fragment></section><section id="59891-d4791e17"><fragment id="59891-d4791e17"><block label="NoteText"><para>Molnlycke Health Care products are distributed through leading pharmacy distributors. To best ensure product availability at the RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email: customerservice@independenceaustralia.com. Molnlycke Health Care is not able to ensure product availability or pricing on listed products beyond these two suppliers.</para></block></fragment></section><section id="59891-4673Y"><fragment id="59891-4673Y"><block label="FormAndStrength">bandage tubular light weight 10 m large limb size bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4673Y<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">29.97</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tubifast 2438 [MH]<inline label="genericindexfieldbrand"><italic>XE "Tubifast 2438(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59891-4672X"><fragment id="59891-4672X"><block label="FormAndStrength">bandage tubular light weight 10 m medium limb size bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4672X<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">28.74</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tubifast 2436 [MH]<inline label="genericindexfieldbrand"><italic>XE "Tubifast 2436(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59891-4671W"><fragment id="59891-4671W"><block label="FormAndStrength">bandage tubular light weight 10 m small limb size bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4671W<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">25.30</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tubifast 2434 [MH]<inline label="genericindexfieldbrand"><italic>XE "Tubifast 2434(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50728011000036105"><xref-fragment id="60316-V07AY50728011000036105"><blockxref id="106417" title="BANDAGE TUBULAR LONG STOCKING" frag="default" reversefrag="V07AY50728011000036105" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60399" href="dynamic/R1/drug/50728011000036105-V07AY.psml" urititle="BANDAGE TUBULAR LONG STOCKING" mediatype="application/vnd.pageseeder.psml+xml"><document id="60399" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60399" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50728011000036105-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50728011000036105-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:27+10:00" modified="2018-06-15T10:34:27+10:00" title="BANDAGE TUBULAR LONG STOCKING"><displaytitle>BANDAGE TUBULAR LONG STOCKING</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50728011000036105" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106417" title="R1" type="none" forwardtype="embed" forwardtitle="BANDAGE TUBULAR LONG STOCKING" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60399-50728011000036105-1"><fragment id="60399-50728011000036105-1"><block label="DrugName">BANDAGE TUBULAR LONG STOCKING<inline label="genericindexfield">XE "BANDAGE TUBULAR LONG STOCKING"</inline></block></fragment></section><section id="60399-d4793e17"><fragment id="60399-d4793e17"><block label="NoteText"><para>Molnlycke Health Care products are distributed through leading pharmacy distributors. To best ensure product availability at the RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email: customerservice@independenceaustralia.com. Molnlycke Health Care is not able to ensure product availability or pricing on listed products beyond these two suppliers.</para></block></fragment></section><section id="60399-4675C"><fragment id="60399-4675C"><block label="FormAndStrength">bandage tubular long stocking XX/large size bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4675C<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>37.81</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tubigrip 1486 [MH]<inline label="genericindexfieldbrand"><italic>XE "Tubigrip 1486(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60399-4674B"><fragment id="60399-4674B"><block label="FormAndStrength">bandage tubular long stocking small size bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4674B<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>37.79</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tubigrip 1482 [MH]<inline label="genericindexfieldbrand"><italic>XE "Tubigrip 1482(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60399-4799N"><fragment id="60399-4799N"><block label="FormAndStrength">bandage tubular long stocking large size bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4799N<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>37.79</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tubigrip 1484 [MH]<inline label="genericindexfieldbrand"><italic>XE "Tubigrip 1484(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60399-4797L"><fragment id="60399-4797L"><block label="FormAndStrength">bandage tubular long stocking medium size bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4797L<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>37.79</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tubigrip 1483 [MH]<inline label="genericindexfieldbrand"><italic>XE "Tubigrip 1483(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50724011000036103"><xref-fragment id="60316-V07AY50724011000036103"><blockxref id="106432" title="BANDAGE TUBULAR SHORT STOCKING" frag="default" reversefrag="V07AY50724011000036103" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60808" href="dynamic/R1/drug/50724011000036103-V07AY.psml" urititle="BANDAGE TUBULAR SHORT STOCKING" mediatype="application/vnd.pageseeder.psml+xml"><document id="60808" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60808" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50724011000036103-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50724011000036103-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:32+10:00" modified="2018-06-15T10:34:27+10:00" title="BANDAGE TUBULAR SHORT STOCKING"><displaytitle>BANDAGE TUBULAR SHORT STOCKING</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50724011000036103" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106432" title="R1" type="none" forwardtype="embed" forwardtitle="BANDAGE TUBULAR SHORT STOCKING" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60808-50724011000036103-1"><fragment id="60808-50724011000036103-1"><block label="DrugName">BANDAGE TUBULAR SHORT STOCKING<inline label="genericindexfield">XE "BANDAGE TUBULAR SHORT STOCKING"</inline></block></fragment></section><section id="60808-d4795e17"><fragment id="60808-d4795e17"><block label="NoteText"><para>Molnlycke Health Care products are distributed through leading pharmacy distributors. To best ensure product availability at the RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email: customerservice@independenceaustralia.com. Molnlycke Health Care is not able to ensure product availability or pricing on listed products beyond these two suppliers.</para></block></fragment></section><section id="60808-4816L"><fragment id="60808-4816L"><block label="FormAndStrength">bandage tubular short stocking large D/E size bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4816L<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>27.57</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tubigrip 1481 [MH]<inline label="genericindexfieldbrand"><italic>XE "Tubigrip 1481(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60808-4815K"><fragment id="60808-4815K"><block label="FormAndStrength">bandage tubular short stocking medium C/D size bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4815K<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>27.57</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tubigrip 1480 [MH]<inline label="genericindexfieldbrand"><italic>XE "Tubigrip 1480(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60808-4661H"><fragment id="60808-4661H"><block label="FormAndStrength">bandage tubular short stocking small B/C size bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4661H<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>27.57</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tubigrip 1479 [MH]<inline label="genericindexfieldbrand"><italic>XE "Tubigrip 1479(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50700011000036104"><xref-fragment id="60316-V07AY50700011000036104"><blockxref id="106446" title="BANDAGE ZINC PASTE" frag="default" reversefrag="V07AY50700011000036104" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59916" href="dynamic/R1/drug/50700011000036104-V07AY.psml" urititle="BANDAGE ZINC PASTE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59916" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="59916" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50700011000036104-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50700011000036104-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:27+10:00" title="BANDAGE ZINC PASTE"><displaytitle>BANDAGE ZINC PASTE</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50700011000036104" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106446" title="R1" type="none" forwardtype="embed" forwardtitle="BANDAGE ZINC PASTE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59916-50700011000036104-1"><fragment id="59916-50700011000036104-1"><block label="DrugName">BANDAGE ZINC PASTE<inline label="genericindexfield">XE "BANDAGE ZINC PASTE"</inline></block></fragment></section><section id="59916-d4797e17"><fragment id="59916-d4797e17"><block label="NoteText"><para>Used as an adjunct in the management of leg ulceration and associated eczema and skin conditions.</para></block></fragment></section><section id="59916-4670T"><fragment id="59916-4670T"><block label="FormAndStrength">bandage zinc paste 10 cm x 9.1 m bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4670T<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>30.53</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Flexidress 650941 [CC]<inline label="genericindexfieldbrand"><italic>XE "Flexidress 650941(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59916-50700011000036104-2"><fragment id="59916-50700011000036104-2"><block label="DrugName">BANDAGE ZINC PASTE<inline label="genericindexfield">XE "BANDAGE ZINC PASTE"</inline></block></fragment></section><section id="59916-d4799e17"><fragment id="59916-d4799e17"><block label="NoteText"><para>Used as an adjunct in the management of leg ulceration and associated eczema and skin conditions.</para></block></fragment></section><section id="59916-d4799e20"><fragment id="59916-d4799e20"><block label="NoteText"><para>Molnlycke Health Care products are distributed through leading pharmacy distributors. To best ensure product availability at the RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email: customerservice@independenceaustralia.com. Molnlycke Health Care is not able to ensure product availability or pricing on listed products beyond these two suppliers.</para></block></fragment></section><section id="59916-4669R"><fragment id="59916-4669R"><block label="FormAndStrength">bandage zinc paste 7.5 cm x 6 m bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4669R<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>31.29</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Steripaste 3610 [MH]<inline label="genericindexfieldbrand"><italic>XE "Steripaste 3610(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59916-50700011000036104-3"><fragment id="59916-50700011000036104-3"><block label="DrugName">BANDAGE ZINC PASTE<inline label="genericindexfield">XE "BANDAGE ZINC PASTE"</inline></block></fragment></section><section id="59916-d4801e17"><fragment id="59916-d4801e17"><block label="NoteText"><para>Used as an adjunct in the management of leg ulceration and associated eczema and skin conditions.</para></block></fragment></section><section id="59916-d4801e20"><fragment id="59916-d4801e20"><block label="NoteText"><para>Smith &amp; Nephew products are distributed via the three major wholesalers, API, Sigma &amp; Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith &amp; Nephew Customer Service on 13 13 60. Smith &amp; Nephew cannot ensure RPBS pricing from distributors other than those aforementioned.</para></block></fragment></section><section id="59916-4760M"><fragment id="59916-4760M"><block label="FormAndStrength">bandage zinc paste 80 cm (stockings) bandage, 4</block><table role="R1"><row><cell><block label="DrugItemCode">4760M<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">98.90</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">ZipZoc 66000747 [SN]<inline label="genericindexfieldbrand"><italic>XE "ZipZoc 66000747(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59916-4750B"><fragment id="59916-4750B"><block label="FormAndStrength">bandage zinc paste 7.5 cm x 6 m bandage, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4750B<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>86.29</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Viscopaste 4948 [SN]<inline label="genericindexfieldbrand"><italic>XE "Viscopaste 4948(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY111251000036105"><xref-fragment id="60316-V07AY111251000036105"><blockxref id="106422" title="BETAINE + POLYAMINOPROPYL BIGUANIDE" frag="default" reversefrag="V07AY111251000036105" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59633" href="dynamic/R1/drug/111251000036105-V07AY.psml" urititle="BETAINE + POLYAMINOPROPYL BIGUANIDE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59633" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="59633" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/111251000036105-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/111251000036105-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:19+10:00" modified="2018-06-15T10:34:27+10:00" title="BETAINE + POLYAMINOPROPYL BIGUANIDE"><displaytitle>BETAINE + POLYAMINOPROPYL BIGUANIDE</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY111251000036105" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106422" title="R1" type="none" forwardtype="embed" forwardtitle="BETAINE + POLYAMINOPROPYL BIGUANIDE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59633-111251000036105-1"><fragment id="59633-111251000036105-1"><block label="DrugName">BETAINE + POLYAMINOPROPYL BIGUANIDE<inline label="genericindexfield">XE "BETAINE + POLYAMINOPROPYL BIGUANIDE"</inline></block></fragment></section><section id="59633-2525X"><fragment id="59633-2525X"><block label="FormAndStrength">betaine 0.1% + polyaminopropyl biguanide 0.1% solution, 6 x 40 mL ampoules</block><table role="R1"><row><cell><block label="DrugItemCode">2525X<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">28.70</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Prontosan Wound Irrigation Solution [BR]<inline label="genericindexfieldbrand"><italic>XE "Prontosan Wound Irrigation Solution(BR)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY21550011000036106"><xref-fragment id="60316-V07AY21550011000036106"><blockxref id="106401" title="CADEXOMER-IODINE" frag="default" reversefrag="V07AY21550011000036106" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59775" href="dynamic/R1/drug/21550011000036106-V07AY.psml" urititle="CADEXOMER-IODINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59775" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="59775" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21550011000036106-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21550011000036106-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:27+10:00" title="CADEXOMER-IODINE"><displaytitle>CADEXOMER-IODINE</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY21550011000036106" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106401" title="R1" type="none" forwardtype="embed" forwardtitle="CADEXOMER-IODINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59775-21550011000036106-1"><fragment id="59775-21550011000036106-1"><block label="DrugName">CADEXOMER-IODINE<inline label="genericindexfield">XE "CADEXOMER-IODINE"</inline></block></fragment></section><section id="59775-d4804e17"><fragment id="59775-d4804e17"><block label="NoteText"><para>Suitable for yellow sloughy infected and malodorous wounds.</para></block></fragment></section><section id="59775-d4804e20"><fragment id="59775-d4804e20"><block label="NoteText"><para>Smith &amp; Nephew products are distributed via the three major wholesalers, API, Sigma and Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith &amp; Nephew Customer Service on 13 13 60. Smith &amp; Nephew cannot ensure RPBS agreed pricing from distributors other than those aforementioned.</para></block></fragment></section><section id="59775-4936T"><fragment id="59775-4936T"><block label="FormAndStrength">cadexomer-iodine 8 cm x 6 cm dressing, 3 x 10 g sheet</block><table role="R1"><row><cell><block label="DrugItemCode">4936T<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">165.18</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Iodosorb 66051340 [SN]<inline label="genericindexfieldbrand"><italic>XE "Iodosorb 66051340(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59775-4937W"><fragment id="59775-4937W"><block label="FormAndStrength">DRESSING with CADEXOMER IODINE Sheets 17 g (10 cm x 8 cm), 2, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4937W<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">173.84</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Iodosorb 66051360 [SN]<inline label="genericindexfieldbrand"><italic>XE "Iodosorb 66051360(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59775-4933P"><fragment id="59775-4933P"><block label="FormAndStrength">cadexomer-iodine 50% ointment, 2 x 20 g</block><table role="R1"><row><cell><block label="DrugItemCode">4933P<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">120.88</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Iodosorb Ointment 66051230 [SN]<inline label="genericindexfieldbrand"><italic>XE "Iodosorb Ointment 66051230(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59775-4931M"><fragment id="59775-4931M"><block label="FormAndStrength">cadexomer-iodine 3 g sterile dusting powder, 7 sachets</block><table role="R1"><row><cell><block label="DrugItemCode">4931M<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">77.25</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Iodosorb Powder 66051070 [SN]<inline label="genericindexfieldbrand"><italic>XE "Iodosorb Powder 66051070(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59775-4935R"><fragment id="59775-4935R"><block label="FormAndStrength">DRESSING with CADEXOMER IODINE Sheets 5 g (6 cm x 4 cm), 5, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4935R<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">115.50</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Iodosorb 66051330 [SN]<inline label="genericindexfieldbrand"><italic>XE "Iodosorb 66051330(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59775-4932N"><fragment id="59775-4932N"><block label="FormAndStrength">cadexomer-iodine 50% ointment, 4 x 10 g</block><table role="R1"><row><cell><block label="DrugItemCode">4932N<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">121.99</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Iodosorb Ointment 66051240 [SN]<inline label="genericindexfieldbrand"><italic>XE "Iodosorb Ointment 66051240(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50710011000036101"><xref-fragment id="60316-V07AY50710011000036101"><blockxref id="106431" title="DRESSING ACTIVATED CHARCOAL MALODOROUS WOUND" frag="default" reversefrag="V07AY50710011000036101" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="61066" href="dynamic/R1/drug/50710011000036101-V07AY.psml" urititle="DRESSING ACTIVATED CHARCOAL MALODOROUS WOUND" mediatype="application/vnd.pageseeder.psml+xml"><document id="61066" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="61066" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50710011000036101-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50710011000036101-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:34+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING ACTIVATED CHARCOAL MALODOROUS WOUND"><displaytitle>DRESSING ACTIVATED CHARCOAL MALODOROUS WOUND</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50710011000036101" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106431" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING ACTIVATED CHARCOAL MALODOROUS WOUND" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="61066-50710011000036101-1"><fragment id="61066-50710011000036101-1"><block label="DrugName">DRESSING ACTIVATED CHARCOAL MALODOROUS WOUND<inline label="genericindexfield">XE "DRESSING ACTIVATED CHARCOAL MALODOROUS WOUND"</inline></block></fragment></section><section id="61066-4742N"><fragment id="61066-4742N"><block label="FormAndStrength">dressing activated charcoal malodorous wound 10 cm x 10 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4742N<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">77.05</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">CarboFLEX 403202 [CC]<inline label="genericindexfieldbrand"><italic>XE "CarboFLEX 403202(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="61066-4743P"><fragment id="61066-4743P"><block label="FormAndStrength">dressing activated charcoal malodorous wound 15 cm x 20 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">4743P<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">86.95</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">CarboFLEX 403204 [CC]<inline label="genericindexfieldbrand"><italic>XE "CarboFLEX 403204(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="61066-4681J"><fragment id="61066-4681J"><block label="FormAndStrength">dressing activated charcoal malodorous wound 10.5 cm x 10.5 cm dressing, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4681J<br></br></block></cell><cell><block label="MaxQuantity">10</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>96.95</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Actisorb Plus MAP105 [KI]<inline label="genericindexfieldbrand"><italic>XE "Actisorb Plus MAP105(KI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50720011000036108"><xref-fragment id="60316-V07AY50720011000036108"><blockxref id="106441" title="DRESSING ALGINATE CAVITY WOUND" frag="default" reversefrag="V07AY50720011000036108" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60086" href="dynamic/R1/drug/50720011000036108-V07AY.psml" urititle="DRESSING ALGINATE CAVITY WOUND" mediatype="application/vnd.pageseeder.psml+xml"><document id="60086" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60086" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50720011000036108-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50720011000036108-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:24+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING ALGINATE CAVITY WOUND"><displaytitle>DRESSING ALGINATE CAVITY WOUND</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50720011000036108" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106441" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING ALGINATE CAVITY WOUND" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60086-50720011000036108-1"><fragment id="60086-50720011000036108-1"><block label="DrugName">DRESSING ALGINATE CAVITY WOUND<inline label="genericindexfield">XE "DRESSING ALGINATE CAVITY WOUND"</inline></block></fragment></section><section id="60086-d4807e17"><fragment id="60086-d4807e17"><block label="NoteText"><para>This dressing should be used only on moderately to heavily exuding wounds and should remain in place until saturated or for a maximum of 3 days.</para></block></fragment></section><section id="60086-4832H"><fragment id="60086-4832H"><block label="FormAndStrength">DRESSING-ALGINATE (CAVITY WOUND) Rope 2 g, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4832H<br></br></block></cell><cell><block label="MaxQuantity">10</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>104.45</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Sorbsan 1411 [UM]<inline label="genericindexfieldbrand"><italic>XE "Sorbsan 1411(UM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60086-1905G"><fragment id="60086-1905G"><block label="FormAndStrength">DRESSING-ALGINATE (CAVITY WOUND) Rope 2 g, 5</block><table role="R1"><row><cell><block label="DrugItemCode">1905G<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>110.03</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Kaltostat 168117 [CC]<inline label="genericindexfieldbrand"><italic>XE "Kaltostat 168117(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60086-50720011000036108-2"><fragment id="60086-50720011000036108-2"><block label="DrugName">DRESSING ALGINATE CAVITY WOUND<inline label="genericindexfield">XE "DRESSING ALGINATE CAVITY WOUND"</inline></block></fragment></section><section id="60086-d4809e17"><fragment id="60086-d4809e17"><block label="NoteText"><para>This dressing should be used only on moderately to heavily exuding wounds and should remain in place until saturated or for a maximum of 3 days.</para></block></fragment></section><section id="60086-d4809e20"><fragment id="60086-d4809e20"><block label="NoteText"><para>Coloplast dressings are available via a range of distributors. However, Coloplast's principal agreement to ensure correct RPBS Price to Pharmacy and ready supply has been secured with Independence Australia on 1300 788 855 and BrightSky on 1300 290 400. Please note that Coloplast is unable to guarantee ready supply or rebate for price differences on purchases outside these distributors.</para></block></fragment></section><section id="60086-4682K"><fragment id="60086-4682K"><block label="FormAndStrength">dressing alginate cavity wound 2 g (40 cm) rope, 6 x 2 g</block><table role="R1"><row><cell><block label="DrugItemCode">4682K<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>130.45</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Comfeel SeaSorb Filler 3740 [CT]<inline label="genericindexfieldbrand"><italic>XE "Comfeel SeaSorb Filler 3740(CT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50715011000036105"><xref-fragment id="60316-V07AY50715011000036105"><blockxref id="106392" title="DRESSING ALGINATE SUPERFICIAL WOUND" frag="default" reversefrag="V07AY50715011000036105" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60558" href="dynamic/R1/drug/50715011000036105-V07AY.psml" urititle="DRESSING ALGINATE SUPERFICIAL WOUND" mediatype="application/vnd.pageseeder.psml+xml"><document id="60558" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60558" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50715011000036105-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50715011000036105-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:29+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING ALGINATE SUPERFICIAL WOUND"><displaytitle>DRESSING ALGINATE SUPERFICIAL WOUND</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50715011000036105" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106392" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING ALGINATE SUPERFICIAL WOUND" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60558-50715011000036105-1"><fragment id="60558-50715011000036105-1"><block label="DrugName">DRESSING ALGINATE SUPERFICIAL WOUND<inline label="genericindexfield">XE "DRESSING ALGINATE SUPERFICIAL WOUND"</inline></block></fragment></section><section id="60558-d4811e17"><fragment id="60558-d4811e17"><block label="NoteText"><para>This dressing should be used only on moderately to heavily exuding wounds and should remain in place until saturated or for a maximum of 3 days.</para></block></fragment></section><section id="60558-4683L"><fragment id="60558-4683L"><block label="FormAndStrength">dressing alginate superficial wound 7.5 cm x 12 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4683L<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">88.05</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Kaltostat 168212 [CC]<inline label="genericindexfieldbrand"><italic>XE "Kaltostat 168212(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60558-50715011000036105-2"><fragment id="60558-50715011000036105-2"><block label="DrugName">DRESSING ALGINATE SUPERFICIAL WOUND<inline label="genericindexfield">XE "DRESSING ALGINATE SUPERFICIAL WOUND"</inline></block></fragment></section><section id="60558-d4813e17"><fragment id="60558-d4813e17"><block label="NoteText"><para>This dressing should be used only on moderately to heavily exuding wounds and should remain in place until saturated or for a maximum of 3 days.</para></block></fragment></section><section id="60558-d4813e20"><fragment id="60558-d4813e20"><block label="NoteText"><para>Smith &amp; Nephew products are distributed via the three major wholesalers, API, Sigma and Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith &amp; Nephew Customer Service on 13 13 60. Smith &amp; Nephew cannot ensure RPBS agreed pricing from distributors other than those aforementioned.</para></block></fragment></section><section id="60558-4700J"><fragment id="60558-4700J"><block label="FormAndStrength">dressing alginate superficial wound 10 cm x 10 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4700J<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">113.67</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Algisite M 66000520 [SN]<inline label="genericindexfieldbrand"><italic>XE "Algisite M 66000520(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60558-4699H"><fragment id="60558-4699H"><block label="FormAndStrength">dressing alginate superficial wound 5 cm x 5 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4699H<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">49.57</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Kaltostat 168210 [CC]<inline label="genericindexfieldbrand"><italic>XE "Kaltostat 168210(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">60.59</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Algisite M 66000519 [SN]<inline label="genericindexfieldbrand"><italic>XE "Algisite M 66000519(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60558-4691X"><fragment id="60558-4691X"><block label="FormAndStrength">dressing alginate superficial wound 15 cm x 20 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4691X<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">273.44</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Algisite M 66000521 [SN]<inline label="genericindexfieldbrand"><italic>XE "Algisite M 66000521(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60558-50715011000036105-3"><fragment id="60558-50715011000036105-3"><block label="DrugName">DRESSING ALGINATE SUPERFICIAL WOUND<inline label="genericindexfield">XE "DRESSING ALGINATE SUPERFICIAL WOUND"</inline></block></fragment></section><section id="60558-d4815e17"><fragment id="60558-d4815e17"><block label="NoteText"><para>This dressing should be used only on moderately to heavily exuding wounds and should remain in place until saturated or for a maximum of 3 days.</para></block></fragment></section><section id="60558-d4815e20"><fragment id="60558-d4815e20"><block label="NoteText"><para>Coloplast dressings are available via a range of distributors. However, Coloplast's principal agreement to ensure correct RPBS Price to Pharmacy and ready supply has been secured with Independence Australia on 1300 788 855 and BrightSky on 1300 290 400. Please note that Coloplast is unable to guarantee ready supply or rebate for price differences on purchases outside these distributors.</para></block></fragment></section><section id="60558-4684M"><fragment id="60558-4684M"><block label="FormAndStrength">dressing alginate superficial wound 5 cm x 5 cm dressing, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4684M<br></br></block></cell><cell><block label="MaxQuantity">10</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>47.05</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Comfeel SeaSorb Dressing 3705 [CT]<inline label="genericindexfieldbrand"><italic>XE "Comfeel SeaSorb Dressing 3705(CT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60558-4831G"><fragment id="60558-4831G"><block label="FormAndStrength">dressing alginate superficial wound 10 cm x 10 cm dressing, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4831G<br></br></block></cell><cell><block label="MaxQuantity">10</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>81.95</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Sorbsan 1410 [UM]<inline label="genericindexfieldbrand"><italic>XE "Sorbsan 1410(UM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>87.15</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Comfeel SeaSorb Dressing 3710 [CT]<inline label="genericindexfieldbrand"><italic>XE "Comfeel SeaSorb Dressing 3710(CT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY733051000168108"><xref-fragment id="60316-V07AY733051000168108"><blockxref id="106398" title="DRESSING ALGINATE WITH MANUKA HONEY" frag="default" reversefrag="V07AY733051000168108" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60424" href="dynamic/R1/drug/733051000168108-V07AY.psml" urititle="DRESSING ALGINATE WITH MANUKA HONEY" mediatype="application/vnd.pageseeder.psml+xml"><document id="60424" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60424" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/733051000168108-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/733051000168108-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING ALGINATE WITH MANUKA HONEY"><displaytitle>DRESSING ALGINATE WITH MANUKA HONEY</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY733051000168108" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106398" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING ALGINATE WITH MANUKA HONEY" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60424-733051000168108-1"><fragment id="60424-733051000168108-1"><block label="DrugName">DRESSING ALGINATE WITH MANUKA HONEY<inline label="genericindexfield">XE "DRESSING ALGINATE WITH MANUKA HONEY"</inline></block></fragment></section><section id="60424-d4817e17"><fragment id="60424-d4817e17"><block label="NoteText"><para>Suitable for yellow sloughy infected and malodorous wounds.</para></block></fragment></section><section id="60424-10849B"><fragment id="60424-10849B"><block label="FormAndStrength">dressing alginate with manuka honey 10 cm x 10 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">10849B<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">4</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">63.56</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Algivon Plus CR4225 [DJ]<inline label="genericindexfieldbrand"><italic>XE "Algivon Plus CR4225(DJ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60424-10857K"><fragment id="60424-10857K"><block label="FormAndStrength">dressing alginate with manuka honey 2.5 cm x 20 cm ribbon, 5</block><table role="R1"><row><cell><block label="DrugItemCode">10857K<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">4</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">114.85</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Algivon Plus Ribbon &amp; Probe CR4231 [DJ]<inline label="genericindexfieldbrand"><italic>XE "Algivon Plus Ribbon &amp; Probe CR4231(DJ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50711011000036108"><xref-fragment id="60316-V07AY50711011000036108"><blockxref id="106442" title="DRESSING FILM" frag="default" reversefrag="V07AY50711011000036108" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59830" href="dynamic/R1/drug/50711011000036108-V07AY.psml" urititle="DRESSING FILM" mediatype="application/vnd.pageseeder.psml+xml"><document id="59830" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="59830" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50711011000036108-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50711011000036108-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING FILM"><displaytitle>DRESSING FILM</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50711011000036108" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106442" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING FILM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59830-50711011000036108-1"><fragment id="59830-50711011000036108-1"><block label="DrugName">DRESSING FILM<inline label="genericindexfield">XE "DRESSING FILM"</inline></block></fragment></section><section id="59830-4687Q"><fragment id="59830-4687Q"><block label="FormAndStrength">dressing film 10 cm x 12 cm dressing, 4</block><table role="R1"><row><cell><block label="DrugItemCode">4687Q<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">22.59</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Nexcare Tegaderm Transparent H1626 [MM]<inline label="genericindexfieldbrand"><italic>XE "Nexcare Tegaderm Transparent H1626(MM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59830-4688R"><fragment id="59830-4688R"><block label="FormAndStrength">dressing film 15 cm x 20 cm dressing, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4688R<br></br></block></cell><cell><block label="MaxQuantity">6</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>32.17</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tegaderm Transparent 1628 [MM]<inline label="genericindexfieldbrand"><italic>XE "Tegaderm Transparent 1628(MM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59830-4686P"><fragment id="59830-4686P"><block label="FormAndStrength">dressing film 6 cm x 7 cm dressing, 8</block><table role="R1"><row><cell><block label="DrugItemCode">4686P<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">19.11</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Nexcare Tegaderm Transparent H1624 [MM]<inline label="genericindexfieldbrand"><italic>XE "Nexcare Tegaderm Transparent H1624(MM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59830-50711011000036108-2"><fragment id="59830-50711011000036108-2"><block label="DrugName">DRESSING FILM<inline label="genericindexfield">XE "DRESSING FILM"</inline></block></fragment></section><section id="59830-d4820e17"><fragment id="59830-d4820e17"><block label="NoteText"><para>Smith &amp; Nephew products are distributed via the three major wholesalers, API, Sigma and Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith &amp; Nephew Customer Service on 13 13 60. Smith &amp; Nephew cannot ensure RPBS agreed pricing from distributors other than those aforementioned.</para></block></fragment></section><section id="59830-4893M"><fragment id="59830-4893M"><block label="FormAndStrength">dressing film 10 cm x 12 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4893M<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">38.38</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Op-Site Flexigrid 4629 [SN]<inline label="genericindexfieldbrand"><italic>XE "Op-Site Flexigrid 4629(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50727011000036109"><xref-fragment id="60316-V07AY50727011000036109"><blockxref id="106413" title="DRESSING FILM ISLAND" frag="default" reversefrag="V07AY50727011000036109" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59927" href="dynamic/R1/drug/50727011000036109-V07AY.psml" urititle="DRESSING FILM ISLAND" mediatype="application/vnd.pageseeder.psml+xml"><document id="59927" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="59927" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50727011000036109-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50727011000036109-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING FILM ISLAND"><displaytitle>DRESSING FILM ISLAND</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50727011000036109" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106413" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING FILM ISLAND" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59927-50727011000036109-1"><fragment id="59927-50727011000036109-1"><block label="DrugName">DRESSING FILM ISLAND<inline label="genericindexfield">XE "DRESSING FILM ISLAND"</inline></block></fragment></section><section id="59927-4689T"><fragment id="59927-4689T"><block label="FormAndStrength">dressing film island 5 cm x 7 cm dressing, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4689T<br></br></block></cell><cell><block label="MaxQuantity">10</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>19.55</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tegaderm Transparent Island 3582 [MM]<inline label="genericindexfieldbrand"><italic>XE "Tegaderm Transparent Island 3582(MM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59927-4690W"><fragment id="59927-4690W"><block label="FormAndStrength">dressing film island 9 cm x 10 cm dressing, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4690W<br></br></block></cell><cell><block label="MaxQuantity">10</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>29.55</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tegaderm Transparent Island 3586 [MM]<inline label="genericindexfieldbrand"><italic>XE "Tegaderm Transparent Island 3586(MM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59927-50727011000036109-2"><fragment id="59927-50727011000036109-2"><block label="DrugName">DRESSING FILM ISLAND<inline label="genericindexfield">XE "DRESSING FILM ISLAND"</inline></block></fragment></section><section id="59927-d4823e17"><fragment id="59927-d4823e17"><block label="NoteText"><para>Smith &amp; Nephew products are distributed via the three major wholesalers, API, Sigma and Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith &amp; Nephew Customer Service on 13 13 60. Smith &amp; Nephew cannot ensure RPBS agreed pricing from distributors other than those aforementioned.</para></block></fragment></section><section id="59927-4899W"><fragment id="59927-4899W"><block label="FormAndStrength">dressing film island 8 cm x 10 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">4899W<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>49.21</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Cutifilm Plus 36361371 [SN]<inline label="genericindexfieldbrand"><italic>XE "Cutifilm Plus 36361371(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59927-4898T"><fragment id="59927-4898T"><block label="FormAndStrength">dressing film island 5 cm x 7.2 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">4898T<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>32.65</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Cutifilm Plus 36361370 [SN]<inline label="genericindexfieldbrand"><italic>XE "Cutifilm Plus 36361370(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50757011000036108"><xref-fragment id="60316-V07AY50757011000036108"><blockxref id="106394" title="DRESSING FOAM HEAVY EXUDATE" frag="default" reversefrag="V07AY50757011000036108" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60225" href="dynamic/R1/drug/50757011000036108-V07AY.psml" urititle="DRESSING FOAM HEAVY EXUDATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60225" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60225" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50757011000036108-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50757011000036108-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:26+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING FOAM HEAVY EXUDATE"><displaytitle>DRESSING FOAM HEAVY EXUDATE</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50757011000036108" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106394" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING FOAM HEAVY EXUDATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60225-50757011000036108-1"><fragment id="60225-50757011000036108-1"><block label="DrugName">DRESSING FOAM HEAVY EXUDATE<inline label="genericindexfield">XE "DRESSING FOAM HEAVY EXUDATE"</inline></block></fragment></section><section id="60225-d4825e17"><fragment id="60225-d4825e17"><block label="NoteText"><para>This dressing should remain in place until saturated or up to a maximum of 7 days. Allow a minimum of 2 cm to 3 cm in excess of the wound size of the dressing around the wound.</para></block></fragment></section><section id="60225-d4825e20"><fragment id="60225-d4825e20"><block label="NoteText"><para>Smith &amp; Nephew products are distributed via the three major wholesalers, API, Sigma and Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith &amp; Nephew Customer Service on 13 13 60. Smith &amp; Nephew cannot ensure RPBS agreed pricing from distributors other than those aforementioned.</para></block></fragment></section><section id="60225-4795J"><fragment id="60225-4795J"><block label="FormAndStrength">dressing foam heavy exudate 10 cm x 10 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4795J<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">141.63</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Allevyn 66007637 [SN]<inline label="genericindexfieldbrand"><italic>XE "Allevyn 66007637(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50698011000036108"><xref-fragment id="60316-V07AY50698011000036108"><blockxref id="106412" title="DRESSING FOAM MODERATE EXUDATE" frag="default" reversefrag="V07AY50698011000036108" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60883" href="dynamic/R1/drug/50698011000036108-V07AY.psml" urititle="DRESSING FOAM MODERATE EXUDATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60883" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60883" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50698011000036108-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50698011000036108-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:33+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING FOAM MODERATE EXUDATE"><displaytitle>DRESSING FOAM MODERATE EXUDATE</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50698011000036108" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106412" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING FOAM MODERATE EXUDATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60883-50698011000036108-1"><fragment id="60883-50698011000036108-1"><block label="DrugName">DRESSING FOAM MODERATE EXUDATE<inline label="genericindexfield">XE "DRESSING FOAM MODERATE EXUDATE"</inline></block></fragment></section><section id="60883-d4827e17"><fragment id="60883-d4827e17"><block label="NoteText"><para>Smith &amp; Nephew products are distributed via the three major wholesalers, API, Sigma and Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith &amp; Nephew Customer Service on 13 13 60. Smith &amp; Nephew cannot ensure RPBS agreed pricing from distributors other than those aforementioned.</para></block></fragment></section><section id="60883-4694C"><fragment id="60883-4694C"><block label="FormAndStrength">dressing foam moderate exudate cavity conforming foam, 20 g sachet</block><table role="R1"><row><cell><block label="DrugItemCode">4694C<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">98.92</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Cavicare 4563 [SN]<inline label="genericindexfieldbrand"><italic>XE "Cavicare 4563(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60883-50698011000036108-2"><fragment id="60883-50698011000036108-2"><block label="DrugName">DRESSING FOAM MODERATE EXUDATE<inline label="genericindexfield">XE "DRESSING FOAM MODERATE EXUDATE"</inline></block></fragment></section><section id="60883-d4829e17"><fragment id="60883-d4829e17"><block label="NoteText"><para>This dressing should remain in place until saturated or up to a maximum of 7 days. Allow a minimum of 2 cm to 3 cm in excess of the wound size of the dressing around the wound.</para></block></fragment></section><section id="60883-d4829e20"><fragment id="60883-d4829e20"><block label="NoteText"><para>Smith &amp; Nephew products are distributed via the three major wholesalers, API, Sigma and Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith &amp; Nephew Customer Service on 13 13 60. Smith &amp; Nephew cannot ensure RPBS agreed pricing from distributors other than those aforementioned.</para></block></fragment></section><section id="60883-4590N"><fragment id="60883-4590N"><block label="FormAndStrength">dressing foam moderate exudate 12.5 cm x 12.5 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4590N<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">141.33</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Allevyn Adhesive 66000044 [SN]<inline label="genericindexfieldbrand"><italic>XE "Allevyn Adhesive 66000044(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY157031000036107"><xref-fragment id="60316-V07AY157031000036107"><blockxref id="106388" title="DRESSING FOAM WITH SILICONE" frag="default" reversefrag="V07AY157031000036107" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60149" href="dynamic/R1/drug/157031000036107-V07AY.psml" urititle="DRESSING FOAM WITH SILICONE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60149" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60149" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/157031000036107-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/157031000036107-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:25+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING FOAM WITH SILICONE"><displaytitle>DRESSING FOAM WITH SILICONE</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY157031000036107" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106388" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING FOAM WITH SILICONE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60149-157031000036107-1"><fragment id="60149-157031000036107-1"><block label="DrugName">DRESSING FOAM WITH SILICONE<inline label="genericindexfield">XE "DRESSING FOAM WITH SILICONE"</inline></block></fragment></section><section id="60149-d4831e17"><fragment id="60149-d4831e17"><block label="NoteText"><para>Smith &amp; Nephew products are distributed via the three major wholesalers, API, Sigma and Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith &amp; Nephew Customer Service on 13 13 60. Smith &amp; Nephew cannot ensure RPBS agreed pricing from distributors other than those aforementioned.</para></block></fragment></section><section id="60149-10021K"><fragment id="60149-10021K"><block label="FormAndStrength">dressing foam with silicone 21 cm x 21 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">10021K<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">232.10</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Allevyn Life 66801070 [SN]<inline label="genericindexfieldbrand"><italic>XE "Allevyn Life 66801070(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60149-10017F"><fragment id="60149-10017F"><block label="FormAndStrength">dressing foam with silicone 10.3 cm x 10.3 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">10017F<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">60.55</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Allevyn Life 66801067 [SN]<inline label="genericindexfieldbrand"><italic>XE "Allevyn Life 66801067(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60149-10029W"><fragment id="60149-10029W"><block label="FormAndStrength">dressing foam with silicone 12.9 cm x 12.9 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">10029W<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">85.30</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Allevyn Life 66801068 [SN]<inline label="genericindexfieldbrand"><italic>XE "Allevyn Life 66801068(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60149-10023M"><fragment id="60149-10023M"><block label="FormAndStrength">dressing foam with silicone 15.4 cm x 15.4 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">10023M<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">116.86</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Allevyn Life 66801069 [SN]<inline label="genericindexfieldbrand"><italic>XE "Allevyn Life 66801069(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY111231000036102"><xref-fragment id="60316-V07AY111231000036102"><blockxref id="106419" title="DRESSING FOAM WITH SILICONE AND SILVER" frag="default" reversefrag="V07AY111231000036102" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60324" href="dynamic/R1/drug/111231000036102-V07AY.psml" urititle="DRESSING FOAM WITH SILICONE AND SILVER" mediatype="application/vnd.pageseeder.psml+xml"><document id="60324" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60324" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/111231000036102-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/111231000036102-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:27+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING FOAM WITH SILICONE AND SILVER"><displaytitle>DRESSING FOAM WITH SILICONE AND SILVER</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY111231000036102" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106419" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING FOAM WITH SILICONE AND SILVER" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60324-111231000036102-1"><fragment id="60324-111231000036102-1"><block label="DrugName">DRESSING FOAM WITH SILICONE AND SILVER<inline label="genericindexfield">XE "DRESSING FOAM WITH SILICONE AND SILVER"</inline></block></fragment></section><section id="60324-d4833e29"><fragment id="60324-d4833e29"><block label="NoteText"><para>Molnlycke Health Care products are distributed through leading pharmacy distributors. To best ensure product availability at the RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email: customerservice@independenceaustralia.com. Molnlycke Health Care is not able to ensure product availability or pricing on listed products beyond these two suppliers.</para></block></fragment></section><section id="60324-d4833e16"><fragment id="60324-d4833e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Wounds</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a wound where there is evidence of critical colonisation; OR</para></item><item><para>Patient must have a well-assessed chronic wound that has not responded to conventional dressings.</para></item></list></block></fragment></section><section id="60324-2439J"><fragment id="60324-2439J"><block label="FormAndStrength">dressing foam with silicone and silver 10 cm x 10 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">2439J<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">104.62</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Mepilex Ag [MH]<inline label="genericindexfieldbrand"><italic>XE "Mepilex Ag(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60324-2470B"><fragment id="60324-2470B"><block label="FormAndStrength">dressing foam with silicone and silver 10 cm x 10 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">2470B<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">111.67</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Mepilex Border Ag [MH]<inline label="genericindexfieldbrand"><italic>XE "Mepilex Border Ag(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50761011000036107"><xref-fragment id="60316-V07AY50761011000036107"><blockxref id="106426" title="DRESSING FOAM WITH SILICONE HEAVY EXUDATE" frag="default" reversefrag="V07AY50761011000036107" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60935" href="dynamic/R1/drug/50761011000036107-V07AY.psml" urititle="DRESSING FOAM WITH SILICONE HEAVY EXUDATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60935" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60935" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50761011000036107-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50761011000036107-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:33+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING FOAM WITH SILICONE HEAVY EXUDATE"><displaytitle>DRESSING FOAM WITH SILICONE HEAVY EXUDATE</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50761011000036107" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106426" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING FOAM WITH SILICONE HEAVY EXUDATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60935-50761011000036107-1"><fragment id="60935-50761011000036107-1"><block label="DrugName">DRESSING FOAM WITH SILICONE HEAVY EXUDATE<inline label="genericindexfield">XE "DRESSING FOAM WITH SILICONE HEAVY EXUDATE"</inline></block></fragment></section><section id="60935-d4835e17"><fragment id="60935-d4835e17"><block label="NoteText"><para>Smith &amp; Nephew products are distributed via the three major wholesalers, API, Sigma and Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith &amp; Nephew Customer Service on 13 13 60. Smith &amp; Nephew cannot ensure RPBS agreed pricing from distributors other than those aforementioned.</para></block></fragment></section><section id="60935-4196W"><fragment id="60935-4196W"><block label="FormAndStrength">dressing foam with silicone heavy exudate 10 cm x 10 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4196W<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">80.43</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Allevyn Gentle 66800248 [SN]<inline label="genericindexfieldbrand"><italic>XE "Allevyn Gentle 66800248(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60935-4230P"><fragment id="60935-4230P"><block label="FormAndStrength">dressing foam with silicone heavy exudate 10 cm x 10 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4230P<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">80.43</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Allevyn Gentle Border 66800270 [SN]<inline label="genericindexfieldbrand"><italic>XE "Allevyn Gentle Border 66800270(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60935-4207K"><fragment id="60935-4207K"><block label="FormAndStrength">dressing foam with silicone heavy exudate 7.5 cm x 7.5 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4207K<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">57.32</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Allevyn Gentle Border 66800269 [SN]<inline label="genericindexfieldbrand"><italic>XE "Allevyn Gentle Border 66800269(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60935-50761011000036107-2"><fragment id="60935-50761011000036107-2"><block label="DrugName">DRESSING FOAM WITH SILICONE HEAVY EXUDATE<inline label="genericindexfield">XE "DRESSING FOAM WITH SILICONE HEAVY EXUDATE"</inline></block></fragment></section><section id="60935-d4837e17"><fragment id="60935-d4837e17"><block label="NoteText"><para>Molnlycke Healthcare products are distributed through leading pharmacy distributors. To best ensure product availability at RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email customerservice@independenceaustralia.com. Molnlycke Healthcare are not able to ensure product availability or pricing on listed products beyond these two suppliers.</para></block></fragment></section><section id="60935-4643J"><fragment id="60935-4643J"><block label="FormAndStrength">dressing foam with silicone heavy exudate 10 cm x 10 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">4643J<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">42.85</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Mepilex Border 295300 [MH]<inline label="genericindexfieldbrand"><italic>XE "Mepilex Border 295300(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60935-4642H"><fragment id="60935-4642H"><block label="FormAndStrength">dressing foam with silicone heavy exudate 7.5 cm x 7.5 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">4642H<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">32.26</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Mepilex Border 295200 [MH]<inline label="genericindexfieldbrand"><italic>XE "Mepilex Border 295200(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50744011000036100"><xref-fragment id="60316-V07AY50744011000036100"><blockxref id="106443" title="DRESSING FOAM WITH SILICONE LIGHT EXUDATE" frag="default" reversefrag="V07AY50744011000036100" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59912" href="dynamic/R1/drug/50744011000036100-V07AY.psml" urititle="DRESSING FOAM WITH SILICONE LIGHT EXUDATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59912" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="59912" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50744011000036100-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50744011000036100-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:22+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING FOAM WITH SILICONE LIGHT EXUDATE"><displaytitle>DRESSING FOAM WITH SILICONE LIGHT EXUDATE</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50744011000036100" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106443" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING FOAM WITH SILICONE LIGHT EXUDATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59912-50744011000036100-1"><fragment id="59912-50744011000036100-1"><block label="DrugName">DRESSING FOAM WITH SILICONE LIGHT EXUDATE<inline label="genericindexfield">XE "DRESSING FOAM WITH SILICONE LIGHT EXUDATE"</inline></block></fragment></section><section id="59912-d4839e17"><fragment id="59912-d4839e17"><block label="NoteText"><para>Molnlycke Healthcare products are distributed through leading pharmacy distributors. To best ensure product availability at RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email customerservice@independenceaustralia.com. Molnlycke Healthcare are not able to ensure product availability or pricing on listed products beyond these two suppliers.</para></block></fragment></section><section id="59912-4645L"><fragment id="59912-4645L"><block label="FormAndStrength">dressing foam with silicone light exudate 10 cm x 10 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">4645L<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">38.73</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Mepilex Lite 284100 [MH]<inline label="genericindexfieldbrand"><italic>XE "Mepilex Lite 284100(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59912-4644K"><fragment id="59912-4644K"><block label="FormAndStrength">dressing foam with silicone light exudate 6 cm x 8.5 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">4644K<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">29.91</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Mepilex Lite 284000 [MH]<inline label="genericindexfieldbrand"><italic>XE "Mepilex Lite 284000(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50767011000036104"><xref-fragment id="60316-V07AY50767011000036104"><blockxref id="106433" title="DRESSING FOAM WITH SILICONE MODERATE EXUDATE" frag="default" reversefrag="V07AY50767011000036104" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59736" href="dynamic/R1/drug/50767011000036104-V07AY.psml" urititle="DRESSING FOAM WITH SILICONE MODERATE EXUDATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59736" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="59736" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50767011000036104-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50767011000036104-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:20+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING FOAM WITH SILICONE MODERATE EXUDATE"><displaytitle>DRESSING FOAM WITH SILICONE MODERATE EXUDATE</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50767011000036104" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106433" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING FOAM WITH SILICONE MODERATE EXUDATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59736-50767011000036104-1"><fragment id="59736-50767011000036104-1"><block label="DrugName">DRESSING FOAM WITH SILICONE MODERATE EXUDATE<inline label="genericindexfield">XE "DRESSING FOAM WITH SILICONE MODERATE EXUDATE"</inline></block></fragment></section><section id="59736-d4841e17"><fragment id="59736-d4841e17"><block label="NoteText"><para>Molnlycke Healthcare products are distributed through leading pharmacy distributors. To best ensure product availability at RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email customerservice@independenceaustralia.com. Molnlycke Healthcare are not able to ensure product availability or pricing on listed products beyond these two suppliers.</para></block></fragment></section><section id="59736-4626L"><fragment id="59736-4626L"><block label="FormAndStrength">dressing foam with silicone moderate exudate 10 cm x 10 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">4626L<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">42.85</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Mepilex 294100 [MH]<inline label="genericindexfieldbrand"><italic>XE "Mepilex 294100(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY933247641000036101"><xref-fragment id="60316-V07AY933247641000036101"><blockxref id="106409" title="DRESSING FOAM WITH SILVER" frag="default" reversefrag="V07AY933247641000036101" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59649" href="dynamic/R1/drug/933247641000036101-V07AY.psml" urititle="DRESSING FOAM WITH SILVER" mediatype="application/vnd.pageseeder.psml+xml"><document id="59649" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="59649" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/933247641000036101-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/933247641000036101-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:19+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING FOAM WITH SILVER"><displaytitle>DRESSING FOAM WITH SILVER</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY933247641000036101" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106409" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING FOAM WITH SILVER" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59649-933247641000036101-1"><fragment id="59649-933247641000036101-1"><block label="DrugName">DRESSING FOAM WITH SILVER<inline label="genericindexfield">XE "DRESSING FOAM WITH SILVER"</inline></block></fragment></section><section id="59649-d4843e29"><fragment id="59649-d4843e29"><block label="NoteText"><para>Smith &amp; Nephew products are distributed via the three major wholesalers, API, Sigma and Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith &amp; Nephew Customer Service on 13 13 60. Smith &amp; Nephew cannot ensure RPBS agreed pricing from distributors other than those aforementioned.</para></block></fragment></section><section id="59649-d4843e16"><fragment id="59649-d4843e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Wounds</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a wound where there is evidence of critical colonisation; OR</para></item><item><para>Patient must have a well-assessed chronic wound that has not responded to conventional dressings.</para></item></list></block></fragment></section><section id="59649-4255Y"><fragment id="59649-4255Y"><block label="FormAndStrength">dressing foam with silver 10 cm x 10 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4255Y<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">214.69</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Allevyn Ag Adhesive 66800075 [SN]<inline label="genericindexfieldbrand"><italic>XE "Allevyn Ag Adhesive 66800075(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59649-4259E"><fragment id="59649-4259E"><block label="FormAndStrength">dressing foam with silver 10 cm x 10 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4259E<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">218.86</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Allevyn Ag Non-Adhesive 66800086 [SN]<inline label="genericindexfieldbrand"><italic>XE "Allevyn Ag Non-Adhesive 66800086(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59649-4266M"><fragment id="59649-4266M"><block label="FormAndStrength">dressing foam with silver 10 cm x 10 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4266M<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">214.69</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Allevyn Ag Gentle Border 66800461 [SN]<inline label="genericindexfieldbrand"><italic>XE "Allevyn Ag Gentle Border 66800461(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59649-4252T"><fragment id="59649-4252T"><block label="FormAndStrength">dressing foam with silver 7.5 cm x 7.5 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4252T<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">145.29</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Allevyn Ag Adhesive 66800073 [SN]<inline label="genericindexfieldbrand"><italic>XE "Allevyn Ag Adhesive 66800073(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59649-4263J"><fragment id="59649-4263J"><block label="FormAndStrength">dressing foam with silver 7.5 cm x 7.5 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4263J<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">145.29</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Allevyn Ag Gentle Border 66800460 [SN]<inline label="genericindexfieldbrand"><italic>XE "Allevyn Ag Gentle Border 66800460(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59649-4258D"><fragment id="59649-4258D"><block label="FormAndStrength">dressing foam with silver 12.5 cm x 12.5 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4258D<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">267.18</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Allevyn Ag Adhesive 66800078 [SN]<inline label="genericindexfieldbrand"><italic>XE "Allevyn Ag Adhesive 66800078(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59649-4270R"><fragment id="59649-4270R"><block label="FormAndStrength">dressing foam with silver 12.5 cm x 12.5 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4270R<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">267.18</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Allevyn Ag Gentle Border 66800462 [SN]<inline label="genericindexfieldbrand"><italic>XE "Allevyn Ag Gentle Border 66800462(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50763011000036108"><xref-fragment id="60316-V07AY50763011000036108"><blockxref id="106439" title="DRESSING GAUZE ABSORBENT" frag="default" reversefrag="V07AY50763011000036108" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60654" href="dynamic/R1/drug/50763011000036108-V07AY.psml" urititle="DRESSING GAUZE ABSORBENT" mediatype="application/vnd.pageseeder.psml+xml"><document id="60654" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60654" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50763011000036108-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50763011000036108-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:30+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING GAUZE ABSORBENT"><displaytitle>DRESSING GAUZE ABSORBENT</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50763011000036108" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106439" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING GAUZE ABSORBENT" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60654-50763011000036108-1"><fragment id="60654-50763011000036108-1"><block label="DrugName">DRESSING GAUZE ABSORBENT<inline label="genericindexfield">XE "DRESSING GAUZE ABSORBENT"</inline></block></fragment></section><section id="60654-4708T"><fragment id="60654-4708T"><block label="FormAndStrength">dressing gauze absorbent 10 cm x 10 cm pad, 100</block><table role="R1"><row><cell><block label="DrugItemCode">4708T<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">32.42</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Handy 71117-06 [BV]<inline label="genericindexfieldbrand"><italic>XE "Handy 71117-06(BV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60654-4707R"><fragment id="60654-4707R"><block label="FormAndStrength">dressing gauze absorbent 5 cm x 5 cm pad, 100</block><table role="R1"><row><cell><block label="DrugItemCode">4707R<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.69</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Handy 71117-05 [BV]<inline label="genericindexfieldbrand"><italic>XE "Handy 71117-05(BV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY7601000144108"><xref-fragment id="60316-V07AY7601000144108"><blockxref id="106397" title="DRESSING GAUZE EYE" frag="default" reversefrag="V07AY7601000144108" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60015" href="dynamic/R1/drug/7601000144108-V07AY.psml" urititle="DRESSING GAUZE EYE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60015" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60015" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/7601000144108-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/7601000144108-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:23+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING GAUZE EYE"><displaytitle>DRESSING GAUZE EYE</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY7601000144108" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106397" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING GAUZE EYE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60015-7601000144108-1"><fragment id="60015-7601000144108-1"><block label="DrugName">DRESSING GAUZE EYE<inline label="genericindexfield">XE "DRESSING GAUZE EYE"</inline></block></fragment></section><section id="60015-4768Y"><fragment id="60015-4768Y"><block label="FormAndStrength">dressing gauze eye pad, 12 pads</block><table role="R1"><row><cell><block label="DrugItemCode">4768Y<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">16.66</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Curity 4112 [KE]<inline label="genericindexfieldbrand"><italic>XE "Curity 4112(KE)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50779011000036103"><xref-fragment id="60316-V07AY50779011000036103"><blockxref id="106389" title="DRESSING GAUZE PARAFFIN" frag="default" reversefrag="V07AY50779011000036103" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59598" href="dynamic/R1/drug/50779011000036103-V07AY.psml" urititle="DRESSING GAUZE PARAFFIN" mediatype="application/vnd.pageseeder.psml+xml"><document id="59598" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="59598" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50779011000036103-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50779011000036103-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:19+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING GAUZE PARAFFIN"><displaytitle>DRESSING GAUZE PARAFFIN</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50779011000036103" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106389" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING GAUZE PARAFFIN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59598-50779011000036103-1"><fragment id="59598-50779011000036103-1"><block label="DrugName">DRESSING GAUZE PARAFFIN<inline label="genericindexfield">XE "DRESSING GAUZE PARAFFIN"</inline></block></fragment></section><section id="59598-d4847e17"><fragment id="59598-d4847e17"><block label="NoteText"><para>Smith &amp; Nephew products are distributed via the three major wholesalers, API, Sigma and Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith &amp; Nephew Customer Service on 13 13 60. Smith &amp; Nephew cannot ensure RPBS agreed pricing from distributors other than those aforementioned.</para></block></fragment></section><section id="59598-4759L"><fragment id="59598-4759L"><block label="FormAndStrength">dressing gauze paraffin 10 cm x 10 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4759L<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">25.50</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Jelonet 7404 [SN]<inline label="genericindexfieldbrand"><italic>XE "Jelonet 7404(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50734011000036101"><xref-fragment id="60316-V07AY50734011000036101"><blockxref id="106444" title="DRESSING GAUZE PARAFFIN WITH CHLORHEXIDINE ACETATE" frag="default" reversefrag="V07AY50734011000036101" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60522" href="dynamic/R1/drug/50734011000036101-V07AY.psml" urititle="DRESSING GAUZE PARAFFIN WITH CHLORHEXIDINE ACETATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60522" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60522" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50734011000036101-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50734011000036101-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:29+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING GAUZE PARAFFIN WITH CHLORHEXIDINE ACETATE"><displaytitle>DRESSING GAUZE PARAFFIN WITH CHLORHEXIDINE ACETATE</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50734011000036101" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106444" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING GAUZE PARAFFIN WITH CHLORHEXIDINE ACETATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60522-50734011000036101-1"><fragment id="60522-50734011000036101-1"><block label="DrugName">DRESSING GAUZE PARAFFIN WITH CHLORHEXIDINE ACETATE<inline label="genericindexfield">XE "DRESSING GAUZE PARAFFIN WITH CHLORHEXIDINE ACETATE"</inline></block></fragment></section><section id="60522-d4849e17"><fragment id="60522-d4849e17"><block label="NoteText"><para>Smith &amp; Nephew products are distributed via the three major wholesalers, API, Sigma and Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith &amp; Nephew Customer Service on 13 13 60. Smith &amp; Nephew cannot ensure RPBS agreed pricing from distributors other than those aforementioned.</para></block></fragment></section><section id="60522-4845B"><fragment id="60522-4845B"><block label="FormAndStrength">dressing gauze paraffin with chlorhexidine acetate 10 cm x 10 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4845B<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">32.48</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Bactigras 7457 [SN]<inline label="genericindexfieldbrand"><italic>XE "Bactigras 7457(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50721011000036101"><xref-fragment id="60316-V07AY50721011000036101"><blockxref id="106429" title="DRESSING HYDROACTIVE DEBRIDEMENT" frag="default" reversefrag="V07AY50721011000036101" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60256" href="dynamic/R1/drug/50721011000036101-V07AY.psml" urititle="DRESSING HYDROACTIVE DEBRIDEMENT" mediatype="application/vnd.pageseeder.psml+xml"><document id="60256" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60256" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50721011000036101-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50721011000036101-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:26+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING HYDROACTIVE DEBRIDEMENT"><displaytitle>DRESSING HYDROACTIVE DEBRIDEMENT</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50721011000036101" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106429" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING HYDROACTIVE DEBRIDEMENT" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60256-50721011000036101-1"><fragment id="60256-50721011000036101-1"><block label="DrugName">DRESSING HYDROACTIVE DEBRIDEMENT<inline label="genericindexfield">XE "DRESSING HYDROACTIVE DEBRIDEMENT"</inline></block></fragment></section><section id="60256-d4851e17"><fragment id="60256-d4851e17"><block label="NoteText"><para>Hartmann wound dressings are available through HARTMANN and Independence Australia only. If you would like to order Hartmann Wound Care products, please call HARTMANN customer service on 1800 805 839 or Independence Australia on 1300 788 855.</para></block></fragment></section><section id="60256-4950M"><fragment id="60256-4950M"><block label="FormAndStrength">DRESSING-HYDROACTIVE (DEBRIDEMENT) Dressings 7.5 cm x 7.5 cm, 10, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4950M<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">110.02</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">TenderWet 24 Active 609213 [HR]<inline label="genericindexfieldbrand"><italic>XE "TenderWet 24 Active 609213(HR)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60256-4948K"><fragment id="60256-4948K"><block label="FormAndStrength">DRESSING-HYDROACTIVE (DEBRIDEMENT) Dressings 5.5 cm, 10, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4948K<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">84.28</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">TenderWet Active Cavity 609272 [HR]<inline label="genericindexfieldbrand"><italic>XE "TenderWet Active Cavity 609272(HR)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60256-4949L"><fragment id="60256-4949L"><block label="FormAndStrength">DRESSING-HYDROACTIVE (DEBRIDEMENT) Dressings 4 cm, 10, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4949L<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">82.42</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">TenderWet 24 Active 609210 [HR]<inline label="genericindexfieldbrand"><italic>XE "TenderWet 24 Active 609210(HR)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50713011000036109"><xref-fragment id="60316-V07AY50713011000036109"><blockxref id="106427" title="DRESSING HYDROACTIVE SUPERFICIAL WOUND HIGH EXUDATE SEMI-PERMEABLE ABSORBENT FOAM" frag="default" reversefrag="V07AY50713011000036109" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60366" href="dynamic/R1/drug/50713011000036109-V07AY.psml" urititle="DRESSING HYDROACTIVE SUPERFICIAL WOUND HIGH EXUDATE SEMI-PERMEABLE ABSORBENT FOAM" mediatype="application/vnd.pageseeder.psml+xml"><document id="60366" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60366" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50713011000036109-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50713011000036109-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:27+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING HYDROACTIVE SUPERFICIAL WOUND HIGH EXUDATE SEMI-PERMEABLE ABSORBENT FOAM"><displaytitle>DRESSING HYDROACTIVE SUPERFICIAL WOUND HIGH EXUDATE SEMI-PERMEABLE ABSORBENT FOAM</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50713011000036109" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106427" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING HYDROACTIVE SUPERFICIAL WOUND HIGH EXUDATE SEMI-PERMEABLE ABSORBENT FOAM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60366-50713011000036109-1"><fragment id="60366-50713011000036109-1"><block label="DrugName">DRESSING HYDROACTIVE SUPERFICIAL WOUND HIGH EXUDATE SEMI-PERMEABLE ABSORBENT FOAM<inline label="genericindexfield">XE "DRESSING HYDROACTIVE SUPERFICIAL WOUND HIGH EXUDATE SEMI-PERMEABLE ABSORBENT FOAM"</inline></block></fragment></section><section id="60366-4696E"><fragment id="60366-4696E"><block label="FormAndStrength">dressing hydroactive superficial wound high exudate semi-permeable absorbent foam 18 cm x 18 cm dressing: island, 5 dressings</block><table role="R1"><row><cell><block label="DrugItemCode">4696E<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">128.74</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tielle MTL103 [KI]<inline label="genericindexfieldbrand"><italic>XE "Tielle MTL103(KI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60366-4693B"><fragment id="60366-4693B"><block label="FormAndStrength">dressing hydroactive superficial wound high exudate semi-permeable absorbent foam 15 cm x 18 cm (foam alternative) dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">4693B<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">70.45</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">CombiDERM 651027 [CC]<inline label="genericindexfieldbrand"><italic>XE "CombiDERM 651027(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60366-4692Y"><fragment id="60366-4692Y"><block label="FormAndStrength">dressing hydroactive superficial wound high exudate semi-permeable absorbent foam 10 cm x 10 cm (foam alternative) dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4692Y<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">55.07</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">CombiDERM 651031 [CC]<inline label="genericindexfieldbrand"><italic>XE "CombiDERM 651031(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60366-4695D"><fragment id="60366-4695D"><block label="FormAndStrength">dressing hydroactive superficial wound high exudate semi-permeable absorbent foam 11 cm x 11 cm dressing: island, 10 dressings</block><table role="R1"><row><cell><block label="DrugItemCode">4695D<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">106.38</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Tielle MTL101E [KI]<inline label="genericindexfieldbrand"><italic>XE "Tielle MTL101E(KI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60366-50713011000036109-2"><fragment id="60366-50713011000036109-2"><block label="DrugName">DRESSING HYDROACTIVE SUPERFICIAL WOUND HIGH EXUDATE SEMI-PERMEABLE ABSORBENT FOAM<inline label="genericindexfield">XE "DRESSING HYDROACTIVE SUPERFICIAL WOUND HIGH EXUDATE SEMI-PERMEABLE ABSORBENT FOAM"</inline></block></fragment></section><section id="60366-d4854e17"><fragment id="60366-d4854e17"><block label="NoteText"><para>Coloplast dressings are available via a range of distributors. However, Coloplast's principal agreement to ensure correct RPBS Price to Pharmacy and ready supply has been secured with Independence Australia on 1300 788 855 and BrightSky on 1300 290 400. Please note that Coloplast is unable to guarantee ready supply or rebate for price differences on purchases outside these distributors.</para></block></fragment></section><section id="60366-4927H"><fragment id="60366-4927H"><block label="FormAndStrength">dressing hydroactive superficial wound high exudate semi-permeable absorbent foam 10 cm x 10 cm waterproof pad, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4927H<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">85.19</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Biatain Non-adhesive 3410 [CT]<inline label="genericindexfieldbrand"><italic>XE "Biatain Non-adhesive 3410(CT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60366-4928J"><fragment id="60366-4928J"><block label="FormAndStrength">dressing hydroactive superficial wound high exudate semi-permeable absorbent foam 15 cm x 15 cm waterproof pad, 5</block><table role="R1"><row><cell><block label="DrugItemCode">4928J<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">83.84</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Biatain Non-adhesive 3413 [CT]<inline label="genericindexfieldbrand"><italic>XE "Biatain Non-adhesive 3413(CT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60366-4929K"><fragment id="60366-4929K"><block label="FormAndStrength">dressing hydroactive superficial wound high exudate semi-permeable absorbent foam 12 cm x 12 cm waterproof pad, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4929K<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">93.39</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Biatain Adhesive 3420 [CT]<inline label="genericindexfieldbrand"><italic>XE "Biatain Adhesive 3420(CT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60366-4930L"><fragment id="60366-4930L"><block label="FormAndStrength">dressing hydroactive superficial wound high exudate semi-permeable absorbent foam 18 cm x 18 cm waterproof pad, 5</block><table role="R1"><row><cell><block label="DrugItemCode">4930L<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">90.54</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Biatain Adhesive 3423 [CT]<inline label="genericindexfieldbrand"><italic>XE "Biatain Adhesive 3423(CT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50765011000036109"><xref-fragment id="60316-V07AY50765011000036109"><blockxref id="106437" title="DRESSING HYDROACTIVE SUPERFICIAL WOUND LIGHT EXUDATE" frag="default" reversefrag="V07AY50765011000036109" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60103" href="dynamic/R1/drug/50765011000036109-V07AY.psml" urititle="DRESSING HYDROACTIVE SUPERFICIAL WOUND LIGHT EXUDATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60103" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60103" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50765011000036109-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50765011000036109-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:24+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING HYDROACTIVE SUPERFICIAL WOUND LIGHT EXUDATE"><displaytitle>DRESSING HYDROACTIVE SUPERFICIAL WOUND LIGHT EXUDATE</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50765011000036109" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106437" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING HYDROACTIVE SUPERFICIAL WOUND LIGHT EXUDATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60103-50765011000036109-1"><fragment id="60103-50765011000036109-1"><block label="DrugName">DRESSING HYDROACTIVE SUPERFICIAL WOUND LIGHT EXUDATE<inline label="genericindexfield">XE "DRESSING HYDROACTIVE SUPERFICIAL WOUND LIGHT EXUDATE"</inline></block></fragment></section><section id="60103-d4856e17"><fragment id="60103-d4856e17"><block label="NoteText"><para>Smith &amp; Nephew products are distributed via the three major wholesalers, API, Sigma and Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith &amp; Nephew Customer Service on 13 13 60. Smith &amp; Nephew cannot ensure RPBS agreed pricing from distributors other than those aforementioned.</para></block></fragment></section><section id="60103-4906F"><fragment id="60103-4906F"><block label="FormAndStrength">dressing hydroactive superficial wound light exudate 10 cm x 10 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">4906F<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>121.77</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Allevyn Thin 66047578 [SN]<inline label="genericindexfieldbrand"><italic>XE "Allevyn Thin 66047578(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60103-4905E"><fragment id="60103-4905E"><block label="FormAndStrength">dressing hydroactive superficial wound light exudate 5 cm x 6 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4905E<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">68.37</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Allevyn Thin 66047576 [SN]<inline label="genericindexfieldbrand"><italic>XE "Allevyn Thin 66047576(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50754011000036102"><xref-fragment id="60316-V07AY50754011000036102"><blockxref id="106430" title="DRESSING HYDROACTIVE SUPERFICIAL WOUND MODERATE EXUDATE" frag="default" reversefrag="V07AY50754011000036102" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59991" href="dynamic/R1/drug/50754011000036102-V07AY.psml" urititle="DRESSING HYDROACTIVE SUPERFICIAL WOUND MODERATE EXUDATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="59991" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="59991" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50754011000036102-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50754011000036102-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:23+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING HYDROACTIVE SUPERFICIAL WOUND MODERATE EXUDATE"><displaytitle>DRESSING HYDROACTIVE SUPERFICIAL WOUND MODERATE EXUDATE</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50754011000036102" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106430" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING HYDROACTIVE SUPERFICIAL WOUND MODERATE EXUDATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59991-50754011000036102-1"><fragment id="59991-50754011000036102-1"><block label="DrugName">DRESSING HYDROACTIVE SUPERFICIAL WOUND MODERATE EXUDATE<inline label="genericindexfield">XE "DRESSING HYDROACTIVE SUPERFICIAL WOUND MODERATE EXUDATE"</inline></block></fragment></section><section id="59991-d4858e17"><fragment id="59991-d4858e17"><block label="NoteText"><para>Smith &amp; Nephew products are distributed via the three major wholesalers, API, Sigma and Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith &amp; Nephew Customer Service on 13 13 60. Smith &amp; Nephew cannot ensure RPBS agreed pricing from distributors other than those aforementioned.</para></block></fragment></section><section id="59991-4886E"><fragment id="59991-4886E"><block label="FormAndStrength">dressing hydroactive superficial wound moderate exudate 10 cm x 10 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">4886E<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>92.49</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Cutinova Hydro 66047443 [SN]<inline label="genericindexfieldbrand"><italic>XE "Cutinova Hydro 66047443(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59991-4885D"><fragment id="59991-4885D"><block label="FormAndStrength">dressing hydroactive superficial wound moderate exudate 5 cm x 6 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4885D<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">56.44</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Cutinova Hydro 66047441 [SN]<inline label="genericindexfieldbrand"><italic>XE "Cutinova Hydro 66047441(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50740011000036105"><xref-fragment id="60316-V07AY50740011000036105"><blockxref id="106425" title="DRESSING HYDROCOLLOID CAVITY WOUND" frag="default" reversefrag="V07AY50740011000036105" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60914" href="dynamic/R1/drug/50740011000036105-V07AY.psml" urititle="DRESSING HYDROCOLLOID CAVITY WOUND" mediatype="application/vnd.pageseeder.psml+xml"><document id="60914" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60914" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50740011000036105-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50740011000036105-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:33+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING HYDROCOLLOID CAVITY WOUND"><displaytitle>DRESSING HYDROCOLLOID CAVITY WOUND</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50740011000036105" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106425" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING HYDROCOLLOID CAVITY WOUND" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60914-50740011000036105-1"><fragment id="60914-50740011000036105-1"><block label="DrugName">DRESSING HYDROCOLLOID CAVITY WOUND<inline label="genericindexfield">XE "DRESSING HYDROCOLLOID CAVITY WOUND"</inline></block></fragment></section><section id="60914-d4860e17"><fragment id="60914-d4860e17"><block label="NoteText"><para>This dressing should remain in place until saturated or strike through occurs for a maximum of 7 days.</para></block></fragment></section><section id="60914-4896Q"><fragment id="60914-4896Q"><block label="FormAndStrength">dressing hydrocolloid cavity wound paste, 30 g</block><table role="R1"><row><cell><block label="DrugItemCode">4896Q<br></br></block></cell><cell><block label="MaxQuantity">10</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>137.15</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">DuoDERM Paste 187930 [CC]<inline label="genericindexfieldbrand"><italic>XE "DuoDERM Paste 187930(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50714011000036106"><xref-fragment id="60316-V07AY50714011000036106"><blockxref id="106393" title="DRESSING HYDROCOLLOID SUPERFICIAL WOUND LIGHT EXUDATE" frag="default" reversefrag="V07AY50714011000036106" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60096" href="dynamic/R1/drug/50714011000036106-V07AY.psml" urititle="DRESSING HYDROCOLLOID SUPERFICIAL WOUND LIGHT EXUDATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60096" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60096" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50714011000036106-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50714011000036106-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:24+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING HYDROCOLLOID SUPERFICIAL WOUND LIGHT EXUDATE"><displaytitle>DRESSING HYDROCOLLOID SUPERFICIAL WOUND LIGHT EXUDATE</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50714011000036106" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106393" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING HYDROCOLLOID SUPERFICIAL WOUND LIGHT EXUDATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60096-50714011000036106-1"><fragment id="60096-50714011000036106-1"><block label="DrugName">DRESSING HYDROCOLLOID SUPERFICIAL WOUND LIGHT EXUDATE<inline label="genericindexfield">XE "DRESSING HYDROCOLLOID SUPERFICIAL WOUND LIGHT EXUDATE"</inline></block></fragment></section><section id="60096-d4862e17"><fragment id="60096-d4862e17"><block label="NoteText"><para>This dressing should be applied to a thickness of 3 mm to 5 mm. It should be covered with a hydrocolloid dressing and may be left in place for up to 7 days.</para></block></fragment></section><section id="60096-4907G"><fragment id="60096-4907G"><block label="FormAndStrength">dressing hydrocolloid superficial wound light exudate 10 cm x 10 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4907G<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">70.45</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">DuoDERM Extra Thin 187955 [CC]<inline label="genericindexfieldbrand"><italic>XE "DuoDERM Extra Thin 187955(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60096-50714011000036106-2"><fragment id="60096-50714011000036106-2"><block label="DrugName">DRESSING HYDROCOLLOID SUPERFICIAL WOUND LIGHT EXUDATE<inline label="genericindexfield">XE "DRESSING HYDROCOLLOID SUPERFICIAL WOUND LIGHT EXUDATE"</inline></block></fragment></section><section id="60096-d4864e17"><fragment id="60096-d4864e17"><block label="NoteText"><para>This dressing should be applied to a thickness of 3 mm to 5 mm. It should be covered with a hydrocolloid dressing and may be left in place for up to 7 days.</para></block></fragment></section><section id="60096-d4864e20"><fragment id="60096-d4864e20"><block label="NoteText"><para>Coloplast dressings are available via a range of distributors. However, Coloplast's principal agreement to ensure correct RPBS Price to Pharmacy and ready supply has been secured with Independence Australia on 1300 788 855 and BrightSky on 1300 290 400. Please note that Coloplast is unable to guarantee ready supply or rebate for price differences on purchases outside these distributors.</para></block></fragment></section><section id="60096-4889H"><fragment id="60096-4889H"><block label="FormAndStrength">dressing hydrocolloid superficial wound light exudate 9 cm x 14 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4889H<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">82.09</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Comfeel Plus Transparent 3536 [CT]<inline label="genericindexfieldbrand"><italic>XE "Comfeel Plus Transparent 3536(CT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60096-4924E"><fragment id="60096-4924E"><block label="FormAndStrength">dressing hydrocolloid superficial wound light exudate 10 cm x 10 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4924E<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">68.69</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Comfeel Plus Transparent 3533 [CT]<inline label="genericindexfieldbrand"><italic>XE "Comfeel Plus Transparent 3533(CT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60096-4888G"><fragment id="60096-4888G"><block label="FormAndStrength">dressing hydrocolloid superficial wound light exudate 5 cm x 7 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4888G<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">41.89</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Comfeel Plus Transparent 3530 [CT]<inline label="genericindexfieldbrand"><italic>XE "Comfeel Plus Transparent 3530(CT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60096-50714011000036106-3"><fragment id="60096-50714011000036106-3"><block label="DrugName">DRESSING HYDROCOLLOID SUPERFICIAL WOUND LIGHT EXUDATE<inline label="genericindexfield">XE "DRESSING HYDROCOLLOID SUPERFICIAL WOUND LIGHT EXUDATE"</inline></block></fragment></section><section id="60096-d4866e17"><fragment id="60096-d4866e17"><block label="NoteText"><para>This dressing should be applied to a thickness of 3 mm to 5 mm. It should be covered with a hydrocolloid dressing and may be left in place for up to 7 days.</para></block></fragment></section><section id="60096-d4866e20"><fragment id="60096-d4866e20"><block label="NoteText"><para>Hartmann wound dressings are available through HARTMANN and Independence Australia only. If you would like to order Hartmann Wound Care products, please call HARTMANN customer service on 1800 805 839 or Independence Australia on 1300 788 855.</para></block></fragment></section><section id="60096-4947J"><fragment id="60096-4947J"><block label="FormAndStrength">dressing hydrocolloid superficial wound light exudate 10 cm x 10 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4947J<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">48.32</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Hydrocoll Thin 900758 [HR]<inline label="genericindexfieldbrand"><italic>XE "Hydrocoll Thin 900758(HR)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50718011000036104"><xref-fragment id="60316-V07AY50718011000036104"><blockxref id="106396" title="DRESSING HYDROCOLLOID SUPERFICIAL WOUND MODERATE EXUDATE" frag="default" reversefrag="V07AY50718011000036104" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60715" href="dynamic/R1/drug/50718011000036104-V07AY.psml" urititle="DRESSING HYDROCOLLOID SUPERFICIAL WOUND MODERATE EXUDATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60715" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60715" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50718011000036104-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50718011000036104-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:31+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING HYDROCOLLOID SUPERFICIAL WOUND MODERATE EXUDATE"><displaytitle>DRESSING HYDROCOLLOID SUPERFICIAL WOUND MODERATE EXUDATE</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50718011000036104" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106396" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING HYDROCOLLOID SUPERFICIAL WOUND MODERATE EXUDATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60715-50718011000036104-1"><fragment id="60715-50718011000036104-1"><block label="DrugName">DRESSING HYDROCOLLOID SUPERFICIAL WOUND MODERATE EXUDATE<inline label="genericindexfield">XE "DRESSING HYDROCOLLOID SUPERFICIAL WOUND MODERATE EXUDATE"</inline></block></fragment></section><section id="60715-d4868e17"><fragment id="60715-d4868e17"><block label="NoteText"><para>This dressing should remain in place until saturated or strike through occurs for a maximum of 7 days.</para></block></fragment></section><section id="60715-4920Y"><fragment id="60715-4920Y"><block label="FormAndStrength">dressing hydrocolloid superficial wound moderate exudate 20 cm x 20 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">4920Y<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>209.61</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">DuoDERM CGF 187662 [CC]<inline label="genericindexfieldbrand"><italic>XE "DuoDERM CGF 187662(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60715-4897R"><fragment id="60715-4897R"><block label="FormAndStrength">dressing hydrocolloid superficial wound moderate exudate 10 cm x 10 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">4897R<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>79.25</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">DuoDERM CGF 187660 [CC]<inline label="genericindexfieldbrand"><italic>XE "DuoDERM CGF 187660(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60715-50718011000036104-2"><fragment id="60715-50718011000036104-2"><block label="DrugName">DRESSING HYDROCOLLOID SUPERFICIAL WOUND MODERATE EXUDATE<inline label="genericindexfield">XE "DRESSING HYDROCOLLOID SUPERFICIAL WOUND MODERATE EXUDATE"</inline></block></fragment></section><section id="60715-d4870e17"><fragment id="60715-d4870e17"><block label="NoteText"><para>This dressing should remain in place until saturated or strike through occurs for a maximum of 7 days.</para></block></fragment></section><section id="60715-d4870e20"><fragment id="60715-d4870e20"><block label="NoteText"><para>Smith &amp; Nephew products are distributed via the three major wholesalers, API, Sigma and Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith &amp; Nephew Customer Service on 13 13 60. Smith &amp; Nephew cannot ensure RPBS agreed pricing from distributors other than those aforementioned.</para></block></fragment></section><section id="60715-4921B"><fragment id="60715-4921B"><block label="FormAndStrength">dressing hydrocolloid superficial wound moderate exudate 10 cm x 10 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4921B<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">93.46</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Replicare Ultra 66000434 [SN]<inline label="genericindexfieldbrand"><italic>XE "Replicare Ultra 66000434(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60715-50718011000036104-3"><fragment id="60715-50718011000036104-3"><block label="DrugName">DRESSING HYDROCOLLOID SUPERFICIAL WOUND MODERATE EXUDATE<inline label="genericindexfield">XE "DRESSING HYDROCOLLOID SUPERFICIAL WOUND MODERATE EXUDATE"</inline></block></fragment></section><section id="60715-d4872e17"><fragment id="60715-d4872e17"><block label="NoteText"><para>This dressing should remain in place until saturated or strike through occurs for a maximum of 7 days.</para></block></fragment></section><section id="60715-d4872e20"><fragment id="60715-d4872e20"><block label="NoteText"><para>Hartmann wound dressings are available through HARTMANN and Independence Australia only. If you would like to order Hartmann Wound Care products, please call HARTMANN customer service on 1800 805 839 or Independence Australia on 1300 788 855.</para></block></fragment></section><section id="60715-4945G"><fragment id="60715-4945G"><block label="FormAndStrength">dressing hydrocolloid superficial wound moderate exudate 10 cm x 10 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4945G<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">48.32</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Hydrocoll 900744 [HR]<inline label="genericindexfieldbrand"><italic>XE "Hydrocoll 900744(HR)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60715-4946H"><fragment id="60715-4946H"><block label="FormAndStrength">dressing hydrocolloid superficial wound moderate exudate 15 cm x 15 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4946H<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">86.99</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Hydrocoll 900936 [HR]<inline label="genericindexfieldbrand"><italic>XE "Hydrocoll 900936(HR)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60715-50718011000036104-4"><fragment id="60715-50718011000036104-4"><block label="DrugName">DRESSING HYDROCOLLOID SUPERFICIAL WOUND MODERATE EXUDATE<inline label="genericindexfield">XE "DRESSING HYDROCOLLOID SUPERFICIAL WOUND MODERATE EXUDATE"</inline></block></fragment></section><section id="60715-d4874e17"><fragment id="60715-d4874e17"><block label="NoteText"><para>This dressing should remain in place until saturated or strike through occurs for a maximum of 7 days.</para></block></fragment></section><section id="60715-d4874e20"><fragment id="60715-d4874e20"><block label="NoteText"><para>Coloplast dressings are available via a range of distributors. However, Coloplast's principal agreement to ensure correct RPBS Price to Pharmacy and ready supply has been secured with Independence Australia on 1300 788 855 and BrightSky on 1300 290 400. Please note that Coloplast is unable to guarantee ready supply or rebate for price differences on purchases outside these distributors.</para></block></fragment></section><section id="60715-4678F"><fragment id="60715-4678F"><block label="FormAndStrength">dressing hydrocolloid superficial wound moderate exudate 7cm (butterfly shape) dressing, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4678F<br></br></block></cell><cell><block label="MaxQuantity">5</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>55.35</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Comfeel Plus Pressure Relieving 3350 [CT]<inline label="genericindexfieldbrand"><italic>XE "Comfeel Plus Pressure Relieving 3350(CT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60715-4923D"><fragment id="60715-4923D"><block label="FormAndStrength">DRESSING-HYDROCOLLOID (SUPERFICIAL WOUND-MODERATE EXUDATE) Dressings with alginate 10 cm x 10 cm, 10, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4923D<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">79.80</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Comfeel Plus Ulcer Dressing 3110 [CT]<inline label="genericindexfieldbrand"><italic>XE "Comfeel Plus Ulcer Dressing 3110(CT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60715-4679G"><fragment id="60715-4679G"><block label="FormAndStrength">dressing hydrocolloid superficial wound moderate exudate 10cm (round) dressing, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4679G<br></br></block></cell><cell><block label="MaxQuantity">5</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>59.45</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Comfeel Plus Pressure Relieving 3353 [CT]<inline label="genericindexfieldbrand"><italic>XE "Comfeel Plus Pressure Relieving 3353(CT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50717011000036100"><xref-fragment id="60316-V07AY50717011000036100"><blockxref id="106387" title="DRESSING HYDROFIBRE ALTERNATE TO ALGINATES" frag="default" reversefrag="V07AY50717011000036100" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60475" href="dynamic/R1/drug/50717011000036100-V07AY.psml" urititle="DRESSING HYDROFIBRE ALTERNATE TO ALGINATES" mediatype="application/vnd.pageseeder.psml+xml"><document id="60475" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60475" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50717011000036100-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50717011000036100-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING HYDROFIBRE ALTERNATE TO ALGINATES"><displaytitle>DRESSING HYDROFIBRE ALTERNATE TO ALGINATES</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50717011000036100" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106387" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING HYDROFIBRE ALTERNATE TO ALGINATES" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60475-50717011000036100-1"><fragment id="60475-50717011000036100-1"><block label="DrugName">DRESSING HYDROFIBRE ALTERNATE TO ALGINATES<inline label="genericindexfield">XE "DRESSING HYDROFIBRE ALTERNATE TO ALGINATES"</inline></block></fragment></section><section id="60475-10837J"><fragment id="60475-10837J"><block label="FormAndStrength">dressing hydrofibre alternate to alginates 10 cm x 10 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">10837J<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">120.20</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Aquacel Foam Non-Adhesive [CC]<inline label="genericindexfieldbrand"><italic>XE "Aquacel Foam Non-Adhesive(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60475-2797F"><fragment id="60475-2797F"><block label="FormAndStrength">dressing hydrofibre alternate to alginates 10 cm x 10 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">2797F<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">97.05</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Aquacel Extra 420672 [CC]<inline label="genericindexfieldbrand"><italic>XE "Aquacel Extra 420672(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60475-10832D"><fragment id="60475-10832D"><block label="FormAndStrength">dressing hydrofibre alternate to alginates 12.5 cm x 12.5 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">10832D<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">116.73</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Aquacel Foam Adhesive [CC]<inline label="genericindexfieldbrand"><italic>XE "Aquacel Foam Adhesive(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60475-4698G"><fragment id="60475-4698G"><block label="FormAndStrength">dressing hydrofibre alternate to alginates 2 g (30 cm) rope, 5 x 2 g</block><table role="R1"><row><cell><block label="DrugItemCode">4698G<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">81.35</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Aquacel 403770 [CC]<inline label="genericindexfieldbrand"><italic>XE "Aquacel 403770(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60475-2803M"><fragment id="60475-2803M"><block label="FormAndStrength">dressing hydrofibre alternate to alginates 15 cm x 15 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">2803M<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>195.51</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Aquacel Extra 420673 [CC]<inline label="genericindexfieldbrand"><italic>XE "Aquacel Extra 420673(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY282011000144106"><xref-fragment id="60316-V07AY282011000144106"><blockxref id="106395" title="DRESSING HYDROFIBRE GELLING FIBRE" frag="default" reversefrag="V07AY282011000144106" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60062" href="dynamic/R1/drug/282011000144106-V07AY.psml" urititle="DRESSING HYDROFIBRE GELLING FIBRE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60062" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60062" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/282011000144106-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/282011000144106-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:24+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING HYDROFIBRE GELLING FIBRE"><displaytitle>DRESSING HYDROFIBRE GELLING FIBRE</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY282011000144106" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106395" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING HYDROFIBRE GELLING FIBRE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60062-282011000144106-1"><fragment id="60062-282011000144106-1"><block label="DrugName">DRESSING HYDROFIBRE GELLING FIBRE<inline label="genericindexfield">XE "DRESSING HYDROFIBRE GELLING FIBRE"</inline></block></fragment></section><section id="60062-d4877e17"><fragment id="60062-d4877e17"><block label="NoteText"><para>Smith &amp; Nephew products are distributed via the three major wholesalers, API, Sigma and Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith &amp; Nephew Customer Service on 13 13 60. Smith &amp; Nephew cannot ensure RPBS agreed pricing from distributors other than those aforementioned.</para></block></fragment></section><section id="60062-2462N"><fragment id="60062-2462N"><block label="FormAndStrength">dressing hydrofibre gelling fibre 2 cm x 45 cm rope, 5</block><table role="R1"><row><cell><block label="DrugItemCode">2462N<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">87.24</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Durafiber 66800563 [SN]<inline label="genericindexfieldbrand"><italic>XE "Durafiber 66800563(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60062-2486W"><fragment id="60062-2486W"><block label="FormAndStrength">dressing hydrofibre gelling fibre 10 cm x 10 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">2486W<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">103.62</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Durafiber 66800560 [SN]<inline label="genericindexfieldbrand"><italic>XE "Durafiber 66800560(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60062-2445Q"><fragment id="60062-2445Q"><block label="FormAndStrength">dressing hydrofibre gelling fibre 15 cm x 15 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">2445Q<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>2</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>211.59</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Durafiber 66800561 [SN]<inline label="genericindexfieldbrand"><italic>XE "Durafiber 66800561(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY171041000036105"><xref-fragment id="60316-V07AY171041000036105"><blockxref id="106424" title="DRESSING HYDROFIBRE WITH SILVER" frag="default" reversefrag="V07AY171041000036105" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59990" href="dynamic/R1/drug/171041000036105-V07AY.psml" urititle="DRESSING HYDROFIBRE WITH SILVER" mediatype="application/vnd.pageseeder.psml+xml"><document id="59990" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="59990" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/171041000036105-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/171041000036105-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:23+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING HYDROFIBRE WITH SILVER"><displaytitle>DRESSING HYDROFIBRE WITH SILVER</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY171041000036105" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106424" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING HYDROFIBRE WITH SILVER" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59990-171041000036105-1"><fragment id="59990-171041000036105-1"><block label="DrugName">DRESSING HYDROFIBRE WITH SILVER<inline label="genericindexfield">XE "DRESSING HYDROFIBRE WITH SILVER"</inline></block></fragment></section><section id="59990-d4879e16"><fragment id="59990-d4879e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Wounds</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a wound where there is evidence of critical colonisation; OR</para></item><item><para>Patient must have a well-assessed chronic wound that has not responded to conventional dressings.</para></item></list></block></fragment></section><section id="59990-10105W"><fragment id="59990-10105W"><block label="FormAndStrength">dressing hydrofibre with silver 2 cm x 45 cm rope, 5</block><table role="R1"><row><cell><block label="DrugItemCode">10105W<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">211.81</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Aquacel Ag 403771 [CC]<inline label="genericindexfieldbrand"><italic>XE "Aquacel Ag 403771(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59990-10098L"><fragment id="59990-10098L"><block label="FormAndStrength">dressing hydrofibre with silver 15 cm x 15 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">10098L<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">268.39</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Aquacel Ag 403710 [CC]<inline label="genericindexfieldbrand"><italic>XE "Aquacel Ag 403710(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59990-10097K"><fragment id="59990-10097K"><block label="FormAndStrength">dressing hydrofibre with silver 10 cm x 10 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">10097K<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">250.75</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Aquacel Ag 403708 [CC]<inline label="genericindexfieldbrand"><italic>XE "Aquacel Ag 403708(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY111261000036108"><xref-fragment id="60316-V07AY111261000036108"><blockxref id="106390" title="DRESSING HYDROGEL" frag="default" reversefrag="V07AY111261000036108" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60636" href="dynamic/R1/drug/111261000036108-V07AY.psml" urititle="DRESSING HYDROGEL" mediatype="application/vnd.pageseeder.psml+xml"><document id="60636" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60636" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/111261000036108-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/111261000036108-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:30+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING HYDROGEL"><displaytitle>DRESSING HYDROGEL</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY111261000036108" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106390" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING HYDROGEL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60636-111261000036108-1"><fragment id="60636-111261000036108-1"><block label="DrugName">DRESSING HYDROGEL<inline label="genericindexfield">XE "DRESSING HYDROGEL"</inline></block></fragment></section><section id="60636-2471C"><fragment id="60636-2471C"><block label="FormAndStrength">dressing hydrogel 10 cm x 10 cm dressing, 20</block><table role="R1"><row><cell><block label="DrugItemCode">2471C<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">108.93</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Sorbact Absorption Dressing S98222 [QL]<inline label="genericindexfieldbrand"><italic>XE "Sorbact Absorption Dressing S98222(QL)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50771011000036102"><xref-fragment id="60316-V07AY50771011000036102"><blockxref id="106423" title="DRESSING HYDROGEL AMORPHOUS" frag="default" reversefrag="V07AY50771011000036102" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60451" href="dynamic/R1/drug/50771011000036102-V07AY.psml" urititle="DRESSING HYDROGEL AMORPHOUS" mediatype="application/vnd.pageseeder.psml+xml"><document id="60451" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60451" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50771011000036102-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50771011000036102-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING HYDROGEL AMORPHOUS"><displaytitle>DRESSING HYDROGEL AMORPHOUS</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50771011000036102" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106423" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING HYDROGEL AMORPHOUS" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60451-50771011000036102-1"><fragment id="60451-50771011000036102-1"><block label="DrugName">DRESSING HYDROGEL AMORPHOUS<inline label="genericindexfield">XE "DRESSING HYDROGEL AMORPHOUS"</inline></block></fragment></section><section id="60451-d4882e17"><fragment id="60451-d4882e17"><block label="NoteText"><para>This dressing should be applied to a thickness of 3 mm to 5 mm and remain in situ in infected wounds for 24 hours and in clean wounds for up to 3 days. It should be covered with a secondary dressing such as foam or film. It should not be covered with gauze or combine.</para></block></fragment></section><section id="60451-4914P"><fragment id="60451-4914P"><block label="FormAndStrength">dressing hydrogel amorphous gel, 50 g</block><table role="R1"><row><cell><block label="DrugItemCode">4914P<br></br></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>34.30</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Solugel 10336 [JJ]<inline label="genericindexfieldbrand"><italic>XE "Solugel 10336(JJ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60451-4913N"><fragment id="60451-4913N"><block label="FormAndStrength">dressing hydrogel amorphous gel, 3 x 30 g</block><table role="R1"><row><cell><block label="DrugItemCode">4913N<br></br></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>93.52</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">DuoDERM Gel H7987 [CC]<inline label="genericindexfieldbrand"><italic>XE "DuoDERM Gel H7987(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60451-50771011000036102-2"><fragment id="60451-50771011000036102-2"><block label="DrugName">DRESSING HYDROGEL AMORPHOUS<inline label="genericindexfield">XE "DRESSING HYDROGEL AMORPHOUS"</inline></block></fragment></section><section id="60451-d4884e17"><fragment id="60451-d4884e17"><block label="NoteText"><para>This dressing should be applied to a thickness of 3 mm to 5 mm and remain in situ in infected wounds for 24 hours and in clean wounds for up to 3 days. It should be covered with a secondary dressing such as foam or film. It should not be covered with gauze or combine.</para></block></fragment></section><section id="60451-d4884e20"><fragment id="60451-d4884e20"><block label="NoteText"><para>Coloplast dressings are available via a range of distributors. However, Coloplast's principal agreement to ensure correct RPBS Price to Pharmacy and ready supply has been secured with Independence Australia on 1300 788 855 and BrightSky on 1300 290 400. Please note that Coloplast is unable to guarantee ready supply or rebate for price differences on purchases outside these distributors.</para></block></fragment></section><section id="60451-4912M"><fragment id="60451-4912M"><block label="FormAndStrength">dressing hydrogel amorphous gel, 10 x 15 g</block><table role="R1"><row><cell><block label="DrugItemCode">4912M<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">63.87</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">DuoDERM Gel 187990 [CC]<inline label="genericindexfieldbrand"><italic>XE "DuoDERM Gel 187990(CC)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row><row><cell></cell><cell></cell><cell></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">70.79</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Comfeel Purilon Gel 3900 [CT]<inline label="genericindexfieldbrand"><italic>XE "Comfeel Purilon Gel 3900(CT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60451-50771011000036102-3"><fragment id="60451-50771011000036102-3"><block label="DrugName">DRESSING HYDROGEL AMORPHOUS<inline label="genericindexfield">XE "DRESSING HYDROGEL AMORPHOUS"</inline></block></fragment></section><section id="60451-d4886e17"><fragment id="60451-d4886e17"><block label="NoteText"><para>This dressing should be applied to a thickness of 3 mm to 5 mm and remain in situ in infected wounds for 24 hours and in clean wounds for up to 3 days. It should be covered with a secondary dressing such as foam or film. It should not be covered with gauze or combine.</para></block></fragment></section><section id="60451-d4886e20"><fragment id="60451-d4886e20"><block label="NoteText"><para>Smith &amp; Nephew products are distributed via the three major wholesalers, API, Sigma and Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith &amp; Nephew Customer Service on 13 13 60. Smith &amp; Nephew cannot ensure RPBS agreed pricing from distributors other than those aforementioned.</para></block></fragment></section><section id="60451-4599C"><fragment id="60451-4599C"><block label="FormAndStrength">dressing hydrogel amorphous gel, 50 g</block><table role="R1"><row><cell><block label="DrugItemCode">4599C<br></br></block></cell><cell><block label="MaxQuantity">3</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>35.62</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">SoloSite Gel 36361338 [SN]<inline label="genericindexfieldbrand"><italic>XE "SoloSite Gel 36361338(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60451-4894N"><fragment id="60451-4894N"><block label="FormAndStrength">dressing hydrogel amorphous gel, 25 g</block><table role="R1"><row><cell><block label="DrugItemCode">4894N<br></br></block></cell><cell><block label="MaxQuantity">4</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>73.31</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Intrasite Gel 7313 [SN]<inline label="genericindexfieldbrand"><italic>XE "Intrasite Gel 7313(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY282941000144106"><xref-fragment id="60316-V07AY282941000144106"><blockxref id="106404" title="DRESSING HYDROGEL FOAM" frag="default" reversefrag="V07AY282941000144106" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60946" href="dynamic/R1/drug/282941000144106-V07AY.psml" urititle="DRESSING HYDROGEL FOAM" mediatype="application/vnd.pageseeder.psml+xml"><document id="60946" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60946" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/282941000144106-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/282941000144106-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:33+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING HYDROGEL FOAM"><displaytitle>DRESSING HYDROGEL FOAM</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY282941000144106" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106404" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING HYDROGEL FOAM" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60946-282941000144106-1"><fragment id="60946-282941000144106-1"><block label="DrugName">DRESSING HYDROGEL FOAM<inline label="genericindexfield">XE "DRESSING HYDROGEL FOAM"</inline></block></fragment></section><section id="60946-2533H"><fragment id="60946-2533H"><block label="FormAndStrength">dressing hydrogel foam 10 cm x 10 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">2533H<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">77.48</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Sorbact Foam Dressing S98310 [QL]<inline label="genericindexfieldbrand"><italic>XE "Sorbact Foam Dressing S98310(QL)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY282751000144107"><xref-fragment id="60316-V07AY282751000144107"><blockxref id="106406" title="DRESSING HYDROGEL RIBBON" frag="default" reversefrag="V07AY282751000144107" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59741" href="dynamic/R1/drug/282751000144107-V07AY.psml" urititle="DRESSING HYDROGEL RIBBON" mediatype="application/vnd.pageseeder.psml+xml"><document id="59741" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="59741" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/282751000144107-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/282751000144107-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:20+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING HYDROGEL RIBBON"><displaytitle>DRESSING HYDROGEL RIBBON</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY282751000144107" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106406" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING HYDROGEL RIBBON" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59741-282751000144107-1"><fragment id="59741-282751000144107-1"><block label="DrugName">DRESSING HYDROGEL RIBBON<inline label="genericindexfield">XE "DRESSING HYDROGEL RIBBON"</inline></block></fragment></section><section id="59741-2512F"><fragment id="59741-2512F"><block label="FormAndStrength">dressing hydrogel ribbon 1 cm x 50 cm dressing, 20</block><table role="R1"><row><cell><block label="DrugItemCode">2512F<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">112.43</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Sorbact Ribbon Gauze S98118 [QL]<inline label="genericindexfieldbrand"><italic>XE "Sorbact Ribbon Gauze S98118(QL)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59741-2529D"><fragment id="59741-2529D"><block label="FormAndStrength">dressing hydrogel ribbon 5 cm x 200 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">2529D<br></br></block></cell><cell><block label="MaxQuantity">1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">108.93</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Sorbact Ribbon Gauze S98120 [QL]<inline label="genericindexfieldbrand"><italic>XE "Sorbact Ribbon Gauze S98120(QL)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50742011000036109"><xref-fragment id="60316-V07AY50742011000036109"><blockxref id="106447" title="DRESSING HYDROGEL SHEET" frag="default" reversefrag="V07AY50742011000036109" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60612" href="dynamic/R1/drug/50742011000036109-V07AY.psml" urititle="DRESSING HYDROGEL SHEET" mediatype="application/vnd.pageseeder.psml+xml"><document id="60612" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60612" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50742011000036109-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50742011000036109-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:30+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING HYDROGEL SHEET"><displaytitle>DRESSING HYDROGEL SHEET</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50742011000036109" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106447" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING HYDROGEL SHEET" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60612-50742011000036109-1"><fragment id="60612-50742011000036109-1"><block label="DrugName">DRESSING HYDROGEL SHEET<inline label="genericindexfield">XE "DRESSING HYDROGEL SHEET"</inline></block></fragment></section><section id="60612-d4890e17"><fragment id="60612-d4890e17"><block label="NoteText"><para>This dressing should be applied to a thickness of 3 mm to 5 mm and remain in situ in infected wounds for 24 hours and in clean wounds for up to 3 days. It should be covered with a secondary dressing such as foam or film. It should not be covered with gauze or combine.</para></block></fragment></section><section id="60612-4911L"><fragment id="60612-4911L"><block label="FormAndStrength">dressing hydrogel sheet 9.5 cm x 10.2 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">4911L<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>80.89</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Nu-Gel 2497 [KI]<inline label="genericindexfieldbrand"><italic>XE "Nu-Gel 2497(KI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60612-50742011000036109-2"><fragment id="60612-50742011000036109-2"><block label="DrugName">DRESSING HYDROGEL SHEET<inline label="genericindexfield">XE "DRESSING HYDROGEL SHEET"</inline></block></fragment></section><section id="60612-d4892e17"><fragment id="60612-d4892e17"><block label="NoteText"><para>This dressing should be applied to a thickness of 3 mm to 5 mm and remain in situ in infected wounds for 24 hours and in clean wounds for up to 3 days. It should be covered with a secondary dressing such as foam or film. It should not be covered with gauze or combine.</para></block></fragment></section><section id="60612-d4892e20"><fragment id="60612-d4892e20"><block label="NoteText"><para>Hartmann wound dressings are available through HARTMANN and Independence Australia only. If you would like to order Hartmann Wound Care products, please call HARTMANN customer service on 1800 805 839 or Independence Australia on 1300 788 855.</para></block></fragment></section><section id="60612-4806Y"><fragment id="60612-4806Y"><block label="FormAndStrength">dressing hydrogel sheet 10 cm x 10 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">4806Y<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>53.45</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Hydrosorb 900854 [HR]<inline label="genericindexfieldbrand"><italic>XE "Hydrosorb 900854(HR)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50699011000036100"><xref-fragment id="60316-V07AY50699011000036100"><blockxref id="106420" title="DRESSING NON ADHERENT" frag="default" reversefrag="V07AY50699011000036100" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="59781" href="dynamic/R1/drug/50699011000036100-V07AY.psml" urititle="DRESSING NON ADHERENT" mediatype="application/vnd.pageseeder.psml+xml"><document id="59781" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="59781" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50699011000036100-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50699011000036100-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:21+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING NON ADHERENT"><displaytitle>DRESSING NON ADHERENT</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50699011000036100" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106420" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING NON ADHERENT" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59781-50699011000036100-1"><fragment id="59781-50699011000036100-1"><block label="DrugName">DRESSING NON ADHERENT<inline label="genericindexfield">XE "DRESSING NON ADHERENT"</inline></block></fragment></section><section id="59781-d4894e17"><fragment id="59781-d4894e17"><block label="NoteText"><para>Molnlycke Healthcare products are distributed through leading pharmacy distributors. To best ensure product availability at RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email customerservice@independenceaustralia.com. Molnlycke Healthcare are not able to ensure product availability or pricing on listed products beyond these two suppliers.</para></block></fragment></section><section id="59781-4244J"><fragment id="59781-4244J"><block label="FormAndStrength">DRESSING SELF ADHESIVE NON-ADHERENT DRY ABSORBENT Dressings, non-woven, with silicone 7.5 cm x 10 cm, 10, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4244J<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">103.09</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Mepitel 290710 [MH]<inline label="genericindexfieldbrand"><italic>XE "Mepitel 290710(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59781-4243H"><fragment id="59781-4243H"><block label="FormAndStrength">DRESSING SELF ADHESIVE NON-ADHERENT DRY ABSORBENT Dressings, non-woven, with silicone 5 cm x 7.5 cm, 10, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4243H<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">63.09</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Mepitel 290510 [MH]<inline label="genericindexfieldbrand"><italic>XE "Mepitel 290510(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59781-50699011000036100-2"><fragment id="59781-50699011000036100-2"><block label="DrugName">DRESSING NON ADHERENT<inline label="genericindexfield">XE "DRESSING NON ADHERENT"</inline></block></fragment></section><section id="59781-d4896e17"><fragment id="59781-d4896e17"><block label="NoteText"><para>Hartmann wound dressings are available through HARTMANN and Independence Australia only. If you would like to order Hartmann Wound Care products, please call HARTMANN customer service on 1800 805 839 or Independence Australia on 1300 788 855.</para></block></fragment></section><section id="59781-4944F"><fragment id="59781-4944F"><block label="FormAndStrength">dressing non adherent 7.5 cm x 10 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4944F<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">18.76</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Atrauman 499513 [HR]<inline label="genericindexfieldbrand"><italic>XE "Atrauman 499513(HR)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59781-50699011000036100-3"><fragment id="59781-50699011000036100-3"><block label="DrugName">DRESSING NON ADHERENT<inline label="genericindexfield">XE "DRESSING NON ADHERENT"</inline></block></fragment></section><section id="59781-d4898e17"><fragment id="59781-d4898e17"><block label="NoteText"><para>Smith &amp; Nephew products are distributed via the three major wholesalers, API, Sigma and Symbion. To best ensure product availability at RPBS agreed prices, please order from one of these suppliers. In the event that your preferred wholesaler cannot supply, please contact Smith &amp; Nephew Customer Service on 13 13 60. Smith &amp; Nephew cannot ensure RPBS agreed pricing from distributors other than those aforementioned.</para></block></fragment></section><section id="59781-4862X"><fragment id="59781-4862X"><block label="FormAndStrength">dressing non adherent 10 cm x 10 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">4862X<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>28.93</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Cutilin Non-Stick Wound Pad 36361375 [SN]<inline label="genericindexfieldbrand"><italic>XE "Cutilin Non-Stick Wound Pad 36361375(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59781-4861W"><fragment id="59781-4861W"><block label="FormAndStrength">dressing non adherent 10 cm x 10 cm dressing, 10</block><table role="R1"><row><cell><block label="DrugItemCode">4861W<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">39.21</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Melolin 66974933 [SN]<inline label="genericindexfieldbrand"><italic>XE "Melolin 66974933(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59781-4819P"><fragment id="59781-4819P"><block label="FormAndStrength">dressing non adherent 5 cm x 5 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">4819P<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>19.89</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Cutilin Non-Stick Wound Pad 36361374 [SN]<inline label="genericindexfieldbrand"><italic>XE "Cutilin Non-Stick Wound Pad 36361374(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="59781-4860T"><fragment id="59781-4860T"><block label="FormAndStrength">dressing non adherent 5 cm x 5 cm dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">4860T<br></br></block></cell><cell><block label="MaxQuantity">2</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>21.13</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Melolin 36361357 [SN]<inline label="genericindexfieldbrand"><italic>XE "Melolin 36361357(SN)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY12941000144101"><xref-fragment id="60316-V07AY12941000144101"><blockxref id="106418" title="DRESSING TULLE NON GAUZE PARAFFIN" frag="default" reversefrag="V07AY12941000144101" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60912" href="dynamic/R1/drug/12941000144101-V07AY.psml" urititle="DRESSING TULLE NON GAUZE PARAFFIN" mediatype="application/vnd.pageseeder.psml+xml"><document id="60912" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60912" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/12941000144101-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/12941000144101-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:33+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING TULLE NON GAUZE PARAFFIN"><displaytitle>DRESSING TULLE NON GAUZE PARAFFIN</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY12941000144101" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106418" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING TULLE NON GAUZE PARAFFIN" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60912-12941000144101-1"><fragment id="60912-12941000144101-1"><block label="DrugName">DRESSING TULLE NON GAUZE PARAFFIN<inline label="genericindexfield">XE "DRESSING TULLE NON GAUZE PARAFFIN"</inline></block></fragment></section><section id="60912-4909J"><fragment id="60912-4909J"><block label="FormAndStrength">dressing tulle non gauze paraffin 7.6 cm x 7.6 cm dressing, 1</block><table role="R1"><row><cell><block label="DrugItemCode">4909J<br></br></block></cell><cell><block label="MaxQuantity">10</block></cell><cell><block label="NumberOfRepeats">1</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ"><inline label="PackSizeException">*</inline>19.15</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Adaptic 2012 [KI]<inline label="genericindexfieldbrand"><italic>XE "Adaptic 2012(KI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50760011000036100"><xref-fragment id="60316-V07AY50760011000036100"><blockxref id="106416" title="DRESSING WITH SILVER" frag="default" reversefrag="V07AY50760011000036100" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60516" href="dynamic/R1/drug/50760011000036100-V07AY.psml" urititle="DRESSING WITH SILVER" mediatype="application/vnd.pageseeder.psml+xml"><document id="60516" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60516" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50760011000036100-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50760011000036100-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:29+10:00" modified="2018-06-15T10:34:27+10:00" title="DRESSING WITH SILVER"><displaytitle>DRESSING WITH SILVER</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50760011000036100" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106416" title="R1" type="none" forwardtype="embed" forwardtitle="DRESSING WITH SILVER" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60516-50760011000036100-1"><fragment id="60516-50760011000036100-1"><block label="DrugName">DRESSING WITH SILVER<inline label="genericindexfield">XE "DRESSING WITH SILVER"</inline></block></fragment></section><section id="60516-d4901e29"><fragment id="60516-d4901e29"><block label="NoteText"><para>Coloplast dressings are available via a range of distributors. However, Coloplast's principal agreement to ensure correct RPBS Price to Pharmacy and ready supply has been secured with Independence Australia on 1300 788 855 and BrightSky on 1300 290 400. Please note that Coloplast is unable to guarantee ready supply or rebate for price differences on purchases outside these distributors.</para></block></fragment></section><section id="60516-d4901e16"><fragment id="60516-d4901e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Wounds</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a wound where there is evidence of critical colonisation; OR</para></item><item><para>Patient must have a well-assessed chronic wound that has not responded to conventional dressings.</para></item></list></block></fragment></section><section id="60516-4647N"><fragment id="60516-4647N"><block label="FormAndStrength">dressing with silver 12.5 cm x 12.5 cm hydroactive dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">4647N<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">179.15</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Biatain Ag 9632 [CT]<inline label="genericindexfieldbrand"><italic>XE "Biatain Ag 9632(CT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60516-4646M"><fragment id="60516-4646M"><block label="FormAndStrength">dressing with silver 10 cm x 10 cm hydroactive dressing, 5</block><table role="R1"><row><cell><block label="DrugItemCode">4646M<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">165.14</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Biatain Ag 9622 [CT]<inline label="genericindexfieldbrand"><italic>XE "Biatain Ag 9622(CT)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60516-50760011000036100-2"><fragment id="60516-50760011000036100-2"><block label="DrugName">DRESSING WITH SILVER<inline label="genericindexfield">XE "DRESSING WITH SILVER"</inline></block></fragment></section><section id="60516-d4903e29"><fragment id="60516-d4903e29"><block label="NoteText"><para>Hartmann wound dressings are available through HARTMANN and Independence Australia only. If you would like to order Hartmann Wound Care products, please call HARTMANN customer service on 1800 805 839 or Independence Australia on 1300 788 855.</para></block></fragment></section><section id="60516-d4903e16"><fragment id="60516-d4903e16"><block label="RestrictionHead"><para>Authority required</para></block><block label="RestrictionText"><para>Wounds</para><para><bold>Clinical criteria:</bold></para><list><item><para>Patient must have a wound where there is evidence of critical colonisation; OR</para></item><item><para>Patient must have a well-assessed chronic wound that has not responded to conventional dressings.</para></item></list></block></fragment></section><section id="60516-4648P"><fragment id="60516-4648P"><block label="FormAndStrength">dressing with silver 10 cm x 10 cm tulle dressing, 3</block><table role="R1"><row><cell><block label="DrugItemCode">4648P<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">43.95</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Atrauman Ag 499572 [HR]<inline label="genericindexfieldbrand"><italic>XE "Atrauman Ag 499572(HR)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50777011000036105"><xref-fragment id="60316-V07AY50777011000036105"><blockxref id="106438" title="GAUZE AND COTTON TISSUE COMBINE ROLL" frag="default" reversefrag="V07AY50777011000036105" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="61003" href="dynamic/R1/drug/50777011000036105-V07AY.psml" urititle="GAUZE AND COTTON TISSUE COMBINE ROLL" mediatype="application/vnd.pageseeder.psml+xml"><document id="61003" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="61003" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50777011000036105-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50777011000036105-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:34+10:00" modified="2018-06-15T10:34:27+10:00" title="GAUZE AND COTTON TISSUE COMBINE ROLL"><displaytitle>GAUZE AND COTTON TISSUE COMBINE ROLL</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50777011000036105" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106438" title="R1" type="none" forwardtype="embed" forwardtitle="GAUZE AND COTTON TISSUE COMBINE ROLL" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="61003-50777011000036105-1"><fragment id="61003-50777011000036105-1"><block label="DrugName">GAUZE AND COTTON TISSUE COMBINE ROLL<inline label="genericindexfield">XE "GAUZE AND COTTON TISSUE COMBINE ROLL"</inline></block></fragment></section><section id="61003-4761N"><fragment id="61003-4761N"><block label="FormAndStrength">gauze and cotton tissue combine roll 10 cm x 10 m roll: wrapped pack, 1 pack</block><table role="R1"><row><cell><block label="DrugItemCode">4761N<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">20.47</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">JJ 12010 [JJ]<inline label="genericindexfieldbrand"><italic>XE "JJ 12010(JJ)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="61003-4767X"><fragment id="61003-4767X"><block label="FormAndStrength">gauze and cotton tissue combine roll 9 cm x 10 m roll: wrapped pack, 1 pack</block><table role="R1"><row><cell><block label="DrugItemCode">4767X<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">15.78</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">BSN 2902165 [BV]<inline label="genericindexfieldbrand"><italic>XE "BSN 2902165(BV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY21660011000036108"><xref-fragment id="60316-V07AY21660011000036108"><blockxref id="106403" title="POVIDONE-IODINE" frag="default" reversefrag="V07AY21660011000036108" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60650" href="dynamic/R1/drug/21660011000036108-V07AY.psml" urititle="POVIDONE-IODINE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60650" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60650" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/21660011000036108-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/21660011000036108-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:30+10:00" modified="2018-06-15T10:34:27+10:00" title="POVIDONE-IODINE"><displaytitle>POVIDONE-IODINE</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY21660011000036108" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106403" title="R1" type="none" forwardtype="embed" forwardtitle="POVIDONE-IODINE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60650-21660011000036108-1"><fragment id="60650-21660011000036108-1"><block label="DrugName">POVIDONE-IODINE<inline label="genericindexfield">XE "POVIDONE-IODINE:.Repatriation Pharmaceutical Benefits Scheme"</inline></block></fragment></section><section id="60650-10847X"><fragment id="60650-10847X"><block label="FormAndStrength">povidone-iodine 9.5 cm x 9.5 cm dressing, 25</block><table role="R1"><row><cell><block label="DrugItemCode">10847X<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">2</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">77.64</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Inadine [KI]<inline label="genericindexfieldbrand"><italic>XE "Inadine(KI)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY430321000144107"><xref-fragment id="60316-V07AY430321000144107"><blockxref id="106440" title="SODIUM CHLORIDE + HYPOCHLOROUS ACID + SODIUM HYPOCHLORITE" frag="default" reversefrag="V07AY430321000144107" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60310" href="dynamic/R1/drug/430321000144107-V07AY.psml" urititle="SODIUM CHLORIDE + HYPOCHLOROUS ACID + SODIUM HYPOCHLORITE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60310" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60310" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/430321000144107-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/430321000144107-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:27+10:00" modified="2018-06-15T10:34:27+10:00" title="SODIUM CHLORIDE + HYPOCHLOROUS ACID + SODIUM HYPOCHLORITE"><displaytitle>SODIUM CHLORIDE + HYPOCHLOROUS ACID + SODIUM HYPOCHLORITE</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY430321000144107" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106440" title="R1" type="none" forwardtype="embed" forwardtitle="SODIUM CHLORIDE + HYPOCHLOROUS ACID + SODIUM HYPOCHLORITE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60310-430321000144107-1"><fragment id="60310-430321000144107-1"><block label="DrugName">SODIUM CHLORIDE + HYPOCHLOROUS ACID + SODIUM HYPOCHLORITE<inline label="genericindexfield">XE "SODIUM CHLORIDE + HYPOCHLOROUS ACID + SODIUM HYPOCHLORITE"</inline></block></fragment></section><section id="60310-11134B"><fragment id="60310-11134B"><block label="FormAndStrength">sodium chloride 0.022% + hypochlorous acid 0.004% + sodium hypochlorite 0.004% irrigation solution, 250 mL</block><table role="R1"><row><cell><block label="DrugItemCode">11134B<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">3</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">30.44</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Microdacyn [TF]<inline label="genericindexfieldbrand"><italic>XE "Microdacyn(TF)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50701011000036106"><xref-fragment id="60316-V07AY50701011000036106"><blockxref id="106435" title="TAPE NON WOVEN RETENTION POLYACRYLATE" frag="default" reversefrag="V07AY50701011000036106" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60485" href="dynamic/R1/drug/50701011000036106-V07AY.psml" urititle="TAPE NON WOVEN RETENTION POLYACRYLATE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60485" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60485" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50701011000036106-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50701011000036106-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:27+10:00" title="TAPE NON WOVEN RETENTION POLYACRYLATE"><displaytitle>TAPE NON WOVEN RETENTION POLYACRYLATE</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50701011000036106" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106435" title="R1" type="none" forwardtype="embed" forwardtitle="TAPE NON WOVEN RETENTION POLYACRYLATE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60485-50701011000036106-1"><fragment id="60485-50701011000036106-1"><block label="DrugName">TAPE NON WOVEN RETENTION POLYACRYLATE<inline label="genericindexfield">XE "TAPE NON WOVEN RETENTION POLYACRYLATE"</inline></block></fragment></section><section id="60485-4915Q"><fragment id="60485-4915Q"><block label="FormAndStrength">tape non woven retention polyacrylate 2.5 cm x 9.1 m tape, 1 roll</block><table role="R1"><row><cell><block label="DrugItemCode">4915Q<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">16.70</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Medipore 2961 [MM]<inline label="genericindexfieldbrand"><italic>XE "Medipore 2961(MM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60485-50701011000036106-2"><fragment id="60485-50701011000036106-2"><block label="DrugName">TAPE NON WOVEN RETENTION POLYACRYLATE<inline label="genericindexfield">XE "TAPE NON WOVEN RETENTION POLYACRYLATE"</inline></block></fragment></section><section id="60485-d4909e17"><fragment id="60485-d4909e17"><block label="NoteText"><para>Molnlycke Healthcare products are distributed through leading pharmacy distributors. To best ensure product availability at RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email customerservice@independenceaustralia.com. Molnlycke Healthcare are not able to ensure product availability or pricing on listed products beyond these two suppliers.</para></block></fragment></section><section id="60485-4917T"><fragment id="60485-4917T"><block label="FormAndStrength">tape non woven retention polyacrylate 2.5 cm x 10 m tape, 1 roll</block><table role="R1"><row><cell><block label="DrugItemCode">4917T<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">15.11</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Mefix 310250 [MH]<inline label="genericindexfieldbrand"><italic>XE "Mefix 310250(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50730011000036106"><xref-fragment id="60316-V07AY50730011000036106"><blockxref id="106421" title="TAPE PLASTER ADHESIVE ELASTIC" frag="default" reversefrag="V07AY50730011000036106" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60353" href="dynamic/R1/drug/50730011000036106-V07AY.psml" urititle="TAPE PLASTER ADHESIVE ELASTIC" mediatype="application/vnd.pageseeder.psml+xml"><document id="60353" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60353" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50730011000036106-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50730011000036106-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:27+10:00" modified="2018-06-15T10:34:27+10:00" title="TAPE PLASTER ADHESIVE ELASTIC"><displaytitle>TAPE PLASTER ADHESIVE ELASTIC</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50730011000036106" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106421" title="R1" type="none" forwardtype="embed" forwardtitle="TAPE PLASTER ADHESIVE ELASTIC" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60353-50730011000036106-1"><fragment id="60353-50730011000036106-1"><block label="DrugName">TAPE PLASTER ADHESIVE ELASTIC<inline label="genericindexfield">XE "TAPE PLASTER ADHESIVE ELASTIC"</inline></block></fragment></section><section id="60353-4782Q"><fragment id="60353-4782Q"><block label="FormAndStrength">tape plaster adhesive elastic 7.5 cm x 2.5 m tape, 1 roll</block><table role="R1"><row><cell><block label="DrugItemCode">4782Q<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">27.24</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Leukoplast 01073-00 [BV]<inline label="genericindexfieldbrand"><italic>XE "Leukoplast 01073-00(BV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60353-4781P"><fragment id="60353-4781P"><block label="FormAndStrength">tape plaster adhesive elastic 5 cm x 2.5 m tape, 1 roll</block><table role="R1"><row><cell><block label="DrugItemCode">4781P<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">23.56</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Leukoplast 01072-00 [BV]<inline label="genericindexfieldbrand"><italic>XE "Leukoplast 01072-00(BV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60353-4780N"><fragment id="60353-4780N"><block label="FormAndStrength">tape plaster adhesive elastic 2.5 cm x 2.5 m tape, 1 roll</block><table role="R1"><row><cell><block label="DrugItemCode">4780N<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.62</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Leukoplast 01071-00 [BV]<inline label="genericindexfieldbrand"><italic>XE "Leukoplast 01071-00(BV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY50731011000036104"><xref-fragment id="60316-V07AY50731011000036104"><blockxref id="106434" title="TAPE PLASTER ADHESIVE HYPOALLERGENIC" frag="default" reversefrag="V07AY50731011000036104" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60226" href="dynamic/R1/drug/50731011000036104-V07AY.psml" urititle="TAPE PLASTER ADHESIVE HYPOALLERGENIC" mediatype="application/vnd.pageseeder.psml+xml"><document id="60226" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60226" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/50731011000036104-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/50731011000036104-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:26+10:00" modified="2018-06-15T10:34:27+10:00" title="TAPE PLASTER ADHESIVE HYPOALLERGENIC"><displaytitle>TAPE PLASTER ADHESIVE HYPOALLERGENIC</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY50731011000036104" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106434" title="R1" type="none" forwardtype="embed" forwardtitle="TAPE PLASTER ADHESIVE HYPOALLERGENIC" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60226-50731011000036104-1"><fragment id="60226-50731011000036104-1"><block label="DrugName">TAPE PLASTER ADHESIVE HYPOALLERGENIC<inline label="genericindexfield">XE "TAPE PLASTER ADHESIVE HYPOALLERGENIC"</inline></block></fragment></section><section id="60226-4849F"><fragment id="60226-4849F"><block label="FormAndStrength">tape plaster adhesive hypoallergenic 1.9 cm x 7.3 m dispenser tape, 1 roll</block><table role="R1"><row><cell><block label="DrugItemCode">4849F<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">15.12</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Nexcare Gentle Paper First Aid Tape 789 [MM]<inline label="genericindexfieldbrand"><italic>XE "Nexcare Gentle Paper First Aid Tape 789(MM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60226-4788B"><fragment id="60226-4788B"><block label="FormAndStrength">tape plaster adhesive hypoallergenic 5 cm x 5 m stretch tape, 1 roll</block><table role="R1"><row><cell><block label="DrugItemCode">4788B<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">20.47</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Leukoflex 1124 [BV]<inline label="genericindexfieldbrand"><italic>XE "Leukoflex 1124(BV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60226-4789C"><fragment id="60226-4789C"><block label="FormAndStrength">tape plaster adhesive hypoallergenic 5 cm x 5 m stretch tape, 1 roll</block><table role="R1"><row><cell><block label="DrugItemCode">4789C<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">21.79</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Leukosilk 1024 [BV]<inline label="genericindexfieldbrand"><italic>XE "Leukosilk 1024(BV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60226-4790D"><fragment id="60226-4790D"><block label="FormAndStrength">tape plaster adhesive hypoallergenic 5 cm x 5 m stretch tape, 1 roll</block><table role="R1"><row><cell><block label="DrugItemCode">4790D<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">20.96</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Leukopor 2474 [BV]<inline label="genericindexfieldbrand"><italic>XE "Leukopor 2474(BV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60226-4783R"><fragment id="60226-4783R"><block label="FormAndStrength">tape plaster adhesive hypoallergenic 1.25 cm x 5 m tape, 1 roll</block><table role="R1"><row><cell><block label="DrugItemCode">4783R<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">15.03</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Leukopor 2471 [BV]<inline label="genericindexfieldbrand"><italic>XE "Leukopor 2471(BV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60226-4785W"><fragment id="60226-4785W"><block label="FormAndStrength">tape plaster adhesive hypoallergenic 1.25 cm x 5 m tape, 1 roll</block><table role="R1"><row><cell><block label="DrugItemCode">4785W<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">15.32</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Leukosilk 1021 [BV]<inline label="genericindexfieldbrand"><italic>XE "Leukosilk 1021(BV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60226-4787Y"><fragment id="60226-4787Y"><block label="FormAndStrength">tape plaster adhesive hypoallergenic 2.5 cm x 5 m tape, 1 roll</block><table role="R1"><row><cell><block label="DrugItemCode">4787Y<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.97</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Leukosilk 1022 [BV]<inline label="genericindexfieldbrand"><italic>XE "Leukosilk 1022(BV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60226-4794H"><fragment id="60226-4794H"><block label="FormAndStrength">tape plaster adhesive hypoallergenic 2.5 cm x 5 m tape, 1 roll</block><table role="R1"><row><cell><block label="DrugItemCode">4794H<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">17.44</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Leukopor 2472 [BV]<inline label="genericindexfieldbrand"><italic>XE "Leukopor 2472(BV)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60226-4848E"><fragment id="60226-4848E"><block label="FormAndStrength">tape plaster adhesive hypoallergenic 1.9 cm x 5.4 m dispenser tape, 1 roll</block><table role="R1"><row><cell><block label="DrugItemCode">4848E<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">15.12</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Nexcare Durable Cloth First Aid Tape 799 [MM]<inline label="genericindexfieldbrand"><italic>XE "Nexcare Durable Cloth First Aid Tape 799(MM)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section><section id="60316-V07AY85068011000036107"><xref-fragment id="60316-V07AY85068011000036107"><blockxref id="106445" title="TAPE PLASTER ADHESIVE WITH SILICONE" frag="default" reversefrag="V07AY85068011000036107" reversetitle="R1" reverselink="true" reversetype="none" display="document" type="embed" uriid="60219" href="dynamic/R1/drug/85068011000036107-V07AY.psml" urititle="TAPE PLASTER ADHESIVE WITH SILICONE" mediatype="application/vnd.pageseeder.psml+xml"><document id="60219" schemaversion="0.12" date="2018-06-15T10:34:27+10:00" version="current" level="processed"><documentinfo><uri id="60219" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/R1/drug/85068011000036107-V07AY.psml" decodedpath="/ps/test/local3/books/dynamic/R1/drug/85068011000036107-V07AY.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:26+10:00" modified="2018-06-15T10:34:27+10:00" title="TAPE PLASTER ADHESIVE WITH SILICONE"><displaytitle>TAPE PLASTER ADHESIVE WITH SILICONE</displaytitle></uri><reversexrefs><reversexref uriid="60316" href="dynamic/R1/atc/V.psml" frag="V07AY85068011000036107" urititle="VARIOUS" mediatype="application/vnd.pageseeder.psml+xml" id="106445" title="R1" type="none" forwardtype="embed" forwardtitle="TAPE PLASTER ADHESIVE WITH SILICONE" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60219-85068011000036107-1"><fragment id="60219-85068011000036107-1"><block label="DrugName">TAPE PLASTER ADHESIVE WITH SILICONE<inline label="genericindexfield">XE "TAPE PLASTER ADHESIVE WITH SILICONE"</inline></block></fragment></section><section id="60219-d4913e17"><fragment id="60219-d4913e17"><block label="NoteText"><para>Molnlycke Healthcare products are distributed through leading pharmacy distributors. To best ensure product availability at RPBS agreed prices, special arrangements have been made with API and Independence Australia Health Solutions (IAHS). IAHS orders can be placed on: Tel: 1300 788 855; or Email customerservice@independenceaustralia.com. Molnlycke Healthcare are not able to ensure product availability or pricing on listed products beyond these two suppliers.</para></block></fragment></section><section id="60219-4239D"><fragment id="60219-4239D"><block label="FormAndStrength">tape plaster adhesive with silicone 2 cm x 3 m tape, 1 roll</block><table role="R1"><row><cell><block label="DrugItemCode">4239D<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">24.09</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Mepitac 298300 [MH]<inline label="genericindexfieldbrand"><italic>XE "Mepitac 298300(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section><section id="60219-4240E"><fragment id="60219-4240E"><block label="FormAndStrength">tape plaster adhesive with silicone 4 cm x 1.5 m tape, 1 roll</block><table role="R1"><row><cell><block label="DrugItemCode">4240E<br></br></block></cell><cell><block label="MaxQuantity"><inline label="PrescribeAndSupplyMaximumQuantityException">‡</inline>1</block></cell><cell><block label="NumberOfRepeats">..</block></cell><cell><block label="BrandPricePremium">..</block></cell><cell><block label="DPMQ">24.09</block></cell><cell><block label="MRVSN">6.40</block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName">Mepitac 298400 [MH]<inline label="genericindexfieldbrand"><italic>XE "Mepitac 298400(MH)" \i </italic></inline></block></cell><cell><block label="Bioequivalent"></block></cell><cell><block label="BrandName"></block></cell></row></table></fragment></section></document></blockxref></xref-fragment></section></document></blockxref></xref-fragment></section></document></blockxref>
<blockxref id="107720" title="book-main-section4-drugtariff.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="59599" href="dynamic/book-main-section4-drugtariff.psml" urititle="Drug Tariff" mediatype="application/vnd.pageseeder.psml+xml"><document id="59599" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="59599" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/book-main-section4-drugtariff.psml" decodedpath="/ps/test/local3/books/dynamic/book-main-section4-drugtariff.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:19+10:00" modified="2018-06-15T10:34:32+10:00" title="Drug Tariff"><displaytitle>Drug Tariff</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107720" title="" type="none" forwardtype="embed" forwardtitle="book-main-section4-drugtariff.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59599-1"><fragment id="59599-1"><block label="mps3sectionbreak">SECTION4</block><heading level="1">Extemporaneously Prepared Benefits</heading><block label="pagebreak">pagebreak</block><block label="schedule-heading">Drug Tariff</block><para><br></br><br></br></para></fragment><fragment id="59599-2"><table role="section4drugtariff"><row><hcell rowspan="2">Drug</hcell><hcell rowspan="2">Standard</hcell><hcell colspan="4">Recovery Prices</hcell></row><row><hcell>0.1 g/mL<br></br>$</hcell><hcell>1 g/mL<br></br>$</hcell><hcell>10 g/mL<br></br>$</hcell><hcell>100 g/mL<br></br>$</hcell></row><row><cell>Acacia Mucilage (by weight)</cell><cell>APF 15</cell><cell>0.02</cell><cell>0.12</cell><cell>0.96</cell><cell>8.49</cell></row><row><cell>Acacia, powdered</cell><cell>BP</cell><cell>0.03</cell><cell>0.22</cell><cell>1.79</cell><cell>15.91</cell></row><row><cell>Acetic Acid (33 per cent)</cell><cell>BP</cell><cell>0.01</cell><cell>0.06</cell><cell>0.46</cell><cell>4.07</cell></row><row><cell>Acetic Acid (6 per cent)</cell><cell>BP</cell><cell>0.01</cell><cell>0.02</cell><cell>0.15</cell><cell>1.31</cell></row><row><cell>Acetic Acid Glacial BP</cell><cell>BP</cell><cell>0.02</cell><cell>0.14</cell><cell>1.09</cell><cell>9.69</cell></row><row><cell>Acetone (use as additive only)</cell><cell>BP</cell><cell>0.03</cell><cell>0.20</cell><cell>1.63</cell><cell>14.50</cell></row><row><cell>Alum</cell><cell>BP</cell><cell>0.01</cell><cell>0.07</cell><cell>0.59</cell><cell>5.25</cell></row><row><cell>Aluminium Acetate Solution</cell><cell>BP</cell><cell>0.02</cell><cell>0.17</cell><cell>1.38</cell><cell>12.27</cell></row><row><cell>Anise Oil BP</cell><cell>BP</cell><cell>0.18</cell><cell>1.44</cell><cell>11.52</cell><cell>102.44</cell></row><row><cell>Anise Water Concentrated 1 in 40</cell><cell>BP</cell><cell>0.01</cell><cell>0.07</cell><cell>0.57</cell><cell>5.03</cell></row><row><cell>Aqueous Cream (for use only as a base combined with active ingredients)</cell><cell>APF</cell><cell>0.01</cell><cell>0.03</cell><cell>0.24</cell><cell>2.10</cell></row><row><cell>Ascorbic Acid (for use only as an ingredient of ferrous sulfate mixtures)</cell><cell>BP</cell><cell>0.37</cell><cell>2.99</cell><cell>23.94</cell><cell>212.76</cell></row><row><cell>Aspirin</cell><cell>BP</cell><cell>0.14</cell><cell>1.15</cell><cell>9.22</cell><cell>81.94</cell></row><row><cell>Belladonna Tincture</cell><cell>BP</cell><cell>0.10</cell><cell>0.81</cell><cell>6.44</cell><cell>57.28</cell></row><row><cell>Benzocaine</cell><cell>BP</cell><cell>0.12</cell><cell>0.97</cell><cell>7.76</cell><cell>68.94</cell></row><row><cell>Benzoic Acid</cell><cell>BP</cell><cell>0.06</cell><cell>0.48</cell><cell>3.80</cell><cell>33.80</cell></row><row><cell>Benzoic Acid Compound Ointment</cell><cell>APF</cell><cell>0.02</cell><cell>0.16</cell><cell>1.26</cell><cell>11.22</cell></row><row><cell>Benzoic Acid Solution</cell><cell>BP</cell><cell>0.02</cell><cell>0.14</cell><cell>1.09</cell><cell>9.73</cell></row><row><cell>Benzoin Compound Tincture</cell><cell>BP</cell><cell>0.05</cell><cell>0.43</cell><cell>3.47</cell><cell>30.81</cell></row><row><cell>Boric Acid (use as additive only)</cell><cell>BP</cell><cell>0.02</cell><cell>0.19</cell><cell>1.55</cell><cell>13.79</cell></row><row><cell>Boric Acid, Olive Oil and Zinc Oxide Ointment</cell><cell>QHF</cell><cell>0.02</cell><cell>0.14</cell><cell>1.09</cell><cell>9.67</cell></row><row><cell>Calcium Hydroxide</cell><cell>BP</cell><cell>0.10</cell><cell>0.83</cell><cell>6.64</cell><cell>59.00</cell></row><row><cell>Calcium Hydroxide Solution</cell><cell>BP</cell><cell>0.01</cell><cell>0.02</cell><cell>0.17</cell><cell>1.52</cell></row><row><cell>Castor Oil (use as additive only)</cell><cell>BP</cell><cell>0.02</cell><cell>0.18</cell><cell>1.41</cell><cell>12.50</cell></row><row><cell>Cetomacrogol Aqueous Cream (for use only as a base combined with active ingredients)</cell><cell>APF</cell><cell>0.01</cell><cell>0.04</cell><cell>0.28</cell><cell>2.48</cell></row><row><cell>Cetrimide Aqueous Cream (for use only as a base combined with active ingredients)</cell><cell>APF</cell><cell>0.02</cell><cell>0.17</cell><cell>1.37</cell><cell>12.21</cell></row><row><cell>Chlorhexidine Acetate (use as additive only)</cell><cell>BP</cell><cell>0.63</cell><cell>5.03</cell><cell>40.21</cell><cell>357.42</cell></row><row><cell>Chlorhexidine Aqueous Cream (for use only as a base combined with active ingredients)</cell><cell>APF</cell><cell>0.03</cell><cell>0.24</cell><cell>1.95</cell><cell>17.36</cell></row><row><cell>Chloroform (use as additive only)</cell><cell>BP</cell><cell>0.09</cell><cell>0.72</cell><cell>5.77</cell><cell>51.29</cell></row><row><cell>Chloroform Spirit</cell><cell>BP</cell><cell>0.01</cell><cell>0.08</cell><cell>0.67</cell><cell>5.94</cell></row><row><cell>Chloroform Water Concentrated 1 in 40</cell><cell>APF 15</cell><cell>0.01</cell><cell>0.11</cell><cell>0.84</cell><cell>7.45</cell></row><row><cell>Citric Acid Monohydrate</cell><cell>BP</cell><cell>0.04</cell><cell>0.29</cell><cell>2.28</cell><cell>20.25</cell></row><row><cell>Coal Tar</cell><cell>BP</cell><cell>0.28</cell><cell>2.21</cell><cell>17.70</cell><cell>157.34</cell></row><row><cell>Coal Tar Solution</cell><cell>BP</cell><cell>0.02</cell><cell>0.16</cell><cell>1.25</cell><cell>11.15</cell></row><row><cell>Cocaine Hydrochloride</cell><cell>BP</cell><cell>5.41</cell><cell>43.26</cell><cell>346.09</cell><cell>3076.38</cell></row><row><cell>Coconut Oil</cell><cell>BP</cell><cell>0.01</cell><cell>0.05</cell><cell>0.42</cell><cell>3.73</cell></row><row><cell>Codeine Linctus</cell><cell>APF</cell><cell>0.01</cell><cell>0.10</cell><cell>0.79</cell><cell>7.03</cell></row><row><cell>Codeine Phosphate (may only be prescribed in linctuses, mixtures or mixtures for children)</cell><cell>BP</cell><cell>3.82</cell><cell>30.58</cell><cell>244.67</cell><cell>2174.84</cell></row><row><cell>Collodion Flexible</cell><cell>BP</cell><cell>0.19</cell><cell>1.55</cell><cell>12.37</cell><cell>109.92</cell></row><row><cell>Dithranol</cell><cell>BP</cell><cell>4.31</cell><cell>34.48</cell><cell>275.84</cell><cell>2451.94</cell></row><row><cell>Emulsifying Ointment (for use only as a base combined with active ingredients)</cell><cell>BP</cell><cell>0.01</cell><cell>0.09</cell><cell>0.71</cell><cell>6.27</cell></row><row><cell>Ephedrine Hydrochloride (may only be prescribed in nasal instillations)</cell><cell>BP</cell><cell>2.05</cell><cell>16.43</cell><cell>131.45</cell><cell>1168.43</cell></row><row><cell>Ethanol (90 per cent) (use as additive only)</cell><cell>BP</cell><cell>0.01</cell><cell>0.04</cell><cell>0.28</cell><cell>2.45</cell></row><row><cell>Ethanol (96 per cent) (use as additive only)</cell><cell>BP</cell><cell>0.01</cell><cell>0.04</cell><cell>0.35</cell><cell>3.10</cell></row><row><cell>Ether Solvent (use as additive only)</cell><cell>BP</cell><cell>0.25</cell><cell>1.97</cell><cell>15.73</cell><cell>139.82</cell></row><row><cell>Eucalyptus Oil (use as additive only)</cell><cell>BP</cell><cell>0.02</cell><cell>0.18</cell><cell>1.42</cell><cell>12.64</cell></row><row><cell>Ferrous Sulfate</cell><cell>BP</cell><cell>0.04</cell><cell>0.29</cell><cell>2.32</cell><cell>20.59</cell></row><row><cell>Formaldehyde Solution</cell><cell>BP</cell><cell>0.07</cell><cell>0.53</cell><cell>4.26</cell><cell>37.86</cell></row><row><cell>Gentian Alkaline Mixture</cell><cell>APF</cell><cell>0.01</cell><cell>0.09</cell><cell>0.68</cell><cell>6.00</cell></row><row><cell>Glycerol</cell><cell>BP</cell><cell>0.02</cell><cell>0.12</cell><cell>0.98</cell><cell>8.72</cell></row><row><cell>Honey Purified (use as additive only)</cell><cell>BP 1993</cell><cell>0.01</cell><cell>0.03</cell><cell>0.27</cell><cell>2.44</cell></row><row><cell>Hydroxybenzoate Compound Solution</cell><cell>APF</cell><cell>0.07</cell><cell>0.59</cell><cell>4.73</cell><cell>42.08</cell></row><row><cell>Iodine</cell><cell>BP</cell><cell>0.37</cell><cell>2.98</cell><cell>23.85</cell><cell>211.97</cell></row><row><cell>Iodine Alcoholic Solution</cell><cell>BP</cell><cell>0.04</cell><cell>0.28</cell><cell>2.26</cell><cell>20.11</cell></row><row><cell>Iodine Aqueous Oral Solution</cell><cell>BP</cell><cell>0.03</cell><cell>0.26</cell><cell>2.11</cell><cell>18.72</cell></row><row><cell>Kaolin Mixture</cell><cell>BPC 1968</cell><cell>0.03</cell><cell>0.21</cell><cell>1.71</cell><cell>15.19</cell></row><row><cell>Kaolin and Opium Mixture</cell><cell>APF 14</cell><cell>0.01</cell><cell>0.10</cell><cell>0.82</cell><cell>7.27</cell></row><row><cell>Lactic Acid</cell><cell>BP</cell><cell>0.36</cell><cell>2.87</cell><cell>22.94</cell><cell>203.95</cell></row><row><cell>Lavender Spike Oil</cell><cell>BPC 1968</cell><cell>0.13</cell><cell>1.04</cell><cell>8.32</cell><cell>73.91</cell></row><row><cell>Liquorice Liquid Extract</cell><cell>BP</cell><cell>0.03</cell><cell>0.23</cell><cell>1.84</cell><cell>16.37</cell></row><row><cell>Magnesium Carbonate Light</cell><cell>BP</cell><cell>0.05</cell><cell>0.37</cell><cell>2.92</cell><cell>25.99</cell></row><row><cell>Magnesium Sulfate (may only be prescribed for other than oral use)</cell><cell>BP</cell><cell>0.01</cell><cell>0.03</cell><cell>0.24</cell><cell>2.10</cell></row><row><cell>Magnesium Trisilicate</cell><cell>BP</cell><cell>0.05</cell><cell>0.36</cell><cell>2.91</cell><cell>25.82</cell></row><row><cell>Menthol, Racemic or Levomenthol</cell><cell>BP</cell><cell>0.25</cell><cell>2.02</cell><cell>16.19</cell><cell>143.87</cell></row><row><cell>Methyl Hydroxybenzoate</cell><cell>BP</cell><cell>0.41</cell><cell>3.28</cell><cell>26.22</cell><cell>233.03</cell></row><row><cell>Methyl Hydroxybenzoate Solution</cell><cell>APF</cell><cell>0.04</cell><cell>0.35</cell><cell>2.80</cell><cell>24.87</cell></row><row><cell>Methylated Industrial Spirit (use as additive only)</cell><cell>BP</cell><cell>0.01</cell><cell>0.01</cell><cell>0.08</cell><cell>0.73</cell></row><row><cell>Olive Oil (use as additive only)</cell><cell>BP</cell><cell>0.02</cell><cell>0.14</cell><cell>1.08</cell><cell>9.62</cell></row><row><cell>Paraffin Hard</cell><cell>BP</cell><cell>0.05</cell><cell>0.41</cell><cell>3.29</cell><cell>29.28</cell></row><row><cell>Paraffin Light Liquid</cell><cell>BP</cell><cell>0.02</cell><cell>0.17</cell><cell>1.39</cell><cell>12.32</cell></row><row><cell>Paraffin Liquid (use as additive only)</cell><cell>BP</cell><cell>0.01</cell><cell>0.06</cell><cell>0.51</cell><cell>4.56</cell></row><row><cell>Paraffin Soft White</cell><cell>BP</cell><cell>0.01</cell><cell>0.05</cell><cell>0.42</cell><cell>3.71</cell></row><row><cell>Paraffin Soft Yellow</cell><cell>BP</cell><cell>0.01</cell><cell>0.05</cell><cell>0.42</cell><cell>3.75</cell></row><row><cell>Peppermint Oil (use as additive only)</cell><cell>BP</cell><cell>0.07</cell><cell>0.57</cell><cell>4.55</cell><cell>40.44</cell></row><row><cell>Peppermint Water Concentrated 1 in 40 (use as additive only)</cell><cell>APF 16</cell><cell>0.04</cell><cell>0.34</cell><cell>2.72</cell><cell>24.17</cell></row><row><cell>Phenobarbitone Sodium (may only be prescribed for the treatment of epilepsy)</cell><cell>BP</cell><cell>9.37</cell><cell>74.92</cell><cell>599.36</cell><cell>5327.61</cell></row><row><cell>Phenol Liquefied (not available for ear drops)</cell><cell>BP</cell><cell>0.13</cell><cell>1.02</cell><cell>8.17</cell><cell>72.64</cell></row><row><cell>Podophyllum Resin</cell><cell>BP</cell><cell>3.78</cell><cell>30.25</cell><cell>242.03</cell><cell>2151.34</cell></row><row><cell>Potassium Citrate</cell><cell>BP</cell><cell>0.02</cell><cell>0.19</cell><cell>1.53</cell><cell>13.64</cell></row><row><cell>Potassium Iodide</cell><cell>BP</cell><cell>0.14</cell><cell>1.11</cell><cell>8.88</cell><cell>78.94</cell></row><row><cell>Potassium Permanganate</cell><cell>BP</cell><cell>0.04</cell><cell>0.31</cell><cell>2.44</cell><cell>21.65</cell></row><row><cell>Propyl Hydroxybenzoate</cell><cell>BP</cell><cell>0.42</cell><cell>3.35</cell><cell>26.78</cell><cell>238.01</cell></row><row><cell>Propylene Glycol</cell><cell>BP</cell><cell>0.02</cell><cell>0.12</cell><cell>0.95</cell><cell>8.48</cell></row><row><cell>Red Syrup</cell><cell>APF 15</cell><cell>0.02</cell><cell>0.13</cell><cell>1.04</cell><cell>9.23</cell></row><row><cell>Resorcinol</cell><cell>BP</cell><cell>0.42</cell><cell>3.32</cell><cell>26.54</cell><cell>235.88</cell></row><row><cell>Salicylic Acid</cell><cell>BP</cell><cell>0.05</cell><cell>0.40</cell><cell>3.18</cell><cell>28.25</cell></row><row><cell>Salicylic Acid Ointment</cell><cell>APF</cell><cell>0.02</cell><cell>0.17</cell><cell>1.38</cell><cell>12.23</cell></row><row><cell>Salicylic Acid Ointment</cell><cell>BP</cell><cell>0.02</cell><cell>0.17</cell><cell>1.38</cell><cell>12.23</cell></row><row><cell>Simple Ointment (white) (for use only as a base combined with active ingredients)</cell><cell>BP</cell><cell>0.02</cell><cell>0.14</cell><cell>1.11</cell><cell>9.88</cell></row><row><cell>Simple Ointment (yellow) (for use only as a base combined with active ingredients)</cell><cell>BP</cell><cell>0.02</cell><cell>0.14</cell><cell>1.11</cell><cell>9.88</cell></row><row><cell>Sodium Bicarbonate</cell><cell>BP</cell><cell>0.04</cell><cell>0.28</cell><cell>2.24</cell><cell>19.91</cell></row><row><cell>Sodium Chloride</cell><cell>BP</cell><cell>0.02</cell><cell>0.17</cell><cell>1.34</cell><cell>11.88</cell></row><row><cell>Sodium Chloride Solution</cell><cell>BP</cell><cell>0.01</cell><cell>0.01</cell><cell>0.09</cell><cell>0.84</cell></row><row><cell>Sodium Citrate</cell><cell>BP</cell><cell>0.04</cell><cell>0.28</cell><cell>2.23</cell><cell>19.81</cell></row><row><cell>Sodium Thiosulfate (use as additive only)</cell><cell>BP</cell><cell>0.04</cell><cell>0.34</cell><cell>2.74</cell><cell>24.37</cell></row><row><cell>Starch</cell><cell>BP</cell><cell>0.02</cell><cell>0.19</cell><cell>1.55</cell><cell>13.79</cell></row><row><cell>Sulfur Ointment (for use only as a base combined with active ingredients)</cell><cell>BP 1980</cell><cell>0.02</cell><cell>0.15</cell><cell>1.21</cell><cell>10.75</cell></row><row><cell>Sulfur Precipitated</cell><cell>BP 1980</cell><cell>0.03</cell><cell>0.23</cell><cell>1.86</cell><cell>16.49</cell></row><row><cell>Syrup</cell><cell>BP</cell><cell>0.01</cell><cell>0.05</cell><cell>0.42</cell><cell>3.71</cell></row><row><cell>Talc Purified, sterilised</cell><cell>BP</cell><cell>0.06</cell><cell>0.46</cell><cell>3.71</cell><cell>32.94</cell></row><row><cell>Thymol</cell><cell>BP</cell><cell>0.46</cell><cell>3.71</cell><cell>29.66</cell><cell>263.61</cell></row><row><cell>Thymol Compound Mouth Wash</cell><cell>APF 15</cell><cell>0.01</cell><cell>0.11</cell><cell>0.89</cell><cell>7.91</cell></row><row><cell>Tragacanth Compound Powder</cell><cell>BP 1980</cell><cell>0.07</cell><cell>0.57</cell><cell>4.58</cell><cell>40.73</cell></row><row><cell>Tragacanth Mucilage</cell><cell>APF 13</cell><cell>0.01</cell><cell>0.07</cell><cell>0.58</cell><cell>5.14</cell></row><row><cell>Tragacanth Mucilage</cell><cell>BPC 1973</cell><cell>0.01</cell><cell>0.06</cell><cell>0.51</cell><cell>4.56</cell></row><row><cell>Tragacanth, powdered</cell><cell>BP</cell><cell>0.36</cell><cell>2.84</cell><cell>22.72</cell><cell>201.94</cell></row><row><cell>Trichloroacetic Acid</cell><cell>BP 1980</cell><cell>0.33</cell><cell>2.65</cell><cell>21.23</cell><cell>188.68</cell></row><row><cell>Triethanolamine</cell><cell>BP</cell><cell>0.12</cell><cell>0.96</cell><cell>7.68</cell><cell>68.28</cell></row><row><cell>Water For Injections, sterilised (b) (extemporaneously prepared eye drops and eye lotions)</cell><cell>BP</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Water Purified</cell><cell>BP</cell><cell>0.01</cell><cell>0.01</cell><cell>0.08</cell><cell>0.69</cell></row><row><cell>Wool Alcohols Ointment (white) (for use only as a base combined with active ingredients)</cell><cell>BP</cell><cell>0.02</cell><cell>0.17</cell><cell>1.33</cell><cell>11.86</cell></row><row><cell>Wool Alcohols Ointment (yellow) (for use only as a base combined with active ingredients)</cell><cell>BP</cell><cell>0.02</cell><cell>0.19</cell><cell>1.48</cell><cell>13.18</cell></row><row><cell>Wool Fat</cell><cell>BP</cell><cell>0.02</cell><cell>0.12</cell><cell>0.97</cell><cell>8.63</cell></row><row><cell>Wool Fat Hydrous</cell><cell>BP</cell><cell>0.03</cell><cell>0.25</cell><cell>2.03</cell><cell>18.01</cell></row><row><cell>Zinc Compound Paste</cell><cell>BP</cell><cell>0.05</cell><cell>0.40</cell><cell>3.17</cell><cell>28.17</cell></row><row><cell>Zinc Cream (for use only as a base combined with active ingredients)</cell><cell>BP</cell><cell>0.01</cell><cell>0.08</cell><cell>0.61</cell><cell>5.39</cell></row><row><cell>Zinc Oxide</cell><cell>BP</cell><cell>0.03</cell><cell>0.21</cell><cell>1.66</cell><cell>14.79</cell></row><row><cell>Zinc Sulfate</cell><cell>BP</cell><cell>0.04</cell><cell>0.28</cell><cell>2.21</cell><cell>19.63</cell></row><row><cell>Zinc and Salicylic Acid Paste</cell><cell>BP</cell><cell>0.04</cell><cell>0.32</cell><cell>2.53</cell><cell>22.47</cell></row></table><block label="pagebreak">pagebreak</block></fragment></section></document></blockxref>
<blockxref id="107721" title="book-main-section4-containers.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="59716" href="dynamic/book-main-section4-containers.psml" urititle="Container Prices" mediatype="application/vnd.pageseeder.psml+xml"><document id="59716" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="59716" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/book-main-section4-containers.psml" decodedpath="/ps/test/local3/books/dynamic/book-main-section4-containers.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:20+10:00" modified="2018-06-15T10:34:32+10:00" title="Container Prices"><displaytitle>Container Prices</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107721" title="" type="none" forwardtype="embed" forwardtitle="book-main-section4-containers.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59716-1"><fragment id="59716-1"><block label="schedule-heading">Container Prices</block><para><br></br><br></br></para></fragment><fragment id="59716-2"><table role="section4containers"><row><hcell>Type</hcell><hcell>Container</hcell><hcell>Price $</hcell></row><row><cell>Dispensing Bottles</cell><cell>25mL</cell><cell>0.64</cell></row><row><cell>Dispensing Bottles</cell><cell>50mL</cell><cell>0.53</cell></row><row><cell>Dispensing Bottles</cell><cell>100mL</cell><cell>0.87</cell></row><row><cell>Dispensing Bottles</cell><cell>200mL</cell><cell>1.03</cell></row><row><cell>Dispensing Bottles</cell><cell>500mL</cell><cell>1.28</cell></row><row><cell>Poison Bottles</cell><cell>25mL</cell><cell>0.67</cell></row><row><cell>Poison Bottles</cell><cell>50mL</cell><cell>0.54</cell></row><row><cell>Poison Bottles</cell><cell>100mL</cell><cell>0.79</cell></row><row><cell>Poison Bottles</cell><cell>200mL</cell><cell>1.02</cell></row><row><cell>Poison Bottles</cell><cell>500mL</cell><cell>1.69</cell></row><row><cell>Dropper Containers (Glass)</cell><cell>15mL</cell><cell>1.21</cell></row><row><cell>Dropper Containers (Polythene)</cell><cell>15mL</cell><cell>0.98</cell></row><row><cell></cell><cell>150ml</cell><cell>0.83</cell></row><row><cell>Screw Cap Jars</cell><cell>25g</cell><cell>0.90</cell></row><row><cell>Screw Cap Jars</cell><cell>50g</cell><cell>0.96</cell></row><row><cell>Screw Cap Jars</cell><cell>100g</cell><cell>0.99</cell></row><row><cell>Screw Cap Jars</cell><cell>200g</cell><cell>0.85</cell></row><row><cell>Screw Cap Jars</cell><cell>500g</cell><cell>2.19</cell></row><row><cell></cell><cell>25ml</cell><cell>0.41</cell></row></table><block label="pagebreak">pagebreak</block></fragment></section></document></blockxref>
<blockxref id="107722" title="book-main-section4-standard-formula-preparations.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="59638" href="dynamic/book-main-section4-standard-formula-preparations.psml" urititle="Standard Formula Preparations" mediatype="application/vnd.pageseeder.psml+xml"><document id="59638" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="59638" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/book-main-section4-standard-formula-preparations.psml" decodedpath="/ps/test/local3/books/dynamic/book-main-section4-standard-formula-preparations.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:19+10:00" modified="2018-06-15T10:34:32+10:00" title="Standard Formula Preparations"><displaytitle>Standard Formula Preparations</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107722" title="" type="none" forwardtype="embed" forwardtitle="book-main-section4-standard-formula-preparations.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59638-1"><fragment id="59638-1"><block label="schedule-heading">Standard Formula Preparations</block><para><br></br><br></br></para></fragment><fragment id="59638-2"><table role="section4standardpreparation"><row><hcell>Code</hcell><hcell>Item</hcell><hcell>Reference</hcell><hcell>DPMQ<br></br>$</hcell><hcell>MRVSN<br></br>$</hcell></row><row><cell></cell><cell colspan="4"><para><bold>Creams</bold><br></br><bold>(Maximum Quantity 100 g and 1 Repeat)</bold></para></cell></row><row><cell>7502W</cell><cell>Salicylic Acid and Sulfur Aqueous</cell><cell>APF</cell><cell>13.47</cell><cell>15.04</cell></row><row><cell></cell><cell colspan="4"><para><bold>Dusting Powders</bold><br></br><bold>(Maximum Quantity 100 g and 1 Repeat)</bold></para></cell></row><row><cell>7458M</cell><cell>Zinc, Starch and Talc</cell><cell>APF 15 &amp; BPC 1973</cell><cell>36.61</cell><cell>38.18</cell></row><row><cell></cell><cell colspan="4"><para><bold>Ear Drops</bold><br></br><bold>(Maximum Quantity 15 ml and 2 Repeats)</bold></para></cell></row><row><cell>7643G</cell><cell>Aluminium Acetate</cell><cell>BP</cell><cell>12.24</cell><cell>13.81</cell></row><row><cell>7642F</cell><cell>Aluminium Acetate</cell><cell>APF</cell><cell>11.47</cell><cell>13.04</cell></row><row><cell>7314Y</cell><cell>Sodium Bicarbonate</cell><cell>APF &amp; BP</cell><cell>11.01</cell><cell>12.58</cell></row><row><cell>7313X</cell><cell>Spirit</cell><cell>APF</cell><cell>10.44</cell><cell>12.01</cell></row><row><cell></cell><cell colspan="4"><para><bold>Inhalations</bold><br></br><bold>(Maximum Quantity 50 ml and 1 Repeat)</bold></para></cell></row><row><cell>7484X</cell><cell>Benzoin and Menthol</cell><cell>APF</cell><cell>29.08</cell><cell>30.65</cell></row><row><cell>7308P</cell><cell>Menthol</cell><cell>APF</cell><cell>13.13</cell><cell>14.70</cell></row><row><cell>7310R</cell><cell>Menthol and Eucalyptus</cell><cell>BP1980</cell><cell>14.27</cell><cell>15.84</cell></row><row><cell></cell><cell colspan="4"><para><bold>Linctuses containing Codeine Phosphate</bold><br></br><bold>(Maximum Quantity 100 ml and 0 Repeat)</bold></para></cell></row><row><cell>7530H</cell><cell>Codeine</cell><cell>APF</cell><cell>17.09</cell><cell>18.66</cell></row><row><cell></cell><cell colspan="4"><para><bold>Lotions</bold><br></br><bold>(Maximum Quantity 200 ml and 2 Repeats)</bold></para></cell></row><row><cell>7709R</cell><cell>Aluminium Acetate Aqueous</cell><cell>APF</cell><cell>12.90</cell><cell>14.47</cell></row><row><cell></cell><cell colspan="4"><para><bold>Mixtures, Other</bold><br></br><bold>(Maximum Quantity 200 ml and 4 Repeats)</bold></para></cell></row><row><cell>7604F</cell><cell>Gentian Alkaline</cell><cell>APF</cell><cell>22.22</cell><cell>23.79</cell></row><row><cell>7348R</cell><cell>Kaolin</cell><cell>BPC 1968</cell><cell>40.59</cell><cell>39.50</cell></row><row><cell>7301G</cell><cell>Kaolin and Opium</cell><cell>APF 14</cell><cell>24.76</cell><cell>26.33</cell></row><row><cell>7342K</cell><cell>Magnesium Trisilicate</cell><cell>BPC 1968</cell><cell>21.34</cell><cell>22.91</cell></row><row><cell>7343L</cell><cell>Magnesium Trisilicate and Belladonna</cell><cell>BPC 1968</cell><cell>27.63</cell><cell>29.20</cell></row><row><cell></cell><cell colspan="4"><para><bold>Mouth Washes</bold><br></br><bold>(Maximum Quantity 200 ml and 1 Repeat)</bold></para></cell></row><row><cell>7457L</cell><cell>Thymol Compound</cell><cell>APF 15</cell><cell>26.03</cell><cell>27.60</cell></row><row><cell></cell><cell colspan="4"><para><bold>Ointments, Waxes</bold><br></br><bold>(Maximum Quantity 100 g and 1 Repeat)</bold></para></cell></row><row><cell>7914M</cell><cell>Benzoic Acid Compound</cell><cell>APF &amp; BP</cell><cell>21.40</cell><cell>22.97</cell></row><row><cell>7902X</cell><cell>Boric Acid, Olive Oil and Zinc Oxide</cell><cell>QHF</cell><cell>19.85</cell><cell>21.42</cell></row><row><cell>7926E</cell><cell>Salicylic Acid</cell><cell>APF</cell><cell>22.41</cell><cell>23.98</cell></row><row><cell>7928G</cell><cell>Salicylic Acid (extemporaneous formula)</cell><cell>BP</cell><cell>22.41</cell><cell>23.98</cell></row><row><cell></cell><cell colspan="4"><para><bold>Paints</bold><br></br><bold>(Maximum Quantity 25 ml and 1 Repeat)</bold></para></cell></row><row><cell>7567G</cell><cell>Podophyllin Compound</cell><cell>APF 16 &amp; BP</cell><cell>131.97</cell><cell>39.50</cell></row><row><cell>7568H</cell><cell>Salicylic Acid</cell><cell>APF</cell><cell>41.77</cell><cell>39.50</cell></row><row><cell></cell><cell colspan="4"><para><bold>Pastes, Other</bold><br></br><bold>(Maximum Quantity 100 g and 1 Repeat)</bold></para></cell></row><row><cell>7558T</cell><cell>Zinc</cell><cell>APF &amp; BP</cell><cell>38.35</cell><cell>39.50</cell></row><row><cell></cell><cell colspan="4"><para><bold>Powders for Internal Use</bold><br></br><bold>(Maximum Quantity 100 g and 2 Repeats)</bold></para></cell></row><row><cell>7545D</cell><cell>Magnesium Trisilicate</cell><cell>BP</cell><cell>35.86</cell><cell>37.43</cell></row></table><block label="pagebreak">pagebreak</block></fragment></section></document></blockxref>
<blockxref id="107723" title="book-main-section4-codes-maxqty-numrpts.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="60455" href="dynamic/book-main-section4-codes-maxqty-numrpts.psml" urititle="Codes, Maximum Quantities, and Number of Repeats for Extemporaneously Prepared Benefits" mediatype="application/vnd.pageseeder.psml+xml"><document id="60455" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="60455" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/book-main-section4-codes-maxqty-numrpts.psml" decodedpath="/ps/test/local3/books/dynamic/book-main-section4-codes-maxqty-numrpts.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:28+10:00" modified="2018-06-15T10:34:32+10:00" title="Codes, Maximum Quantities, and Number of Repeats for Extemporaneously Prepared Benefits"><displaytitle>Codes, Maximum Quantities, and Number of Repeats for Extemporaneously Prepared Benefits</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107723" title="" type="none" forwardtype="embed" forwardtitle="book-main-section4-codes-maxqty-numrpts.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60455-1"><fragment id="60455-1"><block label="schedule-heading">Codes, Maximum Quantities, and Number of Repeats for Extemporaneously Prepared Benefits</block><para><br></br><br></br></para></fragment><fragment id="60455-2"><table role="section4codesmaxqtynumrtps"><row><hcell>Code</hcell><hcell>Preparation</hcell><hcell>Maximum Quantity</hcell><hcell>Number of Repeats</hcell></row><row><cell>13Q</cell><cell>Creams</cell><cell>100 g</cell><cell>1</cell></row><row><cell>48M</cell><cell>Dusting Powders</cell><cell>100 g</cell><cell>1</cell></row><row><cell>15T</cell><cell>Ear Drops</cell><cell>15 ml</cell><cell>2</cell></row><row><cell>19B</cell><cell>Eye Drops containing Cocaine Hydrochloride</cell><cell>15 ml</cell><cell>..</cell></row><row><cell>22E</cell><cell>Eye Drops, Other</cell><cell>15 ml</cell><cell>5</cell></row><row><cell>23F</cell><cell>Eye Lotions</cell><cell>200 ml</cell><cell>2</cell></row><row><cell>29M</cell><cell>Inhalations</cell><cell>50 ml</cell><cell>1</cell></row><row><cell>64J</cell><cell>Linctuses containing Codeine Phosphate</cell><cell>100 ml</cell><cell>..</cell></row><row><cell>34T</cell><cell>Linctuses, Other</cell><cell>100 ml</cell><cell>2</cell></row><row><cell>39C</cell><cell>Lotions</cell><cell>200 ml</cell><cell>2</cell></row><row><cell>65K</cell><cell>Mixtures containing Codeine Phosphate</cell><cell>200 ml</cell><cell>..</cell></row><row><cell>66L</cell><cell>Mixtures for Children containing Codeine Phosphate</cell><cell>100 ml</cell><cell>..</cell></row><row><cell>41E</cell><cell>Mixtures for Children, Other</cell><cell>100 ml</cell><cell>4</cell></row><row><cell>40D</cell><cell>Mixtures, Other</cell><cell>200 ml</cell><cell>4</cell></row><row><cell>30N</cell><cell>Mouth Washes</cell><cell>200 ml</cell><cell>1</cell></row><row><cell>42F</cell><cell>Nasal Instillations</cell><cell>15 ml</cell><cell>2</cell></row><row><cell>43G</cell><cell>Ointments, Waxes</cell><cell>100 g</cell><cell>1</cell></row><row><cell>44H</cell><cell>Paints</cell><cell>25 ml</cell><cell>1</cell></row><row><cell>63H</cell><cell>Pastes containing Cocaine Hydrochloride</cell><cell>25 g</cell><cell>..</cell></row><row><cell>45J</cell><cell>Pastes, Other</cell><cell>100 g</cell><cell>1</cell></row><row><cell>49N</cell><cell>Powders for Internal Use</cell><cell>100 g</cell><cell>2</cell></row><row><cell>52R</cell><cell>Solutions</cell><cell>200 ml</cell><cell>2</cell></row></table><block label="pagebreak">pagebreak</block></fragment></section></document></blockxref>
<blockxref id="107724" title="book-main-manufacturer.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="60312" href="dynamic/book-main-manufacturer.psml" urititle="Book Main Index of Manufacturers' Code" mediatype="application/vnd.pageseeder.psml+xml"><document id="60312" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="60312" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/book-main-manufacturer.psml" decodedpath="/ps/test/local3/books/dynamic/book-main-manufacturer.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:27+10:00" modified="2018-06-15T10:34:32+10:00" title="Book Main Index of Manufacturers' Code"><displaytitle>Book Main Index of Manufacturers' Code</displaytitle></uri><reversexrefs><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107724" title="" type="none" forwardtype="embed" forwardtitle="book-main-manufacturer.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="60312-1"><fragment id="60312-1"><block label="mps3sectionbreak">TIMC</block><heading level="1">Index of Manufacturers' Code</heading><block label="pagebreak">pagebreak</block><block label="mps3sectionbreak">IMC</block><table width="500px" role="manufacturer"><row><hcell><bold>Code</bold></hcell><hcell><bold>Manufacturer</bold></hcell></row><row><cell><bold>AB</bold></cell><cell>Abbott Australasia Pty Ltd</cell></row><row><cell><bold>AE</bold></cell><cell>AFT Pharmaceuticals Pty Ltd</cell></row><row><cell><bold>AF</bold></cell><cell>Alphapharm Pty Ltd</cell></row><row><cell><bold>AG</bold></cell><cell>Allergan Australia Pty Limited</cell></row><row><cell><bold>AL</bold></cell><cell>Alphapharm Pty Ltd</cell></row><row><cell><bold>AN</bold></cell><cell>Amgen Australia Pty Limited</cell></row><row><cell><bold>AP</bold></cell><cell>AstraZeneca Pty Ltd</cell></row><row><cell><bold>AQ</bold></cell><cell>Alcon Laboratories (Australia) Pty Ltd</cell></row><row><cell><bold>AS</bold></cell><cell>Aspen Pharmacare Australia Pty Limited</cell></row><row><cell><bold>AT</bold></cell><cell>Actelion Pharmaceuticals Australia Pty Ltd</cell></row><row><cell><bold>AV</bold></cell><cell>sanofi-aventis Australia Pty Ltd</cell></row><row><cell><bold>BB</bold></cell><cell>Blackmores Limited</cell></row><row><cell><bold>BD</bold></cell><cell>Biogen Australia Pty Ltd</cell></row><row><cell><bold>BE</bold></cell><cell>Beiersdorf Australia Ltd</cell></row><row><cell><bold>BG</bold></cell><cell>Sandoz Pty Ltd</cell></row><row><cell><bold>BI</bold></cell><cell>Biotech Pharmaceuticals Pty Ltd</cell></row><row><cell><bold>BN</bold></cell><cell>Bayer Australia Ltd</cell></row><row><cell><bold>BQ</bold></cell><cell>Bristol-Myers Squibb Australia Pty Ltd</cell></row><row><cell><bold>BR</bold></cell><cell>B. Braun Australia Pty Ltd</cell></row><row><cell><bold>BV</bold></cell><cell>BSN medical (Aust.) Pty Ltd</cell></row><row><cell><bold>BX</bold></cell><cell>Baxter Healthcare Pty Limited</cell></row><row><cell><bold>BY</bold></cell><cell>Boehringer Ingelheim Pty Ltd</cell></row><row><cell><bold>BZ</bold></cell><cell>Boucher &amp; Muir Pty Ltd</cell></row><row><cell><bold>CC</bold></cell><cell>ConvaTec A Division of Bristol-Myers Squibb Australia Pty Ltd</cell></row><row><cell><bold>CF</bold></cell><cell>CNS Pharma Pty Ltd</cell></row><row><cell><bold>CH</bold></cell><cell>Apotex Pty Ltd</cell></row><row><cell><bold>CJ</bold></cell><cell>Celgene Pty Limited</cell></row><row><cell><bold>CR</bold></cell><cell>Pharmacor Pty Limited</cell></row><row><cell><bold>CS</bold></cell><cell>Seqirus (Australia) Pty Ltd</cell></row><row><cell><bold>CT</bold></cell><cell>Coloplast Pty Ltd</cell></row><row><cell><bold>CU</bold></cell><cell>Care Pharmaceuticals Pty Limited</cell></row><row><cell><bold>CX</bold></cell><cell>Contact Lens Centre Australia Limited</cell></row><row><cell><bold>DE</bold></cell><cell>Stallergenes Australia Pty Ltd</cell></row><row><cell><bold>DJ</bold></cell><cell>De Fries Industries Pty Ltd</cell></row><row><cell><bold>DO</bold></cell><cell>Aurobindo Pharma (Australia) Pty Limited</cell></row><row><cell><bold>DQ</bold></cell><cell>Church &amp; Dwight (Australia) Pty Ltd</cell></row><row><cell><bold>DV</bold></cell><cell>Medical Developments International Limited</cell></row><row><cell><bold>DZ</bold></cell><cell>Medsurge Healthcare Pty Ltd</cell></row><row><cell><bold>EA</bold></cell><cell>Amneal Pharmaceuticals Pty Ltd</cell></row><row><cell><bold>ED</bold></cell><cell>Amneal Pharmaceuticals Pty Ltd</cell></row><row><cell><bold>EF</bold></cell><cell>Amneal Pharmaceuticals Pty Ltd</cell></row><row><cell><bold>EI</bold></cell><cell>Eisai Australia Pty Ltd</cell></row><row><cell><bold>EL</bold></cell><cell>Eli Lilly Australia Pty Ltd</cell></row><row><cell><bold>EO</bold></cell><cell>Ego Pharmaceuticals Proprietary Limited</cell></row><row><cell><bold>ER</bold></cell><cell>Eris Pharmaceuticals (Australia) Pty Ltd</cell></row><row><cell><bold>EU</bold></cell><cell>Emerge Health Pty Ltd</cell></row><row><cell><bold>EZ</bold></cell><cell>Merz Australia Pty Ltd</cell></row><row><cell><bold>FB</bold></cell><cell>Pierre Fabre Medicament Australia Pty Ltd</cell></row><row><cell><bold>FI</bold></cell><cell>Boehringer Ingelheim Pty Ltd</cell></row><row><cell><bold>FK</bold></cell><cell>A. Menarini Australia Pty Limited</cell></row><row><cell><bold>FM</bold></cell><cell>Fawns and McAllan Proprietary Limited</cell></row><row><cell><bold>FN</bold></cell><cell>Fresenius Medical Care Australia Pty Ltd</cell></row><row><cell><bold>FO</bold></cell><cell>For Benefit Medicines Pty Ltd</cell></row><row><cell><bold>FP</bold></cell><cell>Ferring Pharmaceuticals Pty Limited</cell></row><row><cell><bold>FR</bold></cell><cell>Merck Sharp &amp; Dohme (Australia) Pty Ltd</cell></row><row><cell><bold>FX</bold></cell><cell>Gedeon Richter Australia Pty Ltd</cell></row><row><cell><bold>FZ</bold></cell><cell>Pfizer Australia Pty Ltd</cell></row><row><cell><bold>GA</bold></cell><cell>Galderma Australia Pty Ltd</cell></row><row><cell><bold>GC</bold></cell><cell>GlaxoSmithKline Australia Pty Ltd</cell></row><row><cell><bold>GH</bold></cell><cell>Amdipharm Mercury (Australia) Pty Limited</cell></row><row><cell><bold>GI</bold></cell><cell>Gilead Sciences Pty Limited</cell></row><row><cell><bold>GK</bold></cell><cell>GlaxoSmithKline Australia Pty Ltd</cell></row><row><cell><bold>GN</bold></cell><cell>Actavis Pty Ltd</cell></row><row><cell><bold>GO</bold></cell><cell>Mylan Health Pty Ltd</cell></row><row><cell><bold>GQ</bold></cell><cell>Generic Health Pty Ltd</cell></row><row><cell><bold>GT</bold></cell><cell>Mylan Health Pty Ltd</cell></row><row><cell><bold>GV</bold></cell><cell>Amgen Australia Pty Limited</cell></row><row><cell><bold>GX</bold></cell><cell>Apotex Pty Ltd</cell></row><row><cell><bold>GZ</bold></cell><cell>sanofi-aventis Australia Pty Ltd</cell></row><row><cell><bold>HB</bold></cell><cell>Besins Healthcare Australia Pty Ltd</cell></row><row><cell><bold>HN</bold></cell><cell>Horizon Hospital Healthcare Pty Ltd</cell></row><row><cell><bold>HQ</bold></cell><cell>Generic Health Pty Ltd</cell></row><row><cell><bold>HR</bold></cell><cell>Paul Hartmann Pty Ltd</cell></row><row><cell><bold>HX</bold></cell><cell>Sandoz Pty Ltd</cell></row><row><cell><bold>IB</bold></cell><cell>Apotex Pty Ltd</cell></row><row><cell><bold>IL</bold></cell><cell>iNova Pharmaceuticals (Australia) Pty Limited</cell></row><row><cell><bold>IM</bold></cell><cell>iNova Pharmaceuticals (Australia) Pty Limited</cell></row><row><cell><bold>IO</bold></cell><cell>BioMarin Pharmaceutical Australia Pty Ltd</cell></row><row><cell><bold>IQ</bold></cell><cell>Alcon Laboratories (Australia) Pty Ltd</cell></row><row><cell><bold>IR</bold></cell><cell>Indivior Pty Ltd</cell></row><row><cell><bold>IS</bold></cell><cell>Ipsen Pty Ltd</cell></row><row><cell><bold>IX</bold></cell><cell>Clinect Pty Ltd</cell></row><row><cell><bold>IY</bold></cell><cell>Clinect Pty Ltd</cell></row><row><cell><bold>JC</bold></cell><cell>Janssen-Cilag Pty Ltd</cell></row><row><cell><bold>JJ</bold></cell><cell>Johnson &amp; Johnson Medical Pty Ltd</cell></row><row><cell><bold>JO</bold></cell><cell>Juno Pharmaceuticals Pty Ltd</cell></row><row><cell><bold>JT</bold></cell><cell>Johnson &amp; Johnson Pacific Pty Limited</cell></row><row><cell><bold>JU</bold></cell><cell>Juno Pharmaceuticals Pty Ltd</cell></row><row><cell><bold>KE</bold></cell><cell>Kendall Australasia Pty Ltd</cell></row><row><cell><bold>KI</bold></cell><cell>KCI Medical Australia Pty Ltd</cell></row><row><cell><bold>KP</bold></cell><cell>Eli Lilly Australia Pty Ltd</cell></row><row><cell><bold>KY</bold></cell><cell>Key Pharmaceuticals Pty Ltd</cell></row><row><cell><bold>LI</bold></cell><cell>Luminarie Pty Ltd</cell></row><row><cell><bold>LL</bold></cell><cell>Astellas Pharma Australia Pty Ltd</cell></row><row><cell><bold>LM</bold></cell><cell>Link Medical Products Pty Ltd</cell></row><row><cell><bold>LN</bold></cell><cell>Aspen Pharmacare Australia Pty Limited</cell></row><row><cell><bold>LO</bold></cell><cell>Leo Pharma Pty Ltd</cell></row><row><cell><bold>LQ</bold></cell><cell>Astellas Pharma Australia Pty Ltd</cell></row><row><cell><bold>LR</bold></cell><cell>Cipla Australia Pty Ltd</cell></row><row><cell><bold>LS</bold></cell><cell>Astellas Pharma Australia Pty Ltd</cell></row><row><cell><bold>LU</bold></cell><cell>Lundbeck Australia Pty Ltd</cell></row><row><cell><bold>LX</bold></cell><cell>Lawley Pharmaceuticals Pty Ltd</cell></row><row><cell><bold>LY</bold></cell><cell>Eli Lilly Australia Pty Ltd</cell></row><row><cell><bold>MF</bold></cell><cell>Mundipharma Pty Limited</cell></row><row><cell><bold>MH</bold></cell><cell>Molnlycke Health Care Pty Ltd</cell></row><row><cell><bold>MK</bold></cell><cell>Merck Sharp &amp; Dohme (Australia) Pty Ltd</cell></row><row><cell><bold>MM</bold></cell><cell>3M Pharmaceuticals Australia Pty Ltd</cell></row><row><cell><bold>MT</bold></cell><cell>Mentholatum Australasia Pty Ltd</cell></row><row><cell><bold>MW</bold></cell><cell>Biomed Aust Pty Limited</cell></row><row><cell><bold>NE</bold></cell><cell>Norgine Pty Limited</cell></row><row><cell><bold>NF</bold></cell><cell>Novo Nordisk Pharmaceuticals Pty Limited</cell></row><row><cell><bold>NI</bold></cell><cell>Novo Nordisk Pharmaceuticals Pty Limited</cell></row><row><cell><bold>NM</bold></cell><cell>Novartis Pharmaceuticals Australia Pty Limited</cell></row><row><cell><bold>NO</bold></cell><cell>Novo Nordisk Pharmaceuticals Pty Limited</cell></row><row><cell><bold>NQ</bold></cell><cell>Takeda Pharmaceuticals Australia Pty Ltd</cell></row><row><cell><bold>NT</bold></cell><cell>Nestle Australia Ltd</cell></row><row><cell><bold>NU</bold></cell><cell>Nutricia Australia Pty Limited</cell></row><row><cell><bold>NV</bold></cell><cell>Novartis Pharmaceuticals Australia Pty Limited</cell></row><row><cell><bold>OA</bold></cell><cell>Orphan Australia Pty Ltd</cell></row><row><cell><bold>OB</bold></cell><cell>Oral B Laboratories Pty Ltd</cell></row><row><cell><bold>OC</bold></cell><cell>Accord Healthcare Pty Ltd</cell></row><row><cell><bold>OD</bold></cell><cell>Accord Healthcare Pty Ltd</cell></row><row><cell><bold>OE</bold></cell><cell>Omegapharm Pty Ltd</cell></row><row><cell><bold>OH</bold></cell><cell>Orpharma Pty Ltd</cell></row><row><cell><bold>OL</bold></cell><cell>Owen Laboratories Division of Galderma Australia Pty Ltd</cell></row><row><cell><bold>OM</bold></cell><cell>Colgate Oral Care</cell></row><row><cell><bold>ON</bold></cell><cell>Orion Laboratories Pty Ltd</cell></row><row><cell><bold>OS</bold></cell><cell>Otsuka Australia Pharmaceutical Pty Ltd</cell></row><row><cell><bold>OW</bold></cell><cell>Arrow Pharma Pty Ltd</cell></row><row><cell><bold>PB</bold></cell><cell>Pharmaco (Australia) Limited</cell></row><row><cell><bold>PE</bold></cell><cell>Allergan Australia Pty Limited</cell></row><row><cell><bold>PF</bold></cell><cell>Pfizer Australia Pty Ltd</cell></row><row><cell><bold>PK</bold></cell><cell>Fresenius Kabi Australia Pty Limited</cell></row><row><cell><bold>PL</bold></cell><cell>The Trustee for Virgo Unit Trust (trading as Phebra)</cell></row><row><cell><bold>PM</bold></cell><cell>Pharmaceutical Manufacturing Company Pty Limited</cell></row><row><cell><bold>PP</bold></cell><cell>Petrus Pharmaceuticals Pty Ltd</cell></row><row><cell><bold>PQ</bold></cell><cell>PMIP Pty Ltd</cell></row><row><cell><bold>PY</bold></cell><cell>Procter &amp; Gamble Pharmaceuticals Australia Pty Ltd</cell></row><row><cell><bold>QA</bold></cell><cell>Aspen Pharma Pty Ltd</cell></row><row><cell><bold>QH</bold></cell><cell>Cortex Health Pty Ltd</cell></row><row><cell><bold>QL</bold></cell><cell>Amcla Pty Limited</cell></row><row><cell><bold>RA</bold></cell><cell>Sun Pharma ANZ Pty Ltd</cell></row><row><cell><bold>RB</bold></cell><cell>Bio Revive Pty Ltd</cell></row><row><cell><bold>RC</bold></cell><cell>Reckitt Benckiser (Australia) Pty Limited</cell></row><row><cell><bold>RF</bold></cell><cell>Arrow Pharma Pty Ltd</cell></row><row><cell><bold>RI</bold></cell><cell>Dr Reddy's Laboratories (Australia) Pty Ltd</cell></row><row><cell><bold>RN</bold></cell><cell>Sun Pharma ANZ Pty Ltd</cell></row><row><cell><bold>RO</bold></cell><cell>Roche Products Pty Ltd</cell></row><row><cell><bold>RW</bold></cell><cell>Arrow Pharma Pty Ltd</cell></row><row><cell><bold>RX</bold></cell><cell>Servier Laboratories (Aust.) Pty Ltd</cell></row><row><cell><bold>RZ</bold></cell><cell>Dr Reddy's Laboratories (Australia) Pty Ltd</cell></row><row><cell><bold>SA</bold></cell><cell>SciGen (Australia) Pty Limited</cell></row><row><cell><bold>SB</bold></cell><cell>Nutricia Australia Pty Limited</cell></row><row><cell><bold>SE</bold></cell><cell>Servier Laboratories (Aust.) Pty Ltd</cell></row><row><cell><bold>SG</bold></cell><cell>Merck Serono Australia Pty Ltd</cell></row><row><cell><bold>SI</bold></cell><cell>Sigma Company Limited</cell></row><row><cell><bold>SN</bold></cell><cell>Smith &amp; Nephew Pty Limited</cell></row><row><cell><bold>SS</bold></cell><cell>SSL Australia Pty Ltd</cell></row><row><cell><bold>SW</bold></cell><cell>sanofi-aventis Australia Pty Ltd</cell></row><row><cell><bold>SY</bold></cell><cell>Bayer Australia Ltd</cell></row><row><cell><bold>SZ</bold></cell><cell>Sandoz Pty Ltd</cell></row><row><cell><bold>TB</bold></cell><cell>Teva Pharma Australia Pty Limited</cell></row><row><cell><bold>TD</bold></cell><cell>STADA Pharmaceuticals Australia Pty Limited</cell></row><row><cell><bold>TF</bold></cell><cell>Te Arai BioFarma Limited</cell></row><row><cell><bold>TK</bold></cell><cell>Takeda Pharmaceuticals Australia Pty Ltd</cell></row><row><cell><bold>TL</bold></cell><cell>Tolmar Australia Pty Ltd</cell></row><row><cell><bold>TM</bold></cell><cell>Technipro Marketing Pty Ltd</cell></row><row><cell><bold>TS</bold></cell><cell>Specialised Therapeutics Australia Pty Ltd</cell></row><row><cell><bold>TW</bold></cell><cell>Apotex Pty Ltd</cell></row><row><cell><bold>TX</bold></cell><cell>Apotex Pty Ltd</cell></row><row><cell><bold>UA</bold></cell><cell>Actavis Pty Ltd</cell></row><row><cell><bold>UC</bold></cell><cell>UCB Australia Proprietary Limited</cell></row><row><cell><bold>UL</bold></cell><cell>Bausch &amp; Lomb (Australia) Pty Ltd</cell></row><row><cell><bold>UM</bold></cell><cell>Unomedical Pty Ltd</cell></row><row><cell><bold>UN</bold></cell><cell>Unilever Australia Limited</cell></row><row><cell><bold>UO</bold></cell><cell>Bausch &amp; Lomb (Australia) Pty Ltd</cell></row><row><cell><bold>VE</bold></cell><cell>AbbVie Pty Ltd</cell></row><row><cell><bold>VF</bold></cell><cell>Vitaflo Australia Pty Limited</cell></row><row><cell><bold>VI</bold></cell><cell>ViiV Healthcare Pty Ltd</cell></row><row><cell><bold>VL</bold></cell><cell>Vifor Pharma Pty Limited</cell></row><row><cell><bold>VR</bold></cell><cell>Vertex Pharmaceuticals (Australia) Pty Ltd</cell></row><row><cell><bold>VZ</bold></cell><cell>Sanofi-aventis Healthcare Pty Ltd</cell></row><row><cell><bold>WA</bold></cell><cell>sanofi-aventis Australia Pty Ltd</cell></row><row><cell><bold>XA</bold></cell><cell>Pharmaxis Ltd</cell></row><row><cell><bold>XC</bold></cell><cell>Southern Cross Pharma Pty Ltd</cell></row><row><cell><bold>XH</bold></cell><cell>MS Health Pty Ltd</cell></row><row><cell><bold>XI</bold></cell><cell>Alexion Pharmaceuticals Australasia Pty Ltd</cell></row><row><cell><bold>XM</bold></cell><cell>The Medicines Company (Australia) Pty Limited</cell></row><row><cell><bold>YC</bold></cell><cell>Cipla Australia Pty Ltd</cell></row><row><cell><bold>YN</bold></cell><cell>Mayne Pharma International Pty Ltd</cell></row><row><cell><bold>YT</bold></cell><cell>Mayne Products Pty Ltd</cell></row><row><cell><bold>ZA</bold></cell><cell>AstraZeneca Pty Ltd</cell></row><row><cell><bold>ZI</bold></cell><cell>Shire Australia Pty Limited</cell></row><row><cell><bold>ZP</bold></cell><cell>Medis Pharma Pty Ltd</cell></row><row><cell><bold>ZX</bold></cell><cell>Zenex Pharmaceuticals Pty Ltd</cell></row></table></fragment></section></document></blockxref>
<blockxref id="107725" title="book-genericindex.psml" frag="default" reversefrag="toc" reversetitle="" reverselink="true" reversetype="none" display="document" type="embed" uriid="59724" href="dynamic/book-genericindex.psml" urititle="Generic/Proprietary Index" mediatype="application/vnd.pageseeder.psml+xml"><document id="59724" schemaversion="0.12" date="2018-06-15T10:34:32+10:00" version="current" level="processed"><documentinfo><uri id="59724" scheme="http" host="localhost" port="80" path="/ps/test/local3/books/dynamic/book-genericindex.psml" decodedpath="/ps/test/local3/books/dynamic/book-genericindex.psml" external="false" mediatype="application/vnd.pageseeder.psml+xml" created="2018-06-15T10:34:20+10:00" modified="2018-06-15T10:34:32+10:00" title="Generic/Proprietary Index"><displaytitle>Generic/Proprietary Index</displaytitle></uri><reversexrefs><reversexref uriid="60041" href="../book-efc.psml" frag="toc" urititle="EFC Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="efc" id="106032" title="" type="none" forwardtype="embed" forwardtitle="book-genericindex.psml" forwarddisplay="document" forwardfrag="default"></reversexref><reversexref uriid="60796" href="book-main.psml" frag="toc" urititle="Main Book" mediatype="application/vnd.pageseeder.psml+xml" documenttype="main" id="107725" title="" type="none" forwardtype="embed" forwardtitle="book-genericindex.psml" forwarddisplay="document" forwardfrag="default"></reversexref></reversexrefs></documentinfo><fragmentinfo></fragmentinfo><metadata></metadata><section id="59724-1"><fragment id="59724-1"><block label="mps3sectionbreak">GPI</block><heading level="1">Generic/Proprietary Index</heading><block label="pagebreak">pagebreak</block></fragment><fragment id="59724-2"><block label="generic-index-filedcode"><para>INDEX \e "" \h "A" \c "2" \z "3081"</para></block></fragment></section></document></blockxref>
</xref-fragment></section></document>